额外检查,肿瘤组织位置,其他诊断,性别,生存状态,去世间隔天数,随访时间,种族,病人条形码,组织部位,病人id,新辅助治疗,知情同意验证,肿瘤原发部位,肿瘤组织类型,编码系统,初次诊断年份,肿瘤状态,初次淋巴结状态,淋巴结数量,ER检测,PR检测,解剖位置,HER2状态检测,ALN分期检测,ALN分期检测补充,手术类型,手术类型补充,外科手术名,额外手术信息,常规组织学特征,非常规组织学特征,绝经状态,孕激素受体,细胞角蛋白免疫组化微小转移检测法,乳腺癌ER免疫组化阳性评分量表,免疫组化阳性细胞评分,HER2免疫组化水平检测结果,乳腺癌手术切缘状态,切缘状态,初始病理诊断方法,病理诊断方法,其他初始病理诊断方法,乳腺癌雌激素受体状态,HER2免疫组化受体状态,阳性淋巴结数,H&E染色阳性淋巴结数,PR阳性其他测量,ER阳性其他测量描述,HER2阳性细胞百分比分类,HER2其他检测描述,HER2检测计算方法,HER2/CEP17拷贝数计数,HER2/CEP17其他测量结果,HER2 FISH计算方法,组织前瞻性收集指标,组织样本回顾性收集指标,FISH染色体17信号范围,非淋巴结首转部位,ER水平细胞百分比分类,PR水平细胞百分比分类,转移性乳腺癌ER状态,转移性乳腺癌ER表达分类,转移性乳腺癌IHC评分,转移性乳腺癌PR状态,转移性乳腺癌HER2 IHC状态,转移性乳腺癌孕激素受体水平细胞百分比类别,转移性乳腺癌免疫组化孕激素受体阳性细胞评分,转移性乳腺癌HER2/ERBB阳性细胞百分比类别,转移性乳腺癌ERBB2免疫组化水平结果,转移性乳腺癌实时荧光原位杂交结果类型,转移性乳腺癌HER2/neu染色体17信号比值,乳腺癌HER2/neu拷贝分析输入总数,乳腺癌免疫组化孕激素受体阳性发现评分,乳腺癌免疫组化阳性细胞分数,分期事件,术后治疗,放射治疗,新肿瘤事件,填表日期,填表月份,填表年份,随访,药物,放疗
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1918.0,WHITE,TCGA-A2-A0CT,A2,A0CT,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,2.0,Allred score 7 (outside facility),Allred 5 = 2+3,Right Upper Outer Quadrant,1.3,Sentinel node biopsy alone,Pateys surgery,Simple Mastectomy,surgical resection,Modified radical mastectomy,Excision,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,4 Point Scale,1+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.0,0.0,Allred Score 4,10-75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,100.3984375,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,50,"Other, specifySkin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,816,3 Point Scale,0,6thStage IIAT2N0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,9,2010,TCGA-A2-A0CT-F13730E5069DEC-D655-42B1-81A6-4F008FC9EF78Scheduled Follow-up SubmissionNOYESAlive2289TUMOR FREENO962011,4TCGA-A2-A0CT-D1976fe69a660-e936-4a3f-8e5d-8cbfbb6dfeb420mg/day5591537Hormone TherapyTamoxifenADJUVANTPONO9920102TCGA-A2-A0CT-D197476a54d5e-e978-4768-b8d6-d25277ef98033600mg900mg475138ChemotherapyCytoxanADJUVANTIVNO9920103TCGA-A2-A0CT-D1975b6f4f507-e6ee-45bc-b50b-d9a2bb53bcaa1mg160433Hormone TherapyArimidexADJUVANTPONO9920101TCGA-A2-A0CT-D197346d7f184-146c-4978-a041-32b27f642b48360mg90mg475138ChemotherapyAdriamycinADJUVANTIVNO992010,TCGA-S3-AA15-R67624FE3E452E-46DC-46B1-9014-9F6A43D28C78286359External114Gy57Primary Tumor FieldNOComplete Response7112014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,1309.0,WHITE,TCGA-GM-A2DD,GM,A2DD,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,2.0,image cytometry,IHC,Right,1.11,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Left breast reexcision,Modified radical mastectomy,Wide Local Excision,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Equivocal,0.0,0.0,240 H,Allred Score 5,<10%,0,Hercep Test  TM Dako,60.0,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.45,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.62,3 Point Scale,2+,6thStage IT1cN0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,29,9,2011,TCGA-GM-A2DD-F470701AC34321-8651-4F6E-B962-E0E9FC7860ECNONOYESTUMOR FREEAlive2282NO2282013,NOTCGA-GM-A2DD-D470712664E496-34C1-4DFB-893B-7102CD0171B390202ChemotherapyFluorouracilNOComplete Response2282013NOTCGA-GM-A2DD-D47072A4DAE917-9FC6-409F-9FDD-1E8F876394CA90202ChemotherapyAdriamycinNOComplete Response2282013NOTCGA-GM-A2DD-D4707330DC9EB0-B305-4BC7-B006-221E80F1AE2590202ChemotherapyCytoxanNOComplete Response2282013,TCGA-BH-A0B1-R154346CBDF1E7-E2BB-4EEC-9C61-547430A54E0A287343EXTERNAL BEAM6040cGy28Primary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,238.0,WHITE,TCGA-D8-A1JM,D8,A1JM,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,manual counting,manual counting,Right Upper Outer Quadrant,1.138642578124999,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,Pateys surgery,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.0361328125,3.0,0%,Allred score = 0,30-39%,Dako,DAKOHercepTest TM,179.2265625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,4.43,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,52,3 Point Scale,1+,7thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",29,3,2011,TCGA-D8-A1JM-F20742F44EA1FB-71B0-4586-9DA1-F4C78A24F0E4Scheduled Follow-up SubmissionYESYESAlive590TUMOR FREENO1512012,TCGA-D8-A1JM-D20743D067FC8D-6FF0-4230-B498-599F566005F67200+720+20mg/m21200+120+20mg/m2639144ChemotherapyHormone Therapydoxorubicine cyclophosphamide tamoxifenADJUVANTIVNO1512012,TCGA-D8-A1JM-R20744DC5F01FD-AD1B-448F-8D51-F62F280E4F7D171196EXTERNAL BEAM9000cGy45Primary Tumor FieldADJUVANTNO1512012
TCGAFPPP,Breast,No,FEMALE,Dead,1692.0,660.39453125,WHITE,TCGA-BH-A18Q,BH,A18Q,No,YES,C50.8,8500/3,C50.8,2001.0,WITH TUMOR,YES,25.0,H-SCORE 136,Allred 5 = 2+3,Left,1.7962890624999983,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Positive,2.0,2.0,100,Allred Score = 7,10-19%,ACIS,Hercep Test  TM Dako,89.8818359375,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,NO,YES,1.45,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,1.67,3 Point Scale,2+,Stage IIBT2N1bM0,NO,NO,YES1543Distant MetastasisBoneNONOYESPositive4 Point Scale3+8Positive4 Point Scale2+Allred score=5Negative1+,24,6,2011,TCGA-A8-A08C-F40842EE8A8BCF-C75E-4E24-9DA3-1CD8DFA9B713NOYESYESTUMOR FREEAlive881NO232013,1TCGA-E2-A14R-D1884002D7B362-61D3-42D6-85CD-44CEAFE39454572mg143mg489131ChemotherapyDoxorubicinADJUVANTIVNO241020113TCGA-E2-A14R-D188424742335F-157B-4689-A300-FE62F824234D1832mg610mg3128187ChemotherapyPaclitaxel (Protein-Bound)ADJUVANTIVNO241020112TCGA-E2-A14R-D1884171BC8838-707A-4B8B-A57B-65DF043E1B53413mg413mg1145145ChemotherapyPaclitaxelADJUVANTIVNO241020111TCGA-E2-A14R-D188391F3203CD-3D0A-40D3-95B5-5B07E49877955712mg1428mg489131ChemotherapyCyclophosphamideADJUVANTIVNO24102011,TCGA-B6-A401-R4109747DF79D5-C4F9-437F-9C6B-79FD20A4F17D205284ExternalPrimary Tumor FieldNO1232013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12P,C8,A12P,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,8.0,H-SCORE 280,Allred score 4+3 = 7,Left,1.4917089843750029,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Negative,Positive,0.0302734375,1.4736328125,allred score = 8,0,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,81.361328125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.38,"Other, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,441,3 Point Scale,1+,6thStage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,13,4,2011,TCGA-C8-A12P-F20267E314B6FE-D28B-4608-B290-CC684F3A2B1AScheduled Follow-up SubmissionNONOAlive358TUMOR FREENO912012,YESTCGA-S3-A6ZF-D510614503FC44-1AA6-4A16-BE16-63146AF1ECEB65170ChemotherapytaxotereNOComplete Response12112013YESTCGA-S3-A6ZF-D510622B4A620C-E5B7-45D0-823B-A7D09CD7F72D65429ImmunotherapyTrastuzumabNOComplete Response12112013YESTCGA-S3-A6ZF-D51087DA38E0A7-A07F-4D6E-85AD-465748551C9778170AncillaryNeulastaNOComplete Response12112013YESTCGA-S3-A6ZF-D51086E2F5E7F8-10E2-4432-A00A-7087B5955C9E65170ChemotherapyCytoxanNOComplete Response12112013YESTCGA-S3-A6ZF-D63998CEDA468F-784C-42EC-B0C6-8B42B8C5BEE1191278Hormone TherapyLETROZOLENO2782014YESTCGA-S3-A6ZF-D640051F99661D-577D-4D3C-BFF3-6436D7DA50A3278Hormone TherapyANASTROZOLEYES2782014,TCGA-GM-A2DC-R4706262127898-C5DE-49F3-853B-892863D6FAD6236278External60Gy30Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,212.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-A6ZF,S3,A6ZF,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,1.0,CAP scoring guideline 2010,CAP scoring guideline 2010,RightRight Upper Outer Quadrant,1.5,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Pateys surgery,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.0,0.0,moderate,Moderate,50-59%,CISH,CAP scoring guideline 2010,20.0,HER2 amplification - negative,>= 2.0 Positive,YES,NO,39,"Other, specifyskin",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,60,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,NO,12,11,2013,TCGA-S3-A6ZF-F59305B9F9D3D7-E836-4C18-A8AA-1F7DA4D37DDANONOYESTUMOR FREEAlive502NO2782014TCGA-S3-A6ZF-F67764376B6C8B-37BD-46AA-8323-631C9C20E5C8NONOYESTUMOR FREEAlive572NO11112014,YESTCGA-S3-A6ZF-D510614503FC44-1AA6-4A16-BE16-63146AF1ECEB65170ChemotherapytaxotereNOComplete Response12112013YESTCGA-S3-A6ZF-D510622B4A620C-E5B7-45D0-823B-A7D09CD7F72D65429ImmunotherapyTrastuzumabNOComplete Response12112013YESTCGA-S3-A6ZF-D51087DA38E0A7-A07F-4D6E-85AD-465748551C9778170AncillaryNeulastaNOComplete Response12112013YESTCGA-S3-A6ZF-D51086E2F5E7F8-10E2-4432-A00A-7087B5955C9E65170ChemotherapyCytoxanNOComplete Response12112013YESTCGA-S3-A6ZF-D63998CEDA468F-784C-42EC-B0C6-8B42B8C5BEE1191278Hormone TherapyLETROZOLENO2782014YESTCGA-S3-A6ZF-D640051F99661D-577D-4D3C-BFF3-6436D7DA50A3278Hormone TherapyANASTROZOLEYES2782014,TCGA-E2-A1L9-R20602FB33C7DC-7439-4DE4-B8CE-2F122C0D2BB8140177EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11112012
TCGAFPPP,Breast,No,FEMALE,Dead,2763.0,626.4443359375,WHITE,TCGA-BH-A18K,BH,A18K,No,YES,C50.9,8500/3,C50.9,1999.0,WITH TUMOR,YES,11.0,H-SCORE 190,H-SCORE 150,Left Lower Inner Quadrant,1.6092773437499996,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Margin resection,Other,segmental mastectomy with axillary dissection,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,1.03125,0.0,Allred Score 8,0%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,52.8759765625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,1.57,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0495312500000025,1.66,3 Point Scale,2+,5thStage IT1N0M0,NO,NO,PositiveNegative1+,9,6,2011,TCGA-AN-A0FF-F689439B3D0EEE-F464-4E46-B81D-A11ED9A05517NONONOTUMOR FREEAlive172NO23122014,NOTCGA-D8-A3Z6-D51368FA44D3C7-5509-4E8A-8B5F-C6C804AE85E32286ChemotherapycyclophosphamidumNOStable Disease18112013NOTCGA-D8-A3Z6-D51370FEEC29B8-84BD-4F1D-AF6E-93F1592B2E13108185ChemotherapytaxolNOStable Disease18112013NOTCGA-D8-A3Z6-D51372D00B426C-3576-4D63-AFD6-FBEFFDB9ADA7260Hormone TherapytamoxifenYES18112013NOTCGA-D8-A3Z6-D5924125ADCD91-C55B-445C-8B2D-4008D97434AE2286ChemotherapyDoxorubicinumNOStable Disease652014,TCGA-D8-A1Y3-R30091A12F5CAC-72A2-430B-893C-10338084842F145169EXTERNAL BEAM9000cGy40Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,11.0,WHITE,TCGA-AN-A0FW,AN,A0FW,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,IHC,CAP scoring guideline 2010,Left Upper Outer Quadrant,2.624208984374995,No axillary staging,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Indeterminate,NO,3 Point Scale,4+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Negative,0.0,2.0,10,180,20-29%,0,Venten,100.5498046875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,51,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5.8,3 Point Scale,1+,Stage IIIAT2N2M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,28,12,2010,TCGA-AN-A0FW-F6896609AE2056-27E8-4B1D-B3BA-67034B18CFECYESNONOTUMOR FREEAlive11NO24122014,1TCGA-E2-A14R-D1884002D7B362-61D3-42D6-85CD-44CEAFE39454572mg143mg489131ChemotherapyDoxorubicinADJUVANTIVNO241020113TCGA-E2-A14R-D188424742335F-157B-4689-A300-FE62F824234D1832mg610mg3128187ChemotherapyPaclitaxel (Protein-Bound)ADJUVANTIVNO241020112TCGA-E2-A14R-D1884171BC8838-707A-4B8B-A57B-65DF043E1B53413mg413mg1145145ChemotherapyPaclitaxelADJUVANTIVNO241020111TCGA-E2-A14R-D188391F3203CD-3D0A-40D3-95B5-5B07E49877955712mg1428mg489131ChemotherapyCyclophosphamideADJUVANTIVNO24102011,TCGA-E9-A1R2-R56895D7CA210D-C2B0-4BF4-8D15-3C719E3FD2D8174223External6240cGyPrimary Tumor FieldNOComplete Response2522014TCGA-E9-A1R2-R56896850B4523-573A-4F66-A0BA-85E00855505E174223External5040cGyRegional siteNOComplete Response2522014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,27.0,WHITE,TCGA-D8-A140,D8,A140,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,15.0,manual counting,manual counting,Left Upper Outer QuadrantLeft,1.176220703124997,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Margin resection,Other,Surgical resection,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Positive,0.0078125,1.0,<10%,>75%,90-99%,Dako,Hercep Test TM DAKO,130.9990234375,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,4.43,"LungBoneLiverOther, specifyskin",70-79%,<10%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,71,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",26,2,2011,TCGA-D8-A140-F1380839F74CEF-2C48-4800-B82A-92DCBA81257CScheduled Follow-up SubmissionNOYESAlive403TUMOR FREENO2062011,4x chemotherapyTCGA-D8-A140-D13809CD6D1C59-F2A8-4AC6-9E8B-74835E6187BD60 doxorubicin+ 600 CPHmg/m260 doxorubicin+ 600 CPH427181Chemotherapydoxorubicin+cyclophosphamidADJUVANTIVNO2062011,TCGA-GM-A2DB-R47157D6AC4D25-3614-447E-8DF4-09A1DBE09817271317ExternalPrimary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,845.0,WHITE,TCGA-E2-A14R,E2,A14R,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,8.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Left,1.4414257812499995,Sentinel lymph node biopsy plus axillary dissection,Pateys surgery,Lumpectomy,Reexcision,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Negative,0.3642578125,0.0,Allred score = 0,Allred score = 0,<10%,Dako,CAP SCORING GUIDELINE 2010,129.5537109375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,74,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.83,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,6,4,2011,"TCGA-E2-A14R-F18838818079A8-A928-4AC6-9779-E8A587D960DBScheduled Follow-up SubmissionYESYESAlive1174TUMOR FREEYES971New Primary TumorOther, specifyEndometrialYES971YESNO24102011",1TCGA-E2-A14R-D1884002D7B362-61D3-42D6-85CD-44CEAFE39454572mg143mg489131ChemotherapyDoxorubicinADJUVANTIVNO241020113TCGA-E2-A14R-D188424742335F-157B-4689-A300-FE62F824234D1832mg610mg3128187ChemotherapyPaclitaxel (Protein-Bound)ADJUVANTIVNO241020112TCGA-E2-A14R-D1884171BC8838-707A-4B8B-A57B-65DF043E1B53413mg413mg1145145ChemotherapyPaclitaxelADJUVANTIVNO241020111TCGA-E2-A14R-D188391F3203CD-3D0A-40D3-95B5-5B07E49877955712mg1428mg489131ChemotherapyCyclophosphamideADJUVANTIVNO24102011,TCGA-E2-A14R-R1884371319FB6-5CE9-4A19-8D5C-34C64A295435210259EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO124102011TCGA-E2-A14R-R188450DD87532-955B-43DE-A40E-7952D899390810261061EXTERNAL BEAM4500cGy25Regional siteADJUVANTNO224102011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,608.0,WHITE,TCGA-A8-A08C,A8,A08C,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.0810546875,CAP scoring guideline 2010,image cytometry,Left Upper Inner Quadrant,1.8477148437499888,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.3125,0.0,Allred Score,Allred Score 8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,112.0478515625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,40,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,59,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,27,5,2011,TCGA-A8-A08C-F40842EE8A8BCF-C75E-4E24-9DA3-1CD8DFA9B713NOYESYESTUMOR FREEAlive881NO232013,NOTCGA-A8-A08C-D37815316BC7DA-9F45-49F7-92C4-16831B2B6BE731151Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08C-D37816DE7131F0-268C-4FA4-B008-01D742EDF24231151ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08C-D37817FE9DA209-FD04-42A5-B165-8596370AC78C31151ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08C-D3781812320A9F-0C0D-402C-92BD-95A4C989BA15243Hormone TherapyTamoxifenn/aYES6122012,TCGA-A8-A08C-R381700D8A37D3-AE94-4C70-8872-27E4BDAFA181182243ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,185.0,WHITE,TCGA-D8-A3Z6,D8,A3Z6,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,22.0,% IHC,%IHC,Left,1.4488183593750037,Other (specify),mastectomy with TLND,Modified Radical Mastectomy,Right Breast reexcision,Other,Wide re-excisional biopsy,Infiltrating Lobular Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.791015625,19.0,Allred score = 8,0%,90-99%,ACIS,Dako Hercept test,200.8388671875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,2.5,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,<4.0,3 Point Scale,2+,7thStage IIICT3N3aM0,YES,YES,NO,3,7,2012,TCGA-D8-A3Z6-F513679DD39B06-7D2B-4656-9C5F-90AAA50D3A64NOYESYESTUMOR FREEAlive563NO18112013,NOTCGA-D8-A3Z6-D51368FA44D3C7-5509-4E8A-8B5F-C6C804AE85E32286ChemotherapycyclophosphamidumNOStable Disease18112013NOTCGA-D8-A3Z6-D51370FEEC29B8-84BD-4F1D-AF6E-93F1592B2E13108185ChemotherapytaxolNOStable Disease18112013NOTCGA-D8-A3Z6-D51372D00B426C-3576-4D63-AFD6-FBEFFDB9ADA7260Hormone TherapytamoxifenYES18112013NOTCGA-D8-A3Z6-D5924125ADCD91-C55B-445C-8B2D-4008D97434AE2286ChemotherapyDoxorubicinumNOStable Disease652014,TCGA-D8-A3Z6-R513697BE92C39-4EED-4E33-85EB-996F80FEC082234260External45Gy22Primary Tumor FieldNOStable Disease18112013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-C8-A133,C8,A133,No,YES,C50.9,8523/3,C50.9,2010.0,TUMOR FREE,YES,26.0,Image Analysis,Image Analysis,Right,1.3166503906250018,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Total Mastectomy,"Other, specify",ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,"Other method, specify:",Modified Radical Masectomy,Negative,Positive,Negative,0.2177734375,2.5439453125,Allred Score 8,Allred Score 8,90-99%,Hercep Test  TM Dako,Venten,65.5751953125,HER2 amplification - negative,Ratio >=2.0,YES,NO,2.38,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,131,4 Point Scale,2+,6thStage IIIAT3N1M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",15,4,2011,TCGA-AN-A0FF-F689439B3D0EEE-F464-4E46-B81D-A11ED9A05517NONONOTUMOR FREEAlive172NO23122014,NOTCGA-A8-A08C-D37815316BC7DA-9F45-49F7-92C4-16831B2B6BE731151Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08C-D37816DE7131F0-268C-4FA4-B008-01D742EDF24231151ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08C-D37817FE9DA209-FD04-42A5-B165-8596370AC78C31151ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08C-D3781812320A9F-0C0D-402C-92BD-95A4C989BA15243Hormone TherapyTamoxifenn/aYES6122012,TCGA-E9-A5FK-R56480E57FDF1C-1CD3-4800-9D55-07CDC326E434130154External80GyRegional siteNOComplete Response1022014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,172.0,WHITE,TCGA-AN-A0FF,AN,A0FF,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,dextran coated charcoal,dextran coated charcoal,Left Upper Outer Quadrant,2.845800781249998,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,0,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Negative,0.0,0.0,Intensity=Weak,Allred Score 6,<10%,0,dextran coated charcoal,111.8671875,HER2 amplification - negative,PathVysion,NO,YES,4.43,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,47,3 Point Scale,3+,Stage IAT1bN0M0,YES,NO,YES181Locoregional RecurrenceYES181NOYES,27,12,2010,TCGA-AN-A0FF-F689439B3D0EEE-F464-4E46-B81D-A11ED9A05517NONONOTUMOR FREEAlive172NO23122014,NOTCGA-A8-A08C-D37815316BC7DA-9F45-49F7-92C4-16831B2B6BE731151Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08C-D37816DE7131F0-268C-4FA4-B008-01D742EDF24231151ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08C-D37817FE9DA209-FD04-42A5-B165-8596370AC78C31151ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08C-D3781812320A9F-0C0D-402C-92BD-95A4C989BA15243Hormone TherapyTamoxifenn/aYES6122012,TCGA-AQ-A04H-R4982d113adb3-5e01-4acc-b1c5-f15e6762bb51138166EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO116122010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,0.0,WHITE,TCGA-AC-A5EI,AC,A5EI,No,YES,C50.9,9020/3,C50.9,2012.0,TUMOR FREE,YES,2.0,H-SCORE 260,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.841630859374999,Sentinel node biopsy alone,SN+1 non sentinel node,Simple Mastectomy,Right Breast reexcision,Other,Excisional biospy,"Other, specify",Malignant Phyllodes Tumor,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Modified Radical Masectomy,Negative,Positive,Negative,0.9248046875,1.0,Two-tier,Allred Score 5,10-19%,ACIS,CAP SCORING GUIDELINE 2010,103.634765625,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,35,"Other, specifyskin",90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,131,3 Point Scale,2+,7thStage IBT1cN1miMX,YES,YES,NO,12,7,2013,TCGA-AC-A5EI-F601849AE528AA-45A7-458E-8361-B5B6123CE23DNONONOTUMOR FREEAlive442NO3152014,NOTCGA-D8-A3Z6-D51368FA44D3C7-5509-4E8A-8B5F-C6C804AE85E32286ChemotherapycyclophosphamidumNOStable Disease18112013NOTCGA-D8-A3Z6-D51370FEEC29B8-84BD-4F1D-AF6E-93F1592B2E13108185ChemotherapytaxolNOStable Disease18112013NOTCGA-D8-A3Z6-D51372D00B426C-3576-4D63-AFD6-FBEFFDB9ADA7260Hormone TherapytamoxifenYES18112013NOTCGA-D8-A3Z6-D5924125ADCD91-C55B-445C-8B2D-4008D97434AE2286ChemotherapyDoxorubicinumNOStable Disease652014,TCGA-EW-A3E8-R3999391E4B957-C918-4E13-B0E0-48ECCA77D430165196External60Gy30Primary Tumor FieldNOComplete Response822013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,146.0,WHITE,TCGA-D8-A27N,D8,A27N,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,19.0,manual counting,manual counting,Right Upper Outer Quadrant,1.46765625,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Margin resection,Mastectomy NOS,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Positive,0.0,4.0,10-75%,>75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,64.0322265625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,50,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.66,3 Point Scale,2+,7thStage IIIAT2N2aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",18,7,2011,TCGA-D8-A27N-F295943121479E-1AAE-4F1E-98CA-0ED26BDCC3CFScheduled Follow-up SubmissionNOYESAlive519TUMOR FREENO2632012,TCGA-D8-A27N-D295957055CBBE-07D0-4F99-B7A5-FC251DAE2E28mg60+600mg/m268Chemotherapytaxol+adriamycin+cyclophosphamide+herceptinADJUVANTIVYES2632012,TCGA-BH-A0BA-R15467074F0CFD-17CA-47A8-88C5-A36FF8978CF4187262EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,171.0,WHITE,TCGA-D8-A1X5,D8,A1X5,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,16.0,manual counting,manual counting,Right Upper Outer QuadrantRight Lower Inner QuadrantRight Lower Outer Quadrant,1.704921874999997,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Margin resection,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Negative,Positive,Positive,0.703125,14.0,10-75%,>75%,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,56.4677734375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,33,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,<4.0,3 Point Scale,2+,7thStage IIICT2N3aMX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",9,6,2011,TCGA-D8-A1X5-F29934EB83DACE-75EE-47C9-A706-ED4628EBAC90Scheduled Follow-up SubmissionYESYESAlive565TUMOR FREENO3032012,TCGA-D8-A1X5-D299359E4AF981-5926-4017-BB6E-25B7554E7645280mg20mg/day1455Hormone TherapyTamoxifenADJUVANTPOYES3032012TCGA-D8-A1X5-D30115972E329F-848E-4B00-AB12-F25F7C073C6Amg20mg/day55Hormone TherapyTamoxifenADJUVANTPOYES242012,TCGA-D8-A1X5-R29936E2E68231-4608-4580-8B41-5293428ED8EB113140EXTERNAL BEAM9000cGy45Primary Tumor FieldADJUVANTNO3032012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1730.0,BLACK OR AFRICAN AMERICAN,TCGA-AR-A0TT,AR,A0TT,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,19.0,Allred score 0+0 = 0,Image Analysis,Right Upper Outer Quadrant,1.310000000000001,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Other,Right Breast reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.3779296875,5.0,Allred Score 7,Allred Score 8,90-99%,Dako,Venten,160.7158203125,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,NO,YES,2.13,"Other, specifyskin",10-19%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,145,3 Point Scale,0,6thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,8,3,2011,TCGA-AR-A0TT-F185765291BA86-C47C-46B6-93B4-14BB7A3F40DBScheduled Follow-up SubmissionYESYESAlive1730NO15122011TCGA-AR-A0TT-F495172EA565CB-7360-4D0F-B645-52EC58950B49YESYESTUMOR FREEAlive2636NO2102013TCGA-AR-A0TT-F71737F362532A-12F9-4FC6-99ED-E2AA217CB5C1NOYESYESTUMOR FREEAlive3316NO3032015,1TCGA-AR-A0TT-D1911729A541D6-25FE-4E6E-9273-3A8AC33916A91360mg175mg/m24105147ChemotherapyPaclitaxelADJUVANTIVNO151220113TCGA-AR-A0TT-D1912459EF98F0-0F7E-49BE-A00D-AE33AE3F59D120mg/day4385Hormone TherapyTamoxifenADJUVANTPOYES151220112TCGA-AR-A0TT-D1912170A14733-C2D0-4715-8FA2-FA9E1030DC2E1mg/day4230376Hormone TherapyAnastrozoleADJUVANTPONO151220111TCGA-AR-A0TT-D19112AC332E3C-15EC-4568-B022-BC18DD15AC5F465mg60mg/m244891ChemotherapyDoxorubicinADJUVANTIVNO151220111TCGA-AR-A0TT-D191133F6361BB-149D-4D35-A1E0-7968FB1EC94A4680mg600mg/m244891ChemotherapyCytoxanADJUVANTIVNO15122011,TCGA-AR-A0TT-R19573A3F2C813-7858-4900-AEE3-694EBB16901F211ADJUVANTNO115122011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,549.0,WHITE,TCGA-A8-A08F,A8,A08F,Yes,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,10.830078125,CAP scoring guideline 2010,Allred (Biocare),Right Upper Inner Quadrant,1.8418945312499893,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Margin resection,Mastectomy NOS,Surgical Resection,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.31640625,3.80078125,Allred Score,H-Score,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,109.64453125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,4,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,<4.0,3 Point Scale,3+,6thStage IIICT2N3aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A08F-F408436303FB2D-9618-4364-8331-667962F57160NOYESYESTUMOR FREEAlive1004NO232013,NOTCGA-A8-A08F-D37756A407F51A-F51F-4CCD-B64B-41D298C30F9C3192Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08F-D37757BD575045-6AED-4137-9E4C-2BB9C02A1E893192ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08F-D37758D0945071-31AC-4310-AF0A-4AC89DC8D74D3192ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08F-D377594213A223-3502-4936-813C-875A28B2F16192123ChemotherapyDocetaxeln/aNOComplete Response6122012NOTCGA-A8-A08F-D377604B4B76FD-2BE6-4E59-9D03-D67BFF3D823F243Hormone TherapyLetrozolen/aYES6122012,TCGA-A8-A08F-R38156669B30AD-2747-4953-BAC9-E5E3AFAE9216184215ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1132.0,WHITE,TCGA-BH-A0BA,BH,A0BA,No,YES,C50.9,8522/3,C50.9,2006.0,TUMOR FREE,YES,27.0,Allred score 7 (outside facility),allred score 5 +3 = 8,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft Lower Inner QuadrantLeft Lower Outer QuadrantLeft,1.699072265624995,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,total mastectomy,Mixed Histology (please specify),Infiltrating ductal & lobular,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.5908203125,27.0,0,allred score = 8,10-19%,ACIS,CAP scoring guideline 2010,56.2685546875,Vysis AutoVysion System,PathVysion,NO,YES,66,"LungBoneLiverOther, specifyskin",80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.9,3 Point Scale,1+,Stage IIICT3N3aM0,NO,YES,YES994Distant MetastasisBoneNOYESYES,4,11,2010,TCGA-BH-A0BA-F15461A7C13A2B-D403-4A9E-AA4C-8206CDD41509Scheduled Follow-up SubmissionYESYESAlive1132TUMOR FREENO4112010,1TCGA-BH-A0BA-D15464DF60161D-106E-4FB8-8D03-71A048D7C3AA046394ChemotherapyCytoxanADJUVANTIVNO41120101TCGA-BH-A0BA-D15465DACDCDBB-0BA5-4572-A515-6E4831F172454119171ChemotherapyPaclitaxelADJUVANTIVNO41120101TCGA-BH-A0BA-D1546222BBDDCD-4D31-43CF-BA69-28A677A615E446394ChemotherapyAdriamycinADJUVANTIVNO4112010,TCGA-BH-A0BA-R15467074F0CFD-17CA-47A8-88C5-A36FF8978CF4187262EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,647.0,WHITE,TCGA-EW-A3E8,EW,A3E8,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,2.0,allred score 0 + 0 = 0,Allred (Biocare),LeftLeft Upper Outer Quadrant,1.2617773437499986,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Simple Mastectomy,Margin resection,Other,biopsy,Infiltrating Lobular Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.2822265625,0.0,90 H,Allred Score = 7,10-19%,ACIS,CAP SCORING GUIDELINE 2010,129.0234375,HER2 amplification - negative,Ratio >=2.0,YES,NO,1.78,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,131,3 Point Scale,2+,7thStage IIBT3N0MX,YES,YES,NO,8,2,2013,TCGA-EW-A3E8-F5761771B7D2CC-2481-4609-94CB-593371E7EE7DNOYESYESTUMOR FREEAlive1035NO1832014,NOTCGA-EW-A3E8-D399966D645F63-EEF8-43F6-AC29-34CBBEC01722196Hormone TherapyAnastrozoleYES822013,TCGA-EW-A3E8-R3999391E4B957-C918-4E13-B0E0-48ECCA77D430165196External60Gy30Primary Tumor FieldNOComplete Response822013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,75.0,WHITE,TCGA-D8-A1XG,D8,A1XG,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,% IHC,%IHC,Right Upper Inner Quadrant,1.966152343749994,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,Excision,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Positive,Negative,0.0,2.0,H-SCORE,10-75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,62.5810546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,69,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.80,3 Point Scale,2+,7thStage IIIBT4bN1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",16,5,2011,TCGA-D8-A1XG-F29444F26CFC15-575E-4E12-B7A9-B4319F986FF9Scheduled Follow-up SubmissionNONOAlive448TUMOR FREENO2632012,NOTCGA-EW-A3E8-D399966D645F63-EEF8-43F6-AC29-34CBBEC01722196Hormone TherapyAnastrozoleYES822013,TCGA-EW-A3E8-R3999391E4B957-C918-4E13-B0E0-48ECCA77D430165196External60Gy30Primary Tumor FieldNOComplete Response822013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,331.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A15L,E2,A15L,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,3.0,Allred score 5+3 = 8,Allred score 5+3 = 8,Right,0.9,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast reexcision,Other,Mastectomy,Infiltrating Lobular Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Equivocal,0.298828125,0.0,Allred score = 8,Allred score = 8,30-39%,Dako,Venten,75.0869140625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,40,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,21,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",13,4,2011,TCGA-E2-A15L-F18885CA37A855-FA95-4FBE-A554-B8424DF1544FScheduled Follow-up SubmissionNOYESAlive626TUMOR FREENO15112011,1TCGA-E2-A15L-D1888750C9B52E-A733-4A39-89C6-A845EDDC1CC51mg/day1mg/day45Hormone TherapyArimidexADJUVANTPOYES15112011,TCGA-LL-A73Z-R51329D11B1721-EDD8-4F57-98D6-8B5F3BBE1EEF125151External42.72Gy16Primary Tumor FieldNORadiographic Progressive Disease15112013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A1HG,C8,A1HG,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,6.7255859375,H-SCORE 280,H-SCORE 280,Right,1.7705859374999886,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.013671875,0.0,Allred Score 7,Allred Score 8,10-19%,Hercep Test  TM Dako,Venten,114.1279296875,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,2.6,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.80,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,Negative<10%3 Point ScaleNegative<10%3 Point ScaleEquivocal<10%1+,24,5,2011,TCGA-C8-A1HG-F19096E5B2D364-8B39-452F-9930-E30DA170B55FScheduled Follow-up SubmissionNOYESAlive345TUMOR FREENO2122011,1TCGA-E2-A15L-D1888750C9B52E-A733-4A39-89C6-A845EDDC1CC51mg/day1mg/day45Hormone TherapyArimidexADJUVANTPOYES15112011,TCGA-E2-A15K-R18879597CFDF4-47EE-4CFD-8D2B-66BD1D75DE2B232273EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO115112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1172.0,WHITE,TCGA-AO-A0JI,AO,A0JI,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,10.0,H-SCORE 300,Allred score 0+0 = 0,Left Upper Outer QuadrantLeft,1.8944921874999905,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Margin resection,Modified radical mastectomy,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Apocrine,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,1.0,0.0,90 H,STRONG,<10%,CISH,3+ Positive,115.3271484375,Vysis AutoVysion System,CAP SCORING GUIDELINE 2010,NO,YES,66,"Other, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,42,3 Point Scale,2+,Stage IIAT1cN1M0,YES,YES,PositivePositiveNegativeNegative1.09,7,12,2010,TCGA-AO-A0JI-F586794F45AAD-C6E1-4501-A451-AE8266BA9D5C1172AliveTUMOR FREENOYES7122010TCGA-AO-A0JI-F19410EE8F19C6-3BDA-4398-96EF-7D72609886E1Scheduled Follow-up SubmissionNOYESAlive1528TUMOR FREENO12122011,1TCGA-AO-A0JI-D59292d6ad2f6-0769-4ee4-b690-7c424bd9fc6a4176mg600mg/m2498140ChemotherapyCyclophosphamideADJUVANTIVNO10120112TCGA-AO-A0JI-D5931927d22e8-916f-43bb-b085-eacbf3eda2ce1mg/day224Hormone TherapyArimidex (Anastrozole)ADJUVANTPOYES10120111TCGA-AO-A0JI-D5928cc046508-1134-4ceb-8184-57f1637e4e3e416mg60mg/m2498140ChemotherapyDoxorubicinADJUVANTIVNO10120111TCGA-AO-A0JI-D5930ddd8f77f-5e9f-443d-afba-17082d2bdb031220mg175mg/m24154196ChemotherapyPaclitaxelADJUVANTIVNO1012011,TCGA-AC-A62V-R601786A2AE9B0-D973-40FF-9BC8-C68CA90494082146External3250cGy13Distant siteNOPartial Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,137.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A73Z,LL,A73Z,No,YES,C50.9,8500/3,C50.9,2013.0,WITH TUMOR,NO,10.3291015625,allred score 5 + 3 = 8,CAP SCORING GUIDELINE 2010,LeftLeft Lower Inner Quadrant,1.1,No axillary staging,Sentinel lymph node and axillary lymph node biopsy,Lumpectomy,Margin resection,Other,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,1+,2+,Negative,Positive,Excisional Biopsy,Biopsy not specified,Negative,Positive,Equivocal,1.0126953125,4.61328125,moderately to strongly,250,90-99%,0,CAP SCORING GUIDELINE 2010,243.0,HER2 amplification - negative,PathVysion Her-2 DNA,YES,NO,2.2,"Other, specifyskin",10-19%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.5,3 Point Scale,1+,7thStage IVT1cNXM1,YES,YES,NO,15,11,2013,TCGA-LL-A73Z-F64983C93234C7-BF07-45D1-B6C1-80938475F7B5NOYESYESWITH TUMORDead227YES192Distant MetastasisBrainNONONO1692014,NOTCGA-LL-A73Z-D513247720FC0E-5AB6-4C6A-8EE4-97B0882078E71860ChemotherapyAdriamycinNOClinical Progressive Disease15112013NOTCGA-LL-A73Z-D51326C1E53020-8C36-4C1C-89EB-FFA09DCF92E61860ChemotherapyCytoxanNOClinical Progressive Disease15112013NOTCGA-LL-A73Z-D513273E79EC05-9045-43FC-94DB-E1CD163B0D8874109ChemotherapytaxolNOClinical Progressive Disease15112013NOTCGA-LL-A73Z-D51328D00B1B78-354F-4C0A-BA7A-27A54ECC394D123179Hormone TherapyfaslodexNOClinical Progressive Disease15112013,TCGA-LL-A73Z-R51329D11B1721-EDD8-4F57-98D6-8B5F3BBE1EEF125151External42.72Gy16Primary Tumor FieldNORadiographic Progressive Disease15112013
TCGAFPPP,Breast,No,MALE,Alive,0.0,2.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A62V,AC,A62V,No,YES,C50.9,8500/3,C50.9,2013.0,WITH TUMOR,YES,17.0,Allread score 5+3 = 8,CAP SCORING GUIDELINE 2010,Right Lower Outer Quadrant,3.590986328124968,Axillary lymph node dissection alone,SN+1 non sentinel node,Modified Radical Mastectomy,Margin resection,Modified radical mastectomy,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.8779296875,3.0,allred score = 4,205,90-99%,ACIS,Venten,163.1591796875,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,YES,NO,3.2,Bone,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,42,3 Point Scale,2+,7thStage IVT2N1aM1,YES,NO,NO,21,10,2013,TCGA-AC-A62V-F60177CB4E105E-D21E-4F43-A860-F45AEEAD0E9ANOYESYESWITH TUMORDead348NO3152014,NOTCGA-AC-A62V-D601791206FBA9-884A-4E22-8D01-5CFD61F171AD21266AncillaryDenosumabNOPartial Response3152014NOTCGA-AC-A62V-D60180356FD6D4-61DF-485A-AB87-3A4A43CFC9B7114245ChemotherapyPaclitaxelNOPartial Response3152014,TCGA-AC-A62V-R601786A2AE9B0-D973-40FF-9BC8-C68CA90494082146External3250cGy13Distant siteNOPartial Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1014.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A1LL,E2,A1LL,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,44.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Left Upper Outer Quadrant,2.234296874999987,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Right Breast reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Positive,Negative,Negative,0.7646484375,5.0,Allred score = 0,Allred score = 0,<10%,ACIS,Dako Hercept test,198.6962890625,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,2.5,BoneLiver,<10%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.73,3 Point Scale,2+,6thStage IIIAT3N2aMX,YES,NO,PositivePositiveNegativeNegative1.09,3,6,2011,TCGA-E2-A1LL-F20616A4E4C69D-7D3F-41E4-AF0A-681E4603326EScheduled Follow-up SubmissionYESYESAlive1309WITH TUMORYES1303Distant MetastasisLiverNONONO1712012,1TCGA-E2-A1LL-D206179EECED51-430D-48E6-9828-E3E8CF095C2A158mg158mg14949ChemotherapyDocetaxelADJUVANTIVNO17120121TCGA-E2-A1LL-D206188FE9F6AA-8F33-41C4-8D94-56C3DA00BD0B1260mg1260mg14949ChemotherapyCyclophosphamideADJUVANTIVNO1712012,TCGA-E2-A1LL-R20619544DB6E4-9E02-45A2-ACCB-0254D6BB05D9105147EXTERNAL BEAM5040cGy28Regional siteADJUVANTNO11712012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,187.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A1PC,EW,A1PC,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,2.0,Allred 0 = 0+0,Allred score 5+3 = 8,Left,1.5970996093749932,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,240 H,Allred Score 6,<10%,0,CAP SCORING GUIDELINE 2010,70.6845703125,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,1.57,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,68,3 Point Scale,3+,7thStage IIBT3N0 (i-)MX,YES,NO,YES994Distant MetastasisBoneNOYESYES,28,9,2011,TCGA-EW-A1PC-F29681A626E120-7532-413F-8810-E8EA00F76B76Scheduled Follow-up SubmissionNOYESAlive187TUMOR FREENO2632012,TAMTCGA-EW-A1PC-D296824784F718-8BC9-4960-AF35-7D27BE174EA220mg/day98Hormone TherapyTamoxifenADJUVANTPOYES2632012,TCGA-AQ-A04H-R4982d113adb3-5e01-4acc-b1c5-f15e6762bb51138166EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO116122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,439.0,WHITE,TCGA-AQ-A04H,AQ,A04H,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,15.0,Allred score 5+3=8,dextran coated charcoal,Left Lower Inner Quadrant,3.2,Axillary lymph node dissection alone,SN+1 non sentinel node,Modified Radical Mastectomy,Margin resection,Modified radical mastectomy,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Indeterminate,0.322265625,4.0,>10%,>10%,10-19%,0,dextran coated charcoal,30.0,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,40,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1,3 Point Scale,1+,6thStage IIIAT2N2aMX,YES,NO,YES994Distant MetastasisBoneNOYESYES,15,12,2010,TCGA-AQ-A04H-F4906E074679E-8C42-46DC-A7E2-16B90D502AEE439AliveTUMOR FREEYESYES15122010TCGA-AQ-A04H-F35322E5147793-FAA6-44C5-BE7E-D11656CD8119NOYESYESTUMOR FREEAlive754NO2492012,1TCGA-AQ-A04H-D4977178f263e-df57-4fc7-befd-4ea1a346680d2.5mg175Hormone TherapyFemaraADJUVANTPOYES161220101TCGA-AQ-A04H-D4976984f482a-0e8b-423e-a98f-af30f5c8a883629133ChemotherapyTaxotereADJUVANTIVNO16122010NOTCGA-AQ-A04H-D4087257AFEA30-9D59-45E4-A309-6717F0FBB64A29133ChemotherapyCarboplatinNOComplete Response432013NOTCGA-AQ-A04H-D40873A6C7F4F8-93C6-435A-A59A-88ED37540B8829133ChemotherapyHerceptinNOComplete Response432013,TCGA-AQ-A04H-R4982d113adb3-5e01-4acc-b1c5-f15e6762bb51138166EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO116122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1374.0,WHITE,TCGA-AR-A251,AR,A251,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,7.0,dextran coated charcoal,Image Analysis,Left Upper Outer Quadrant,2.291533203124988,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Mastectomy NOS,Wide local excision,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,4+,2+,Negative,Positive,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,0.517578125,4.0,10-75%,0,10-19%,Hercep Test  TM Dako,Dako Hercept test,82.8232421875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.5,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5.8,4 Point Scale,1+,6thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,30,8,2011,TCGA-AR-A251-F31818AA1DA6BC-6231-42AC-B67A-A97549A902BDScheduled Follow-up SubmissionYESYESAlive1374NO952012TCGA-AR-A251-F49509796BE9A5-BB26-4986-8913-3657208A0538YESYESTUMOR FREEAlive2387NO2102013TCGA-AR-A251-F71716093C1D48-92BC-4598-A3EE-B841A4259944NOYESYESTUMOR FREEAlive3030NO3032015,NOTCGA-AR-A251-D31823B8F1A566-55CF-4FF1-A3EE-9C35DD719C784487ChemotherapyDoxorubicinNO2252012NOTCGA-AR-A251-D31825999250A8-21B7-48BC-8677-4FC3B42AA6174487ChemotherapyCytoxanNO2252012NOTCGA-AR-A251-D318272B479B1F-F3B2-41EF-B929-49E70C892BB5100141ChemotherapyPaclitaxelNO2252012NOTCGA-AR-A251-D3182896941235-258D-4BEE-85A3-8CFDAAAA042F1751969Hormone TherapyTamoxifenNO2252012,TCGA-AR-A251-R318218995BFD6-45E6-4008-9BEE-8F0AA9E64948160195EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1952012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,867.0,WHITE,TCGA-BH-A0AZ,BH,A0AZ,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,13.0,H-SCORE 136,H-Score 290,Right,1.8759277343749976,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Margin resection,Other,total mastectomy with sentinel lymph node biopsy with tissue reconstruction,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.7392578125,1.0,Intensity=Weak,270 H,10-19%,ACIS,CAP SCORING GUIDELINE 2010,106.3662109375,HER2 amplification - negative,Positive >2.2,NO,YES,64,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.3,3 Point Scale,2+,6thStage IIIAT3N1acM0 (i+),NO,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,7,2011,TCGA-BH-A0AZ-F5860240B2DDD4-6B7C-471E-AD6F-4FCF39C6E504NONOYESTUMOR FREEAlive1919NO1542014,YESTCGA-BH-A0AZ-D58604A79EE713-028A-4292-8C92-BDC9735D026F126209ChemotherapyDoxorubicinNOComplete Response1542014YESTCGA-BH-A0AZ-D58605862279A3-EF42-4533-8CE4-301C7CD7D3D8126209ChemotherapyCytoxanNOComplete Response1542014YESTCGA-BH-A0AZ-D5860699401709-0B70-4391-88F9-E458D2839E9E209293ChemotherapyTaxolNOComplete Response1542014YESTCGA-BH-A0AZ-D58608BA304867-79FD-4DED-96AF-D5D57DA4D09C126482ImmunotherapyAvastinNOComplete Response1542014,"TCGA-EW-A1IZ-R21549FA7E93F3-A23C-4264-83BF-68B207E736B2197261EXTERNAL BEAM6,100cGy8Local RecurrenceADJUVANTNO11522012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,26.0,WHITE,TCGA-E9-A245,E9,A245,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,H-SCORE 0,H-SCORE 0,Left Upper Outer Quadrant,2.984589843750009,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.00390625,3.0,60,250,90-99%,Dako,Venten,152.3125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.38,"Other, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.83,3 Point Scale,1+,7thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,16,3,2011,TCGA-E9-A245-F3116974AC779B-F5F6-466E-8318-6C6459C1609DScheduled Follow-up SubmissionNOYESDeadTUMOR FREENO2442012,1TCGA-E9-A245-D31172015CA647-3EBD-4950-A3AA-A0672ED5011F20mg/day20Hormone TherapyTamoxifenADJUVANTPONO2442012,TCGA-LL-A73Z-R51329D11B1721-EDD8-4F57-98D6-8B5F3BBE1EEF125151External42.72Gy16Primary Tumor FieldNORadiographic Progressive Disease15112013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,827.0,WHITE,TCGA-BH-A0BQ,BH,A0BQ,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,2.0,H-SCORE 280,H-Score 15,Left,2.0803515625000006,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Reexcision,Other,Total mastectomy with retromammary lymph node excision,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,0.283203125,0.0,Allred Score 3,STRONG,10-19%,Hercep Test  TM Dako,Dako Hecept Test,70.205078125,HER2 amplification - negative,Ratio >=2.0,NO,YES,40,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.58,3 Point Scale,1+,6thStage IT1cN0M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,10,8,2011,"TCGA-BH-A0BQ-F5869525CF786D-560F-4C04-A050-A7C323A6D649NONONOTUMOR FREEAlive2255YES1709Locoregional RecurrenceOther, specifyDermis and epidermisYES17502242014",4x chemotherapyTCGA-D8-A140-D13809CD6D1C59-F2A8-4AC6-9E8B-74835E6187BD60 doxorubicin+ 600 CPHmg/m260 doxorubicin+ 600 CPH427181Chemotherapydoxorubicin+cyclophosphamidADJUVANTIVNO2062011,TCGA-AO-A03L-R58595fb3a572-ca52-4caf-8a15-9bf2aa8e7bba167208EXTERNAL BEAM10080cGy28Regional siteADJUVANTNO17122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,31.0,WHITE,TCGA-A8-A09N,A8,A09N,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,10.8857421875,Allred score 5+3=8,Allred (Biocare),Right Lower Outer Quadrant,1.852675781249987,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Margin resection,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,Lumpectomy,Positive,Positive,Positive,0.31640625,3.818359375,Allred Score,H-Score,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,101.966796875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,4,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,59,3 Point Scale,3+,6thStage IIICT2N3aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-E9-A245-F3116974AC779B-F5F6-466E-8318-6C6459C1609DScheduled Follow-up SubmissionNOYESDeadTUMOR FREENO2442012,1TCGA-E9-A1N4-D29812FC7FE4AB-6ABA-44ED-847B-11390559C9F6480mg80mg/day6118194ChemotherapyDoxorubicinADJUVANTIVNO29320121TCGA-E9-A1N4-D298144237DC30-5933-4DD7-95C8-33FFC7D78A054800mg800mg/day6118194Chemotherapy5-FluorouracilADJUVANTIVNO29320121TCGA-E9-A1N4-D2981303BC90EC-3B30-4864-B67F-CD5A00D65BFC4800mg800mg/day6118194ChemotherapyCyclophosphaneADJUVANTIVNO2932012NOTCGA-E9-A1N4-D3976880B1429D-E3E0-4E41-B47E-344887D4864D230Hormone TherapyTamoxifenYES122013,TCGA-AR-A1AL-R221579613B599-7554-4DD1-BFA1-DD813EC257DB153192EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5.0,WHITE,TCGA-E9-A1N4,E9,A1N4,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,7.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,Left Upper Inner Quadrant,1.8328710937499948,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Other,Right Breast reexcision,Other,Wide local excision,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Positive,0.0,4.0,60,Intensity=Strong,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,106.9453125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,50,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.62,3 Point Scale,3+,7thStage IIIAT2N2M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",26,5,2011,TCGA-E9-A1N4-F29811F2EEEE1E-A44E-4B8B-B9BC-AED21CA10D22Scheduled Follow-up SubmissionYESYESAlive341TUMOR FREENO2932012TCGA-E9-A1N4-F397677A3C4560-6D33-44A1-BC57-E835DFEC288CNOYESYESTUMOR FREEAlive1000NO122013,1TCGA-E9-A1N4-D29812FC7FE4AB-6ABA-44ED-847B-11390559C9F6480mg80mg/day6118194ChemotherapyDoxorubicinADJUVANTIVNO29320121TCGA-E9-A1N4-D298144237DC30-5933-4DD7-95C8-33FFC7D78A054800mg800mg/day6118194Chemotherapy5-FluorouracilADJUVANTIVNO29320121TCGA-E9-A1N4-D2981303BC90EC-3B30-4864-B67F-CD5A00D65BFC4800mg800mg/day6118194ChemotherapyCyclophosphaneADJUVANTIVNO2932012NOTCGA-E9-A1N4-D3976880B1429D-E3E0-4E41-B47E-344887D4864D230Hormone TherapyTamoxifenYES122013,TCGA-E9-A1N4-R29815B5ADCED0-177B-4804-9589-C6F334CE467D6996EXTERNAL BEAM400cGy20Regional siteADJUVANTNO2932012
TCGAFPPP,Breast,No,FEMALE,Dead,4456.0,3332.75,WHITE,TCGA-B6-A0IG,B6,A0IG,No,YES,C50.9,8500/3,C50.9,1994.0,WITH TUMOR,YES,16.0,Image Analysis,Image Analysis,Left,1.6521582031250002,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Ductal partially papillary,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Positive,Equivocal,0.494140625,4.0,Allred score = 5,moderate,10-19%,ACIS,Venten,195.435546875,HER2 amplification - negative,Positive >2.2,NO,YES,2.13,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,1.73,4 Point Scale,1+,4thStage IIBT2N1bM0,YES,NO,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,2,11,2010,TCGA-B6-A0IG-F126168FD670AC-8E65-4365-8F5F-B23F906ED929Scheduled Follow-up SubmissionYESYESDead4456262011,NOTCGA-E9-A5FK-D56477310AAC92-87DD-46B7-8666-4F20C9B2A40021200ChemotherapyCyclophosphamideNOComplete Response1022014NOTCGA-E9-A5FK-D56478DE81480C-4511-40D7-8778-F558CCA5717A21200ChemotherapyMethotrexateNOComplete Response1022014NOTCGA-E9-A5FK-D56479255555A4-D618-436B-9BDC-9D9FDC22430D21200Chemotherapy5-FluorouracilNOComplete Response1022014,TCGA-A8-A097-R38168ECEF383E-6DE5-4F26-A795-39412649FDC7153184ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,905.0,WHITE,TCGA-AR-A0TV,AR,A0TV,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,3.0,H-SCORE 260,IHC,Left Upper Outer Quadrant,3.8273730468749982,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Other,Excisional biopsy,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,0.052734375,0.0,10-75%,H-Score,90-99%,Dako,Venten,153.2470703125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.38,"Other, specifyskin",90-99%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.62,3 Point Scale,0,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,10,3,2011,TCGA-AR-A0TV-F18574B795EB26-8475-47E2-9011-44D1A2624880Scheduled Follow-up SubmissionNONOAlive1288TUMOR FREENO12122011TCGA-AR-A0TV-F717347EDE43D9-4F69-47CC-86A2-583C68ECC646NONONOTUMOR FREEAlive2288NO3032015,NOTCGA-AR-A2LQ-D37597D4763C71-C17E-46DB-A137-2B5B9908DEAE89152ChemotherapyDocetaxelNO6122012NOTCGA-AR-A2LQ-D3759828848860-0F93-4CE5-A7CA-7C85A90EBBC789152ChemotherapyCytoxanNO6122012NOTCGA-AR-A2LQ-D37599409752F6-5669-4168-8F31-54550EB34917176Hormone TherapyAnastrozoleYES6122012,TCGA-BH-A0B0-R5920760C2C230-CDAF-4194-B9B2-F90127A231E7194236External6000cGy30Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1542.0,WHITE,TCGA-AC-A2FO,AC,A2FO,No,YES,C50.9,8520/3,C50.9,2005.0,TUMOR FREE,YES,10.0,H-SCORE 300,IHC,Left Upper Outer Quadrant,2.669277343749988,Other (specify),Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Other,right segmental mastectomy,Infiltrating Lobular Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Indeterminate,Positive,Negative,0.517578125,2.0,Allred score 0,Strong,10-19%,ACIS,Hercep Test  TM Dako,64.6708984375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.1,"Other, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,42,3 Point Scale,2+,6thStage IIBT2N1MX,YES,NO,YES994Distant MetastasisBoneNOYESYES,21,9,2011,TCGA-AC-A2FO-F43223EF71A0D0-16AB-45A4-A42D-625AFEF971B8NONOYESTUMOR FREEAlive2255NO1552013,"NOTCGA-AC-A2FO-D43224E2156068-0D07-42BF-877C-C70B71322A3E105ChemotherapyChemo, NOSNOComplete Response1552013NOTCGA-AC-A2FO-D4322774E898D7-9552-4550-9764-4F924FC55872225Hormone TherapyHormone, NOSNOComplete Response1552013",TCGA-A8-A097-R38168ECEF383E-6DE5-4F26-A795-39412649FDC7153184ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,26.0,WHITE,TCGA-AR-A24P,AR,A24P,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,3.0,dextran coated charcoal,Image Analysis,Left Upper Outer Quadrant,2.1347949218749958,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Mastectomy NOS,Wide local excision,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,0.0078125,0.0,Allred score = 0,Allred score = 0,<10%,Hercep Test  TM Dako,Dako Hecept Test,73.0341796875,HER2 amplification - negative,Ratio >=2.0,NO,YES,40,"Other, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5.8,4 Point Scale,1+,6thStage IT1N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,16,8,2011,TCGA-AR-A24P-F31403FD010A17-3FAC-4DBB-BD62-A3A5C0361049Scheduled Follow-up SubmissionAlive84NO252012,TACTCGA-EW-A1IZ-D21547748A06A9-BBDF-473E-A546-C7831FAD5211834mg139mg670176ChemotherapyTaxotereADJUVANTIVNO1522012TCGA-EW-A1IZ-D2157331800857-4883-46B8-B764-56614F4F4DD82.5mg/day199Hormone TherapyFemaraADJUVANTPOYES1522012TACTCGA-EW-A1IZ-D29260F8E114ED-A2E9-45CF-8C5D-262BC6C1502D414mg69mg670176ChemotherapyAdriamycinADJUVANTIVNO1332012TACTCGA-EW-A1IZ-D292618F111407-47A7-4A8E-AAFB-EB76FC42375C4164mg694mg670176ChemotherapyCyclophosphamideADJUVANTIVNO1332012,TCGA-A8-A097-R38168ECEF383E-6DE5-4F26-A795-39412649FDC7153184ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,260.0,WHITE,TCGA-EW-A1IZ,EW,A1IZ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,H-Score 300,CAP scoring guideline 2010,Left Lower Outer Quadrant,1.8096289062499893,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Partial Mastectomy,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,"Other method, specify:",stereotactic biopsy,Negative,Positive,Negative,0.0791015625,5.0,230,Allred Score 6,<10%,CISH,Venten,33.33203125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,33,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.9,3 Point Scale,3+,7thStage IIIAT2N2aMX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",11,5,2011,TCGA-EW-A1IZ-F2154378FCD753-17E1-4043-8A55-B3DB082E3A80Scheduled Follow-up SubmissionYESYESAlive554TUMOR FREENO622012,TACTCGA-EW-A1IZ-D21547748A06A9-BBDF-473E-A546-C7831FAD5211834mg139mg670176ChemotherapyTaxotereADJUVANTIVNO1522012TCGA-EW-A1IZ-D2157331800857-4883-46B8-B764-56614F4F4DD82.5mg/day199Hormone TherapyFemaraADJUVANTPOYES1522012TACTCGA-EW-A1IZ-D29260F8E114ED-A2E9-45CF-8C5D-262BC6C1502D414mg69mg670176ChemotherapyAdriamycinADJUVANTIVNO1332012TACTCGA-EW-A1IZ-D292618F111407-47A7-4A8E-AAFB-EB76FC42375C4164mg694mg670176ChemotherapyCyclophosphamideADJUVANTIVNO1332012,"TCGA-EW-A1IZ-R21549FA7E93F3-A23C-4264-83BF-68B207E736B2197261EXTERNAL BEAM6,100cGy8Local RecurrenceADJUVANTNO11522012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,268.0,WHITE,TCGA-BH-A18F,BH,A18F,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,allred score 0 + 0 = 0,allred score 5 +3 = 8,Right Lower Outer Quadrant,2.145048828125002,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,needle localized segmental mastectomy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.2216796875,0.0,MODERATE,allred score = 0,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,68.5625,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,54,"Other, specifyskin",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,441,3 Point Scale,3+,7thStage IIAT2N0M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,1,6,2011,TCGA-BH-A18F-F59193092E4639-8456-481D-8DF3-0C60E99CDCB5NOYESYESTUMOR FREEAlive1001NO252014,NOTCGA-BH-A18F-D591969FCC797A-A7A9-48C4-8908-C2C04931C24A101189ChemotherapyTaxotereNOComplete Response252014NOTCGA-BH-A18F-D5919760625A51-8E18-4F71-B2D7-27A2C7FB9C2C101189ChemotherapyCytoxanNOComplete Response252014,TCGA-BH-A18F-R59194489DC839-6E29-4F08-9016-7E127CE41069189223External5000cGy25Primary Tumor FieldNOComplete Response252014TCGA-BH-A18F-R59195808DBF60-68C3-472B-B148-479088B903AE224233External1600cGy8Regional siteNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,64.0,WHITE,TCGA-OK-A5Q2,OK,A5Q2,No,YES,C50.9,8520/3,C50.9,2012.0,WITH TUMOR,YES,13.0,H-SCORE 300,CAP SCORING GUIDELINE 2010,Right,3.0952441406249798,Axillary lymph node dissection alone,SN+1 non sentinel node,Modified Radical Mastectomy,Margin resection,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Lobular Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,SKIN BIOPSY,Negative,Positive,Negative,2.0,2.0,200,moderately to strongly,30-39%,CISH,Venten,393.3583984375,HER2 amplification - negative,Positive >2.2,YES,NO,2.38,"Other, specifyskin",90-99%,20-29%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.789433593749996,131,3 Point Scale,3+,7thStage IIT2N1aMX,YES,YES,NO,22,1,2013,TCGA-BH-A18F-F59193092E4639-8456-481D-8DF3-0C60E99CDCB5NOYESYESTUMOR FREEAlive1001NO252014,2TCGA-A2-A0T3-D9215b41bdca7-b0bf-4308-b906-1dcc9bf77b23618mg103mg670177ChemotherapyAdriamycinADJUVANTIVNO21220114TCGA-A2-A0T3-D9218f9514221-8f9b-403b-99d4-e4843d0b2eb6Hormone TherapyTamoxifenADJUVANTPOYES21220113TCGA-A2-A0T3-D92162a946428-c9e3-4910-8589-57d6230d7cd46180mg1030mg670177ChemotherapyCytoxanADJUVANTIVNO21220111TCGA-A2-A0T3-D92144c04520d-d4ae-4202-b00b-a2782b640207930mg155mg670177ChemotherapyTaxotereADJUVANTIVNO2122011,TCGA-A8-A097-R38168ECEF383E-6DE5-4F26-A795-39412649FDC7153184ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,65.0,WHITE,TCGA-A7-A26H,A7,A26H,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,5.0,Allred (Biocare),dextran coated charcoal,Left,2.6,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Other,Right Breast reexcision,Modified radical mastectomy,Bilateral Mastectomy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Positive,Positive,Equivocal,1.0,0.0,Allred score 7 per outside facility report,Intensity=Strong,10-19%,CISH,Dako Hercept test,20.0,HER2 amplification - negative,PathVysion Her-2 DNA,YES,NO,2.2,BoneLiver,90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5.8,3 Point Scale,2+,7thStage IIAT1N1aM0,YES,YES,PositivePositiveNegativeNegative1.09,4,8,2011,TCGA-A7-A26H-F29621FD079079-3AC7-4D84-A3E4-04CDD759A2FFScheduled Follow-up SubmissionNOYESAlive400WITH TUMORYES291Distant MetastasisLiverNONOYESPositive10-19%NegativeNegative2632012TCGA-A7-A26H-F398905F40A4B3-5B64-42A8-BC00-6DCDCBE7883DNONOYESWITH TUMORAlive724YES311522013,1TCGA-A7-A26H-D296225ABD5AE2-14DC-45D0-8CD9-C1CE4EE9A336253mg1mg/day44296Hormone TherapyAnastrozoleADJUVANTPONO26320122TCGA-A7-A26H-D29623B0A12ECD-CF75-4AE7-BE0D-05D6941192221535mg139-141mg8311486ChemotherapyTaxolRECURRENCEIVNO2632012,TCGA-A8-A0A2-R381921E9265EA-89C2-4B29-A848-0DA6F4AD95B93192External60GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0FZ,AN,A0FZ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,allred score 5+3=8,Allred score 2+2 = 4,Left Upper Outer Quadrant,2.8370312499999955,No axillary staging,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,1+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Positive,0.0,1.0,0,120,20-29%,0,Dako Hercept test,102.3505859375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.4,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5.8,3 Point Scale,1+,Stage IIIAT2N2M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,29,12,2010,TCGA-AN-A0FZ-F689695E7AC543-2D63-4F9A-95A9-9F1AA3C5B8A0YESNONOTUMOR FREEAlive1024122014,NOTCGA-A7-A5ZX-D513329C29891D-CFA8-48D4-A646-C3AD561F20DA76118ChemotherapyDoxorubicinNOComplete Response15112013NOTCGA-A7-A5ZX-D51333F5C792BC-E5C5-4C56-9434-A746E1B1703876118ChemotherapyCyclophosphamideNOComplete Response15112013NOTCGA-A7-A5ZX-D5133446461AEB-BAB0-45F1-A893-FCD00A28BBEA132174ChemotherapyPaclitaxelNOComplete Response15112013NOTCGA-A7-A5ZX-D52815056878FC-D30B-4BF4-8BD2-972B61510B2D268Hormone TherapyTamoxifenYESComplete Response6122013,TCGA-AR-A1AL-R221579613B599-7554-4DD1-BFA1-DD813EC257DB153192EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1753.0,WHITE,TCGA-GM-A4E0,GM,A4E0,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,22.0,allred score 5+3=8,CAP SCORING GUIDELINE 2010,LeftLeft Upper Inner QuadrantLeft Upper Outer QuadrantLeft Lower Inner QuadrantLeft Lower Outer Quadrant,2.802529296874993,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,1.0,10.0,230,Intensity=Weak,10-19%,0,Dako Hecept Test,61.7177734375,HER2 amplification - negative,Positive >2.2,NO,YES,2.38,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.57,3 Point Scale,2+,6thStage IIICT3N3aM0,YES,YES,NO,26,11,2012,TCGA-GM-A4E0-F4703050501D80-A3CE-4BD5-AA63-FBFB3EB907A3NOYESYESTUMOR FREEAlive2191NO2182013,YESTCGA-GM-A4E0-D3711376CCB5FF-A056-43DA-8555-AEDB5683ADAE121184ChemotherapyXelodaNOComplete Response26112012YESTCGA-GM-A4E0-D371154C24BBBE-85D7-4F91-867A-F3565F4E8AFB121184ChemotherapyTaxotereNOComplete Response26112012YESTCGA-GM-A4E0-D37116503948AA-4087-417D-8768-32F533FEBEBE226289Chemotherapy5-FUNOComplete Response26112012YESTCGA-GM-A4E0-D37117D672E4DB-472F-4FCA-A031-1EAA79128C90226289ChemotherapyEpirubicinNOComplete Response26112012YESTCGA-GM-A4E0-D3711884DD5400-4F97-4F5B-BD39-228348DC7862226289ChemotherapyCytoxanNOComplete Response26112012NOTCGA-GM-A4E0-D37119E59D3AC8-259B-48CF-A95F-9328FB248A09320Hormone TherapyArimidexYES26112012,TCGA-GM-A4E0-R3711172264053-A738-4D71-9A92-C677B67CB408315357External60Gy30Primary Tumor FieldNOComplete Response26112012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,168.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A4SD,A7,A4SD,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,6.0,Allred score = 8,Allred score 5+3=8,Right,1.3,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Equivocal,0.0,0.0,allred score = 4,allred score = 7,90-99%,ACIS,CAP scoring guideline 2010,20.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe Kit,YES,NO,5,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,6.4,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,NO,19,2,2013,TCGA-A7-A4SD-F52732DDAD5580-4821-46F0-9F96-9C8F4615A7DFNONOYESTUMOR FREEAlive441NO5122013,NOTCGA-A7-A4SD-D40418AC6661B8-5744-4B0F-99D8-1C6C82FF86D464134ChemotherapyTaxotereNOComplete Response1922013NOTCGA-A7-A4SD-D40420642ABB42-0832-4A3A-9FB0-AE825D90EEC664134ChemotherapyCytoxanNOComplete Response1922013,TCGA-A2-A0T1-R371306674eb1-647c-45ef-8d3f-63cb7fd97891189252EXTERNAL BEAM11840cGy30Primary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,397.0,WHITE,TCGA-A2-A0T7,A2,A0T7,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,Allred score 5+3= 8,H-Score 15,Right Upper Inner Quadrant,1.6456054687499948,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Skin excision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,1+,Negative,Positive,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,1.0,0.0,Allred Score 3,Moderate,<10%,ACIS,CAP scoring guideline 2010,57.6904296875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.0,"LungBoneLiverOther, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,6.4,3 Point Scale,2+,Stage IIAT2N0 (i+)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,17,11,2010,TCGA-A2-A0T7-F13953ADD4998E-EC7F-4B93-8D24-3920CCC4FE34Scheduled Follow-up SubmissionNOYESAlive631TUMOR FREENO1272011,1TCGA-A2-A0T7-D399955597860-77c6-472c-8515-75406e8ee3b4mg110mg3117145ChemotherapyAdriamycinADJUVANTIVNO171120103TCGA-A2-A0T7-D40013a7507c1-490c-40f0-b3fb-dc14638ea9b7mg145mg12159243ChemotherapyTaxolADJUVANTIVNO171120104TCGA-A2-A0T7-D4002c5d05f28-9eff-492b-9d3d-086b3d55ffddmg20mg365Hormone TherapyTamoxifenADJUVANTPOYES171120102TCGA-A2-A0T7-D4000045f1736-1059-4fa3-bfeb-d36fc7a6c693mg1100mg3117145ChemotherapyCytoxanADJUVANTIVNO17112010,TCGA-A2-A0T1-R371306674eb1-647c-45ef-8d3f-63cb7fd97891189252EXTERNAL BEAM11840cGy30Primary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1148.0,WHITE,TCGA-BH-A0B1,BH,A0B1,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,15.0,allred score 0 + 0 = 0,H-SCORE 120,Right Upper Outer QuadrantRight,1.8211523437500037,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Excisional biopsy,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,1.0,Allred score = 8,Strong,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,58.5302734375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,64,"LungBoneLiverOther, specifyskin",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,42,3 Point Scale,3+,Stage IIBT2N1aM0,NO,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",3,11,2010,TCGA-BH-A0B1-F15429555CC286-5677-4A66-8FD4-E7B131D2E99BScheduled Follow-up SubmissionYESYESAlive1148TUMOR FREENO3112010,1TCGA-BH-A0B1-D154301B65710D-8E59-4084-9524-988DEC29A8B3453232ChemotherapyAdriamycinADJUVANTIVNO31120101TCGA-BH-A0B1-D1543203678C40-36FA-410E-8D6E-C971338392FB4251311ChemotherapyPaclitaxelADJUVANTIVNO31120101TCGA-BH-A0B1-D154317DBDAF3F-FD88-4F6B-8AD8-B6E6830A8D92453232ChemotherapyCytoxanADJUVANTIVNO31120101TCGA-BH-A0B1-D1543379FCFCBC-5F07-4265-95FB-659E6537BF461mg/day269Hormone TherapyArimidexADJUVANTPOYES3112010,TCGA-BH-A0B1-R154346CBDF1E7-E2BB-4EEC-9C61-547430A54E0A287343EXTERNAL BEAM6040cGy28Primary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,588.0,WHITE,TCGA-E2-A152,E2,A152,No,YES,C50.9,8500/3,C50.9,2009.0,WITH TUMOR,YES,3.0,dextran coated charcoal,IHC,Right Upper Inner Quadrant,1.1664257812499947,Sentinel node biopsy alone,Pateys surgery,Lumpectomy,Right Breast reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Positive,0.3408203125,0.0,Allred score = 4,H-Score,90-99%,Dako,Venten,74.138671875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,3.1,"Other, specifyskin",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,21,3 Point Scale,2+,6thStage IT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,6,4,2011,"TCGA-E2-A152-F19122E6A03A68-6E7C-49D0-8D66-D9C338FBC42AScheduled Follow-up SubmissionNOYESAlive825WITH TUMORYES83Distant MetastasisBoneNONOYES17112011TCGA-E2-A152-F191238E3CDBC2-055A-4D81-A95C-70137ABE5F3DScheduled Follow-up SubmissionNOYESAlive825WITH TUMORYES54Distant MetastasisLiverNONOYES17112011TCGA-E2-A152-F71067F7360C7C-03AE-4B54-B8FB-ED6923473E88NONOYESWITH TUMORAlive1994NO1832015TCGA-E2-A152-F72471F8357F98-0281-4FE8-9B0B-288221E20B2DNONOYESTUMOR FREEAlive2128YES966Locoregional RecurrenceOther, specifyBreastYES1044NONONegativeNegativePositive3+2362015",1TCGA-E2-A152-D19134BF017551-9DD2-4283-A0AD-FA9F13FC697212678mg460mg42ChemotherapyTrastuzumabADJUVANTIVYES171120111TCGA-E2-A152-D19126CE4C026E-0255-4BF9-93C9-FBA8B76E0AA6942mg942mg14242ChemotherapyCyclophosphamideADJUVANTIVNO171120111TCGA-E2-A152-D19125EA9D6B7D-D495-46D4-BF2D-BC35E0F65BFB118mg118mg14242ChemotherapyDocetaxelADJUVANTIVNO171120113TCGA-E2-A152-D1913374FB0D62-6C47-4269-B25C-6A6340F18D061mg/day1mg/day231Hormone TherapyArimidexADJUVANTPOYES171120112TCGA-E2-A152-D191274DDAC9D3-0FF6-47D1-8863-6BA83B231D432641mg156mg663217ChemotherapyPaclitaxel (Protein-Bound)ADJUVANTIVNO17112011,TCGA-AR-A1AL-R221579613B599-7554-4DD1-BFA1-DD813EC257DB153192EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,252.0,WHITE,TCGA-EW-A1J3,EW,A1J3,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,3.0,allred score 0 + 0 = 0,image cytometry,Left Lower Outer Quadrant,1.816249999999988,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Margin resection,Other,TOTAL MASTECTOMY,Infiltrating Lobular Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Positive,0.0,0.0,170,Allred Score 6,90-99%,CISH,Hercep Test  TM Dako,34.0390625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4.43,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,59,3 Point Scale,3+,7thStage IAT1cN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",18,5,2011,TCGA-EW-A1J3-F2135154FFFA80-83D5-486F-9A9C-5D2F9B13221FScheduled Follow-up SubmissionNOYESAlive504TUMOR FREENO622012,TCHTCGA-EW-A1J3-D21352FB07AE31-7F2E-4B1D-887E-770458A579BB6AUC6189294ChemotherapyCarboplatinADJUVANTIVNO1022012TCGA-EW-A1J3-D216171A6110CD-1997-41AA-8625-90D2731C06FF1mg/day336Hormone TherapyArimidexADJUVANTPOYES1622012TCHTCGA-EW-A1J3-D292685C005F17-6282-4637-A5C3-3E033262CDBD100mg6189294ChemotherapyDocetaxelADJUVANTIVNO1332012TCHTCGA-EW-A1J3-D29269683A449C-7376-4BF2-BF3D-29B8A6B2B6A76mg/kg6189294ChemotherapyTrastuzumabADJUVANTIVNO1332012,TCGA-BH-A0B1-R154346CBDF1E7-E2BB-4EEC-9C61-547430A54E0A287343EXTERNAL BEAM6040cGy28Primary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,365.0,WHITE,TCGA-A8-A097,A8,A097,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,7.826171875,image cytometry,H-SCORE 0,Left,2.3398925781249886,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.33203125,1.05859375,Allred score 8,230,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,118.0048828125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,33,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.66,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A097-F40553E01ADA75-EA29-473E-8F48-7E4B21F2D04CNOYESYESTUMOR FREEAlive365NO2322013,NOTCGA-A8-A097-D3780898353B03-FA94-480C-BB09-9F440783BCA761153ChemotherapyDocetaxeln/aNOComplete Response6122012NOTCGA-A8-A097-D37809E6EE618F-B8F8-4389-93CE-F97B35570AC161153ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A097-D37810ED10C356-D8E5-44B6-A777-8AF1E49CDD4931Hormone TherapyTamoxifenn/aYES6122012,TCGA-A8-A097-R38168ECEF383E-6DE5-4F26-A795-39412649FDC7153184ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Dead,2520.0,895.111328125,WHITE,TCGA-BH-A1ET,BH,A1ET,No,YES,C50.9,8500/3,C50.9,1999.0,TUMOR FREE,YES,19.0,H-Score 300,allred score 5 +3 = 8,Left,2.345078124999989,Sentinel node biopsy alone,Pateys surgery,Other,Right Breast reexcision,Other,Left segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.9990234375,1.0,Allred Score 3,Intensity=Strong,10-19%,ACIS,Dako Hercept test,65.322265625,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,1.45,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,47,3 Point Scale,2+,5thStage IT1N0M0,NO,NO,NONO,7,9,2011,TCGA-E9-A22G-F29939EB1E348F-175B-4412-8994-A50BF74DCD2AScheduled Follow-up SubmissionNOYESAlive715TUMOR FREENO3042014TCGA-E9-A22G-F62594B265DE44-B99C-489D-BD86-D6AE6272402ENONOYESTUMOR FREEAlive1239NO2172014,NOTCGA-E9-A5FK-D56477310AAC92-87DD-46B7-8666-4F20C9B2A40021200ChemotherapyCyclophosphamideNOComplete Response1022014NOTCGA-E9-A5FK-D56478DE81480C-4511-40D7-8778-F558CCA5717A21200ChemotherapyMethotrexateNOComplete Response1022014NOTCGA-E9-A5FK-D56479255555A4-D618-436B-9BDC-9D9FDC22430D21200Chemotherapy5-FluorouracilNOComplete Response1022014,TCGA-A8-A097-R38168ECEF383E-6DE5-4F26-A795-39412649FDC7153184ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,516.0,WHITE,TCGA-AR-A2LQ,AR,A2LQ,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,3.0,Allred score 5+3=8,CAP scoring guideline 2010,Right Upper Inner QuadrantRight Upper Outer Quadrant,2.4874218749999844,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Simple Mastectomy,Margin resection,Mastectomy NOS,TOTAL MASTECTOMY,Infiltrating Lobular Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.1396484375,0.0,Intensity=Strong,10-75%,90-99%,Dako,CAP scoring guideline 2010,97.443359375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.38,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,<10%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.8985937499999987,816,3 Point Scale,2+,7thStage IIBT3N0M0,YES,NO,Positive70-79%Positive<10%Negative1+,12,1,2012,TCGA-AR-A2LQ-F375584A4F9815-80A4-4954-A2E6-416F0316C65ANOYESYESAlive895NO6122012TCGA-AR-A2LQ-F495001ED84A46-2DBF-4319-A235-9D33D7DCE14FYESYESTUMOR FREEAlive1233NO2102013,NOTCGA-AR-A2LQ-D37597D4763C71-C17E-46DB-A137-2B5B9908DEAE89152ChemotherapyDocetaxelNO6122012NOTCGA-AR-A2LQ-D3759828848860-0F93-4CE5-A7CA-7C85A90EBBC789152ChemotherapyCytoxanNO6122012NOTCGA-AR-A2LQ-D37599409752F6-5669-4168-8F31-54550EB34917176Hormone TherapyAnastrozoleYES6122012,TCGA-AR-A2LQ-R37595BC8640F7-F340-4B7A-8B3E-7FD66D6DA282201240External5040cGy28Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,12.0,WHITE,TCGA-E9-A5FK,E9,A5FK,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,10.0,Allred (Biocare),Allred score 2+2 = 4,Right Upper Outer Quadrant,1.888935546875,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Margin resection,Other,Excisional biospy,Infiltrating Lobular Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),stereotactic biopsy,Negative,Positive,Negative,0.4326171875,10.0,Intensity=Strong,Allred Score 6,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,123.7900390625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.8,"Other, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.83,3 Point Scale,3+,7thStage IIICT2N3M0,YES,NO,NO,22,5,2013,TCGA-E9-A5FK-F56473FB6BC71D-5609-451F-A7A5-CF362F0DA12CNOYESYESTUMOR FREEAlive447NO1022014TCGA-E9-A5FK-F70209E5BA687C-99E5-4D48-BAD2-53A5EFF74BD1NOYESYESTUMOR FREEAlive812NO3012015,NOTCGA-E9-A5FK-D56477310AAC92-87DD-46B7-8666-4F20C9B2A40021200ChemotherapyCyclophosphamideNOComplete Response1022014NOTCGA-E9-A5FK-D56478DE81480C-4511-40D7-8778-F558CCA5717A21200ChemotherapyMethotrexateNOComplete Response1022014NOTCGA-E9-A5FK-D56479255555A4-D618-436B-9BDC-9D9FDC22430D21200Chemotherapy5-FluorouracilNOComplete Response1022014,TCGA-E9-A5FK-R56480E57FDF1C-1CD3-4800-9D55-07CDC326E434130154External80GyRegional siteNOComplete Response1022014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A22G,E9,A22G,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,6.0,No value Given,H-Score 160,Left Upper Outer Quadrant,2.8266015624999814,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Reexcision,Other,Partial Mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Negative,Positive,0.0,0.0,Allred score 0,allred score = 7,<10%,Hercep Test  TM Dako,Dako Hecept Test,222.7626953125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,2.8,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.57,4 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,8,2011,TCGA-E9-A22G-F29939EB1E348F-175B-4412-8994-A50BF74DCD2AScheduled Follow-up SubmissionNOYESAlive715TUMOR FREENO3042014TCGA-E9-A22G-F62594B265DE44-B99C-489D-BD86-D6AE6272402ENONOYESTUMOR FREEAlive1239NO2172014,TCGA-E9-A22G-D29941ABA87C32-53D8-46A3-913D-B4D47AD621653200mg800mg/day631170ChemotherapyCyclophosphaneADJUVANTIVNO3032012TCGA-E9-A22G-D299407E19BC38-8238-4EC8-ABE3-5F5165B0FEBD320mg80mg/day614136ChemotherapyDoxorubicinADJUVANTIVNO3032012,TCGA-AR-A2LQ-R37595BC8640F7-F340-4B7A-8B3E-7FD66D6DA282201240External5040cGy28Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,225.0,WHITE,TCGA-GI-A2C8,GI,A2C8,Yes,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,10.0,IHC,Allred score 5+3 = 8,Right,2.103691406249997,Sentinel node biopsy alone,SN+1 non sentinel node,Modified Radical Mastectomy,Margin resection,Modified radical mastectomy,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.8173828125,0.0,allred score =  8,allred score = 7,90-99%,CISH,CAP SCORING GUIDELINE 2010,97.5869140625,HER2 amplification - negative,PathVysion,NO,YES,54,Bone,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.62,3 Point Scale,2+,6thStage IIIBT4bN0MX,YES,YES,PositivePositiveNegativeNegative1.09,21,10,2011,TCGA-GI-A2C8-F2166189C2725E-FFD1-4357-A966-FD0DBFB12860Scheduled Follow-up SubmissionYESYESAlive225NO852012,"TCGA-GI-A2C8-D29371D1A3A8E4-3C2D-46EE-B5D8-1C3994DF73654166ChemotherapyAdriamycinOTHER, SPECIFY IN NOTESneoadjuvantNO852012NOTCGA-GI-A2C8-D333110857F66A-898E-4DBC-8D79-4B31F0552BC4166ChemotherapyCytoxenNO2962012NOTCGA-GI-A2C8-D333868750F85E-D2A1-4936-AE36-C090AA8D373C166ChemotherapyTaxotereNO2962012",TCGA-E9-A5FK-R56480E57FDF1C-1CD3-4800-9D55-07CDC326E434130154External80GyRegional siteNOComplete Response1022014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,70.0,WHITE,TCGA-AC-A8OS,AC,A8OS,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,2.0,Allred score = 8,Allred score 0+0=0,Right Upper Outer Quadrant,1.4497265625000015,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Lobular Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Positive,0.0,0.0,allred score =  8,allred score = 7,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,268.9404296875,HER2 amplification - negative,Ratio >=2.0,YES,NO,33,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,4.70,3 Point Scale,2+,7thStage IIAT2N0 (i-)MX,YES,NO,NO,26,2,2014,TCGA-E9-A22G-F29939EB1E348F-175B-4412-8994-A50BF74DCD2AScheduled Follow-up SubmissionNOYESAlive715TUMOR FREENO3042014TCGA-E9-A22G-F62594B265DE44-B99C-489D-BD86-D6AE6272402ENONOYESTUMOR FREEAlive1239NO2172014,TCGA-E9-A22G-D29941ABA87C32-53D8-46A3-913D-B4D47AD621653200mg800mg/day631170ChemotherapyCyclophosphaneADJUVANTIVNO3032012TCGA-E9-A22G-D299407E19BC38-8238-4EC8-ABE3-5F5165B0FEBD320mg80mg/day614136ChemotherapyDoxorubicinADJUVANTIVNO3032012,TCGA-A2-A0T1-R371306674eb1-647c-45ef-8d3f-63cb7fd97891189252EXTERNAL BEAM11840cGy30Primary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,74.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A7VB,AC,A7VB,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,15.0,Allread score 5+3 = 8,H-SCORE 0,Right Lower Outer Quadrant,1.429062499999993,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Modified Radical Mastectomy,Margin resection,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.63671875,3.0,60,250,90-99%,Hercep Test  TM Dako,Venten,302.06640625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,2.6,"Other, specifyaxilaary node negative but intrammary node positive",80-89%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,1.62,3 Point Scale,2+,7thStage IIAT1cN1aMX,YES,YES,NO,26,2,2014,TCGA-AC-A7VB-F660261B155B86-984D-4C0B-995C-F687FDA6901ENOYESYESTUMOR FREEAlive250NO1102014,"TCGA-GI-A2C8-D29371D1A3A8E4-3C2D-46EE-B5D8-1C3994DF73654166ChemotherapyAdriamycinOTHER, SPECIFY IN NOTESneoadjuvantNO852012NOTCGA-GI-A2C8-D333110857F66A-898E-4DBC-8D79-4B31F0552BC4166ChemotherapyCytoxenNO2962012NOTCGA-GI-A2C8-D333868750F85E-D2A1-4936-AE36-C090AA8D373C166ChemotherapyTaxotereNO2962012",TCGA-E9-A5FK-R56480E57FDF1C-1CD3-4800-9D55-07CDC326E434130154External80GyRegional siteNOComplete Response1022014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,323.0,AMERICAN INDIAN OR ALASKA NATIVE,TCGA-A2-A0T1,A2,A0T1,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,10.0,H-Score-190,H-Score 160,Right Upper Outer Quadrant,2.1847656249999927,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,surgical resection,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Positive,0.5703125,10.0,0%,10-75%,90-99%,ACIS,Venten,89.7783203125,Vysis AutoVysion System,RATIO > 2.2,NO,YES,2.6,"Other, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5.8,3 Point Scale,2+,Stage IIICT3N3M0,YES,NO,YES181Locoregional RecurrenceYES181NOYES,12,11,2010,TCGA-A2-A0T1-F13946C7405E45-2C5E-4447-884E-3AF0DDDF3479Scheduled Follow-up SubmissionYESYESAlive521TUMOR FREENO1872011,3TCGA-A2-A0T1-D37123674b5d0-54ba-4c56-b4d1-096bcdddbe9d46Targeted Molecular therapyHerceptinADJUVANTIVYES121120102TCGA-A2-A0T1-D3711f7aadf3f-5dcd-4cf4-b04d-5b9f6907fc68646187ChemotherapyCarboplatinADJUVANTIVNO121120101TCGA-A2-A0T1-D37108ecf4ba5-9b63-4f13-90be-e4249f4d024b646187ChemotherapyTaxotereADJUVANTIVNO12112010,TCGA-A2-A0T1-R371306674eb1-647c-45ef-8d3f-63cb7fd97891189252EXTERNAL BEAM11840cGy30Primary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,797.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5RW,OL,A5RW,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,4.0,allred score 5 + 3 = 8,CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.91,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Lumpectomy,Right Breast reexcision,Other,Right total mastectomy with lymph node left axillary lymph node excision,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Excisional Biopsy,Biopsy not specified,Negative,Negative,Negative,0.890625,1.0,Two-tier,Allred Score 6,90-99%,CISH,CAP SCORING GUIDELINE 2010,72.7119140625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.5,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.73,3 Point Scale,3+,7thStage IIAT1cN1MX,YES,YES,NO,16,5,2013,TCGA-OL-A5RW-F5656851FA5005-5700-4BB5-8303-4369C6D86E8DNOYESYESTUMOR FREEAlive1106NO1422014,NOTCGA-OL-A5RW-D65259B981AF2A-14CD-4F9E-B7F0-E4097AC4A18C69234ChemotherapyADRIAMYCINNOComplete Response2492014NOTCGA-OL-A5RW-D6526047037AD5-7A17-40F3-B7B7-8FA8F3BF129469234ChemotherapyCytoxanNOComplete Response2492014NOTCGA-OL-A5RW-D652619A883C83-C334-4ADE-9EC6-DEA81CFB722069234ChemotherapyTAXOLNOComplete Response2492014,TCGA-OL-A5RW-R65258FE53ABA6-9490-4966-8236-991863C30A5D184234External5040cGyPrimary Tumor FieldNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1605.0,WHITE,TCGA-AR-A1AJ,AR,A1AJ,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,8.0,Allred score 0+0 = 0,Image Analysis,Right,1.3434472656249994,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Mastectomy NOS,Wide local excision,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0185546875,0.0,Allred score = 0,Allred score = 8,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,81.0927734375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,40,"Other, specifyskin",10-19%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.80,3 Point Scale,2+,6thStage IT1N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",13,6,2011,TCGA-AR-A1AJ-F217243F140F1F-D69C-4523-BA2A-97FEBAC37EACScheduled Follow-up SubmissionYESNOAlive1605TUMOR FREENO2722012TCGA-AR-A1AJ-F69269E2C23026-41E4-4841-8697-7CCCD8C1E45BNOYESNOTUMOR FREEAlive2383NO31122014,NOTCGA-OL-A5RW-D65259B981AF2A-14CD-4F9E-B7F0-E4097AC4A18C69234ChemotherapyADRIAMYCINNOComplete Response2492014NOTCGA-OL-A5RW-D6526047037AD5-7A17-40F3-B7B7-8FA8F3BF129469234ChemotherapyCytoxanNOComplete Response2492014NOTCGA-OL-A5RW-D652619A883C83-C334-4ADE-9EC6-DEA81CFB722069234ChemotherapyTAXOLNOComplete Response2492014,TCGA-AR-A1AJ-R2173177F74A3C-E216-4E1F-B44D-0012EB1473604779EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO12722012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,43.0,WHITE,TCGA-E9-A243,E9,A243,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,Right Upper Inner Quadrant,1.4892968749999955,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Margin resection,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.0048828125,0.0,Intensity=Weak,190,<10%,Hercep Test  TM Dako,Hercep Test  TM Dako,55.923828125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,4.43,"Other, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.67,4 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,17,8,2011,TCGA-E9-A243-F31151636C7B1A-4E10-4150-B546-2EE2D23B7758Scheduled Follow-up SubmissionYESYESAlive612WITH TUMORYES305Distant MetastasisBoneYES305NOYESNegativeNegativeNegative2092013TCGA-E9-A243-F5665692CEDE74-3DBC-4157-911C-633BA5EDB140YES1822014,TCGA-E9-A243-D311530BA723FF-5046-4029-85C3-C41B010E0ED34500mg1500mg353235Chemotherapy5-FluorouracilADJUVANTIVNO2442012TCGA-E9-A243-D311565335CA0B-6AEF-47D7-A8FE-D695892F85DA4mg4mg153235ChemotherapyVincristineADJUVANTIVNO2442012TCGA-E9-A243-D31152144BD67A-2B2B-4DB2-A72D-AF67BE661EC04000mg2000mg253235Chemotherapy5-FluorouracilADJUVANTIVNO2442012TCGA-E9-A243-D31154646C3AEA-2B7C-4B5E-812C-D2539266256A8000mg1600mg553235ChemotherapyCyclophosphamideADJUVANTIVNO2442012TCGA-E9-A243-D311556C115212-2F46-40E5-9300-3FFAF5FD5975400mg100mg453235ChemotherapyMethotrexateADJUVANTIVNO2442012NOTCGA-E9-A243-D39523617EAD96-72A4-41EE-B9EE-608F4B12E6DB305520AncillaryPamidronateNOStable Disease2412013,TCGA-E9-A243-R31157D622640B-F5A9-49CB-9B33-0A297B2BFF85119151EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO12442012TCGA-E9-A243-R48750DCC746D8-2A89-4B3A-8A8B-46ABCB5A9C2F119151External40GyRegional siteNOComplete Response2092013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3021.0,WHITE,TCGA-A2-A0EP,A2,A0EP,No,YES,C50.9,8520/3,C50.9,2004.0,TUMOR FREE,YES,1.0,Allred score 5+3= 8,allred score 5 + 3 = 8,Right Lower Inner Quadrant,1.3,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Margin resection,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,1.0,0.0,Allred score 0,Moderate,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,155.5546875,HER2 amplification - negative,RATIO > 2.2,NO,YES,74,BoneLiver,80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,185,3 Point Scale,2+,6thStage IT1N0 (i+)M0,YES,NO,NO,16,8,2012,TCGA-A2-A0EP-F42402DE19DCC9-C5D2-4C47-812D-3EA19E28A675NONOYESTUMOR FREEAlive3273NO1842013TCGA-A2-A0EP-F584994D539EB8-A316-4209-AA4C-F82A823F47BCNONOYESTUMOR FREEAlive3603NO1142014,NOTCGA-A2-A0EP-D344762B8CBF67-155E-4E57-A98D-DE14635EFF9B92141ChemotherapyCyclophosphamideNOComplete Response1682012NOTCGA-A2-A0EP-D34477173BF0C9-24F6-4410-AFF4-7061C0A143DB92141ChemotherapyAdriamycinNOComplete Response1682012NOTCGA-A2-A0EP-D34479C6483A02-70E1-4780-BC05-4AE04CAF32CB169195ChemotherapyPaclitaxelNOComplete Response1682012NOTCGA-A2-A0EP-D34480FFB9FA64-1267-4A11-8416-9F07A311CF552221781Hormone TherapyArimidexNOComplete Response1682012NOTCGA-A2-A0EP-D344820E2A204E-622E-437C-ADF2-E2DEA2F32B3819592461Hormone TherapyArimidexNOComplete Response1682012,TCGA-AR-A1AJ-R2173177F74A3C-E216-4E1F-B44D-0012EB1473604779EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO12722012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1686.0,ASIAN,TCGA-AC-A2FF,AC,A2FF,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,7.0,Allred (Biocare),Allred score 0+0 = 0,Right,1.7,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,3.0,Allred score = 5,230,10-19%,ACIS,CAP SCORING GUIDELINE 2010,84.1767578125,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.57,BoneLiver,30-39%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.3,3 Point Scale,2+,6thStage IIBT2N1MX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",23,9,2011,TCGA-AC-A2FF-F5616668379DFA-59F3-4129-9B2D-D8107CD335C5NOYESYESTUMOR FREEAlive2420NO2912014TCGA-AC-A2FF-F5865544BE030F-E207-4D98-80C9-F9F658C96AE7NOYESYESTUMOR FREEAlive2759NO1742014,NOTCGA-AC-A2FF-D561702F38E250-56D9-415C-8694-16634DED723D70153ChemotherapyCytoxanNOComplete Response2912014NOTCGA-AC-A2FF-D56171DF17DE1B-3B13-469B-B9AF-F461F5B9791D70153ChemotherapyAdriamycinNOComplete Response2912014NOTCGA-AC-A2FF-D56172C4A61CA0-51A5-4811-8017-090A5DE9AA62153245ChemotherapyTaxolNOComplete Response2912014NOTCGA-AC-A2FF-D56173CA6E2206-6437-4F20-B4CE-07925A8A8D79382Hormone TherapyTamoxifenNOComplete Response2912014,TCGA-AC-A2FF-R561681F8155CE-49F0-4917-AA85-4DF9FBE799B1336377External5040cGy28Primary Tumor FieldNOComplete Response2912014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1485.0,WHITE,TCGA-AR-A1AL,AR,A1AL,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,15.0,Image Analysis,Image Analysis,Left Upper Inner QuadrantLeft Upper Outer Quadrant,1.5378710937499966,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Simple Mastectomy,Margin resection,Mastectomy NOS,Mastectomy,Infiltrating Lobular Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.283203125,3.0,Allred score = 0,H-SCORE,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,51.5625,HER2 amplification - negative,Ratio >=2.0,NO,YES,4.43,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,21,3 Point Scale,2+,6thStage IIIAT3N1M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",15,6,2011,TCGA-AR-A1AL-F221568DFEDF7F-9E87-4602-9619-424358C6560BScheduled Follow-up SubmissionYESYESAlive1485TUMOR FREENO132012TCGA-AR-A1AL-F69272578E2FC1-A2D0-4E95-9683-5CA06AD1313DNOYESYESTUMOR FREEAlive2971NO31122014,1TCGA-AR-A1AL-D22160434BD03D-F052-4518-BA27-5FFA55676AB01ChemotherapyPaclitaxelADJUVANTNO1320121TCGA-AR-A1AL-D221592856DA7C-FB15-45B1-97F6-4D562D8F705F4ChemotherapyCytoxanADJUVANTNO1320122TCGA-AR-A1AL-D2216249AE2F00-CB5D-4C4E-8134-0E856F2452171mg/day192366Hormone TherapyAnastrozoleADJUVANTPONO1320121TCGA-AR-A1AL-D22158377B613B-C56A-444F-9267-A2E5EDFEA3AF4ChemotherapyDoxorubicinADJUVANTNO1320122TCGA-AR-A1AL-D22163D49EE915-818B-484E-BE1B-15C7D3685DF82.5mg/day387Hormone TherapyLetrozoleADJUVANTPOYES1320121TCGA-AR-A1AL-D22161CD0DAAB8-2A50-4F39-ABB3-A57C7DB0E95A3ChemotherapyDocetaxelADJUVANTNO132012,TCGA-AR-A1AL-R221579613B599-7554-4DD1-BFA1-DD813EC257DB153192EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,396.0,WHITE,TCGA-A8-A0A4,A8,A0A4,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,5.9013671875,CAP scoring guideline 2010,Allred score 0+0=0,Left,2.0543359374999945,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Lobular Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.265625,0.0,Allred Score 5,H-Score,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,124.609375,HER2 amplification - negative,Ratio >=2.0,NO,YES,40,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,131,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,Negative<10%3 Point ScaleNegative<10%3 Point ScaleEquivocal<10%1+,27,5,2011,TCGA-A8-A0A4-F40326BE77F294-FAE5-4040-A6EA-671C8915B7F9NONOYESTUMOR FREEAlive396NO1622013,NOTCGA-A8-A0A4-D37899CE92BF3F-277B-41E8-9B20-867CE5DDAC5031215Hormone TherapyTamoxifenNOComplete Response6122012NOTCGA-A8-A0A4-D37900D8E03D97-D2C6-498F-8B32-372ACA5AB2C9215Hormone TherapyLetrozoleYES6122012,TCGA-BH-A0B0-R5920760C2C230-CDAF-4194-B9B2-F90127A231E7194236External6000cGy30Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,18.0,WHITE,TCGA-D8-A1JA,D8,A1JA,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,18.7412109375,manual counting,manual counting,Left Upper Outer Quadrant,2.5012792968750044,No axillary staging,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Pateys surgery,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Negative,Positive,0.4677734375,5.357421875,0%,allred score = 8,30-39%,Dako,Hecep Test TM DAKO,360.5947265625,HER2 amplification - negative,Positive >2.2,YES,NO,64,"LungBoneLiverOther, specifyskin",<10%,70-79%,Negative,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,131,3 Point Scale,2+,7thT4bNXM0,YES,NO,YES181Locoregional RecurrenceYES181NOYES,29,3,2011,TCGA-D8-A1JA-F209412C26170E-B4E3-428E-A2F1-D91B478E0568Scheduled Follow-up SubmissionYESYESAlive502WITH TUMORYES431Locoregional DiseaseNOYESNO1912012,TCGA-D8-A1JA-D2094249D90CDE-D4EF-46EF-94D8-525D69BE2B09240mg60mg/m24340403ChemotherapyadriamycinADJUVANTIVNO1912012NOTCGA-D8-A1JA-D65317954BBBEE-5DA3-43B7-986A-7AA80BA0744F340403ChemotherapycyclophosphamideNO2292014,TCGA-D8-A1JA-R209431A6BC6F2-1938-46E7-9B84-1C48C8AD6921431472EXTERNAL BEAM5000cGyLocal RecurrenceRECURRENCENO1912012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,577.0,WHITE,TCGA-A8-A07G,A8,A07G,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,6.8349609375,CAP scoring guideline 2010,Allred (Biocare),Right Upper Outer Quadrant,1.862021484374988,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Mastectomy NOS,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.36328125,1.208984375,Allred Score,Allred score = 0,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,87.6259765625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,1.45,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.66,3 Point Scale,2+,6thStage IIAT1cN1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A07G-F4082711CBA9E4-00D9-4227-964C-1681DBE988EDNOYESYESTUMOR FREEAlive577NO232013,NOTCGA-A8-A07G-D378790211068A-96FE-4994-9F2A-BA4918363F4759181Chemotherapy5-FluorouracilNOComplete Response6122012NOTCGA-A8-A07G-D3788028A905FA-0749-46CF-9381-CFD29F1403E359181ChemotherapyMethotrexateNOComplete Response6122012NOTCGA-A8-A07G-D37881E2B01A91-364F-43EC-ACE7-587DA794738759181ChemotherapyCyclophosphamideNOComplete Response6122012NOTCGA-A8-A07G-D37882EF6F7284-A441-4DE8-BD6E-C34BC40D261E243Hormone TherapyLetrozoleYES6122012,TCGA-A8-A07G-R3818830302E30-CC2F-48C2-8021-CF4C619A5E21181212ExternalPrimary Tumor FieldComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,748.0,WHITE,TCGA-E2-A10B,E2,A10B,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,28.0,Allred score 5+3= 8,Allred score 5+3= 8,Left Lower Outer Quadrant,1.11,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Margin resection,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Close,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.0,2.0,Allred score 8,Allred score 8,10-19%,Dako,CAP SCORING GUIDELINE 2010,135.5126953125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,64,"Other, specifyskin",<10%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.9215039062499983,145,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",22,2,2011,TCGA-E2-A10B-F17370276DD2FD-D528-42EF-A703-FD3CC598295EScheduled Follow-up SubmissionYESYESAlive1141YES195New Primary TumorLungYES195YESYESNegativeNegative1992011,1TCGA-E2-A10B-D777822a0ab43-d0fb-443a-9af6-411f575586451mg/day1mg/day232Hormone TherapyArimidexADJUVANTPOYES14220112TCGA-E2-A10B-D174147A8C4891-71FD-4118-BEB4-84AC3D858FBC1556mg312mg8252398ChemotherapyPaclitaxelADJUVANTIVNO19920112TCGA-E2-A10B-D17415970F3CF2-E642-4E3C-8819-541DF6437E4E1922mgmg7252398ChemotherapyCarboplatinADJUVANTIVNO19920113TCGA-E2-A10B-D174130FEBDEAC-7A64-4F2D-A282-2BB6ADA48DF4840mg840mg1301301ChemotherapyBevacizumabADJUVANTIVNO19920114TCGA-E2-A10B-D174124513E452-531B-4CB3-A85B-9B4267CABF912484mg624mg4657748ChemotherapyPemetrexedADJUVANTIVNO19920111TCGA-E2-A10B-D17371011EFEBF-C10E-4C0F-871E-99C7222B06B21mg/day230Hormone TherapyArimidexADJUVANTPOYES1992011,TCGA-E2-A10B-R174177DB115F8-D3D7-46CF-8652-9C5C37F11FAC368413EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO11992011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1623.0,WHITE,TCGA-AR-A24U,AR,A24U,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,25.0,Allred score 0+0 = 0,manual counting,Left Upper Outer QuadrantLeft Lower Outer Quadrant,2.594472656249995,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Margin resection,Mastectomy NOS,total mastectomy,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,3+,Negative,Positive,Core needle biopsy,Modified Radical Masectomy,Positive,Negative,Positive,0.4052734375,2.0,Allred score = 8,Allred score = 0,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,85.56640625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.5,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.67,3 Point Scale,2+,6thStage IIAT1N1M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",26,8,2011,TCGA-AR-A24U-F315903692FAD6-E63E-4BF1-9745-6515D89E8595Scheduled Follow-up SubmissionYESYESAlive1623NO752012TCGA-AR-A24U-F49473F1F5C96C-885E-427F-8C7C-3E060C82E8A4YESYESTUMOR FREEAlive2363NO2102013TCGA-AR-A24U-F7173859A7E2D3-3110-4843-96B2-AF1E57B018D9NOYESYESTUMOR FREEAlive3128NO3032015,NOTCGA-AR-A24U-D31594DA32B961-80C8-4D77-A98B-4E9FED2AA1CE5597ChemotherapyDoxorubicinNO2152012NOTCGA-AR-A24U-D315981EA74BAA-C62D-454E-9666-8311D39579495597ChemotherapyCytoxanNO2152012NOTCGA-AR-A24U-D316000F05B513-E5C7-4EBD-9FD0-00D49E148864111188ChemotherapyPaclitaxelNO2152012NOTCGA-AR-A24U-D31603551E1D04-2F7A-4065-A2A5-530D95047532111111ImmunotherapyTrustuzumabNO2152012NOTCGA-AR-A24U-D322293B708795-9361-4DC6-8F7A-E6C5D3BD53E6118476ImmunotherapyTrastuzumabNO2152012NOTCGA-AR-A24U-D31605EC9851E1-A6A6-4E59-AAF1-4F25D1B7EA80118476ImmunotherapyTrustuzumabNO2352012,TCGA-AR-A24U-R31593651DA6E4-2E69-451D-AB97-54875022C4F4207246EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1752012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2521.0,WHITE,TCGA-B6-A40B,B6,A40B,No,YES,C50.9,8520/3,C50.9,2005.0,TUMOR FREE,YES,3.0,image cytometry,H-Score 0,Left Upper Outer Quadrant,2.309599609374995,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,Segmental Mastectomy,Infiltrating Lobular Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Positive,Positive,Negative,0.0,0.0,Allred score 6,250,<10%,Hercep Test  TM Dako,Dako Hercept test,63.0419921875,HER2 amplification - negative,Ratio >=2.2,NO,YES,74,Bone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.73,4 Point Scale,3+,6thStage IT1bN0 (i-)M0,NO,NO,NO,20,9,2012,TCGA-B6-A40B-F59661B9D049E2-D4B2-495F-A644-3E44E9C01D0CNONONOTUMOR FREEAlive3152NO362014,NOTCGA-AC-A5XS-D641093EECF063-E00F-473F-AC9F-C848E33C6EA697Hormone TherapyFemaraYES2682014,TCGA-BH-A0BA-R15467074F0CFD-17CA-47A8-88C5-A36FF8978CF4187262EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,34.0,WHITE,TCGA-E2-A15K,E2,A15K,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,17.0,Allred score 5+3 = 8,Allred score 2+2 = 4,Right Upper Outer Quadrant,0.9,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Equivocal,0.3447265625,2.0,Allred score = 4,Allred score = 8,10-19%,Dako,Venten,68.1669921875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.38,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.62,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",13,4,2011,TCGA-E2-A15K-F188690C192618-60F0-4ED8-B0BA-0873916821EEScheduled Follow-up SubmissionYESYESAlive275TUMOR FREENO15112011,1TCGA-E2-A15K-D188719C486924-7EF1-47D8-B98A-2676AE270FE8461131ChemotherapyAdriamycinADJUVANTNO151120112TCGA-E2-A15K-D18877DFF4C694-40E2-4F27-BDD5-0AF99106E3C54146208ChemotherapyTaxolADJUVANTNO151120111TCGA-E2-A15K-D1887406D39A90-4056-428C-A6A2-7AEF31C3FE5C461131ChemotherapyCytoxanADJUVANTNO15112011,TCGA-E2-A15K-R18879597CFDF4-47EE-4CFD-8D2B-66BD1D75DE2B232273EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO115112011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,47.0,WHITE,TCGA-AC-A5XS,AC,A5XS,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,8.0,H-Score 270,Allred score 4+3 = 7,Left Upper Inner Quadrant,1.4029199218749997,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Segmental mastectomy with sentinel axillary lymph node biopsy,Infiltrating Lobular Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.1953125,0.0,Allred score 7 per outside facility report,8,10-19%,ACIS,Dako Hercept test,54.9638671875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,74,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,441,3 Point Scale,2+,7thStage IIAT2N0MX,YES,NO,NO,15,7,2013,TCGA-AC-A5XS-F64108BA010C17-664A-44B7-ACC2-32E13D6552EBNONOYESTUMOR FREEAlive588NO2682014,NOTCGA-AC-A5XS-D641093EECF063-E00F-473F-AC9F-C848E33C6EA697Hormone TherapyFemaraYES2682014,TCGA-BH-A0BA-R15467074F0CFD-17CA-47A8-88C5-A36FF8978CF4187262EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,371.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A4SE,A7,A4SE,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,3.0,No value Given,allred score 5 +3 = 8,Left,1.6511425781249889,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,Pateys surgery,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.0,0.0,Allred score 7 per outside facility report,Allred score 7 (per outside facility),<10%,ACIS,Venten,224.7822265625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,4.43,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,NO,22,2,2013,TCGA-A7-A4SE-F50162EA17641D-048D-48C9-8C6F-24D1888E0196YESNOYESTUMOR FREEAlive644NO16102013,NOTCGA-A7-A4SE-D418918C1D4FAD-B3C5-4009-94B8-51BE6B4744234991ChemotherapyAdriamycinNOComplete Response242013NOTCGA-A7-A4SE-D41892B8237736-7799-4490-A1CA-2A15E2985B174991ChemotherapyCytoxanNOComplete Response242013NOTCGA-A7-A4SE-D418935FA600E2-E487-4345-A4BE-E4A7AD3738EB105154ChemotherapyTaxolNOComplete Response242013,TCGA-E2-A1LL-R20619544DB6E4-9E02-45A2-ACCB-0254D6BB05D9105147EXTERNAL BEAM5040cGy28Regional siteADJUVANTNO11712012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,412.0,WHITE,TCGA-GM-A5PV,GM,A5PV,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,24.0,H-SCORE 280,Allred score 5+3=8,Right,1.35,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,biopsy,Infiltrating Lobular Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0263671875,1.0,Allred score 6,allred score = 7,90-99%,CISH,CAP SCORING GUIDELINE 2010,40.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.70,"Other, specifyskin",90-99%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.65,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,NO,12,4,2013,TCGA-E9-A295-F353553DDA0B38-4114-4BCD-8EB4-4D82877CC1FCYESYESYESTUMOR FREEAlive375NO2592012,NOTCGA-GM-A5PV-D421561316596D-D637-490A-BC7F-1E1C61EB3AE0107174ChemotherapyTaxotereNOComplete Response1242013NOTCGA-GM-A5PV-D42166F72DFCCB-CAB4-4F6D-8B1B-FC0364E48134107174ChemotherapyCytoxanNOComplete Response1242013,TCGA-EW-A3E8-R3999391E4B957-C918-4E13-B0E0-48ECCA77D430165196External60Gy30Primary Tumor FieldNOComplete Response822013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,22.0,WHITE,TCGA-E9-A295,E9,A295,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,7.0,allred score 5 + 3 = 8,image cytometry,Right Lower Outer Quadrant,1.6791601562499965,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast reexcision,Other,Excision,Infiltrating Lobular Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,2+,1+,Negative,Negative,Tumor resection,Modified Radical Masectomy,Negative,Positive,Positive,0.0,0.0,7,7,<10%,Hercep Test  TM Dako,Dako Hercept test,45.017578125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,4.43,"Other, specifyskin",80-89%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.9,4 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,12,9,2011,TCGA-E9-A295-F353553DDA0B38-4114-4BCD-8EB4-4D82877CC1FCYESYESYESTUMOR FREEAlive375NO2592012,NOTCGA-E9-A295-D35357C6FF0A55-DD00-4370-882C-4CDA4D7F524D152Hormone TherapyTamoxifenYES5102012,TCGA-E9-A295-R3535820725E45-0E63-4739-8B3F-414F2BBAAC474674External130Gy65Regional siteNOComplete Response2592012
TCGAFPPP,Breast,No,MALE,Alive,0.0,1394.0,WHITE,TCGA-BH-A0DD,BH,A0DD,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,22.0,H-Score 280,Allred 5 = 2+3,Right,3.967851562499959,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,partial left mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Positive,Positive,Positive,0.31640625,0.0,Allred score = 5,8,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,65.6796875,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.57,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5.8,3 Point Scale,2+,6thStage IIBT2N1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,18,8,2011,TCGA-BH-A0DD-F60386125C6661-A8F1-4D50-8E0B-28DD4EC98880NONOYESTUMOR FREEAlive2486NO962014,NOTCGA-BH-A0DD-D603875889C498-95E3-4F7F-AFCD-CC096717CD6C105217ChemotherapyDocetaxelNOComplete Response962014NOTCGA-BH-A0DD-D603887421BB29-2783-495B-8C92-73DC7451EEB8105217ChemotherapyCarboplatinNOComplete Response962014,TCGA-AC-A62V-R601786A2AE9B0-D973-40FF-9BC8-C68CA90494082146External3250cGy13Distant siteNOPartial Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,633.0,WHITE,TCGA-AR-A2LO,AR,A2LO,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,16.0,allred score 5 + 3 = 8,H-SCORE 0,Left Lower Outer Quadrant,3.102910156249995,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast reexcision,Other,Wide Local Excision,Infiltrating Lobular Carcinoma,Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.03125,1.0,allred score = 6,STRONG,90-99%,Dako,DAKOHercepTest TM,91.5908203125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,40,"Other, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.8985937499999987,71,3 Point Scale,2+,7thStage IIBT2N1M0,YES,NO,PositiveNegative,12,1,2012,TCGA-AR-A2LO-F37193CDD91705-9314-4F46-A3AA-39BD618E4623NOYESYESAlive935NO7122012TCGA-AR-A2LO-F494987D5DE440-FD86-4C8D-B599-F4AEB2820AA4YESYESTUMOR FREEAlive1198NO2102013,YESTCGA-AR-A2LO-D37194FAE98AD4-647B-4B8A-877A-9A3E35C855154484ChemotherapyAdriamycinNO7122012YESTCGA-AR-A2LO-D37258B5922B72-CFFD-4EE0-9F3E-35C6AE2A69D94484ChemotherapyCytoxanNO7122012YESTCGA-AR-A2LO-D372590751053B-FD4A-4022-A9A0-46243CD85D3298175ChemotherapyPaclitaxelNO7122012YESTCGA-AR-A2LO-D3760797212CFD-8883-4CC9-BED8-3F45E9AB5E7644161ImmunotherapyBevacizumabNO7122012YESTCGA-AR-A2LO-D3760803E05488-13C5-4F00-BB7D-AA459862D124199903Hormone TherapyTamoxifenNO7122012YESTCGA-AR-A2LO-D376096F0A0541-DE11-49E8-914A-2AE90BA4BB39903Hormone TherapyAnastrozoleYES7122012,TCGA-AR-A2LO-R37257ADDD5CDF-B239-4A98-AA02-A5DF64C626FF196228External5000cGy25Primary Tumor FieldNO7122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1N8,E9,A1N8,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,8.0,H-SCORE 190,Allred score 5+3=8,Right Upper Outer Quadrant,1.6538574218749913,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Surgical resection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Negative,Negative,0.0,0.0,Allred Score 4,Two-tier,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,132.62109375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.13,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",23,6,2011,TCGA-E9-A1N8-F29134F1F2BA48-146B-4F38-B7BF-DBB528AC689BScheduled Follow-up SubmissionNOYESAlive365TUMOR FREENO932012TCGA-E9-A1N8-F53518F4D07D12-E2E7-45AA-A24F-D15D9A955DF7NONOYESTUMOR FREEAlive1039NO12122013,1TCGA-E9-A1N8-D291353D42D744-34FF-4E25-862B-1766D65AE0A2320mg80mg/day422107ChemotherapyDoxorubicinADJUVANTIVNO9320121TCGA-E9-A1N8-D29137D95B794D-470B-454C-AD92-C20080A5BB023200mg800mg/day422107Chemotherapy5-FluorouracilADJUVANTIVNO9320121TCGA-E9-A1N8-D291386D5C845C-F385-41B2-ABCB-2CC309BAA5DF3200mg800mg/day422107ChemotherapyCyclophosphaneADJUVANTIVNO932012,TCGA-GM-A2DM-R471058493586C-8C86-4027-959A-2E8975783875237273External52Gy26Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1750.0,WHITE,TCGA-A2-A0CW,A2,A0CW,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,19.0,Allred score 5+3= 8,Allred score = 8,Right,0.5,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.0,2.0,H score,allred score = 0,30-39%,Dako,DAKOHercepTest TM,185.5380859375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.1,LungBone,90-99%,10-19%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.677578124999993,145,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,1,2011,TCGA-A2-A0CW-F137274C41DD4D-C22A-4CDB-8415-B936FDE030FFScheduled Follow-up SubmissionNOYESAlive1948TUMOR FREENO1362011TCGA-A2-A0CW-F7069006E8B614-ABD0-4B06-BC35-0FD8FA585C60NONOYESTUMOR FREEAlive3283NO232015,1TCGA-A2-A0CW-D7229c36b63ba-4a02-4afd-881a-952408223aa41mg156Hormone TherapyAnastrozoleADJUVANTPOYES122011,TCGA-A7-A3J0-R29282D07FF920-EBA1-42B4-BEDE-5A3B68777BCD5763OTHERPartial Breast irradiation using a SAVI catheter3400cGy10Primary Tumor FieldADJUVANTNO11332012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,273.0,WHITE,TCGA-A7-A0DC,A7,A0DC,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,3.0,H-Score 150,image cytometry,Right Upper Outer QuadrantRight,1.1799902343750015,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Right Breast reexcision,Other,Partial Mastectomy,Infiltrating Ductal Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,>10%,allred score = 0,10-19%,0,3+ Positive,61.7939453125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,33,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,5.8,3 Point Scale,2+,Stage IAT1cN0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,4,10,2010,TCGA-A7-A0DC-F3193494F497F-FF25-4604-AC1E-12282CA0AC7E386AliveTUMOR FREEYESYES9112010TCGA-A7-A0DC-F406077D70ECB9-709E-4531-B63D-60B752AA7D2ANOYESYESAlive906NO2522013,1TCGA-A7-A0DC-D3189ca0fef41-cd39-4497-b295-38a48b89774c558mg69-71mg877231ChemotherapyMethotrexateADJUVANTIVNO91120101TCGA-A7-A0DC-D3191cd2fd85e-9fad-473c-b1f1-47ec2596186b8346mg1032-1062mg877231ChemotherapyFluorouracilADJUVANTIVNO91120101TCGA-A7-A0DC-D31879d5ba4cc-c114-4c1d-a59b-c3a11120136a8346mg1032-1062mg877231ChemotherapyCyclophosphamideADJUVANTIVNO91120101TCGA-A7-A0DC-D3192cbcf5f6d-0308-484f-bc64-044efa3d5e86170mg1mg264Hormone TherapyArimidexADJUVANTPOYES91120101TCGA-A7-A0DC-D199738404643D-1E6E-44D8-A955-3B398A0A05AF245mg1mg245264509Hormone TherapyArimidexADJUVANTPONO512012NOTCGA-A7-A0DC-D346250E08C9C8-C699-416C-AE02-F59B9358B98C510Hormone TherapyTamoxifenNO2482012,TCGA-A7-A0DC-R31949939e1ca-953b-4e0a-a861-225fee9920c8309351EXTERNAL BEAM5040cGy28Primary Tumor FieldADJUVANTNO19112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1256.0,WHITE,TCGA-AO-A0J9,AO,A0J9,No,YES,C50.9,8520/3,C50.9,2007.0,WITH TUMOR,YES,32.0,H-SCORE 190,%IHC,Right Upper Inner QuadrantRight Upper Outer QuadrantRight,1.2,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Margin resection,Mastectomy NOS,Excision,Infiltrating Lobular Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Positive,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.0,15.0,H score,Moderate,<10%,CISH,3+ POSITIVE,33.0,HER2 amplification - negative,RATIO >EQUAL 2.0,NO,YES,127,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,149,3 Point Scale,4+,Stage IIICT2N3M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,19,9,2010,TCGA-AO-A0J9-F3151B970A0F3-C779-45C1-A655-7FEC777638DA1256AliveWITH TUMORYESYES1066YES1066Positive90-99%4+Positive10-19%1+Negative<10%1+3+ POSITIVENOYES1992010TCGA-AO-A0J9-F15483FC513014-FCB4-4F42-89F0-37A2DB946EE9Scheduled Follow-up SubmissionYESYESAlive1613WITH TUMORYES1066Distant MetastasisBoneYES1066NOYESPositive90-99%4 Point ScalePositive10-19%4 Point ScaleNegative1+3 Point Scale2282011,"1TCGA-AO-A0J9-D316045f1bb9c-2863-49b6-a2ab-f5bc422f0bd4370mg175mg/m21141141ChemotherapyPACLITAXELADJUVANTIVNO19920101TCGA-AO-A0J9-D315501d99b67-790d-4c94-82b8-faedb014d4e75040mg600mg/m2485128ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO19920101TCGA-AO-A0J9-D316152a37453-0a2a-41e6-a1e6-b5d5bc0d512c630mg100mg/m23161204ChemotherapyDOCETAXELADJUVANTIVNO19920102TCGA-AO-A0J9-D31629943c67b-c3e6-4829-8c90-a843eae505241mg/day2391023Hormone TherapyARIMIDEX (ANASTROZOLE)ADJUVANTPONO19920101TCGA-AO-A0J9-D3158e90c4e19-b755-47c9-9d5e-41881194b7ed500mg60mg/m2485128ChemotherapyDOXORUBICINADJUVANTIVNO19920102TCGA-AO-A0J9-D3164d1156805-edbe-42f7-9472-b3e1a303937016mg4mg41072Other, specify in notesBISPHOSPHONATEZOLEDRONIC ACIDRECURRENCEIVYES19920101TCGA-AO-A0J9-D3163faf150fa-8213-4fec-96fb-069b05d3cb0d25mg/day10721207Hormone TherapyAROMASIN (EXEMESTANE)RECURRENCEPONO19920101TCGA-AO-A0J9-D3165a55ae465-7d58-4b39-9163-396c9a4dbf1520mg/day1207Hormone TherapyTAMOXIFENPROGRESSIONPOYES1992010",TCGA-AO-A0J9-R31545e4bd8f8-0619-48a2-812d-c6f0626c1e60226263EXTERNAL BEAM11117cGy28Regional siteADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,761.0,WHITE,TCGA-A8-A09Q,A8,A09Q,No,YES,C50.9,8500/3,C50.9,2008.0,WITH TUMOR,YES,13.701171875,image cytometry,H-Score 290,Left Lower Inner Quadrant,2.151806640624997,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Margin resection,Other,Surgical Resection,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Tumor resection,stereotactic biopsy,Negative,Positive,Negative,0.3095703125,2.6220703125,Allred Score 5,allred score = 8,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,108.376953125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,66,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,59,3 Point Scale,2+,6thStage IIIBT4bN2aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A09Q-F410224B42D5B1-911A-4C69-9E7E-C9578A82AB6BNONOYESWITH TUMORAlive7611032013,NOTCGA-A8-A09Q-D37769F3220351-3FF6-4231-8B5E-3A27001C00EB31Hormone TherapyAnastrozolen/aYES6122012,TCGA-C8-A26V-R708018A854D11-9805-4A1B-BC0A-6018147BD138212247External50Gy25Regional siteNOComplete Response932015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,9.0,ASIAN,TCGA-C8-A26V,C8,A26V,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,9.529296875,% IHC,Allred score 0+0 = 0,Right,1.4564355468750012,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Modified Radical Masectomy,Negative,Positive,Negative,0.4443359375,3.2265625,Allred Score 8,Allred Score 8,90-99%,ACIS,Venten,101.302734375,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,64,BoneLiver,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,4 Point Scale,2+,6thStage IIIAT3N2M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,7,2011,TCGA-C8-A26V-F70799505ACEFD-F363-4529-B80D-839879624DF1NOYESYESTUMOR FREEAlive616NO932015,NOTCGA-C8-A26V-D7080010D4E1C4-0036-44D9-8206-D14CECDEA307247613Hormone TherapyTamoxifenNOComplete Response932015,TCGA-C8-A26V-R708018A854D11-9805-4A1B-BC0A-6018147BD138212247External50Gy25Regional siteNOComplete Response932015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,463.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A6S9,EW,A6S9,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,3.0,Allred score = 8,H-SCORE 280,RightRight Upper Outer Quadrant,1.4650488281249976,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Lumpectomy,Margin resection,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Positive,1.0,1.0,Allred score 6,Allred Score = 7,50-59%,CISH,CAP scoring guideline 2010,215.125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,3.1,"Other, specifyskin",50-59%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.62,3 Point Scale,2+,7thStage IIAT1cN1M0,NO,NO,NO,13,3,2015,TCGA-EW-A6S9-F71706873F23EE-D1B9-48B8-B112-C6CE519DD5AFNONONOTUMOR FREEAlive463NO3032015,3TCGA-A2-A0YK-D58472805802e-eb3a-4f17-90b5-9fa824b240221mgHormone TherapyArimidexADJUVANTPOYES281220101TCGA-A2-A0YK-D5845c5a7f0c7-a217-4ad7-a621-78da30961ddc4460mg1115mg478141ChemotherapyCytoxanADJUVANTIVNO281220102TCGA-A2-A0YK-D5846c494a6d6-0fcb-4709-b505-fef203efcd1b560mg140mg478141ChemotherapyTaxotereADJUVANTIVNO28122010,TCGA-A2-A3XV-R34634F2E7F201-0A1D-4AD5-B148-EA69A1294BA6211246External50Gy25Primary Tumor FieldNOComplete Response2482012TCGA-A2-A3XV-R34635EFC36FA5-0568-4B56-8EFF-E56B96239F74247258External10Gy5Primary Tumor FieldNOComplete Response2482012
TCGAFPPP,Breast,No,FEMALE,Dead,959.0,926.9853515625,WHITE,TCGA-BH-A1F2,BH,A1F2,No,YES,C50.9,8541/3,C50.9,1999.0,TUMOR FREE,YES,19.0,H-Score 150,allred score 2+2 = 4,Left,2.542714843749985,Sentinel node biopsy alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast reexcision,Other,Right total mastectomy with lymph node left axillary lymph node excision,Infiltrating Ductal Carcinoma,Mixed infiltrating lobular and grade 1 ductal carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Positive,0.8955078125,6.0,Allred Score 3,Allred Score 5,10-19%,ACIS,Dako Hecept Test,100.892578125,Vysis AutoVysion System,Positive >2.2,NO,YES,2.13,"Other, specifyskin",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,<4.0,3 Point Scale,2+,5thStage IIIBT4bN1bM0,NO,NO,NONO,7,9,2011,TCGA-C8-A26V-F70799505ACEFD-F363-4529-B80D-839879624DF1NOYESYESTUMOR FREEAlive616NO932015,"1TCGA-AO-A0J9-D316045f1bb9c-2863-49b6-a2ab-f5bc422f0bd4370mg175mg/m21141141ChemotherapyPACLITAXELADJUVANTIVNO19920101TCGA-AO-A0J9-D315501d99b67-790d-4c94-82b8-faedb014d4e75040mg600mg/m2485128ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO19920101TCGA-AO-A0J9-D316152a37453-0a2a-41e6-a1e6-b5d5bc0d512c630mg100mg/m23161204ChemotherapyDOCETAXELADJUVANTIVNO19920102TCGA-AO-A0J9-D31629943c67b-c3e6-4829-8c90-a843eae505241mg/day2391023Hormone TherapyARIMIDEX (ANASTROZOLE)ADJUVANTPONO19920101TCGA-AO-A0J9-D3158e90c4e19-b755-47c9-9d5e-41881194b7ed500mg60mg/m2485128ChemotherapyDOXORUBICINADJUVANTIVNO19920102TCGA-AO-A0J9-D3164d1156805-edbe-42f7-9472-b3e1a303937016mg4mg41072Other, specify in notesBISPHOSPHONATEZOLEDRONIC ACIDRECURRENCEIVYES19920101TCGA-AO-A0J9-D3163faf150fa-8213-4fec-96fb-069b05d3cb0d25mg/day10721207Hormone TherapyAROMASIN (EXEMESTANE)RECURRENCEPONO19920101TCGA-AO-A0J9-D3165a55ae465-7d58-4b39-9163-396c9a4dbf1520mg/day1207Hormone TherapyTAMOXIFENPROGRESSIONPOYES1992010",TCGA-C8-A26V-R708018A854D11-9805-4A1B-BC0A-6018147BD138212247External50Gy25Regional siteNOComplete Response932015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,774.0,WHITE,TCGA-E2-A1B5,E2,A1B5,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,5.0,Allred score 5+3 = 8,Allred score 2+3 = 5,Left,1.329843749999997,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,segmental mastectomy,Infiltrating Lobular Carcinoma,Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.265625,0.0,Allred score = 5,Allred score = 8,<10%,Dako,CAP SCORING GUIDELINE 2010,130.2216796875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,66,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,21,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,25,4,2011,TCGA-E2-A1B5-F19393C39FB1AF-80F5-4372-B7A6-02C6E902D4DBScheduled Follow-up SubmissionYESYESAlive984TUMOR FREENO8122011,1TCGA-E2-A1B5-D19397CB3816CF-67CB-4392-B82C-D7FC2F387357190ChemotherapytaxolADJUVANTIVNO81220112TCGA-E2-A1B5-D19408EE248DCA-EF7B-4120-BC49-86460A2BD750mg20mg/day190Hormone TherapytamoxifenADJUVANTPOYES81220111TCGA-E2-A1B5-D19400D6F378A8-CE13-4C40-A22C-63B7D803BC36190ChemotherapycytoxanADJUVANTIVNO8122011,TCGA-E2-A1B5-R19413AA902F8D-0E4A-40C2-BE07-BED2DD67E7DC130174EXTERNAL BEAM6000cGyPrimary Tumor FieldADJUVANTNO18122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1813.0,WHITE,TCGA-AO-A0JD,AO,A0JD,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,27.0,Allred 0 = 0+0,%IHC,Left Upper Outer QuadrantLeft,1.4,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,partial mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,3.0,moderately to strongly,STRONG,<10%,CISH,3+ POSITIVE,20.0,HER2 amplification - negative,RATIO > = 2.0,NO,YES,49,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,68,3 Point Scale,2+,Stage IIIAT3N1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",20,9,2010,TCGA-AO-A0JD-F318554A693AC-26E1-4E40-9878-D73CBC2BE8EA1813AliveTUMOR FREEYESYES2092010TCGA-AO-A0JD-F15487A1246D11-43BB-492B-AE6E-FDB6790A8599Scheduled Follow-up SubmissionYESYESAlive2190TUMOR FREENO2282011,2TCGA-AO-A0JD-D31962d8f1a8d-5cbd-4852-b7e3-145eec1554021mg/day261Hormone TherapyANASTROZOLE (ARIMIDEX)ADJUVANTPOYES20920101TCGA-AO-A0JD-D3190447d92b5-bace-4477-9abc-3687a1fab2374536mg600mg/m2462104ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO20920101TCGA-AO-A0JD-D31954c003fb7-7ce0-45bf-bec5-8af6fb62d6b31296mg175mg/m24118160ChemotherapyPACLITAXELADJUVANTIVNO20920101TCGA-AO-A0JD-D3188bf1780f4-0ad9-4861-ab51-bf0698571363452mg60mg/m2462104ChemotherapyDOXORUBICINADJUVANTIVNO2092010,TCGA-AO-A0JD-R3186aaf5b702-d5e8-428b-bab0-d0534119f010195244EXTERNAL BEAM10620cGy33Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,48.0,WHITE,TCGA-E9-A1RI,E9,A1RI,No,YES,C50.9,8522/3,C50.9,2011.0,TUMOR FREE,YES,10.0,CAP scoring guideline 2010,CAP scoring guideline 2010,Left Upper Outer Quadrant,2.055830078125002,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,partial mastectomy,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.55859375,5.0,Intensity=Strong,205,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,97.4970703125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.7,"LungBoneLiverOther, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.66,4 Point Scale,2+,7thStage IIIAT1cN2M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-E9-A1RI-F305557BDF7FC0-36E3-4368-93A4-DD7C98B4B2D0Scheduled Follow-up SubmissionYESYESAlive425TUMOR FREENO2792013TCGA-E9-A1RI-F394438690964A-A2FE-410B-9169-9F815F1D0A93NOYESYESTUMOR FREEAlive1084NO2312013TCGA-E9-A1RI-F70144A958BB89-B31B-4120-984E-F4D5E8BEADEBNOYESYESTUMOR FREEAlive1449NO2812015,TCGA-E9-A1RI-D305607D013691-E913-4D44-BCCA-11F6C13369AB300mg100mg33278ChemotherapyDoxorubicinADJUVANTIVNO1242012TCGA-E9-A1RI-D30556E1C9066D-8569-4D69-A22F-3C031DD1FFD41000mg1000mg13278Chemotherapy5-FluorouracilADJUVANTIVNO1242012TCGA-E9-A1RI-D30562FEF0778A-20C4-491A-BF46-E76657C7B65F20mg/day28Hormone TherapyTamoxifenADJUVANTPOYES1242012NOTCGA-E9-A1RI-D463496D4635CF-24FA-4141-B052-0F162D685C5A418425Hormone TherapyLeuprolideNOComplete Response682013TCGA-E9-A1RI-D305585CC44B06-F81E-4106-A661-6A584D26D12B3000mg1000mg33278ChemotherapyCyclophosphamideADJUVANTIVNO1322014,TCGA-E9-A1RI-R30563FF379776-F8AA-4FCF-B487-555B3031C3FE137169EXTERNAL BEAM12400cGy62Regional siteADJUVANTNO11242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,518.0,WHITE,TCGA-E2-A15E,E2,A15E,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,9.0,Allred score 5+3 = 8,Allred score 5+3 = 8,Left,1.0562499999999984,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Mastectomy NOS,total mastectomy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Equivocal,0.3642578125,1.0,Allred score = 8,Allred score = 8,10-19%,Dako,CAP SCORING GUIDELINE 2010,93.1630859375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,50,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,131,3 Point Scale,2+,6thStage IIAT1cN1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",25,4,2011,TCGA-E2-A15E-F18919D9946A73-A046-481D-A377-E617A25BB8FBScheduled Follow-up SubmissionYESYESAlive630TUMOR FREENO9112011,"2TCGA-E2-A15E-D189259E5B5BB6-2140-4A7E-A602-A78255F5E0C56098mg232mg24119489ChemotherapytrastuzumabADJUVANTIVNO91120113TCGA-E2-A15E-D18927407C7081-6BAE-49FF-BA21-08E9B1FFC04Dmg1600mg/day77Other, specify in notesclinical trial - bisphosphonates as adjuvant therapyclodronateADJUVANTPOYES91120111TCGA-E2-A15E-D1892046743446-EA3E-448F-B26B-48229B9F7E41380mg95mg463105ChemotherapydoxorubicinADJUVANTIVNO91120112TCGA-E2-A15E-D18924AD397BC8-6AFC-4D6E-8808-994CFFAB1FF11560mg130mg12119198ChemotherapypaclitaxelADJUVANTIVNO91120114TCGA-E2-A15E-D18928B5431001-AC5A-44E5-A998-A5071332A8764900mg20mg/day203448Hormone TherapytamoxifenADJUVANTPONO91120115TCGA-E2-A15E-D18930B1551326-BA16-476F-9732-DB302B702454mg25mg/day451Hormone TherapyaromasinADJUVANTPOYES91120111TCGA-E2-A15E-D1892141AF0E0A-6F0D-4BC6-97E8-6D887A9440993816mg954mg463105ChemotherapycyclophosphamideADJUVANTIVNO9112011",TCGA-E2-A15E-R1892247F13F36-41AE-454A-B878-B9F1AE276011218275EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO19112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,304.0,WHITE,TCGA-A8-A09A,A8,A09A,No,YES,C50.9,8500/3,C50.9,2009.0,WITH TUMOR,YES,16.2177734375,H-SCORE 260,Allred 0 = 0+0,Left,1.6997363281249898,Sentinel node biopsy alone,SN+1 non sentinel node,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Positive,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.5341796875,4.5693359375,Allred Score,0,10-19%,ACIS,Hercep Test  TM Dako,112.23828125,HER2 amplification - negative,PathVysion,NO,YES,2.38,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.85,3 Point Scale,2+,6thStage XT2NXM0,YES,NO,YES275Distant MetastasisLung,27,5,2011,TCGA-A8-A09A-F405516D20EF32-98F7-497A-B6E9-A40607FF1FF7NOYESYESWITH TUMORAlive3042322013,NOTCGA-A8-A09A-D37802CD73A61D-093A-4D49-B667-77B33D535F5B31Chemotherapy5-FluorouracilNO6122012NOTCGA-A8-A09A-D3780388F900CF-4B32-407F-8868-F0C403EDE58731ChemotherapyEpirubicinNO6122012NOTCGA-A8-A09A-D378040AF1F61C-EA80-4E11-91D7-55B88B1E1B3D31ChemotherapyCyclophosphamideNO6122012NOTCGA-A8-A09A-D378054C782B94-02AD-4D3A-AC10-A300BDDC79D7182ChemotherapyDocetaxelNO6122012NOTCGA-A8-A09A-D3780692C7BE24-ECD6-4492-AD23-374F8B00872A243Hormone TherapyTamoxifenYES6122012,TCGA-A8-A09A-R3816642E57A30-DD55-4E80-A902-D6DA091B49FD182212ExternalGyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2316.0,WHITE,TCGA-AR-A0TZ,AR,A0TZ,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,30.0,% IHC,Allred score 0+0 = 0,Left Upper Outer Quadrant,1.9218554687499945,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Surgical resection,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.4365234375,6.0,10-75%,Allred score 8,30-39%,Hercep Test  TM Dako,Venten,296.71875,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,3.0,Bone,70-79%,70-79%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1,3 Point Scale,1+,T2N2M1,YES,YES,Positive70-79%Positive<10%Negative1+,7,3,2011,TCGA-AR-A0TZ-F18727D5A8B1ED-5266-4FA7-B07A-15DF222EEFB6Scheduled Follow-up SubmissionYESYESAlive2316YES1313Distant MetastasisBone15122011TCGA-AR-A0TZ-F4947107A8C3D6-9B1A-42F7-8AD6-B5FD24A8CF52NOYESYESDead3262YES13132102013,1TCGA-AR-A0TZ-D195806D665117-F247-42AF-BCEE-58D9E5A8C4AAChemotherapyDoxorubicinADJUVANTNO151220111TCGA-AR-A0TZ-D19585DDAECFBE-9A39-40E2-9949-5BA7F0E59972Hormone TherapyTamoxifenADJUVANTNO151220111TCGA-AR-A0TZ-D1958412E885E0-147E-493C-80A3-3FC7FA47B11AChemotherapyPaclitaxelADJUVANTNO151220111TCGA-AR-A0TZ-D195867476015B-5A4D-4FC4-8716-34E766F01ACCHormone TherapyADJUVANTNO151220111TCGA-AR-A0TZ-D195820D4D40A8-8486-46B8-9F85-FD8B559B4437ChemotherapyCytoxanADJUVANTNO15122011,TCGA-AR-A0TZ-R19575C47F0686-D68D-4811-8F46-437865D65DD7ADJUVANTNO115122011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,161.0,WHITE,TCGA-W8-A86G,W8,A86G,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,1.0,H-Score 150,H-Score 290,LeftLeft Lower Inner Quadrant,2.923037109374987,Sentinel node biopsy alone,SN+1 non sentinel node,Lumpectomy,Mastectomy,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,1+,1+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.0,0.0,Allred score 6,Intensity=Weak,90-99%,ACIS,Venten,299.1162109375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,4,"LungBoneLiverOther, specifyskin",90-99%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,2+,Negative,1.8985937499999987,21,3 Point Scale,1+,7thStage IIAT2aN0 (i-)MX,YES,NO,NO,29,1,2014,TCGA-W8-A86G-F65574A38C6D67-17D8-4B82-804F-1EA3A8D16D03NONOYESTUMOR FREEAlive347NO2592014,NOTCGA-W8-A86G-D561696C2E0E3B-091B-4623-A0A4-027B8D824788161Hormone TherapyArimidexYES2912014,TCGA-E2-A15S-R19141404E4F73-F254-4DB0-A932-852FCB819377191247EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO116112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,274.0,WHITE,TCGA-E2-A15S,E2,A15S,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,17.0,allred score 5+3=8,Allred score 5+3=8,Left Upper Inner QuadrantLeft Upper Outer Quadrant,2.0048437499999907,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.3505859375,1.0,Allred score = 2,Allred score = 7,10-19%,Dako,CAP SCORING GUIDELINE 2010,48.7607421875,HER2 amplification - negative,Ratio >=2.0,NO,YES,33,"Other, specifyskin",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,1,3 Point Scale,2+,7thStage IIBT2N1M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",14,4,2011,TCGA-E2-A15S-F19135E148F43C-C230-4941-9B16-BF0B9D4C9AF4Scheduled Follow-up SubmissionYESYESAlive428TUMOR FREENO16112011,3TCGA-E2-A15S-D19140CEBFFF93-6688-400B-AA11-6CD3B44EFE311mg/day1mg/day314Hormone TherapyArimidexADJUVANTPOYES161120111TCGA-E2-A15S-D19137E2A0AE1A-0AFD-48FC-A05A-64B284BBC153276mg92mg35078ChemotherapyDoxorubicinADJUVANTIVNO161120111TCGA-E2-A15S-D191368460E5C6-9209-4D1B-889B-72D74DE614932754mg918mg35078ChemotherapyCyclophosphamideADJUVANTIVNO161120112TCGA-E2-A15S-D19139F323125C-76E3-4E3E-AFB8-2355B2C63C47ChemotherapyTaxolADJUVANTNO16112011,TCGA-E2-A15S-R19141404E4F73-F254-4DB0-A932-852FCB819377191247EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO116112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,334.0,WHITE,TCGA-A2-A0YK,A2,A0YK,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,3.0,H-SCORE 136,allred score 5 + 3 = 8,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft Lower Inner QuadrantLeft Lower Outer Quadrant,3.292363281250004,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Margin resection,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Lobular Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,1+,Negative,Close,Core needle biopsy,Biopsy not specified,Positive,Positive,Negative,0.0,0.0,allred score = 4,Two-tier,90-99%,Hercep Test  TM Dako,DAKOHercepTest TM,81.4892578125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,160,LungBone,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,1.80,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,12,2010,TCGA-A2-A0YK-F167505352B4DE-D0F2-4460-A22F-4D82A51444FEScheduled Follow-up SubmissionNOYESAlive588TUMOR FREENO1692011,3TCGA-A2-A0YK-D58472805802e-eb3a-4f17-90b5-9fa824b240221mgHormone TherapyArimidexADJUVANTPOYES281220101TCGA-A2-A0YK-D5845c5a7f0c7-a217-4ad7-a621-78da30961ddc4460mg1115mg478141ChemotherapyCytoxanADJUVANTIVNO281220102TCGA-A2-A0YK-D5846c494a6d6-0fcb-4709-b505-fef203efcd1b560mg140mg478141ChemotherapyTaxotereADJUVANTIVNO28122010,TCGA-OL-A5RU-R6525122B829AF-B769-4C42-B835-9B5461DCF6FC160197External5040cGyRegional siteNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Dead,1556.0,696.376953125,WHITE,TCGA-BH-A18V,BH,A18V,No,YES,C50.4,8500/3,C50.4,2001.0,WITH TUMOR,YES,25.0,allred score 0 + 0 = 0,Allred score = 8,Right,2.3709472656249977,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,Modified radical mastectomy with left breast biopsy,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.830078125,0.0,Allred Score 4,180,10-19%,ACIS,CAP SCORING GUIDELINE 2010,123.3974609375,HER2 amplification - negative,PathVysion,NO,YES,2.13,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,40-49%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,1.66,3 Point Scale,1+,5thStage IIBT2N1bM0,NO,YES,NegativeNegativeNegative,2,7,2011,TCGA-BH-A0HK-F4758F754A354-2AFA-4E66-8B81-540A812E244C178AliveTUMOR FREENOYES16112010,1TCGA-E2-A15K-D188719C486924-7EF1-47D8-B98A-2676AE270FE8461131ChemotherapyAdriamycinADJUVANTNO151120112TCGA-E2-A15K-D18877DFF4C694-40E2-4F27-BDD5-0AF99106E3C54146208ChemotherapyTaxolADJUVANTNO151120111TCGA-E2-A15K-D1887406D39A90-4056-428C-A6A2-7AEF31C3FE5C461131ChemotherapyCytoxanADJUVANTNO15112011,TCGA-E2-A15S-R19141404E4F73-F254-4DB0-A932-852FCB819377191247EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO116112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,841.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5RU,OL,A5RU,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,15.0,H-SCORE 0,H-SCORE 280,Left Upper Outer Quadrant,1.02,Sentinel node biopsy alone,SN+1 non sentinel node,Modified Radical Mastectomy,Right Breast reexcision,Other,Right total mastectomy with lymph node left axillary lymph node excision,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.7626953125,1.0,Intensity=Strong,Two-tier,30-39%,CISH,Dako Hercept test,69.291015625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.25,"Other, specifyskin",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5.8,3 Point Scale,3+,7thStage IIAT1cN1MX,YES,YES,NO,16,5,2013,TCGA-OL-A5RU-F56569117AF3FA-5687-4518-936E-40CD09BB40E5NOYESYESTUMOR FREEAlive1219NO1422014,NOTCGA-OL-A5RU-D6525269BA6DFE-4BE6-4D86-BA5B-77352DEA913A71134ChemotherapycyclophosphamideNOComplete Response2492014NOTCGA-OL-A5RU-D652536A5D8B38-7542-47E7-BC90-14735FEA121471134ChemotherapydocetaxelNOComplete Response2492014,TCGA-OL-A5RU-R6525122B829AF-B769-4C42-B835-9B5461DCF6FC160197External5040cGyRegional siteNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,745.0,WHITE,TCGA-BH-A0EB,BH,A0EB,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.0,H-SCORE 300,H-SCORE 210,Right Lower Inner QuadrantRight,1.25,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.72265625,0.0,H-SCORE,H-SCORE,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.0,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,2.13,"LungBoneLiverOther, specifyskin",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.65,3 Point Scale,3+,Stage IAT1cN0 (i-)M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-BH-A0EB-F46629563674B-70FE-4A30-9DB9-85CCA3D7BCB6745AliveTUMOR FREEYESYESNONONONO16112010,1TCGA-BH-A0EB-D4659187080D3-F3AD-4B6D-BEE2-FB2DCA27EA0C1mg/day55Hormone TherapyARIMIDEXADJUVANTPOYES17112010,TCGA-BH-A0EB-R46602612BEAD-4FDA-41EC-99DD-EAF33C89F68573118EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,178.0,WHITE,TCGA-BH-A0HK,BH,A0HK,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,17.0,H-SCORE 260,H-SCORE 0,Right Upper Inner QuadrantRight,1.483847656250005,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.4619140625,2.0,H-SCORE,H-SCORE,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.4833984375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.57,"LungBoneLiverOther, specifyskin",70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,149,3 Point Scale,0,Stage IIBT2N1M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,10,11,2010,TCGA-BH-A0HK-F4758F754A354-2AFA-4E66-8B81-540A812E244C178AliveTUMOR FREENOYES16112010,1TCGA-BH-A0HK-D4755015FC627-C844-4744-8F86-34152041F1271mg/day38Hormone TherapyARIMIDEXADJUVANTPOYES17112010,TCGA-OL-A5RU-R6525122B829AF-B769-4C42-B835-9B5461DCF6FC160197External5040cGyRegional siteNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,162.0,WHITE,TCGA-AQ-A1H3,AQ,A1H3,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,23.0,Allred score 5+3=8,CAP scoring guideline 2010,Right Upper Outer Quadrant,1.829082031250008,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.681640625,14.0,8,H score,10-19%,CISH,CAP SCORING GUIDELINE 2010,93.93359375,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,50,"Other, specifyskin",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,105,3 Point Scale,2+,7thStage IIICT2N3aMX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",20,4,2011,TCGA-AQ-A1H3-F19908C0E98003-E4EE-4BE5-A95E-AEDA30278AC0Scheduled Follow-up SubmissionYESYESAlive402TUMOR FREENO412012TCGA-AQ-A1H3-F5066198A7EDE4-CB1F-4A84-AD74-E1F4C96ABF53NOYESYESTUMOR FREEAlive989NO28102013,1TCGA-AQ-A1H3-D1991880735D66-0D8E-43E8-A65D-695327350EBC175mg/m24120162ChemotherapyTaxolADJUVANTIVNO4120121TCGA-AQ-A1H3-D1990949FE2EE4-C3CA-449E-9041-AADDB7B2789D60mg/m2464106ChemotherapyAdriamycinADJUVANTIVNO4120121TCGA-AQ-A1H3-D1991998F948E1-A62A-41F8-8B73-54326F302C9F20mg/day239Hormone TherapyTamoxifenADJUVANTPOYES4120121TCGA-AQ-A1H3-D19910A00FC9E3-5B49-4A54-A683-C81D3B869DAD600mg/m2464106ChemotherapyCytoxanADJUVANTIVNO412012,TCGA-AQ-A1H3-R19911DD693829-5BDE-49CE-AA8B-42D8FFE43469188233EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1412012TCGA-AQ-A1H3-R19912A77D9CB5-BE36-4F5B-A97C-A8A048732921188226EXTERNAL BEAM5040cGy28Regional siteADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1903.0,WHITE,TCGA-AR-A1AM,AR,A1AM,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,12.0,Allred score 5+3 = 8,CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.5222265625000095,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Simple Mastectomy,Margin resection,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,0.169921875,1.0,H-Score,Allred score = 7,10-19%,Hercep Test  TM Dako,Dako Hercept test,67.37890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,54,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,185,4 Point Scale,2+,6thStage IIIAT3N1M0,YES,NO,NO,20,11,2012,TCGA-AR-A1AM-F3689845E8106C-259E-4F9D-9FDA-FFCDE4772117NONOYESTUMOR FREEAlive1903NO20112012TCGA-AR-A1AM-F49467C59D857B-7316-4208-A40A-0A040A69E09BNONOYESTUMOR FREEAlive2315NO2102013TCGA-AR-A1AM-F717334ECA877E-6675-4BE9-9D8E-962797C4E435NONOYESTUMOR FREEAlive2991NO3032015,NOTCGA-AR-A1AM-D3689966305035-0C04-4F78-9827-C6945903CB215597ChemotherapyAdriamycinNO20112012NOTCGA-AR-A1AM-D36913A6043E89-02FF-41DB-B796-E31AA6778A1F127314Hormone TherapyTamoxifenNO20112012NOTCGA-AR-A1AM-D36914A2E5EB14-9F26-47D5-86B5-95B3B1E65039314336Hormone TherapyAnastrozoleNO20112012NOTCGA-AR-A1AM-D639481F367D89-FCE1-484D-B3CA-93FF5FE8F4E05597ChemotherapycytoxanNO2182014,TCGA-E2-A1B5-R19413AA902F8D-0E4A-40C2-BE07-BED2DD67E7DC130174EXTERNAL BEAM6000cGyPrimary Tumor FieldADJUVANTNO18122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,111.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A5YN,LL,A5YN,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,5.0,H-SCORE 190,H-SCORE 280,RightRight Upper Inner Quadrant,3.2,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Margin resection,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Equivocal,0.0,0.0,<10%,180,10-19%,0,Hercep Test  TM Dako,20.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,54,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,172,3 Point Scale,3+,7thStage IIAT2N0 (i-)M0,YES,NO,NO,20,5,2013,TCGA-LL-A5YN-F59362043E9E03-A7CA-4DA6-BFCA-0FC75F6A5750NOYESYESTUMOR FREEAlive447NO952014,NOTCGA-LL-A5YN-D43375A44314A0-B6F0-45D4-811F-53215A4E052C55166ChemotherapyCarboplatinNO2052013NOTCGA-LL-A5YN-D433768DF86AE2-2A1A-48D5-B349-97263291088C55166ChemotherapyDocetaxelNO2052013NOTCGA-LL-A5YN-D43377C9597303-18A1-441B-99D5-56DE1239A05755421ChemotherapyTrastuzumabNO2052013NOTCGA-LL-A5YN-D59363867990D7-24CC-4A86-A294-79C35DFE9907229Hormone Therapytamoxifen citrateYES952014,TCGA-LL-A5YN-R593268260F398-2067-486D-ABC6-787644B80D64194224External54.72Gy22Primary Tumor FieldNO952014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,972.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A1LB,E2,A1LB,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,25.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Right Upper Outer Quadrant,1.5480761718749958,Axillary lymph node dissection alone,Pateys surgery,Lumpectomy,Reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Positive,0.39453125,2.0,Allred score = 0,Allred score = 0,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,104.025390625,HER2 amplification - negative,Ratio >=2.0,NO,YES,3.1,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.80,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,7,6,2011,TCGA-E2-A1LB-F2065094F7D4C6-179E-443F-BC62-DB1D230AEA53Scheduled Follow-up SubmissionYESYESAlive1231TUMOR FREENO1712012TCGA-E2-A1LB-F70015F04D0FA3-92DD-4833-8390-DD3333635E69NOYESYESTUMOR FREEAlive2306NO922015,02TCGA-E2-A1LB-D206539B62DB92-ACF7-4884-9460-C1634758D79B1860mg155mg12121199ChemotherapytaxolADJUVANTIVNO171201202TCGA-E2-A1LB-D206551B740152-15BF-45B7-AA8A-AC589F8985904824mg1206mg866108ChemotherapycytoxanADJUVANTIVNO171201201TCGA-E2-A1LB-D206512E9325B6-A784-44EF-8EBD-2F8B989A6248484mg121mg466128ChemotherapyadriamycinADJUVANTIVNO171201202TCGA-E2-A1LB-D20654EE4ED476-18BE-4535-BB8A-4781CC63C7E011904mg496mg24121441ChemotherapyherceptinADJUVANTIVNO1712012,TCGA-E2-A1LB-R20656D7FD3A70-1915-43EC-BCE1-09208061AA20241287EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO011712012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,76.0,WHITE,TCGA-A7-A3J0,A7,A3J0,No,YES,C50.9,8480/3,C50.9,2011.0,TUMOR FREE,YES,2.0,Allred score = 8,Allred score = 8,Right,1.2731738281249996,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Mucinous Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.2900390625,0.0,moderately to strongly,250,90-99%,ACIS,Venten,111.5673828125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,1.45,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.62,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,Positive70-79%Positive<10%Negative1+,13,3,2012,TCGA-A7-A3J0-F35965B63F8878-C317-4D4A-8DA0-9A3B4ACEFEA4NOYESYESTUMOR FREEAlive313NO12102012,NOTCGA-A7-A3J0-D35966CDDA22AF-C26F-4051-9D80-3C195030DF0E72Hormone TherapyAnastrazoleYES12102012,TCGA-A7-A3J0-R29282D07FF920-EBA1-42B4-BEDE-5A3B68777BCD5763OTHERPartial Breast irradiation using a SAVI catheter3400cGy10Primary Tumor FieldADJUVANTNO11332012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5383.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0IJ,B6,A0IJ,No,YES,C50.9,8500/3,C50.9,1995.0,TUMOR FREE,YES,27.0,Image Analysis,Image Analysis,Right Upper Outer QuadrantRight,1.5005078124999998,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,ductal and papillary,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,intraoperative examination,Negative,Positive,Equivocal,0.560546875,0.0,110,H score,10-19%,ACIS,dextran coated charcoal,54.705078125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,64,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.73,4 Point Scale,1+,Stage IIBT3N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,2,11,2010,TCGA-B6-A0IJ-F1261940AA9979-4BAB-40CA-BE6C-1787ABDDE22AScheduled Follow-up SubmissionNOYESAlive5383TUMOR FREENO262011TCGA-B6-A0IJ-F71500118F133D-5C79-473C-B86B-7CF50EEBCFB2NONOYESTUMOR FREEAlive7106NO2632015,1TCGA-AO-A0J6-D310773049389-f0b2-42ee-8cb0-3220e24c21321320mg175mg/m24130172ChemotherapyPACLITAXELADJUVANTIVNO19920101TCGA-AO-A0J6-D3105a007109f-8d09-47c0-8962-c3fdccc14bd9440meq60mg/m2474116ChemotherapyDOXORUBICINADJUVANTIVNO19920101TCGA-AO-A0J6-D310356b00f1d-94c6-47aa-bfe8-3475b64b87544400mg600mg/m2474116ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO1992010,TCGA-GM-A2DM-R471058493586C-8C86-4027-959A-2E8975783875237273External52Gy26Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,292.0,WHITE,TCGA-XX-A899,XX,A899,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,22.0,Allred 0 = 0+0,Allred (Biocare),Right Lower Outer Quadrant,1.7941015625000034,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.0,5.0,strong,strong,90-99%,CISH,Hercep Test  TM Dako,289.5419921875,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,2.13,"Other, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,21,3 Point Scale,2+,7thStage IIIAT1cN2aMX,YES,YES,NO,21,2,2014,TCGA-XX-A899-F676265FF6740C-F490-4530-9C62-7816D19C4948NOYESYESTUMOR FREEAlive467NO11112014,NOTCGA-XX-A899-D67388E8DE13D8-49EB-4C42-AE4A-FCBA49BD0CC196201ChemotherapyCytoxanNOComplete Response11112014NOTCGA-XX-A899-D67518A746793A-ADCD-4ED7-A7C7-A3BD3B1403C896201ChemotherapyTaxotereNOComplete Response11112014NOTCGA-XX-A899-D676345A2357E0-00ED-439F-B396-71ABA650DB5E103Hormone TherapyZoladexYES11112014,TCGA-XX-A899-R67395F5A60110-7C0E-413D-9CAA-ACDDA286E5EC230278External5040cGy28Primary Tumor FieldNOComplete Response11112014TCGA-XX-A899-R675103BDE2380-DD79-4356-8EB6-AD64AD3BDB5F230278External5040cGy28Regional siteNOComplete Response11112014TCGA-XX-A899-R675120A440F8C-5815-4F48-9C49-A71D26B1881A230278External1000cGy5Regional siteNOComplete Response11112014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,518.0,WHITE,TCGA-E2-A14Z,E2,A14Z,No,YES,C50.9,8500/3,C50.9,2009.0,WITH TUMOR,YES,1.0,Allred score 5+3 = 8,Allred score 5+3 = 8,Left Upper Outer Quadrant,2.041376953124993,Sentinel node biopsy alone,Pateys surgery,Lumpectomy,Reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.3486328125,0.0,Allred score = 8,Allred score = 8,<10%,Dako,CAP SCORING GUIDELINE 2010,119.0439453125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.8,"Other, specifyskin",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,<4.0,3 Point Scale,1+,6thStage IT1cN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",6,4,2011,TCGA-E2-A14Z-F18790C99B50BB-89E6-456F-B0E0-2F621948028CScheduled Follow-up SubmissionYESYESDead563WITH TUMORYES188Distant MetastasisBoneNO4112011TCGA-E2-A14Z-F1879238E35F76-597F-4510-8395-8A019391EE04Scheduled Follow-up SubmissionYESYESDead563WITH TUMORYES188Distant MetastasisLiverNO28112011,1TCGA-E2-A14Z-D187953094D6D4-29B2-4620-ADE6-E6C60168114A78mg1mg110188Hormone TherapyArimidexADJUVANTPONO71120112TCGA-E2-A14Z-D187998A897AD0-3F9D-48BA-84CA-B26404B7FFBE196266ChemotherapyCarboplatinRECURRENCENO71120112TCGA-E2-A14Z-D187960F2AF5BD-F63F-4EAD-B86B-7BE2BD25AA83196266ChemotherapyTaxolRECURRENCENO7112011,TCGA-E2-A14Z-R18793D536C4BC-3D79-490D-9A5B-503072DE082164110EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO17112011TCGA-E2-A14Z-R1879475F82406-C52F-4EF9-867B-6D2BA36FEEBF236359IMPLANTS5500cGyDistant RecurrencePALLIATIVENO27112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,775.0,WHITE,TCGA-AO-A0J6,AO,A0J6,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.0,H-Score 295,Allred score 2+2 = 4,Left Upper Outer QuadrantLeft,1.532109374999992,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Margin resection,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,0,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Negative,Negative,0.0,0.0,Allread Score 8,205,<10%,CISH,3+ POSITIVE,29.603515625,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.40,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.65,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,19,9,2010,TCGA-AO-A0J6-F30991CD5D03B-E10B-4BB5-B3E9-E49C8054290C775AliveTUMOR FREEYESYES1992010TCGA-AO-A0J6-F15479970D7D07-69A6-4BF8-A92E-04769BB10B85Scheduled Follow-up SubmissionYESYESAlive1140TUMOR FREENO2282011,1TCGA-AO-A0J6-D310773049389-f0b2-42ee-8cb0-3220e24c21321320mg175mg/m24130172ChemotherapyPACLITAXELADJUVANTIVNO19920101TCGA-AO-A0J6-D3105a007109f-8d09-47c0-8962-c3fdccc14bd9440meq60mg/m2474116ChemotherapyDOXORUBICINADJUVANTIVNO19920101TCGA-AO-A0J6-D310356b00f1d-94c6-47aa-bfe8-3475b64b87544400mg600mg/m2474116ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO1992010,TCGA-AO-A0J6-R3101485e54f5-ff71-42b8-a85c-68c5fe3c3f7e241273EXTERNAL BEAM5240cGy21Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,551.0,WHITE,TCGA-GM-A5PX,GM,A5PX,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,13.0,H-SCORE 300,Allred (Biocare),Left,1.9337597656249887,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Simple Mastectomy,Right Breast reexcision,Other,biopsy,Infiltrating Lobular Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,2.0,1.0,110,allred score = 0,30-39%,CISH,Hercep Test  TM Dako,60.0,HER2 amplification - negative,Positive >2.2,NO,YES,1.78,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.98,3 Point Scale,2+,7thStage IIBT2N1miM0,YES,NO,NO,12,4,2013,TCGA-E9-A1QZ-F2972067F347E5-E803-4F86-81E4-70D6BBA65A9DScheduled Follow-up SubmissionNONOAlive362TUMOR FREENO2832012TCGA-E9-A1QZ-F66270E97CFB3D-31E0-4AED-82C6-C775CF5282FENONONOTUMOR FREEAlive755NO7102014,NOTCGA-GM-A5PX-D42160D2BD571D-6658-48CB-88FE-77DAC9870F9C112236Hormone TherapyArimidexNOComplete Response1242013NOTCGA-GM-A5PX-D42161761DB280-F416-45BF-B1C0-88A1E9EFA3EF265339Hormone TherapyAromasinNOComplete Response1242013NOTCGA-GM-A5PX-D421632713B9D0-0CB9-4FD7-B75B-3ED4DEC296C4340Hormone TherapyTamoxifenYES1242013,TCGA-E2-A1BD-R194429FC62023-6140-4514-B9DE-74BCC48157A055108EXTERNAL BEAM6600cGyPrimary Tumor FieldADJUVANTNO19122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1826.0,WHITE,TCGA-AO-A0JM,AO,A0JM,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,23.0,H-Score 150,CAP scoring guideline 2010,Right Lower Inner QuadrantRight Lower Outer QuadrantRight,5.0,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,Total mastectomy,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Positive,Positive,Positive,0.0810546875,2.0,200,Allred Score 5,70-79%,CISH,3+ POSITIVE,30.0,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,74,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,366,3 Point Scale,1+,Stage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,20,9,2010,TCGA-AO-A0JM-F3228049E6CA9-0F3F-4DE6-854E-CB6C131ECBF11826AliveTUMOR FREEYESYES2092010TCGA-AO-A0JM-F154963A5AB256-1C98-41B7-A84A-3BFB46668518YESYESAlive2184TUMOR FREENO2282011,3TCGA-AO-A0JM-D3235140fbd02-a0c1-4e38-99e8-eaaac337f3b220mg/day330Hormone TherapyTAMOXIFENADJUVANTPOYES20920102TCGA-AO-A0JM-D32336106b296-02f3-4373-8d46-4d6c3906a6b49095mg6mg/kg23134498Targeted Molecular therapyTRASTUZUMABADJUVANTIVNO20920101TCGA-AO-A0JM-D3231ad12218d-1986-4f13-bab1-12b1315ad67f452mg60mg/m2478120ChemotherapyDOXORUBICINADJUVANTIVNO20920101TCGA-AO-A0JM-D3232425ca3d3-c246-49e1-9039-fa57865be48a1360mg175mg/m24134177ChemotherapyPACLITAXELADJUVANTIVNO20920101TCGA-AO-A0JM-D3230b2c38850-e368-40ba-afe1-d8faf3c2647d4520mg600mg/m2478120ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO2092010,TCGA-AO-A0JM-R32297e8ccc49-defa-4a33-bd6a-edb852153291260294EXTERNAL BEAM10000cGy25Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1QZ,E9,A1QZ,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,19.0,H-Score 300,H-Score 290,Left Lower Inner Quadrant,2.2031249999999845,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Other,Margin resection,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Tumor resection,stereotactic biopsy,Negative,Positive,Equivocal,0.103515625,0.0,Intensity=Weak,180,90-99%,Hercep Test  TM Dako,Venten,100.9921875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,64,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,<4.0,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-E9-A1QZ-F2972067F347E5-E803-4F86-81E4-70D6BBA65A9DScheduled Follow-up SubmissionNONOAlive362TUMOR FREENO2832012TCGA-E9-A1QZ-F66270E97CFB3D-31E0-4AED-82C6-C775CF5282FENONONOTUMOR FREEAlive755NO7102014,3TCGA-AO-A0JM-D3235140fbd02-a0c1-4e38-99e8-eaaac337f3b220mg/day330Hormone TherapyTAMOXIFENADJUVANTPOYES20920102TCGA-AO-A0JM-D32336106b296-02f3-4373-8d46-4d6c3906a6b49095mg6mg/kg23134498Targeted Molecular therapyTRASTUZUMABADJUVANTIVNO20920101TCGA-AO-A0JM-D3231ad12218d-1986-4f13-bab1-12b1315ad67f452mg60mg/m2478120ChemotherapyDOXORUBICINADJUVANTIVNO20920101TCGA-AO-A0JM-D3232425ca3d3-c246-49e1-9039-fa57865be48a1360mg175mg/m24134177ChemotherapyPACLITAXELADJUVANTIVNO20920101TCGA-AO-A0JM-D3230b2c38850-e368-40ba-afe1-d8faf3c2647d4520mg600mg/m2478120ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO2092010,TCGA-A8-A099-R38167E30C6BD0-6060-41EC-8F04-8DA25A39056F92123ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Dead,538.0,918.71875,WHITE,TCGA-BH-A1EY,BH,A1EY,No,YES,C50.9,8500/3,C50.9,2000.0,WITH TUMOR,YES,12.0,H-SCORE 260,allred score 5 + 3 = 8,Left Upper Outer Quadrant,2.3094238281249924,Sentinel node biopsy alone,Pateys surgery,Modified Radical Mastectomy,Right Breast reexcision,Other,Total mastectomy with retromammary lymph node excision,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Negative,0.4189453125,0.0,Allred Score 5,Intensity=Strong,10-19%,Hercep Test  TM Dako,Dako Hecept Test,63.6240234375,HER2 amplification - negative,Positive >2.2,NO,YES,4,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,6.4,3 Point Scale,2+,5thStage IIAT2N0M0,NO,YES,NONO,7,9,2011,TCGA-BH-A1EY-F591734AD593DC-BD2C-44D2-A851-A2B13659DB85NONONOWITH TUMORDead538YES396Distant MetastasisLungLiver252014,NOTCGA-OL-A5RU-D6525269BA6DFE-4BE6-4D86-BA5B-77352DEA913A71134ChemotherapycyclophosphamideNOComplete Response2492014NOTCGA-OL-A5RU-D652536A5D8B38-7542-47E7-BC90-14735FEA121471134ChemotherapydocetaxelNOComplete Response2492014,TCGA-AR-A0U2-R19591572AD134-752F-4FAD-B70B-3FB15869115BcGy28ADJUVANTNO115122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,317.0,WHITE,TCGA-E2-A1BD,E2,A1BD,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,Allred score 5+3 = 8,Allred score 5+3 = 8,Right Upper Outer Quadrant,1.0,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Equivocal,0.3125,0.0,Allred score = 8,Allred score = 8,10-19%,Dako,Venten,125.0146484375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.38,"Other, specifyaxilaary node negative but intrammary node positive",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,21,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",25,4,2011,TCGA-E2-A1BD-F19439BC31751C-7DEF-4DDF-A6D3-FD1E906BAB71Scheduled Follow-up SubmissionYESYESAlive520TUMOR FREENO9122011TCGA-E2-A1BD-F70021C93AB29A-00FC-49AC-89DC-AC44ED0A1F59NOYESYESTUMOR FREEAlive1133NO922015,1TCGA-E2-A1BD-D194452534A6C5-8DD5-454D-8887-6098E2B7CBB11mg/day1mg/day170Hormone TherapyArimidexADJUVANTPOYES9122011,TCGA-E2-A1BD-R194429FC62023-6140-4514-B9DE-74BCC48157A055108EXTERNAL BEAM6600cGyPrimary Tumor FieldADJUVANTNO19122011
TCGAFPPP,Breast,No,FEMALE,Dead,2551.0,1696.37890625,WHITE,TCGA-AR-A0U2,AR,A0U2,No,YES,C50.9,8500/3,C50.9,2004.0,WITH TUMOR,YES,16.0,Allred score 0+0 = 0,Image Analysis,Left Lower Outer Quadrant,1.5428124999999966,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Margin resection,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Incisional Biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,4.0,Allred Score 5,Allred Score 8,90-99%,Dako,CAP SCORING GUIDELINE 2010,185.4560546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,1.45,BoneLiver,10-19%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.47,145,3 Point Scale,2+,Stage IIIAT2N2M0,YES,NO,Positive70-79%NegativeNegative2+Negative2.47,24,2,2011,TCGA-AR-A0U2-F18483C7F93BF3-479C-4CE3-AC96-DEBDBE56649CScheduled Follow-up SubmissionYESYESDead2551YES1609Distant MetastasisBoneLiver15122011,1TCGA-AR-A0U2-D195932E56AF80-2C77-4EA0-AD75-B645BC14CD634ChemotherapyCytoxanADJUVANTNO151220111TCGA-AR-A0U2-D19594DC973377-2597-4375-8377-9AB28D8847773ChemotherapyPaclitaxelADJUVANTNO151220112TCGA-AR-A0U2-D1959559FD28B5-689E-4E96-AC37-80921DB220F9142Hormone TherapyTamoxifenADJUVANTNO151220111TCGA-AR-A0U2-D19592CB681BE2-02B4-4823-BBE4-E34A66E10E574ChemotherapyDoxorubicinADJUVANTNO151220113TCGA-AR-A0U2-D19596320E795E-E0E7-4F90-9D11-014ABF0FF2BD1603Hormone TherapyExemestaneADJUVANTNO15122011,TCGA-AR-A0U2-R19591572AD134-752F-4FAD-B70B-3FB15869115BcGy28ADJUVANTNO115122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,426.0,BLACK OR AFRICAN AMERICAN,TCGA-UL-AAZ6,UL,AAZ6,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,8.4033203125,H-SCORE 190,Allred 0 = 0+0,Right,1.883876953124996,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Biopsy not specified,Positive,Positive,Positive,0.107421875,0.080078125,H score,270 H,10-19%,0,CAP SCORING GUIDELINE 2010,86.72265625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,1.57,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,21,3 Point Scale,2+,7thStage IIAT2N0MX,YES,YES,NO,28,8,2014,TCGA-UL-AAZ6-F693296E7AC488-7920-46A8-8009-C92426F9D8CCNONOYESTUMOR FREEAlive518NOPositive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Positive50-59%3+512015,NOTCGA-UL-AAZ6-D64302764AAD53-3A9B-4942-82BD-DE5F2932C2B1122ChemotherapyHerceptinYES2882014,TCGA-AR-A0TQ-R187150326E725-9461-46A7-BFFD-3D3CF96A4A0C250289EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO112122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,196.0,WHITE,TCGA-BH-A28Q,BH,A28Q,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,18.0,Allred score 5+3= 8,Allred score 7 per outside facility report,Right,1.6940527343749947,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,Segmental mastectomy with sentinel axillary lymph node biopsy,Infiltrating Lobular Carcinoma,Ductal/Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Indeterminate,Positive,Negative,0.3134765625,2.0,108,270 H,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,86.71875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,1.73,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.3,3 Point Scale,2+,7thStage IIBT2N1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,29,9,2011,TCGA-BH-A28Q-F642725B9A0C32-1B0D-45AA-BD92-C67CD68D5DD6NONONOTUMOR FREEAlive1119NO2882014,1TCGA-E2-A1BD-D194452534A6C5-8DD5-454D-8887-6098E2B7CBB11mg/day1mg/day170Hormone TherapyArimidexADJUVANTPOYES9122011,TCGA-AR-A251-R318218995BFD6-45E6-4008-9BEE-8F0AA9E64948160195EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1952012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,47.0,WHITE,TCGA-AC-A3YI,AC,A3YI,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,13.0,Allred 0 = 0+0,IHC,Right,1.593496093749995,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,Total mastectomy with left sentinel lymph node biospy,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, classical type, focal pleomorphic type",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Positive,1.0537109375,12.0,allred score =  8,205,10-19%,ACIS,Hercep Test  TM Dako,66.166015625,HER2 amplification - negative,Positive >2.2,YES,NO,3.2,BoneLiver,90-99%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.57,3 Point Scale,2+,7thStage IIICT1cN3aMX,YES,YES,NO,8,10,2012,TCGA-AC-A3YI-F615137CA1E88A-71BA-41EA-9D4F-88DAF4FDBF8DNOYESYESTUMOR FREEAlive707NO3062014,NOTCGA-AC-A3YI-D6151453B8EF0C-8F23-4867-B4D9-F4A71B62BED082167ChemotherapyCytoxanNOComplete Response3062014NOTCGA-AC-A3YI-D615152509B84B-EC3A-457C-9E7B-7F7095910A2882167ChemotherapyMethotrexateNOComplete Response3062014NOTCGA-AC-A3YI-D61516710B0219-323F-4EF2-A310-54559049BEDB82167Chemotherapy5-FUNOComplete Response3062014,TCGA-AC-A3YI-R61517F847AE09-DB60-4729-9889-41EF61CD8482250297External6000cGy30Primary Tumor FieldNOComplete Response3062014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7.0,ASIAN,TCGA-C8-A3M8,C8,A3M8,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,7.6484375,Allred (Biocare),H-Score 0,Right Upper Outer Quadrant,1.209003906249997,Axillary lymph node dissection alone,Pateys surgery,Modified Radical Mastectomy,Reexcision,Other,Modified Radical Masectomy,Infiltrating Lobular Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,"Biopsy, NOS",Negative,Positive,Positive,0.025390625,0.310546875,Allred,Allred,90-99%,Dako,DAKOHercepTest TM,166.220703125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,3.1,"Other, specifyskin",<10%,10-19%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,816,4 Point Scale,2+,7thStage IAT1cN0M0,YES,NO,NO,6,3,2012,TCGA-C8-A3M8-F7077936BA9AA0-FB67-44C6-8E4E-E8BDB8C92DB5NONOYESTUMOR FREEAlive394NO932015,NOTCGA-C8-A3M8-D707801A0AC881-C2A3-4989-8D7D-837481DF0F5B79Hormone TherapyTamoxifenYESComplete Response932015,TCGA-E2-A1BD-R194429FC62023-6140-4514-B9DE-74BCC48157A055108EXTERNAL BEAM6600cGyPrimary Tumor FieldADJUVANTNO19122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,22.0,WHITE,TCGA-E9-A248,E9,A248,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.279921874999998,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Lumpectomy,Right Breast reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.0205078125,0.0,110,180,90-99%,Dako,Venten,180.421875,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,33,"Other, specifyskin",80-89%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.3,3 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",22,3,2011,TCGA-E9-A248-F31211A4604D3E-8204-4714-8FD3-27CD2CD423D1Scheduled Follow-up SubmissionNOYESAlive59TUMOR FREENO2542012,TCGA-E9-A248-D31215E530CA0A-DA5E-4FBA-8E45-36898EA1D1712000mg1000mg21659ChemotherapyCyclophosphamideADJUVANTIVNO2542012TCGA-E9-A248-D3121373DBEE28-62F4-469F-B77D-40AD347DBA5B200mg100mg21659ChemotherapyDoxorubicinADJUVANTIVNO2542012,TCGA-E9-A5FK-R56480E57FDF1C-1CD3-4800-9D55-07CDC326E434130154External80GyRegional siteNOComplete Response1022014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,75.0,WHITE,TCGA-A7-A3J1,A7,A3J1,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,1.0,H-Score 300,allred score 5+3+8,Left,1.5859765624999962,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,Fine Needle aspiration biopsy,Infiltrating Lobular Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.1513671875,0.0,90 H,moderate,90-99%,ACIS,Venten,202.7158203125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,54,"Other, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,131,3 Point Scale,2+,7thStage IAT1cN0MX,YES,NO,NO,12,3,2012,TCGA-A7-A3J1-F36693B21A2460-AFDC-43FE-A22E-A2DDF374A03DNOYESYESTUMOR FREEAlive343NO12112012,NOTCGA-A7-A3J1-D36742DD2D3EBE-A0AB-41A9-B7C7-D19BCEF1E844137175Hormone TherapyAnastrazoleNO12112012NOTCGA-A7-A3J1-D36752637756E0-631E-439C-AE4F-8627197B8B18189251Hormone TherapyTamoxifenNO12112012NOTCGA-A7-A3J1-D3675514B7B938-1FD8-4DE7-8846-C4F32A49A5DE300Hormone TherapyAromasinYES12112012,TCGA-A7-A3J1-R366952476582A-72E1-4F42-86D0-721640EC49D689134External6100cGy33Primary Tumor FieldNOComplete Response12112012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1645.0,WHITE,TCGA-AO-A03N,AO,A03N,No,YES,C50.9,8500/3,C50.9,2006.0,WITH TUMOR,YES,19.0,Allred score = 8,Allred (Biocare),Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft,1.6672167968749918,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.00390625,2.0,strong,Moderate,<10%,ACIS,Hecep Test TM DAKO,89.78125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,40,"Other, specifyskin",70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.8985937499999987,4.70,3 Point Scale,1+,6thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",13,1,2011,TCGA-AO-A03N-F61121301663C-BE4E-421C-B0FD-765CA43B6D621645AliveWITH TUMORNOYES1645NO1312011TCGA-AO-A03N-F20915117BE088-A51C-4E7F-B00B-919FF76F2596Scheduled Follow-up SubmissionNOYESAlive2031YES1645Locoregional DiseaseNONOYESNegative4 Point ScaleNegative4 Point ScaleNegative2412012,"2TCGA-AO-A03N-D6118bb405d51-df85-4189-a4ab-9692bcadc16d2.5mg/day450820Hormone TherapyFemaraADJUVANTPONO13120112TCGA-AO-A03N-D61204dc6b6e5-f0c5-4dce-8cbc-a61ccc36b85620mg/day1007Hormone TherapyTamoxifenADJUVANTPOYES13120111TCGA-AO-A03N-D6114a849ee00-3092-4cca-a302-6ecb620fb617600mg/m2455153ChemotherapyCyclophosphamideADJUVANTIVNO13120111TCGA-AO-A03N-D6113bb14e284-9eb3-47cd-b0fa-660a24ff2c7b60mg/m2455153ChemotherapyDoxorubicinADJUVANTIVNO13120111TCGA-AO-A03N-D6116e9d527b8-949b-464a-82d8-3c5b5812ce32175mg/m2455153ChemotherapyPaclitaxelADJUVANTIVNO13120112TCGA-AO-A03N-D61176324b024-c954-4a43-b14e-c5c1a4acb3141mg/day207449Hormone TherapyArimidexADJUVANTPONO13120112TCGA-AO-A03N-D611900512901-db10-4833-8adf-5b3734b5d64f25mg/day8211007Hormone TherapyAromasinADJUVANTPONO131201110TCGA-AO-A03N-D20929182B47E5-FF2D-4BD1-A5D1-EBD1C0CDD4C0280mg80mg/m2218141828ChemotherapyPaclitaxelRECURRENCEIVNO241201211TCGA-AO-A03N-D20930C4226DFD-8E7A-4898-ACD6-2E907F30DD992800mg800mg/m2218351842ChemotherapyGemcitabineRECURRENCEIVNO24120129TCGA-AO-A03N-D20927DC919671-3B3F-4A46-B89C-1B4BB7F356D1230mg27mg/m2416991762ChemotherapyTesetaxelRECURRENCEPONO24120128TCGA-AO-A03N-D20923105C9E04-6F4F-4BC9-98D4-C5E70D9BC2541500mg250/5mg/mL316391667Hormone TherapyFulvestrantRECURRENCEIMNO241201212TCGA-AO-A03N-D209311B00197C-7F84-4429-80E9-471F087D8753704mg25mg/m2161857ChemotherapyVinorelbineRECURRENCEIVYES241201213TCGA-AO-A03N-D209325CB72B1A-283E-4161-A53A-824BC9641E61240mg120mg21989Other, specify in notesBone metastasesXgevaPROGRESSIONSCYES2412012",TCGA-AR-A0U2-R19591572AD134-752F-4FAD-B70B-3FB15869115BcGy28ADJUVANTNO115122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1154.0,WHITE,TCGA-A2-A0SY,A2,A0SY,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,14.0,H-Score 280,allred score 4 + 3 = 7,Left Upper Outer Quadrant,4.8,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Lobular Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Equivocal,0.0,1.0,Allred Score,Strong,10-19%,ACIS,Hercep Test  TM Dako,60.0,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromere 17 >= 2.1 is amplified,NO,YES,33,"LungBoneLiverOther, specifyskin",80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,42,3 Point Scale,2+,Stage IIIAT3N1M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",12,11,2010,TCGA-A2-A0SY-F13943F8198FBA-D635-4B1C-82E7-56851120B8B6Scheduled Follow-up SubmissionYESYESAlive1347TUMOR FREENO1872011,1TCGA-A2-A0SY-D339425d2f8f4-0b06-4677-b483-998d03b900e1mg4ChemotherapyTaxotereADJUVANTIVNO121120104TCGA-A2-A0SY-D340103bf9c75-4ae4-4747-a8b1-e1823ce91368mgmgTargeted Molecular therapyHerceptinADJUVANTIVNO121120105TCGA-A2-A0SY-D340875561abb-f715-4b09-b607-0ebecf96ca9fmg1mg256Hormone TherapyArimidexADJUVANTPOYES121120103TCGA-A2-A0SY-D3399ee88474f-8a2d-4902-9de7-f016aac05379mgmg4ChemotherapyCytoxanADJUVANTIVNO121120102TCGA-A2-A0SY-D3397c8d31da4-4cdc-4236-9aff-f8004227981cmgmg4ChemotherapyAdriamycinADJUVANTIVNO12112010,TCGA-A2-A0SY-R341039a5f3b7-96ba-4021-8108-609f4a14186f216263EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,304.0,WHITE,TCGA-A8-A099,A8,A099,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,8.51953125,allred score 5+3=8,H-SCORE 0,Right,1.7656738281249902,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.21875,1.7734375,Allred Score,H-Score,10-19%,ACIS,CAP SCORING GUIDELINE 2010,120.0947265625,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,33,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,185,3 Point Scale,3+,6thStage XT4bN3aMX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A099-F40552B6F0CCAB-A857-4381-8721-9D235581ADA6NOYESYESAlive304NO2322013,NOTCGA-A8-A099-D378070287D246-1FC1-4967-B545-E9D3A91C35A961Hormone TherapyExemestanen/aYES6122012,TCGA-A8-A099-R38167E30C6BD0-6060-41EC-8F04-8DA25A39056F92123ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1500.0,WHITE,TCGA-AR-A0TQ,AR,A0TQ,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,15.0,Image Analysis,Image Analysis,Right Upper Outer Quadrant,1.3237792968750035,Axillary lymph node dissection alone,Pateys surgery,Simple Mastectomy,Right Breast reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Positive,Positive,Equivocal,0.318359375,2.0,Allred Score 7,Allred Score 8,90-99%,Dako,CAP scoring guideline 2010,213.7529296875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.13,"Other, specifyskin",10-19%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,145,3 Point Scale,1+,6thStage IIIAT3N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,7,3,2011,TCGA-AR-A0TQ-F1871230876F63-82A1-49E6-824C-5ED620F98B30Scheduled Follow-up SubmissionYESYESAlive2784TUMOR FREENO12122011TCGA-AR-A0TQ-F4951563DB2C7C-B641-40D5-97F2-2949A3CACF0DYESYESTUMOR FREEAlive2240NO2102013TCGA-AR-A0TQ-F717171FC3693E-328C-44D8-AF78-067700617492NOYESYESTUMOR FREEAlive2991NO3032015,1TCGA-AR-A0TQ-D191988FD0D2B4-23DC-43ED-BAAE-74845D09E5B9550mg60mg/m243779ChemotherapyDoxorubicinADJUVANTIVNO121220111TCGA-AR-A0TQ-D192505C21AE2A-6F50-48B8-B88B-E34B086D11D39720mg6mg/kg13254482ImmunotherapyTrastuzumabADJUVANTIVNO121220111TCGA-AR-A0TQ-D19240C1517334-59DE-4F7C-BFC3-DBF7226574CC1785mg80mg/m23114226ChemotherapyPaclitaxelADJUVANTIVNO121220111TCGA-AR-A0TQ-D192478BBEC5A9-8FCF-4170-ADB1-F088C1DD8B05495mg4mg/kg9393ImmunotherapyTrastuzumabADJUVANTIVNO121220111TCGA-AR-A0TQ-D1923973DDD614-1A82-4A11-936A-F1450119F352435mg60mg/m2193107ChemotherapyPaclitaxelADJUVANTIVNO121220111TCGA-AR-A0TQ-D19249C7A9FEB7-335D-4E12-8111-4308158A36CF3900mg2mg/kg4100226ImmunotherapyTrastuzumabADJUVANTIVNO121220111TCGA-AR-A0TQ-D1923860A907F7-7E0E-47D5-B9C2-382D8D60B4455560mg600mg/m243779ChemotherapyCytoxanADJUVANTIVNO121220112TCGA-AR-A0TQ-D1927757DEE87D-F4D7-4369-B46B-617DB56ABCD025mg/day2331867Hormone TherapyExemestaneADJUVANTPONO121220112TCGA-AR-A0TQ-D19278306F161F-8B4E-4960-AAA3-774774B68664270mg3.75371864Hormone TherapyTriptorelinADJUVANTIMNO12122011,TCGA-AR-A0TQ-R187150326E725-9461-46A7-BFFD-3D3CF96A4A0C250289EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO112122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2359.0,WHITE,TCGA-AO-A12B,AO,A12B,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,2.0,ER Positive H-Score 95,H-Score 15,Right Upper Inner QuadrantRight Lower Inner QuadrantRight,1.537119140624997,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,0,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,strong,Allred Score 5,<10%,CISH,3+ Positive,32.5263671875,Vysis AutoVysion System,Path Vysion HER2 DNA Probe Kit,NO,YES,2.6,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.85,3 Point Scale,4+,6thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,8,12,2010,TCGA-AO-A12B-F5887C8F9252B-73CB-4886-B7CF-A7628F26138A2359AliveTUMOR FREENOYES8122010TCGA-AO-A12B-F19422F103C9C8-1341-45A9-92A0-ECFC79605ACAScheduled Follow-up SubmissionNOYESAlive2622NO12122011TCGA-AO-A12B-F434733FA3F48A-1DC7-49B7-BA5C-07AB14D891F2NONOYESTUMOR FREEAlive2989NO2252013,1TCGA-AO-A12B-D59592470c06b-34d1-4a59-9d6c-ee4578b7caac261.6mg40mg/m2445118ChemotherapyMethotrexateADJUVANTIVNO10120111TCGA-AO-A12B-D5958adc6778f-388f-403a-af06-ced81e3e0d533924mg600mg/m2445118ChemotherapyCyclophosphamideADJUVANTIVNO10120112TCGA-AO-A12B-D59614455833b-0272-453e-8f0b-2ad2e971c7511mg/day1401980Hormone TherapyArimidexADJUVANTPONO10120111TCGA-AO-A12B-D596036ded530-1c08-428f-a97e-7c11db1a953c3924mg600mg/m2445118ChemotherapyFluorouracilADJUVANTIVNO1012011,TCGA-A8-A099-R38167E30C6BD0-6060-41EC-8F04-8DA25A39056F92123ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,428.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3XV,A2,A3XV,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,4.0,Allred score 5+3= 8,allred score 4 + 3 = 7,Right,2.6,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,1+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Positive,Positive,Equivocal,0.0,0.0,Allred score 6,250,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,60.0,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,1.7,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,4.5,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,NO,24,8,2012,TCGA-A2-A3XV-F43306F58B3842-7B71-4CD6-B9D5-605951079187NOYESYESTUMOR FREEAlive699NO1652013TCGA-A2-A3XV-F59117057E80F7-F449-4E70-8571-4D0D06A94C23NOYESYESTUMOR FREEAlive996NO152014,NOTCGA-A2-A3XV-D3463071D050BF-7E93-4BA7-B969-F1887FC94B8962175ChemotherapyCarboplatinNOComplete Response2482012NOTCGA-A2-A3XV-D346317CF49A37-54D6-47C1-B0FA-F3732990E8A262175ChemotherapyDocetaxelNOComplete Response2482012NOTCGA-A2-A3XV-D34632212FE1BA-E2B8-435A-91E6-5BC6F1B03C9B62428Targeted Molecular therapyTrastuzumabNOComplete Response2482012NOTCGA-A2-A3XV-D34633660D3D61-D8EE-44B2-8CE3-F93CB2202075429Hormone TherapyTamoxifenYES2482012,TCGA-A2-A3XV-R34634F2E7F201-0A1D-4AD5-B148-EA69A1294BA6211246External50Gy25Primary Tumor FieldNOComplete Response2482012TCGA-A2-A3XV-R34635EFC36FA5-0568-4B56-8EFF-E56B96239F74247258External10Gy5Primary Tumor FieldNOComplete Response2482012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,136.0,WHITE,TCGA-D8-A27T,D8,A27T,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,12.0,manual counting,manual counting,Right Upper Outer QuadrantRight Lower Outer Quadrant,2.5811132812499897,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Simple Mastectomy,Margin resection,Mastectomy NOS,Wide Local Excision,Infiltrating Lobular Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Positive,Positive,Negative,0.0791015625,12.0,>75%,>75%,90-99%,Hercep Test  TM Dako,Venten,106.419921875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,64,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,131,3 Point Scale,2+,7thStage IIICT2N3aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,7,2011,TCGA-D8-A27T-F300962B56379D-571E-4B7B-B40D-9720573C8983Scheduled Follow-up SubmissionYESYESAlive398TUMOR FREENO242012,TCGA-D8-A27T-D300972BC3A132-221D-403F-9E82-697C8B87ADFDmg20mg/day227Hormone TherapyTamoxifenADJUVANTPOYES242012TCGA-D8-A27T-D300988592A3D1-BE31-4706-AC39-9C5D149F0914405.6+4056mg101.4+1014mg/day6115220Chemotherapydoxorubicine+cyclophosphamideADJUVANTIVNO242012,TCGA-D8-A27T-R30099FA4577E5-E322-4AEF-9C38-1D265D740A86272301EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2331.0,WHITE,TCGA-GM-A2DM,GM,A2DM,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,2.0,H-SCORE 0,H-Score 160,Right Lower Outer Quadrant,1.607460937499986,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Margin resection,Other,partial mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Positive,Positive,Negative,0.0,0.0,"Strong using Weak, Moderate and Strong",8,<10%,0,Hercep Test  TM Dako,57.7451171875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,51,"Other, specifyaxilaary node negative but intrammary node positive",40-49%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,3.65,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,30,9,2011,TCGA-GM-A2DM-F471043ACB5CDD-7AFC-45D0-9145-0EC2DD8EE8E0NOYESYESTUMOR FREEAlive3226NO2282013,YESTCGA-GM-A2DM-D47106AADE02DF-74F2-4DD1-A0AE-1429B918690681169ChemotherapyTaxolNOComplete Response2282013YESTCGA-GM-A2DM-D47107140AE260-F266-41E9-9467-8C7E03D3AB54176218ChemotherapyFluorouracilNOComplete Response2282013YESTCGA-GM-A2DM-D47108873034B7-62ED-4DD0-AD5C-84DAB7801B20176218ChemotherapyEpirubicinNOComplete Response2282013YESTCGA-GM-A2DM-D471097C8F3B47-B784-4B27-9FB2-7B466008E490176218ChemotherapyCytoxanNOComplete Response2282013NOTCGA-GM-A2DM-D47110B5B25354-BF47-47EA-B68D-748265329F82279772Hormone TherapyArimidexNOComplete Response2282013,TCGA-GM-A2DM-R471058493586C-8C86-4027-959A-2E8975783875237273External52Gy26Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12N,C8,A12N,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,Allred score 7 (outside facility),allred score 2+2 = 4,Right,1.674550781249995,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.0078125,0.0029296875,Allread Score 8,Allred Score 8,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,58.3671875,HER2 amplification - negative,>= 2.0 Positive,YES,NO,33,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,131,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",12,4,2011,TCGA-C8-A12N-F2026496DF27E9-D48D-4A01-8961-1CFFC6B18408Scheduled Follow-up SubmissionNOYESAlive358TUMOR FREENO912012,"02TCGA-E2-A1B1-D194331C0E879C-D0B0-45F3-B530-C9E53A0BFC312145mg195mg11155232ChemotherapypaclitaxelADJUVANTIVNO912201102TCGA-E2-A1B1-D19428607FFFF8-3B83-4A56-8A6B-04F87ECAD6F516128mg672mg24155491ChemotherapyherceptinADJUVANTIVNO912201101TCGA-E2-A1B1-D19424AA17D85A-0FDD-47FB-9D84-B8E632A1937460mg4mg1571969Other, specify in notesbiphosphonatezoledronic acidADJUVANTIVNO912201101TCGA-E2-A1B1-D19438F78B48EF-E33F-4DC4-8527-32A39CF392F3584mg146mg471134ChemotherapyadriamycinADJUVANTIVNO912201104TCGA-E2-A1B1-D194192F50945A-770E-4BAE-A4BA-BF8337D74422mg20mg/day239Hormone TherapytamoxifenADJUVANTPOYES912201103TCGA-E2-A1B1-D19421347D45D4-7A50-4C57-9CAF-B7BE348BDE4Fmg3.75mg71Hormone TherapytriptorelinADJUVANTIMYES912201101TCGA-E2-A1B1-D194358C3CFC3B-88E5-4E90-AE7E-1F4CE327F0365856mg1464mg471134ChemotherapycyclophosphamideADJUVANTIVNO9122011",TCGA-A7-A3J1-R366952476582A-72E1-4F42-86D0-721640EC49D689134External6100cGy33Primary Tumor FieldNOComplete Response12112012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12V,C8,A12V,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,5.0,Allred score 7 (outside facility),Allred score 4+3 = 7,Right,1.3991210937499918,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Negative,Negative,0.01953125,0.0,Allred Score 6,Allred score = 7,90-99%,Dako,DAKOHercepTest TM,140.2060546875,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,33,"Other, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,145,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,YES275Distant MetastasisLung,22,3,2011,TCGA-C8-A12V-F1909512E9D7F7-A7A6-4E0F-B152-CE708D83BA6CScheduled Follow-up SubmissionNOYESAlive385TUMOR FREENO2122011,NOTCGA-AR-A5QM-D43857D7CB0EED-DFD0-48DF-AE12-84DB425177EF36Hormone TherapyAnastrozoleYES1062013,TCGA-BH-A0B1-R154346CBDF1E7-E2BB-4EEC-9C61-547430A54E0A287343EXTERNAL BEAM6040cGy28Primary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1187.0,WHITE,TCGA-AO-A03T,AO,A03T,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,12.0,Allred score = 8,CAP SCORING GUIDELINE 2010,Left Upper Outer QuadrantLeft,1.675292968749995,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,partial mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,0,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0009765625,2.0,Allread Score 8,Allred Score 6,<10%,CISH,3+ POSITIVE,30.4228515625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.40,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,68,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,19,9,2010,TCGA-AO-A03T-F325525D19A8C-2173-4BC0-815E-256998CB41351187AliveTUMOR FREENOYES1992010TCGA-AO-A03T-F154752331CB7A-6AD6-4EE4-93E8-FC79C2F2E561Scheduled Follow-up SubmissionYESYESAlive1456NO2282011TCGA-AO-A03T-F434767BFCB10D-E59D-4D33-92A0-B27E4BE856C9NONOYESTUMOR FREEAlive2124NO2252013,1TCGA-AO-A03T-D3059b907f99e-3495-43b4-b00a-67573ac72ce94032mg600mg/m2480122ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO6920101TCGA-AO-A03T-D3061febd5704-d4cd-477f-8be2-22d0c03c0826404mg60mg/m2480122ChemotherapyDOXORUBICINADJUVANTIVNO19920101TCGA-AO-A03T-D3062faee37a8-911b-420f-a9a3-de6d58ef95831176mg175mg/m24136178ChemotherapyPACLITAXELADJUVANTIVNO19920102TCGA-AO-A03T-D3065ab1ed21c-89e2-4211-8db0-501a91fcb91d20mg/day2321095Hormone TherapyTAMOXIFEN (NOVADEX)ADJUVANTPONO19920103TCGA-AO-A03T-D307089f9ff00-958d-462b-9439-712c34271b9b7.5mg1095Hormone TherapyLUPRONADJUVANTIMYES19920103TCGA-AO-A03T-D306802ff28ad-6659-4062-8dd8-45461526756a2.5mg/day1130Hormone TherapyLETROZOLE (FEMARA)ADJUVANTPOYES1992010,TCGA-A2-A3XV-R34634F2E7F201-0A1D-4AD5-B148-EA69A1294BA6211246External50Gy25Primary Tumor FieldNOComplete Response2482012TCGA-A2-A3XV-R34635EFC36FA5-0568-4B56-8EFF-E56B96239F74247258External10Gy5Primary Tumor FieldNOComplete Response2482012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,236.0,WHITE,TCGA-D8-A1X6,D8,A1X6,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,manual counting,manual counting,Left Upper Inner QuadrantLeft Upper Outer Quadrant,1.4819531249999962,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Margin resection,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Negative,Positive,Negative,0.22265625,5.0,>75%,>75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,66.2451171875,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,3.1,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.80,3 Point Scale,2+,7thStage IIIAT3N2aMX,YES,YES,YES994Distant MetastasisBoneNOYESYES,9,6,2011,TCGA-D8-A1X6-F2998098F6BFFF-5DE5-4EBE-A1E8-B4C971C5155CScheduled Follow-up SubmissionNOYESAlive541TUMOR FREENO3132012,TCGA-D8-A1X6-D299824AC37B69-6DC4-4880-9775-F6A571022CB5mg20mg/day65Hormone TherapytamoxifenADJUVANTPOYES3132012,TCGA-AR-A2LO-R37257ADDD5CDF-B239-4A98-AA02-A5DF64C626FF196228External5000cGy25Primary Tumor FieldNO7122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1236.0,WHITE,TCGA-AR-A252,AR,A252,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,4.0,Allred score 5+3 = 8,manual counting,Left Upper Outer QuadrantLeft Lower Outer Quadrant,2.596699218749992,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Margin resection,Mastectomy NOS,Wide local excision,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Positive,Positive,Negative,0.072265625,0.0,Allred score = 8,Allred score = 0,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,86.291015625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.5,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,42,3 Point Scale,1+,6thStage IT1N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",30,8,2011,TCGA-AR-A252-F318298922C8E4-9215-4E25-A1EE-4F5A07FA1AE0Scheduled Follow-up SubmissionYESYESAlive1236NO952012TCGA-AR-A252-F49510976FA976-190E-4CEA-AFE1-D220E1EF1524YESYESTUMOR FREEAlive2226NO2102013TCGA-AR-A252-F7172752A82191-71D1-4E9A-AB5F-7F3869722CD1NOYESYESTUMOR FREEAlive2838NO3032015,NOTCGA-AR-A252-D318342B107267-0243-41AB-A8D4-E3A877850BFF5597ChemotherapyDoxorubicinNO2252012NOTCGA-AR-A252-D3183515E7A4D2-8203-45A9-B8A1-DAB0C819E8AA5597ChemotherapyCytoxanNO2252012NOTCGA-AR-A252-D31836A51DB83F-929F-44F2-B30E-2A608BEFBB50116Hormone TherapyTamoxifenYES2252012,TCGA-AR-A252-R31832DA3119FA-2C7A-401D-A8D4-5E9BC5396C15118159EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1952012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,99.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A5YP,LL,A5YP,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,12.0,H-Score 300,H-SCORE 280,RightRight Lower Inner Quadrant,3.4,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Negative,0.0,2.0,strong,160,<10%,CISH,CAP SCORING GUIDELINE 2010,20.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,35,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,118,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,NO,20,5,2013,TCGA-LL-A5YP-F59323447B3E95-78F4-48F2-86F1-C67294C4D37CNOYESYESAlive450NO852014,NOTCGA-LL-A5YP-D43371BC6B458B-5E1E-406F-B8B0-210BAEFD39195092ChemotherapyCytoxanNO2052013NOTCGA-LL-A5YP-D43372A1DC4722-1400-4337-B4EF-0797D7BC86025092ChemotherapyAdriamycinNO2052013NOTCGA-LL-A5YP-D59324AB4E3D99-82DD-4221-A645-BAD1768BAEC1113457ImmunotherapyherceptinNO852014NOTCGA-LL-A5YP-D59325F5B3F5A9-5B54-4D89-94D1-B44F2A5E2881302Hormone TherapyarimidexYES852014,TCGA-LL-A5YP-R593271B2D1DFE-6C4A-47FD-98BA-CAF7E1D38BE3225266External6000cGy30Primary Tumor FieldNO852014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,181.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A6VV,A7,A6VV,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,5.0,No value Given,H-Score 290,Right,1.906650390624986,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Pateys surgery,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.2470703125,0.0,Intensity=Strong,Strong,10-19%,CISH,CAP SCORING GUIDELINE 2010,117.2783203125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,40,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,42,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,NO,22,10,2013,TCGA-A7-A6VV-F572492A10E9C7-16B5-4CDC-8548-D21B927922EENONOYESTUMOR FREEAlive313NO632014,NOTCGA-A7-A6VV-D572478A804A22-B193-4C71-8EBB-6FD22D9F605E160266ChemotherapyCyclophosphamideNOComplete Response632014NOTCGA-A7-A6VV-D5724852B5F633-7FB7-42E1-A8EC-60B50825FBCF160266ChemotherapyTaxotereNOComplete Response632014,TCGA-BH-A0B1-R154346CBDF1E7-E2BB-4EEC-9C61-547430A54E0A287343EXTERNAL BEAM6040cGy28Primary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,633.0,WHITE,TCGA-E2-A1L7,E2,A1L7,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,20.0,Allred score 1+1 = 2,Allred score 0+0 = 0,Right Upper Outer Quadrant,1.5090136718750031,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Wide Local Excision,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,4 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Equivocal,Negative,Negative,0.7607421875,7.0,Allred score = 0,Allred score = 2,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,199.7255859375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,2.8,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,441,4 Point Scale,1+,6thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,1,6,2011,"TCGA-E2-A1L7-F205883F50F013-BAFD-4D4C-915F-4D9CF0494F7AScheduled Follow-up SubmissionYESYESAlive834TUMOR FREENO1212012TCGA-E2-A1L7-F702980E0A1363-5109-4CB5-B655-FCBCEF191361NOYESYESTUMOR FREEAlive1836YES1619New Primary TumorOther, specifyleft breastYES1662YESNONegativeNegative1632015","1TCGA-E2-A1L7-D2059036955FD4-89C2-4248-AAA1-8D8CE8F1DA044800mg1200mg44183ChemotherapyCyclophosphamideADJUVANTIVNO12120121TCGA-E2-A1L7-D20589B07261AA-1C81-4C97-9D43-2C0E1543ABFF480mg120mg44183ChemotherapyDoxorubicinADJUVANTIVNO12120123TCGA-E2-A1L7-D205920C4583A4-E88D-4BDE-9CB3-9938094B71F81600mg/day1600mg/day170Other, specify in notesPhase III Clinical TrialClodronateADJUVANTPOYES12120124TCGA-E2-A1L7-D20594EAECF0E4-3985-48CF-AB0D-2AC40D9B40361mg/day1mg/day240Hormone TherapyArimidexADJUVANTPOYES12120122TCGA-E2-A1L7-D2059142D99A31-F6C7-4E6D-9F04-7D6E1901B3921436mg359mg497153ChemotherapyPaclitaxelADJUVANTIVNO1212012",TCGA-E2-A1L7-R20596DB702F0D-3D33-490B-8DBE-AB55654B03A8191237EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO11212012TCGA-E2-A1L7-R70387D9FCDCF6-AA31-494F-918B-042E492EEDF216941735External60Gy30Primary Tumor FieldNOComplete Response1632015
TCGAFPPP,Breast,No,MALE,Alive,0.0,834.0,WHITE,TCGA-E2-A14W,E2,A14W,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,Left Upper Outer Quadrant,6.668300781249946,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Equivocal,0.296875,0.0,Allred Score 8,STRONG,30-39%,Dako,CAP SCORING GUIDELINE 2010,121.9091796875,HER2 amplification - negative,Ratio >=2.0,NO,YES,33,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.66,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,25,4,2011,TCGA-E2-A14W-F1880376297030-41ED-487B-B704-02C9E748CCC0Scheduled Follow-up SubmissionNOYESAlive974TUMOR FREENO4112011,1TCGA-E2-A14W-D1880625E2567F-6AC2-4B0C-BB4C-6288D9260C8F3786mg1122mg443106ChemotherapyCytoxanADJUVANTIVNO41120111TCGA-E2-A14W-D1880444D83D4E-70ED-4A03-8A24-AA0FAF79C3B95964mg585mg1643321ChemotherapyHerceptinADJUVANTIVNO41120111TCGA-E2-A14W-D188089A006D8C-5728-4281-81D4-F33365AFA016473mg140mg443106ChemotherapyDocetaxelADJUVANTIVNO41120112TCGA-E2-A14W-D18811632F839F-82AA-43E0-BC1A-9CFCEB78B2CC20mg/day20mg/day169Hormone TherapyTamoxifenADJUVANTPOYES4112011,TCGA-EW-A1OX-R291009B7F9DE6-C196-489B-8DBA-6BA51CA85C62211253EXTERNAL BEAM6000cGyPrimary Tumor FieldADJUVANTNO1832012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A5UP,E9,A5UP,No,YES,C50.9,8503/3,C50.9,2012.0,TUMOR FREE,YES,10.0,allred score 0 + 0 = 0,Allred score 4+3 = 7,Left Upper Outer Quadrant,7.288535156250001,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Right total mastectomy with lymph node left axillary lymph node excision,"Other, specify",Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Tumor resection,stereotactic biopsy,Positive,Positive,Negative,0.1884765625,0.0,8,120,90-99%,Hercep Test  TM Dako,Dako Hercept test,155.01171875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.13,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,NO,23,5,2013,TCGA-E9-A5UP-F57716E0F63996-79B7-4B36-AAE5-2D10D7A17457NOYESYESTUMOR FREEAlive438NO2132014TCGA-E9-A5UP-F7152595FB53E8-8B32-4656-9B5C-1384676E9BFFNOYESYESTUMOR FREEAlive803NO2632015,NOTCGA-E9-A5UP-D57717DCB3552D-9065-47A4-A78C-6C66D46F8D068Hormone TherapyTamoxifenYES2132014,TCGA-E9-A5UP-R57718B7F0EB25-DAD8-4E55-AFD1-5B1A12F009CD4478External46GyPrimary Tumor FieldNOComplete Response2132014TCGA-E9-A5UP-R577193FAF99BF-83F4-49DE-AE9F-99A2D468D3E94478External44GyRegional siteNOComplete Response2132014TCGA-E9-A5UP-R5772024449F45-1D96-49E5-9300-B5A5F8E063304478External40GyRegional siteNOComplete Response2132014TCGA-E9-A5UP-R5772236D0D37C-2664-4204-9CA1-A61CD78FF6B980101External33GyRegional siteNOComplete Response2132014TCGA-E9-A5UP-R577235578F153-CCB2-4B38-9BD2-2DF088DD9BC280101External30GyRegional siteNOComplete Response2132014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1286.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A259,A2,A259,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,2.0,ER Positive H-Score 95,H-Score 15,Left,1.1,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Close,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,"Strong using Weak, Moderate and Strong","Strong using Weak, Moderate and Strong",10-19%,Hercep Test  TM Dako,Dako Hecept Test,60.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,125,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,132,3 Point Scale,3+,6thStage IT1cN0 (i-)M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",20,6,2011,TCGA-A2-A259-F3103491F2A594-2323-476B-9FE1-3BE4B7A05EFBScheduled Follow-up SubmissionNOYESAlive1596TUMOR FREENO2342012,1TCGA-A2-A259-D14577F4C128EF-E7C2-407A-833B-C1EC52088D3D1mg96Hormone TherapyArimidexADJUVANTPOYES2072011,TCGA-A2-A0CX-R196969e31ee3-a4ba-40bf-b722-f1a229006582305ADJUVANTNO11392010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,777.0,WHITE,TCGA-BH-A0AY,BH,A0AY,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,1.0,Allread score 5+3 = 8,H-SCORE 140,Left Lower Outer QuadrantLeft,1.5460937500000027,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Excisional biopsy,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.271484375,0.0,H-Score,0%,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,62.66796875,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,54,"LungBoneLiverOther, specifyskin",<10%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,816,3 Point Scale,1+,Stage IIAT2N0 (i-)M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",3,11,2010,TCGA-BH-A0AY-F15456A54FAA28-CE61-4E7A-A5C4-2CC9FFE880CAScheduled Follow-up SubmissionNOYESAlive777TUMOR FREENO3112010,1TCGA-BH-A0AY-D154573FA11B70-C4E4-4DA1-954E-E885461FFC9D4131192ChemotherapyADJUVANTIVNO31120101TCGA-BH-A0AY-D15459CEBF2E3D-12FA-496F-96BE-C677BBC8A80150mg/day209Hormone TherapyAromasinADJUVANTPOYES3112010,TCGA-AR-A5QM-R438565B7461B2-C13C-47B1-B736-33437677102C3682External6000cGy30Primary Tumor FieldNO1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1361.0,WHITE,TCGA-E2-A1B1,E2,A1B1,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,6.0,Allred score 3+2 = 5,Allred score 2+2 = 4,Left Upper Outer Quadrant,15.12,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Equivocal,0.31640625,1.0,Allred score = 4,Allred score = 5,70-79%,Dako,Venten,126.36328125,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.38,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.9,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,25,4,2011,TCGA-E2-A1B1-F1941658DADC0D-AD16-4876-BA6E-B0967CF577A0Scheduled Follow-up SubmissionYESYESAlive1613TUMOR FREENO9122011TCGA-E2-A1B1-F7000987D15560-4AE5-45AD-B931-54DE2E14C301NOYESYESTUMOR FREEAlive2653NO922015,"02TCGA-E2-A1B1-D194331C0E879C-D0B0-45F3-B530-C9E53A0BFC312145mg195mg11155232ChemotherapypaclitaxelADJUVANTIVNO912201102TCGA-E2-A1B1-D19428607FFFF8-3B83-4A56-8A6B-04F87ECAD6F516128mg672mg24155491ChemotherapyherceptinADJUVANTIVNO912201101TCGA-E2-A1B1-D19424AA17D85A-0FDD-47FB-9D84-B8E632A1937460mg4mg1571969Other, specify in notesbiphosphonatezoledronic acidADJUVANTIVNO912201101TCGA-E2-A1B1-D19438F78B48EF-E33F-4DC4-8527-32A39CF392F3584mg146mg471134ChemotherapyadriamycinADJUVANTIVNO912201104TCGA-E2-A1B1-D194192F50945A-770E-4BAE-A4BA-BF8337D74422mg20mg/day239Hormone TherapytamoxifenADJUVANTPOYES912201103TCGA-E2-A1B1-D19421347D45D4-7A50-4C57-9CAF-B7BE348BDE4Fmg3.75mg71Hormone TherapytriptorelinADJUVANTIMYES912201101TCGA-E2-A1B1-D194358C3CFC3B-88E5-4E90-AE7E-1F4CE327F0365856mg1464mg471134ChemotherapycyclophosphamideADJUVANTIVNO9122011",TCGA-E2-A1B1-R1944006E5C1F9-947C-4BA4-8F46-AE56691487B8302314EXTERNAL BEAM6000cGy31Primary Tumor FieldADJUVANTNO019122011
TCGAFPPP,Breast,No,FEMALE,Dead,239.0,676.484375,WHITE,TCGA-EW-A1P8,EW,A1P8,No,YES,C50.9,8500/3,C50.9,2010.0,WITH TUMOR,YES,15.0,H-Score 300,CAP scoring guideline 2010,Left Upper Outer Quadrant,4.66942382812501,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Lumpectomy,Reexcision,Modified radical mastectomy,Total mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Positive,Negative,Negative,0.771484375,14.0,Intensity=Weak,Intensity=Strong,<10%,CISH,CAP SCORING GUIDELINE 2010,115.423828125,HER2 amplification - negative,Ratio >=2.2,NO,YES,1.78,"LungBoneLiverOther, specifyskin",<10%,<10%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,1.57,3 Point Scale,2+,7thStage IIICT2N3bM0,YES,NO,Negative<10%3 Point ScaleNegative<10%3 Point ScaleNegative<10%,27,5,2011,TCGA-EW-A1P8-F291218F96B637-28EF-44CB-901F-20EA615880C7Scheduled Follow-up SubmissionNOYESDead239WITH TUMORYES207Distant MetastasisLungNO832012,FEC x3TCGA-EW-A1P8-D29122995CBFB8-E6D5-4374-A924-F0E06B3CCB01340140ChemotherapyFluorouracilADJUVANTIVNO832012FEC x3TCGA-EW-A1P8-D2963224AB482A-B1B6-4E84-B3EA-F5F8952F6019340140ChemotherapyEpirubicinADJUVANTIVNO2232012FEC x3TCGA-EW-A1P8-D29633BE0E1D18-E1B5-4E37-AD2C-75B257D2F899340140ChemotherapyCyclophosphamideADJUVANTIVNO2232012,TCGA-A2-A0CX-R196969e31ee3-a4ba-40bf-b722-f1a229006582305ADJUVANTNO11392010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,464.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A1OW,EW,A1OW,No,YES,C50.9,8090/3,C50.9,2009.0,TUMOR FREE,YES,3.0,H-Score 150,allred score 5+3+8,Left Upper Outer Quadrant,4.070527343749998,Sentinel node biopsy alone,SN+1 non sentinel node,Lumpectomy,Reexcision,Other,Total mastectomy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Positive,Negative,Negative,0.0,0.0,Two-tier,Intensity=Strong,<10%,CISH,Dako Hercept test,85.27734375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4.43,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,3 Point Scale,3+,6thStage IIAT2N0MX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",18,5,2011,TCGA-EW-A1OW-F291177C5B80F1-BF04-41CB-8B91-725221A42BF0Scheduled Follow-up SubmissionYESYESAlive694TUMOR FREENO832012,FEC then TTCGA-EW-A1OW-D29123F1A2F243-E72C-4F14-9F60-6942754A36382895mg965mg3108213ChemotherapyFluorouracilADJUVANTIVNO832012FEC then TTCGA-EW-A1OW-D292802AC7C8DB-4D01-4FE0-9CA5-E7C406356CBE489mg163mg3108213ChemotherapyTaxotereADJUVANTIVNO1332012FEC then TTCGA-EW-A1OW-D29278444E5133-0315-4949-8801-8905B7A49C1F579mg193mg3108213ChemotherapyEpirubicinADJUVANTIVNO1332012FEC then TTCGA-EW-A1OW-D292791684EE5E-6B0E-4898-964A-9055C7ABE13B2895mg965mg3108213ChemotherapyCyclophosphamideADJUVANTIVNO1332012,TCGA-EW-A1OW-R2923080666302-3A99-4636-86B0-790EB34C1D21294338EXTERNAL BEAM6000cGyPrimary Tumor FieldADJUVANTNO11232012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,352.0,WHITE,TCGA-E2-A10A,E2,A10A,No,YES,C50.9,8500/3,C50.9,2007.0,WITH TUMOR,YES,3.0,Allred score 4+3=7,Allred score 5+3=8,Left Upper Outer Quadrant,1.21,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Surgical resection,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Positive,0.0,0.0,Allred score 8,Allred score 7,40-49%,Hercep Test  TM Dako,CAP scoring guideline 2010,437.7890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,74,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,<4.0,3 Point Scale,2+,6thStage IIBT3N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,11,2,2011,TCGA-E2-A10A-F174229389E64B-E562-45E1-8E41-869781EEF1FCScheduled Follow-up SubmissionYESYESAlive1229YES75Distant MetastasisBoneNOYESYES1392011TCGA-E2-A10A-F1752280443D13-7053-4DEE-AB14-7199DF35B8FDScheduled Follow-up SubmissionYESYESAlive1229YES92Distant MetastasisBrainNOYESYES12102011,2TCGA-E2-A10A-D7700932948c9-faaa-4f8d-a773-780433c65a7a20mg/day91Hormone TherapyTamoxifenADJUVANTPOYES14220111TCGA-E2-A10A-D7699de773115-886c-445c-874a-99ed871ca85d3.6mg3.6mg88Hormone TherapyZoladexADJUVANTSCYES14220112TCGA-E2-A10A-D174304729CED9-4A3B-43B6-AB21-95DC86CFA9FE4mg148Targeted Molecular therapyZometaPROGRESSIONIVYES2792011,TCGA-E2-A10A-R7701eceeff60-cf37-412c-958b-cf5faaf96030102102OTHERgamma knife radiasurgery2200cGy1Distant RecurrenceADJUVANTNO21422011TCGA-E2-A10A-R76987ef33888-270b-489f-900d-6d0b83e76ddf119130OTHERstereostatic radiotherapy3000cGy5Distant RecurrenceADJUVANTNO11422011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,85.0,WHITE,TCGA-D8-A1X7,D8,A1X7,No,YES,C50.9,8503/3,C50.9,2010.0,TUMOR FREE,YES,3.0,manual counting,manual counting,Right Upper Outer Quadrant,1.3295996093750044,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Reexcision,Other,Excision,"Other, specify",Ductal partially papillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0341796875,0.0,>75%,>75%,90-99%,Hercep Test  TM Dako,Dako Hercept test,111.283203125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.6,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5,3 Point Scale,2+,7thStage IIAT2N0MX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",9,6,2011,TCGA-D8-A1X7-F29985DBB236CA-AAC6-48BD-B702-95BA93EBE283Scheduled Follow-up SubmissionNOYESAlive509TUMOR FREENO3132012,TCGA-D8-A1X7-D29986F5CBC7F0-42CF-407F-8F28-441B89B91D06mgmg/m264134ChemotherapyHormone Therapydoxorubicine+cyclophosphamide+tamoxifenADJUVANTIVPONO3132012,TCGA-AR-A5QM-R438565B7461B2-C13C-47B1-B736-33437677102C3682External6000cGy30Primary Tumor FieldNO1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7.0,WHITE,TCGA-E9-A5UO,E9,A5UO,No,YES,C50.9,8480/3,C50.9,2012.0,TUMOR FREE,YES,10.0,H-Score 300,H-Score 0,Right Upper Outer Quadrant,3.3585839843749907,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Partial mastectomy,Mucinous Carcinoma,Ductal with mucinous features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Negative,Positive,Negative,0.1904296875,0.0,Allred score = 5,Two-tier,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,163.7265625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,3.1,"Other, specifyaxilaary node negative but intrammary node positive",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,61,3 Point Scale,2+,7thStage IIAT2N0M0,NO,YES,PositiveNegative,23,5,2013,TCGA-E9-A5UO-F564818F3F5F6D-C479-4BDE-AAE8-93351797E3DANONONOTUMOR FREEAlive420NO1022014TCGA-E9-A5UO-F7021030B02ABC-CC95-48D0-985F-42DAC16CAC58NONONOTUMOR FREEAlive785NO3012015,FEC then TTCGA-EW-A1OW-D29123F1A2F243-E72C-4F14-9F60-6942754A36382895mg965mg3108213ChemotherapyFluorouracilADJUVANTIVNO832012FEC then TTCGA-EW-A1OW-D292802AC7C8DB-4D01-4FE0-9CA5-E7C406356CBE489mg163mg3108213ChemotherapyTaxotereADJUVANTIVNO1332012FEC then TTCGA-EW-A1OW-D29278444E5133-0315-4949-8801-8905B7A49C1F579mg193mg3108213ChemotherapyEpirubicinADJUVANTIVNO1332012FEC then TTCGA-EW-A1OW-D292791684EE5E-6B0E-4898-964A-9055C7ABE13B2895mg965mg3108213ChemotherapyCyclophosphamideADJUVANTIVNO1332012,TCGA-AR-A5QM-R438565B7461B2-C13C-47B1-B736-33437677102C3682External6000cGy30Primary Tumor FieldNO1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,14.0,WHITE,TCGA-E9-A1RH,E9,A1RH,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,H-Score 150,H-SCORE 280,Right Lower Outer Quadrant,1.5437597656250013,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.0,0.0,Allred score 6,moderate,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,65.201171875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,69,"Other, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,3.3,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,2,8,2011,TCGA-E9-A1RH-F306545C952C48-A87D-4BD8-8FDC-DC74E3C97E7CScheduled Follow-up SubmissionYESYESAlive626TUMOR FREENO2722014TCGA-E9-A1RH-F395388ADAFC52-311D-493C-A40D-FBC3E4824415NOYESYESTUMOR FREEAlive1052NO2412013TCGA-E9-A1RH-F7014102098C42-1FA6-4F5D-A72C-06E338B58C37NOYESYESTUMOR FREEAlive1417NO2812015,TCGA-E9-A1RH-D30658E0770822-61B3-4C2B-91B4-1BD84EC0ED216000mg1500mg411205Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RH-D306560D76DFE2-D103-4A7A-B578-BFA80C9362DC600mg100mg611214ChemotherapyMethotrexateADJUVANTIVNO1342012TCGA-E9-A1RH-D30655C11A3BB8-098E-40C2-B6AC-2DAB2235186F9600mg1600mg611214ChemotherapyCyclophosphamideADJUVANTIVNO1342012TCGA-E9-A1RH-D30657395299B4-0924-44F0-B3B9-48F4A16726184000mg2000mg211214Chemotherapy5-FluorouracilADJUVANTIVNO1342012,TCGA-E9-A1RH-R306599EC04972-0350-4D5B-80BC-1081E50A0DE463107EXTERNAL BEAM4400cGy22Regional siteADJUVANTNO11342012TCGA-E9-A1RH-R56942F462C0FF-6B78-4FDE-A54F-8C581AB9B68863107External60Gy30Primary Tumor FieldNOComplete Response2622014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,739.0,WHITE,TCGA-AR-A0TW,AR,A0TW,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,27.0,Image Analysis,Image Analysis,Right Upper Outer QuadrantRight Lower Outer Quadrant,1.3305957031249989,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Wide Local Excision,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.1650390625,3.0,0%,Allred score 8,90-99%,Dako,Venten,239.2783203125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2.13,"Other, specifyskin",80-89%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.8,3 Point Scale,1+,Stage IIIAT3N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,10,3,2011,TCGA-AR-A0TW-F1856430E7D95D-390D-4241-91EE-0F69147A5A9DScheduled Follow-up SubmissionNOYESAlive1966YES73912122011TCGA-AR-A0TW-F49464879D832D-C3F4-45C1-BAE3-73FE8D28964BNOYESTUMOR FREEAlive3009NO2102013,1TCGA-AR-A0TW-D19094E7E1F747-7022-4E16-A1E8-F80ECF30503E400mg60mg/m2462111ChemotherapyDoxorubicinADJUVANTIVNO121220111TCGA-AR-A0TW-D191010AA047EB-A95E-4620-BA52-2589D3AE3F8E4050mg600mg/m2462111ChemotherapyCytoxanADJUVANTIVNO121220111TCGA-AR-A0TW-D19103AA7EC35A-9A0F-46CC-B59E-CFC2A343EF761200mg175mg/m24125167ChemotherapyPaclitaxelADJUVANTIVNO12122011,TCGA-A8-A09E-R381521C5F574D-5456-4528-8CC3-DC465F84FBB96091ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1303.0,WHITE,TCGA-A2-A0CX,A2,A0CX,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,2.0,H-SCORE 280,allred score 5 + 3 = 8,Left,2.007548828124999,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Modified radical mastectomy,L Total Mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,1+,3+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,0.0,0.0,Allred Score 3,Intensity=Strong,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,79.03125,Vysis AutoVysion System,Ratio >=2.0,NO,YES,50,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,59,3 Point Scale,0,6thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,10,9,2010,TCGA-A2-A0CX-F137212A0B12FB-64F9-49DF-ACC6-22D1110B827CScheduled Follow-up SubmissionYESYESAlive1728TUMOR FREENO1062011,"5TCGA-A2-A0CX-D1966f97daa85-db58-457f-9c18-66c61a97cfcf3.6mg601Other, specify in notesGiven to induce menopauseZoladexOTHER, SPECIFY IN NOTESGiven to induce menopauseIMNO13920102TCGA-A2-A0CX-D1963dcb6e770-4623-4b7b-81dc-ed8d4d0a0f44504mg126mg464127ChemotherapyAdriamycinADJUVANTIVNO13920101TCGA-A2-A0CX-D196276481ee3-1221-4453-8712-e377d62dadcc5000mg1250mg464127ChemotherapyCytoxanADJUVANTIVNO13920103TCGA-A2-A0CX-D1964b6f6197b-da60-4a3c-8ad3-684df50b6dfa660mg165mg4148169ChemotherapyTaxolADJUVANTIVNO13920104TCGA-A2-A0CX-D1965f31ba050-8c08-4914-b20d-75d85501bb13200-600mg162367Targeted Molecular therapyHerceptinADJUVANTIVNO13920106TCGA-A2-A0CX-D19677eae7122-ba45-4ed8-86c7-0b0b15f5a9e82.5mg686Hormone TherapyLetrozoleADJUVANTPOYES13920107TCGA-A2-A0CX-D1968aa0d58a3-07f6-4683-b664-53d0eec5ffcf20 mg dailymg11841273Hormone TherapyTamoxifenADJUVANTPONO1392010",TCGA-A2-A0CX-R196969e31ee3-a4ba-40bf-b722-f1a229006582305ADJUVANTNO11392010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,1440.0,WHITE,TCGA-AR-A5QM,AR,A5QM,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,9.0,H-SCORE 260,CAP SCORING GUIDELINE 2010,Left,3.122490234375001,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Wide Excision,Infiltrating Lobular Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.2861328125,0.0,0,0%,90-99%,Hercep Test  TM Dako,Dako Hercept test,98.9091796875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.78,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.5,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,"YES968New Primary TumorOther, specifymalignant melanoma",15,5,2013,"TCGA-AR-A5QM-F43848075D1C9B-74C2-4011-925E-872B1109BD5FNOYESYESTUMOR FREEAlive1665YES968New Primary TumorOther, specifyMalignant melanoma1062013TCGA-AR-A5QM-F69264798F4A44-D7B5-4E57-901C-EDE79F981BE7NOYESYESTUMOR FREEAlive2231NO31122014",NOTCGA-AR-A5QM-D43857D7CB0EED-DFD0-48DF-AE12-84DB425177EF36Hormone TherapyAnastrozoleYES1062013,TCGA-AR-A5QM-R438565B7461B2-C13C-47B1-B736-33437677102C3682External6000cGy30Primary Tumor FieldNO1062013
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,943.0,WHITE,TCGA-A8-A09E,A8,A09E,Yes,YES,C50.9,8500/3,C50.9,2008.0,WITH TUMOR,YES,7.3271484375,H-SCORE 0,Allred score 2+3 = 5,Left Lower Outer Quadrant,2.2251660156249917,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Margin resection,Other,Surgical resection,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Tumor resection,Lumpectomy,Positive,Positive,Positive,0.25390625,1.767578125,allred score = 7,10-75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,110.26171875,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,2.38,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,60,3 Point Scale,3+,6thStage IIIBT4bN1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A09E-F40334F6B0C0F3-A72D-419B-8361-645F56B72C5ANOYESYESWITH TUMORAlive1492NO1722013,NOTCGA-A8-A09E-D37745312D7C87-4134-4840-A47E-CA2E186B1CEA335Hormone TherapyAnastrozolen/aYES6122012,TCGA-A8-A09E-R381521C5F574D-5456-4528-8CC3-DC465F84FBB96091ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A03Y,AN,A03Y,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,9.0,allred score 5 + 3 = 8,image cytometry,Left Upper Outer Quadrant,3.361943359374997,No axillary staging,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,0,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Negative,0.0,0.0,210,210,40-49%,0,Dako Hercept test,128.1044921875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.0,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.67,3 Point Scale,1+,Stage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,29,12,2010,TCGA-AN-A03Y-F6897753FFC456-27B7-427B-9E7B-E89905DC80E9YESNONOTUMOR FREEAlive1024122014,1TCGA-AO-A03T-D3059b907f99e-3495-43b4-b00a-67573ac72ce94032mg600mg/m2480122ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO6920101TCGA-AO-A03T-D3061febd5704-d4cd-477f-8be2-22d0c03c0826404mg60mg/m2480122ChemotherapyDOXORUBICINADJUVANTIVNO19920101TCGA-AO-A03T-D3062faee37a8-911b-420f-a9a3-de6d58ef95831176mg175mg/m24136178ChemotherapyPACLITAXELADJUVANTIVNO19920102TCGA-AO-A03T-D3065ab1ed21c-89e2-4211-8db0-501a91fcb91d20mg/day2321095Hormone TherapyTAMOXIFEN (NOVADEX)ADJUVANTPONO19920103TCGA-AO-A03T-D307089f9ff00-958d-462b-9439-712c34271b9b7.5mg1095Hormone TherapyLUPRONADJUVANTIMYES19920103TCGA-AO-A03T-D306802ff28ad-6659-4062-8dd8-45461526756a2.5mg/day1130Hormone TherapyLETROZOLE (FEMARA)ADJUVANTPOYES1992010,TCGA-BH-A0B6-R619488CC21685-71B7-44DA-8672-63853A6F870694143External6640cGy36Primary Tumor FieldNOComplete Response1072014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1849.0,WHITE,TCGA-HN-A2OB,HN,A2OB,No,YES,C50.9,8520/3,C50.9,2009.8505859375,WITH TUMOR,YES,10.0,H-SCORE 0,Allred score 5+3=8,RightRight Lower Outer Quadrant,1.2,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Other,Wide re-excisional biopsy,Infiltrating Lobular Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.2177734375,2.0,100,250,90-99%,CISH,Dako Hecept Test,60.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,1.7,"Other, specifyaxilaary node negative but intrammary node positive",<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.0,3 Point Scale,2+,6thStage IIBT2N1M0,YES,YES,YES1543Distant MetastasisBoneNONOYESPositive4 Point Scale3+8Positive4 Point Scale2+Allred score=5Negative1+,26,9,2013,"TCGA-HN-A2OB-F6501198128139-5012-4344-8CBB-E50007749352NOYESYESWITH TUMORAlive1883NO1792014TCGA-HN-A2OB-F718917B121C24-0BF5-4F56-9B8F-AAC37393C325NOYESYESDead1900YES1552Distant MetastasisBoneNONOYESPositive3 Point Scale3+Positive3 Point Scale2+Negative1+1673Distant MetastasisOther, specifyomentumNOYESPositive3 Point Scale3+Positive3 Point Scale2+Negative1+142015",NOTCGA-HN-A2OB-D4916939B4679E-628C-435B-85C4-25B71BCB04DE105147ChemotherapyFluorouracilNO2692013NOTCGA-HN-A2OB-D49305B7C4F1EB-383C-43B2-B58D-2393FE01811A105147ChemotherapyEpirubicinNO3092013NOTCGA-HN-A2OB-D493077988073B-ABA2-43A5-9498-E039E2CF2F8A105147ChemotherapyCyclophosphamideNO3092013NOTCGA-HN-A2OB-D49308ACF2B357-EB83-4198-95BC-7128DDF3B1EE168210ChemotherapyDocetaxelNO3092013,TCGA-HN-A2OB-R49310708829D0-DA92-473C-8DF3-13C6B3D1054C242276External50Gy25Primary Tumor FieldNO3092013
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,289.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A15O,E2,A15O,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,11.998046875,Allred score 5+2 = 7,Allred score 4+3 = 7,Left Upper Inner Quadrant,0.9,No axillary staging,SN+1 non sentinel node,Lumpectomy,Right Breast reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.5576171875,3.3291015625,Allred score = 7,Allred score = 7,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,154.8017578125,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,69,BoneLiver,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,61,3 Point Scale,2+,7thStage IT1cNXM0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,14,4,2011,TCGA-E2-A15O-F191650918A152-08E1-4845-90BB-A1402B7AEACBScheduled Follow-up SubmissionNOYESAlive289NO16112011TCGA-E2-A15O-F70024BF01F0BA-CC2C-4473-848A-12B4C360742CNONOYESTUMOR FREEAlive289YES289Locoregional RecurrenceYES289NOYESPositive3 Point Scale3+Positive3 Point Scale3+Negative1+1632015,02TCGA-E2-A15O-D1916761BED00F-F2EF-4F91-8BC8-B0F1BEEEE7966000mg20mg/day96289Hormone TherapyaromasinADJUVANTPONO1611201101TCGA-E2-A15O-D191666E587C05-8883-4909-BE96-852F9352E81A56mg1mg/day48104Hormone TherapyarimidexADJUVANTPONO1611201103TCGA-E2-A15O-D19169ABECA7CD-0E93-4DCF-938C-350829939C31mgmg/day289Hormone TherapyfemaraADJUVANTPO16112011NOTCGA-E2-A15O-D70381D54F8164-4FDA-4707-A7AE-8057748B100D289Hormone TherapyFemaraYES1632015,TCGA-BH-A0BJ-R44795F4133B4-BA40-404B-8F1E-98D266078E77398443EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO115112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1896.0,WHITE,TCGA-GM-A2DK,GM,A2DK,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,1.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.711191406249975,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,200,allred score = 7,<10%,0,Dako Hercept test,68.0341796875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.0,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.83,3 Point Scale,2+,6thStage IT1cN0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,29,9,2011,TCGA-GM-A2DK-F470941C4E8267-609B-4503-AFC4-77F7B38531A0NOYESYESTUMOR FREEAlive2645NO2282013,NOTCGA-GM-A2DK-D47097F92A5EEC-9F0D-4B49-8D7C-15E038B017EA791893Hormone TherapyArimidexNOComplete Response2282013,TCGA-GM-A2DK-R470950F34A3E2-169D-4D79-B883-9E14DADAF2DD93135External60Gy30Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,578.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A576,E2,A576,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,5.0,H-Score 300,Allred score 2+3 = 5,Left Upper Outer Quadrant,2.673242187499992,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Reexcision,Other,Excisional biospy,Infiltrating Lobular Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Fine needle aspiration biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.0,0.0,0%,Moderate,90-99%,Hercep Test  TM Dako,Dako Hecept Test,81.3984375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,54,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.66,3 Point Scale,2+,7thStage IAT1cN0MX,YES,YES,NO,10,9,2013,TCGA-E2-A576-F675756FD3ACAD-834B-4DE2-BD60-A40C43793BEBNOYESYESTUMOR FREEAlive1043NO6112014,NOTCGA-E2-A576-D48243D025BAD3-CE6C-4A32-8E2E-A500F7284F31252Hormone TherapyArimidexYES1092013NOTCGA-E2-A576-D482445706041F-0C16-4D3D-AC37-E6AA13567E0B88151ChemotherapyTaxotereNO1092013NOTCGA-E2-A576-D482455A282F3D-A833-4F32-B7F1-29B0C86F8E7988151ChemotherapyCytoxanNO1092013,TCGA-E2-A576-R48246A51C3143-7A2E-4FF2-870E-807996C2F8B0236239External1000cGy5Primary Tumor FieldNO1092013TCGA-E2-A576-R48247BB3AA3C7-55F0-43CA-A75D-F44F77A1F684196235External5040cGy28Primary Tumor FieldNO1092013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,591.0,WHITE,TCGA-E2-A150,E2,A150,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Left Upper Outer Quadrant,4.461572265624992,Sentinel node biopsy alone,Pateys surgery,Lumpectomy,Reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Negative,0.3486328125,0.0,Allred score = 0,Allred score = 0,30-39%,Dako,CAP SCORING GUIDELINE 2010,133.0380859375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,74,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,185,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,6,4,2011,TCGA-E2-A150-F1851538FBBD18-BAE7-4FA6-89D9-DD317944D96BScheduled Follow-up SubmissionYESYESAlive773TUMOR FREENO7102011TCGA-E2-A150-F71066F53AF7A3-7480-40A2-99D1-87493C41A28FNOYESYESTUMOR FREEAlive1935NO1832015,1TCGA-E2-A150-D18517DBDE6E37-20B6-4FD1-9ADE-F324268AEF35488mg122mg42496ChemotherapyDoxorubicinADJUVANTIVNO71120112TCGA-E2-A150-D1851834429660-1923-46C7-9C89-A412C2A9DE791719mg398mg480129ChemotherapyPaclitaxel (Protein-Bound)ADJUVANTIVNO71120111TCGA-E2-A150-D185166E72775A-C321-47EC-B622-DD6248D502F64872mg1218mg42466ChemotherapyCyclophosphamideADJUVANTIVNO7112011,TCGA-E2-A150-R18519D82259A3-46D2-4F2F-A3B4-42F0AF6342D8154202EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO17112011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,203.0,WHITE,TCGA-LD-A74U,LD,A74U,No,YES,C50.9,8524/3,C50.9,2013.0,WITH TUMOR,YES,12.0,H-SCORE 0,allred score 5+3+8,Right,2.3917382812499874,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,"Other, specify","Invasive lobular carcinoma, classical type, focal pleomorphic type",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,1.0732421875,11.0,60,H score,10-19%,CISH,Hercep Test TM DAKO,117.6455078125,HER2 amplification - negative,Ratio >=2.0,YES,NO,50,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.3,3 Point Scale,2+,7thStage IIICT3N3aM0,YES,NO,NO,30,12,2013,TCGA-LD-A74U-F6918664202B52-3947-46FF-B25B-9AC52944E2F5NONOYESWITH TUMORAlive402NO30122014,NOTCGA-LD-A74U-D5516018D6C097-AA64-4C59-9CA9-C6737668C34852301ChemotherapyTaxotereNOStable Disease30122013,TCGA-EW-A1OW-R2923080666302-3A99-4636-86B0-790EB34C1D21294338EXTERNAL BEAM6000cGyPrimary Tumor FieldADJUVANTNO11232012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,68.0,WHITE,TCGA-A7-A26J,A7,A26J,No,YES,C50.9,8500/3,C50.9,2011.0,WITH TUMOR,YES,4.0,H-SCORE 260,H-Score 0,Left,1.8861328124999752,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.005859375,0.0,Allred score = 5,8,10-19%,CISH,Hercep Test  TM Dako,163.716796875,HER2 amplification - negative,Ratio >=2.0,YES,NO,2.13,"LungBoneLiverOther, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,145,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-A7-A26J-F30814880E5F65-E490-4289-BFF2-CA57F3107CDCScheduled Follow-up SubmissionNOYESAlive369TUMOR FREENO1742012TCGA-A7-A26J-F3979333485A24-DB2A-469D-BF9A-D0B33DF4A20ENONOYESTUMOR FREEAlive627NO122013,1TCGA-A7-A26J-D30819486CE20D-4F3C-40CA-B3BB-95A9F2BC54F75540mg20mg92Hormone TherapyTamoxifenADJUVANTPOYES1742012,TCGA-BH-A0BJ-R44795F4133B4-BA40-404B-8F1E-98D266078E77398443EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO115112010
TCGAFPPP,Breast,No,FEMALE,Dead,811.0,810.8046875,WHITE,TCGA-BH-A18L,BH,A18L,No,YES,C50.9,8500/3,C50.9,2003.0,WITH TUMOR,YES,3.0,H-Score 150,allred score 2+2 = 4,Left Upper Outer Quadrant,2.3338476562499904,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Reexcision,Other,total mastectomy and sentinel node biopsy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,1.0,1.0,Allred Score 3,Two-tier,90-99%,ACIS,Dako Hercept test,93.3671875,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,66,BoneLiver,10-19%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,2.58,3 Point Scale,2+,6thStage IIIAT3N1miM0,NO,YES,PositiveNegative1+,9,6,2011,TCGA-GM-A2DK-F470941C4E8267-609B-4503-AFC4-77F7B38531A0NOYESYESTUMOR FREEAlive2645NO2282013,NOTCGA-5T-A9QA-D6689041E877E4-A74A-4E15-A061-03DAFF7922A12394AdriamycinNOComplete Response25102014NOTCGA-5T-A9QA-D66891906BC4D2-3C18-42A8-ABE2-BF47933ABA1F304Hormone TherapyLetrozoleYES25102014NOTCGA-5T-A9QA-D6689270C5FF1B-00BC-47E3-BD00-A0923F47645F115198ChemotherapyTaxolNO25102014NOTCGA-5T-A9QA-D66893DCD07D88-6185-4E6B-B95A-FCBE7B9ECDDB94ChemotherapyCytoxanNOComplete Response25102014,TCGA-5T-A9QA-R66894C8E7F188-6E0A-469B-9BF2-4432E605A7EE227277External6440cGy35Primary Tumor FieldNO31102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3374.0,WHITE,TCGA-B6-A0IP,B6,A0IP,No,YES,C50.9,8520/3,C50.9,1997.0,TUMOR FREE,YES,16.0,IMAGE ANALYSIS,IMAGE ANALYSIS,Left Upper Outer Quadrant,1.7714941406249918,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Excision,Infiltrating Lobular Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,"Biopsy, NOS",Negative,Positive,Equivocal,0.01953125,0.0,110,190,10-19%,ACIS,CAP SCORING GUIDELINE 2010,228.5908203125,HER2 amplification - negative,Positive >2.2,NO,YES,74,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,185,4 Point Scale,2+,Stage IAT1cN0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,11,2010,TCGA-B6-A0IP-F12628EBCDB11A-5EE9-4B27-9CA2-4057C00D1556Scheduled Follow-up SubmissionNONOAlive3374TUMOR FREENO262011TCGA-B6-A0IP-F715016C5ADB8C-AC1E-4330-B52D-BD8A8A9B567BNOTUMOR FREEDead3926NO2632015,NOTCGA-5T-A9QA-D6689041E877E4-A74A-4E15-A061-03DAFF7922A12394AdriamycinNOComplete Response25102014NOTCGA-5T-A9QA-D66891906BC4D2-3C18-42A8-ABE2-BF47933ABA1F304Hormone TherapyLetrozoleYES25102014NOTCGA-5T-A9QA-D6689270C5FF1B-00BC-47E3-BD00-A0923F47645F115198ChemotherapyTaxolNO25102014NOTCGA-5T-A9QA-D66893DCD07D88-6185-4E6B-B95A-FCBE7B9ECDDB94ChemotherapyCytoxanNOComplete Response25102014,TCGA-E2-A150-R18519D82259A3-46D2-4F2F-A3B4-42F0AF6342D8154202EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO17112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,12.0,BLACK OR AFRICAN AMERICAN,TCGA-5T-A9QA,5T,A9QA,No,YES,C50.9,8523/3,C50.9,2013.0,TUMOR FREE,NO,11.638671875,allred score 5 + 3 = 8,Allred score 2+2 = 4,Left,2.417724609374991,No axillary staging,SN+1 non sentinel node,Other,Right Breast reexcision,Modified radical mastectomy,Excisional biospy,"Other, specify",infiltrating ductal and mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Positive,Excisional Biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,1.490234375,4.958984375,H score,H score,10-19%,CISH,Hercep Test TM DAKO,120.361328125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,74,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,52,3 Point Scale,2+,7thStage IIAT2NXMX,YES,YES,NO,23,12,2013,TCGA-5T-A9QA-F668895041DB15-D0C3-4364-8D32-850CD958C0BBNOYESYESAlive303NO25102014,NOTCGA-5T-A9QA-D6689041E877E4-A74A-4E15-A061-03DAFF7922A12394AdriamycinNOComplete Response25102014NOTCGA-5T-A9QA-D66891906BC4D2-3C18-42A8-ABE2-BF47933ABA1F304Hormone TherapyLetrozoleYES25102014NOTCGA-5T-A9QA-D6689270C5FF1B-00BC-47E3-BD00-A0923F47645F115198ChemotherapyTaxolNO25102014NOTCGA-5T-A9QA-D66893DCD07D88-6185-4E6B-B95A-FCBE7B9ECDDB94ChemotherapyCytoxanNOComplete Response25102014,TCGA-5T-A9QA-R66894C8E7F188-6E0A-469B-9BF2-4432E605A7EE227277External6440cGy35Primary Tumor FieldNO31102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,660.0,WHITE,TCGA-BH-A0BJ,BH,A0BJ,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,18.0,H-Score 300,H-Score 260,Left Upper Outer QuadrantLeft,2.113222656250003,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.4072265625,2.0,H-Score,H Score,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.634765625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.5,"LungBoneLiverOther, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,105,3 Point Scale,3+,Stage IIBT2N1aM0,NO,YES,YES994Distant MetastasisBoneNOYESYES,8,11,2010,TCGA-BH-A0BJ-F448075A342F3-7D6D-42F8-961D-523D0100ABE8660AliveTUMOR FREEYESYES15112010,1TCGA-BH-A0BJ-D4477F1AE1E33-905A-4F33-AE9B-5EF9CDF0169A492mg123mg4126198ChemotherapyDOXORUBICINADJUVANTIVNO151120101TCGA-BH-A0BJ-D4478EE8AE120-A73B-4822-ADBB-CF076779A0641640mg164mg10219296ChemotherapyPACLITAXELADJUVANTIVNO151120101TCGA-BH-A0BJ-D447650C21FE3-942E-4B85-BB19-70A6C75B85BE4920mg1230mg4126198ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO151120101TCGA-BH-A0BJ-D447577930396-9746-4296-9C9F-1829EDBF76DB1mg/day343Hormone TherapyARIMIDEXADJUVANTPOYES15112010,TCGA-BH-A0BJ-R44795F4133B4-BA40-404B-8F1E-98D266078E77398443EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO115112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,248.0,WHITE,TCGA-D8-A1J9,D8,A1J9,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,6.0,manual counting,manual counting,Left Upper Outer Quadrant,3.209238281250001,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Mastectomy NOS,segmental mastectomy with sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Positive,0.0322265625,0.0,0%,10-75%,30-39%,Dako,Hecep Test TM DAKO,185.14453125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,1.45,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,29,3,2011,TCGA-D8-A1J9-F209449648DFD3-BFF5-4CC5-BE38-C1D57FEFE0D7Scheduled Follow-up SubmissionNOYESAlive532TUMOR FREENO1912012,1TCGA-BH-A0BJ-D4477F1AE1E33-905A-4F33-AE9B-5EF9CDF0169A492mg123mg4126198ChemotherapyDOXORUBICINADJUVANTIVNO151120101TCGA-BH-A0BJ-D4478EE8AE120-A73B-4822-ADBB-CF076779A0641640mg164mg10219296ChemotherapyPACLITAXELADJUVANTIVNO151120101TCGA-BH-A0BJ-D447650C21FE3-942E-4B85-BB19-70A6C75B85BE4920mg1230mg4126198ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO151120101TCGA-BH-A0BJ-D447577930396-9746-4296-9C9F-1829EDBF76DB1mg/day343Hormone TherapyARIMIDEXADJUVANTPOYES15112010,TCGA-E2-A1IN-R20326EF81F606-FAFB-46F1-82DB-B3285D7A980357101EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Dead,2417.0,1772.533203125,WHITE,TCGA-B6-A0WV,B6,A0WV,No,YES,C50.9,8500/3,C50.9,1995.0,TUMOR FREE,YES,7.0,Image Analysis,Image Analysis,Right,1.4132128906250012,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,3+,Negative,Negative,Incisional Biopsy,intraoperative examination,Negative,Positive,Equivocal,0.431640625,4.0,allred score = 4,Allred Score = 7,10-19%,ACIS,Venten,77.4755859375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,4,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,145,4 Point Scale,2+,4thStage IIBT2N1bM0,YES,YES,PositiveNegative1+,14,12,2010,TCGA-B6-A0WV-F1573219EA87A8-6263-4AB4-99A7-F46F9369F416Scheduled Follow-up SubmissionNOYESDead2417TUMOR FREENO2982011,1TCGA-BH-A0BJ-D4477F1AE1E33-905A-4F33-AE9B-5EF9CDF0169A492mg123mg4126198ChemotherapyDOXORUBICINADJUVANTIVNO151120101TCGA-BH-A0BJ-D4478EE8AE120-A73B-4822-ADBB-CF076779A0641640mg164mg10219296ChemotherapyPACLITAXELADJUVANTIVNO151120101TCGA-BH-A0BJ-D447650C21FE3-942E-4B85-BB19-70A6C75B85BE4920mg1230mg4126198ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO151120101TCGA-BH-A0BJ-D447577930396-9746-4296-9C9F-1829EDBF76DB1mg/day343Hormone TherapyARIMIDEXADJUVANTPOYES15112010,TCGA-EW-A1OY-R322698C92A96B-0D36-494B-A441-16C4148B266C341376EXTERNAL BEAM29Primary Tumor FieldADJUVANTNO11552012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,562.0,WHITE,TCGA-EW-A1OX,EW,A1OX,No,YES,C50.9,8523/3,C50.9,2009.0,TUMOR FREE,YES,4.0,H-Score 150,CAP SCORING GUIDELINE 2010,Right Upper Inner Quadrant,2.5785351562499903,Other (specify),sentinel + non sentinel,Lumpectomy,Right Breast reexcision,Other,Wide Local Excision,Mucinous Carcinoma,Ductal/Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,Allred score 7 per outside facility report,Moderate,<10%,CISH,Hercep Test  TM Dako,47.998046875,HER2 amplification - negative,Ratio >=2.0,NO,YES,4.43,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,61,3 Point Scale,3+,6thStage IIAT2N0MX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",18,5,2011,TCGA-EW-A1OX-F290992D559E4D-6B08-44DF-AB6D-FC122319CE7EScheduled Follow-up SubmissionYESYESAlive911TUMOR FREENO832012,TailorRX protocolTCGA-EW-A1OX-D29101E433F9E6-5D54-429A-8513-1C86731F4B06656mg164mg4120198ChemotherapyTaxotereADJUVANTIVNO832012TailorRx ProtocolTCGA-EW-A1OX-D296640FAF19FA-F141-42D6-AC08-F2F51560A2795256mg1314mg4120198ChemotherapyCytoxanADJUVANTIVNO832012TCGA-EW-A1OX-D2966645F438EC-544B-4FB0-8940-FB5A0C51D2443.6mg227Hormone TherapyZoladexADJUVANTSCYES832012TCGA-EW-A1OX-D29102BB04DDAB-CEB8-48BC-8439-5FE0794AB1C320mg/day227Hormone TherapyTamoxifenADJUVANTPOYES832012,TCGA-EW-A1OX-R291009B7F9DE6-C196-489B-8DBA-6BA51CA85C62211253EXTERNAL BEAM6000cGyPrimary Tumor FieldADJUVANTNO1832012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,242.0,WHITE,TCGA-D8-A1XO,D8,A1XO,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,10.0,% IHC,%IHC,Left Lower Outer Quadrant,2.991445312499988,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast reexcision,Other,Excision,Infiltrating Lobular Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0,1.0,>75%,>75%,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,49.6748046875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,33,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.23,3 Point Scale,3+,7thStage IIBT2N1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",16,5,2011,TCGA-D8-A1XO-F294474C872E64-EB75-4271-B57E-023595983986Scheduled Follow-up SubmissionYESYESAlive473TUMOR FREENO1932012TCGA-D8-A1XO-F72206A139305D-B569-4F6F-B37F-3134FD222946NOYESYESTUMOR FREEAlive1682NO2942015,NOTCGA-D8-A1XO-D72207C1C52C47-5334-40A2-8898-0E1B7949D3A093Hormone TherapyTamoxifenYES2942015,TCGA-D8-A1XO-R294483E9D9BA8-2F52-4028-9284-AD01E58BF05E93119EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,123.0,WHITE,TCGA-D8-A1JT,D8,A1JT,No,YES,C50.9,8523/3,C50.9,2010.0,TUMOR FREE,YES,15.0,manual counting,Allred score 0+0 = 0,Left Lower Outer Quadrant,1.3539648437499991,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,Wide re-excisional biopsy,"Other, specify",ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Equivocal,0.0,0.0,H-Score,Allred score = 0,90-99%,FISH,DAKOHercepTest TM,94.2763671875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,40,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,not amplified,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,3,2011,TCGA-D8-A1JT-F1404861DFE752-C583-4674-9552-F736F4D0D0E5Scheduled Follow-up SubmissionNOYESAlive405TUMOR FREENO1872011,TCGA-D8-A1JT-D14049A1CE4BC2-90C8-4054-8F71-02F9119342A7mg/day1mg/day47Hormone TherapyArimidexADJUVANTPOYES1872011,TCGA-D8-A1XO-R294483E9D9BA8-2F52-4028-9284-AD01E58BF05E93119EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,2968.0,WHITE,TCGA-A2-A25A,A2,A25A,No,YES,C50.9,8520/3,C50.9,2003.0,TUMOR FREE,YES,14.0,H-Score 270,H-Score 15,Left Upper Inner Quadrant,1.1,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast reexcision,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.0,0.0,H score,130,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,115.8896484375,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.57,"Other, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,71,3 Point Scale,2+,6thStage IIAT2N0 (i-)M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,6,2011,TCGA-A2-A25A-F3092723DA0430-B849-4D44-91A7-3099F6931B76Scheduled Follow-up SubmissionYESYESAlive3276TUMOR FREENO1942012,2TCGA-A2-A25A-D1458337B653A5-16F9-4CFA-91C8-7AAE12B3D81DChemotherapyCytoxanADJUVANTIV22720114TCGA-A2-A25A-D14585CD0F0B87-4BE9-4070-BC27-F4217BB6F250Hormone TherapyFemaraADJUVANTPO22720111TCGA-A2-A25A-D14581DAE723E3-48C2-47C6-932F-B670C43AAEF1ChemotherapyAdriamycinADJUVANTIV22720113TCGA-A2-A25A-D14584CDAB626B-3EFA-48B1-A671-C525E974334CChemotherapyTaxolADJUVANTIV2272011,TCGA-A2-A25A-R14586E691C50B-1796-4283-817C-0F5231B1908DEXTERNAL BEAMADJUVANT12272011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7.0,WHITE,TCGA-E9-A54Y,E9,A54Y,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,10.0,H-SCORE 280,Allred (Biocare),Right,1.486601562499999,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Negative,Positive,Negative,0.69921875,8.0,90 H,Allred score 7 (per outside facility),10-19%,Hercep Test  TM Dako,Dako Hercept test,146.087890625,HER2 amplification - negative,Ratio >=2.0,YES,NO,2.25,"Other, specifyskin",90-99%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.0,3 Point Scale,3+,7thStage IIIAT2N2M0,YES,YES,Positive70-79%Positive<10%Negative1+,21,6,2013,TCGA-E9-A54Y-F51391AAE29C65-F5ED-4CC0-BF9C-810CADD3AC3ENONONOTUMOR FREEAlive384NO2312014TCGA-E9-A54Y-F6645070266A12-6442-418F-BE85-E9C3979F2CABNONONOTUMOR FREEAlive725NO15102014,"1TCGA-E2-A1L7-D2059036955FD4-89C2-4248-AAA1-8D8CE8F1DA044800mg1200mg44183ChemotherapyCyclophosphamideADJUVANTIVNO12120121TCGA-E2-A1L7-D20589B07261AA-1C81-4C97-9D43-2C0E1543ABFF480mg120mg44183ChemotherapyDoxorubicinADJUVANTIVNO12120123TCGA-E2-A1L7-D205920C4583A4-E88D-4BDE-9CB3-9938094B71F81600mg/day1600mg/day170Other, specify in notesPhase III Clinical TrialClodronateADJUVANTPOYES12120124TCGA-E2-A1L7-D20594EAECF0E4-3985-48CF-AB0D-2AC40D9B40361mg/day1mg/day240Hormone TherapyArimidexADJUVANTPOYES12120122TCGA-E2-A1L7-D2059142D99A31-F6C7-4E6D-9F04-7D6E1901B3921436mg359mg497153ChemotherapyPaclitaxelADJUVANTIVNO1212012",TCGA-E2-A576-R48246A51C3143-7A2E-4FF2-870E-807996C2F8B0236239External1000cGy5Primary Tumor FieldNO1092013TCGA-E2-A576-R48247BB3AA3C7-55F0-43CA-A75D-F44F77A1F684196235External5040cGy28Primary Tumor FieldNO1092013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1918.0,WHITE,TCGA-A2-A04W,A2,A04W,No,YES,C50.9,8401/3,C50.9,2005.0,TUMOR FREE,YES,19.0,H-Score 295,Allred score 3+3=6,Right Upper Outer Quadrant,3.2,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Total mastectomy,"Other, specify",Apocrine,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Negative,Positive,0.177734375,1.0,Allred score 5,Intensity=Strong,30-39%,Dako,DAKOHercepTest TM,239.587890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.45,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.677578124999993,2.5,3 Point Scale,2+,6thStage IIBT2N1miM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,5,1,2011,TCGA-A2-A04W-F93311A023862-902F-44D7-A002-1D289E1946EB1948AliveTUMOR FREENOYES1832011TCGA-A2-A04W-F59320B47778FE-E5A6-4E67-86BC-1A39A7C39BFENONOYESTUMOR FREEAlive3102NO852014,"1TCGA-A2-A04W-D6687236eedf5-1416-4267-9403-20ce7d6acbf74400mg1100mg458100ChemotherapyCytoxanADJUVANTIVNO7120112TCGA-A2-A04W-D668965ec14e5-944c-4f65-bd7f-af3f9f1de109440mg110mg458100ChemotherapyAdriamycinADJUVANTIVNO7120113TCGA-A2-A04W-D6690ce20855f-bc0d-4156-97a3-58368e52b5fa1768mg147-148mg12114191ChemotherapyTaxolADJUVANTIVNO10120114TCGA-A2-A04W-D6691ed0088f6-01ce-4f8a-99e1-998641ad9eac4187mg146-463mg18198352Targeted Molecular therapyHerceptinADJUVANTIVNO10120115TCGA-A2-A04W-D6692a9c9c08e-0668-48ba-a67a-68928076d8054mg1023Other, specify in notesBisphosphonateZometaADJUVANTIVYES1012011",TCGA-GM-A2DK-R470950F34A3E2-169D-4D79-B883-9E14DADAF2DD93135External60Gy30Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0XS,AN,A0XS,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,allred score 5+3=8,Allred score 2+2 = 4,Left Upper Outer Quadrant,3.342617187499993,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Negative,0.1474609375,1.0,160,0,50-59%,CISH,DAKOHercepTest TM,200.638671875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,64,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,2+,7thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,28,3,2011,TCGA-AN-A0XS-F6895981BF97A6-7C9E-480B-A317-746E9A86CDB8YESNONOTUMOR FREEAlive10NO23122014,"02TCGA-E2-A1B1-D194331C0E879C-D0B0-45F3-B530-C9E53A0BFC312145mg195mg11155232ChemotherapypaclitaxelADJUVANTIVNO912201102TCGA-E2-A1B1-D19428607FFFF8-3B83-4A56-8A6B-04F87ECAD6F516128mg672mg24155491ChemotherapyherceptinADJUVANTIVNO912201101TCGA-E2-A1B1-D19424AA17D85A-0FDD-47FB-9D84-B8E632A1937460mg4mg1571969Other, specify in notesbiphosphonatezoledronic acidADJUVANTIVNO912201101TCGA-E2-A1B1-D19438F78B48EF-E33F-4DC4-8527-32A39CF392F3584mg146mg471134ChemotherapyadriamycinADJUVANTIVNO912201104TCGA-E2-A1B1-D194192F50945A-770E-4BAE-A4BA-BF8337D74422mg20mg/day239Hormone TherapytamoxifenADJUVANTPOYES912201103TCGA-E2-A1B1-D19421347D45D4-7A50-4C57-9CAF-B7BE348BDE4Fmg3.75mg71Hormone TherapytriptorelinADJUVANTIMYES912201101TCGA-E2-A1B1-D194358C3CFC3B-88E5-4E90-AE7E-1F4CE327F0365856mg1464mg471134ChemotherapycyclophosphamideADJUVANTIVNO9122011",TCGA-A2-A25A-R14586E691C50B-1796-4283-817C-0F5231B1908DEXTERNAL BEAMADJUVANT12272011
TCGAFPPP,Breast,No,MALE,Alive,0.0,510.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A6SA,EW,A6SA,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,4.0,Allread score 5+3 = 8,H-Score 0,LeftLeft Lower Inner Quadrant,4.967343749999968,Sentinel node biopsy alone,SN+1 non sentinel node,Simple Mastectomy,Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Negative,1.0,11.4140625,240 H,250,20-29%,CISH,Venten,343.2451171875,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,YES,NO,74,"LungBoneLiverOther, specifyskin",50-59%,70-79%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,60,3 Point Scale,2+,7thStage IIT2N0 (i+)MX,YES,NO,NO,27,2,2015,TCGA-A8-A0AB-F403228A60E4E1-747F-4974-9159-CA9BEAA7E445NONOYESTUMOR FREEAlive518NO1622013,NOTCGA-AC-A2FB-D45600874799CE-92C6-4A14-9087-50637D5A0BFB101205ChemotherapyTaxotereNOComplete Response1772013NOTCGA-AC-A2FB-D4560183D4DEF8-DDC1-4477-B951-DA1E2EE02B89212443ChemotherapyHerceptinNOComplete Response1772013NOTCGA-AC-A2FB-D45602E9BB9D9C-C752-4FC4-AA16-B531C23C1BEF225895Hormone TherapyArimidexNOComplete Response1772013,TCGA-E2-A1IN-R20326EF81F606-FAFB-46F1-82DB-B3285D7A980357101EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1633.0,WHITE,TCGA-BH-A0BR,BH,A0BR,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,3.0,H-SCORE 280,H-Score-230,Left Lower Inner Quadrant,1.350761718750002,Sentinel node biopsy alone,axillary ultrasound,Other,Re-excision of the inferior margin,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.2744140625,0.0,Allred score 8,Allred score = 7,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,46.1103515625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,50,"Other, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,145,3 Point Scale,1+,6thStage IT1cN0M0,NO,YES,YES994Distant MetastasisBoneNOYESYES,10,8,2011,TCGA-BH-A0BR-F619519BA76E22-268F-4181-8B35-A67DC8D99EFCNOYESNOTUMOR FREEAlive2330NO1072014,1TCGA-E2-A1IN-D20324F7685815-0BF1-443B-9F43-01B6887E6A921mg/day1mg/day103Hormone TherapyArimidexADJUVANTPOYES412012,TCGA-BH-A0BR-R61952630A649B-3586-470C-A97A-7698334CFDA558108External64.8Gy36Primary Tumor FieldNOComplete Response1072014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,286.0,WHITE,TCGA-AC-A3QP,AC,A3QP,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,2.0,H-SCORE 300,Allred score 5+3 = 8,Right,1.2,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Re-excision of the inferior margin,Other,Nipple Sparing Total Mastectomy,Infiltrating Lobular Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,1.0,1.0,Intensity=Strong,80,10-19%,ACIS,CAP SCORING GUIDELINE 2010,30.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,2.2,"Other, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.6,3 Point Scale,2+,7thStage IIBT2N1miMX,YES,YES,NO,5,7,2012,TCGA-AC-A3QP-F56161C88A67C7-BD93-497B-9C15-0C721BDE4168NOYESYESTUMOR FREEAlive675NO2912014,NOTCGA-AC-A3QP-D56162112B1EE9-F2CE-42E6-9BAF-6648ACB7226D115Hormone TherapyFemaraYES2912014,TCGA-AC-A3QP-R56164611045A0-C19E-40FE-8A67-7170568A99B262108External6040cGy33Primary Tumor FieldNOComplete Response2912014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7.0,WHITE,TCGA-AN-A041,AN,A041,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,18.0,H-SCORE 0,H-SCORE 280,Left Upper Outer Quadrant,2.824443359375,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Left breast reexcision,Other,partial mastectomy,Infiltrating Ductal Carcinoma,secretory,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Positive,0.046875,1.0,0,170,20-29%,CISH,Venten,269.09375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,3.0,"Other, specifyaxilaary node negative but intrammary node positive",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.66,3 Point Scale,1+,7thStage IIBT2N1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",1,4,2011,TCGA-AN-A041-F68971D69B074B-6C93-4843-B205-6D3254728C90YESNONOTUMOR FREEAlive724122014,02TCGA-E2-A15O-D1916761BED00F-F2EF-4F91-8BC8-B0F1BEEEE7966000mg20mg/day96289Hormone TherapyaromasinADJUVANTPONO1611201101TCGA-E2-A15O-D191666E587C05-8883-4909-BE96-852F9352E81A56mg1mg/day48104Hormone TherapyarimidexADJUVANTPONO1611201103TCGA-E2-A15O-D19169ABECA7CD-0E93-4DCF-938C-350829939C31mgmg/day289Hormone TherapyfemaraADJUVANTPO16112011NOTCGA-E2-A15O-D70381D54F8164-4FDA-4707-A7AE-8057748B100D289Hormone TherapyFemaraYES1632015,TCGA-AC-A3QP-R56164611045A0-C19E-40FE-8A67-7170568A99B262108External6040cGy33Primary Tumor FieldNOComplete Response2912014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,917.0,WHITE,TCGA-BH-A0GY,BH,A0GY,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,26.0,H-Score 150,H-Score 290,Left Lower Outer QuadrantLeft,1.3616796874999952,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.8935546875,3.0,H-Score,H-Score,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,150.134765625,Vysis AutoVysion System,PathVysion Her-2 DNA,NO,YES,66,"Other, specifyskin",40-49%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,3.3,3 Point Scale,3+,Stage IIAT2N1M0,NO,YES,PositivePositiveNegativeNegative1.09,10,11,2010,TCGA-BH-A0GY-F4695426FCA35-2C66-49F8-8A54-D246D2D79D53923AliveTUMOR FREEYESYESNONONONO16112010,1TCGA-BH-A0GY-D46884D4A179C-D0BD-42DC-AD93-EAC585385ACD1mg/day351Hormone TherapyArimidexADJUVANTPOYES171120101TCGA-BH-A0GY-D46926C08A79A-E8ED-4073-B385-8D190A48E158202ChemotherapyCyotxanADJUVANTIVNO181120101TCGA-BH-A0GY-D4690F37A755D-57BF-47B5-BB9B-4656199BC057202ChemotherapyAdriamycinADJUVANTIVNO18112010,TCGA-BH-A0GY-R469478B3B214-FA94-42A3-A70B-7FD74250E365317365EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,14.0,WHITE,TCGA-E2-A1IL,E2,A1IL,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,4.0,allred score 5+3=8,allred score 4 + 3 = 7,Left Upper Outer Quadrant,3.315039062499988,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Lumpectomy,Re-excision of the inferior margin,Mastectomy NOS,Wide re-excisional biopsy,Infiltrating Lobular Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Negative,0.33203125,1.0,allred score = 7,allred score = 8,30-39%,Dako,CAP scoring guideline 2010,103.7880859375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,50,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.66,3 Point Scale,2+,6thStage IIAT1cN1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,29,4,2011,TCGA-E2-A1IL-F202767E6EDBFE-0E8F-4123-97EA-7557145A44C4Scheduled Follow-up SubmissionYESYESAlive118TUMOR FREENO312012,1TCGA-E2-A1IL-D20281383F11A4-7593-479A-95EA-EBB7ED807F661mg/day1mg/day64Hormone TherapyArimidexADJUVANTPOYES312012,TCGA-E2-A1IL-R202833634D556-4A85-4BAC-ABA1-862FFE83DB9184112EXTERNAL BEAM5840cGy24ADJUVANTNO1312012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,30.0,WHITE,TCGA-A8-A0A7,A8,A0A7,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,14.845703125,allred score 5+3=8,Allred score 0+0=0,Right Upper Outer Quadrant,2.1330468749999945,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Left breast reexcision,Other,Surgical Resection,Infiltrating Lobular Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Negative,Positive,0.265625,1.71875,allred score = 7,allred score = 8,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,112.98046875,HER2 amplification - negative,Ratio >=2.0,NO,YES,66,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.0,3 Point Scale,3+,6thStage IIBT2N1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-BH-A0EA-F585664E9DAD81-E003-4EE4-88B8-99136572258CNONOYESTUMOR FREEDead991NO1442014,02TCGA-E2-A15O-D1916761BED00F-F2EF-4F91-8BC8-B0F1BEEEE7966000mg20mg/day96289Hormone TherapyaromasinADJUVANTPONO1611201101TCGA-E2-A15O-D191666E587C05-8883-4909-BE96-852F9352E81A56mg1mg/day48104Hormone TherapyarimidexADJUVANTPONO1611201103TCGA-E2-A15O-D19169ABECA7CD-0E93-4DCF-938C-350829939C31mgmg/day289Hormone TherapyfemaraADJUVANTPO16112011NOTCGA-E2-A15O-D70381D54F8164-4FDA-4707-A7AE-8057748B100D289Hormone TherapyFemaraYES1632015,TCGA-E2-A1IL-R202833634D556-4A85-4BAC-ABA1-862FFE83DB9184112EXTERNAL BEAM5840cGy24ADJUVANTNO1312012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,943.0,WHITE,TCGA-BH-A0EE,BH,A0EE,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,1.0,H-SCORE 280,allred score 5 + 3 = 8,Right Upper Inner QuadrantRight,1.3343652343750003,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Re-excision of the inferior margin,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,0,3+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Positive,0.4501953125,0.0,Allred score = 0,Allred score = 0,30-39%,ACIS,CAP scoring guideline 2010,40.33984375,HER2 amplification - negative,>= 2.0 Positive,NO,YES,1.57,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,816,3 Point Scale,0,Stage IIBT3N0 (i-)M0,NO,YES,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-BH-A0EE-F46746F1C8397-CC8C-47DA-8266-62801060B148943AliveTUMOR FREENOYESNONONONO16112010,1TCGA-BH-A0EE-D4671578D5C85-931D-4D7F-A308-7699D8870212839mg130mg647173ChemotherapyDocetaxelADJUVANTIVNO181120101TCGA-BH-A0EE-D46708B266B9C-45E7-4072-A13E-0146D0834946839mg130mg647173ChemotherapyDocetaxelADJUVANTIVNO181120101TCGA-BH-A0EE-D46725C2E885D-E1C2-409E-BBF0-05B55F3AF8B72632mg540mg647173ChemotherapyCarboplatinADJUVANTIVNO181120101TCGA-BH-A0EE-D467303244A97-6A7C-44C9-86DC-65110C5994376800mg549mg1747411ChemotherapyTrastuzumabADJUVANTIVNO18112010,TCGA-EW-A1PH-R32259B13D295F-A310-4C1A-9812-BFC67F771E56276322EXTERNAL BEAM6120cGy34Primary Tumor FieldADJUVANTNO12042012
TCGAFPPP,Breast,Yes,FEMALE,Dead,991.0,1162.3828125,WHITE,TCGA-BH-A0EA,BH,A0EA,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.0,Allred score = 8,Allred score = 8,Left,1.7894335937500012,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Other,Left breast reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.5859375,2.0,Allred score 5,Allred Score 5,10-19%,Hercep Test  TM Dako,Dako Hecept Test,60.8017578125,HER2 amplification - negative,PathVysion,NO,YES,1.57,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,59,3 Point Scale,2+,6thStage IIAT1cN1aM0,NO,YES,NONO,11,8,2011,TCGA-BH-A0EA-F585664E9DAD81-E003-4EE4-88B8-99136572258CNONOYESTUMOR FREEDead991NO1442014,NOTCGA-BH-A0EA-D5857890419813-A572-48FF-972A-949B5811D2F884363ChemotherapyTaxotereNOComplete Response1442014NOTCGA-BH-A0EA-D58581FECD8A5A-10AD-4DB7-91F2-08A6B16C19B9363522ChemotherapyCytoxanNOComplete Response1442014,TCGA-AC-A3QP-R56164611045A0-C19E-40FE-8A67-7170568A99B262108External6040cGy33Primary Tumor FieldNOComplete Response2912014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1266.0,WHITE,TCGA-AO-A12G,AO,A12G,No,YES,C50.9,8022/3,C50.9,2006.0,TUMOR FREE,YES,4.0,H-SCORE 260,IHC,Right Upper Outer QuadrantRight,1.0,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Re-excision of the inferior margin,Modified radical mastectomy,TOTAL MASTECTOMY,"Other, specify",pleomorphic infiltrating lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Positive,1.0,0.0,Allred score 7 per outside facility report,STRONG,<10%,CISH,3+ Positive,23.0,Vysis AutoVysion System,>=2.0 Positive,NO,YES,67,"LungBoneLiverOther, specifyskin",90-99%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,66,3 Point Scale,2+,6thStage IIAT2N0 (i+)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,8,12,2010,TCGA-AO-A12G-F59070CCA8F63-EBA9-483E-8780-5F9E43AFE3B51266AliveTUMOR FREENOYES8122010TCGA-AO-A12G-F194487E5B69F5-8504-4C78-8405-AC9D2989C122Scheduled Follow-up SubmissionNOYESAlive1639TUMOR FREENO1662011,1TCGA-AO-A12G-D5982b5ce13aa-ba6c-49c3-aa75-d881b89317cb1mg/day177Hormone TherapyArimidex (Anastrozole)ADJUVANTPOYES1012011,TCGA-LL-A5YP-R593271B2D1DFE-6C4A-47FD-98BA-CAF7E1D38BE3225266External6000cGy30Primary Tumor FieldNO852014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,549.0,WHITE,TCGA-A8-A082,A8,A082,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,17.5458984375,allred score 5+3=8,allred score 5+3+8,Right,2.2247558593749885,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Left breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.31640625,1.6904296875,Allred score 8,allred score = 8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,119.060546875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,66,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,60,3 Point Scale,3+,6thStage IIBT2N1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A082-F4083794671AF3-7174-4E0B-9B56-33FFE891B86FNONOYESTUMOR FREEAlive-31NO232013,NOTCGA-A8-A082-D3788707C01032-C857-4682-B8E3-C03FA024ECB931122Chemotherapy5-FluorouracilNOComplete Response6122012NOTCGA-A8-A082-D37888EFA90125-FED8-4301-A595-3CB4798D1F2231122ChemotherapyEpirubicinNOComplete Response6122012NOTCGA-A8-A082-D37889A155B75A-412B-4A2E-921A-67A737A29E6A31122ChemotherapyCyclophosphamideNOComplete Response6122012NOTCGA-A8-A082-D37890122E4A81-1D23-44AB-8070-1F44572B6AE89292ChemotherapyDocetaxelNOComplete Response6122012NOTCGA-A8-A082-D37891BCB4083F-8DF9-4847-8F80-00E4A0CD49F5184Hormone TherapyLetrozoleYES6122012NOTCGA-A8-A082-D3789203AE2E15-1D31-4DAD-8D42-434C2FF4769A852914Hormone TherapyExemestaneNOComplete Response6122012,TCGA-AC-A3QP-R56164611045A0-C19E-40FE-8A67-7170568A99B262108External6040cGy33Primary Tumor FieldNOComplete Response2912014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-D8-A1JK,D8,A1JK,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,13.0,manual counting,manual counting,Left Upper Inner QuadrantLeft Upper Outer Quadrant,1.8216796874999883,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Re-excision of the inferior margin,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Negative,Negative,0.111328125,0.0,Allred Score,0%,90-99%,FISH,DAKOHercepTest TM,92.80078125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,66,"LungBoneLiverOther, specifyskin",70-79%,<10%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,79,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",29,3,2011,TCGA-D8-A1JK-F20751E9360A7B-562C-479B-8705-03D745CA6930Scheduled Follow-up SubmissionNONOAlive0TUMOR FREENO1912012,NOTCGA-HN-A2OB-D4916939B4679E-628C-435B-85C4-25B71BCB04DE105147ChemotherapyFluorouracilNO2692013NOTCGA-HN-A2OB-D49305B7C4F1EB-383C-43B2-B58D-2393FE01811A105147ChemotherapyEpirubicinNO3092013NOTCGA-HN-A2OB-D493077988073B-ABA2-43A5-9498-E039E2CF2F8A105147ChemotherapyCyclophosphamideNO3092013NOTCGA-HN-A2OB-D49308ACF2B357-EB83-4198-95BC-7128DDF3B1EE168210ChemotherapyDocetaxelNO3092013,TCGA-AC-A3QP-R56164611045A0-C19E-40FE-8A67-7170568A99B262108External6040cGy33Primary Tumor FieldNOComplete Response2912014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,580.0,WHITE,TCGA-A8-A08S,A8,A08S,Yes,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,11.681640625,image cytometry,H-Score 0,Left,1.7616894531249925,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Re-excision of the inferior margin,Other,Surgical resection,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.20703125,3.5400390625,Allred score 8,Allred score 8,10-19%,ACIS,Hercep Test  TM Dako,110.5439453125,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,2.13,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,145,3 Point Scale,3+,6thStage IIAT1cN1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A08S-F40560A5D239B1-ABC3-4829-A371-345C8E7AA795NOYESYESTUMOR FREEAlive1004NO2422013,NOTCGA-A8-A08S-D37747F9B9A52B-AF15-41B3-9116-D18A681DCB1B62Hormone TherapyAnastrozolen/aYES6122012,TCGA-A8-A08S-R38153AEAE8ED5-C523-482A-A2FA-F1B6112632483162ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0XT,AN,A0XT,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,17.0,allred score 5+3=8,Allred score 2+2 = 4,Left Upper Outer Quadrant,3.059589843749992,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Left breast reexcision,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.1552734375,1.0,0,120,50-59%,CISH,DAKOHercepTest TM,202.7099609375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,33,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,441,3 Point Scale,2+,7thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,28,3,2011,TCGA-AN-A0XT-F68960837B572D-29D8-4983-8304-068372BD90DCYESNONOTUMOR FREEAlive1023122014,1TCGA-BH-A0HX-D4837D1EDD48C-D395-40FC-AADC-7222D40374191mg/day278Hormone TherapyArimidexADJUVANTPOYES171120101TCGA-BH-A0HX-D4833B906D9FD-E934-49A6-B493-F9E15460BEDE117ChemotherapyAdrimycinADJUVANTIVNO181120101TCGA-BH-A0HX-D4836E0A73F7B-3621-4C44-B73F-4C6B1CEC05B8ChemotherapyTaxotereADJUVANTIVNO181120101TCGA-BH-A0HX-D483480535D9D-13BA-4040-A6CB-E650C6AC3E4D117ChemotherapyCytoxanADJUVANTIVNO18112010,TCGA-MS-A51U-R66068A8E94E4E-431A-46FA-84EF-9001BDAD527D218266ExternalPrimary Tumor FieldNORadiographic Progressive Disease2102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,271.0,WHITE,TCGA-A2-A4S0,A2,A4S0,No,YES,C50.9,8480/3,C50.9,2012.0,TUMOR FREE,YES,1.0,Allread score 5+3 = 8,allred score 5 + 3 = 8,Right Upper Outer Quadrant,1.6503320312499956,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Re-excision of the inferior margin,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Mucinous Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,0.0,allred score =  8,moderate,90-99%,Dako,Venten,242.1689453125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,40,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.0,3 Point Scale,2+,7thStage IIAT2N0M0,NO,NO,NO,26,2,2013,TCGA-A2-A4S0-F59120CE1841D4-C855-440F-8BAD-E62CF9EE60A7NOTUMOR FREEAlive706NO152014,NOTCGA-OL-A5RZ-D6526220672357-AAF4-4236-A2ED-742216DD61B4239331ChemotherapyDoxorubicinNOComplete Response2492014NOTCGA-OL-A5RZ-D6526370A2566A-B315-479A-82BF-250CBCAF6F3B239331ChemotherapyCytoxanNOComplete Response2492014,TCGA-E2-A1IN-R20326EF81F606-FAFB-46F1-82DB-B3285D7A980357101EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,392.0,WHITE,TCGA-E2-A1IN,E2,A1IN,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,allred score 5+3=8,allred score 5+3+8,Right,1.2602832031249986,Sentinel node biopsy alone,SN+1 non sentinel node,Lumpectomy,Re-excision of the inferior margin,Other,L Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.3125,0.0,allred score = 8,allred score = 8,90-99%,Dako,CAP scoring guideline 2010,135.55078125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,66,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.9,3 Point Scale,2+,7thStage IT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,29,4,2011,TCGA-E2-A1IN-F2032314834E52-B0E0-43D7-B13B-32A3D0D390E3Scheduled Follow-up SubmissionYESYESAlive675TUMOR FREENO412012,1TCGA-E2-A1IN-D20324F7685815-0BF1-443B-9F43-01B6887E6A921mg/day1mg/day103Hormone TherapyArimidexADJUVANTPOYES412012,TCGA-E2-A1IN-R20326EF81F606-FAFB-46F1-82DB-B3285D7A980357101EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Dead,362.0,4365.2119140625,WHITE,TCGA-B6-A0I9,B6,A0I9,No,YES,C50.9,8500/3,C50.9,1992.0,WITH TUMOR,YES,17.7705078125,IHC,IHC,Left Lower Outer QuadrantLeft,1.4865332031249954,No axillary staging,axillary ultrasound,Modified Radical Mastectomy,Re-excision of the inferior margin,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,4+,2+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Indeterminate,Equivocal,0.9140625,3.4541015625,allred score = 4,moderate,10-19%,Hercep Test  TM Dako,dextran coated charcoal,160.58203125,Vysis AutoVysion System,PathVysion,NO,YES,2.6,Bone,80-89%,90-99%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,105,4 Point Scale,1+,3rdStage IVT3NXM1,YES,YES,PositivePositiveNegativeNegative,2,11,2010,TCGA-B6-A0I9-F12609A410ADEE-B8AA-4E7F-BD5E-134E99D6BFEEScheduled Follow-up SubmissionYESYESDead362WITH TUMORNO162011,NOTCGA-E9-A5UP-D57717DCB3552D-9065-47A4-A78C-6C66D46F8D068Hormone TherapyTamoxifenYES2132014,TCGA-AC-A3QP-R56164611045A0-C19E-40FE-8A67-7170568A99B262108External6040cGy33Primary Tumor FieldNOComplete Response2912014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,104.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A4S3,A2,A4S3,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,15.0,Allread score 5+3 = 8,allred score 3 + 3 = 6,Left Upper Outer Quadrant,4.145214843750006,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Re-excision of the inferior margin,Other,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,2.0,90 H,190,90-99%,Dako,DAKOHercepTest TM,242.0068359375,HER2 amplification - negative,Ratio >=2.0,YES,NO,1.1,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.9,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,NO,28,2,2013,TCGA-A2-A4S3-F5912806C49930-B182-44EA-8B71-8FCF2306DD46NOAlive666152014,NOTCGA-OL-A5RZ-D6526220672357-AAF4-4236-A2ED-742216DD61B4239331ChemotherapyDoxorubicinNOComplete Response2492014NOTCGA-OL-A5RZ-D6526370A2566A-B315-479A-82BF-250CBCAF6F3B239331ChemotherapyCytoxanNOComplete Response2492014,TCGA-E2-A1IN-R20326EF81F606-FAFB-46F1-82DB-B3285D7A980357101EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12L,C8,A12L,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,3.0,H-Score 150,allred score 4 + 3 = 7,Right,1.8099511718749937,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Re-excision of the inferior margin,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Suregery,Negative,Negative,Equivocal,0.0078125,0.00390625,Allred Score 6,allred score = 8,30-39%,Dako,DAKOHercepTest TM,61.498046875,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,2.38,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.1,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,12,4,2011,TCGA-C8-A12L-F202589A790E77-B373-41E6-98DD-4520857BB46FScheduled Follow-up SubmissionNONOAlive363TUMOR FREENO912012,NOTCGA-AR-A5QM-D43857D7CB0EED-DFD0-48DF-AE12-84DB425177EF36Hormone TherapyAnastrozoleYES1062013,TCGA-BH-A0GY-R469478B3B214-FA94-42A3-A70B-7FD74250E365317365EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-AC-A23H,AC,A23H,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,NO,15.52734375,H-SCORE 300,Allred score 0+0 = 0,Right Upper Inner QuadrantRight Lower Inner Quadrant,1.7168652343749935,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and axillary lymph node biopsy,Simple Mastectomy,Re-excision of the inferior margin,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Positive,Positive,Positive,0.5185546875,4.146484375,Allred Score 6,Allred Score,10-19%,ACIS,CAP SCORING GUIDELINE 2010,149.1064453125,HER2 amplification - negative,PathVysion,NO,YES,69,"Other, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,172,3 Point Scale,2+,7thStage IIAT2NXM0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,13,7,2011,TCGA-AC-A23H-F455729E725427-00DE-4C87-ADEE-5B6A3EC1902CNONONOWITH TUMORDead0NO1772013,"1TCGA-E2-A1L7-D2059036955FD4-89C2-4248-AAA1-8D8CE8F1DA044800mg1200mg44183ChemotherapyCyclophosphamideADJUVANTIVNO12120121TCGA-E2-A1L7-D20589B07261AA-1C81-4C97-9D43-2C0E1543ABFF480mg120mg44183ChemotherapyDoxorubicinADJUVANTIVNO12120123TCGA-E2-A1L7-D205920C4583A4-E88D-4BDE-9CB3-9938094B71F81600mg/day1600mg/day170Other, specify in notesPhase III Clinical TrialClodronateADJUVANTPOYES12120124TCGA-E2-A1L7-D20594EAECF0E4-3985-48CF-AB0D-2AC40D9B40361mg/day1mg/day240Hormone TherapyArimidexADJUVANTPOYES12120122TCGA-E2-A1L7-D2059142D99A31-F6C7-4E6D-9F04-7D6E1901B3921436mg359mg497153ChemotherapyPaclitaxelADJUVANTIVNO1212012",TCGA-BH-A0GY-R469478B3B214-FA94-42A3-A70B-7FD74250E365317365EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,44.0,WHITE,TCGA-AC-A2FB,AC,A2FB,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,1.0,H-SCORE 190,IHC,Left Upper Inner Quadrant,1.3247460937500095,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Re-excision of the inferior margin,Modified radical mastectomy,Wide Local Excision,Infiltrating Lobular Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Positive,0.0244140625,0.0,Allred Score 6,Allred score = 7,10-19%,ACIS,Hercep Test  TM Dako,53.533203125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.1,"Other, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.3,3 Point Scale,3+,6thStage IIAT2N0MX,YES,YES,YES994Distant MetastasisBoneNOYESYES,20,9,2011,TCGA-AC-A2FB-F4557464865AFC-B952-4D29-AEA3-BF902B430461NONOYESTUMOR FREEAlive1234NO1772013,NOTCGA-AC-A2FB-D45600874799CE-92C6-4A14-9087-50637D5A0BFB101205ChemotherapyTaxotereNOComplete Response1772013NOTCGA-AC-A2FB-D4560183D4DEF8-DDC1-4477-B951-DA1E2EE02B89212443ChemotherapyHerceptinNOComplete Response1772013NOTCGA-AC-A2FB-D45602E9BB9D9C-C752-4FC4-AA16-B531C23C1BEF225895Hormone TherapyArimidexNOComplete Response1772013,TCGA-BH-A0GY-R469478B3B214-FA94-42A3-A70B-7FD74250E365317365EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,487.0,WHITE,TCGA-E2-A14P,E2,A14P,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,24.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Right Upper Outer Quadrant,1.3979199218750022,Axillary lymph node dissection alone,SN+1 non sentinel node,Lumpectomy,Reexcision,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Positive,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Positive,0.3115234375,10.0,Allred score = 0,Allred score = 0,90-99%,Dako,Venten,359.94140625,HER2 amplification - negative,Positive >2.2,NO,YES,66,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.8,3 Point Scale,2+,6thStage IIICT2N3M0,YES,YES,PositivePositiveNegativeNegative1.09,31,3,2011,TCGA-E2-A14P-F1884628693AEC-5F7F-45B2-BEA4-2250E4909DBEScheduled Follow-up SubmissionYESNOAlive1246NO20102011,1TCGA-E2-A14P-D188471097E387-AF7B-476A-AE90-ECF89836F10D10568mg570mg339396ChemotherapyTrastuzumabADJUVANTIVNO20102011,TCGA-E2-A14P-R188486DC4F0B6-6E08-4D24-9535-30E94160D27B4790EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO120102011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,12.0,ASIAN,TCGA-C8-A12Z,C8,A12Z,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,H-SCORE 260,H-SCORE 280,Right,1.5073828124999966,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Cribiform,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Negative,Negative,Positive,0.033203125,2.0,Allred score 5,allred score = 8,30-39%,Dako,DAKOHercepTest TM,67.7548828125,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,33,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.1,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,13,4,2011,TCGA-C8-A12Z-F70810CFB88891-DA2A-4058-B2A7-44A8A2E2AFDENONOYESTUMOR FREEAlive382NO932015,NOTCGA-C8-A12Z-D70811DC8851E6-AC37-4E31-80EE-4C4CB77EAFE6102107Chemotherapy5-FlourouracilNOComplete Response932015NOTCGA-C8-A12Z-D7081201F0FCA1-431B-40BF-9290-D82BCD61BA7C102107ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A12Z-D70813302C0CC5-6BC8-4CEF-8936-0BE869DB8E4C102107ChemotherapyCyclophosphamideNOComplete Response932015,TCGA-BH-A0GY-R469478B3B214-FA94-42A3-A70B-7FD74250E365317365EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,30.0,WHITE,TCGA-A8-A09W,A8,A09W,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,10.896484375,allred score 5 + 3 = 8,H-Score 0,Right Upper Inner Quadrant,1.838955078124998,Sentinel node biopsy alone,SN+1 non sentinel node,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Lobular Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,0,Positive,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.4375,4.74609375,Allred score 8,Allred score 8,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,131.97265625,HER2 amplification - negative,PathVysion,NO,YES,33,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,61,3 Point Scale,3+,5thStage IIIBT2N3M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-AO-A0JA-F31669712413C-70D3-4935-AD00-BE1C76671568346AliveWITH TUMORNONO143YES143Negative<10%Positive70-79%2+Negative<10%1+3+ POSITIVENOYES1992010TCGA-AO-A0JA-F15484DE973A94-D71D-421F-9511-557735C21273Scheduled Follow-up SubmissionNOYESAlive655WITH TUMORYES143Distant MetastasisBoneNONegative4 Point ScalePositive70-79%4 Point ScaleNegative1+3 Point Scale2282011,2TCGA-E2-A10A-D7700932948c9-faaa-4f8d-a773-780433c65a7a20mg/day91Hormone TherapyTamoxifenADJUVANTPOYES14220111TCGA-E2-A10A-D7699de773115-886c-445c-874a-99ed871ca85d3.6mg3.6mg88Hormone TherapyZoladexADJUVANTSCYES14220112TCGA-E2-A10A-D174304729CED9-4A3B-43B6-AB21-95DC86CFA9FE4mg148Targeted Molecular therapyZometaPROGRESSIONIVYES2792011,TCGA-A8-A08S-R38153AEAE8ED5-C523-482A-A2FA-F1B6112632483162ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,365.0,WHITE,TCGA-A2-A4S1,A2,A4S1,No,YES,C50.9,8575/3,C50.9,2012.0,TUMOR FREE,YES,1.0,H-SCORE 255,allred score 5 + 3 = 8,Right Upper Outer Quadrant,1.6859082031249968,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Metaplastic Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,1+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,0.0,allred score =  8,moderate,90-99%,Dako,Venten,240.8212890625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,64,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.0,3 Point Scale,2+,7thStage IIAT2N0M0,NO,YES,NO,26,2,2013,TCGA-A2-A4S1-F5892567A3F1E4-5375-4437-89BD-6EF2EB2BCDCCNOYESNOTUMOR FREEAlive820NO2842014,NOTCGA-AC-A23G-D4324310502588-843C-4F06-BCB5-FC3640306A2F109190ChemotherapyCytoxanNOComplete Response1552013NOTCGA-AC-A23G-D43244AD503E66-08BD-4F4E-877D-4D9D499AB832109190ChemotherapyAdriamycinNOComplete Response1552013NOTCGA-AC-A23G-D4324524D15948-49E0-4B96-870D-492C786C0937190220ChemotherapyTaxolNOComplete Response1552013NOTCGA-AC-A23G-D432468C1BBA20-CDAA-4C57-BAE6-BF46E12CFDE0237Hormone TherapyArimidexNOComplete Response1552013,TCGA-A2-A4S1-R406703B3276B7-1916-4C7C-9209-216BCC69461291123External5000cGy25Primary Tumor FieldNOComplete Response2622013TCGA-A2-A4S1-R406718236A730-E0C4-4C4B-8DD0-EFD9FA7D81AC126130External1000cGy5Primary Tumor FieldNOComplete Response2622013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,346.0,BLACK OR AFRICAN AMERICAN,TCGA-AO-A0JA,AO,A0JA,No,YES,C50.9,8500/3,C50.9,2009.0,WITH TUMOR,YES,11.0,H-SCORE 0,%IHC,Right Upper Inner QuadrantRight Lower Inner QuadrantRight,2.2070800781249957,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.1416015625,11.0,allred score = 4,8,<10%,CISH,3+ POSITIVE,31.970703125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,4,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,71,3 Point Scale,1+,Stage IIICT2N3M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,19,9,2010,TCGA-AO-A0JA-F31669712413C-70D3-4935-AD00-BE1C76671568346AliveWITH TUMORNONO143YES143Negative<10%Positive70-79%2+Negative<10%1+3+ POSITIVENOYES1992010TCGA-AO-A0JA-F15484DE973A94-D71D-421F-9511-557735C21273Scheduled Follow-up SubmissionNOYESAlive655WITH TUMORYES143Distant MetastasisBoneNONegative4 Point ScalePositive70-79%4 Point ScaleNegative1+3 Point Scale2282011,"1TCGA-AO-A0JA-D3170357e7201-60df-425e-9cab-dd4722ff6b34980mg80mg/m27292ChemotherapyPACLITAXELPROGRESSIONIVYES19920101TCGA-AO-A0JA-D31683e3ada60-dd5a-4b4e-8cf2-53587263d9387.5mg166Hormone TherapyLEUPROLIDE ACETATE (LUPRON)RECURRENCEIMYES19920101TCGA-AO-A0JA-D3169bdf4593a-cafd-4db8-b132-eb1d37a76eee24mg4mg6166Other, specify in notesBISPHOSPHONATEZOLEDRONIC ACIDRECURRENCEIVYES19920101TCGA-AO-A0JA-D31673c735330-523e-41f1-9fad-ef714a373d2320mg/day166242Hormone TherapyTAMOXIFENRECURRENCEPONO1992010",TCGA-BH-A0GY-R469478B3B214-FA94-42A3-A70B-7FD74250E365317365EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,518.0,WHITE,TCGA-A8-A0AB,A8,A0AB,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,5.638671875,Allred 0 = 0+0,H-Score 0,Left Upper Outer Quadrant,7.978242187499958,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Reexcision,Other,Surgical Resection,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.25,0.0009765625,Strong,Moderate,30-39%,Hercep Test  TM Dako,Hercep Test  TM Dako,125.5830078125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,66,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.66,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,27,5,2011,TCGA-A8-A0AB-F403228A60E4E1-747F-4974-9159-CA9BEAA7E445NONOYESTUMOR FREEAlive518NO1622013,NOTCGA-A8-A0AB-D37905C764E219-0133-4595-A695-9FC0D32C02E661184Chemotherapy5-FluorouracilNOComplete Response6122012NOTCGA-A8-A0AB-D3790624D0F28A-D91B-47A2-AE9C-BD963075AFE461184ChemotherapyDoxorubicinNOComplete Response6122012NOTCGA-A8-A0AB-D37907CB9E17C3-E42E-4B04-9ADC-59AB74070C2561184ChemotherapyCyclophosphamideNOComplete Response6122012NOTCGA-A8-A0AB-D37908E3113882-092E-4FBB-8664-055788237872214Hormone TherapyTamoxifenYES6122012,TCGA-A2-A0T3-R9219f00904bf-c888-403a-a5d4-2d76fcbc5378203248EXTERNAL BEAM10440cGy33Primary Tumor FieldADJUVANTNO12122011
TCGAFPPP,Breast,Yes,FEMALE,Dead,2712.0,976.7060546875,WHITE,TCGA-BH-A1F5,BH,A1F5,No,YES,C50.9,8500/3,C50.9,2002.0,TUMOR FREE,YES,4.0,H-SCORE 280,H-Score 15,Right,2.074804687500001,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,biopsy,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,1.1005859375,1.0,Allred score 8,Intensity=Strong,10-19%,ACIS,CAP SCORING GUIDELINE 2010,68.595703125,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,2.6,BoneLiver,80-89%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,145,3 Point Scale,2+,5thStage IIAT1cN1aM0,NO,YES,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,7,9,2011,TCGA-D8-A1JT-F1404861DFE752-C583-4674-9552-F736F4D0D0E5Scheduled Follow-up SubmissionNOYESAlive405TUMOR FREENO1872011,1TCGA-AR-A0TW-D19094E7E1F747-7022-4E16-A1E8-F80ECF30503E400mg60mg/m2462111ChemotherapyDoxorubicinADJUVANTIVNO121220111TCGA-AR-A0TW-D191010AA047EB-A95E-4620-BA52-2589D3AE3F8E4050mg600mg/m2462111ChemotherapyCytoxanADJUVANTIVNO121220111TCGA-AR-A0TW-D19103AA7EC35A-9A0F-46CC-B59E-CFC2A343EF761200mg175mg/m24125167ChemotherapyPaclitaxelADJUVANTIVNO12122011,TCGA-BH-A0GY-R469478B3B214-FA94-42A3-A70B-7FD74250E365317365EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,191.0,WHITE,TCGA-AN-A0FS,AN,A0FS,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,dextran coated charcoal,dextran coated charcoal,Right Lower Outer Quadrant,1.9819140624999896,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Lobular Carcinoma,Ductal/Mucinous,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Positive,0.0,0.0,7,230,20-29%,0,dextran coated charcoal,47.2958984375,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,NO,YES,1.57,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.83,3 Point Scale,0,7thStage IAT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,20,12,2010,TCGA-AN-A0FS-F6895480A52799-160B-4844-83FC-F6D6F06E60C4YESNONOTUMOR FREEAlive21023122014,NOTCGA-E2-A570-D44535569DEEF9-63F5-49E8-8D2F-AC6BA220410F252Hormone TherapyAnastrozoleYES2162013,TCGA-A8-A08P-R38160CF63E708-3ED7-4F91-9929-41FD1CF62191182244ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,456.0,WHITE,TCGA-A2-A0T3,A2,A0T3,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,13.0,H-SCORE 136,Allred 5 = 2+3,Right Upper Outer Quadrant,1.4,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Margin resection,Other,Mastectomy,Infiltrating Ductal Carcinoma,Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.0,2.0,230,Allred Score = 7,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,556.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.3,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.2,3 Point Scale,3+,7thStage IBT1cN1miM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,2,2011,TCGA-A2-A0T3-F13956AE551901-3B41-40AC-960F-AEEC27B3CD63Scheduled Follow-up SubmissionYESYESAlive569TUMOR FREENO1272011TCGA-A2-A0T3-F593847449E8A7-2B95-489D-BA42-16889AC8E023NOYESYESTUMOR FREEAlive1516NO1252014,2TCGA-A2-A0T3-D9215b41bdca7-b0bf-4308-b906-1dcc9bf77b23618mg103mg670177ChemotherapyAdriamycinADJUVANTIVNO21220114TCGA-A2-A0T3-D9218f9514221-8f9b-403b-99d4-e4843d0b2eb6Hormone TherapyTamoxifenADJUVANTPOYES21220113TCGA-A2-A0T3-D92162a946428-c9e3-4910-8589-57d6230d7cd46180mg1030mg670177ChemotherapyCytoxanADJUVANTIVNO21220111TCGA-A2-A0T3-D92144c04520d-d4ae-4202-b00b-a2782b640207930mg155mg670177ChemotherapyTaxotereADJUVANTIVNO2122011,TCGA-A2-A0T3-R9219f00904bf-c888-403a-a5d4-2d76fcbc5378203248EXTERNAL BEAM10440cGy33Primary Tumor FieldADJUVANTNO12122011
TCGAFPPP,Breast,No,FEMALE,Dead,3063.0,4411.9638671875,WHITE,TCGA-B6-A0RS,B6,A0RS,No,YES,C50.9,8500/3,C50.9,1988.0,WITH TUMOR,YES,15.0,Allred score 0+0 = 0,dextran coated charcoal,Left Lower Inner QuadrantLeft,1.4560156249999965,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast reexcision,Other,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,2+,2+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Negative,Equivocal,0.720703125,0.0,60,moderate,10-19%,Hercep Test  TM Dako,dextran coated charcoal,74.375,Vysis AutoVysion System,PathVysion,NO,YES,33,"Other, specifyskin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,816,4 Point Scale,1+,3rdStage IIAT2N0 (i-)M0,YES,YES,PositivePositiveNegativeNegative,2,11,2010,"TCGA-B6-A0RS-F137883B180A84-15DE-49BC-8E60-E6E97CD0EE18Scheduled Follow-up SubmissionNOYESDead3063WITH TUMORYES2041New Primary TumorOther, specifyBreastYES2041NOYESNegativeNegative1272011","5TCGA-A2-A0CX-D1966f97daa85-db58-457f-9c18-66c61a97cfcf3.6mg601Other, specify in notesGiven to induce menopauseZoladexOTHER, SPECIFY IN NOTESGiven to induce menopauseIMNO13920102TCGA-A2-A0CX-D1963dcb6e770-4623-4b7b-81dc-ed8d4d0a0f44504mg126mg464127ChemotherapyAdriamycinADJUVANTIVNO13920101TCGA-A2-A0CX-D196276481ee3-1221-4453-8712-e377d62dadcc5000mg1250mg464127ChemotherapyCytoxanADJUVANTIVNO13920103TCGA-A2-A0CX-D1964b6f6197b-da60-4a3c-8ad3-684df50b6dfa660mg165mg4148169ChemotherapyTaxolADJUVANTIVNO13920104TCGA-A2-A0CX-D1965f31ba050-8c08-4914-b20d-75d85501bb13200-600mg162367Targeted Molecular therapyHerceptinADJUVANTIVNO13920106TCGA-A2-A0CX-D19677eae7122-ba45-4ed8-86c7-0b0b15f5a9e82.5mg686Hormone TherapyLetrozoleADJUVANTPOYES13920107TCGA-A2-A0CX-D1968aa0d58a3-07f6-4683-b664-53d0eec5ffcf20 mg dailymg11841273Hormone TherapyTamoxifenADJUVANTPONO1392010",TCGA-D8-A1XO-R294483E9D9BA8-2F52-4028-9284-AD01E58BF05E93119EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A8-A08H,A8,A08H,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,5.28515625,allred score 5+3=8,Allred (Biocare),Left Upper Inner Quadrant,2.42415039062499,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.3125,0.0,Allred Score,230,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,113.9716796875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,33,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.0,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,27,5,2011,TCGA-E2-A15O-F191650918A152-08E1-4845-90BB-A1402B7AEACBScheduled Follow-up SubmissionNOYESAlive289NO16112011TCGA-E2-A15O-F70024BF01F0BA-CC2C-4473-848A-12B4C360742CNONOYESTUMOR FREEAlive289YES289Locoregional RecurrenceYES289NOYESPositive3 Point Scale3+Positive3 Point Scale3+Negative1+1632015,1TCGA-AO-A03T-D3059b907f99e-3495-43b4-b00a-67573ac72ce94032mg600mg/m2480122ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO6920101TCGA-AO-A03T-D3061febd5704-d4cd-477f-8be2-22d0c03c0826404mg60mg/m2480122ChemotherapyDOXORUBICINADJUVANTIVNO19920101TCGA-AO-A03T-D3062faee37a8-911b-420f-a9a3-de6d58ef95831176mg175mg/m24136178ChemotherapyPACLITAXELADJUVANTIVNO19920102TCGA-AO-A03T-D3065ab1ed21c-89e2-4211-8db0-501a91fcb91d20mg/day2321095Hormone TherapyTAMOXIFEN (NOVADEX)ADJUVANTPONO19920103TCGA-AO-A03T-D307089f9ff00-958d-462b-9439-712c34271b9b7.5mg1095Hormone TherapyLUPRONADJUVANTIMYES19920103TCGA-AO-A03T-D306802ff28ad-6659-4062-8dd8-45461526756a2.5mg/day1130Hormone TherapyLETROZOLE (FEMARA)ADJUVANTPOYES1992010,TCGA-A2-A04N-R7483bcef384b-a85a-4552-b96a-7c0b94f8b4c2143191EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12812011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3153.0,WHITE,TCGA-A2-A04N,A2,A04N,No,YES,C50.9,8500/3,C50.9,2002.0,TUMOR FREE,YES,6.0,ER Positive H-Score 95,H-Score 160,Right,1.2,Other (specify),Sentinel lymph node biopsy plus non-sentinel lymph node biopsy,Lumpectomy,Re-excision of the inferior margin,Other,Excision,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,3+,Negative,Negative,Fine needle aspiration biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.0,0.0,240 H,250,90-99%,Hercep Test  TM Dako,Venten,421.8837890625,HER2 amplification - negative,Positive >2.2,NO,YES,4.43,LungBone,70-79%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.677578124999993,60,3 Point Scale,3+,5thStage IAT1cN0 (i-)M0,YES,YES,PositivePositiveNegativeNegative1.09,27,1,2011,TCGA-A2-A04N-F9336B8DC7DC2-B3A7-4D0A-BFD6-936C986524393188AliveTUMOR FREEYESYES1832011TCGA-A2-A04N-F593110BCE4BB0-63D3-4F46-91B3-622ACD436F79NOYESYESTUMOR FREEAlive4354NO852014,3TCGA-A2-A04N-D748287e62dc0-ef4f-4a7c-9870-8919bc8772261mg3082121Hormone TherapyArimidexADJUVANTPONO28120112TCGA-A2-A04N-D74816e45013f-a69c-43a0-8972-435c99dafbd94520mg1130mg442107ChemotherapyCytoxanADJUVANTIVNO28120111TCGA-A2-A04N-D74809eaef08e-aeb6-4f55-b9dd-61803a467369452mg113mg442107ChemotherapyAdriamycinADJUVANTIVNO2812011,TCGA-A2-A04N-R7483bcef384b-a85a-4552-b96a-7c0b94f8b4c2143191EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12812011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,64.0,WHITE,TCGA-E9-A1R3,E9,A1R3,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,% IHC,Allred score 0+0 = 0,Right Upper Outer Quadrant,1.4982128906249956,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,0.1796875,10.0,Allred Score 6,Allred Score 6,10-19%,Hercep Test  TM Dako,Venten,91.2109375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,4,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5,3 Point Scale,2+,7thStage IIICT2N3M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-E9-A1R3-F30820441B7AE0-63A1-4A1B-9FF4-89DB394CF0DEScheduled Follow-up SubmissionYESYESAlive78TUMOR FREENO1742012TCGA-E9-A1R3-F48697CC3C4599-3B2A-41F5-B233-DDCD72DFC819YES1992013,TCGA-E9-A1R3-D3082342526DF7-F5F2-4212-80D8-73443892CEB6100mg100mg14150ChemotherapyMethotrexateADJUVANTIVNO1742012TCGA-E9-A1R3-D3082457C90782-1DBC-41F4-8674-D1FB85B985422000mg2000mg14150ChemotherapyCyclophosphamideADJUVANTIVNO1742012TCGA-E9-A1R3-D3082663FBD160-E49D-4A37-ADC7-7BF300319F6A20mg/day45Hormone TherapyTamoxifenADJUVANTPOYES1742012TCGA-E9-A1R3-D308228AAB711A-821D-49F2-97B5-DB26D061A35B2000mg2000mg14150Chemotherapy5-FluorouracilADJUVANTIVNO1742012,TCGA-E9-A1R3-R30827BF0CBEB8-1696-468C-B183-5EE4D72E45AC5578EXTERNAL BEAM37400cGyRegional siteADJUVANTNO11742012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,328.0,WHITE,TCGA-BH-A0GZ,BH,A0GZ,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,14.0,H-SCORE 300,H-SCORE 280,Left Upper Inner QuadrantLeft,1.05,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Margin resection,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.9326171875,1.0,H-SCORE,H-SCORE,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.0,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,2.08,LungBone,90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.2,3 Point Scale,3+,Stage IIAT1cN1aM0,NO,YES,YES994Distant MetastasisBoneNOYESYES,10,11,2010,TCGA-BH-A0GZ-F46976B3FE8B6-3E78-48C6-8CE0-77EFFD2F5DF5328AliveTUMOR FREEYESYESNONONONO16112010,1TCGA-BH-A0GZ-D4691DF515EB3-0AC1-4BBE-B0F5-D74BBA8B245C1mg/day157Hormone TherapyARIMIDEXADJUVANTPOYES17112010,TCGA-BH-A0GZ-R46932C0E7F31-3FAC-443E-BBDB-9DDEF10114BAEXTERNAL BEAMPrimary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,943.0,WHITE,TCGA-A8-A08P,A8,A08P,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,12.9111328125,allred score 5+3=8,H-SCORE 0,Right,2.1155957031249844,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Mastectomy NOS,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.373046875,3.984375,Allred score 8,Allred Score 7,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,129.548828125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,4,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,71,3 Point Scale,3+,6thStage IIIAT2N2aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A08P-F405615AC6BE92-4C93-419D-A6B8-65C8B218B5D4NOYESYESTUMOR FREEAlive943NO2422013,NOTCGA-A8-A08P-D37773BB038A0C-0856-4FB6-B98B-8CC6ACAAB26B60182Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08P-D37774234F1043-A0C4-49F6-A6ED-C6290863D7BF60182ChemotherapyDoxorubicinn/aNOComplete Response6122012NOTCGA-A8-A08P-D377751253B515-4F10-40BF-B18B-2AA5B260D82160182ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08P-D3777612F7BB14-6DC6-4008-9BF1-55DA9355226060182ChemotherapyDocetaxeln/aNOComplete Response6122012NOTCGA-A8-A08P-D3777766F6BB3D-C124-464B-ADA7-88793D0C636F244Hormone TherapyExemestanen/aYES6122012NOTCGA-A8-A08P-D3777805503837-81F2-4017-88A9-C22758556147213578Targeted Molecular therapyTrastuzumabn/aNOComplete Response6122012,TCGA-A8-A08P-R38160CF63E708-3ED7-4F91-9929-41FD1CF62191182244ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,293.0,WHITE,TCGA-A7-A425,A7,A425,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,19.0,Allred 0 = 0+0,Allred score 2+2 = 4,Right,1.1,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,L Total Mastectomy,Infiltrating Lobular Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Indeterminate,0.3359375,12.0,Allred Score 6,Moderate,30-39%,CISH,Dako Hecept Test,228.0,HER2 amplification - negative,Pathvysion HER-2 DNA Probe Kit,YES,NO,2.5,"Other, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.8,3 Point Scale,2+,7thStage IIICT3N3aMX,YES,YES,NO,5,11,2012,"TCGA-A7-A425-F416488EE1DAAF-2EFE-4CA4-B494-4674A8AC9C79NOYESYESWITH TUMORAlive447YES419Locoregional RecurrenceOther, specifyLeft BreastYES419Positive90-99%3 Point ScaleNegative<10%3 Point ScaleNegative1+443Distant MetastasisBoneNO2532013",NOTCGA-A7-A425-D365877AA4AFE0-6678-4A17-96DE-062AB5E85D67127197ChemotherapyAdriamycinNO5112012NOTCGA-A7-A425-D3658865234BE9-7E88-41BF-9163-37261DF76FED127197ChemotherapyCytoxanNO5112012NOTCGA-A7-A425-D36589D8A19C0E-E2E4-410F-B480-D1FC1EAEA6CD211288ChemotherapyTaxolNO5112012NOTCGA-A7-A425-D416903E02A5A3-AF45-42DE-BF76-E56FAE2440DA378Hormone TherapyArimidexYES2632013,TCGA-A7-A425-R416993E540589-038B-4233-A130-F771D76578D6317359External5040cGy28Primary Tumor FieldNORadiographic Progressive Disease2632013TCGA-A7-A425-R41726F05F3412-8D0F-4DA4-9950-3B625351074E317352External4500cGy25Regional siteNORadiographic Progressive Disease2632013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,502.0,WHITE,TCGA-E2-A15A,E2,A15A,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,19.0,dextran coated charcoal,dextran coated charcoal,Left,1.3825585937499991,Sentinel lymph node biopsy plus axillary dissection,Pateys surgery,Simple Mastectomy,Reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.4990234375,13.0,Allred score = 8,allred score = 8,10-19%,Dako,CAP SCORING GUIDELINE 2010,78.041015625,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.78,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,105,3 Point Scale,2+,6thStage IIICT2N3aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,4,2011,TCGA-E2-A15A-F1892689F6BF10-DB74-4BB3-B5DC-B8C065538CDBScheduled Follow-up SubmissionYESYESAlive710TUMOR FREENO10112011,2TCGA-E2-A15A-D18932EDEDBFBC-2FEA-4A60-929F-17C65470B8741120mg280mg4103145ChemotherapyPaclitaxelADJUVANTIVNO101120111TCGA-E2-A15A-D1892903F02177-F519-4582-80D5-FB49841CED1B3792mg948mg44789ChemotherapyCyclophosphamideADJUVANTIVNO101120111TCGA-E2-A15A-D18931D589DD76-9CC5-49F7-AB78-94321F8B1402380mg95mg44789ChemotherapyDoxorubicinADJUVANTIVNO101120113TCGA-E2-A15A-D18933F855C3B6-E0E7-4A87-9CF5-5BB51DD2E35444mg4mg103ChemotherapyZoledronic AcidADJUVANTIVYES10112011,TCGA-E2-A15A-R1893878528A96-4A5C-4ADD-8526-E921E5238F87145222EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO110112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,85.0,WHITE,TCGA-MS-A51U,MS,A51U,No,YES,C50.9,8520/3,C50.9,2012.0,WITH TUMOR,YES,18.0,H-SCORE 300,CAP SCORING GUIDELINE 2010,Left Upper Outer QuadrantLeft Lower Outer QuadrantLeft,2.6936328124999886,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Lobular Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Negative,Positive,Negative,0.048828125,2.0,Moderate,270 H,90-99%,CISH,Hercep Test TM DAKO,36.2021484375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,2.38,"Other, specifyskin",90-99%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,172,3 Point Scale,2+,7thStage IIBT2N1M0,YES,NO,PositiveNegative,12,9,2012,TCGA-MS-A51U-F598185CC7E973-2B41-4164-B766-828CA02625F3NOYESYESTUMOR FREEAlive681NO462014,NOTCGA-MS-A51U-D64920011802B1-AEBD-4C2D-8258-19D929C01583130178ChemotherapyPaclitaxelNOStable Disease17102014NOTCGA-MS-A51U-D64916E6091FDA-563B-4A0F-A091-666380676D1E57116ChemotherapyAdriamycinNOStable Disease17102014NOTCGA-MS-A51U-D649194E4467F8-D750-4B3D-9A07-CED8733E681357116ChemotherapyCytoxanNOStable Disease17102014,TCGA-MS-A51U-R66068A8E94E4E-431A-46FA-84EF-9001BDAD527D218266ExternalPrimary Tumor FieldNORadiographic Progressive Disease2102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,8.0,ASIAN,TCGA-C8-A8HP,C8,A8HP,No,YES,C50.9,8575/3,C50.9,2013.0,TUMOR FREE,YES,9.0,Allred score 7 (outside facility),Allred score 4+3 = 7,Left Upper Outer Quadrant,3.439736328124992,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node dissection,Metaplastic Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,4 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Positive,Negative,Positive,2.32421875,6.0,Allred Score 6,Allred Score 6,90-99%,ACIS,Dako Hercept test,125.4443359375,HER2 amplification - negative,Ratio >=2.0,YES,NO,2.7,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.66,4 Point Scale,2+,7thStage IIIAT2N2M0,NO,NO,NO,29,12,2014,TCGA-C8-A8HP-F6961091FF3ABD-E5CD-49E0-BDE9-3D9971E451A6NONOYESTUMOR FREEAlive396NO1512015,NOTCGA-C8-A8HP-D6961197270AB3-9E3D-45C5-9D19-C829F713523B31224Chemotherapy5-FlourouracilNOComplete Response1512015NOTCGA-C8-A8HP-D69612E21CE453-A911-46D4-8A86-10840F94F4FB31224ChemotherapyEpirubicinNOComplete Response1512015NOTCGA-C8-A8HP-D69613FDA16E46-3280-4A4A-914B-F4BC3F88932331224ChemotherapyCyclophosphamideNOComplete Response1512015,TCGA-S3-A6ZG-R636482C875BB6-139D-4B69-95DF-8D8F732E4308269326External6040cGy33Primary Tumor FieldNOComplete Response2782014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,132.0,WHITE,TCGA-A7-A5ZX,A7,A5ZX,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,24.0,H-SCORE 260,H-SCORE 0,Left,2.3773339843749888,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Reexcision,Other,Bilateral skin sparing Mastectomy and Bilateral breast reconstruction with tissue expanders.,Infiltrating Lobular Carcinoma,tubular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.11328125,21.0,Intensity=Strong,8,10-19%,CISH,Dako Hecept Test,98.046875,HER2 amplification - negative,Ratio >=2.0,YES,NO,69,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,21,3 Point Scale,3+,7thStage IIICT2N3aM0,YES,NO,NO,13,5,2013,TCGA-A7-A5ZX-F527214168828D-E26A-4495-896F-2164A95A9FC2NOYESYESTUMOR FREEAlive336NO6122013,NOTCGA-A7-A5ZX-D513329C29891D-CFA8-48D4-A646-C3AD561F20DA76118ChemotherapyDoxorubicinNOComplete Response15112013NOTCGA-A7-A5ZX-D51333F5C792BC-E5C5-4C56-9434-A746E1B1703876118ChemotherapyCyclophosphamideNOComplete Response15112013NOTCGA-A7-A5ZX-D5133446461AEB-BAB0-45F1-A893-FCD00A28BBEA132174ChemotherapyPaclitaxelNOComplete Response15112013NOTCGA-A7-A5ZX-D52815056878FC-D30B-4BF4-8BD2-972B61510B2D268Hormone TherapyTamoxifenYESComplete Response6122013,TCGA-A7-A5ZX-R513350352DA94-E095-4DB4-96EE-242B04B52219227263External5040cGy28Primary Tumor FieldNOComplete Response15112013TCGA-A7-A5ZX-R51336F1E49549-94E9-4C73-BEE1-843F26ACAF97227263External5040cGy28Regional siteNOComplete Response15112013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,365.0,WHITE,TCGA-A8-A09B,A8,A09B,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,12.8515625,CAP SCORING GUIDELINE 2010,H-SCORE 280,Left,1.9302441406249864,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.3544921875,3.4853515625,Allred score 8,Allred score 8,10-19%,ACIS,Hercep Test  TM Dako,102.3037109375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,2.38,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.83,3 Point Scale,3+,6thStage IIIBT4bN1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A09B-F4055067B93484-7627-4EB4-82E5-189B57D36AC1NOYESYESTUMOR FREEAlive3652322013,NOTCGA-A8-A09B-D37797DB9805C1-DC29-4382-829A-BC707E2688613030Chemotherapy5-Fluorouraciln/aNO6122012NOTCGA-A8-A09B-D37798D8720C19-DA4E-4B7C-AD4B-82EFBFDBF3E23030ChemotherapyEpirubicinn/aNO6122012NOTCGA-A8-A09B-D377991BC9A48C-10DD-439C-A959-4DD7B05CDF823030ChemotherapyCyclophosphamiden/aNO6122012NOTCGA-A8-A09B-D37800C0BCD5E9-32B6-4BA1-96BB-FB00CB9DA2E4122ChemotherapyDocetaxeln/aNO6122012NOTCGA-A8-A09B-D37801A108C623-BC80-4675-931F-301E1BA62157153242Hormone TherapyAnastrozolen/aNO6122012,TCGA-A8-A09B-R381651528A1EE-7C4B-4B8A-AFCC-46098B902021153181External50GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,263.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-A6ZH,S3,A6ZH,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,21.0,image cytometry,CAP scoring guideline 2010,LeftLeft Upper Outer Quadrant,1.1,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Margin resection,Other,Pateys surgery,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, classical type, focal pleomorphic type",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.0,14.0,Strong,Strong,10-19%,0,CAP scoring guideline 2010,20.0,HER2 amplification - negative,CAP scoring guideline 2010,YES,NO,69,"Other, specifyskin",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,79,3 Point Scale,2+,7thStage IIICT3N3aMX,YES,NO,NO,12,11,2013,TCGA-S3-A6ZH-F636258AB33E9F-54C0-49A3-862C-14A9E04C144CNOYESYESTUMOR FREEAlive515NO2782014TCGA-S3-A6ZH-F683061E35CDDC-BA24-44AD-9A84-E53B710C9969NOYESYESTUMOR FREEAlive641NO14112014,YESTCGA-S3-A6ZH-D510934FF7C7C8-9204-4234-8E32-E4E647B7A669141185ChemotherapyAdriamycinNOComplete Response12112013YESTCGA-S3-A6ZH-D510959A50CE8C-5949-4FBC-9D18-2BF7A3C8FFC6141185ChemotherapyCytoxanNOComplete Response12112013YESTCGA-S3-A6ZH-D510971AF804F2-0DDD-4DC3-9977-DA151A2F69AE141185AncillaryNeulastaNOComplete Response12112013YESTCGA-S3-A6ZH-D51098DCCCBA1E-1B61-46C7-A824-650991F2032E200ChemotherapyTaxolYES12112013YESTCGA-S3-A6ZH-D6364358C4FEBB-B269-490F-9AB4-8D95373717EF293Hormone TherapyTAMOXIFENYES2782014,TCGA-S3-A6ZH-R63634AFC090C0-5CB1-47EF-B9B4-4D7AEE7ADCA5304351External110Gy55Regional siteNOComplete Response2782014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,289.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A0YF,A2,A0YF,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,H-Score 295,allred score 3 + 3 = 6,Right,1.7591796874999903,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Right Breast reexcision,Modified radical mastectomy,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,1.0,0.0,Allred Score 7,Intensity=Strong,<10%,ACIS,Venten,173.6357421875,Vysis AutoVysion System,PathVysion,NO,YES,54,"Other, specifyskin",90-99%,<10%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,<4.0,3 Point Scale,0,6thStage IT1bN0 (i+)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",2,12,2010,TCGA-A2-A0YF-F167555F7B4D0A-13E7-4308-A1C2-670BB17D88C7Scheduled Follow-up SubmissionNOYESAlive469TUMOR FREENO1692011TCGA-A2-A0YF-F59385AEE7A858-E746-4B8D-85F5-75D4F0F185F9NONOYESTUMOR FREEAlive1535NO1252014,1TCGA-A2-A0YF-D5507481c8460-6527-43a9-a403-f39ee68057e2mg1mg/dayHormone TherapyArimidexADJUVANTPOYES2122010,TCGA-E2-A15P-R19147747DC091-0514-4945-B09E-1CAD551849C85198EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO116112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,221.0,WHITE,TCGA-A2-A1FW,A2,A1FW,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,19.0,H-SCORE 136,H-Score 160,Right Upper Outer Quadrant,2.360048828124984,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.603515625,5.0,Allred Score 3,Moderate,10-19%,ACIS,CAP SCORING GUIDELINE 2010,75.810546875,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,YES,NO,40,BoneLiver,90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,441,3 Point Scale,2+,7thStage IIIAT3N2aM0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,11,5,2011,TCGA-A2-A1FW-F2081045FA1D4F-ECD9-4962-8D88-C93EFFAFBCD2Scheduled Follow-up SubmissionYESYESAlive528TUMOR FREENO1212012,3TCGA-A2-A1FW-D118311c60eee0-e3cd-4edb-8287-bf56a9f4efa9465154ChemotherapyCytoxanADJUVANTIVNO17520111TCGA-A2-A1FW-D118234ea58c35-fcc2-4136-9aa0-752ace9b87e0465154ChemotherapyAdriamycinADJUVANTIVNO17520112TCGA-A2-A1FW-D1183086b10331-62e5-40e8-bdc7-80184a5896d44175245ChemotherapyTaxotereADJUVANTIVNO17520114TCGA-A2-A1FW-D208124F2494FD-3934-42BA-8414-FE4FEFF62B75mg2.5mg364Hormone TherapyFemaraADJUVANTPOYES1212012,TCGA-A2-A1FW-R152729FDD44F3-884C-407E-B5B9-D1064D91CDA9277324EXTERNAL BEAM18120cGy52Primary Tumor FieldADJUVANTNO11682011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,376.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A0E2,BH,A0E2,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,26.0,H-SCORE 300,H-SCORE 1,Right Upper Inner QuadrantRight,1.602031249999999,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Margin resection,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Ductal partially papillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.521484375,4.0,H-SCORE,H-SCORE,10-19%,ACIS,CAP scoring guideline 2010,40.7724609375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.0,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.83,3 Point Scale,1+,Stage IIIAT2N2aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-BH-A0E2-F4639DD8C6D58-8E0A-47A6-BEB4-FA08BBC73CF3435AliveTUMOR FREENOYES16112010,1TCGA-BH-A0E2-D463386CFCEA0-9EEF-48CD-BA6A-C91C8062960120mg/day256Hormone TherapyTAMOXIFENADJUVANTPOYES171120101TCGA-BH-A0E2-D46362DA42AF6-78FA-4A56-B03C-9732F565896A438mg110mg481151ChemotherapyDOXORUBICINADJUVANTIVNO181120101TCGA-BH-A0E2-D46353DA5FC61-EF46-4724-959A-D97A1AC066DE4392mg1104mg481151ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO181120101TCGA-BH-A0E2-D4637DBDA746D-4CC8-48BC-B2DA-84801984F92A1589mg146mg11172221ChemotherapyPACLITAXELADJUVANTIVNO18112010,TCGA-OL-A5S0-R65264BDA0BB3D-2C0A-4827-898B-070CC5BFA0E9153202External60.4GyRegional siteNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1ND,E9,A1ND,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,11.0,Allred 0 = 0+0,Allred (Biocare),Left Upper Outer Quadrant,3.08350585937498,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Lumpectomy,Positive,Negative,Positive,0.0,1.0,Allred Score 6,180,10-19%,Hercep Test  TM Dako,Dako Hecept Test,104.111328125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,66,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,42,3 Point Scale,2+,7thStage IIBT2N1M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",23,6,2011,TCGA-E9-A1ND-F2916384404451-1487-4C94-8B63-BB1DDD0B95D9Scheduled Follow-up SubmissionNOYESAlive383TUMOR FREENO932012TCGA-E9-A1ND-F5557071D7CEFF-D60F-4294-8529-C2647A2961D0NONOYESTUMOR FREEAlive838NO912014TCGA-E9-A1ND-F6258620D9D392-E622-4E6B-9D2D-1D2616A9F585NONOYESTUMOR FREEAlive1266NO2172014,1TCGA-E9-A1ND-D30738FE127B51-D86A-4837-BD0A-0BE45831808C25mg/day31Hormone TherapyAromasinADJUVANTPOYES16420121TCGA-E9-A1ND-D30736C52B4951-6F14-4E15-850F-E75D2A3B32AC20mg/day3178Hormone TherapyTamoxifenADJUVANTPONO1642012,TCGA-E9-A229-R2980496F0A1DE-9AD4-4E84-B783-31C0475F7C9A207235EXTERNAL BEAM3800cGy19Regional siteADJUVANTNO2932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,241.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-AA10,S3,AA10,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,4.0,CAP scoring guideline 2010,CAP scoring guideline 2010,RightRight Upper Outer Quadrant,1.8159765624999904,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Pateys surgery,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,1+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.0078125,0.0,Allred score 6,180,90-99%,ACIS,CAP scoring guideline 2010,24.0517578125,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,1.45,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,NO,18,4,2014,TCGA-S3-AA10-F67528B1B67534-2F82-46FC-896D-E6CFB68E03A2NONOYESTUMOR FREEAlive468NO11112014TCGA-S3-AA10-F703514F48B8A5-A0CB-4E1C-8ADA-12F1C6814B66NONOYESTUMOR FREEAlive523NO2622015TCGA-S3-AA10-F70441D3E73401-5961-4C83-8C9D-2E93151A962CNONOYESTUMOR FREEAlive586NO2622015,NOTCGA-S3-AA10-D58351765A1845-816A-48C0-B600-D8D63C2E7DE975199ChemotherapyCYTOXANNOComplete Response1842014NOTCGA-S3-AA10-D58352A162E470-A31A-43EF-B7CC-48C25D10E12175199ChemotherapyTAXOTERENOComplete Response1842014NOTCGA-S3-AA10-D58354DFEAFB3D-F85C-4E98-96CE-3BB8DAE7C12E75199AncillaryNEULASTANOComplete Response1842014NOTCGA-S3-AA10-D67781DA1D7D41-7834-410C-959E-8D9D35DD679C265Hormone TherapyANASTROZOLEYES11112014,TCGA-E9-A1R7-R3060492D394C7-C929-4904-9E75-59276EFD6FA75076EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5749.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0RH,B6,A0RH,No,YES,C50.9,8500/3,C50.9,1991.0,TUMOR FREE,YES,23.0,Immunohistochemistry,Immunohistochemistry,Left Lower Inner Quadrant,1.4305175781249948,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,Excision,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Indeterminate (neither Pre or Postmenopausal),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Incisional Biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.0400390625,0.0,Moderate,190,30-39%,Dako,CAP scoring guideline 2010,52.2880859375,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,NO,YES,66,"Other, specifyskin",70-79%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,61,4 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",15,3,2011,"TCGA-B6-A0RH-F137947C07AC9E-BAE5-4C5C-9BCB-956AAEB7A12CScheduled Follow-up SubmissionNOYESAlive5749TUMOR FREEYES2165Locoregional DiseaseOther, specifyChest WallYES2268YESYES1272011TCGA-B6-A0RH-F715128AD42059-F3DB-4B45-B375-F6321BA31CCFNONOYESTUMOR FREEDead6456NO2632015",NOTCGA-A8-A09B-D37797DB9805C1-DC29-4382-829A-BC707E2688613030Chemotherapy5-Fluorouraciln/aNO6122012NOTCGA-A8-A09B-D37798D8720C19-DA4E-4B7C-AD4B-82EFBFDBF3E23030ChemotherapyEpirubicinn/aNO6122012NOTCGA-A8-A09B-D377991BC9A48C-10DD-439C-A959-4DD7B05CDF823030ChemotherapyCyclophosphamiden/aNO6122012NOTCGA-A8-A09B-D37800C0BCD5E9-32B6-4BA1-96BB-FB00CB9DA2E4122ChemotherapyDocetaxeln/aNO6122012NOTCGA-A8-A09B-D37801A108C623-BC80-4675-931F-301E1BA62157153242Hormone TherapyAnastrozolen/aNO6122012,TCGA-AC-A3BB-R58954DE55AD06-AA01-4B82-90E5-16F511E133AD217261External6040cGy28Primary Tumor FieldNOComplete Response2942014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,200.0,WHITE,TCGA-A7-A4SB,A7,A4SB,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,2.0,H-Score 300,CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.9257910156249889,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,Wide local excision and simple mastectomy,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,1.0,0.0,H score,250,90-99%,ACIS,Venten,426.9658203125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.25,"Other, specifyskin",70-79%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,52,3 Point Scale,2+,7thStage IIIAT3N1miM0,YES,YES,NO,20,2,2013,TCGA-A7-A4SB-F49625DF6EE235-5417-41D0-A77B-0237FC3EC31BNOYESYESTUMOR FREEAlive418NO4102013,NOTCGA-A7-A4SB-D4044450FAB4F7-9961-47ED-A399-7EA0F55FF5EC61124ChemotherapyDocetaxelNOComplete Response2022013NOTCGA-A7-A4SB-D404459F679293-FBF6-4C18-8842-A0A4A2E1080561124ChemotherapyCyclophosphamideNOComplete Response2022013NOTCGA-A7-A4SB-D496268051EB4D-DE3F-4F20-B2D4-F5559D2AE0AD218Hormone TherapyAnastrozoleYES4102013,TCGA-A7-A4SB-R4188104E0A0FD-1492-4ADA-97BD-0DC43F53D491167217External6100cGy31Primary Tumor FieldNOComplete Response242013TCGA-A7-A4SB-R418836AC058D6-3E65-4193-AF2C-58D23B788B99167206External4500cGyRegional siteNOComplete Response242013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,315.0,WHITE,TCGA-E2-A15P,E2,A15P,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,Allred score 5+3 = 8,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.317841796874998,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.345703125,0.0,Allred score = 4,Allred score = 8,10-19%,Dako,Venten,69.3369140625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.38,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,816,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,14,4,2011,TCGA-E2-A15P-F19144FF988B0B-A019-44FD-8CB3-0DEF979A82D9Scheduled Follow-up SubmissionYESYESAlive595TUMOR FREENO16112011,1TCGA-E2-A15P-D19145F89D7938-6B30-4AF5-84F0-30B5D1B87F69115mg1mg/day105220Hormone TherapyArimidexADJUVANTPONO161120112TCGA-E2-A15P-D19146CEE4C48F-410A-452E-9C36-DF6142898E8D25mg/day25mg/day223Hormone TherapyAromasinADJUVANTPOYES16112011,TCGA-E2-A15P-R19147747DC091-0514-4945-B09E-1CAD551849C85198EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO116112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,167.0,WHITE,TCGA-A7-A0CG,A7,A0CG,No,YES,C50.9,8522/3,C50.9,2010.0,TUMOR FREE,YES,5.0,H-SCORE 280,image cytometry,Right Upper Outer QuadrantRight,1.195351562499999,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Mixed Histology (please specify),Mixed infiltrating lobular and grade 1 ductal carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,1+,Negative,Close,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.0,0.0,170,8,10-19%,0,dextran coated charcoal,39.853515625,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,50,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.83,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,7,10,2010,TCGA-A7-A0CG-F3066390BC631-A036-45D1-B4F2-9E55C4B00237231AliveTUMOR FREEYESNO8112010TCGA-A7-A0CG-F392021A0EDC84-2E6A-4F64-80E3-F86E7F597E1ANOYESNOAlive1043NO1512013,2TCGA-A2-A0T3-D9215b41bdca7-b0bf-4308-b906-1dcc9bf77b23618mg103mg670177ChemotherapyAdriamycinADJUVANTIVNO21220114TCGA-A2-A0T3-D9218f9514221-8f9b-403b-99d4-e4843d0b2eb6Hormone TherapyTamoxifenADJUVANTPOYES21220113TCGA-A2-A0T3-D92162a946428-c9e3-4910-8589-57d6230d7cd46180mg1030mg670177ChemotherapyCytoxanADJUVANTIVNO21220111TCGA-A2-A0T3-D92144c04520d-d4ae-4202-b00b-a2782b640207930mg155mg670177ChemotherapyTaxotereADJUVANTIVNO2122011,TCGA-A7-A0CG-R30538a3d7282-2622-42f4-a841-7621c3e442c7146176EXTERNAL BEAM10480cGy42Primary Tumor FieldADJUVANTNO18112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1217.0,BLACK OR AFRICAN AMERICAN,TCGA-3C-AALK,3C,AALK,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,2.0,H-SCORE 0,allred score 5+3+8,Right,2.041367187499988,Sentinel node biopsy alone,SN+1 non sentinel node,Simple Mastectomy,Right Breast reexcision,Other,breast conserving therapy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Close,Core needle biopsy,Biopsy not specified,Negative,Positive,Positive,1.0,0.0,Allred score = 5,Allred score 7 (per outside facility),10-19%,0,Venten,127.1767578125,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,33,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,105,3 Point Scale,2+,7thStage IAT1cN0 (i+)M0,YES,NO,NO,28,7,2014,TCGA-3C-AALK-F68063508BF78A-4516-408C-90B2-CA6EC2BA9F5ENONOYESTUMOR FREEAlive1221NO13112014TCGA-3C-AALK-F716769A947236-6EF3-47DF-9F4B-E9AC47728F13NONOTUMOR FREEAlive1448NO2732015,NOTCGA-3C-AALK-D62908571B5F2E-D8FE-48A4-8649-10F230CC8BB9371528ChemotherapyDocetaxelNO2872014NOTCGA-3C-AALK-D655106E4745D5-0034-4021-9CF7-C578C4793766507829ChemotherapyHerceptinNO2492014NOTCGA-3C-AALK-D655250E79A684-C8F1-4AEB-9831-77AA9B72957E371528ChemotherapyCarboplatinNO2492014NOTCGA-3C-AALK-D65526404CEE87-D8B8-4CEE-92A7-3A7FAD80183C371528ChemotherapyTrastuzumabNO2492014,TCGA-A7-A0CG-R30538a3d7282-2622-42f4-a841-7621c3e442c7146176EXTERNAL BEAM10480cGy42Primary Tumor FieldADJUVANTNO18112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,21.0,WHITE,TCGA-E9-A244,E9,A244,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,H-SCORE 0,allred score 5+3+8,Left Upper Outer Quadrant,2.336025390625,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,Excisional biopsy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.0146484375,0.0,allred score = 4,allred score = 7,30-39%,Dako,Venten,155.123046875,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.13,"Other, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,441,3 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,15,3,2011,TCGA-E9-A244-F3116439F4E7E2-641B-4D72-8E4C-8066AAD6A679Scheduled Follow-up SubmissionNOYESAlive21TUMOR FREENO2442012,1TCGA-E9-A244-D31166B71D5E8E-B7EF-4786-8FB2-E7ACF5FE2C751000mg1000mg11616ChemotherapyCyclophosphamideADJUVANTIVNO24420121TCGA-E9-A244-D31168E07A4B20-C911-4AB0-81F9-1D66E0F74A44100mg100mg11616ChemotherapyDoxorubicinADJUVANTIVNO2442012,TCGA-E9-A1R7-R3060492D394C7-C929-4904-9E75-59276EFD6FA75076EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2442.0,ASIAN,TCGA-AO-A03L,AO,A03L,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,17.0,Allred 0 = 0+0,Allred score 0+0 = 0,Right Upper Inner QuadrantRight Upper Outer QuadrantRight Lower Inner QuadrantRight Lower Outer QuadrantRight,1.0,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,Wide Local Excision,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, classical type, focal pleomorphic type",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Positive,0.7177734375,4.0,240 H,10-75%,10-19%,CISH,3+ Positive,30.0,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,63,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,47,3 Point Scale,2+,6thStage IIIAT3N2M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,12,2010,TCGA-AO-A03L-F585846CF8472-9AC2-4CA9-AE52-1D40A3A5AA0A2442AliveTUMOR FREEYESYES7122010TCGA-AO-A03L-F19390CC654247-3426-49B3-B47E-C503B40F898CScheduled Follow-up SubmissionYESYESAlive2442NO12122011,1TCGA-AO-A03L-D5921f4461ec4-9a69-4f0c-a38c-2fb57692c388600mg/m2436140ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A03L-D5920bdf77be9-8a97-410e-9290-fe7f9076188560mg/m2436140ChemotherapyDoxorubicinADJUVANTIVNO10120112TCGA-AO-A03L-D592557884874-30e3-4850-a42c-bf89ec191ccd20mg/day2272057Hormone TherapyTamoxifenADJUVANTPONO10120112TCGA-AO-A03L-D59261def3807-a1e2-4d1c-a417-9b8d8302d0653632057Hormone TherapyLupronADJUVANTIMNO10120111TCGA-AO-A03L-D592370c52b36-df70-4dd1-b109-5d7c12ef900e175mg/m2436140ChemotherapyPaclitaxelADJUVANTIVNO1012011,TCGA-AO-A03L-R58595fb3a572-ca52-4caf-8a15-9bf2aa8e7bba167208EXTERNAL BEAM10080cGy28Regional siteADJUVANTNO17122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,298.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5S0,OL,A5S0,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,12.0,H-SCORE 190,image cytometry,Right,3.8,Axillary lymph node dissection alone,SN+1 non sentinel node,Modified Radical Mastectomy,Right Breast reexcision,Other,partial left mastectomy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Negative,0.291015625,2.0,8,8,90-99%,CISH,Hercep Test  TM Dako,68.7841796875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,3.1,"Other, specifyskin",30-39%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,3+,7thStage IIBT2N1aMX,YES,YES,NO,16,5,2013,TCGA-OL-A5S0-F565675E87825C-A737-4301-8FAD-C577C69C56AFNOYESYESTUMOR FREEAlive620NO1422014,NOTCGA-OL-A5S0-D652658498E674-7702-4F90-9214-66B02D73543D67228ChemotherapyTAXOLNOComplete Response2492014NOTCGA-OL-A5S0-D65266BFE8B8D7-C0CE-4D2E-A587-DDC39BE732B167228Hormone TherapyHERCEPTINNOComplete Response2492014,TCGA-OL-A5S0-R65264BDA0BB3D-2C0A-4827-898B-070CC5BFA0E9153202External60.4GyRegional siteNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,549.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A570,E2,A570,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,7.0,Allred 7 = 5+2,Allred 8 = 5+3,Right Lower Inner Quadrant,1.1,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Margin resection,Other,Pateys surgery,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.6904296875,1.0,Allred Score,Allred Score,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,200.0,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.0,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.2,3 Point Scale,3+,7thStage IBT1cN1miM0,YES,NO,NO,21,6,2013,TCGA-E2-A570-F61335D033E907-A771-48E7-AC23-E1DC385C5CD1NONOYESTUMOR FREEAlive931NO2762014,NOTCGA-E2-A570-D44535569DEEF9-63F5-49E8-8D2F-AC6BA220410F252Hormone TherapyAnastrozoleYES2162013,TCGA-AO-A03L-R58595fb3a572-ca52-4caf-8a15-9bf2aa8e7bba167208EXTERNAL BEAM10080cGy28Regional siteADJUVANTNO17122010
TCGAFPPP,Breast,No,FEMALE,Dead,1699.0,1144.9462890625,WHITE,TCGA-AR-A0TY,AR,A0TY,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,15.0,dextran coated charcoal,Image Analysis,Right Upper Outer Quadrant,1.5234667968750004,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.0751953125,0.0,Allred Score 7,Allred Score 8,90-99%,Dako,CAP scoring guideline 2010,157.8935546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,2.6,"Other, specifyskin",10-19%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,172,3 Point Scale,0,Stage IIAT2N0M0,YES,YES,PositiveNegative1+,10,3,2011,TCGA-AR-A0TY-F1856178C812FE-1E96-434A-AA4B-15BF524153A4Scheduled Follow-up SubmissionNOYESDead1699WITH TUMORYES544Distant MetastasisBone15122011,1TCGA-AR-A0TY-D195898AF1AE1C-AC88-42CF-85CB-59C890EFBCA74ChemotherapyPaclitaxelADJUVANTNO151220112TCGA-AR-A0TY-D1959067BBC709-F34C-473D-AFB4-E8E35852ED65557Hormone TherapyAnastrozoleADJUVANTNO151220111TCGA-AR-A0TY-D19587035DEB95-23A9-4215-B3F4-9D2A08D941C94ChemotherapyDoxorubicinADJUVANTNO151220111TCGA-AR-A0TY-D19588B06C690B-5D84-4092-8606-77F7AC010E764ChemotherapyCytoxanADJUVANTNO15122011,TCGA-AO-A03L-R58595fb3a572-ca52-4caf-8a15-9bf2aa8e7bba167208EXTERNAL BEAM10080cGy28Regional siteADJUVANTNO17122010
TCGAFPPP,Breast,No,FEMALE,Dead,2854.0,1396.4033203125,WHITE,TCGA-AR-A256,AR,A256,No,YES,C50.9,8500/3,C50.9,2001.0,WITH TUMOR,YES,5.0,Allred score 5+3 = 8,Image Analysis,Right Lower Inner Quadrant,1.6142285156249898,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Margin resection,Other,Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,4+,1+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Negative,Negative,Negative,0.1357421875,0.0,H-Score,Allred Score 8,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,90.7685546875,HER2 amplification - negative,Positive >2.2,NO,YES,160,"Other, specifyaxilaary node negative but intrammary node positive",80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,<4.0,4 Point Scale,1+,5thStage IIAT2N0M0,YES,NO,PositivePositiveNegative,31,8,2011,TCGA-AR-A256-F31923ABDB80D8-BC00-469D-9827-36679803F8EFScheduled Follow-up SubmissionNOYESDead2854YES1640Locoregional Disease1152012,NOTCGA-AR-A256-D31926B6C966AC-D18C-4B33-BFE1-11776EA2F33838101ChemotherapyDoxorubicinNO2252012NOTCGA-AR-A256-D31927B4890692-5CC2-43F9-B3F9-89528DD2F72038101ChemotherapyCytoxanNO2252012,TCGA-AC-A3BB-R58954DE55AD06-AA01-4B82-90E5-16F511E133AD217261External6040cGy28Primary Tumor FieldNOComplete Response2942014
TCGAFPPP,Breast,No,FEMALE,Dead,1286.0,943.205078125,WHITE,TCGA-BH-A1EU,BH,A1EU,No,YES,C50.9,8500/3,C50.9,1999.0,TUMOR FREE,NO,13.98828125,H-Score 300,allred score 5 +3 = 8,Right,2.2499316406249963,Sentinel node biopsy alone,Pateys surgery,Other,Right Breast reexcision,Other,Right segmental mastectomy,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,1.06640625,1.419921875,MODERATE,Intensity=Strong,10-19%,ACIS,CAP SCORING GUIDELINE 2010,60.6162109375,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,1.57,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,1.73,3 Point Scale,2+,5thStage IT1N0M0,NO,NO,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,7,9,2011,TCGA-AR-A0TY-F1856178C812FE-1E96-434A-AA4B-15BF524153A4Scheduled Follow-up SubmissionNOYESDead1699WITH TUMORYES544Distant MetastasisBone15122011,TCGA-D8-A1XF-D294430C6384BF-1F92-4793-B12E-4B62D23851CCmg60+600mg/m24311356Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO2632012,TCGA-AO-A03L-R58595fb3a572-ca52-4caf-8a15-9bf2aa8e7bba167208EXTERNAL BEAM10080cGy28Regional siteADJUVANTNO17122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,80.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A6FQ,LL,A6FQ,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,18.0,H-SCORE 0,H-Score 0,Right Upper Outer Quadrant,1.6216015624999895,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,7.0,Allred Score 3,8,<10%,0,Hercep Test  TM Dako,83.7548828125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,4.43,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,4.70,3 Point Scale,2+,7thStage IIIAT2N2aMX,NO,NO,NO,30,8,2013,TCGA-LL-A6FQ-F58204804405B3-E0C3-4F4D-985A-1AF09F39E17FYESAlive80242014,NOTCGA-GM-A2DI-D470907B5D9D98-20F4-4180-8CAC-4343CFA7FCD370133ChemotherapyTaxotereNOComplete Response2282013NOTCGA-GM-A2DI-D470915CFA2517-8901-4EA6-A4C7-92DA88C6C423154217ChemotherapyFluorouracilNOComplete Response2282013NOTCGA-GM-A2DI-D470927D31035E-0AC6-403A-B734-CA72E210C75F154217ChemotherapyEpirubicinNOComplete Response2282013NOTCGA-GM-A2DI-D470932D81179B-0BEB-492F-8B9F-5FA57D8F59D0154217ChemotherapyCytoxanNOComplete Response2282013,TCGA-E9-A1R7-R3060492D394C7-C929-4904-9E75-59276EFD6FA75076EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1883.0,WHITE,TCGA-GM-A2DI,GM,A2DI,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,9.0,Allred score 5+3=8,CAP scoring guideline 2010,Left Upper Inner Quadrant,1.06,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Margin resection,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,1.0,0.0,Allred Score 3,80,10-19%,0,CAP SCORING GUIDELINE 2010,60.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,3.33,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.53,3 Point Scale,2+,6thStage IT1cN0 (i+)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,29,9,2011,TCGA-GM-A2DI-F4708964BBFF53-4A07-4474-8016-57DEE132EC2ENONOYESTUMOR FREEAlive2590NO2282013,NOTCGA-GM-A2DI-D470907B5D9D98-20F4-4180-8CAC-4343CFA7FCD370133ChemotherapyTaxotereNOComplete Response2282013NOTCGA-GM-A2DI-D470915CFA2517-8901-4EA6-A4C7-92DA88C6C423154217ChemotherapyFluorouracilNOComplete Response2282013NOTCGA-GM-A2DI-D470927D31035E-0AC6-403A-B734-CA72E210C75F154217ChemotherapyEpirubicinNOComplete Response2282013NOTCGA-GM-A2DI-D470932D81179B-0BEB-492F-8B9F-5FA57D8F59D0154217ChemotherapyCytoxanNOComplete Response2282013,TCGA-EW-A3U0-R420336E6A19AF-0B87-410E-AFCA-59AC61E7336D229281External109GyRegional siteNOComplete Response942013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,141.0,WHITE,TCGA-A7-A0DB,A7,A0DB,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.0,H-Score 300,Allred score 2+2 = 4,Right,1.313867187499996,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Reexcision,Other,surgical resection,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Close,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,230,205,10-19%,0,DAKOHercepTest TM,178.7880859375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,69,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.67,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",4,10,2010,TCGA-A7-A0DB-F293136D2F1C0-4545-438D-A3CD-F1E072A82DB2267AliveTUMOR FREEYESYES5112010TCGA-A7-A0DB-F38479675A6559-DE14-437A-A6D4-3F931CBCEDC7NOYESYESTUMOR FREEAlive1007NO14122012,1TCGA-A7-A0DB-D2932bcfb5d3f-efe5-4ea8-be83-bee5a5a802a4216mg1mg141Hormone TherapyArimidexADJUVANTPOYES5112010,TCGA-A7-A0DB-R293320c16888-67e5-4b28-8f59-2b6d1f28d23a92138EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO15112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1117.0,WHITE,TCGA-BH-A0BM,BH,A0BM,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,24.0,H-SCORE 280,PR Negative H-Score 0,Right Upper Inner QuadrantRight Upper Outer QuadrantRight,1.556679687500002,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Lumpectomy,Right Breast reexcision,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.2578125,3.0,H-Score,230,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.6103515625,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,1.57,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,1.67,3 Point Scale,0,6thStage IIBT2N1aM0,NO,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,11,2010,TCGA-BH-A0BM-F3406423464ADF-8E8E-4359-AA9A-0D6C5E3A3BBDScheduled Follow-up SubmissionNOYESAlive1876TUMOR FREENO2972012,1TCGA-BH-A0BM-D448407017073-10D9-4DD4-878C-E519D915D61312164229ChemotherapyTAXOTEREADJUVANTIVNO151120101TCGA-BH-A0BM-D44813C72F82E-10E8-4A73-AAA4-B3074877D2B1480138ChemotherapyADRIAMYCINADJUVANTIVNO151120101TCGA-BH-A0BM-D4483E9AF4E21-72D8-4812-B417-6233FC2911FF480138ChemotherapyCYTOXANADJUVANTIVNO15112010,TCGA-AC-A3BB-R58954DE55AD06-AA01-4B82-90E5-16F511E133AD217261External6040cGy28Primary Tumor FieldNOComplete Response2942014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A8-A081,A8,A081,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.10546875,CAP scoring guideline 2010,image cytometry,Right,1.950361328124984,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.31640625,0.0,Allred Score,0,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,120.15234375,HER2 amplification - negative,>= 2.0 Positive,NO,YES,66,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,441,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,27,5,2011,TCGA-A8-A09B-F4055067B93484-7627-4EB4-82E5-189B57D36AC1NOYESYESTUMOR FREEAlive3652322013,NOTCGA-AC-A2FB-D45600874799CE-92C6-4A14-9087-50637D5A0BFB101205ChemotherapyTaxotereNOComplete Response1772013NOTCGA-AC-A2FB-D4560183D4DEF8-DDC1-4477-B951-DA1E2EE02B89212443ChemotherapyHerceptinNOComplete Response1772013NOTCGA-AC-A2FB-D45602E9BB9D9C-C752-4FC4-AA16-B531C23C1BEF225895Hormone TherapyArimidexNOComplete Response1772013,TCGA-A2-A0CX-R196969e31ee3-a4ba-40bf-b722-f1a229006582305ADJUVANTNO11392010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3767.0,WHITE,TCGA-3C-AAAU,3C,AAAU,No,YES,C50.9,8520/3,C50.9,2004.0,WITH TUMOR,YES,13.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,Left Lower Outer Quadrant,3.2062109374999808,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and axillary lymph node biopsy,Modified Radical Mastectomy,Margin resection,Other,Pateys surgery,Infiltrating Lobular Carcinoma,tubular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Biopsy not specified,Negative,Positive,Negative,1.2158203125,4.0,90 H,Intensity=Weak,30-39%,CISH,Venten,325.1669921875,HER2 amplification - negative,Positive >2.2,NO,YES,1.78,"Other, specifyskin",50-59%,50-59%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,2+,Negative,1.8985937499999987,105,3 Point Scale,2+,6thStage XTXNXMX,YES,NO,NO,13,1,2014,TCGA-3C-AAAU-F68069238F65F8-617D-4508-B006-20A31E09D1C6NONOYESWITH TUMORAlive3928YES1808Distant MetastasisLung13112014TCGA-3C-AAAU-F71341D7B0BC51-D86F-4554-939E-EA9A24DE581DNONONOWITH TUMORAlive4047NO2432015,YESTCGA-3C-AAAU-D60350B8C5D175-54E9-4659-A630-DC1EA2BBD3151828ChemotherapyZoladexYES662014,TCGA-E2-A15P-R19147747DC091-0514-4945-B09E-1CAD551849C85198EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO116112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,97.0,WHITE,TCGA-D8-A1XF,D8,A1XF,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,8.0,% IHC,%IHC,Left Upper Outer Quadrant,6.241308593750015,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,secretory,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",intraoperative examination,Positive,Positive,Negative,0.0,0.0,>75%,>75%,30-39%,Hercep Test  TM Dako,Dako Hercept test,79.15625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.38,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.3,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,16,5,2011,TCGA-D8-A1XF-F29442F9DFA106-1DBD-4EB8-9586-DF8D2300FB35Scheduled Follow-up SubmissionNOYESAlive463TUMOR FREENO1932012,TCGA-D8-A1XF-D294430C6384BF-1F92-4793-B12E-4B62D23851CCmg60+600mg/m24311356Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO2632012,TCGA-A2-A1G6-R20946AF32408D-BB2D-4910-8E8A-B62DC6DDE68E249283EXTERNAL BEAM4500cGy25Regional siteADJUVANTNO12512012TCGA-A2-A1G6-R317798A5DBB7F-2FCD-45AF-807E-57F4DE9EA749249283EXTERNAL BEAM4500cGy25Regional siteADJUVANTNO2952012TCGA-A2-A1G6-R317800C5AA321-F0DC-4B91-9633-0CABB1EDE7C7284293EXTERNAL BEAM1600cGy8Regional siteADJUVANTNO3952012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A229,E9,A229,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,14.0,allred score 5 + 3 = 8,IHC,Right Lower Inner Quadrant,1.257529296874999,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Other,Right Breast reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Equivocal,0.037109375,0.0,108,250,10-19%,Hercep Test  TM Dako,Dako Hercept test,63.4296875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,3.1,"Other, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,105,4 Point Scale,1+,7thStage IAT1cN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,2,8,2011,TCGA-E9-A229-F29798155219BA-2CDA-407F-B8C7-00AADE3DB297Scheduled Follow-up SubmissionYESYESAlive405TUMOR FREENO2932012TCGA-E9-A229-F65803F2689D1C-F153-4432-93F5-54D768688BB2NOYESYESTUMOR FREEAlive1148NO3092014,TCGA-E9-A229-D298037E071032-AA10-4F23-BDD1-ADB1512543394200mg700mg/day624182Chemotherapy5-FluorouracilADJUVANTIVNO2932012TCGA-E9-A229-D298025D1A648D-B766-45C5-A426-F17BEA87EFD8360mg90mg/day624182ChemotherapyDoxorubicinADJUVANTIVNO2932012TCGA-E9-A229-D29800B1E9251D-B543-4832-9798-633B74C588FB3600mg900mg/day624182ChemotherapyCyclophosphamideADJUVANTIVNO2932012,TCGA-E9-A229-R2980496F0A1DE-9AD4-4E84-B783-31C0475F7C9A207235EXTERNAL BEAM3800cGy19Regional siteADJUVANTNO2932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,223.0,WHITE,TCGA-D8-A4Z1,D8,A4Z1,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,1.0,Allred (Biocare),IHC,RightRight Upper Inner Quadrant,1.2920214843750004,No axillary staging,SLN and non-SLN biopsy,Simple Mastectomy,Right Breast reexcision,Other,Pateys surgery,Infiltrating Lobular Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Positive,Positive,Negative,0.57421875,0.0,Allred score = 5,205,90-99%,Dako,Venten,94.787109375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,54,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,52,3 Point Scale,1+,7thStage IAT1cN0M0,YES,NO,NO,1,2,2013,TCGA-D8-A4Z1-F5848500555AC3-B1C1-4712-A6CD-9FDF98F9D2B3NONOYESTUMOR FREEAlive659NO1142014,NOTCGA-D8-A4Z1-D397603EDA844D-C123-4BB2-8172-06DB3BAD4DD4104Hormone TherapyTamoxifenYES122013,TCGA-BH-A0HO-R476995039DE4-9BE0-4A86-A302-3D44887F8231312369EXTERNAL BEAM6060cGy33Primary Tumor FieldADJUVANTNO130112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,429.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5RY,OL,A5RY,No,YES,C50.9,8500/3,C50.9,2011.0,WITH TUMOR,YES,25.0,H-SCORE 300,Allred score 2+2 = 4,Right,7.6,Sentinel node biopsy alone,Sentinel lymph node and axillary lymph node biopsy,Lumpectomy,Right Breast reexcision,Mastectomy NOS,partial left mastectomy,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Positive,"Other method, specify:",Ultrasound-guided biopsy,Positive,Positive,Negative,1.01953125,1.0,Allred score 0,8,90-99%,CISH,CAP SCORING GUIDELINE 2010,63.6650390625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.9,"Other, specifyskin",10-19%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,71,3 Point Scale,3+,7thStage IIAT1cN1MX,YES,YES,NO,16,5,2013,TCGA-OL-A5RY-F56565EC19B71A-1285-42EF-836D-0AEA3910712BNOYESYESTUMOR FREEAlive752NO1422014,TCGA-E9-A1R3-D3082342526DF7-F5F2-4212-80D8-73443892CEB6100mg100mg14150ChemotherapyMethotrexateADJUVANTIVNO1742012TCGA-E9-A1R3-D3082457C90782-1DBC-41F4-8674-D1FB85B985422000mg2000mg14150ChemotherapyCyclophosphamideADJUVANTIVNO1742012TCGA-E9-A1R3-D3082663FBD160-E49D-4A37-ADC7-7BF300319F6A20mg/day45Hormone TherapyTamoxifenADJUVANTPOYES1742012TCGA-E9-A1R3-D308228AAB711A-821D-49F2-97B5-DB26D061A35B2000mg2000mg14150Chemotherapy5-FluorouracilADJUVANTIVNO1742012,TCGA-EW-A3U0-R420336E6A19AF-0B87-410E-AFCA-59AC61E7336D229281External109GyRegional siteNOComplete Response942013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,330.0,WHITE,TCGA-AC-A23G,AC,A23G,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,8.0,Allred (Biocare),Image Analysis,Right Upper Inner Quadrant,2.160439453124994,Sentinel node biopsy alone,Sentinel lymph node and axillary lymph node biopsy,Other,Right Breast reexcision,Other,Right Total Mastectomy and Sentinel Node Biopsy,Infiltrating Lobular Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Positive,Positive,Positive,0.3876953125,2.0,Allred Score 6,Allred score 8,10-19%,ACIS,CAP SCORING GUIDELINE 2010,63.0390625,HER2 amplification - negative,PathVysion,NO,YES,3.0,BoneLiver,90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.1,3 Point Scale,2+,6thStage IIAT1cN1MX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",14,7,2011,TCGA-AC-A23G-F43241CBABBD3D-7093-4CB3-9F87-A561F537C731NONOYESTUMOR FREEAlive2248NO1552013,NOTCGA-AC-A23G-D4324310502588-843C-4F06-BCB5-FC3640306A2F109190ChemotherapyCytoxanNOComplete Response1552013NOTCGA-AC-A23G-D43244AD503E66-08BD-4F4E-877D-4D9D499AB832109190ChemotherapyAdriamycinNOComplete Response1552013NOTCGA-AC-A23G-D4324524D15948-49E0-4B96-870D-492C786C0937190220ChemotherapyTaxolNOComplete Response1552013NOTCGA-AC-A23G-D432468C1BBA20-CDAA-4C57-BAE6-BF46E12CFDE0237Hormone TherapyArimidexNOComplete Response1552013,TCGA-EW-A3U0-R420336E6A19AF-0B87-410E-AFCA-59AC61E7336D229281External109GyRegional siteNOComplete Response942013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,34.0,WHITE,TCGA-E9-A1R7,E9,A1R7,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,H-SCORE 0,H-Score 0,Right Upper Outer Quadrant,1.7712890624999813,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Negative,0.0,0.0,8,Intensity=Strong,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,132.7353515625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.38,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,172,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-E9-A1R7-F3060200EA1897-A753-48AF-AC29-15ECF12D8DDEScheduled Follow-up SubmissionYESYESAlive645TUMOR FREENO2412014TCGA-E9-A1R7-F62721D71AEB4E-FB69-4AA9-8C01-AF812A2C7AECNOYESYESTUMOR FREEAlive1130NO2372014TCGA-E9-A1R7-F71424AA507418-EBDE-4FAF-95FB-60332FE04D0ENOYESYESTUMOR FREEAlive1467NO2532015,TCGA-E9-A1R7-D306038895D57C-039B-4650-9D2E-7EEDF6FCE7A360mg/day25Hormone TherapyFarestonADJUVANTPOYES1342012NOTCGA-E9-A1R7-D714252294BAB6-88C3-4F06-BA09-D2EDFDDB7C4153Hormone TherapyTamoxifenYES2532015,TCGA-E9-A1R7-R3060492D394C7-C929-4904-9E75-59276EFD6FA75076EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,30.0,ASIAN,TCGA-C8-A27B,C8,A27B,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,NO,11.365234375,IHC,Allred score 5+3 = 8,Left,1.6514257812499995,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Negative,Negative,0.0400390625,3.13671875,Allred score 5,Allred Score 7,90-99%,ACIS,Hercep Test  TM Dako,87.9716796875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,64,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,145,4 Point Scale,2+,6thStage IIBT3N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,7,2011,TCGA-C8-A27B-F70781034E528F-AA4B-4323-B33B-521853E5E8E5NONOYESTUMOR FREEAlive439NO932015,NOTCGA-C8-A27B-D70782DA6B28FB-BAD1-4A40-9E5F-0B1F39CF04966285Chemotherapy5-FlourouracilNOComplete Response932015NOTCGA-C8-A27B-D70783C4415E67-02A8-44F6-A28B-1ADA98E0EFC96285ChemotherapyCyclophosphamideNOComplete Response932015NOTCGA-C8-A27B-D70784AB7C57F0-657B-482F-BAD3-11C849B1AD7D6285ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A27B-D7078518D1F0D1-A458-40F2-B27C-6E5C94FED2136285ChemotherapyTaxolNOComplete Response932015,TCGA-EW-A3U0-R420336E6A19AF-0B87-410E-AFCA-59AC61E7336D229281External109GyRegional siteNOComplete Response942013
TCGAFPPP,Breast,No,FEMALE,Dead,573.0,980.2333984375,BLACK OR AFRICAN AMERICAN,TCGA-B6-A409,B6,A409,No,YES,C50.9,8500/3,C50.9,2008.0,WITH TUMOR,YES,22.0,dextran coated charcoal,Allred score 5+3 = 8,Right Upper Outer Quadrant,1.2,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Modified radical mastectomy,L Total Mastectomy,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,4 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Negative,Equivocal,0.1865234375,6.0,230,allred score = 7,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,60.0,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,1.8,BoneLiver,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,2,4 Point Scale,1+,6thStage IIIAT1cN2aM0,YES,NO,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,20,9,2012,TCGA-BH-A0B0-F592048DFE37F5-C1F5-45C1-BCE9-70A5209079F1NOYESYESTUMOR FREEAlive2477NO252014,NOTCGA-B6-A409-D41060FF0971AD-14FB-4A85-8FBB-FC306D52E3765193ChemotherapyCyclophosphamideNO1132013NOTCGA-B6-A409-D41061E376E464-0759-47CF-A9BD-2B247D16DA205193ChemotherapyDoxorubicinNO1132013NOTCGA-B6-A409-D410622FE8275D-A6CE-4337-A4BE-E37271CD0124107149ChemotherapyPaclitaxelNO1132013,TCGA-E2-A14O-R18525C94602E4-7139-4008-BDC3-9058B35B1E2168105EXTERNAL BEAM5000cGyPrimary Tumor FieldADJUVANTNO120102011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1172.0,WHITE,TCGA-E2-A109,E2,A109,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,6.0,Allred score 5+3=8,Allred score 0+0=0,Right Upper Outer Quadrant,1.46,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.353515625,0.0,Allred score 0,Allred score 8,50-59%,Dako,CAP scoring guideline 2010,215.55859375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.38,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.0,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",11,2,2011,TCGA-E2-A109-F1741852DADCDC-5F66-4C71-8D5F-3BCE69F19291Scheduled Follow-up SubmissionNOYESAlive1417TUMOR FREENO992011,6TCGA-E2-A109-D7772c3820a88-cd09-4aa5-bfb5-d4812af05d332.5mg/day2.5mg/day857Hormone TherapyFemaraADJUVANTPOYES14220113TCGA-E2-A109-D7765c11ab503-55a1-4706-8e19-4306df0021b625mg/day25mg/day643685Hormone TherapyAromasinADJUVANTPONO14220111TCGA-E2-A109-D776087fba7ad-05d6-4c59-a6de-0c0c59379e51125mg/day60mg/m2/day15111215ChemotherapyCytoxanADJUVANTPONO14220115TCGA-E2-A109-D7769c186939c-e896-47d0-8370-b151b3b79e0020mg/day20mg/day734807Hormone TherapyTamoxifenADJUVANTPONO14220111TCGA-E2-A109-D7762596420b7-1032-4b1e-bac4-031b00ef07c252mg/wk24mg/m2/day15111209ChemotherapyAdriamycinADJUVANTIVNO14220112TCGA-E2-A109-D7764c755119e-684b-49ba-9d65-985dcde6d41b1mg/day1mg/day318608Hormone TherapyArimidexADJUVANTPONO14220111TCGA-E2-A109-D77638df90aa0-372a-4649-9663-282c2d48b5442202mg367mg6230300ChemotherapyTaxolADJUVANTIVNO14220114TCGA-E2-A109-D7767db4b5ad5-5f00-43e8-8a2c-e32766f985ff2.5mg/day2.5mg/day699734Hormone TherapyFemaraADJUVANTPONO1422011,TCGA-AR-A1AO-R21773E8DA70B1-BB41-4DD0-B17B-EFDEC13F33EE168210EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12722012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,30.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A3BB,AC,A3BB,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,14.0,H-SCORE 0,CAP scoring guideline 2010,Right Upper Outer Quadrant,1.4259375000000016,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Lobular Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.953125,5.0,moderately to strongly,190,90-99%,Hercep Test  TM Dako,DAKOHercepTest TM,408.828125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,3.0,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.8,3 Point Scale,2+,7thStage IIIAT3N2aMX,YES,YES,Positive70-79%Positive<10%Negative1+,3,2,2012,TCGA-AC-A3BB-F589534140D0AE-C992-47B8-BB8C-23A0F298C461NOYESYESTUMOR FREEAlive987NO2942014,NOTCGA-AC-A3BB-D5895529980E13-140D-4302-8067-9256665BC67392197ChemotherapyCytoxanNOComplete Response2942014NOTCGA-AC-A3BB-D58956CAB74A66-0CCF-4E51-8F5A-FF613B5A43C792197ChemotherapyAdriamycinNOComplete Response2942014NOTCGA-AC-A3BB-D58957260FF621-0F12-4118-8D3F-AA44CC70F34592197ChemotherapyTaxotereNOComplete Response2942014,TCGA-AC-A3BB-R58954DE55AD06-AA01-4B82-90E5-16F511E133AD217261External6040cGy28Primary Tumor FieldNOComplete Response2942014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,229.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A3U0,EW,A3U0,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,25.0,H-SCORE 0,IHC,Left,2.834414062499997,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,partial left mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Negative,Negative,0.958984375,1.0,230,Intensity=Strong,<10%,CISH,CAP SCORING GUIDELINE 2010,105.556640625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.8,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,816,3 Point Scale,3+,7thStage IIIAT3N1aM0,YES,YES,NO,24,5,2012,TCGA-EW-A3U0-F420325FBF8A7F-C830-4250-B7C4-A372BC4DB5A7NOYESYESTUMOR FREEAlive532NO942013,NOTCGA-EW-A3U0-D42035FD889A7B-41D1-42B5-A58A-BE562B86552585127ChemotherapyCisplatinNOComplete Response942013NOTCGA-EW-A3U0-D420367D3EE7E9-9692-488D-866E-054AF4EC0EAD85127ChemotherapyTaxotereNOComplete Response942013NOTCGA-EW-A3U0-D4203739091340-4E3F-492C-9FA3-3FC1468ADDDD148197ChemotherapyDoxorubicinNOComplete Response942013NOTCGA-EW-A3U0-D420382ACE8F03-CCD2-49E1-BB73-5DC383D76E8C148197ChemotherapyCyclophosphamideNOComplete Response942013,TCGA-EW-A3U0-R420336E6A19AF-0B87-410E-AFCA-59AC61E7336D229281External109GyRegional siteNOComplete Response942013
TCGAFPPP,Breast,No,FEMALE,Dead,548.0,1327.724609375,BLACK OR AFRICAN AMERICAN,TCGA-A2-A04P,A2,A04P,No,YES,C50.9,8500/3,C50.9,2003.0,WITH TUMOR,YES,20.0,H-Score 270,H-Score 160,Left,1.3,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Mastectomy NOS,breast conserving therapy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Positive,Positive,Excisional Biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.0,18.0,200,200,10-19%,ACIS,Venten,79.458984375,HER2 amplification - negative,RATIO > 2.2,NO,YES,4,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,2.83,3 Point Scale,2+,6thStage IIICT2N3cM0,YES,YES,NONO,26,8,2010,"TCGA-A2-A04P-F26520D1BD57A-F783-438D-9F39-8A75193DDDCCDeadWITH TUMOR548YESYES179YES179NegativeNegativeNegative1.0NOYESYES2682010TCGA-A2-A04P-F102411966A070-7389-434A-BE2F-01ABFB19B3ABDeadWITH TUMOR548YESYES180NONONONO1832011TCGA-A2-A04P-F710214B4F5FA2-A9FE-49A8-914E-F8256897A51ANOYESYESWITH TUMORDead548YES179Locoregional RecurrenceOther, specifyAxillaYES179YESYESNegativeNegativeNegative1.0102Distant MetastasisBoneNOYESYES180Distant MetastasisLungNONOYES313Distant MetastasisLiverNONOYES1332015",8TCGA-A2-A04P-D26633a1d9f6f-f1ca-46c5-b2a8-de1975c543bc25mg424Hormone TherapyExemestanePROGRESSIONPONO27820103TCGA-A2-A04P-D265882ad8e80-6818-481d-83da-17868130a545242303ChemotherapyTAXOTEREPROGRESSIONIVNO27820105TCGA-A2-A04P-D2660365f5d4a-5bca-494e-82fa-3648ee6acfaa303424ChemotherapyADRIAMYCINPROGRESSIONIVNO27820107TCGA-A2-A04P-D2662021fbfcb-44dd-4dcd-952e-486a8aa9ecd01424424ChemotherapyNAVELBINEPROGRESSIONIVNO27820106TCGA-A2-A04P-D266117d09ea1-32bc-4cc2-998e-e9368e4723351424424ChemotherapyCisplatinPROGRESSIONIVNO27820101TCGA-A2-A04P-D2656355b6e7c-0b78-4127-8a9b-218b7e9c260b1269180ChemotherapyTAXOLADJUVANTIVNO27820102TCGA-A2-A04P-D26578779d88c-d7d4-492c-b46f-bebb3650f0e8180242ChemotherapyXELODARECURRENCEPONO27820104TCGA-A2-A04P-D26592af268e5-309a-4cc6-8239-5fad8fe2c4e1242303ChemotherapyGEMZARPROGRESSIONIVNO2782010,TCGA-A2-A04P-R2654c8ef8b75-f636-4aa7-be8c-fa7dc58b779c237EXTERNAL BEAM900cGy3Local RecurrenceRECURRENCENO2782010TCGA-A2-A04P-R265587499c44-a2db-4134-9bcf-76dfea4a507c193237EXTERNAL BEAM4393cGy23Distant RecurrencePROGRESSIONNO2782010TCGA-A2-A04P-R26538cb52952-9ade-48ce-84fc-1ec9cece1fc5193237EXTERNAL BEAM10620cGy59Primary Tumor FieldADJUVANTNO2782010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A8-A083,A8,A083,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,13.224609375,Allred score 5+3=8,Allred score 0+0=0,Left,2.340693359374994,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Mastectomy NOS,Surgical Resection,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.3125,3.30078125,MODERATE,Allred score 8,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,88.6318359375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,105,3 Point Scale,3+,6thStage IIBT3N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-BH-A0B0-F592048DFE37F5-C1F5-45C1-BCE9-70A5209079F1NOYESYESTUMOR FREEAlive2477NO252014,1TCGA-E2-A14O-D185244F298221-2D3F-4F83-8DBB-15844934BAA01mg/day1mg/day53Hormone TherapyArimidexADJUVANTPOYES20102011,TCGA-D8-A73W-R7219809B56850-CF72-433D-B179-43E43E8213F8-652-652External800cGy1Distant siteNOStable Disease2942015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1173.0,WHITE,TCGA-E2-A14O,E2,A14O,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,18.0,Allred score 5+3 = 8,Allred score 5+2 = 7,Left Upper Outer Quadrant,1.65,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.3828125,2.0,Allred score = 7,Allred score = 8,50-59%,Dako,Venten,250.3330078125,HER2 amplification - negative,Ratio >=2.0,NO,YES,118,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,59,3 Point Scale,2+,6thStage IIIAT3N1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",31,3,2011,TCGA-E2-A14O-F18521D8933DE8-A517-4142-9C1D-E9CB01F4932FScheduled Follow-up SubmissionYESYESAlive1359TUMOR FREENO19102011,1TCGA-E2-A14O-D185244F298221-2D3F-4F83-8DBB-15844934BAA01mg/day1mg/day53Hormone TherapyArimidexADJUVANTPOYES20102011,TCGA-E2-A14O-R18525C94602E4-7139-4008-BDC3-9058B35B1E2168105EXTERNAL BEAM5000cGyPrimary Tumor FieldADJUVANTNO120102011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1428.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A0B0,BH,A0B0,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,2.0,ER Positive H-Score 95,Allred score = 8,Left Upper Outer Quadrant,3.005644531249989,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,left segmental mastectomy with axillary sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Positive,Positive,Negative,0.3017578125,0.0,10,"Moderate using the scale of Weak, Moderate, Strong",90-99%,Hercep Test  TM Dako,Dako Hercept test,98.4228515625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.5,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5.8,3 Point Scale,1+,6thStage IT1cN0M0,NO,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,7,2011,TCGA-BH-A0B0-F592048DFE37F5-C1F5-45C1-BCE9-70A5209079F1NOYESYESTUMOR FREEAlive2477NO252014,YESTCGA-BH-A0B0-D592057588271F-B241-4AE6-AE91-0065CCD2FE3782194ChemotherapyAdriamycinNOComplete Response252014YESTCGA-BH-A0B0-D592069A3AEC18-4AD6-47E3-B8CA-EA762943F95082194ChemotherapyCytoxanNOComplete Response252014,TCGA-BH-A0B0-R5920760C2C230-CDAF-4194-B9B2-F90127A231E7194236External6000cGy30Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,244.0,WHITE,TCGA-D8-A73W,D8,A73W,No,YES,C50.9,8480/3,C50.9,2013.0,TUMOR FREE,YES,13.0,allred score 5 + 3 = 8,image cytometry,Right Upper Outer Quadrant,1.5867382812500057,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Other,segmental mastectomy with sentinel lymph node dissection,Mucinous Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,stereotactic biopsy,Negative,Positive,Negative,0.439453125,1.0,Allred Score 7,80,90-99%,Dako,DAKOHercepTest TM,226.7236328125,HER2 amplification - negative,Ratio >=2.0,YES,NO,40,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.8,3 Point Scale,2+,7thStage IIIAT3N1aMX,YES,YES,NONO,28,3,2014,TCGA-D8-A73W-F57875139213E3-53E1-401C-ADFB-412395451F9ANOYESYESAlive244NO2832014TCGA-D8-A73W-F721978CD03DE3-D51F-4514-B1A4-CC559A84B5C3NOYESYESWITH TUMORDead385YES21Distant MetastasisLungNOYESNO2942015,NOTCGA-D8-A73W-D72199A09294E3-9DBD-4A35-B806-8C3B050532A1-709-620Hormone TherapyTamoxifenNOClinical Progressive Disease2942015,TCGA-D8-A73W-R7219809B56850-CF72-433D-B179-43E43E8213F8-652-652External800cGy1Distant siteNOStable Disease2942015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,244.0,WHITE,TCGA-AN-A0AJ,AN,A0AJ,No,YES,C50.9,8522/3,C50.9,2010.0,TUMOR FREE,YES,9.0,dextran coated charcoal,dextran coated charcoal,Left Upper Outer Quadrant,3.055253906250006,Axillary lymph node dissection alone,SN+1 non sentinel node,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,3+,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Positive,0.0,0.0,120,230,90-99%,0,Venten,101.9912109375,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,33,"Other, specifyskin",80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,185,3 Point Scale,2+,Stage IIBT3N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,20,12,2010,TCGA-AN-A0AJ-F68941F68BDA17-ACE3-4591-B611-EC8C99FDBD17NONONOTUMOR FREEAlive303NO23122014,1TCGA-E2-A14O-D185244F298221-2D3F-4F83-8DBB-15844934BAA01mg/day1mg/day53Hormone TherapyArimidexADJUVANTPOYES20102011,TCGA-EW-A3U0-R420336E6A19AF-0B87-410E-AFCA-59AC61E7336D229281External109GyRegional siteNOComplete Response942013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,11.0,ASIAN,TCGA-C8-A26X,C8,A26X,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,13.4521484375,IHC,dextran coated charcoal,Right Upper Outer Quadrant,2.287275390624986,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,partial mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Negative,Negative,0.369140625,3.408203125,Allred score = 7,allred score = 8,90-99%,ACIS,Venten,88.8759765625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,66,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.3,4 Point Scale,2+,6thStage IIAT1N1M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,7,2011,TCGA-C8-A26X-F70792521990DD-93CE-4A11-ABED-112046F3A659NONOYESTUMOR FREEAlive376NO932015,NOTCGA-C8-A26X-D70793C99DA711-C86E-4BA8-8AD6-9274208C28D7200207Chemotherapy5-FlourouracilNOComplete Response932015NOTCGA-C8-A26X-D70794CFD4307C-F098-4A9C-A34B-E337C15B7BDC200207ChemotherapyCyclophosphamideNOComplete Response932015NOTCGA-C8-A26X-D7079569033C6A-572E-4B72-BB72-027C7F663381200207ChemotherapyDoxorubicinNOComplete Response932015,TCGA-A2-A04P-R2654c8ef8b75-f636-4aa7-be8c-fa7dc58b779c237EXTERNAL BEAM900cGy3Local RecurrenceRECURRENCENO2782010TCGA-A2-A04P-R265587499c44-a2db-4134-9bcf-76dfea4a507c193237EXTERNAL BEAM4393cGy23Distant RecurrencePROGRESSIONNO2782010TCGA-A2-A04P-R26538cb52952-9ade-48ce-84fc-1ec9cece1fc5193237EXTERNAL BEAM10620cGy59Primary Tumor FieldADJUVANTNO2782010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,23.0,WHITE,TCGA-D8-A27P,D8,A27P,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,1.0,manual counting,manual counting,Right Upper Inner Quadrant,1.8857812499999889,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Positive,Negative,0.0,0.0,>75%,>75%,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,64.5830078125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,4.43,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,145,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",18,7,2011,TCGA-D8-A27P-F295960A7EBF73-2279-485B-AF1C-E49CDB81922FScheduled Follow-up SubmissionNONOAlive49TUMOR FREENO26102012,NOTCGA-GM-A5PX-D42160D2BD571D-6658-48CB-88FE-77DAC9870F9C112236Hormone TherapyArimidexNOComplete Response1242013NOTCGA-GM-A5PX-D42161761DB280-F416-45BF-B1C0-88A1E9EFA3EF265339Hormone TherapyAromasinNOComplete Response1242013NOTCGA-GM-A5PX-D421632713B9D0-0CB9-4FD7-B75B-3ED4DEC296C4340Hormone TherapyTamoxifenYES1242013,TCGA-D8-A73W-R7219809B56850-CF72-433D-B179-43E43E8213F8-652-652External800cGy1Distant siteNOStable Disease2942015
TCGAFPPP,Breast,Yes,FEMALE,Dead,295.0,406.3251953125,WHITE,TCGA-BH-A8FY,BH,A8FY,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,2.0,H-SCORE 255,Allred 5 = 2+3,LeftLeft Upper Outer QuadrantLeft Lower Outer Quadrant,3.023740234375,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Margin resection,Other,breast conserving therapy,Infiltrating Lobular Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Biopsy not specified,Positive,Positive,Negative,1.0263671875,0.0,100,H score,90-99%,Dako,CAP SCORING GUIDELINE 2010,274.125,HER2 amplification - negative,PathVysion Her-2 DNA,YES,NO,2.38,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,80-89%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0495312500000025,71,3 Point Scale,2+,7thStage IAT1cN0 (i+)M0,NO,NO,NO,25,3,2014,TCGA-AR-A1AK-F22154DF7EF2E1-3F76-4517-A7B5-8A638431A253Scheduled Follow-up SubmissionNOYESAlive1559TUMOR FREENO132012TCGA-AR-A1AK-F692714D10493E-351E-498F-A607-D7E32C755D8ANONOYESTUMOR FREEAlive3159NO31122014,02TCGA-E2-A1LB-D206539B62DB92-ACF7-4884-9460-C1634758D79B1860mg155mg12121199ChemotherapytaxolADJUVANTIVNO171201202TCGA-E2-A1LB-D206551B740152-15BF-45B7-AA8A-AC589F8985904824mg1206mg866108ChemotherapycytoxanADJUVANTIVNO171201201TCGA-E2-A1LB-D206512E9325B6-A784-44EF-8EBD-2F8B989A6248484mg121mg466128ChemotherapyadriamycinADJUVANTIVNO171201202TCGA-E2-A1LB-D20654EE4ED476-18BE-4535-BB8A-4781CC63C7E011904mg496mg24121441ChemotherapyherceptinADJUVANTIVNO1712012,TCGA-E2-A15A-R1893878528A96-4A5C-4ADD-8526-E921E5238F87145222EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO110112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,313.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5RZ,OL,A5RZ,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,3.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,Left Upper Outer Quadrant,10.3,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Simple Mastectomy,Right Breast reexcision,Other,partial left mastectomy,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Negative,0.8955078125,1.802734375,8,Allred Score 6,30-39%,CISH,Dako Hercept test,73.84375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.0,"Other, specifyskin",30-39%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,21.0,3 Point Scale,3+,7thStage IAT1bN0MX,YES,NO,NO,16,5,2013,TCGA-OL-A5RZ-F565711921F25F-EC28-4E7A-A12E-A445D1DDBE0DNONOYESTUMOR FREEAlive679NO1422014,NOTCGA-OL-A5RZ-D6526220672357-AAF4-4236-A2ED-742216DD61B4239331ChemotherapyDoxorubicinNOComplete Response2492014NOTCGA-OL-A5RZ-D6526370A2566A-B315-479A-82BF-250CBCAF6F3B239331ChemotherapyCytoxanNOComplete Response2492014,TCGA-A2-A04P-R2654c8ef8b75-f636-4aa7-be8c-fa7dc58b779c237EXTERNAL BEAM900cGy3Local RecurrenceRECURRENCENO2782010TCGA-A2-A04P-R265587499c44-a2db-4134-9bcf-76dfea4a507c193237EXTERNAL BEAM4393cGy23Distant RecurrencePROGRESSIONNO2782010TCGA-A2-A04P-R26538cb52952-9ade-48ce-84fc-1ec9cece1fc5193237EXTERNAL BEAM10620cGy59Primary Tumor FieldADJUVANTNO2782010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,523.0,WHITE,TCGA-EW-A1OV,EW,A1OV,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,6.0,Allred 0 = 0+0,Allred score 5+3 = 8,Right Lower Outer Quadrant,1.8,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Margin resection,Modified radical mastectomy,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Close,Core needle biopsy,Modified Radical Masectomy,Negative,Negative,Negative,1.0,0.0,240 H,80,<10%,CISH,CAP SCORING GUIDELINE 2010,63.1591796875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.6,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,105,3 Point Scale,3+,6thStage IIBT2N1miMX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-EW-A1OV-F29119803F6927-592D-459C-AC6D-DBEB52CA6344Scheduled Follow-up SubmissionNOYESAlive789TUMOR FREENO832012,1TCGA-EW-A1OV-D30309A35B4531-1DC9-46D1-A861-9056798B1594538mg178mg3203252ChemotherapyEpirubicinADJUVANTIVNO7320121TCGA-EW-A1OV-D30310D43BD34B-E399-4B01-9711-CFC5C3099BB2545mg180mg3273314ChemotherapyDocetaxelADJUVANTIVNO7320121TCGA-EW-A1OV-D30308438AC993-E582-4312-9218-95B3B4AF3C802690mg890mg3203252ChemotherapyCyclophosphamideADJUVANTIVNO7320121TCGA-EW-A1OV-D291200F1217D3-7BF4-4145-9240-DE1C87BE3F502690mg890mg3203252ChemotherapyFluorouracilADJUVANTIVNO832012,TCGA-E2-A14O-R18525C94602E4-7139-4008-BDC3-9058B35B1E2168105EXTERNAL BEAM5000cGyPrimary Tumor FieldADJUVANTNO120102011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1325.0,WHITE,TCGA-AR-A1AO,AR,A1AO,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,39.0,% IHC,Image Analysis,Left Upper Inner Quadrant,1.4621777343749986,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Other,Right Breast reexcision,Mastectomy NOS,Wide local excision,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.466796875,2.0,Allred score = 0,Allred Score 8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,62.390625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,40,"Other, specifyskin",80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.5,3 Point Scale,2+,6thStage IIAT1N1M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",13,6,2011,TCGA-AR-A1AO-F217561C4B1995-A5EE-466D-99ED-A906B6376D1CScheduled Follow-up SubmissionYESYESAlive1325TUMOR FREENO2722012TCGA-AR-A1AO-F69274C5985991-91B3-4B10-BFF1-93DACCAD48F5NOYESYESTUMOR FREEAlive2618NO31122014,2TCGA-AR-A1AO-D21783FC942EEA-FF1B-4138-9AF0-ACAEB4587C8820mg/day160Hormone TherapyTamoxifenADJUVANTPOYES27220121TCGA-AR-A1AO-D217763FAD143B-6FA0-4A68-BD62-F68CF5C5E212425mg60mg/m2476118ChemotherapyDoxorubicinADJUVANTIVNO27220121TCGA-AR-A1AO-D217816AEEDC5D-E064-4E5B-A0BD-E4026DE10F964250mg600mg/m2476118ChemotherapyCytoxanADJUVANTIVNO27220121TCGA-AR-A1AO-D21782486A390E-63A5-40C5-871A-82F3EB768849310mg175mg/m21139139ChemotherapyPaclitaxelADJUVANTIVNO2722012,TCGA-AR-A1AO-R21773E8DA70B1-BB41-4DD0-B17B-EFDEC13F33EE168210EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12722012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,54.0,WHITE,TCGA-AN-A04C,AN,A04C,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,15.0,Allred (Biocare),Allred (Biocare),Left Upper Outer Quadrant,3.0132128906249966,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,0,3+,Negative,Positive,Tumor resection,Patey's Suregery,Positive,Negative,Positive,0.0,2.0,0,0,20-29%,0,Dako Hecept Test,115.1572265625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.93,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.73,3 Point Scale,0,Stage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,29,12,2010,TCGA-AN-A04C-F689746E0AB9FC-6CD3-4762-AD22-CCA478E6C580YESTUMOR FREEAlive5424122014,TCGA-D8-A27E-D301133D420476-7EB9-4632-B3F8-3BB85B979A0Dmg20+1mg/day125Hormone Therapytamoxiphen+anastrazolumADJUVANTPOYES242012,TCGA-EW-A3U0-R420336E6A19AF-0B87-410E-AFCA-59AC61E7336D229281External109GyRegional siteNOComplete Response942013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2511.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A25E,A2,A25E,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,10.0,H-SCORE 136,Allred score = 8,Left Upper Outer Quadrant,2.1,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Mastectomy NOS,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,Patey's Suregery,Equivocal,Positive,Equivocal,0.01953125,6.0,"Strong, using scale of Weak, Moderate and Strong","Moderate using scale of Weak, Moderate, Strong",90-99%,Hercep Test  TM Dako,Dako Hecept Test,93.8837890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.40,"Other, specifyskin",80-89%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,6.4,3 Point Scale,2+,6thStage IIIAT2N2aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,7,2011,"TCGA-A2-A25E-F310569F95AA80-AEE0-46FA-8B16-BB4787BD8D32Scheduled Follow-up SubmissionYESYESAlive2796TUMOR FREENO2342012TCGA-A2-A25E-F449826AAA3968-F33A-48E5-AFBE-404BF56B0F02NOYESYESTUMOR FREEAlive3204YES2989Locoregional RecurrenceOther, specifyLeft Chest WallYES3024NOYESPositive90-99%3 Point Scale3+Positive<10%3 Point Scale2+Negative1+272013","4TCGA-A2-A25E-D14568189903E4-A8AF-4AE4-A953-0928F10646D23600mg900mg467136ChemotherapyCytoxanADJUVANTIVNO21720115TCGA-A2-A25E-D14569335FCDB6-340C-4A4F-B08B-F509B2B0DEF5360mg90mg467136ChemotherapyAdriamycinADJUVANTIVNO21720111TCGA-A2-A25E-D14564019B2AA1-9E61-4BE6-BDE1-B885EEE5589B5142mg98-196mg47250601ImmunotherapyHerceptinADJUVANTIVNO21720113TCGA-A2-A25E-D145670D2DEFB3-3E8B-4761-8BD1-897AB03EFA981440mg120mg12158242ChemotherapyTaxolADJUVANTIVNO21720116TCGA-A2-A25E-D14570029F44F2-9A34-45CF-8E9F-2AFEB11BE5CD3.6mg2380Hormone TherapyGoserelinOTHER, SPECIFY IN NOTESPreventativeSCYES21720112TCGA-A2-A25E-D1456563600442-2336-493D-BC5F-CECB9800FD5310mg/m2/day3342155Hormone TherapyTamoxifenADJUVANTPONO2272011NOTCGA-A2-A25E-D4498199D343A1-BE9A-407D-80DC-45B049932EE13055Hormone TherapyAnastrozoleYES272013",TCGA-A2-A25E-R145725A937750-CD3F-454B-99C4-779547CF9062292333EXTERNAL BEAM10640cGy84Primary Tumor FieldADJUVANTNO12172011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,132.0,WHITE,TCGA-A2-A1G6,A2,A1G6,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,9.0,H-Score-190,H-Score 160,Right,1.5562011718750002,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.3017578125,4.0,90 H,200,10-19%,Dako,Venten,120.15234375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,78,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.3,3 Point Scale,3+,7thStage IIIAT2N2aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",22,4,2011,TCGA-A2-A1G6-F209473427FD70-83B5-4A78-A617-838013915E15Scheduled Follow-up SubmissionYESYESAlive501TUMOR FREENO912012,3TCGA-A2-A1G6-D1253703170c14-0cc8-47b8-8211-e7feae86ed653132172ChemotherapyDocetaxelADJUVANTIVNO28420111TCGA-A2-A1G6-D12532b86d0b45-cd36-46d7-9964-b170549420ac469119ChemotherapyAdriamycinADJUVANTIVNO28420112TCGA-A2-A1G6-D1253557fef464-1259-484f-8b66-7473fa062401469119ChemotherapyCytoxanADJUVANTIVNO2842011,TCGA-A2-A1G6-R20946AF32408D-BB2D-4910-8E8A-B62DC6DDE68E249283EXTERNAL BEAM4500cGy25Regional siteADJUVANTNO12512012TCGA-A2-A1G6-R317798A5DBB7F-2FCD-45AF-807E-57F4DE9EA749249283EXTERNAL BEAM4500cGy25Regional siteADJUVANTNO2952012TCGA-A2-A1G6-R317800C5AA321-F0DC-4B91-9633-0CABB1EDE7C7284293EXTERNAL BEAM1600cGy8Regional siteADJUVANTNO3952012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1559.0,WHITE,TCGA-AR-A1AK,AR,A1AK,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,5.0,Allred score 5+3 = 8,Image Analysis,Right,1.5891113281249976,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Mastectomy NOS,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Lobular Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.029296875,0.0,H-SCORE,H-SCORE,10-19%,Hercep Test  TM Dako,Dako Hercept test,90.4453125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,33,"Other, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,172,3 Point Scale,3+,6thStage IT1N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",15,6,2011,TCGA-AR-A1AK-F22154DF7EF2E1-3F76-4517-A7B5-8A638431A253Scheduled Follow-up SubmissionNOYESAlive1559TUMOR FREENO132012TCGA-AR-A1AK-F692714D10493E-351E-498F-A607-D7E32C755D8ANONOYESTUMOR FREEAlive3159NO31122014,1TCGA-AR-A1AK-D2215537D99581-850D-476B-8328-D3E0BD6DC0491mg/day331843Hormone TherapyAnastrozoleADJUVANTPONO132012,TCGA-A2-A25E-R145725A937750-CD3F-454B-99C4-779547CF9062292333EXTERNAL BEAM10640cGy84Primary Tumor FieldADJUVANTNO12172011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,0.0,WHITE,TCGA-AC-A3W6,AC,A3W6,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,3.0,H-SCORE 300,Allred score 5+3 = 8,Right,1.8864160156250032,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,surgical resection,Infiltrating Lobular Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,1+,3+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,3.0,3.0,Allred Score 6,Moderate,10-19%,ACIS,Hercep Test  TM Dako,85.486328125,HER2 amplification - negative,Positive >2.2,YES,NO,2.8,BoneLiver,90-99%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.3,3 Point Scale,1+,7thStage IIIAT3N1MX,YES,YES,NO,24,9,2012,TCGA-AC-A3W6-F57046533C3FB1-7B9B-41B8-8BC4-63C503E2A3EFNONONOTUMOR FREEAlive0NO2822014,ACTCGA-D8-A1JG-D140618AC1E40A-2939-4FD6-93E8-DE97A4C64960mg/m260mg/m2269ChemotherapydoxorubicinADJUVANTIVYES1872011NOTCGA-D8-A1JG-D6532579FA201D-29D2-4F82-BD32-02AAC1E0DE5E269ChemotherapycyclophosphamideYES2292014,TCGA-E2-A14O-R18525C94602E4-7139-4008-BDC3-9058B35B1E2168105EXTERNAL BEAM5000cGyPrimary Tumor FieldADJUVANTNO120102011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,76.0,WHITE,TCGA-BH-A0HO,BH,A0HO,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,18.0,H-Score 200,H-Score 290,Right Upper Outer QuadrantRight,1.7851562500000044,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Margin resection,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal partially papillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,1.0,1.0,H-Score,H-Score,10-19%,ACIS,CAP scoring guideline 2010,40.1328125,HER2 amplification - negative,Ratio >=2.0,NO,YES,51,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,4.70,3 Point Scale,3+,Stage IIAT1cN1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,11,11,2010,TCGA-BH-A0HO-F477158E9756A-3F14-478E-8CF9-BFFB2908910276AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0HO-D4766DA5665DF-7CBC-43C3-8336-3A83A34713D93440mg860mg4119182ChemotherapyCyclophosphamideADJUVANTIVNO221120101TCGA-BH-A0HO-D4767DADE4DB6-CB27-4D06-88B6-8C4F1526C9921380mg115mg12210287ChemotherapyPaclitaxelADJUVANTIVNO221120101TCGA-BH-A0HO-D4765A3D353FB-8B2F-42C9-BD6E-D38D90A0568E344mg86mg4119182ChemotherapyDoxorubicinADJUVANTIVNO221120101TCGA-BH-A0HO-D476355BAEF2A-C3A1-470D-92D7-80BF180C405420mg/day378Hormone TherapyTamoxifenADJUVANTPOYES30112010,TCGA-BH-A0HO-R476995039DE4-9BE0-4A86-A302-3D44887F8231312369EXTERNAL BEAM6060cGy33Primary Tumor FieldADJUVANTNO130112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,207.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-A6ZG,S3,A6ZG,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,3.0,CAP scoring guideline 2010,CAP scoring guideline 2010,LeftLeft Upper Outer Quadrant,2.489833984374987,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Mixed Histology (please specify),Invasive mixed ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,1.0,Moderate,Moderate,<10%,0,CAP scoring guidelines 2010,27.515625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,66,"Other, specifyskin",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,172,3 Point Scale,2+,7thStage IIBT2N1M0,YES,NO,NO,12,11,2013,TCGA-S3-A6ZG-F6364517174B64-048E-4778-9D5E-70492306C048NOYESYESTUMOR FREEAlive399NO2782014TCGA-S3-A6ZG-F70438CF08A13B-D885-4AB3-A818-92AC66A01A70NOYESYESTUMOR FREEAlive562NO2622015,NOTCGA-S3-A6ZG-D510884FFDEFCC-4989-4FE3-9F8C-2F66D9CD5EF852100ChemotherapyDoxorubicinNOComplete Response12112013NOTCGA-S3-A6ZG-D510899C1469D0-34BE-4520-A928-C8222B9AA84A52100ChemotherapyCytoxanNOComplete Response12112013NOTCGA-S3-A6ZG-D51090592DBC73-6BBC-49B6-8C4D-DE2812D431D8116221Hormone TherapyTaxolNOComplete Response12112013YESTCGA-S3-A6ZG-D636499E65EFA0-05D8-47EB-A1E0-6E44A31DBA3D256Hormone TherapyAnastrozoleYES2782014NOTCGA-S3-A6ZG-D64188CE65FD9A-E5F7-42B1-8603-9979F90ABD5F52100AncillaryNEULASTANOComplete Response2782014,TCGA-S3-A6ZG-R636482C875BB6-139D-4B69-95DF-8D8F732E4308269326External6040cGy33Primary Tumor FieldNOComplete Response2782014
TCGAFPPP,Breast,No,FEMALE,Dead,1927.0,810.5498046875,WHITE,TCGA-BH-A1FJ,BH,A1FJ,No,YES,C50.9,8500/3,C50.9,1998.0,WITH TUMOR,YES,35.0,H-SCORE 260,H-Score 15,Right Upper Outer Quadrant,2.295683593749996,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Right Breast reexcision,Other,Bilateral Mastectomy,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.982421875,6.0,MODERATE,Two-tier,10-19%,ACIS,Hercep Test  TM Dako,69.0751953125,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,1.45,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,1.62,3 Point Scale,2+,5thStage IIIAT3N1bM0,NO,NO,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,8,9,2011,TCGA-E2-A15A-F1892689F6BF10-DB74-4BB3-B5DC-B8C065538CDBScheduled Follow-up SubmissionYESYESAlive710TUMOR FREENO10112011,NOTCGA-EW-A2FR-D32313DCEB895A-E1A5-4FD9-BE38-21E232DE56843476ChemotherapyEpirubicinNO2352012NOTCGA-EW-A2FR-D32314252D689B-BC80-47B8-B3C2-74104D0126743476ChemotherapyFluorouracilNO2352012NOTCGA-EW-A2FR-D323158A8AD4DD-2321-44FD-8088-8EC827E71D203476ChemotherapyCyclophosphamideNO2352012NOTCGA-EW-A2FR-D3231648579EAC-39AF-415C-B6DF-893430FC303F97174ChemotherapyPaclitaxelNOStable Disease2352012,TCGA-S3-A6ZG-R636482C875BB6-139D-4B69-95DF-8D8F732E4308269326External6040cGy33Primary Tumor FieldNOComplete Response2782014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,755.0,WHITE,TCGA-E2-A1IG,E2,A1IG,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,3.0,allred score 5+3=8,H-Score 0,Right Upper Inner Quadrant,1.341689453124996,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Margin resection,Other,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.2783203125,1.0,MODERATE,Allred Score 7,10-19%,Dako,CAP scoring guideline 2010,111.123046875,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.1,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,172,3 Point Scale,2+,6thStage IIBT2N1miM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,4,2011,TCGA-E2-A1IG-F1993247ADEC2D-3377-4579-9805-CD96D949C94DScheduled Follow-up SubmissionYESYESAlive997TUMOR FREENO21122011TCGA-E2-A1IG-F70394F362DE95-E046-4400-8D1C-27C92BCA588ANOYESYESTUMOR FREEAlive2140NO1632015,2TCGA-E2-A1IG-D1993535DF36F9-799F-4E34-98BB-453D807A55AF1160mg290mg4108150ChemotherapyPaclitaxelADJUVANTIVNO211220113TCGA-E2-A1IG-D1993683E712C3-ABC5-4875-A5A1-4AEBEA1D27BA20mg/day20mg/day234Hormone TherapyTamoxifenADJUVANTPOYES211220111TCGA-E2-A1IG-D19933521E6E77-C1C4-4361-8566-1E7AE45D7CC43960mg990mg45294ChemotherapyCyclophosphamideADJUVANTIVNO211220111TCGA-E2-A1IG-D199343DAFFE53-CA87-4B06-A70E-1F55782E3964396mg99mg45294ChemotherapyDoxorubicinADJUVANTIVNO21122011NOTCGA-E2-A1IG-D7039386F3FAA8-97CD-4A7E-B217-21DCAB6419BA1991Hormone TherapyLetrozoleYES1632015,TCGA-E2-A1IG-R199374215BF0B-2E69-49EA-8801-5539FE4BC44D178222EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO121122011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,1732.0,WHITE,TCGA-BH-A0B6,BH,A0B6,Yes,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,4.0,allred score 0 + 0 = 0,allred score 5 + 3 = 8,Left Upper Outer Quadrant,2.404404296874992,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,0.2197265625,0.0,Strong,205,10-19%,Hercep Test  TM Dako,Dako Hecept Test,144.6533203125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,2.13,"Other, specifyaxilaary node negative but intrammary node positive",<10%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,42,3 Point Scale,1+,6thStage IT1cN0M0,NO,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",4,8,2011,TCGA-BH-A0B6-F61943DBFF7E03-09CD-4687-B14C-277D6E8073C5NOYESNOTUMOR FREEAlive2483NO1072014,NOTCGA-BH-A0BZ-D58689B11042C3-48A4-4427-AD8F-54AE2DE97D0076167ChemotherapyDoxorubicinNOComplete Response2242014NOTCGA-BH-A0BZ-D58690025FAF2B-F67F-42A2-86B3-DFC2BBB2148776167ChemotherapyCyclophosphamideNOComplete Response2242014NOTCGA-BH-A0BZ-D5869127F92F87-436A-44BE-A7AE-0AE19498D67C167197ChemotherapyAbraxaneNOComplete Response2242014,TCGA-BH-A0B6-R619488CC21685-71B7-44DA-8672-63853A6F870694143External6640cGy36Primary Tumor FieldNOComplete Response1072014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,183.0,WHITE,TCGA-AN-A0FT,AN,A0FT,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,dextran coated charcoal,dextran coated charcoal,Right Lower Outer Quadrant,2.261074218749988,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,3+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Positive,0.0,1.0,60,230,90-99%,0,dextran coated charcoal,64.4384765625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,NO,YES,1.40,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,<4.0,3 Point Scale,3+,Stage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,28,12,2010,TCGA-AN-A0FT-F68964A4DE618B-9DF9-4C32-89BA-4C48D4E00DEEYESNONOTUMOR FREEAlive21424122014,YESTCGA-S3-A6ZF-D510614503FC44-1AA6-4A16-BE16-63146AF1ECEB65170ChemotherapytaxotereNOComplete Response12112013YESTCGA-S3-A6ZF-D510622B4A620C-E5B7-45D0-823B-A7D09CD7F72D65429ImmunotherapyTrastuzumabNOComplete Response12112013YESTCGA-S3-A6ZF-D51087DA38E0A7-A07F-4D6E-85AD-465748551C9778170AncillaryNeulastaNOComplete Response12112013YESTCGA-S3-A6ZF-D51086E2F5E7F8-10E2-4432-A00A-7087B5955C9E65170ChemotherapyCytoxanNOComplete Response12112013YESTCGA-S3-A6ZF-D63998CEDA468F-784C-42EC-B0C6-8B42B8C5BEE1191278Hormone TherapyLETROZOLENO2782014YESTCGA-S3-A6ZF-D640051F99661D-577D-4D3C-BFF3-6436D7DA50A3278Hormone TherapyANASTROZOLEYES2782014,TCGA-EW-A3U0-R420336E6A19AF-0B87-410E-AFCA-59AC61E7336D229281External109GyRegional siteNOComplete Response942013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,760.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A6SB,EW,A6SB,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,8.0,Allread score 5+3 = 8,Allred score 2+3 = 5,LeftLeft Upper Inner Quadrant,2.0109472656249974,Sentinel node biopsy alone,Sentinel lymph node and axillary lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.0,0.0,H score,160,30-39%,CISH,Venten,278.4951171875,HER2 amplification - negative,PathVysion,YES,NO,2.8,"Other, specifyskin",10-19%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.62,3 Point Scale,2+,7thStage IIT2N0M0,YES,YES,NO,12,3,2015,TCGA-WT-AB41-F66639BF795D81-B99B-4A0E-9A01-42FDB7F837BDNONOYESTUMOR FREEAlive1611NO21102014,YESTCGA-AR-A2LO-D37194FAE98AD4-647B-4B8A-877A-9A3E35C855154484ChemotherapyAdriamycinNO7122012YESTCGA-AR-A2LO-D37258B5922B72-CFFD-4EE0-9F3E-35C6AE2A69D94484ChemotherapyCytoxanNO7122012YESTCGA-AR-A2LO-D372590751053B-FD4A-4022-A9A0-46243CD85D3298175ChemotherapyPaclitaxelNO7122012YESTCGA-AR-A2LO-D3760797212CFD-8883-4CC9-BED8-3F45E9AB5E7644161ImmunotherapyBevacizumabNO7122012YESTCGA-AR-A2LO-D3760803E05488-13C5-4F00-BB7D-AA459862D124199903Hormone TherapyTamoxifenNO7122012YESTCGA-AR-A2LO-D376096F0A0541-DE11-49E8-914A-2AE90BA4BB39903Hormone TherapyAnastrozoleYES7122012,TCGA-OL-A5RU-R6525122B829AF-B769-4C42-B835-9B5461DCF6FC160197External5040cGyRegional siteNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3836.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0IM,B6,A0IM,No,YES,C50.9,8523/3,C50.9,1997.0,TUMOR FREE,YES,9.0,Image Analysis,Image Analysis,Right Upper Outer QuadrantRight,1.3163476562500032,Axillary lymph node dissection alone,Pateys surgery,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,Excision,"Other, specify",Ductal/cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Negative,Positive,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Equivocal,0.734375,0.0,allred score =  8,H score,10-19%,ACIS,dextran coated charcoal,60.1318359375,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,40,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,185,4 Point Scale,1+,4thStage IIBT3N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,2,11,2010,TCGA-B6-A0IM-F126232BD40A19-71A1-4898-94DA-8EFD7FC2F2A2Scheduled Follow-up SubmissionNOYESDead3873TUMOR FREENO262011,1TCGA-AO-A128-D5943e2154fbe-e02b-44f3-a61a-e08146c61db2480mg62mg/m2482124ChemotherapyDoxorubicinADJUVANTIVNO10120111TCGA-AO-A128-D594539C00F42-C756-42EC-98DC-BB6F6434718B1360mg175mg/m24160222ChemotherapyPaclitaxelADJUVANTIVNO10120111TCGA-AO-A128-D5942554dcbf2-b7a5-4237-9b68-7484e41a52ab4800mg619mg/m2482124ChemotherapyCyclophosphamideADJUVANTIVNO1012011,TCGA-C8-A26V-R708018A854D11-9805-4A1B-BC0A-6018147BD138212247External50Gy25Regional siteNOComplete Response932015
TCGAFPPP,Breast,No,FEMALE,Dead,2483.0,913.7158203125,BLACK OR AFRICAN AMERICAN,TCGA-AO-A03O,AO,A03O,No,YES,C50.9,8500/3,C50.9,2002.0,TUMOR FREE,YES,17.0,>10% STAINING = POSITIVE,Allred score 2+2 = 4,Right Upper Outer QuadrantRight,1.1,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,Wide Local Excision,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,>10% STAINING = POSITIVE,205,<10%,CISH,3+ POSITIVE,29.0,HER2 amplification - negative,> = 2.0,NO,YES,68,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,73,3 Point Scale,1+,Stage IIAT2N0 (i-)M0,YES,NO,PositivePositiveNegativeNegative,19,9,2010,TCGA-AO-A03O-F3141740A6308-84E3-4231-995D-82D7D5A34C86DeadTUMOR FREE2483NOYES1992010,2TCGA-AO-A03O-D314961963f8b-da23-40f1-9f6b-787d38f7651a1mg/day182993Hormone TherapyANASTROZOLE (ARIMIDEX)ADJUVANTPONO19920101TCGA-AO-A03O-D3144fe3f418d-b735-4bd3-8ed0-0b7ad64da47d436mg300mg/m245498ChemotherapyDOXORUBICINADJUVANTIVNO19920101TCGA-AO-A03O-D3145dc3d1205-5393-48bd-bdeb-9f9a8ac66e734380mg300mg/m245498ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO19920101TCGA-AO-A03O-D314746526dc6-105c-4615-981d-3ce9f318d5ab1276mg300mg/m24112158ChemotherapyPACLITAXELADJUVANTIVNO1992010,TCGA-E2-A1B0-R1946107FCCE4F-84AC-4AC3-A6BE-A677BDAD8EF3257300EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO17122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,743.0,WHITE,TCGA-BH-A0EI,BH,A0EI,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,Allred score 5+2 = 7,H-SCORE 210,Right,2.014326171875012,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,segmental mastectomy with right sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.392578125,2.0,Allred Score 5,STRONG,10-19%,Hercep Test  TM Dako,Hercep Test TM DAKO,61.958984375,HER2 amplification - negative,Ratio >=2.0,NO,YES,33,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,6.4,3 Point Scale,2+,6thStage IIAT1cN1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,11,8,2011,TCGA-BH-A0EI-F59115E894DC0C-AE6E-4101-A406-2A464420B984NOYESNOTUMOR FREEAlive1926NO152014,1TCGA-AR-A0U4-D19342E0C6F2ED-E72F-409A-BB26-85708A763D795380mg600mg/m245398ChemotherapyCytoxanADJUVANTIVNO121220111TCGA-AR-A0U4-D19341324CC111-37BE-4840-A581-F1CED82AA6C5540mg60mg/m245398ChemotherapyDoxorubicinADJUVANTIVNO121220111TCGA-AR-A0U4-D1934334F346D8-CBF0-4AA7-8B08-1A238EAED7151560mg175mg/m24112154ChemotherapyPaclitaxelADJUVANTIVNO12122011,TCGA-BH-A0EI-R59119669FAA2A-602A-4BED-A5DD-084DAE9E91F7274321External5040cGy33Primary Tumor FieldNOComplete Response152014TCGA-BH-A0EI-R59121AAB0EEA5-BADE-4CBB-BBD8-3F0FBC725701350350External900cGyPrimary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Dead,612.0,716.3759765625,WHITE,TCGA-BH-A18J,BH,A18J,No,YES,C50.9,8500/3,C50.9,2000.0,WITH TUMOR,YES,12.8193359375,H-SCORE 255,H-Score 190,Right,2.4206347656249867,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision,Other,Bilateral Mastectomy,Infiltrating Ductal Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Positive,Negative,Tumor resection,Ultrasound-guided biopsy,Positive,Positive,Negative,1.3330078125,2.8310546875,Allred Score 3,Moderate,10-19%,ACIS,Hercep Test TM DAKO,149.564453125,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,74,Bone,40-49%,30-39%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,185,3 Point Scale,2+,5thStage IVT4bN2M1,NO,NO,PositivePositiveNegativeNegative,8,6,2011,"TCGA-B6-A0X5-F1572651D5C754-2AD5-4C88-9D30-FB526027E827Scheduled Follow-up SubmissionNOYESDead2097WITH TUMORYES1343Distant MetastasisOther, specifyLiver and Pleura and BoneNONONO2982011",NOTCGA-S3-A6ZG-D510884FFDEFCC-4989-4FE3-9F8C-2F66D9CD5EF852100ChemotherapyDoxorubicinNOComplete Response12112013NOTCGA-S3-A6ZG-D510899C1469D0-34BE-4520-A928-C8222B9AA84A52100ChemotherapyCytoxanNOComplete Response12112013NOTCGA-S3-A6ZG-D51090592DBC73-6BBC-49B6-8C4D-DE2812D431D8116221Hormone TherapyTaxolNOComplete Response12112013YESTCGA-S3-A6ZG-D636499E65EFA0-05D8-47EB-A1E0-6E44A31DBA3D256Hormone TherapyAnastrozoleYES2782014NOTCGA-S3-A6ZG-D64188CE65FD9A-E5F7-42B1-8603-9979F90ABD5F52100AncillaryNEULASTANOComplete Response2782014,TCGA-A2-A3XV-R34634F2E7F201-0A1D-4AD5-B148-EA69A1294BA6211246External50Gy25Primary Tumor FieldNOComplete Response2482012TCGA-A2-A3XV-R34635EFC36FA5-0568-4B56-8EFF-E56B96239F74247258External10Gy5Primary Tumor FieldNOComplete Response2482012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2.0,ASIAN,TCGA-C8-A1HN,C8,A1HN,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,8.2060546875,Allred score 7 (outside facility),Allred score 5+3=8,Left,1.533994140625001,Axillary lymph node dissection alone,Pateys surgery,Modified Radical Mastectomy,Re-excision of the inferior margin,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Positive,Negative,Core needle biopsy,Patey's Surgery,Negative,Positive,Equivocal,0.005859375,0.0009765625,Allred Score 3,Allred Score 8,90-99%,ACIS,Dako Hecept Test,247.7724609375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,3.0,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,4.70,4 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",2,6,2011,TCGA-C8-A1HN-F190891DC4D8DA-D0F5-4B8E-A72E-38531C64E95AScheduled Follow-up SubmissionNOYESAlive99TUMOR FREENO2122011TCGA-C8-A1HN-F7188560E148CB-FB45-4819-918F-BD620D94710ENONOYESTUMOR FREEAlive394NO3132015,NOTCGA-EW-A1OY-D3226403D8BE5B-C488-4B80-B892-D6A4C2EE03B5478Hormone TherapyFemaraYES2252012NOTCGA-EW-A1OY-D32265E5516788-6C73-4B51-B902-5B5FE65F9658109161ChemotherapyDoxorubicinNO3052012NOTCGA-EW-A1OY-D32267EBCAFCA5-6D9C-465B-B053-FE7F6CA8EADA109161ChemotherapyCyclophosphamideNO3052012NOTCGA-EW-A1OY-D32268B36F48F2-F93A-4964-B8B9-7CF74F5CB0B1180308ChemotherapyPaclitaxelNOStable Disease3052012,TCGA-BH-A0B1-R154346CBDF1E7-E2BB-4EEC-9C61-547430A54E0A287343EXTERNAL BEAM6040cGy28Primary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5909.0,WHITE,TCGA-GM-A2DA,GM,A2DA,No,YES,C50.9,8500/3,C50.9,1993.0,WITH TUMOR,YES,13.0,Allred score 5+3=8,Allred score 5+3 = 8,Right Upper Inner QuadrantRight Upper Outer Quadrant,4.05,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Positive,Equivocal,0.0,2.0,Allred score = 5,Intensity=Strong,90-99%,0,Dako Hercept test,60.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,3.70,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,15,3 Point Scale,2+,4thStage IIBT2N1bM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,28,9,2011,"TCGA-GM-A2DA-F470401FE24E96-5D31-480A-9AA9-C2702EE3ABAFNOYESYESWITH TUMORDead6593YES3014Distant MetastasisBoneNOYESYES4343Distant MetastasisLiverYES6359NOYES6535Distant MetastasisOther, specifyIntrathoracic Lymph NodeNONONO6536Distant MetastasisBrainNOYESNO2182013",YESTCGA-GM-A2DA-D472111CE4C77C-03D8-4A3E-9B4E-17A37FEBF57474147ChemotherapyfluorouracilNOComplete Response2382013YESTCGA-GM-A2DA-D472139DBAC4E4-29D1-4620-BB0E-E85862C78A1674147ChemotherapyAdriamycinNOComplete Response2382013YESTCGA-GM-A2DA-D47214FBF6B10E-F9FA-412E-8317-7BC12FDECECD74147ChemotherapyCytoxanNOComplete Response2382013YESTCGA-GM-A2DA-D47215A308134D-A87B-4D38-A1B5-AD5A5BACFF22203276ChemotherapyMethotrexateNOComplete Response2382013YESTCGA-GM-A2DA-D47217F1691109-2DFB-4D93-B667-029E43AFA481203276ChemotherapyVinblastineNOComplete Response2382013YESTCGA-GM-A2DA-D47219FDBDD508-2625-4646-B410-82178F238FB530613131Hormone TherapyTamoxifenNOClinical Progressive Disease2382013YESTCGA-GM-A2DA-D47220A9D3732A-4B83-435F-AFE7-98604C52FEAF30613131Hormone TherapyAromasinNOClinical Progressive Disease2382013NOTCGA-GM-A2DA-D47221E6B44B72-350F-4D39-ACA6-4751D537EC2931413415ChemotherapyTaxotereNOStable Disease2382013NOTCGA-GM-A2DA-D4722234A11D07-D395-44A8-B0FA-B6785948D3FE34344307Hormone TherapyLetrozoleNOClinical Progressive Disease2382013NOTCGA-GM-A2DA-D47223B90F3A89-5CDC-406E-B9B8-C850C6C5DD7643474435Hormone TherapyMegaceNOClinical Progressive Disease2382013YESTCGA-GM-A2DA-D4722466BF0675-E5AC-453D-B319-3E0DCE3C4C2A44704494ChemotherapyXelodaNOClinical Progressive Disease2382013YESTCGA-GM-A2DA-D47225D8B2FED7-8269-47D8-90DC-E1A16E08E05F44704494ChemotherapyYondelisNOClinical Progressive Disease2382013NOTCGA-GM-A2DA-D47228A7B8633B-19CD-4008-887D-77BE720AF86745154720ChemotherapyXelodaNOStable Disease2382013NOTCGA-GM-A2DA-D47229E41E7973-FE0F-4D97-A8DB-69BFE8B0D08C47215015Hormone TherapyAromasinNOStable Disease2382013NOTCGA-GM-A2DA-D47230F503B87E-A4F9-4FA8-9508-93B7658C1FDA50215455ChemotherapyXelodaNOStable Disease2382013NOTCGA-GM-A2DA-D47231B9F6747C-A8E8-4DFF-B2FF-6378094F03E154555678ChemotherapyAbraxaneNOStable Disease2382013NOTCGA-GM-A2DA-D472323411631A-3C34-4A06-A5E7-DB6F0E49CA2556845797ChemotherapyIxabepiloneNOClinical Progressive Disease2382013NOTCGA-GM-A2DA-D47234BAE1A1F1-6EDC-4E7E-BA5E-632C9F3E6AA957976028ImmunotherapyHerceptinNOStable Disease2382013NOTCGA-GM-A2DA-D4723628B70E98-675A-4649-A171-1CCC398CFB9F59096029Hormone TherapyTamoxifenNOClinical Progressive Disease2382013NOTCGA-GM-A2DA-D47237D2F15985-953A-4B07-B205-27967C46571D60516213ChemotherapyXelodaNOStable Disease2382013NOTCGA-GM-A2DA-D4723889719FBA-E180-4F48-AE3B-75CBFB12714660516536ChemotherapyLapatinibNOStable Disease2382013NOTCGA-GM-A2DA-D472404CDD3F8E-EFF0-49C7-972E-40AE2CAB2B7A63726422ChemotherapyNavelbineNOClinical Progressive Disease2382013NOTCGA-GM-A2DA-D47241EEBDC3B3-BCF1-4629-9C08-8129305599B763726536ImmunotherapyHerceptinNOStable Disease2382013,TCGA-GM-A2DA-R47042E29E83F2-FD9A-4339-A928-6DACBFBF05BD284326ExternalPrimary Tumor FieldNOComplete Response2182013TCGA-GM-A2DA-R472031F70E01D-1936-4BA1-A6E6-C6BFB3BECB5050985111External30Gy10Distant RecurrenceNOStable Disease2382013TCGA-GM-A2DA-R47204B67CB273-F63A-44AD-B63E-1CCFBAD5DD1060486052External20Gy5Distant RecurrenceNOStable Disease2382013TCGA-GM-A2DA-R472050E0EB0C4-1A13-47AF-BBA6-45B73E378A4E65386552External30Gy10Distant RecurrenceNOStable Disease2382013
TCGAFPPP,Breast,No,FEMALE,Dead,1127.0,427.1669921875,WHITE,TCGA-A8-A08J,A8,A08J,No,YES,C50.9,8541/3,C50.9,2005.0,WITH TUMOR,YES,16.998046875,Allred 0 = 0+0,H-Score 160,Right,1.726328124999993,Sentinel node biopsy alone,SN+1 non sentinel node,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, classical type, focal pleomorphic type",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Positive,Positive,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Negative,0.791015625,6.6220703125,Strong,0%,90-99%,ACIS,Dako Hercept test,191.69140625,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,NO,YES,4.43,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,3.3,3 Point Scale,2+,6thStage IVT4bN3M1,YES,NO,PositivePositiveNegativeNegative,27,5,2011,TCGA-A8-A08J-F40846511A5351-B4EC-4B3F-8F4E-00AFD1613ED1NONOWITH TUMORDead1127232013,NOTCGA-A8-A0A2-D379013C849DD1-A3D9-4F0A-A1B2-332514713CC692Hormone TherapyTamoxifenYES6122012,TCGA-E2-A15P-R19147747DC091-0514-4945-B09E-1CAD551849C85198EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO116112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,140.0,WHITE,TCGA-EW-A1PH,EW,A1PH,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,H-Score 300,IHC,Right Upper Outer Quadrant,1.6193847656249911,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.0,1.0,Allred Score,STRONG,<10%,CISH,Dako Hecept Test,138.2041015625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.1,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.80,3 Point Scale,3+,7thStage IIAT1cN1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-EW-A1PH-F291107268DC2D-2021-4105-BF63-E0D421464BDBScheduled Follow-up SubmissionYESYESAlive425TUMOR FREENO832012TCGA-EW-A1PH-F411451D45F7E0-49FF-4FE9-AB11-639270B50BAFNOYESYESTUMOR FREEAlive607NO1232013,1TCGA-EW-A1PH-D303042DDB37C1-2B90-4032-8C74-3AB053366DB02505mg835mg398140ChemotherapyCyclophosphamideADJUVANTIVNO8320121TCGA-EW-A1PH-D303068C772D08-80AB-49A9-9CAC-40EEADDB8D31169mg169mg1161161ChemotherapyDocetaxelADJUVANTIVNO8320121TCGA-EW-A1PH-D29111E98E3894-4A1F-4559-AA6C-977995AAADD42505mg835mg398140ChemotherapyFluorouracilADJUVANTIVNO8320121TCGA-EW-A1PH-D303053C59E6BD-8791-41EF-A738-A127DA2E0088501mg167mg398140ChemotherapyEpirubicinADJUVANTIVNO8320122TCGA-EW-A1PH-D29113CE3771B3-13A0-460B-B9C7-C17BAA64C06A992mg124mg8215271ChemotherapyTaxolADJUVANTIVNO832012,TCGA-EW-A1PH-R32259B13D295F-A310-4C1A-9812-BFC67F771E56276322EXTERNAL BEAM6120cGy34Primary Tumor FieldADJUVANTNO12042012
TCGAFPPP,Breast,No,FEMALE,Dead,2097.0,1886.2490234375,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0X5,B6,A0X5,No,YES,C50.9,8500/3,C50.9,1995.0,WITH TUMOR,YES,14.0,Image Analysis,Image Analysis,Left,1.6635937500000004,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,Malignant Phyllodes Tumor,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,4+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),"Biopsy, NOS",Negative,Positive,Equivocal,0.33203125,3.0,allred score = 8,270 H,10-19%,ACIS,CAP scoring guideline 2010,133.9921875,Vysis AutoVysion System,Positive >2.2,NO,YES,1.1,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,118,4 Point Scale,1+,4thStage IIBT2N1bM0,YES,NO,PositivePositiveNegativeNegative,14,12,2010,"TCGA-B6-A0X5-F1572651D5C754-2AD5-4C88-9D30-FB526027E827Scheduled Follow-up SubmissionNOYESDead2097WITH TUMORYES1343Distant MetastasisOther, specifyLiver and Pleura and BoneNONONO2982011",2TCGA-E2-A1IG-D1993535DF36F9-799F-4E34-98BB-453D807A55AF1160mg290mg4108150ChemotherapyPaclitaxelADJUVANTIVNO211220113TCGA-E2-A1IG-D1993683E712C3-ABC5-4875-A5A1-4AEBEA1D27BA20mg/day20mg/day234Hormone TherapyTamoxifenADJUVANTPOYES211220111TCGA-E2-A1IG-D19933521E6E77-C1C4-4361-8566-1E7AE45D7CC43960mg990mg45294ChemotherapyCyclophosphamideADJUVANTIVNO211220111TCGA-E2-A1IG-D199343DAFFE53-CA87-4B06-A70E-1F55782E3964396mg99mg45294ChemotherapyDoxorubicinADJUVANTIVNO21122011NOTCGA-E2-A1IG-D7039386F3FAA8-97CD-4A7E-B217-21DCAB6419BA1991Hormone TherapyLetrozoleYES1632015,TCGA-A8-A07G-R3818830302E30-CC2F-48C2-8021-CF4C619A5E21181212ExternalPrimary Tumor FieldComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,593.0,WHITE,TCGA-EW-A1OY,EW,A1OY,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,H-SCORE 260,IHC,Left,1.2559960937500043,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Re-excision of the inferior margin,Other,Surgical resection,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,Allred Score,205,<10%,CISH,+ or -,136.8828125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,54,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.9,3 Point Scale,3+,6thStage IIAT2N0MX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",10,6,2011,TCGA-EW-A1OY-F3095026FD0127-AD2F-4FAB-B570-B297E9CC4EFDScheduled Follow-up SubmissionYESYESAlive908TUMOR FREENO2332012,NOTCGA-EW-A1OY-D3226403D8BE5B-C488-4B80-B892-D6A4C2EE03B5478Hormone TherapyFemaraYES2252012NOTCGA-EW-A1OY-D32265E5516788-6C73-4B51-B902-5B5FE65F9658109161ChemotherapyDoxorubicinNO3052012NOTCGA-EW-A1OY-D32267EBCAFCA5-6D9C-465B-B053-FE7F6CA8EADA109161ChemotherapyCyclophosphamideNO3052012NOTCGA-EW-A1OY-D32268B36F48F2-F93A-4964-B8B9-7CF74F5CB0B1180308ChemotherapyPaclitaxelNOStable Disease3052012,TCGA-EW-A1OY-R322698C92A96B-0D36-494B-A441-16C4148B266C341376EXTERNAL BEAM29Primary Tumor FieldADJUVANTNO11552012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,168.0,WHITE,TCGA-BH-A2L8,BH,A2L8,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,1.0,Allred 7 = 5+2,Immunohistochemistry,Right Upper Outer Quadrant,1.338476562500004,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,TOTAL MASTECTOMY,Infiltrating Lobular Carcinoma,Lobular carcinoma with ductal features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,Oncotype Dx test,Oncotype Dx test,30-39%,Dako,Hercep Test  TM Dako,196.494140625,HER2 amplification - negative,Ratio >=2.0,YES,NO,1.57,"LungBoneLiverOther, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.8,3 Point Scale,2+,7thStage IIAT2N0 (i-)M0,NO,NO,NO,27,3,2012,TCGA-BH-A2L8-F39616C86ACD7B-AFEA-462D-BDA8-0A6980460D1ENONOYESTUMOR FREEAlive612NO2812013,NOTCGA-BH-A2L8-D43167D1B01084-E040-4E41-ACAC-3A7D4A79E959136197ChemotherapyCytoxanNOComplete Response1452013,TCGA-A2-A0T1-R371306674eb1-647c-45ef-8d3f-63cb7fd97891189252EXTERNAL BEAM11840cGy30Primary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Dead,1673.0,871.80078125,WHITE,TCGA-BH-A1FL,BH,A1FL,No,YES,C50.9,8500/3,C50.9,1998.0,WITH TUMOR,YES,22.0,H-SCORE 255,Allred score 5+3= 8,Left Upper Outer Quadrant,2.1173730468750027,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Reexcision,Other,needle directed right breast biopsy with left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, classical type, focal pleomorphic type",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.439453125,4.0,Allred score = 7,Two-tier,10-19%,Hercep Test  TM Dako,+ or -,137.158203125,HER2 amplification - negative,Positive >2.2,NO,YES,2.7,"Other, specifyskin",80-89%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,4.5,3 Point Scale,2+,5thStage IIBT2N1bM0,NO,NO,PositivePositiveNegativeNegative,8,9,2011,TCGA-AO-A03M-F58611F587B26-56C6-43CE-B5E9-1666DA4EAB4D1455AliveTUMOR FREENOYES912011TCGA-AO-A03M-F3018662767797-1CEB-468B-A320-FB552F1B6627Scheduled Follow-up SubmissionNOYESAlive1866NO442012,2TCGA-E2-A1IG-D1993535DF36F9-799F-4E34-98BB-453D807A55AF1160mg290mg4108150ChemotherapyPaclitaxelADJUVANTIVNO211220113TCGA-E2-A1IG-D1993683E712C3-ABC5-4875-A5A1-4AEBEA1D27BA20mg/day20mg/day234Hormone TherapyTamoxifenADJUVANTPOYES211220111TCGA-E2-A1IG-D19933521E6E77-C1C4-4361-8566-1E7AE45D7CC43960mg990mg45294ChemotherapyCyclophosphamideADJUVANTIVNO211220111TCGA-E2-A1IG-D199343DAFFE53-CA87-4B06-A70E-1F55782E3964396mg99mg45294ChemotherapyDoxorubicinADJUVANTIVNO21122011NOTCGA-E2-A1IG-D7039386F3FAA8-97CD-4A7E-B217-21DCAB6419BA1991Hormone TherapyLetrozoleYES1632015,TCGA-AR-A0TT-R19573A3F2C813-7858-4900-AEE3-694EBB16901F211ADJUVANTNO115122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7.0,WHITE,TCGA-C8-A9FZ,C8,A9FZ,No,YES,C50.9,8524/3,C50.9,2013.0,TUMOR FREE,YES,10.0,Allred score 7 (outside facility),Allred score 7 per outside facility report,Left,2.263984374999995,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Total mastectomy with sentinel lymoh node biopsy,Mixed Histology (please specify),Infiltrating Tubulo-Lobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,4 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Positive,Positive,Negative,2.4599609375,3.0,Allred score 5,120,90-99%,ACIS,Dako Hecept Test,173.71484375,HER2 amplification - negative,Ratio >=2.0,YES,NO,1.73,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,4.70,4 Point Scale,2+,7thStage IIBT2N1M0,NO,NO,NO,29,12,2014,TCGA-C8-A9FZ-F6996648655EEB-7E9F-4726-9820-88FFF609A953NOYESYESTUMOR FREEAlive592NO2312015,NOTCGA-C8-A9FZ-D699675EE9E222-CE90-4A1B-91F3-2A38CF4DC1ED2999ChemotherapyDoxorubicinNOComplete Response2312015NOTCGA-C8-A9FZ-D69968F8280902-5A96-471B-9127-AA1A6C7235C82999Chemotherapy5-FlourouracilNOComplete Response2312015NOTCGA-C8-A9FZ-D69969614A0F5A-4696-4BB3-8D04-8673AD02C4862999ChemotherapyCyclophosphamideNOComplete Response2312015NOTCGA-C8-A9FZ-D69970B038BA42-8ECD-4542-84B8-B748DBC4FA52169Hormone TherapyTamoxifenYES2312015,TCGA-C8-A9FZ-R699713D376E22-7CAA-4664-A6AC-505C83C6D30B119155External44Gy2Regional siteNOComplete Response2312015
TCGAFPPP,Breast,No,FEMALE,Dead,860.0,1863.7236328125,WHITE,TCGA-B6-A0X4,B6,A0X4,No,YES,C50.9,8500/3,C50.9,1996.0,WITH TUMOR,YES,21.0,Image Analysis,Image Analysis,Left,1.6563769531250008,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,Malignant Phyllodes Tumor,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,4+,2+,Negative,Negative,Incisional Biopsy,"Biopsy, NOS",Negative,Positive,Equivocal,0.326171875,2.0,allred score = 8,270 H,10-19%,ACIS,CAP scoring guideline 2010,136.3583984375,Vysis AutoVysion System,Positive >2.2,NO,YES,2.7,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,118,4 Point Scale,1+,4thStage IIBT2N1bM0,YES,NO,PositivePositiveNegativeNegative,14,12,2010,TCGA-B6-A0X4-F1572329FCF3A8-AC74-45DF-8A7F-9B4EABACE410Scheduled Follow-up SubmissionNOYESDead860WITH TUMORYES716Distant MetastasisBoneNOYESYES2982011,1TCGA-EW-A1PH-D303042DDB37C1-2B90-4032-8C74-3AB053366DB02505mg835mg398140ChemotherapyCyclophosphamideADJUVANTIVNO8320121TCGA-EW-A1PH-D303068C772D08-80AB-49A9-9CAC-40EEADDB8D31169mg169mg1161161ChemotherapyDocetaxelADJUVANTIVNO8320121TCGA-EW-A1PH-D29111E98E3894-4A1F-4559-AA6C-977995AAADD42505mg835mg398140ChemotherapyFluorouracilADJUVANTIVNO8320121TCGA-EW-A1PH-D303053C59E6BD-8791-41EF-A738-A127DA2E0088501mg167mg398140ChemotherapyEpirubicinADJUVANTIVNO8320122TCGA-EW-A1PH-D29113CE3771B3-13A0-460B-B9C7-C17BAA64C06A992mg124mg8215271ChemotherapyTaxolADJUVANTIVNO832012,TCGA-AC-A3YI-R61517F847AE09-DB60-4729-9889-41EF61CD8482250297External6000cGy30Primary Tumor FieldNOComplete Response3062014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1455.0,WHITE,TCGA-AO-A03M,AO,A03M,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,2.0,Allred score = 8,CAP SCORING GUIDELINE 2010,Left Upper Outer QuadrantLeft,1.3,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Reexcision,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,200,250,30-39%,ACIS,3+ Positive,99.873046875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.13,"Other, specifyskin",70-79%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.8985937499999987,60,3 Point Scale,3+,6thStage IT1cN0 (i-)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",9,1,2011,TCGA-AO-A03M-F58611F587B26-56C6-43CE-B5E9-1666DA4EAB4D1455AliveTUMOR FREENOYES912011TCGA-AO-A03M-F3018662767797-1CEB-468B-A320-FB552F1B6627Scheduled Follow-up SubmissionNOYESAlive1866NO442012,1TCGA-AO-A03M-D599520c31de8-d96e-4867-8335-719ccb5806a31100mg175mg/m24119161ChemotherapyPaclitaxelADJUVANTIVNO10120112TCGA-AO-A03M-D5996c13d0b89-a948-4f3f-ac88-4e9387d555db20mg/day161Hormone TherapyTamoxifenADJUVANTPOYES10120111TCGA-AO-A03M-D59949bdbaaed-6f6d-4d45-a7c0-dd1366b813db3768mg600mg/m2463105ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A03M-D5992e5a69005-a19c-4fc9-a8f2-9a2c939cb391376mg60mg/m2463105ChemotherapyDoxorubicinADJUVANTIVNO1012011,TCGA-OL-A5RU-R6525122B829AF-B769-4C42-B835-9B5461DCF6FC160197External5040cGyRegional siteNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,120.0,BLACK OR AFRICAN AMERICAN,TCGA-PL-A8LZ,PL,A8LZ,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,10.9755859375,H-SCORE 300,Allred 0 = 0+0,LeftLeft Upper Outer Quadrant,2.6663867187499912,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Other,Reexcision,Other,Right total mastectomy with lymph node left axillary lymph node excision,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,2+,Positive,Negative,Excisional Biopsy,Ultrasound-guided biopsy,Positive,Positive,Equivocal,1.1025390625,4.3896484375,240 H,200,30-39%,CISH,Dako Hecept Test,168.486328125,HER2 amplification - negative,Positive >2.2,YES,NO,69,BoneLiver,70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,105,3 Point Scale,2+,7thStage IIIBT4bN2M0,YES,NO,NO,5,5,2014,TCGA-PL-A8LZ-F648507245952D-7C0E-4FF3-BAD0-8A21D5524A97NONOYESTUMOR FREEAlive302NO1592014,NOTCGA-PL-A8LZ-D60805B7CC5531-DE12-4FCF-A668-AD54FDDCB143448ChemotherapypaclitaxelNO2662014,TCGA-E2-A15E-R1892247F13F36-41AE-454A-B878-B9F1AE276011218275EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO19112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2955.0,ASIAN,TCGA-A2-A0CR,A2,A0CR,No,YES,C50.9,8520/3,C50.9,2004.0,TUMOR FREE,YES,16.0,H-Score 270,H-SCORE 250,Left Upper Inner Quadrant,1.2,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Modified Radical Mastectomy,Reexcision,Other,L Total Mastectomy,Infiltrating Lobular Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,1+,2+,Negative,Close,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,allred score = 8,Intensity=Strong,90-99%,Hercep Test  TM Dako,Hercep Test TM DAKO,84.40234375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,1.78,"Other, specifyskin",60-69%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.3,3 Point Scale,3+,7thStage IIBT3N0M0,YES,NO,NO,5,6,2012,TCGA-A2-A0CR-F42400C3D189CF-D8DD-4B02-9DD3-68CCA1F0579FNONOYESTUMOR FREEAlive3283NO1842013,NOTCGA-A2-A0CR-D32690D0B85F79-B3D8-4E9F-A1AA-E2C032E70AB5105147ChemotherapyAdriamycinNOComplete Response762012NOTCGA-A2-A0CR-D32691A7033B5A-843E-4899-98F4-FAA742F71CB5105147ChemotherapyCyclophosphamideNOComplete Response762012NOTCGA-A2-A0CR-D32692B04147AD-6DB7-426E-AA27-E42D79761AE0140203ChemotherapyPaclitaxelNOComplete Response762012NOTCGA-A2-A0CR-D3269315734CC3-5FE8-44C0-8E0B-651B026DFC80224300Hormone TherapyTamoxifenNOComplete Response762012NOTCGA-A2-A0CR-D326954B109ECE-53BB-4544-A269-3DBBEFFDF432315Hormone TherapyAnastrazoleYES762012,TCGA-5L-AAT0-R63722F11A131E-E0C5-4BCE-A06B-BFEB0058AEDD371411External5000cGy25Primary Tumor FieldNO1582014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,579.0,WHITE,TCGA-A8-A0A2,A8,A0A2,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,6.1435546875,CAP SCORING GUIDELINE 2010,H-Score 160,Right Lower Outer Quadrant,1.7286523437499968,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Lobular Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,0,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.2431640625,0.0009765625,Strong,Allred score 8,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,109.4697265625,HER2 amplification - negative,Ratio >=2.0,NO,YES,4,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,61,3 Point Scale,2+,6thStage IIAT2N0M0,YES,NO,PositivePositiveNegativeNegative1.09,27,5,2011,TCGA-A2-A0CR-F42400C3D189CF-D8DD-4B02-9DD3-68CCA1F0579FNONOYESTUMOR FREEAlive3283NO1842013,NOTCGA-A8-A0A2-D379013C849DD1-A3D9-4F0A-A1B2-332514713CC692Hormone TherapyTamoxifenYES6122012,TCGA-A8-A0A2-R381921E9265EA-89C2-4B29-A848-0DA6F4AD95B93192External60GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,171.0,WHITE,TCGA-A7-A0CD,A7,A0CD,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,Allred 0 = 0+0,CAP scoring guideline 2010,Left,1.2,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Re-excision of the inferior margin,Modified radical mastectomy,L Total Mastectomy,Infiltrating Ductal Carcinoma,pleomorphic infiltrating lobular carcinoma,Indeterminate (neither Pre or Postmenopausal),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.015625,0.0,MODERATE,Allred Score 6,10-19%,CISH,DAKOHercepTest TM,279.0,Vysis AutoVysion System,PathVysion HER-2 DNA Probe Kit,YES,NO,4.0,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,4.6,3 Point Scale,2+,6thStage IT1N0M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",5,10,2010,TCGA-A7-A0CD-F331067DED7B1-E8A4-4E39-A848-1D9113D6382F372AliveTUMOR FREEYESYES8122010TCGA-A7-A0CD-F39827131C07DA-8E6A-44E7-898D-DEB2E3D91277NOYESYESTUMOR FREEAlive1165NO422013,1TCGA-A7-A0CD-D437394451533-8be6-41aa-a175-9eaa6aae73811 mg Dailymg112Hormone TherapyArimidexADJUVANTPOYES2122010,TCGA-A7-A0CD-R43835258db1e-4a32-4ee1-9be3-24a2494241277074OTHERHigh-dose rate brachytherapy of intracavitary type Mammosite3400cGy10Primary Tumor FieldADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,365.0,WHITE,TCGA-EW-A1P5,EW,A1P5,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,40.0,Allred score 7 (outside facility),CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.12,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0,3.0,Allred Score 5,Two-tier,<10%,CISH,Hercep Test  TM Dako,112.59765625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.8,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,3+,7thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",11,5,2011,TCGA-EW-A1P5-F322498E77875E-E696-4AE3-86E6-544E806A0DD8Scheduled Follow-up SubmissionYESYESAlive703TUMOR FREENO1552012,NOTCGA-EW-A1P5-D32250ADFE3F98-9CCF-4A9C-99A0-279B5FBE82B5199Hormone TherapyAnastrozoleYES2252012,TCGA-EW-A1P5-R32257ABC06C94-9A7F-4CD6-B371-E40477EF4EBC124185EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO11552012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,498.0,WHITE,TCGA-E2-A1IO,E2,A1IO,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,CAP SCORING GUIDELINE 2010,H-Score 15,Right,1.1,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.3779296875,0.0,Strong,Strong,30-39%,Dako,CAP scoring guideline 2010,139.2802734375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,118,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5,3 Point Scale,2+,6thStage IT1cN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",29,4,2011,TCGA-E2-A1IO-F203183AD0463E-614D-4388-ACC7-44A21F87E0EBScheduled Follow-up SubmissionYESYESAlive687TUMOR FREENO412012TCGA-E2-A1IO-F70391E33C2350-FCFD-48B6-9444-E29E22BB64DDNOYESYESTUMOR FREEAlive1855NO1632015,1TCGA-E2-A1IO-D20320BFC8334A-C530-4EE0-860A-3473046CCE9F462mg115.5mg484147ChemotherapyDocetaxelADJUVANTIVNO4120121TCGA-E2-A1IO-D203195CAD1231-055C-4E7F-AA97-689B30AEE8873696mg924mg484147ChemotherapyCyclophosphamideADJUVANTIVNO4120122TCGA-E2-A1IO-D2032107023BDC-054F-4A18-BA92-A01D49FC2F1D20mg/day20mg/day266Hormone TherapyTamoxifenADJUVANTPOYES412012,TCGA-E2-A1IO-R20322F2339939-5A10-4BDB-A1F4-6DBF9094FF35175220EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Dead,30.0,418.3310546875,WHITE,TCGA-A8-A08L,A8,A08L,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,16.7998046875,allred score 5+3=8,Allred score 7 per outside facility report,Left,1.7876367187499949,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Negative,0.4072265625,3.9931640625,Allred Score 3,0%,10-19%,ACIS,Hercep Test TM DAKO,139.9072265625,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,78,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,1.80,3 Point Scale,2+,6thStage IIIAT3N2aM0,YES,NO,PositivePositiveNegativeNegative,27,5,2011,TCGA-A8-A08L-F40847621DB5E5-F1F5-43B1-8D8C-45A3E8C58EECNOYESTUMOR FREEDead30232013,NOTCGA-C8-A9FZ-D699675EE9E222-CE90-4A1B-91F3-2A38CF4DC1ED2999ChemotherapyDoxorubicinNOComplete Response2312015NOTCGA-C8-A9FZ-D69968F8280902-5A96-471B-9127-AA1A6C7235C82999Chemotherapy5-FlourouracilNOComplete Response2312015NOTCGA-C8-A9FZ-D69969614A0F5A-4696-4BB3-8D04-8673AD02C4862999ChemotherapyCyclophosphamideNOComplete Response2312015NOTCGA-C8-A9FZ-D69970B038BA42-8ECD-4542-84B8-B748DBC4FA52169Hormone TherapyTamoxifenYES2312015,TCGA-A8-A08L-R38161D73DFE9C-A7EF-4DD0-8879-04052984D07D3030External45GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1359.0,WHITE,TCGA-AR-A2LJ,AR,A2LJ,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,18.0,image cytometry,H-SCORE 0,Left,3.119443359374993,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Reexcision,Other,Total Mastectomy,Infiltrating Lobular Carcinoma,neuroendocrine and ductal,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Positive,Positive,Positive,0.6494140625,1.0,Allred Score 5,moderate,30-39%,Hercep Test  TM Dako,Hercep Test  TM Dako,439.9853515625,HER2 amplification - negative,PathVysion,NO,YES,69,BoneLiver,70-79%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.789433593749996,2.5,3 Point Scale,2+,6thStage IIIAT3N1MX,YES,NO,Positive70-79%Positive<10%Negative1+,12,1,2012,TCGA-AR-A2LJ-F35167B4BFC81E-8655-457D-93D0-43609FAF7A31NOYESYESAlive1865NO7122012TCGA-AR-A2LJ-F494908B02FE2E-1AD4-4C80-A4D5-973A8BF7D516YESYESTUMOR FREEAlive1912NO2102013TCGA-AR-A2LJ-F717213502778E-0BFA-4CEE-A207-74D9CAE57F6ANOYESYESTUMOR FREEAlive2632NO3032015,NOTCGA-AR-A2LJ-D3726340A4371F-CF9D-4587-93C3-21D91D80BB9A4284ChemotherapyAdriamycinNO7122012NOTCGA-AR-A2LJ-D3726446FEDD0F-87E6-4C31-AB41-4B1DA8FAD9294284ChemotherapyCytoxanNO7122012NOTCGA-AR-A2LJ-D372655D6D171A-7CB5-4A45-B2B7-EAAF05E65A2998175ChemotherapyPaclitaxelNO7122012NOTCGA-AR-A2LJ-D3769674F13BD2-4E94-41A3-885F-6E52D52D744698465ImmunotherapyTrastuzumabNO7122012NOTCGA-AR-A2LJ-D376975C63D548-84D8-4253-AC3F-91CB50B0178B190Hormone TherapyTamoxifenYES7122012,TCGA-AR-A2LJ-R3726697483A09-7652-4CE8-940E-A82D5C9F5E30196231External5000cGy25Primary Tumor FieldNO7122012
TCGAFPPP,Breast,No,FEMALE,Dead,3472.0,813.7294921875,BLACK OR AFRICAN AMERICAN,TCGA-BH-A1FC,BH,A1FC,No,YES,C50.9,8510/3,C50.9,1998.0,TUMOR FREE,YES,23.0,ER Positive H-Score 95,H-SCORE 290,Right Upper Outer Quadrant,2.475810546874984,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Reexcision,Modified radical mastectomy,localized segmental mastectomy with axillary node dissection,Medullary Carcinoma,Ductal/cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Positive,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Negative,Negative,1.12109375,1.0,Allred Score 3,8,10-19%,ACIS,Dako Hecept Test,181.8525390625,HER2 amplification - negative,PathVysion,NO,YES,2.13,BoneLiver,10-19%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,131,3 Point Scale,2+,5thStage IIAT1cN1bM0,NO,NO,PositivePositiveNegativeNegative,8,9,2011,TCGA-A8-A08L-F40847621DB5E5-F1F5-43B1-8D8C-45A3E8C58EECNOYESTUMOR FREEDead30232013,1TCGA-E2-A1IO-D20320BFC8334A-C530-4EE0-860A-3473046CCE9F462mg115.5mg484147ChemotherapyDocetaxelADJUVANTIVNO4120121TCGA-E2-A1IO-D203195CAD1231-055C-4E7F-AA97-689B30AEE8873696mg924mg484147ChemotherapyCyclophosphamideADJUVANTIVNO4120122TCGA-E2-A1IO-D2032107023BDC-054F-4A18-BA92-A01D49FC2F1D20mg/day20mg/day266Hormone TherapyTamoxifenADJUVANTPOYES412012,TCGA-AR-A2LJ-R3726697483A09-7652-4CE8-940E-A82D5C9F5E30196231External5000cGy25Primary Tumor FieldNO7122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,30.0,WHITE,TCGA-A8-A08A,A8,A08A,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,5.96875,CAP SCORING GUIDELINE 2010,Allred 5 = 2+3,Left Upper Inner Quadrant,1.628535156249996,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.4912109375,2.568359375,allred score = 7,Allred score 8,10-19%,ACIS,Dako Hecept Test,118.43359375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,78,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,59,3 Point Scale,3+,5thStage IT1cN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A08L-F40847621DB5E5-F1F5-43B1-8D8C-45A3E8C58EECNOYESTUMOR FREEDead30232013,NOTCGA-C8-A9FZ-D699675EE9E222-CE90-4A1B-91F3-2A38CF4DC1ED2999ChemotherapyDoxorubicinNOComplete Response2312015NOTCGA-C8-A9FZ-D69968F8280902-5A96-471B-9127-AA1A6C7235C82999Chemotherapy5-FlourouracilNOComplete Response2312015NOTCGA-C8-A9FZ-D69969614A0F5A-4696-4BB3-8D04-8673AD02C4862999ChemotherapyCyclophosphamideNOComplete Response2312015NOTCGA-C8-A9FZ-D69970B038BA42-8ECD-4542-84B8-B748DBC4FA52169Hormone TherapyTamoxifenYES2312015,TCGA-AR-A2LJ-R3726697483A09-7652-4CE8-940E-A82D5C9F5E30196231External5000cGy25Primary Tumor FieldNO7122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1953.0,ASIAN,TCGA-PE-A5DD,PE,A5DD,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,2.0,H-Score 300,Allred score 7 per outside facility report,Right Lower Inner Quadrant,2.332412109375,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision,Other,Reexc of biopsy site for gross/micro residual disease,Infiltrating Lobular Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Incisional Biopsy,Biopsy not specified,Positive,Positive,Positive,0.150390625,0.0,moderately to strongly,200,30-39%,CISH,Dako Hecept Test,59.859375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,64,"Other, specifyskin",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,172,3 Point Scale,2+,6thStage IIAT2N0M0,NO,NO,NO,6,5,2013,TCGA-PE-A5DD-F663610E7AB498-2BA4-460B-896C-866D724D7640YESYESYESTUMOR FREEAlive1953NO13102014,NOTCGA-PE-A5DD-D6636256C0330D-81DB-48E3-B677-CA6765713AB6191Hormone TherapyFemaraYES13102014NOTCGA-PE-A5DD-D4297407D66B09-526B-4452-AD8F-860E0674487B38ChemotherapyNOComplete Response13102014,TCGA-PE-A5DD-R663637414F39D-4F10-4955-B284-72E857327754130160ExternalPrimary Tumor FieldNOComplete Response13102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,711.0,BLACK OR AFRICAN AMERICAN,TCGA-GI-A2C9,GI,A2C9,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,4.0,CAP scoring guideline 2010,Allred score 5+3 = 8,Right,2.109765625000005,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,Strong,250,90-99%,CISH,Dako Hercept test,135.33984375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,50,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,2+,6thStage IIBT3N0MX,YES,YES,YES994Distant MetastasisBoneNOYESYES,21,10,2011,TCGA-GI-A2C9-F21663C2067CDA-E620-41E9-9545-34875B29BC1FScheduled Follow-up SubmissionYESYESAlive3342NO852012,TCGA-GI-A2C9-D21685EDBFE34C-5F81-4C58-B519-A7D28AB60B383349ChemotherapyADJUVANTNO852012,TCGA-GI-A2C9-R21683817932FB-2657-4409-8D5B-35D4DDD5E0173342Primary Tumor FieldADJUVANTNO852012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,145.0,WHITE,TCGA-D8-A27M,D8,A27M,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,1.0,Image Analysis,Image Analysis,Left Upper Outer Quadrant,1.8528613281249997,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Other,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Negative,Negative,0.0009765625,0.087890625,Allred score = 8,H-Score,90-99%,Hercep Test  TM Dako,Hercep Test TM DAKO,126.216796875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,1.45,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,4 Point Scale,1+,7thStage IAT1cN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,17,7,2011,TCGA-D8-A27M-F29592F7028889-8575-484F-8C51-2F75DA0740BCScheduled Follow-up SubmissionNOYESAlive410TUMOR FREENO2632012,TCGA-D8-A27M-D295930BE1EFFF-4959-45B6-A90D-D5954D024746240+3600+600mg40+600+100mg/m2684238Chemotherapymethotrexate+5 fluorouracil+cyclophosphamideADJUVANTIVNO2632012,TCGA-PE-A5DD-R663637414F39D-4F10-4955-B284-72E857327754130160ExternalPrimary Tumor FieldNOComplete Response13102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,38.0,WHITE,TCGA-E9-A1RF,E9,A1RF,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,H-SCORE 260,Allred score 2+3 = 5,Left Upper Outer Quadrant,1.4384179687500025,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-excision of the inferior margin,Other,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.2353515625,5.0,Allred score 5,allred score = 7,10-19%,Hercep Test  TM Dako,+ or -,245.3798828125,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,YES,NO,69,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.3,4 Point Scale,1+,7thStage IIIAT2N2M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,2,8,2011,TCGA-E9-A1RF-F306338239B7BC-A659-4F20-BD86-9185AA136FA4Scheduled Follow-up SubmissionYESYESAlive200TUMOR FREENO1342012TCGA-E9-A1RF-F4870335166AFC-AAC8-4F95-931D-11660E40DDCFYES1992013,TCGA-E9-A1RF-D30635BB320C8C-AD02-463F-904A-B4301628BB5B500mg100mg554194ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RF-D30636E24DA2B4-5273-4C8A-A468-E3BCF7FCD2145000mg1000mg554194Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RF-D3063790F42AFB-EFAC-4C90-999B-DA0E246EF30020mg/day30Hormone TherapyTamoxifenADJUVANTPOYES1342012TCGA-E9-A1RF-D3063459D29C9B-773E-49D8-B79E-18BCF84061DC5000mg1000mg554194ChemotherapyCyclophosphamideADJUVANTIVNO1642012,TCGA-E9-A1RF-R3063810729565-ADC4-4C6F-891E-1606E11ABA81118144EXTERNAL BEAM3740cGyRegional siteADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,21.0,WHITE,TCGA-E9-A1RB,E9,A1RB,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,Allred 0 = 0+0,Allred score 2+3 = 5,Left Upper Inner Quadrant,1.5167382812499888,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.0,0.0,Allred Score 5,120,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,114.55078125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,4,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,441,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-E9-A1RB-F30854D5AED3F9-5484-41CC-B13E-8B9FD4CBB938Scheduled Follow-up SubmissionNOYESAlive633TUMOR FREENO1742012TCGA-E9-A1RB-F39530EEE00A97-63CE-4A0A-A552-0F2F2D98CCC8NONOYESTUMOR FREEDead976NO2412013,TCGA-E9-A1RB-D30858ED42B1AF-E7F0-4598-9EFE-12B6AEA180C320mg/day15Hormone TherapyTamoxifenADJUVANTPOYES1742012TCGA-E9-A1RB-D3085625429B7D-51F9-4C70-AC60-B8148B735388500mg100mg511107ChemotherapyMethotrexateADJUVANTIVNO1742012TCGA-E9-A1RB-D308575E138DC3-70C8-4195-8DF7-2EFC4FA2740710000mg2000mg511107Chemotherapy5-FluorouracilADJUVANTIVNO1742012TCGA-E9-A1RB-D3085927022DC0-5FA3-4EB4-B968-C35A4655475D10000mg2000mg511107ChemotherapyCyclophosphamideADJUVANTIVNO1742012,TCGA-AR-A2LJ-R3726697483A09-7652-4CE8-940E-A82D5C9F5E30196231External5000cGy25Primary Tumor FieldNO7122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A8-A096,A8,A096,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.4599609375,image cytometry,Allred 5 = 2+3,Right,1.856249999999988,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.318359375,0.0,Allred Score 3,0%,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,136.470703125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.45,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,21,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,PositivePositiveNegativeNegative1.09,27,5,2011,TCGA-E9-A1RF-F306338239B7BC-A659-4F20-BD86-9185AA136FA4Scheduled Follow-up SubmissionYESYESAlive200TUMOR FREENO1342012TCGA-E9-A1RF-F4870335166AFC-AAC8-4F95-931D-11660E40DDCFYES1992013,2TCGA-A2-A3KD-D30120AB03C3FC-D1ED-4F17-8BFB-C5123D0EC3B1480mg120mg4127190ChemotherapyTaxotereADJUVANTIVNO14220121TCGA-A2-A3KD-D3011902CCA825-E874-4DCB-A863-18EF852249773848mg962mg4127190ChemotherapyCytoxanADJUVANTIVNO14220123TCGA-A2-A3KD-D30121042F7696-E248-4F7D-AC91-A50E35E2E99F20mg/day282Hormone TherapyTamoxifenADJUVANTPOYES1422012,TCGA-AR-A2LJ-R3726697483A09-7652-4CE8-940E-A82D5C9F5E30196231External5000cGy25Primary Tumor FieldNO7122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,187.0,WHITE,TCGA-D8-A1JG,D8,A1JG,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,Image Analysis,dextran coated charcoal,Right Upper Outer Quadrant,1.2120507812499988,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,breast conserving therapy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Negative,Equivocal,0.0,0.0,Allred Score 7,Allred score 8,90-99%,Dako,DAKOHercepTest TM,198.9404296875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,4,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,not amplified,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,3,2011,TCGA-D8-A1JG-F140607C44E839-34A8-49E0-A07D-4465FD24CA33Scheduled Follow-up SubmissionYESYESAlive366TUMOR FREENO1872011TCGA-D8-A1JG-F7220843A0E4B3-430E-4554-9982-A15A1C5DF509NOYESYESTUMOR FREEAlive1612NO2942015,ACTCGA-D8-A1JG-D140618AC1E40A-2939-4FD6-93E8-DE97A4C64960mg/m260mg/m2269ChemotherapydoxorubicinADJUVANTIVYES1872011NOTCGA-D8-A1JG-D6532579FA201D-29D2-4F82-BD32-02AAC1E0DE5E269ChemotherapycyclophosphamideYES2292014,TCGA-D8-A1JG-R14062C24109D8-C044-41DF-BAF0-A3B8FC106D1B131156EXTERNAL BEAM42.5+10cGy21Primary Tumor FieldADJUVANTNO11872011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,525.0,WHITE,TCGA-BH-A0DO,BH,A0DO,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,Allred score 5+2 = 7,H-SCORE 210,Left Upper Inner Quadrant,1.8611914062500012,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Reexcision,Modified radical mastectomy,Right segmental mastectomy with sentinel lymph node and axillary lymph node biopsy,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.283203125,0.0,Allred score 5,80,10-19%,Hercep Test  TM Dako,Dako Hercept test,65.58203125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2.13,"Other, specifyskin",70-79%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,>6.0,3 Point Scale,2+,6thStage IT1cN0M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,11,8,2011,TCGA-BH-A0DO-F63671609BA6DE-5B63-4ABA-A085-21880B110253NONONOTUMOR FREEAlive1644NO1582014,2TCGA-E2-A1IG-D1993535DF36F9-799F-4E34-98BB-453D807A55AF1160mg290mg4108150ChemotherapyPaclitaxelADJUVANTIVNO211220113TCGA-E2-A1IG-D1993683E712C3-ABC5-4875-A5A1-4AEBEA1D27BA20mg/day20mg/day234Hormone TherapyTamoxifenADJUVANTPOYES211220111TCGA-E2-A1IG-D19933521E6E77-C1C4-4361-8566-1E7AE45D7CC43960mg990mg45294ChemotherapyCyclophosphamideADJUVANTIVNO211220111TCGA-E2-A1IG-D199343DAFFE53-CA87-4B06-A70E-1F55782E3964396mg99mg45294ChemotherapyDoxorubicinADJUVANTIVNO21122011NOTCGA-E2-A1IG-D7039386F3FAA8-97CD-4A7E-B217-21DCAB6419BA1991Hormone TherapyLetrozoleYES1632015,TCGA-GI-A2C9-R21683817932FB-2657-4409-8D5B-35D4DDD5E0173342Primary Tumor FieldADJUVANTNO852012
TCGAFPPP,Breast,Yes,MALE,Alive,0.0,665.0,BLACK OR AFRICAN AMERICAN,TCGA-AQ-A54O,AQ,A54O,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,14.0,Allred score 7 (outside facility),allred score 5 + 3 = 8,Right Upper Outer Quadrant,4.83409179687497,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Other,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Biopsy not specified,Positive,Positive,Negative,0.0,0.0,8,Allred Score = 7,30-39%,ACIS,Venten,229.103515625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,118,"LungBoneLiverOther, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.5,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,NO,26,2,2013,TCGA-AQ-A54O-F557318B3E15A7-7C5B-4B61-869F-74A0E7751612NONOYESTUMOR FREEAlive1001NO1412014,NOTCGA-AQ-A54O-D40684D051B585-6A82-4408-B25B-3CB75C56A0C877118ChemotherapyAdriamycinNOComplete Response2622013NOTCGA-AQ-A54O-D4068669C618BF-24A2-46C0-BA45-AAD9D605E8E677118ChemotherapyCytoxanNOComplete Response2622013NOTCGA-AQ-A54O-D40687D56A18AB-9A5D-4B8F-B5FE-4CFDE2C87A45132176ChemotherapyTaxolNOComplete Response2622013NOTCGA-AQ-A54O-D4068802A79C21-928D-4FE9-BD1D-934CD3ABE809199Hormone TherapyTamoxifenYES2622013,TCGA-BH-A0BP-R59124F27E0482-22DF-4596-9362-2054248AF498124153External5000cGy33Primary Tumor FieldNOComplete Response152014TCGA-BH-A0BP-R591253F5C1BF6-607D-47CE-BCE8-FA3A3A183E79162162External1600cGyPrimary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,554.0,WHITE,TCGA-A1-A0SQ,A1,A0SQ,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,15.0,Allred score 5+3=8,CAP scoring guideline 2010,Left,1.5938867187499977,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,surgical resection,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Positive,Positive,Negative,0.716796875,1.0,Allred score 8,Intensity=Strong,10-19%,CISH,Hercep Test TM DAKO,177.9501953125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,1.40,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,131,3 Point Scale,3+,6thStage IIBT2N1MX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",30,6,2011,TCGA-A8-A08J-F40846511A5351-B4EC-4B3F-8F4E-00AFD1613ED1NONOWITH TUMORDead1127232013,TCGA-A1-A0SQ-D155416EF5104B-825D-4C69-94C9-85CB727D54574148ChemotherapyacADJUVANTIVNO2482011TCGA-A1-A0SQ-D15544CC54C460-ED66-4313-9C2B-BA4816081388299Hormone TherapytamoxifenADJUVANTPOYES2482011TCGA-A1-A0SQ-D15542DE1DD233-6EE9-4C5D-8CAB-CF9336114C4A4237ChemotherapytaxolADJUVANTIVNO2482011,TCGA-A1-A0SQ-R15543DB4CABEB-052D-429F-ACF7-B550C6495F80268329EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO2482011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,160.0,WHITE,TCGA-BH-A6R9,BH,A6R9,No,YES,C50.9,8575/3,C50.9,2012.0,TUMOR FREE,YES,4.2138671875,H-Score 200,H-SCORE 210,Left,1.7542285156250013,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Metaplastic Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Positive,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Negative,0.6787109375,0.005859375,240 H,160,30-39%,Dako,CAP SCORING GUIDELINE 2010,219.15234375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,66,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,61,3 Point Scale,2+,7thStage IIAT2N0M0,NO,NO,NO,13,2,2014,TCGA-BH-A6R9-F63678D2AF96B0-8735-4AE4-9821-E64B25949D6ENONONOTUMOR FREEAlive160NO1582014,1TCGA-AR-A1AK-D2215537D99581-850D-476B-8328-D3E0BD6DC0491mg/day331843Hormone TherapyAnastrozoleADJUVANTPONO132012,TCGA-A7-A3IZ-R34492B45436BD-3C65-4EC5-9C41-1D009B1E0435181226External6100cGy33Primary Tumor FieldNOComplete Response1682012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,210.0,WHITE,TCGA-LL-A50Y,LL,A50Y,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,8.0,Allred 0 = 0+0,Allred score 2+3 = 5,Right Upper Outer Quadrant,1.0,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Re-excision of the inferior margin,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Lobular Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.0,0.0,230,Allred Score = 7,30-39%,CISH,Hercep Test  TM Dako,167.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.5,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.6,3 Point Scale,2+,7thStage IIAT2N0MX,YES,NO,NO,8,3,2013,TCGA-LL-A50Y-F504061D4C9AE4-C224-413E-8A94-874FE75F06CFNONOYESTUMOR FREEAlive762NO23102013,NOTCGA-LL-A50Y-D40968AAE548CC-C906-4B50-9987-4BEAC371569C54608Hormone TherapyARIMIDEXNOComplete Response832013,TCGA-WT-AB44-R62428491AD153-4239-4288-A7BE-B32A0155FEB492153External6040cGy33Primary Tumor FieldNOComplete Response1672014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,1015.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A1L8,E2,A1L8,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,13.0,allred score 5 + 3 = 8,allred score 4 + 3 = 7,Left Upper Outer Quadrant,1.1,Sentinel lymph node biopsy plus axillary dissection,Pateys surgery,Simple Mastectomy,Re-excision of the inferior margin,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Positive,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.3154296875,2.0,allred score = 7,allred score = 8,40-49%,Hercep Test  TM Dako,+ or -,103.5419921875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.8,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,71,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,7,6,2011,TCGA-E2-A1L8-F205780B9DBEFA-1DF5-45D1-89E1-30BB4C92D599Scheduled Follow-up SubmissionYESYESAlive1205TUMOR FREENO1112012TCGA-E2-A1L8-F700188F1CA815-127E-49BE-AB1C-538DC9D42ACANOYESYESTUMOR FREEAlive2240NO922015,"1TCGA-E2-A1L8-D2057993A3B706-6851-4D5B-94A6-715C910C68253960mg1320mg35799ChemotherapyCyclophosphamideADJUVANTIVNO11120123TCGA-E2-A1L8-D205825D31DD41-67CF-4788-B56F-452F014B78211600mg/day1600mg/day211Other, specify in notesPhase III Clinical TrialClodronateADJUVANTPOYES11120124TCGA-E2-A1L8-D2058404419A9C-960A-495A-B91F-48F2C88765971mg/day1mg/day246Hormone TherapyArimidexADJUVANTPOYES11120121TCGA-E2-A1L8-D20580D86361A9-8F77-4C1D-AF65-1E775A676B4E396mg132mg35799ChemotherapyDoxorubicinADJUVANTIVNO11120122TCGA-E2-A1L8-D2058100FD3E45-CD1B-4F71-915F-C2CF8C467F221712mg428mg4113155ChemotherapyPaclitaxelADJUVANTIVNO1112012",TCGA-E2-A1L8-R20585FD3CF554-DCE8-4A47-B16B-CFC4D70AF7DA198245EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO11112012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,13.0,ASIAN,TCGA-C8-A132,C8,A132,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,4.0,H-Score 150,H-Score 290,Left,1.4910839843749928,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Surgery,Negative,Positive,Equivocal,0.0322265625,1.0,Allred Score 7,Allred Score 8,90-99%,Hercep Test  TM Dako,Venten,86.6923828125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,1.78,"Other, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,145,4 Point Scale,1+,6thStage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,15,4,2011,TCGA-C8-A132-F19090704DF98E-8B9C-4FE9-9D66-0F0709FE6144Scheduled Follow-up SubmissionNOYESAlive57TUMOR FREENO2122011TCGA-C8-A132-F708269BDF73D9-8363-4F50-92EC-41537B282632NONOTUMOR FREEAlive383NO932015,1TCGA-AR-A0U4-D19342E0C6F2ED-E72F-409A-BB26-85708A763D795380mg600mg/m245398ChemotherapyCytoxanADJUVANTIVNO121220111TCGA-AR-A0U4-D19341324CC111-37BE-4840-A581-F1CED82AA6C5540mg60mg/m245398ChemotherapyDoxorubicinADJUVANTIVNO121220111TCGA-AR-A0U4-D1934334F346D8-CBF0-4AA7-8B08-1A238EAED7151560mg175mg/m24112154ChemotherapyPaclitaxelADJUVANTIVNO12122011,TCGA-E2-A1L8-R20585FD3CF554-DCE8-4A47-B16B-CFC4D70AF7DA198245EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO11112012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1120.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A2FR,EW,A2FR,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,21.0,H-SCORE 190,dextran coated charcoal,Right Upper Outer Quadrant,3.0,Axillary lymph node dissection alone,Sentinel lymph node and axillary lymph node biopsy,Lumpectomy,Reexcision,Modified radical mastectomy,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,Mixed infiltrating lobular and grade 1 ductal carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,1+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Positive,Negative,Equivocal,0.4404296875,19.0,Allred Score 4,STRONG,10-19%,CISH,Dako Hecept Test,40.0,HER2 amplification - negative,ratio > 2.2 is positive,NO,YES,2,Bone,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,>6,3 Point Scale,1+,6thStage IIICT1bN3aMX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",12,10,2011,TCGA-EW-A2FR-F323111B368505-DA61-46F6-AA01-9AA6978FE665Scheduled Follow-up SubmissionYESYESAlive1309TUMOR FREENO2352012TCGA-EW-A2FR-F420567816276A-1574-408C-B73B-519C7DE42D56NOYESYESTUMOR FREEAlive1673NO1042013,NOTCGA-EW-A2FR-D32313DCEB895A-E1A5-4FD9-BE38-21E232DE56843476ChemotherapyEpirubicinNO2352012NOTCGA-EW-A2FR-D32314252D689B-BC80-47B8-B3C2-74104D0126743476ChemotherapyFluorouracilNO2352012NOTCGA-EW-A2FR-D323158A8AD4DD-2321-44FD-8088-8EC827E71D203476ChemotherapyCyclophosphamideNO2352012NOTCGA-EW-A2FR-D3231648579EAC-39AF-415C-B6DF-893430FC303F97174ChemotherapyPaclitaxelNOStable Disease2352012,TCGA-EW-A2FR-R32312832B0491-C707-42CA-AFC9-E9F3E321C30EEXTERNAL BEAMPrimary Tumor FieldADJUVANTNO12352012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1684.0,WHITE,TCGA-AR-A0U4,AR,A0U4,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,10.0,H-SCORE 260,Allred score 2+2 = 4,Left Upper Outer Quadrant,3.6665722656249793,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Re-excision of the inferior margin,Other,Surgical resection,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,4+,2+,Positive,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.052734375,0.0,10-75%,Allred score 8,30-39%,Dako,CAP SCORING GUIDELINE 2010,158.29296875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,1.78,"Other, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,60,3 Point Scale,0,6thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",10,3,2011,TCGA-AR-A0U4-F187240A78AC62-8CD2-4BCF-9F75-0E07C79431C2Scheduled Follow-up SubmissionNOYESAlive1684NO12122011TCGA-AR-A0U4-F494836FC7B699-27CB-43BD-96E2-BED36D990E97NOYESTUMOR FREEAlive2615NO2102013TCGA-AR-A0U4-F717392E6CB219-767B-4D70-8ED4-CA0032345759NONOYESTUMOR FREEAlive3261NO3032015,1TCGA-AR-A0U4-D19342E0C6F2ED-E72F-409A-BB26-85708A763D795380mg600mg/m245398ChemotherapyCytoxanADJUVANTIVNO121220111TCGA-AR-A0U4-D19341324CC111-37BE-4840-A581-F1CED82AA6C5540mg60mg/m245398ChemotherapyDoxorubicinADJUVANTIVNO121220111TCGA-AR-A0U4-D1934334F346D8-CBF0-4AA7-8B08-1A238EAED7151560mg175mg/m24112154ChemotherapyPaclitaxelADJUVANTIVNO12122011,TCGA-AR-A2LJ-R3726697483A09-7652-4CE8-940E-A82D5C9F5E30196231External5000cGy25Primary Tumor FieldNO7122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,736.0,WHITE,TCGA-A2-A0D3,A2,A0D3,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,1.0,Allred 7 = 5+2,H-SCORE 210,Left Lower Outer Quadrant,1.41,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Other,biopsy,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,0.0,110,moderately to strongly,30-39%,Dako,Venten,190.083984375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,58,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,2+,Negative,1.7867382812499957,5,3 Point Scale,2+,6thStage IAT1cN0 (i-)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,1,2011,TCGA-A2-A0D3-F13715C5EF3C66-6096-4F1F-BF13-223A064C292DScheduled Follow-up SubmissionNOYESAlive875TUMOR FREENO962011TCGA-A2-A0D3-F59451A98415CB-B3AF-4EF9-A0C2-EE010FC9D9E6NONOYESTUMOR FREEAlive1873NO1352014,2TCGA-A2-A0D3-D72484676c63b-5c36-433a-a19d-b77bd02a97474608mg768mg669173ChemotherapyCarboplatinADJUVANTIVNO31120113TCGA-A2-A0D3-D7252490b634f-290f-4617-ab36-d0b91a1def7510mg195Hormone TherapyTamoxifenADJUVANTPOYES31120111TCGA-A2-A0D3-D72468f0c0628-9dff-4a13-bd14-246b3416cee2852mg142mg669173ChemotherapyDocetaxelADJUVANTIVNO31120114TCGA-A2-A0D3-D7254b8248a0e-7dbf-47a8-a4d5-83d530250db92917mg2-460mg1969196Targeted Molecular therapyHerceptinADJUVANTIVNO3112011,TCGA-AC-A3TN-R60191F59786E2-ADDA-4D6F-AD25-572BB54CEA1E96144External6040cGyPrimary Tumor FieldNOComplete Response3152014
TCGAFPPP,Breast,No,FEMALE,Dead,1688.0,811.435546875,WHITE,TCGA-BH-A1FU,BH,A1FU,No,YES,C50.9,8500/3,C50.9,1997.0,WITH TUMOR,YES,5.0,H-SCORE 255,H-Score 190,Right Upper Outer Quadrant,2.591679687499985,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,total mastectomy and sentinel node biopsy,Infiltrating Ductal Carcinoma,pleomorphic infiltrating lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Positive,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Negative,Negative,1.1025390625,0.0,Allred score 8,Moderate,10-19%,ACIS,Hercep Test TM DAKO,63.3837890625,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,NO,YES,3.1,BoneLiver,80-89%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,132,3 Point Scale,2+,5thStage IAT1cN0M0,NO,NO,PositivePositiveNegativeNegative,8,9,2011,TCGA-WT-AB44-F666400A7190BA-575B-41F4-8F55-012383288578NOYESYESTUMOR FREEAlive883NO21102014,1TCGA-AR-A0U4-D19342E0C6F2ED-E72F-409A-BB26-85708A763D795380mg600mg/m245398ChemotherapyCytoxanADJUVANTIVNO121220111TCGA-AR-A0U4-D19341324CC111-37BE-4840-A581-F1CED82AA6C5540mg60mg/m245398ChemotherapyDoxorubicinADJUVANTIVNO121220111TCGA-AR-A0U4-D1934334F346D8-CBF0-4AA7-8B08-1A238EAED7151560mg175mg/m24112154ChemotherapyPaclitaxelADJUVANTIVNO12122011,TCGA-AC-A3TN-R60191F59786E2-ADDA-4D6F-AD25-572BB54CEA1E96144External6040cGyPrimary Tumor FieldNOComplete Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1N6,E9,A1N6,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,Allred (Biocare),image cytometry,Left Upper Outer Quadrant,2.671103515624985,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Positive,Negative,Tumor resection,Lumpectomy,Positive,Positive,Positive,0.0,2.0,Allred Score 5,120,10-19%,Hercep Test  TM Dako,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,106.892578125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,50,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,185,3 Point Scale,2+,7thStage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,23,6,2011,TCGA-E9-A1N6-F2915261B7B175-64BF-4960-B4A5-D2AEFE1B9A17Scheduled Follow-up SubmissionYESYESAlive410TUMOR FREENO932012TCGA-E9-A1N6-F63536D6C11D26-4FA8-426C-B4FC-9A280F1ED8D3NOYESYESWITH TUMORDead678YES443Distant MetastasisBoneNONOYES648Locoregional RecurrenceNONONO672Distant MetastasisLiverNONONO1282014,NOTCGA-E9-A1N6-D328961602F6B3-37E4-4305-9B0F-60739FCAE4A1128Hormone TherapyTamoxifenYES1562012NOTCGA-E9-A1N6-D635459C2EBE7E-9BD0-4B27-A254-6B5EF6E962A3447574ChemotherapyDoxorubicinNOStable Disease1282014NOTCGA-E9-A1N6-D635465A20287E-F225-416A-9A83-86038A1BE690447574ChemotherapyCyclophosphaneNOStable Disease1282014NOTCGA-E9-A1N6-D63562E69B2ABD-369B-40EF-BC6B-8FE52DC62E45575678Hormone TherapyLetrozoleNOClinical Progressive Disease1382014,TCGA-E9-A1N6-R29155A2417E8F-0B84-4931-A517-4609148E727882117EXTERNAL BEAM3800cGy19Regional siteADJUVANTNO932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,495.0,WHITE,TCGA-BH-A0DZ,BH,A0DZ,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,5.0,H-SCORE 140,H-SCORE 15,Right Upper Inner QuadrantRight Upper Outer QuadrantRight Lower Inner QuadrantRight Lower Outer QuadrantRight,1.5521679687500112,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,pleomorphic infiltrating lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Positive,0.482421875,1.0,H-SCORE,H-SCORE,30-39%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.9814453125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,40,"LungBoneLiverOther, specifyskin",50-59%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,3.53,3 Point Scale,2+,Stage IIBT2N1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-BH-A0DZ-F4588F7218F8F-0D41-4B86-B276-C020CA69412E495AliveTUMOR FREENOYES16112010,1TCGA-BH-A0DZ-D4577AC6C5D22-298B-4E01-A4BB-024810BF148A20mg/day234Hormone TherapyTAMOXIFENADJUVANTPOYES171120101TCGA-BH-A0DZ-D4582C1100150-9A45-4A80-86C7-05997DFF9557689217ChemotherapyDOCETAXELADJUVANTIVNO181120101TCGA-BH-A0DZ-D45855C77B282-C471-4C6B-83CC-468EB487B8F51289224ChemotherapyHERCEPTINADJUVANTIVNO181120101TCGA-BH-A0DZ-D4580DD38FE68-F847-493F-A1B3-73A5A98F41C1689217ChemotherapyCARBOPLATINADJUVANTIVNO18112010,TCGA-AQ-A1H3-R19911DD693829-5BDE-49CE-AA8B-42D8FFE43469188233EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1412012TCGA-AQ-A1H3-R19912A77D9CB5-BE36-4F5B-A97C-A8A048732921188226EXTERNAL BEAM5040cGy28Regional siteADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,253.0,WHITE,TCGA-A2-A0YE,A2,A0YE,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,19.0,Allred score 1+1 = 2,H-Score 260,Right Upper Outer Quadrant,1.3556152343750028,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Lumpectomy,Reexcision,Modified radical mastectomy,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Ductal Carcinoma,Invasive mixed ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.1708984375,1.0,H-Score,Allred Score,<10%,ACIS,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,82.537109375,HER2 amplification - negative,Ratio >=2.0,NO,YES,40,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,366,3 Point Scale,1+,Stage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,10,12,2010,TCGA-A2-A0YE-F157717D263191-4081-4DD8-9E46-6D37D7714745Scheduled Follow-up SubmissionYESYESAlive554TUMOR FREENO3082011,1TCGA-A2-A0YE-D56688aff8385-be06-4dc8-900a-bd3755cdd8e55ChemotherapyTaxotereADJUVANTIVNO81220102TCGA-A2-A0YE-D5669635760ed-24dd-4491-bd61-c6793eb02a355ChemotherapyAdriamycinADJUVANTIVNO81220103TCGA-A2-A0YE-D5670a2d7f767-e939-4557-b767-387f1623d5ba5ChemotherapyCytoxanADJUVANTIVNO8122010,TCGA-A2-A0YE-R56712fe7a331-456c-44f1-913e-6bb5abdea657225267EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,804.0,WHITE,TCGA-A2-A3KD,A2,A3KD,No,YES,C50.9,8480/3,C50.9,2010.0,TUMOR FREE,YES,19.0,H-SCORE 255,H-Score 190,Right Upper Outer Quadrant,1.2,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Mastectomy NOS,Excision,Mucinous Carcinoma,Invasive mixed ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,4+,1+,Close,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,1.0,1.0,Strong,Strong,30-39%,Hercep Test  TM Dako,Hercep Test  TM Dako,207.7470703125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,3.1,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,52,3 Point Scale,1+,7thStage IIIAT3N1miM0,YES,NO,Positive90-99%,2,4,2012,TCGA-A2-A3KD-F37343F2E6F4BD-FA19-43B2-BFCD-124FE5BFF06BNOYESYESTUMOR FREEAlive1206NO3122012,2TCGA-A2-A3KD-D30120AB03C3FC-D1ED-4F17-8BFB-C5123D0EC3B1480mg120mg4127190ChemotherapyTaxotereADJUVANTIVNO14220121TCGA-A2-A3KD-D3011902CCA825-E874-4DCB-A863-18EF852249773848mg962mg4127190ChemotherapyCytoxanADJUVANTIVNO14220123TCGA-A2-A3KD-D30121042F7696-E248-4F7D-AC91-A50E35E2E99F20mg/day282Hormone TherapyTamoxifenADJUVANTPOYES1422012,TCGA-A2-A3KD-R30122C063B997-34B9-44F4-B7CA-6F5540ED5D27222272EXTERNAL BEAMADJUVANTNO11422012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,441.0,WHITE,TCGA-D8-A3Z5,D8,A3Z5,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,21.0,Allred score 0+0 = 0,CAP SCORING GUIDELINE 2010,Right,1.2790917968750126,Other (specify),mastectomy with TLND,Simple Mastectomy,Re-excision of the inferior margin,Other,Wide re-excisional biopsy,Infiltrating Lobular Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Positive,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.134765625,19.0,Allred score = 8,Allred score = 7,90-99%,Hercep Test  TM Dako,Hercep Test TM DAKO,140.36328125,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,YES,NO,1.67,"Other, specifyskin",80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.3,3 Point Scale,2+,7thStage IIICT2N3aM0,YES,NO,NO,3,7,2012,TCGA-D8-A3Z5-F57869FBAE89FD-F5B0-4393-928B-00C4DAD6776ENONONOTUMOR FREEAlive1015NO2832014,NOTCGA-LL-A740-D51204FFDC6873-66C3-41A3-9043-746A13AF38C6122164ChemotherapyADRIAMYCINNOComplete Response12112013NOTCGA-LL-A740-D5120553BF41C6-4FAA-40E5-80B2-E3ED637A4E30122164ChemotherapyCYTOXANNOComplete Response12112013NOTCGA-LL-A740-D6506225DBA480-441A-4F69-9824-94ADC2AACDB4178255ChemotherapyTAXOLNOComplete Response1892014,TCGA-AC-A3TN-R60191F59786E2-ADDA-4D6F-AD25-572BB54CEA1E96144External6040cGyPrimary Tumor FieldNOComplete Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,137.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A740,LL,A740,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,1.0,Allred 0 = 0+0,Allred 0 = 0+0,Right Upper Outer Quadrant,1.2,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,pleomorphic infiltrating lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Positive,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Equivocal,0.0,0.0,Allred Score 5,80,90-99%,0,Hercep Test TM DAKO,113.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.9,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.3,3 Point Scale,2+,7thStage IAT1cN0 (i-)MX,YES,NO,NO,12,11,2013,TCGA-LL-A740-F650591639524D-0C7A-4F66-8F84-322D2A41C448NONOYESTUMOR FREEAlive441NO1892014,NOTCGA-LL-A740-D51204FFDC6873-66C3-41A3-9043-746A13AF38C6122164ChemotherapyADRIAMYCINNOComplete Response12112013NOTCGA-LL-A740-D5120553BF41C6-4FAA-40E5-80B2-E3ED637A4E30122164ChemotherapyCYTOXANNOComplete Response12112013NOTCGA-LL-A740-D6506225DBA480-441A-4F69-9824-94ADC2AACDB4178255ChemotherapyTAXOLNOComplete Response1892014,TCGA-A7-A26F-R294081A7DD856-99F0-40D6-90A7-1BA2202515F0178224EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO11632012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,34.0,WHITE,TCGA-AC-A3TN,AC,A3TN,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,2.0,H-Score 150,allred score 5+3+8,Right,1.4310937500000105,Sentinel lymph node biopsy plus axillary dissection,Pateys surgery,Simple Mastectomy,Reexcision,Other,surgical resection,Infiltrating Lobular Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,4+,2+,Positive,Negative,"Other method, specify:","Biopsy, NOS",Indeterminate,Positive,Positive,0.4677734375,0.0,Allred Score 4,Two-tier,10-19%,ACIS,Dako Hecept Test,131.1328125,HER2 amplification - negative,PathVysion,YES,NO,2.5,"Other, specifyskin",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.62,4 Point Scale,1+,7thStage IIBT3N0MX,YES,NO,NO,1,8,2012,TCGA-AC-A3TN-F60190DF2E666E-E3D8-430F-8006-49177FDA1884NOYESYESTUMOR FREEAlive456NO3152014,NOTCGA-AC-A3TN-D6019266521E70-01FD-49E2-B58C-E2A9B05E4F2C55Hormone TherapyArimidexYES3152014,TCGA-AC-A3TN-R60191F59786E2-ADDA-4D6F-AD25-572BB54CEA1E96144External6040cGyPrimary Tumor FieldNOComplete Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,304.0,WHITE,TCGA-A8-A07W,A8,A07W,No,YES,C50.9,8500/3,C50.9,2009.0,WITH TUMOR,YES,17.8896484375,CAP SCORING GUIDELINE 2010,Allred score 2+3 = 5,Left Upper Outer Quadrant,2.7288476562500006,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.5341796875,5.1748046875,Allred score = 4,230,90-99%,ACIS,Hercep Test TM DAKO,92.931640625,HER2 amplification - negative,PathVysion,NO,YES,33,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.3,3 Point Scale,2+,6thStage IVT2NXM1,YES,NO,PositivePositiveNegativeNegative1.09,25,5,2011,TCGA-A8-A07W-F408354E5B10A4-29A2-4AB4-A3D4-1654295E7FDBNONOYESWITH TUMORAlive304232013,NOTCGA-A8-A07W-D37852F73231E4-FFC8-4EE0-8B3C-49503701A0E1212Hormone TherapyExemestanen/aYES6122012TCGA-A8-A07W-D3785365DF696C-50FD-4538-824D-29D00F8BAB9AChemotherapy6122012,TCGA-AR-A24M-R31289993D8611-83E6-452A-8153-DD07E97149A3172221EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO12742012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1286.0,WHITE,TCGA-GM-A2DH,GM,A2DH,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,2.0,Allred score 5+3=8,CAP scoring guideline 2010,Right Upper Outer Quadrant,1.0,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,1.0,0.0,MODERATE,8,10-19%,0,Dako Hercept test,60.0,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.80,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.80,3 Point Scale,2+,6thStage IT1cN0 (i+)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,29,9,2011,TCGA-GM-A2DH-F4708142FCC169-41BB-48F3-BB58-86689559BD62NONOYESTUMOR FREEAlive2193NO2282013,NOTCGA-GM-A2DH-D47082556C375B-CFAB-497E-AE7A-22BC00FC382686163ChemotherapyTaxolNOComplete Response2282013NOTCGA-GM-A2DH-D47083BA77ECF0-0A86-4F8A-9268-57921470CEC6170233ChemotherapyFluorouracilNOComplete Response2282013NOTCGA-GM-A2DH-D470845D627B00-9BA1-4D32-971B-CCE6AF02327A170233ChemotherapyAdriamycinNOComplete Response2282013NOTCGA-GM-A2DH-D470854B6748E0-604F-422B-9752-189DFFF16BD8170233ChemotherapyCytoxanNOComplete Response2282013,TCGA-A2-A3KD-R30122C063B997-34B9-44F4-B7CA-6F5540ED5D27222272EXTERNAL BEAMADJUVANTNO11422012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A22B,E9,A22B,No,YES,C50.9,8522/3,C50.9,2011.0,TUMOR FREE,YES,4.0,image cytometry,CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.270234375000001,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Re-excision of the inferior margin,Other,Nipple Sparing Total Mastectomy,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Positive,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.0,0.0,Intensity=Strong,allred score = 7,10-19%,Hercep Test  TM Dako,Hercep Test TM DAKO,223.955078125,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,1.67,"Other, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,816,4 Point Scale,1+,7thStage IAT1cN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,2,8,2011,TCGA-E9-A22B-F3066273E4C2B9-86C7-4A6F-8CB5-AAF19812E59EScheduled Follow-up SubmissionNOYESAlive315TUMOR FREENO2172014TCGA-E9-A22B-F397869E2ED482-C9F8-4510-9A4A-BFA94732EE48NONOYESTUMOR FREEAlive692NO122013TCGA-E9-A22B-F644256867212E-A944-4228-844E-00D426464E1FNONOYESTUMOR FREEAlive1167NO292014,1TCGA-E9-A22B-D3066339291295-C212-4E0E-8B9F-08F63DD0A88F7240mg20mg/day50Hormone TherapyTamoxifenADJUVANTPOYES1342012,TCGA-A2-A0YE-R56712fe7a331-456c-44f1-913e-6bb5abdea657225267EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2.0,ASIAN,TCGA-C8-A12Q,C8,A12Q,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,Image Analysis,Image Analysis,Left,1.6019824218749987,Axillary lymph node dissection alone,SN+1 non sentinel node,Other,Reexcision,Modified radical mastectomy,Patey's Surgery,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Positive,Negative,"Other method, specify:",Patey's Surgery,Negative,Negative,Positive,0.60546875,6.4013671875,Allred Score 4,allred score = 8,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,82.763671875,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,YES,NO,1.67,BoneLiver,70-79%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.83,4 Point Scale,2+,Stage IIIAT1N2M0,YES,NO,PositivePositiveNegativeNegative1.09,13,4,2011,TCGA-C8-A12Q-F2025384D2BF2F-915F-41A5-8B6E-DE88C2A7A96BScheduled Follow-up SubmissionNONODead385WITH TUMORYESDistant MetastasisLiverNO912012,1TCGA-E9-A22B-D3066339291295-C212-4E0E-8B9F-08F63DD0A88F7240mg20mg/day50Hormone TherapyTamoxifenADJUVANTPOYES1342012,TCGA-A2-A0YE-R56712fe7a331-456c-44f1-913e-6bb5abdea657225267EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO18122010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,1249.0,WHITE,TCGA-A8-A06T,A8,A06T,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,13.029296875,allred score 5+3=8,Allred score 7 per outside facility report,Left Upper Outer Quadrant,2.462392578125,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.291015625,3.599609375,Allred Score,Allred score 8,90-99%,Hercep Test  TM Dako,Hercep Test TM DAKO,95.7939453125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,78,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,185,3 Point Scale,2+,6thStage IIIAT3N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A06T-F40816989E9C4A-0708-4FBE-BC59-EFEB8FBA5FBBNONOYESTUMOR FREEAlive1614232013,NOTCGA-A8-A06T-D37762686C3C70-6D5F-4633-B169-6268CF0EF5A70Hormone TherapyAnastrozolen/aYES6122012,TCGA-BH-A0DS-R45709D8636BF-0DD9-40C4-830F-ACEF70BE5B34245EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTYES122112010
TCGAFPPP,Breast,No,FEMALE,Dead,468.0,788.2431640625,WHITE,TCGA-BH-A18N,BH,A18N,No,YES,C50.9,8500/3,C50.9,2001.0,WITH TUMOR,YES,26.0,Allred score 4+3=7,H-SCORE 290,Left,2.078574218749999,Axillary lymph node dissection alone,SN+1 non sentinel node,Modified Radical Mastectomy,Reexcision,Other,biopsy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,2.0,2.0,Allred score = 5,8,10-19%,ACIS,+ or -,75.005859375,HER2 amplification - negative,>2.2 Positive,NO,YES,2.13,BoneLiver,80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,1.67,3 Point Scale,2+,Stage IIAT2N1bM0,NO,NO,NONO,15,6,2011,TCGA-BH-A18N-F591532F3D622E-63F7-4090-9D6F-974AA4A2CCABNONONODead468152014,1TCGA-E9-A22B-D3066339291295-C212-4E0E-8B9F-08F63DD0A88F7240mg20mg/day50Hormone TherapyTamoxifenADJUVANTPOYES1342012,TCGA-AR-A0U1-R185232FB31685-A717-4F66-94C3-D496AC6DD159152200EXTERNAL BEAM6080cGy33Primary Tumor FieldADJUVANTNO115122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,78.0,WHITE,TCGA-BH-A0DS,BH,A0DS,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,H-SCORE 190,H-SCORE 162,Right Upper Inner QuadrantRight Lower Inner QuadrantRight,1.6610449218750087,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Apocrine,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.6943359375,8.0,H-SCORE,H-SCORE,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.939453125,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,4,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,3.53,3 Point Scale,2+,7thStage IIIAT2N2aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-BH-A0DS-F45732A2365B3-1F58-4BEF-B339-62EC3E2DF7E078AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0DS-D4565BD1D875E-B540-4026-831D-F6E299CD76BE447ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO171120101TCGA-BH-A0DS-D456765485195-3F60-4437-BB26-7445C4269376478ChemotherapyTAXOTEREADJUVANTIVNO17112010,TCGA-BH-A0DS-R45709D8636BF-0DD9-40C4-830F-ACEF70BE5B34245EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTYES122112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2134.0,WHITE,TCGA-AR-A0U1,AR,A0U1,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,31.0,H-SCORE 300,CAP scoring guideline 2010,Left Upper Outer Quadrant,7.1192480468749695,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,wide local excision,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,4+,1+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Negative,Negative,0.0263671875,1.0,Allred score = 7,Two-tier,30-39%,Dako,CAP scoring guideline 2010,256.2060546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.57,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.0,3 Point Scale,0,6thStage IIBT2N1M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,2,2011,TCGA-AR-A0U1-F1852293833C57-FF00-4C8F-A42B-E8955E57E2DFScheduled Follow-up SubmissionYESYESAlive2134NO15122011TCGA-AR-A0U1-F49477E66A8970-F7F3-4E60-BDA5-3E9DC9624B3AYESYESTUMOR FREEAlive3101NO2102013TCGA-AR-A0U1-F71729055E3024-866F-4E2A-BA13-31E14C4DEC7FNOYESYESTUMOR FREEAlive4052NO3032015,1TCGA-AR-A0U1-D19569257BEE3C-93D1-422F-8D83-C9A0D7BF86ADChemotherapyPaclitaxelADJUVANTNO151220111TCGA-AR-A0U1-D19568449863BE-C8F7-4FFC-BF24-F45FC0017C16ChemotherapyCytoxanADJUVANTNO151220111TCGA-AR-A0U1-D19567128732AA-7BD1-4411-94E4-8EE57ED82476ChemotherapyDoxorubicinADJUVANTNO15122011,TCGA-AR-A0U1-R185232FB31685-A717-4F66-94C3-D496AC6DD159152200EXTERNAL BEAM6080cGy33Primary Tumor FieldADJUVANTNO115122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5677.0,WHITE,TCGA-B6-A0X1,B6,A0X1,No,YES,C50.9,8500/3,C50.9,1994.0,TUMOR FREE,YES,21.0,Image Analysis,Image Analysis,Left,2.057519531249996,Axillary lymph node dissection alone,SN+1 non sentinel node,Other,Reexcision,Modified radical mastectomy,Fine needle aspiration biopsy,Infiltrating Ductal Carcinoma,Invasive Papillary,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,4+,2+,Negative,Negative,Fine needle aspiration biopsy,"Biopsy, NOS",Positive,Negative,Equivocal,0.38671875,16.0,Allred score = 5,270 H,10-19%,ACIS,CAP scoring guideline 2010,90.388671875,Vysis AutoVysion System,Ratio >=2.2,NO,YES,69,BoneLiver,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,118,4 Point Scale,2+,4thT2N1M1,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",14,12,2010,TCGA-B6-A0X1-F15717B60E0EDC-7C1B-48E9-AEA3-2D6C0B1A99DBScheduled Follow-up SubmissionNOYESAlive5677TUMOR FREEYES490Distant MetastasisBrainNOYESYES2982011TCGA-B6-A0X1-F71498B774767E-92CC-4BD1-A7EE-6615FE09C623NONONOTUMOR FREEDead7455NO2632015,3TCGA-A2-A1G6-D1253703170c14-0cc8-47b8-8211-e7feae86ed653132172ChemotherapyDocetaxelADJUVANTIVNO28420111TCGA-A2-A1G6-D12532b86d0b45-cd36-46d7-9964-b170549420ac469119ChemotherapyAdriamycinADJUVANTIVNO28420112TCGA-A2-A1G6-D1253557fef464-1259-484f-8b66-7473fa062401469119ChemotherapyCytoxanADJUVANTIVNO2842011,TCGA-BH-A0DS-R45709D8636BF-0DD9-40C4-830F-ACEF70BE5B34245EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTYES122112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1437.0,WHITE,TCGA-A1-A0SH,A1,A0SH,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,2.0,H-SCORE 300,H-Score 290,Left Upper Inner Quadrant,1.4,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Modified radical mastectomy,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,Ductal partially papillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Negative,Negative,Equivocal,0.0009765625,0.0,Allred score 5,8,30-39%,0,Hecep Test TM DAKO,88.5810546875,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.8,"LungBoneLiverOther, specifyskin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.5,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",6,12,2010,TCGA-E2-A1AZ-F1946263961B20-F6AE-45FA-B444-3430F85E6CBFScheduled Follow-up SubmissionYESYESAlive2329NO6122011,1TCGA-A1-A0SH-D448813E24868-A281-4960-AF6C-21F950AF311B4102179ChemotherapyTCADJUVANTIVNO7122010,TCGA-AC-A3TN-R60191F59786E2-ADDA-4D6F-AD25-572BB54CEA1E96144External6040cGyPrimary Tumor FieldNOComplete Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1247.0,WHITE,TCGA-BH-A0H9,BH,A0H9,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,1.0,H-SCORE 140,Allred 8 = 5+3,Right Upper Outer QuadrantRight,1.5,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.306640625,0.0,Allred Score 3,Strong,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.98,"LungBoneLiverOther, specifyskin",90-99%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,3.43,3 Point Scale,1+,Stage IIAT2N0 (i-)M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,17,11,2010,TCGA-BH-A0H9-F4703F47167AF-0722-4448-88DC-80918DF82E281247AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0H9-D4699DA3E47E4-D137-485D-BB51-268013C132C21mg/day101Hormone TherapyArimidexADJUVANTPOYES17112010,TCGA-BH-A0H9-R47012EBAC797-F05A-4DEA-A427-709B2D7D5B39225263EXTERNAL BEAM6300cGy35Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,72.0,WHITE,TCGA-BH-A0HL,BH,A0HL,No,YES,C50.9,8503/3,C50.9,2009.0,TUMOR FREE,YES,17.0,H-SCORE 295,H-SCORE 200,Right Lower Inner QuadrantRight Lower Outer QuadrantRight,0.99,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.673828125,2.0,H-SCORE,H-SCORE,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.0,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,2.25,"LungBoneLiverOther, specifyskin",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.23,3 Point Scale,3+,Stage IIBT2N1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,10,11,2010,TCGA-BH-A0HL-F4792AE1F5D23-CBC5-4BC8-9B75-9EC9624A5E3472AliveTUMOR FREENOYES16112010,1TCGA-BH-A0HL-D47852320DBDB-D9E1-4E90-B4E3-9D754C69377B4800mg1200mg472135ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO181120101TCGA-BH-A0HL-D478386629B94-BA88-49F7-8D40-3226D6F4AE4B480mg120mg472135ChemotherapyDOXORUBICINADJUVANTIVNO181120101TCGA-BH-A0HL-D4775FE6D45BC-6826-4206-A202-F4B08A55B85B1mg/day492Hormone TherapyARIMIDEXADJUVANTPOYES221120101TCGA-BH-A0HL-D47876C6B9022-14ED-4E07-9EF6-71CDD596E65Fmg4156237ChemotherapyTAXOTEREADJUVANTIVNO22112010,TCGA-AO-A1KT-R9906e031925b-8fc6-4d32-9a26-d3fdf0ae7662238280EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1142011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1965.0,WHITE,TCGA-E2-A1AZ,E2,A1AZ,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,3.0,CAP SCORING GUIDELINE 2010,H-Score 290,Left Upper Inner Quadrant,0.42,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Indeterminate,0.3134765625,1.0,0%,Allred Score 7,90-99%,Dako,CAP SCORING GUIDELINE 2010,113.9130859375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4,"Other, specifyaxilaary node negative but intrammary node positive",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",25,4,2011,TCGA-E2-A1AZ-F1946263961B20-F6AE-45FA-B444-3430F85E6CBFScheduled Follow-up SubmissionYESYESAlive2329NO6122011,1TCGA-E2-A1AZ-D19468A7A7027F-58E3-4B34-B912-C6A0C84BECC8460mg115mg461121ChemotherapyAdriamycinADJUVANTIVNO61220111TCGA-E2-A1AZ-D1947664F31114-ABD4-4E0D-BAAD-06531F01F8A04500mg1125mg461121ChemotherapyCytoxanADJUVANTIVNO6122011,TCGA-E2-A1AZ-R194792A546C14-A33E-4C74-BA07-B68C803BD4AA167211EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO16122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,30.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A42T,BH,A42T,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,2.0,Allred score 4+3=7,Allred score 5+3= 8,Left,1.8303710937500055,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Reexcision,Other,biopsy,Infiltrating Lobular Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Equivocal,Positive,Positive,1.0,4.1650390625,<10%,moderately to strongly,10-19%,ACIS,Hercep Test TM DAKO,138.4736328125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,58,"LungBoneLiverOther, specifyskin",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.57,3 Point Scale,2+,7thStage IIAT2N0 (i+)M0,NO,NO,NO,28,9,2012,TCGA-BH-A42T-F6192294A68C9F-6AE9-4265-8FB9-C05BC75D0B91NONONOTUMOR FREEDead320NO1072014,1TCGA-BH-A0H9-D4699DA3E47E4-D137-485D-BB51-268013C132C21mg/day101Hormone TherapyArimidexADJUVANTPOYES17112010,TCGA-A8-A06X-R381790E1337C9-4541-4CCF-B78A-A3CF4F763A066192External52GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,210.0,WHITE,TCGA-D8-A27G,D8,A27G,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,31.0,manual counting,manual counting,Left Lower Outer Quadrant,1.349746093749996,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,surgical resection,Infiltrating Lobular Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,0.0,0.0,>75%,>75%,30-39%,Hercep Test  TM Dako,Dako Hercept test,60.021484375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,1.45,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,not amplified,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",18,7,2011,TCGA-D8-A27G-F29519370A2AC1-5396-4903-BD8B-07F1F32B4725Scheduled Follow-up SubmissionNONOAlive409TUMOR FREENO2132012,1TCGA-E2-A156-D187879FA71240-8DEF-42FE-9235-91CC3980DDF71mg/day1mg/day119Hormone TherapyArimidexADJUVANTPOYES8112011,TCGA-D8-A1JG-R14062C24109D8-C044-41DF-BAF0-A3B8FC106D1B131156EXTERNAL BEAM42.5+10cGy21Primary Tumor FieldADJUVANTNO11872011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,257.0,WHITE,TCGA-A7-A26F,A7,A26F,No,YES,C50.9,8575/3,C50.9,2010.0,TUMOR FREE,YES,1.0,Allred (Biocare),Allred score 5+3 = 8,Left,1.1,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Re-excision of the inferior margin,Modified radical mastectomy,EXCISION WITH NEEDLE WIRE LOCALIZATION,"Other, specify","Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Close,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Negative,Equivocal,0.3984375,0.0,Allred Score 5,8,10-19%,CISH,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,330.0,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,YES,NO,1.8,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.9,3 Point Scale,2+,7thStage IAT1N0M0,NO,YES,YES994Distant MetastasisBoneNOYESYES,8,8,2011,TCGA-A7-A26F-F29372CE91BB2A-703B-4B86-8623-955310BB6B5AScheduled Follow-up SubmissionYESYESAlive459TUMOR FREENO1632012TCGA-A7-A26F-F3849929E46924-1FDE-481F-BD36-F129490E2FD3NOYESYESTUMOR FREEAlive738NO14122012,1TCGA-A7-A26F-D15010C3FD872C-2A13-45EF-9151-361979053F67600mg150mg477140ChemotherapyTaxotereADJUVANTIVNO11820111TCGA-A7-A26F-D1501152516E85-91DF-4339-92FC-15606CA088754800mg1200mg477140ChemotherapyCytoxanADJUVANTIVNO1182011,TCGA-A7-A26F-R294081A7DD856-99F0-40D6-90A7-1BA2202515F0178224EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO11632012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3324.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A42U,BH,A42U,No,YES,C50.9,8520/3,C50.9,2004.0,TUMOR FREE,YES,1.0,H-Score 270,PR Negative H-Score 0,Right,2.1509082031250046,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,Re-excision of the inferior margin,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Lobular Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Positive,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Negative,Negative,0.2197265625,0.0068359375,allred score = 8,allred score = 7,90-99%,Hercep Test  TM Dako,Dako Hecept Test,179.685546875,HER2 amplification - negative,PathVysion,YES,NO,54,"Other, specifyskin",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,131,3 Point Scale,1+,6thStage IIAT2N0M0,NO,NO,NO,1,10,2012,TCGA-BH-A42U-F6192319515634-4B7A-46FC-8FFD-C9C2EB15C93ANONONOTUMOR FREEAlive3364NO1072014,1TCGA-E2-A1IO-D20320BFC8334A-C530-4EE0-860A-3473046CCE9F462mg115.5mg484147ChemotherapyDocetaxelADJUVANTIVNO4120121TCGA-E2-A1IO-D203195CAD1231-055C-4E7F-AA97-689B30AEE8873696mg924mg484147ChemotherapyCyclophosphamideADJUVANTIVNO4120122TCGA-E2-A1IO-D2032107023BDC-054F-4A18-BA92-A01D49FC2F1D20mg/day20mg/day266Hormone TherapyTamoxifenADJUVANTPOYES412012,TCGA-A2-A0YE-R56712fe7a331-456c-44f1-913e-6bb5abdea657225267EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Dead,943.0,454.92578125,WHITE,TCGA-A8-A06X,A8,A06X,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,16.08984375,Allred score 5+3=8,H-Score 290,Right Upper Outer Quadrant,1.6485937499999956,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Positive,Positive,Positive,0.3271484375,2.98828125,Allred Score,230,10-19%,Hercep Test  TM Dako,Dako Hecept Test,132.2705078125,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,78,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,131,3 Point Scale,2+,6thStage IIBT3N0M0,YES,NO,PositivePositiveNegativeNegative,27,5,2011,TCGA-A8-A06X-F408181791687B-A509-4CA3-B10E-4EDB80B779B6NOYESTUMOR FREEDead943232013,NOTCGA-S3-A6ZG-D510884FFDEFCC-4989-4FE3-9F8C-2F66D9CD5EF852100ChemotherapyDoxorubicinNOComplete Response12112013NOTCGA-S3-A6ZG-D510899C1469D0-34BE-4520-A928-C8222B9AA84A52100ChemotherapyCytoxanNOComplete Response12112013NOTCGA-S3-A6ZG-D51090592DBC73-6BBC-49B6-8C4D-DE2812D431D8116221Hormone TherapyTaxolNOComplete Response12112013YESTCGA-S3-A6ZG-D636499E65EFA0-05D8-47EB-A1E0-6E44A31DBA3D256Hormone TherapyAnastrozoleYES2782014NOTCGA-S3-A6ZG-D64188CE65FD9A-E5F7-42B1-8603-9979F90ABD5F52100AncillaryNEULASTANOComplete Response2782014,TCGA-A8-A06X-R381790E1337C9-4541-4CCF-B78A-A3CF4F763A066192External52GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,541.0,WHITE,TCGA-AO-A1KT,AO,A1KT,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,5.0,H-Score 150,dextran coated charcoal,Left Upper Outer QuadrantLeft,1.4,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Reexcision,Other,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,1.0,1.0,Two-tier,205,10-19%,ACIS,CAP SCORING GUIDELINE 2010,40.0,HER2 amplification - negative,>2.2 Positive,NO,YES,1.7,"Other, specifyskin",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.4,4 Point Scale,4+,6thStage IIAT1N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,1,4,2011,TCGA-AO-A1KT-F9905F0B207F5-C16E-4C68-98E9-69D908E9DFB5541AliveTUMOR FREEYESYES142011,1TCGA-AO-A1KT-D99109e5254ab-c0ac-4253-bf73-2858ca59bc891mg/day323Hormone TherapyArimidexADJUVANTPOYES1420111TCGA-AO-A1KT-D99074daf246a-634a-4387-94f0-f90e6ef5ed438448mg600mg/m2862209ChemotherapyFluorouracilADJUVANTIVNO1420111TCGA-AO-A1KT-D99096667d908-2ed7-4435-b5ed-adee0dae9f78560mg40mg/m2862209ChemotherapyMethotrexateADJUVANTIVNO1420111TCGA-AO-A1KT-D99088515c4c8-a540-40dd-a831-e564158b5a238448mg600mg/m2862209ChemotherapyCyclophosphamideADJUVANTIVNO142011,TCGA-AO-A1KT-R9906e031925b-8fc6-4d32-9a26-d3fdf0ae7662238280EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1142011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,791.0,WHITE,TCGA-WT-AB44,WT,AB44,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,4.0,Allred 0 = 0+0,Allred score 2+3 = 5,Left,1.9337792968750056,No axillary staging,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Lobular Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Negative,0.267578125,0.0,Allred score = 7,190,90-99%,CISH,+ or -,161.4404296875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,54,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,52,3 Point Scale,3+,7thStage IAT1cN0 (i-)MX,YES,YES,NO,16,7,2014,TCGA-WT-AB44-F666400A7190BA-575B-41F4-8F55-012383288578NOYESYESTUMOR FREEAlive883NO21102014,NOTCGA-WT-AB44-D62427670B2675-CB98-412D-B3C0-FE647880FDCA31Hormone TherapyArimidexYES1672014,TCGA-WT-AB44-R62428491AD153-4239-4288-A7BE-B32A0155FEB492153External6040cGy33Primary Tumor FieldNOComplete Response1672014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,242.0,WHITE,TCGA-AN-A0FJ,AN,A0FJ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,dextran coated charcoal,dextran coated charcoal,Left Upper Outer Quadrant,2.6253808593749994,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,1+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Positive,Positive,Positive,0.0,8.0,Allred score 8,Intensity=Strong,40-49%,0,dextran coated charcoal,183.3466796875,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,1.5,LungBone,10-19%,<10%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,66,3 Point Scale,0,Stage IVT2N2M1,NO,NO,YES994Distant MetastasisBoneNOYESYES,27,12,2010,TCGA-AN-A0FJ-F689506A061E72-8985-4C17-AB5A-BAE6F2AAEB10YESNONOTUMOR FREEAlive24223122014,2TCGA-A2-A04R-D255380d22cd5-ee42-4e09-b192-f6b2183cf0b34800mg1200mg4119184ChemotherapyCYTOXANADJUVANTIVNO121020103TCGA-A2-A04R-D2554575ace17-a333-4457-837f-9f4210296cb5480mg120mg4119184ChemotherapyAdriamycinADJUVANTIVNO121020105TCGA-A2-A04R-D2556258814a0-8e67-4ac2-84ec-1353588f2f9d1mg/day910Hormone TherapyAnastrozoleADJUVANTPOYES121020104TCGA-A2-A04R-D255559cf62c8-9052-43df-aefa-ea940996727a20mg/day399909Hormone TherapyTamoxifenADJUVANTPONO121020101TCGA-A2-A04R-D25527430b157-f641-4b64-86b4-38f47b845980354mg354mg14545ChemotherapyTAXOLADJUVANTIVNO12102010,TCGA-A8-A08L-R38161D73DFE9C-A7EF-4DD0-8879-04052984D07D3030External45GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,747.0,WHITE,TCGA-BH-A0H6,BH,A0H6,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,0.0,H-SCORE 230,H-SCORE 250,Right Upper Inner QuadrantRight Upper Outer QuadrantRight,1.87675781250001,No axillary staging,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive mixed ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,0.0,H-SCORE,H-SCORE,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,134.5859375,Vysis AutoVysion System,Ratio >=2.2,NO,YES,33,"Other, specifyskin",50-59%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,>6,3 Point Scale,3+,Stage IT1bNXM0,NO,NO,PositivePositiveNegativeNegative1.09,10,11,2010,TCGA-BH-A0H6-F4711529564A6-8E4A-4B86-A79C-43009E0AB551747AliveTUMOR FREEYESYES16112010,TCGA-E9-A1RA-D305470CAD78B5-EA56-4810-802C-C8376A508B74380mg100mg41080ChemotherapyDoxorubicinADJUVANTIVNO1242012TCGA-E9-A1RA-D305521A3D7515-4506-4F8C-AA69-7638A7FE0EAD20mg/day9Hormone TherapyTamoxifenADJUVANTPOYES1242012TCGA-E9-A1RA-D30550AFDB7AB8-943C-45D1-8584-CD15359E6AA54000mg1000mg41080ChemotherapyCyclophosphamideADJUVANTIVNO1242012,TCGA-BH-A0H6-R470730C78395-364D-4EDC-97D5-D54F537597586497EXTERNAL BEAM5208cGy20Primary Tumor FieldADJUVANTNO122112010
TCGAFPPP,Breast,No,FEMALE,Dead,0.0,4520.8974609375,WHITE,TCGA-B6-A0IC,B6,A0IC,No,YES,C50.9,8503/3,C50.9,1992.0,TUMOR FREE,YES,16.0810546875,IHC,IHC,Right,1.941982421875,No axillary staging,axillary ultrasound,Other,Reexcision,Modified radical mastectomy,Excisional biopsy,"Other, specify",Invasive Papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Positive,Negative,Fine needle aspiration biopsy,"Biopsy, NOS",Positive,Positive,Equivocal,0.8388671875,3.28515625,230,moderate,10-19%,ACIS,DAKOHercepTest TM,229.044921875,Vysis AutoVysion System,PathVysion Her-2 DNA,NO,YES,54,"Other, specifyskin",80-89%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,<4.0,4 Point Scale,1+,3rdStage XT2NXMX,NO,NO,NONO,2,11,2010,TCGA-B6-A0IC-F12613CF95FD2E-C76A-41EB-9F33-EBE7067B8203Scheduled Follow-up SubmissionNONODead0TUMOR FREENO162011,TCGA-EW-A1P0-D2966882BB1AF4-6610-45A8-BCFE-5A38D177760E1mg/day10331245Hormone TherapyArimidexADJUVANTPONO832012,TCGA-AR-A0U1-R185232FB31685-A717-4F66-94C3-D496AC6DD159152200EXTERNAL BEAM6080cGy33Primary Tumor FieldADJUVANTNO115122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,252.0,WHITE,TCGA-EW-A1IW,EW,A1IW,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,10.0,H-SCORE 280,image cytometry,Right Lower Inner QuadrantRight Lower Outer Quadrant,2.949736328125021,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,total mastectomy,Infiltrating Lobular Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Positive,0.0,2.0,Allred score 7 per outside facility report,130,90-99%,CISH,+ or -,112.7841796875,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,1.45,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.62,3 Point Scale,3+,7thStage IIBT2N1aMX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-EW-A1IW-F21380F2B8499E-0A1A-45DA-86EA-531D38617555Scheduled Follow-up SubmissionNOYESAlive371TUMOR FREENO622012,TCGA-EW-A1IW-D211786E6AFF49-706F-44B0-8ED2-F4AB626A549125mg/day671Hormone TherapyAromasinADJUVANTPOYES1022012,TCGA-EW-A2FR-R32312832B0491-C707-42CA-AFC9-E9F3E321C30EEXTERNAL BEAMPrimary Tumor FieldADJUVANTNO12352012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,265.0,WHITE,TCGA-D8-A1JL,D8,A1JL,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,manual counting,manual counting,Left Lower Inner Quadrant,1.805439453124992,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,1+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Negative,Negative,0.201171875,0.0,0%,0%,90-99%,FISH,DAKOHercepTest TM,138.41015625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,4,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,3.0,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",29,3,2011,TCGA-D8-A1JL-F20747DCA53598-A604-4C2E-BC24-67A6AD8B8D49Scheduled Follow-up SubmissionNOYESAlive611TUMOR FREENO1512012,TCGA-EW-A1IW-D211786E6AFF49-706F-44B0-8ED2-F4AB626A549125mg/day671Hormone TherapyAromasinADJUVANTPOYES1022012,TCGA-E9-A1RF-R3063810729565-ADC4-4C6F-891E-1606E11ABA81118144EXTERNAL BEAM3740cGyRegional siteADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,148.0,WHITE,TCGA-A7-A3IZ,A7,A3IZ,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,1.0,H-SCORE 0,H-SCORE 0,Right,1.0,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Lumpectomy,Reexcision,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,1.0,2.1123046875,Two-tier,H score,30-39%,ACIS,Hercep Test  TM Dako,569.0,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,3.0,"Other, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.0,3 Point Scale,2+,7thStage IIAT2N0 (i+)M0,YES,NO,NO,12,3,2012,TCGA-A7-A3IZ-F3449169577EC0-0532-4A9C-BCBA-5A79E096D13BNOYESYESTUMOR FREEAlive322NO1682012,1TCGA-A7-A3IZ-D29226D6D7C497-BCC6-4864-94CB-FCD2B53EC7B64000mg1000mg473134ChemotherapyCytoxanADJUVANTIVNO12320121TCGA-A7-A3IZ-D29225A1B93297-6E83-4565-943F-92213D0BA738522mg129-131mg473134ChemotherapyTaxotereADJUVANTIVNO1232012NOTCGA-A7-A3IZ-D34493D4791F16-F661-488F-9546-AE3B6AC25372124Hormone TherapyAnastrozoleYES1682012,TCGA-A7-A3IZ-R34492B45436BD-3C65-4EC5-9C41-1D009B1E0435181226External6100cGy33Primary Tumor FieldNOComplete Response1682012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1209.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3XW,A2,A3XW,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,18.0,H-Score 280,IMAGE ANALYSIS,Right,1.31,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Other,Right total mastectomy with lymph node left axillary lymph node excision,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,3.0,240 H,Two-tier,<10%,Hercep Test  TM Dako,Dako Hecept Test,172.3583984375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,69,"Other, specifyskin",90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.3,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,NO,15,8,2012,TCGA-A2-A3XW-F433081833A0D9-50FC-4878-803D-9D8BDDA26F14NOYESYESTUMOR FREEAlive1505NO1652013TCGA-A2-A3XW-F558430965C5D1-3E7F-4325-8355-E437AA49DB2BNOYESYESTUMOR FREEAlive1712NO1612014,YESTCGA-A2-A3XW-D344315DE33005-8993-4B5B-8D3A-F74A18EAE60069139ChemotherapyAdriamyicinNOComplete Response1582012YESTCGA-A2-A3XW-D34432FBBE5DDA-17FD-4605-B38C-1F391379A51469139ChemotherapyCyclophosphamideNOComplete Response1582012YESTCGA-A2-A3XW-D3443317ED55A4-16C3-4F43-8986-3714A71F0F78153223ChemotherapyTaxolNOComplete Response1582012YESTCGA-A2-A3XW-D344345E8166C0-1206-4A0B-9FC3-806B511A494D341Hormone TherapyTamoxifenYES1582012,TCGA-A2-A3XW-R3443555FB44FC-EA5B-4AB8-BA96-EFED1BD9AE21265308External5040cGy28Primary Tumor FieldNOComplete Response1582012TCGA-A2-A3XW-R34436D8B2A178-D939-450D-8DCA-F834111F718B265308External5040cGy28Regional siteNOComplete Response1582012
TCGAFPPP,Breast,No,FEMALE,Dead,1694.0,852.8388671875,WHITE,TCGA-BH-A1EW,BH,A1EW,No,YES,C50.9,8500/3,C50.9,1999.0,WITH TUMOR,YES,16.0,Allread score 5+3 = 8,H-Score 190,Left Upper Outer Quadrant,2.6420019531249896,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Reexcision,Modified radical mastectomy,Left segmental mastectomy with level 1 and level 2 axillary dissection,Infiltrating Ductal Carcinoma,Apocrine,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,4 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Negative,Negative,1.109375,1.0,Allred score = 7,Allred Score 6,10-19%,ACIS,+ or -,198.486328125,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,54,BoneLiver,10-19%,30-39%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,3.65,3 Point Scale,2+,5thStage IIAT2N1bM0,NO,NO,PositivePositiveNegativeNegative,7,9,2011,TCGA-E9-A1R4-F3053533A6D6A9-9F24-4721-8CE5-F64203765025Scheduled Follow-up SubmissionYESYESAlive186TUMOR FREENO1242012TCGA-E9-A1R4-F48699F48BBDBA-2E52-4977-B5C5-4644216DD354YES1992013,TCGA-EW-A1IW-D211786E6AFF49-706F-44B0-8ED2-F4AB626A549125mg/day671Hormone TherapyAromasinADJUVANTPOYES1022012,TCGA-E2-A1AZ-R194792A546C14-A33E-4C74-BA07-B68C803BD4AA167211EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO16122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,29.0,WHITE,TCGA-E9-A1R4,E9,A1R4,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,Allred (Biocare),image cytometry,Left Upper Outer Quadrant,2.4030371093749925,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,surgical resection,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,1+,Negative,Negative,"Other method, specify:",Lumpectomy,Negative,Negative,Equivocal,0.0693359375,0.0,Allred score = 7,120,10-19%,Hercep Test  TM Dako,Dako Hecept Test,196.501953125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,118,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,185,4 Point Scale,1+,7thStage IAT1cN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-E9-A1R4-F3053533A6D6A9-9F24-4721-8CE5-F64203765025Scheduled Follow-up SubmissionYESYESAlive186TUMOR FREENO1242012TCGA-E9-A1R4-F48699F48BBDBA-2E52-4977-B5C5-4644216DD354YES1992013,TCGA-E9-A1R4-D305413B9C6105-0363-4B73-BD5F-CE0FB88008F320mg/day12Hormone TherapyTamoxifenADJUVANTPOYES1242012TCGA-E9-A1R4-D3053848222E9D-20E8-452B-8E46-E5FA688812434000mg2000mg2945Chemotherapy5-FluorouracilADJUVANTIVNO1242012TCGA-E9-A1R4-D305374D26049E-F78C-4164-BDC1-E00DB74121E8200mg100mg2945ChemotherapyMethotrexateADJUVANTIVNO1242012TCGA-E9-A1R4-D305368102DE2B-8388-4BD3-8699-A8575DAE40A44000mg2000mg2945ChemotherapyCyclophosphamideADJUVANTIVNO1242012,TCGA-E9-A1R4-R30543831EC698-4241-43B9-B8DD-2281430ED0B2125155EXTERNAL BEAM4600cGy23Primary Tumor FieldADJUVANTNO11242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,140.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A1J2,EW,A1J2,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,21.0,H-SCORE 0,CAP scoring guideline 2010,Right Lower Inner Quadrant,1.8526562499999912,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and axillary lymph node biopsy,Other,Right Breast reexcision,Modified radical mastectomy,total mastectomy,Infiltrating Lobular Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,1.0,1.0,Allred Score 6,Allred Score 6,<10%,CISH,Dako Hecept Test,186.4853515625,HER2 amplification - negative,PathVysion,NO,YES,64,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,131,3 Point Scale,3+,7thT1cN1miMX,YES,NO,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-EW-A1J2-F21544D0492C5F-C48F-4FF0-92F1-074003210DFEScheduled Follow-up SubmissionNOYESAlive403TUMOR FREENO622012,TCTCGA-EW-A1J2-D216140BA44965-31D8-40C3-B712-C60B3D7BA6E7135mg476140ChemotherapyTaxotereADJUVANTIVNO1622012TCGA-EW-A1J2-D21615D15551D0-9A3A-448E-9FAF-EEB581FFD0771mg/day150Hormone TherapyArimidexADJUVANTPOYES1622012TCTCGA-EW-A1J2-D292667CC33BB1-6AF2-42C9-9E77-17C799E6CB7E1080mg476140ChemotherapyCytoxanADJUVANTIVNO1332012,TCGA-A2-A0YE-R56712fe7a331-456c-44f1-913e-6bb5abdea657225267EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,806.0,WHITE,TCGA-BH-A0HB,BH,A0HB,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,H-Score 300,H-Score 70,Right Upper Outer QuadrantRight,1.21,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Right Breast reexcision,Modified radical mastectomy,Segmental mastectomy,Infiltrating Ductal Carcinoma,Apocrine,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.3544921875,0.0,H-Score,H-Score,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.0,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,2.13,"LungBoneLiverOther, specifyskin",90-99%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.58,3 Point Scale,1+,Stage IAT1cN0 (i-)M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,10,11,2010,TCGA-BH-A0HB-F4718557DF182-2E69-4738-AAFF-52D3BE340928806AliveTUMOR FREEYESYES16112010,"1TCGA-BH-A0HB-D47096E82BA52-E171-47BE-96D0-A82FDC86A2051mg/day317Hormone TherapyArimidexADJUVANTPOYES171120101TCGA-BH-A0HB-D4710FF1D11E0-7156-4A41-A367-D9A6CCF223CC539mg133mg471134ChemotherapyDocetaxelADJUVANTIVNO181120101TCGA-BH-A0HB-D47127BC6F0D1-914E-49DD-897E-F07AE5696A994326mg1068mg471134ChemotherapyCyclophosphamideADJUVANTIVNO181120101TCGA-BH-A0HB-D471473F72881-D3E3-4B35-B34A-E93F48E3254F48mg4mg12162893Other, specify in notesancillaryZoledronic AcidADJUVANTIVNO18112010",TCGA-BH-A0HB-R47166E84E476-DE82-4DF3-B4A6-C0EA750613AD175221EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,30.0,WHITE,TCGA-A8-A08R,A8,A08R,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,13.970703125,image cytometry,H-Score 190,Left,1.8422558593749965,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Negative,Negative,0.5849609375,1.4521484375,Allred score = 7,STRONG,10-19%,Hercep Test  TM Dako,Dako Hecept Test,188.8447265625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,4,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,441,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-BH-A0HB-F4718557DF182-2E69-4738-AAFF-52D3BE340928806AliveTUMOR FREEYESYES16112010,TCGA-E9-A1R4-D305413B9C6105-0363-4B73-BD5F-CE0FB88008F320mg/day12Hormone TherapyTamoxifenADJUVANTPOYES1242012TCGA-E9-A1R4-D3053848222E9D-20E8-452B-8E46-E5FA688812434000mg2000mg2945Chemotherapy5-FluorouracilADJUVANTIVNO1242012TCGA-E9-A1R4-D305374D26049E-F78C-4164-BDC1-E00DB74121E8200mg100mg2945ChemotherapyMethotrexateADJUVANTIVNO1242012TCGA-E9-A1R4-D305368102DE2B-8388-4BD3-8699-A8575DAE40A44000mg2000mg2945ChemotherapyCyclophosphamideADJUVANTIVNO1242012,TCGA-GI-A2C9-R21683817932FB-2657-4409-8D5B-35D4DDD5E0173342Primary Tumor FieldADJUVANTNO852012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1121.0,WHITE,TCGA-EW-A1P0,EW,A1P0,No,YES,C50.9,8523/3,C50.9,2008.0,WITH TUMOR,YES,21.0,H-SCORE 190,CAP SCORING GUIDELINE 2010,Left Upper Outer Quadrant,2.437753906249991,Axillary lymph node dissection alone,Sentinel lymph node and axillary lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Total mastectomy with sentinel lymph node biopsy,"Other, specify",IDC+ mucinous carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Positive,Positive,Negative,0.7216796875,1.0,Intensity=Strong,Intensity=Strong,<10%,CISH,Hercep Test TM DAKO,211.09765625,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,2.5,BoneLiver,90-99%,<10%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.83,3 Point Scale,3+,6thStage IIBT2N1bMX,NO,NO,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,10,5,2011,"TCGA-EW-A1P0-F2910514E24F35-F5DD-4CE1-B35A-7E14ED9BFFBBScheduled Follow-up SubmissionYESYESAlive1251TUMOR FREEYES1094Distant MetastasisOther, specifymediastinal lymph nodeYES1105NOYESPositiveNegativeNegative832012",TCGA-EW-A1P0-D2966882BB1AF4-6610-45A8-BCFE-5A38D177760E1mg/day10331245Hormone TherapyArimidexADJUVANTPONO832012,TCGA-A7-A26F-R294081A7DD856-99F0-40D6-90A7-1BA2202515F0178224EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO11632012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,134.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A5ZW,A7,A5ZW,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,1.0,allred score 0 + 0 = 0,Allred score 2+3 = 5,Right Upper Outer Quadrant,2.0050683593749983,Sentinel node biopsy alone,SN+1 non sentinel node,Lumpectomy,Reexcision,Other,Right segmental mastectomy with sentinel lymph node and axillary lymph node biopsy,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.3974609375,1.0,allred score = 7,Allred Score 6,10-19%,CISH,Hercep Test TM DAKO,223.9912109375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,69,"Other, specifyskin",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,<4.0,3 Point Scale,3+,7thStage IIAT1cN1aM0,YES,NO,NO,13,5,2013,TCGA-A7-A5ZW-F5150999C27BED-2BF4-4438-BFF1-18A08C754731NOYESYESTUMOR FREEAlive326NO19112013,NOTCGA-A7-A5ZW-D501654AF33B96-C484-42DE-8F9B-AAB6DC4E168D71176ChemotherapyCyclophosphamideNOComplete Response16102013NOTCGA-A7-A5ZW-D50166C795DC4E-1F39-460D-9E49-17CB3709BE9E71176ChemotherapyTaxotereNOComplete Response16102013NOTCGA-A7-A5ZW-D50168D46476DA-66D7-47D9-9AAA-19A388D19BAA269Hormone TherapyTamoxifenYES16102013,TCGA-A7-A5ZW-R501792208C54F-FD2C-457C-A3A5-E5433888EA9E207252External6100cGy33Primary Tumor FieldNOComplete Response16102013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,8.0,WHITE,TCGA-AR-A0U0,AR,A0U0,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,4.0,Allred score 5+3 = 8,Allred score 0+0 = 0,Left Lower Inner Quadrant,1.3743945312500048,Sentinel lymph node biopsy plus axillary dissection,Pateys surgery,Simple Mastectomy,Reexcision,Other,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,2.0,0.0,Allred score = 4,Allred Score 7,90-99%,Dako,Hercep Test  TM Dako,110.58203125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,74,"Other, specifyskin",80-89%,10-19%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,172,3 Point Scale,0,Stage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,7,3,2011,TCGA-AR-A0U0-F185266EC1894A-DB87-4B55-844F-3FE18EC1F09DScheduled Follow-up SubmissionYESAlive1988NO16122011TCGA-AR-A0U0-F65068795958AD-2E03-4480-B9E3-2EDF04451128NOYESTUMOR FREEAlive1988NO1892014,NOTCGA-A7-A5ZW-D501654AF33B96-C484-42DE-8F9B-AAB6DC4E168D71176ChemotherapyCyclophosphamideNOComplete Response16102013NOTCGA-A7-A5ZW-D50166C795DC4E-1F39-460D-9E49-17CB3709BE9E71176ChemotherapyTaxotereNOComplete Response16102013NOTCGA-A7-A5ZW-D50168D46476DA-66D7-47D9-9AAA-19A388D19BAA269Hormone TherapyTamoxifenYES16102013,TCGA-AR-A0U0-R19618DBAB51CF-D502-4C13-9478-26E924967804ADJUVANT116122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,272.0,WHITE,TCGA-D8-A1X8,D8,A1X8,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,11.0,% IHC,%IHC,Left Lower Outer Quadrant,1.974658203124997,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,Excision,Infiltrating Lobular Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Indeterminate,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.0,9.0,>75%,>75%,90-99%,Hercep Test  TM Dako,Dako Hecept Test,101.9755859375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,64,"Other, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,3.3,4 Point Scale,2+,7thStage IIIAT1cN2aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",16,5,2011,TCGA-D8-A1X8-F29428516F8A4D-F178-4835-BF60-28271EF03221Scheduled Follow-up SubmissionYESYESAlive783TUMOR FREENO19102012,TCGA-D8-A1X8-D294292392ED50-8D05-4D26-A5D9-F2EA353735BCmg60+600mg/m223182Chemotherapyadrimicin+cyclophosphamideADJUVANTIVNO1932012,TCGA-D8-A1X8-R2943046DDC44D-57CB-439D-BB1D-66ECCB9B9718209239EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,4.0,ASIAN,TCGA-C8-A130,C8,A130,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,8.0,% IHC,Allred score 0+0 = 0,Left,1.3329003906250012,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Ductal partially papillary,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Negative,Positive,Equivocal,0.62890625,3.333984375,Allred Score 7,Allred Score 7,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,160.595703125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,54,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,131,4 Point Scale,2+,6thStage IIIAT3N2M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,13,4,2011,TCGA-C8-A130-F19091D72089AC-6F2C-4D82-BAF8-B9BC85F4C19EScheduled Follow-up SubmissionNOYESAlive96TUMOR FREENO2122011TCGA-C8-A130-F70814ACA661FA-1BC0-459D-89D8-025D8D39E976NONOTUMOR FREEAlive370NO932015,2TCGA-A2-A0SX-D40248f6e3477-88fd-4f1b-b06f-0e3510b0ac5d600mg100mg662132ChemotherapyAdriamycinADJUVANTIVNO121120101TCGA-A2-A0SX-D401976901188-6afa-4900-ae30-7d296985c5de6000mg1000mg662132ChemotherapyCytoxanADJUVANTIVNO201120103TCGA-A2-A0SX-D4023a0280f47-3ba8-42cf-ab14-ff4fd7db88b02203mg610mg412891359ChemotherapyCarboplatinRECURRENCEIVNO241120104TCGA-A2-A0SX-D402516e4fd14-6c2b-4c7e-964a-c240c2b36ceb7200mg1800mg412891359ChemotherapyGemcitabineRECURRENCEIVNO241120105TCGA-A2-A0SX-D14036634383B8-9F0E-4A8B-84FE-B308540A6F381500-2000mg/day1429ChemotherapyXelodaPROGRESSIONPOYES1152011,TCGA-A2-A0YE-R56712fe7a331-456c-44f1-913e-6bb5abdea657225267EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2876.0,WHITE,TCGA-E2-A1LH,E2,A1LH,No,YES,C50.9,8500/3,C50.9,2002.0,TUMOR FREE,YES,2.0,allred score 5+3=8,Allred 0 = 0+0,Right,1.3900292968750048,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Negative,0.826171875,0.0,0%,0%,90-99%,ACIS,Hercep Test TM DAKO,211.5322265625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,3.0,"Other, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.83,3 Point Scale,2+,5thStage IT1cN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,3,6,2011,TCGA-E2-A1LH-F2064929497476-76A6-4D7C-9478-FBA0801FDFDFScheduled Follow-up SubmissionYESYESAlive3247TUMOR FREENO1212012,1TCGA-E2-A1LH-D20652908E780C-09EB-4CBC-AD5A-75B352A71460441104ChemotherapyAdriamycinADJUVANTNO12120121TCGA-E2-A1LH-D206592D696153-39F9-4F7D-8E35-5B056E1F654F441104ChemotherapyCytoxanADJUVANTNO1212012,TCGA-E2-A1LH-R2066208EE86D2-364F-4AA5-9959-6D8413398AD2147189EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO11212012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,615.0,WHITE,TCGA-AR-A1AY,AR,A1AY,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.0,Allred score 5+3 = 8,Image Analysis,Left Upper Outer Quadrant,1.6088281250000027,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Wide Local Excision,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Negative,Negative,0.232421875,0.0,Allred score = 8,Allred Score 7,10-19%,Hercep Test  TM Dako,CISH,188.58984375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2.13,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.66,3 Point Scale,2+,6thStage IT1N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,14,6,2011,TCGA-AR-A1AY-F21977B606F4FD-7228-4416-8B81-02C8861CF309Scheduled Follow-up SubmissionYESYESAlive1026NO2822012TCGA-AR-A1AY-F49482E5648A84-5439-451B-A1FB-234DA91B8F76NOYESYESTUMOR FREEAlive1026NO2102013,1TCGA-AR-A1AY-D219814898241A-D0FD-474A-AB71-1B9BC5FBE3F14117ChemotherapyDoxorubicinADJUVANTNO28220121TCGA-AR-A1AY-D219824BBF53A3-33EC-452E-ABEB-55BC506B0EBD4117ChemotherapyCytoxanADJUVANTNO2822012,TCGA-AR-A1AY-R21978D74AC1F9-01CC-47D6-8F12-D8FBADBC40A92086040cGy33ADJUVANTNO12822012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,1471.0,WHITE,TCGA-5L-AAT1,5L,AAT1,No,YES,C50.9,8520/3,C50.9,2010.0,WITH TUMOR,YES,1.0,H-SCORE 300,Allred 0 = 0+0,Left,2.169882812499996,Other (specify),Level 1 clearance,Simple Mastectomy,Reexcision,Other,biopsy,Infiltrating Lobular Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Biopsy not specified,Positive,Positive,Equivocal,1.6455078125,0.0,Two-tier,H score,90-99%,CISH,CISH,252.6171875,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,69,Bone,80-89%,10-19%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,105,3 Point Scale,2+,7thStage IVT2N0M1,YES,NO,NO,15,8,2014,TCGA-B6-A0IO-F126262E99B735-8834-4DF8-B3D5-512337319C15Scheduled Follow-up SubmissionNOYESAlive3350TUMOR FREENO262011TCGA-B6-A0IO-F71503E3BA117D-59D6-449B-9AC8-88BECDB2682ANONOYESTUMOR FREEAlive5042NO2632015,NOTCGA-5L-AAT1-D63716747059AE-DC7B-409F-9178-2DD683C19A6F46Hormone TherapyLetrozolYES1582014,TCGA-AR-A2LJ-R3726697483A09-7652-4CE8-940E-A82D5C9F5E30196231External5000cGy25Primary Tumor FieldNO7122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A22H,E9,A22H,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,8.0,H-Score 150,Allred score 5+3=8,Left Upper Outer Quadrant,2.189814453125,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-excision of the inferior margin,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Positive,0.0,1.0,Allred score 5,moderate,<10%,Hercep Test  TM Dako,+ or -,276.236328125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,2.8,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,4 Point Scale,1+,7thStage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,2,8,2011,TCGA-E9-A22H-F29943A7CD3C92-FA95-4FCF-8BDE-2480F7E8E4C0Scheduled Follow-up SubmissionYESYESAlive330TUMOR FREENO2272014TCGA-E9-A22H-F4064296EF7CF3-8F22-4C87-873C-B9949AF32410NOYESYESTUMOR FREEAlive630NO2622013TCGA-E9-A22H-F632247BF83619-D8BE-48D5-A1F5-A812D36024B4NOYESYESTUMOR FREEAlive1232NO482014,TCGA-E9-A22H-D29944F67CF379-4420-4D5D-8FEC-0FD435A79B193600mg90mg/day615226ChemotherapyDoxorubicinADJUVANTIVNO3032012TCGA-E9-A22H-D29947FA024AFC-6558-412D-81F5-3D0FD0A1566B130mg20mg/day330Hormone TherapyTamoxifenADJUVANTPOYES3032012TCGA-E9-A22H-D29946499F5082-99DF-470D-84D6-9FBBFC0249943600mg900mg/day615226Chemotherapy5-FluorouracilADJUVANTIVNO27112013TCGA-E9-A22H-D2994588E1A537-55BC-4B26-9B5E-576C51D8AA0A3600mg900mg/day615226ChemotherapyCyclophosphaneADJUVANTIVNO27112013,TCGA-E9-A22H-R29948F3897CAB-461B-410A-97F0-4EF8AEBC50BF7878EXTERNAL BEAM4000cGy20Regional siteADJUVANTNO27112013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,282.0,WHITE,TCGA-EW-A1J1,EW,A1J1,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,17.0,Allred score 7 (outside facility),image cytometry,Right Upper Inner Quadrant,1.8539062499999928,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,tubular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,1.0,allred score = 4,180,<10%,CISH,Hercep Test  TM Dako,101.4423828125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,3.0,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,<4.0,3 Point Scale,3+,7thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",11,5,2011,TCGA-EW-A1J1-F211818786A7FF-0211-4148-99E6-B23F288119FFScheduled Follow-up SubmissionYESYESAlive575TUMOR FREENO322012,TACTCGA-EW-A1J1-D211821094FF5B-1F3C-4697-9925-DD22ACA691F9152mg671176ChemotherapyTaxotereADJUVANTIVNO322012TAMTCGA-EW-A1J1-D21576BD1F4D4A-4C61-4D48-8C60-7CAA2CA2711B20mg/day276497Hormone TherapyTamoxifenADJUVANTPONO1522012TCGA-EW-A1J1-D21578B6FC4524-6804-4773-A716-4B32CEBBA3043.6mg513Hormone TherapyZoladexADJUVANTSCYES1522012TACTCGA-EW-A1J1-D2926321F38CCA-34D8-4B6E-BFB0-AAF97BD3D511101mg671176ChemotherapyAdriamycinADJUVANTIVNO1332012TACTCGA-EW-A1J1-D29264B86DC55B-25BC-4C74-BE20-F8219FCC983D1015mg671176ChemotherapyCytoxanADJUVANTIVNO1332012,"TCGA-EW-A1J1-R21183C8A9D52C-E1FF-467E-A30D-5BB45741DE6E209254EXTERNAL BEAM6,100cGy42Primary Tumor FieldADJUVANTNO1322012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,98.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A7T0,LL,A7T0,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,4.0,H-SCORE 190,Allred score 5+3=8,Left Lower Inner Quadrant,1.8294238281250017,Axillary lymph node dissection alone,axillary ultrasound,Simple Mastectomy,Reexcision,Other,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,3+,Negative,Negative,Tumor resection,Biopsy not specified,Negative,Positive,Positive,0.3037109375,1.0,100,160,30-39%,ACIS,DAKOHercepTest TM,119.5869140625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,33,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,<10%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.8985937499999987,145,3 Point Scale,1+,7thStage IIBT2N1aM0,NO,NO,NO,3,1,2014,TCGA-LL-A7T0-F649705E8482F3-AA4B-4156-A3DD-F383B7FF97D8NONONOTUMOR FREEAlive376NO1692014,TACTCGA-EW-A1J1-D211821094FF5B-1F3C-4697-9925-DD22ACA691F9152mg671176ChemotherapyTaxotereADJUVANTIVNO322012TAMTCGA-EW-A1J1-D21576BD1F4D4A-4C61-4D48-8C60-7CAA2CA2711B20mg/day276497Hormone TherapyTamoxifenADJUVANTPONO1522012TCGA-EW-A1J1-D21578B6FC4524-6804-4773-A716-4B32CEBBA3043.6mg513Hormone TherapyZoladexADJUVANTSCYES1522012TACTCGA-EW-A1J1-D2926321F38CCA-34D8-4B6E-BFB0-AAF97BD3D511101mg671176ChemotherapyAdriamycinADJUVANTIVNO1332012TACTCGA-EW-A1J1-D29264B86DC55B-25BC-4C74-BE20-F8219FCC983D1015mg671176ChemotherapyCytoxanADJUVANTIVNO1332012,TCGA-A2-A0SX-R4026b73451cc-daa2-4f73-bf06-517ddecd777f213EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3350.0,WHITE,TCGA-B6-A0IO,B6,A0IO,No,YES,C50.9,8500/3,C50.9,2001.0,TUMOR FREE,YES,17.0,Image Analysis,Image Analysis,Left,1.385546875000006,Axillary lymph node dissection alone,Pateys surgery,Modified Radical Mastectomy,Re-excision of the inferior margin,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Mixed infiltrating lobular and grade 1 ductal carcinoma,Indeterminate (neither Pre or Postmenopausal),Indeterminate,NO,4 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Negative,Positive,Equivocal,0.1181640625,0.0,allred score = 6,Moderate to strong,10-19%,ACIS,CAP scoring guideline 2010,290.6533203125,Vysis AutoVysion System,CAP SCORING GUIDELINE 2010,NO,YES,54,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,>6.0,4 Point Scale,1+,Stage IIAT2N0 (i-)M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,2,11,2010,TCGA-B6-A0IO-F126262E99B735-8834-4DF8-B3D5-512337319C15Scheduled Follow-up SubmissionNOYESAlive3350TUMOR FREENO262011TCGA-B6-A0IO-F71503E3BA117D-59D6-449B-9AC8-88BECDB2682ANONOYESTUMOR FREEAlive5042NO2632015,NOTCGA-5L-AAT1-D63716747059AE-DC7B-409F-9178-2DD683C19A6F46Hormone TherapyLetrozolYES1582014,TCGA-A2-A0SX-R4026b73451cc-daa2-4f73-bf06-517ddecd777f213EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,324.0,WHITE,TCGA-BH-A28O,BH,A28O,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,14.0,H-SCORE 255,H-SCORE 140,Right Lower Outer Quadrant,2.270087890624998,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Lobular Carcinoma,Ductal partially papillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,4+,2+,Positive,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,1.1845703125,14.0,allred score = 6,270 H,90-99%,Hercep Test  TM Dako,Dako Hecept Test,205.0234375,HER2 amplification - negative,PathVysion,YES,NO,2.8,BoneLiver,50-59%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,4.70,3 Point Scale,1+,7thStage IIICT3aN3M0,NO,NO,Positive90-99%,2,7,2012,TCGA-BH-A28O-F6423778078E02-494D-4954-BA84-31674011235ANOYESYESTUMOR FREEAlive1120NO2782014,NOTCGA-BH-A28O-D64238CAD6922D-31F1-401F-AAA4-FCD9176D8DE1338430ChemotherapyCytoxanNOComplete Response2782014NOTCGA-BH-A28O-D64239103854BD-AAE1-4387-84DC-33377016C730338430ChemotherapyDoxorubicinNOComplete Response2782014,TCGA-AO-A0JE-R3198a51218ad-d05c-4f75-9d0b-4a9a4bd51689202243EXTERNAL BEAM16000cGy30Primary Tumor FieldADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,952.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A6SC,EW,A6SC,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,2.0,H-Score-190,allred score 3 + 3 = 6,LeftLeft Upper Outer Quadrant,1.642832031249998,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Lobular Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,90 H,H score,<10%,ACIS,Venten,101.677734375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,4.43,"Other, specifyskin",50-59%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,52,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,NO,12,3,2015,TCGA-EW-A6SC-F71017CF93EC15-3023-43A4-9CE7-8B0AFDF5AF21NOYESYESTUMOR FREEAlive952NO1232015,NOTCGA-EW-A6SC-D710182A348DA5-AB1A-4268-ABFA-73790E39D18B114Hormone Therapyaromatase exemestaneYES1832015,TCGA-EW-A6SC-R71019C86CAA33-C1B6-417A-A173-40841EA07E68162169External38.510Primary Tumor FieldNO1332015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,158.0,WHITE,TCGA-4H-AAAK,4H,AAAK,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,14.0,Allred 0 = 0+0,Allred score 2+3 = 5,LeftLeft Upper Outer Quadrant,1.9684277343750056,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Lobular Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.505859375,4.0,Allred score 7 per outside facility report,190,10-19%,CISH,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,89.0576171875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,2.38,"Other, specifyskin",60-69%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,145,3 Point Scale,2+,7thStage IIIAT2N2aM0,YES,NO,NO,13,11,2014,TCGA-4H-AAAK-F674142BC6A238-0838-44AB-9DEA-7A127FF96BEFNONOYESTUMOR FREEAlive348NO13112014,NOTCGA-4H-AAAK-D6806508F129B2-D118-4CA1-B51F-A648445EC84E2798ChemotherapyCyclophosphamideNOComplete Response13112014NOTCGA-4H-AAAK-D68067D675535D-A6A0-4634-8E6C-A5B7C8E612892798ChemotherapyDoxorubicinNOComplete Response13112014NOTCGA-4H-AAAK-D68072A6A3B982-CF4E-4E87-9F53-A31FE7AD6C2E2798Chemotherapy5-FluorouracilNOComplete Response13112014,TCGA-AO-A0JE-R3198a51218ad-d05c-4f75-9d0b-4a9a4bd51689202243EXTERNAL BEAM16000cGy30Primary Tumor FieldADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,4088.0,WHITE,TCGA-A2-A0EN,A2,A0EN,No,YES,C50.9,8520/3,C50.9,2003.0,TUMOR FREE,YES,4.0,Allred score 5+3= 8,H-SCORE 1,Right,1.4,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Lobular Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,1.0,0.0,Moderate,strong,30-39%,Hercep Test  TM Dako,Hercep Test  TM Dako,265.86328125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,4,"LungBoneLiverOther, specifyskin",80-89%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5,3 Point Scale,2+,6thStage IIAT2N0 (i+)M0,YES,NO,NO,27,2,2015,TCGA-A2-A0EN-F1372578F26CBF-3BA6-4DB3-80C7-C632F90A271BScheduled Follow-up SubmissionYESYESAlive2718TUMOR FREENO1062011,2TCGA-A2-A0EN-D2544b71d60f7-798d-44c2-8d89-f63514233b1e1mg/day1985Hormone TherapyAnastrozoleADJUVANTPOYES121020101TCGA-A2-A0EN-D25434d55dd20-b5b7-40c3-8015-41a32a41767320mg/day641926Hormone TherapyTamoxifenADJUVANTPONO12102010,TCGA-A2-A0EN-R25457820e82d-3f7c-446c-ad1a-a7f9dd96744091134EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO112102010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,956.0,WHITE,TCGA-E2-A1IF,E2,A1IF,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.0,allred score 5+3=8,allred score 4+2=6,Left Upper Outer Quadrant,2.9862402343749856,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.41796875,0.0,allred score = 6,allred scrore = 8,<10%,Dako,Venten,187.9423828125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,1.1,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,105,3 Point Scale,2+,6thStage IT1cN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,4,2011,TCGA-E2-A1IF-F19962CE3CD2D3-5B39-4490-BD37-8EA5028464DBScheduled Follow-up SubmissionNOYESAlive1138TUMOR FREENO21122011,1TCGA-E2-A1IF-D19963B72C6A80-3E80-4683-A073-49251E7CF7801mg/day1mg/day41Hormone TherapyArimidexADJUVANTPOYES21122011,TCGA-E9-A1RA-R305532918CA71-A1A5-4A84-A168-C8FF9C942B1193134EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO11242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,791.0,WHITE,TCGA-A8-A06Y,A8,A06Y,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.6337890625,Allred (Biocare),H-SCORE 290,Left Upper Outer Quadrant,6.775048828124971,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.392578125,0.0009765625,Allred Score 4,Intensity=Weak,30-39%,Hercep Test  TM Dako,Dako Hecept Test,193.869140625,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,50,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,441,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,PositivePositiveNegativeNegative1.09,27,5,2011,TCGA-A8-A06Y-F40819CAEFEE71-9247-4AAD-80DA-82865D83AC02NOYESYESTUMOR FREEAlive791YES791791232013,NOTCGA-A8-A06Y-D37851E625C1D0-D92D-46AE-8C5E-BD0D9436E19192Hormone TherapyAnastrozoleYES6122012,TCGA-A8-A06Y-R3817808A51480-CA83-4DDC-853D-0644DC66360461122ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,496.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A0D4,A2,A0D4,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,23.0,H-Score 280,H-Score 260,Left,1.14,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Modified radical mastectomy,Excisional biospy,Infiltrating Ductal Carcinoma,secretory,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,1.0,Intensity=weak,Intensity=moderate,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,182.8388671875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,1.0,"LungBoneLiverOther, specifyskin",90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,149,3 Point Scale,1+,6thStage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,21,9,2010,TCGA-A2-A0D4-F13726F768A36A-1B8C-45BE-9D50-F05E55C3BF24Scheduled Follow-up SubmissionYESYESAlive767TUMOR FREENO1062011,4TCGA-A2-A0D4-D184904ba8237-4afb-4363-8a82-459dabc3dae320 mg dailymg279Hormone TherapyTamoxifenADJUVANTPOYES22920102TCGA-A2-A0D4-D1846dfa2e5c7-323c-4d7a-bd29-45874eb4249b520mg130mg45799ChemotherapyAdriamycinADJUVANTIVNO22920101TCGA-A2-A0D4-D1845ccf14e19-fbff-4548-b109-e64aeb37f5b75216mg1304mg45799ChemotherapyCytoxanADJUVANTIVNO22920103TCGA-A2-A0D4-D18488883ac5c-2a78-4739-b762-eb643646c2261520mg380mg4113155ChemotherapyTaxolADJUVANTIVNO2292010,TCGA-A2-A0D4-R184457d650d1-6d75-46ef-8f36-bd6e5b1b1a09203244EXTERNAL BEAM5040cGyPrimary Tumor FieldADJUVANTNO12292010TCGA-A2-A0D4-R70744181DB4A2-4173-4660-AEAF-01855F51CBFA203244External5040cGyRegional siteNOComplete Response332015TCGA-A2-A0D4-R7074550296DE4-49F9-46B7-AEAA-C7505915F783245251External1000cGyPrimary Tumor FieldNOComplete Response332015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,385.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5D6,OL,A5D6,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,H-Score 150,Allred score 5+3=8,Left Lower Outer Quadrant,1.13,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Fine needle aspiration biopsy,Biopsy not specified,Negative,Negative,Equivocal,0.0,2.345703125,Two-tier,allred score = 7,20-29%,ACIS,Dako Hercept test,86.5947265625,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.38,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,21,3 Point Scale,2+,6thStage IIAT2N0MX,YES,NO,NO,19,4,2013,TCGA-OL-A5D6-F554379B1D5A06-6684-47E7-B1BC-96A9FFE8BA2ANONOYESTUMOR FREEDead1104NO1012014,1TCGA-E2-A1IF-D19963B72C6A80-3E80-4683-A073-49251E7CF7801mg/day1mg/day41Hormone TherapyArimidexADJUVANTPOYES21122011,TCGA-AO-A0J4-R2747a5875abd-4fb2-48ad-9f4e-56c021726547265294EXTERNAL BEAM5240cGy21Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,55.0,WHITE,TCGA-AC-A62Y,AC,A62Y,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,1.0,Allread score 5+3 = 8,Allred 0 = 0+0,Right,1.4919824218750035,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Lobular Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Positive,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.8583984375,1.0,Allred score 5,120,10-19%,ACIS,Dako Hercept test,190.4892578125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,2.38,BoneLiver,90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.9,3 Point Scale,2+,7thStage IIBT2N1MX,YES,NO,NO,19,9,2013,TCGA-AC-A62Y-F65833566B4F48-EA89-45EB-B57F-28D307B98C2CNOYESYESTUMOR FREEAlive530NO3092014,1TCGA-E2-A1LH-D20652908E780C-09EB-4CBC-AD5A-75B352A71460441104ChemotherapyAdriamycinADJUVANTNO12120121TCGA-E2-A1LH-D206592D696153-39F9-4F7D-8E35-5B056E1F654F441104ChemotherapyCytoxanADJUVANTNO1212012,TCGA-E9-A1RF-R3063810729565-ADC4-4C6F-891E-1606E11ABA81118144EXTERNAL BEAM3740cGyRegional siteADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,941.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A1OZ,EW,A1OZ,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.0,H-SCORE 255,Allred score 7 per outside facility report,Left Upper Outer Quadrant,2.2,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Re-excision of the inferior margin,Other,total mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Positive,Positive,Equivocal,0.0,0.0,allred score = 7,Allred Score 6,20-29%,CISH,Dako Hecept Test,40.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2,"Other, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.85,3 Point Scale,2+,6thStage IIAT2N0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,11,5,2011,TCGA-EW-A1OZ-F29098652D6657-335D-47DD-B917-8793B786C736Scheduled Follow-up SubmissionNOYESAlive1229TUMOR FREENO832012,1TCGA-EW-A1OZ-D3029639ED2156-1E5E-4477-ACB2-C08C764C86FB8772mg516mg17144487ChemotherapyTrastuzumabADJUVANTIVNO8320121TCGA-EW-A1OZ-D30295AABA0EBE-E734-4D86-883A-695AB14363E4599mg152mg5256291ChemotherapyPaclitaxelADJUVANTIVNO8320121TCGA-EW-A1OZ-D30293D68A7ED2-A4F6-4C19-A54D-7340BF4717081961mg552mg4144228ChemotherapyCarboplatinADJUVANTIVNO8320122TCGA-EW-A1OZ-D302973E70EEE7-3272-4696-9D31-32FA4D397B0525mg/day301ChemotherapyAromasinADJUVANTPOYES8320121TCGA-EW-A1OZ-D302924D0A2FAD-1E7F-4624-B437-150EF0D4E686426mg142mg3144186ChemotherapyDocetaxelADJUVANTIVNO832012,TCGA-A2-A04R-R25577b76f4d4-65c9-4ff3-abef-09844e8fc56a300342EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112102010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,34.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A62X,AC,A62X,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,10.0,H-Score-190,Allred score 5+3=8,Left Upper Inner Quadrant,1.5736035156250046,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Pateys surgery,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.4931640625,0.0,Allred score = 7,Two-tier,10-19%,ACIS,Dako Hercept test,80.44921875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,40,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,366,3 Point Scale,2+,7thStage IIAT2N0MX,YES,NO,NO,21,10,2013,TCGA-AC-A62X-F64105197F52A1-868A-492C-8E1B-A887CED07862NONONOTUMOR FREEAlive417NO2682014,NOTCGA-C8-A135-D70818E75ED433-A561-43B5-B3E0-5F8E12B99B404051Chemotherapy5-FlourouracilNOComplete Response932015NOTCGA-C8-A135-D708192930DEE3-D647-42B8-9950-5BB8905B9DA24051ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A135-D70820C5031114-238E-45D7-9918-30514B75F06A4051ChemotherapyCyclophosphamideNOComplete Response932015NOTCGA-C8-A135-D70821CD8B26E1-2982-4CDF-ACD5-FE6293F7B1934051ChemotherapyTaxolNOComplete Response932015,TCGA-A2-A0SX-R4026b73451cc-daa2-4f73-bf06-517ddecd777f213EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,481.0,WHITE,TCGA-E2-A156,E2,A156,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,3.0,allred score 5+3=8,H-Score 160,Left,1.406269531250001,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Re-excision of the inferior margin,Other,partial mastectomy,Infiltrating Ductal Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.3779296875,0.0,MODERATE,Strong,90-99%,Dako,Hercep Test  TM Dako,139.17578125,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,2.8,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1,3 Point Scale,1+,6thStage IT1cN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,7,4,2011,TCGA-E2-A156-F187869E28761C-EBC4-40AB-9207-41291C7D40E8Scheduled Follow-up SubmissionYESYESAlive726TUMOR FREENO8112011,1TCGA-E2-A156-D187879FA71240-8DEF-42FE-9235-91CC3980DDF71mg/day1mg/day119Hormone TherapyArimidexADJUVANTPOYES8112011,TCGA-E2-A156-R187880AF5A75E-1E2C-4321-9544-A1774FEBC9B074123EXTERNAL BEAM33Primary Tumor FieldADJUVANTNO18102011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,84.0,WHITE,TCGA-E9-A1R6,E9,A1R6,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,Allred 0 = 0+0,Allred score 2+3 = 5,Right Upper Outer Quadrant,1.604775390624987,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Negative,Equivocal,0.0009765625,0.0,Strong,Two-tier,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,160.23828125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,1.45,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,441,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-E9-A1R6-F308479F411262-22A5-4C5D-952D-6F805D9C2FCAScheduled Follow-up SubmissionYESYESAlive339TUMOR FREENO2592013TCGA-E9-A1R6-F3952060A76A6C-E151-40D3-8D86-79F68C50F4E4YESYESYESTUMOR FREEAlive339NO2412013,TCGA-E9-A1R6-D3084804E8410B-36AD-4102-B74E-60586DD6717C20mg/day66Hormone TherapyTamoxifenADJUVANTPOYES1742012,TCGA-E9-A1R6-R30849CB247066-616B-43C5-8432-131360C166F196125EXTERNAL BEAM4600cGy23Primary Tumor FieldADJUVANTNO11742012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,595.0,WHITE,TCGA-EW-A1J6,EW,A1J6,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,3.0,H-SCORE 280,IHC,Right Upper Inner Quadrant,1.822949218749984,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,Partial Mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,Allred score 7 per outside facility report,120,<10%,CISH,Hercep Test  TM Dako,52.1611328125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,69,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.80,3 Point Scale,3+,6thStage IT1cN0 (i-)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",11,5,2011,TCGA-EW-A1J6-F213478D84D7F5-C455-4390-BCC6-C33048E6CC19Scheduled Follow-up SubmissionNOYESAlive875TUMOR FREENO622012,TCGA-EW-A1J6-D21611DE34FA0A-12BB-466B-9E7B-053B947EC6962.5mg/day111Hormone TherapyFemaraADJUVANTPOYES1622012,TCGA-BH-A0AU-R607831F29756B-02AC-49AA-BE44-BC4EDCEFBD8E65NOComplete Response1662014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,29.0,WHITE,TCGA-E9-A1RA,E9,A1RA,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,Allred (Biocare),CAP SCORING GUIDELINE 2010,Left Upper Outer Quadrant,2.384931640624992,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,"Other method, specify:",Lumpectomy,Positive,Positive,Equivocal,0.0009765625,0.0,Allred score = 7,120,10-19%,Hercep Test  TM Dako,Dako Hecept Test,146.7822265625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,2.7,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,3 Point Scale,1+,7thStage IAT1cN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-E9-A1RA-F305446249CDE0-2155-4C90-964B-81E4418161AFScheduled Follow-up SubmissionYESYESAlive608TUMOR FREENO1242012TCGA-E9-A1RA-F3951946EE054F-0DB7-413D-9436-92212E47D209NOYESYESTUMOR FREEAlive976NO2412013TCGA-E9-A1RA-F68493B963B3A4-E4B3-449D-A222-A537A95F05E9NOYESYESTUMOR FREEAlive1369NO20112014,TCGA-E9-A1RA-D305470CAD78B5-EA56-4810-802C-C8376A508B74380mg100mg41080ChemotherapyDoxorubicinADJUVANTIVNO1242012TCGA-E9-A1RA-D305521A3D7515-4506-4F8C-AA69-7638A7FE0EAD20mg/day9Hormone TherapyTamoxifenADJUVANTPOYES1242012TCGA-E9-A1RA-D30550AFDB7AB8-943C-45D1-8584-CD15359E6AA54000mg1000mg41080ChemotherapyCyclophosphamideADJUVANTIVNO1242012,TCGA-E9-A1RA-R305532918CA71-A1A5-4A84-A168-C8FF9C942B1193134EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO11242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1888.0,WHITE,TCGA-AR-A24S,AR,A24S,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,4.0,Allred score 0+0 = 0,manual counting,Right Lower Outer Quadrant,1.426025390624998,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0625,0.0,H-Score,H-Score,10-19%,Hercep Test  TM Dako,Hercep Test TM DAKO,92.662109375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,1.73,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,5.8,3 Point Scale,1+,6thStage IT1N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",30,8,2011,TCGA-AR-A24S-F31496C02A0731-B37F-4A25-87C8-C4BAE202D900Scheduled Follow-up SubmissionYESYESAlive2976NO452012,2TCGA-AR-A24S-D31500D4ADA29C-A0D8-40B4-9BC1-5C021EE0D1CA25mg/day1291124Hormone TherapyExemestaneADJUVANTPONO4520121TCGA-AR-A24S-D31499F328D456-9B78-4357-99E0-40F41C3314CE1mg/day32126Hormone TherapyAnastrozoleADJUVANTPONO452012,TCGA-AR-A24S-R314976158469F-BAE7-4222-BAF2-A95FF4534F275562EXTERNAL BEAM3850cGy10Primary Tumor FieldADJUVANTNO1452012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,196.0,WHITE,TCGA-AN-A0FD,AN,A0FD,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,dextran coated charcoal,dextran coated charcoal,Left Upper Outer Quadrant,2.103017578125,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,stereotactic biopsy,Positive,Positive,Positive,0.0,0.0,Allred Score 8,STRONG,60-69%,0,dextran coated charcoal,191.369140625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,1.93,"LungBoneLiverOther, specifyskin",80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,132,3 Point Scale,1+,Stage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,20,12,2010,TCGA-AN-A0FD-F689499FB2953C-EB8B-42E6-AF03-F9EF349ADA40YESNONOTUMOR FREEAlive19623122014,NOTCGA-BH-A202-D642300D4881E9-AE20-4588-920D-75E5D8AB81ED47169ChemotherapyCarboplatinNOComplete Response2782014NOTCGA-BH-A202-D64231C3C5CF2E-3889-4D44-A699-9F66D21CE0E147169ChemotherapyTaxotereNOComplete Response2782014,TCGA-AO-A0J4-R2747a5875abd-4fb2-48ad-9f4e-56c021726547265294EXTERNAL BEAM5240cGy21Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,8.0,WHITE,TCGA-E9-A5FL,E9,A5FL,No,YES,C50.9,8575/3,C50.9,2012.0,TUMOR FREE,YES,10.0,H-SCORE 260,Allred score 5+3=8,Right Upper Outer Quadrant,1.8104296875000032,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Segmental mastectomy with left axillary lymph node dissection,Metaplastic Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Patey's Suregery,Negative,Negative,Negative,0.4228515625,0.0,Allred score 5,allred score = 0,10-19%,Hercep Test  TM Dako,Dako Hercept test,187.2841796875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,2.6,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,172,3 Point Scale,3+,7thStage IIBT3N0M0,YES,NO,NO,22,5,2013,TCGA-E9-A5FL-F5606120890005-DE58-433A-9DDF-39C1F4A0FDDFYESNONOTUMOR FREEAlive24NO2412014,NOTCGA-C8-A135-D70818E75ED433-A561-43B5-B3E0-5F8E12B99B404051Chemotherapy5-FlourouracilNOComplete Response932015NOTCGA-C8-A135-D708192930DEE3-D647-42B8-9950-5BB8905B9DA24051ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A135-D70820C5031114-238E-45D7-9918-30514B75F06A4051ChemotherapyCyclophosphamideNOComplete Response932015NOTCGA-C8-A135-D70821CD8B26E1-2982-4CDF-ACD5-FE6293F7B1934051ChemotherapyTaxolNOComplete Response932015,TCGA-AO-A0J4-R2747a5875abd-4fb2-48ad-9f4e-56c021726547265294EXTERNAL BEAM5240cGy21Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1.0,WHITE,TCGA-AC-A7VC,AC,A7VC,No,YES,C50.9,8575/3,C50.9,2013.0,TUMOR FREE,YES,1.0,No value Given,allred score 4 + 3 = 7,Left,1.3735742187500026,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Other,segmental mastectomy with sentinel lymph node dissection,Metaplastic Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,stereotactic biopsy,Negative,Negative,Negative,0.0,0.0,Allred score 0,moderate,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,277.962890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,4,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,60,3 Point Scale,2+,7thStage IIBT3N0MX,YES,NO,NO,29,3,2014,TCGA-PE-A5DE-F6637318DA1661-A5A3-419D-B7FA-A5B9C32431B1NOYESYESTUMOR FREEAlive2645NO13102014,NOTCGA-A8-A06Y-D37851E625C1D0-D92D-46AE-8C5E-BD0D9436E19192Hormone TherapyAnastrozoleYES6122012,TCGA-AO-A126-R5877a3a403cf-f4f1-46ae-a7b9-d614b4e1266c384421EXTERNAL BEAM10000cGy25Local RecurrenceRECURRENCENO17122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,267.0,WHITE,TCGA-EW-A1PA,EW,A1PA,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,13.0,allred score 0 + 0 = 0,H-SCORE 0,Left Upper Outer Quadrant,2.012275390624992,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Re-excision of the inferior margin,Other,Excisional biopsy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.001953125,1.0,allred score = 7,180,<10%,CISH,Dako Hecept Test,108.705078125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2.25,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,3 Point Scale,3+,7thStage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,11,5,2011,TCGA-EW-A1PA-F30937E558B7BC-59D7-435C-8ADA-7B2B8B280FBEScheduled Follow-up SubmissionYESYESAlive575TUMOR FREENO832012,FEC then TTCGA-EW-A1PA-D30944576A0855-EEB0-4E10-A8B5-6D5961A63A9E3120mg1040mg3143206ChemotherapyCyclophosphamideADJUVANTIVNO832012FECTCGA-EW-A1PA-D30938CDEC6B0A-4685-44B6-89A0-A9459569D2CF3120mg1040mg3143206ChemotherapyFluorouracilADJUVANTIVNO832012FECTCGA-EW-A1PA-D309415D03E3B4-4612-47BD-8BD5-9BCC599F8B5C157.5mg52.5mg3143206ChemotherapyEpirubicinADJUVANTIVNO832012FEC then TTCGA-EW-A1PA-D3094587CC0E37-421A-47F8-8637-29FB7DC684C3320mg160mg2143206ChemotherapyDocetaxelADJUVANTIVNO832012TAMTCGA-EW-A1PA-D309483518E805-38B9-4A27-8C05-6997651B6FA820mg/day262Hormone TherapyNolvadexADJUVANTPOYES832012,"TCGA-EW-A1PA-R309477EF75334-1718-4EDB-A178-B2E9D80D8952225262EXTERNAL BEAM11,032cGy56Primary Tumor FieldADJUVANTNO1832012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1855.0,WHITE,TCGA-PE-A5DE,PE,A5DE,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,1.0,H-SCORE 260,Allred score 7 per outside facility report,Left,1.8642773437499984,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,secretory,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0859375,0.0,allred score = 8,moderate,90-99%,ACIS,Hercep Test  TM Dako,167.5185546875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,1.45,"Other, specifyskin",<10%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,NO,24,4,2013,TCGA-PE-A5DE-F6637318DA1661-A5A3-419D-B7FA-A5B9C32431B1NOYESYESTUMOR FREEAlive2645NO13102014,NOTCGA-PE-A5DE-D42973F709235A-EEE6-4F2B-BCB5-C273A7BC66D042105ChemotherapyTaxotereNOComplete Response652013NOTCGA-PE-A5DE-D663691E2B873D-3AE8-418A-8727-97077CF103B542105ChemotherapyCytoxanNOComplete Response13102014NOTCGA-PE-A5DE-D66370444F6B72-2D26-488F-AE79-26A7C0CEA076182Hormone TherapyTamoxifenYES13102014,TCGA-PE-A5DE-R663728C0689B9-FFAA-4060-86D2-7CEFD920316E124167External4600cGy32Primary Tumor FieldNOComplete Response13102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,13.0,ASIAN,TCGA-C8-A135,C8,A135,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,3.0,H-Score 150,H-Score 290,Left,1.5341308593749918,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Patey's Surgery,Negative,Negative,Positive,0.0322265625,1.0,Allred Score,Strong,90-99%,Hercep Test  TM Dako,Venten,129.8603515625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,1.78,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,105,4 Point Scale,1+,6thStage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,15,4,2011,TCGA-C8-A135-F190812EB99E29-CFEC-47C3-AE81-9035B00BA8BAScheduled Follow-up SubmissionNONOAlive32TUMOR FREENO2122011TCGA-C8-A135-F708172713E11E-2440-4519-9A50-B0E7F2C3B23ENONOYESTUMOR FREEAlive393NO932015,NOTCGA-C8-A135-D70818E75ED433-A561-43B5-B3E0-5F8E12B99B404051Chemotherapy5-FlourouracilNOComplete Response932015NOTCGA-C8-A135-D708192930DEE3-D647-42B8-9950-5BB8905B9DA24051ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A135-D70820C5031114-238E-45D7-9918-30514B75F06A4051ChemotherapyCyclophosphamideNOComplete Response932015NOTCGA-C8-A135-D70821CD8B26E1-2982-4CDF-ACD5-FE6293F7B1934051ChemotherapyTaxolNOComplete Response932015,TCGA-AC-A2QJ-R440223B3D8F3B-C6C9-4D81-A6BB-E1EA9484B841241279External05000cGy20Primary Tumor FieldNORadiographic Progressive Disease1062013TCGA-AC-A2QJ-R440238AD664BA-6C40-4CAA-8CB1-F5CDAD9C7202299312External01800cGy10Regional siteNORadiographic Progressive Disease1062013
TCGAFPPP,Breast,No,FEMALE,Dead,785.0,637.3642578125,WHITE,TCGA-BH-A1F0,BH,A1F0,No,YES,C50.9,8500/3,C50.9,2000.0,WITH TUMOR,YES,9.0,H-Score 270,H-Score 190,Left,2.4435742187499856,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Pateys surgery,Infiltrating Ductal Carcinoma,Ductal/cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Indeterminate,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Negative,Negative,1.466796875,1.0,allred score = 8,205,10-19%,ACIS,+ or -,167.9765625,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,54,BoneLiver,50-59%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,132,3 Point Scale,2+,5thStage IIAT1aN1cM0,NO,NO,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,7,9,2011,TCGA-BH-A202-F6422632ACC3F7-B74B-4080-8297-329EDC6A00D5NOYESYESTUMOR FREEAlive795NO2782014,TCGA-EW-A1J6-D21611DE34FA0A-12BB-466B-9E7B-053B947EC6962.5mg/day111Hormone TherapyFemaraADJUVANTPOYES1622012,TCGA-A2-A0SX-R4026b73451cc-daa2-4f73-bf06-517ddecd777f213EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Dead,1508.0,950.171875,WHITE,TCGA-BH-A1EX,BH,A1EX,No,YES,C50.9,8500/3,C50.9,2000.0,WITH TUMOR,YES,24.0,H-Score 270,H-SCORE 210,Right Lower Inner Quadrant,1.9344531250000108,Sentinel node biopsy alone,Pateys surgery,Other,Right Breast reexcision,Other,Right segmental mastectomy with sentinel lymph node and axillary lymph node biopsy,Infiltrating Ductal Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Positive,0.423828125,2.0,MODERATE,Allred Score,10-19%,Hercep Test  TM Dako,Hercep Test TM DAKO,47.642578125,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,NO,YES,4,"Other, specifyskin",10-19%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0495312500000025,132,3 Point Scale,2+,5thStage IIBT2N1bM0,NO,NO,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,7,9,2011,TCGA-AO-A126-F58768C48C547-31D9-439C-AFE6-E5450D7820652850AliveTUMOR FREEYESYES267YES295Positive20-29%2+Positive60-69%2+Negative<10%03+ PositiveNegative6249311.3>=2.0 PositiveNOYESYES7122010TCGA-AO-A126-F1940207D7BA23-00A6-491E-A381-1B93BB686C33Scheduled Follow-up SubmissionYESYESAlive3307TUMOR FREEYES267Locoregional DiseaseYES295YESNOPositive20-29%4 Point ScalePositive60-69%4 Point ScaleNegative<10%0Negative1.312122011,TCGA-EW-A1J6-D21611DE34FA0A-12BB-466B-9E7B-053B947EC6962.5mg/day111Hormone TherapyFemaraADJUVANTPOYES1622012,TCGA-A2-A04R-R25577b76f4d4-65c9-4ff3-abef-09844e8fc56a300342EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112102010
TCGAFPPP,Breast,No,FEMALE,Dead,116.0,1134.1171875,BLACK OR AFRICAN AMERICAN,TCGA-UU-A93S,UU,A93S,No,YES,C50.9,8500/3,C50.9,2013.0,WITH TUMOR,NO,12.265625,H-SCORE 190,Allred 0 = 0+0,RightRight Upper Inner QuadrantRight Upper Outer QuadrantRight Lower Inner QuadrantRight Lower Outer Quadrant,2.4057714843749967,No axillary staging,Sentinel lymph node and axillary lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,3+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Positive,Negative,Positive,1.3212890625,6.4384765625,Allred score 7 per outside facility report,"Moderate using the scale of Weak, Moderate, Strong",90-99%,CISH,Dako Hecept Test,163.189453125,HER2 amplification - negative,Ratio >=2.2,YES,NO,3.1,BoneLiver,10-19%,80-89%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,125,3 Point Scale,2+,7thStage IVT4dN3bM1,NO,NO,NO,11,11,2014,TCGA-A2-A0SX-F40182FBA2DC6-991D-4F21-A885-0C9489F2546E1288AliveWITH TUMORYESYES1239YES1239NegativeNegativeNegative0NOYES9112010TCGA-A2-A0SX-F14037FD49FD62-003E-47C4-82ED-06FDB0E1CF23Scheduled Follow-up SubmissionYESYESAlive1534WITH TUMORNO1472011,NOTCGA-S3-A6ZG-D510884FFDEFCC-4989-4FE3-9F8C-2F66D9CD5EF852100ChemotherapyDoxorubicinNOComplete Response12112013NOTCGA-S3-A6ZG-D510899C1469D0-34BE-4520-A928-C8222B9AA84A52100ChemotherapyCytoxanNOComplete Response12112013NOTCGA-S3-A6ZG-D51090592DBC73-6BBC-49B6-8C4D-DE2812D431D8116221Hormone TherapyTaxolNOComplete Response12112013YESTCGA-S3-A6ZG-D636499E65EFA0-05D8-47EB-A1E0-6E44A31DBA3D256Hormone TherapyAnastrozoleYES2782014NOTCGA-S3-A6ZG-D64188CE65FD9A-E5F7-42B1-8603-9979F90ABD5F52100AncillaryNEULASTANOComplete Response2782014,TCGA-AO-A0JE-R3198a51218ad-d05c-4f75-9d0b-4a9a4bd51689202243EXTERNAL BEAM16000cGy30Primary Tumor FieldADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,69.0,WHITE,TCGA-AC-A2QJ,AC,A2QJ,No,YES,C50.9,8575/3,C50.9,2011.0,TUMOR FREE,YES,2.0,H-SCORE 0,%IHC,Left Upper Outer QuadrantLeft Lower Outer Quadrant,1.6641699218749992,Other (specify),Sentinel lymph node and axillary lymph node biopsy,Other,Right Breast reexcision,Other,Mastectomy,Metaplastic Carcinoma,Infiltrating papillary adenocarcinoma,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Negative,Negative,0.6904296875,0.0,Allred Score 6,Allred Score 5,10-19%,ACIS,Dako Hercept test,49.921875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,58,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,59,3 Point Scale,2+,7thStage IIIBT4bN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,18,10,2011,TCGA-AC-A2QJ-F440213A8D4436-79F0-4371-8E16-9ABB1EC95ECANOYESYESWITH TUMORDead446YES237Distant MetastasisBoneNOYESYES2862013,NOTCGA-AC-A2QJ-D44024C5CB5329-7C61-47A9-A6C2-1BA45837EE1969111ChemotherapyCytoxanNOClinical Progressive Disease1062013NOTCGA-AC-A2QJ-D44025ED128C91-BA77-4FBB-B670-962EA86F936569111ChemotherapyAdriamycinNOClinical Progressive Disease1062013NOTCGA-AC-A2QJ-D44026900E4830-C0E0-4B02-8648-811C3D9C6780125202ChemotherapyAbraxaneNOClinical Progressive Disease1062013NOTCGA-AC-A2QJ-D44873D4B923DD-9936-4FD1-B31D-7EC1BD1E03EB322385ChemotherapyGemzarNOClinical Progressive Disease2862013NOTCGA-AC-A2QJ-D44874AE31D0D7-2D48-4096-8A15-44362B8615FB386407ChemotherapyCarboplatinNOClinical Progressive Disease2862013NOTCGA-AC-A2QJ-D44876A7788968-8449-4721-9548-BFB6C599C876349418Hormone TherapyFaslodexNOClinical Progressive Disease2862013,TCGA-AC-A2QJ-R440223B3D8F3B-C6C9-4D81-A6BB-E1EA9484B841241279External05000cGy20Primary Tumor FieldNORadiographic Progressive Disease1062013TCGA-AC-A2QJ-R440238AD664BA-6C40-4CAA-8CB1-F5CDAD9C7202299312External01800cGy10Regional siteNORadiographic Progressive Disease1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,22.0,WHITE,TCGA-BH-A202,BH,A202,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,4.0,H-SCORE 136,H-SCORE 290,Left,2.467412109374983,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Invasive mixed ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Positive,1.171875,0.0,allred score = 8,8,10-19%,ACIS,+ or -,164.8173828125,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,1.78,BoneLiver,50-59%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,132,3 Point Scale,2+,6thStage IIT2N0M0,NO,NO,YES181Locoregional RecurrenceYES181NOYES,8,9,2011,TCGA-BH-A202-F6422632ACC3F7-B74B-4080-8297-329EDC6A00D5NOYESYESTUMOR FREEAlive795NO2782014,NOTCGA-BH-A202-D642300D4881E9-AE20-4588-920D-75E5D8AB81ED47169ChemotherapyCarboplatinNOComplete Response2782014NOTCGA-BH-A202-D64231C3C5CF2E-3889-4D44-A699-9F66D21CE0E147169ChemotherapyTaxotereNOComplete Response2782014,TCGA-BH-A202-R642322384CC18-9597-4204-8AD1-330A44034AC4182231External6100cGy25Primary Tumor FieldNOComplete Response2782014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2850.0,ASIAN,TCGA-AO-A126,AO,A126,No,YES,C50.9,8500/3,C50.9,2002.0,TUMOR FREE,YES,5.0,Allred score 7 (outside facility),CAP scoring guideline 2010,Right Upper Inner QuadrantRight,1.1,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Modified radical mastectomy,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,Mixed infiltrating lobular and grade 1 ductal carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,Intensity=Weak,Moderate,<10%,CISH,3+ Positive,30.0,Vysis AutoVysion System,>=2.2 Positive,NO,YES,69,"LungBoneLiverOther, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,74,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,7,12,2010,TCGA-AO-A126-F58768C48C547-31D9-439C-AFE6-E5450D7820652850AliveTUMOR FREEYESYES267YES295Positive20-29%2+Positive60-69%2+Negative<10%03+ PositiveNegative6249311.3>=2.0 PositiveNOYESYES7122010TCGA-AO-A126-F1940207D7BA23-00A6-491E-A381-1B93BB686C33Scheduled Follow-up SubmissionYESYESAlive3307TUMOR FREEYES267Locoregional DiseaseYES295YESNOPositive20-29%4 Point ScalePositive60-69%4 Point ScaleNegative<10%0Negative1.312122011,1TCGA-AO-A126-D5938e3937ee2-ef17-48fd-b613-38d265529590520mg40mg/m2891238ChemotherapyMethotrexateADJUVANTIVNO10120111TCGA-AO-A126-D5937ee9c3d89-3e97-48d7-8e7c-269fe8ad0fd07776mg600mg/m2891238ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A126-D59398994c71e-c50a-46fe-bd93-196c3b435d657776mg600mg/m2891238ChemotherapyFluorouracilADJUVANTIVNO10120111TCGA-AO-A126-D59403d58aed6-c8a0-4506-834b-a58fa3a24e6e20mg/day3201795Hormone TherapyTamoxifenRECURRENCEPONO10120111TCGA-AO-A126-D59419948fc14-eaff-4311-a8e0-5c0941e2316c3231639Hormone TherapyZoladexRECURRENCESCNO1012011,TCGA-AO-A126-R5877a3a403cf-f4f1-46ae-a7b9-d614b4e1266c384421EXTERNAL BEAM10000cGy25Local RecurrenceRECURRENCENO17122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,360.0,WHITE,TCGA-AR-A0TU,AR,A0TU,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,4.0,H-Score 300,Allred score 2+2 = 4,Right Lower Outer Quadrant,1.2052539062499998,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.06640625,0.0,Allred Score 7,0%,30-39%,Dako,Venten,63.17578125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,54,"Other, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,61,3 Point Scale,0,6thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",10,3,2011,TCGA-AR-A0TU-F18575080FECF7-066F-4CB4-9E67-5ABAE2FBA3EFScheduled Follow-up SubmissionNOYESAlive417TUMOR FREENO15122011TCGA-AR-A0TU-F717353BBB4DAF-8684-4AE4-A54B-691A404D0A5DNONOYESTUMOR FREEAlive709NO3032015,1TCGA-AR-A0TU-D19570EFEB5E4B-A824-4B78-B373-603E8A1C7BBA4ChemotherapyDoxorubicinADJUVANTNO151220111TCGA-AR-A0TU-D19572EE4C23A8-EDAC-4DE6-9B48-CD0BCB2D99784ChemotherapyDocetaxelADJUVANTNO151220111TCGA-AR-A0TU-D195718B38DA0D-2D5D-4484-BC07-F2BF3584123C4ChemotherapyCytoxanADJUVANTNO15122011,TCGA-AO-A0J4-R2747a5875abd-4fb2-48ad-9f4e-56c021726547265294EXTERNAL BEAM5240cGy21Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,294.0,BLACK OR AFRICAN AMERICAN,TCGA-AO-A0J4,AO,A0J4,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.0,Allred score 7 (outside facility),Allred score 2+2 = 4,Left Upper Outer QuadrantLeft,1.3832519531249987,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.0,0.0,Intensity=Weak,Intensity=Strong,<10%,CISH,3+ POSITIVE,35.3408203125,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,2.4,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,>6,3 Point Scale,2+,Stage IAT1cN0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,19,9,2010,TCGA-AO-A0J4-F2742D22091C4-FC26-42F1-AF72-46DADE0922AC294AliveTUMOR FREEYESYES1992010TCGA-AO-A0J4-F15478303D8EF0-9002-4B68-8E12-C5C5C5119275Scheduled Follow-up SubmissionYESYESAlive1587TUMOR FREENO2282011,1TCGA-AO-A0J4-D274960d39515-fbed-4588-80f8-0a3c0172f94e400mg60mg/m24131175ChemotherapyDoxorubicinADJUVANTIVNO19920101TCGA-AO-A0J4-D2748e8d55b3d-7228-4fe0-b888-86ebfb98dc594000mg600mg/m24131175ChemotherapyCyclophasphamideADJUVANTIVNO19920101TCGA-AO-A0J4-D27501a7870eb-a79b-421d-af13-fcf0d3654788580mg175mg/m22189203ChemotherapyPaclitaxelADJUVANTIVNO1992010,TCGA-AO-A0J4-R2747a5875abd-4fb2-48ad-9f4e-56c021726547265294EXTERNAL BEAM5240cGy21Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1288.0,WHITE,TCGA-A2-A0SX,A2,A0SX,No,YES,C50.9,8500/3,C50.9,2007.0,WITH TUMOR,YES,1.0,Allred score 5+3= 8,H-SCORE 1,Left Upper Inner Quadrant,1.4311718749999978,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Right Breast reexcision,Lumpectomy,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,Ductal/cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,1+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.0,0.0,Allred Score 7,0%,10-19%,ACIS,Venten,67.1083984375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,1.1,"LungBoneLiverOther, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,4.6,3 Point Scale,2+,6thStage IAT1cN0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-A2-A0SX-F40182FBA2DC6-991D-4F21-A885-0C9489F2546E1288AliveWITH TUMORYESYES1239YES1239NegativeNegativeNegative0NOYES9112010TCGA-A2-A0SX-F14037FD49FD62-003E-47C4-82ED-06FDB0E1CF23Scheduled Follow-up SubmissionYESYESAlive1534WITH TUMORNO1472011,2TCGA-A2-A0SX-D40248f6e3477-88fd-4f1b-b06f-0e3510b0ac5d600mg100mg662132ChemotherapyAdriamycinADJUVANTIVNO121120101TCGA-A2-A0SX-D401976901188-6afa-4900-ae30-7d296985c5de6000mg1000mg662132ChemotherapyCytoxanADJUVANTIVNO201120103TCGA-A2-A0SX-D4023a0280f47-3ba8-42cf-ab14-ff4fd7db88b02203mg610mg412891359ChemotherapyCarboplatinRECURRENCEIVNO241120104TCGA-A2-A0SX-D402516e4fd14-6c2b-4c7e-964a-c240c2b36ceb7200mg1800mg412891359ChemotherapyGemcitabineRECURRENCEIVNO241120105TCGA-A2-A0SX-D14036634383B8-9F0E-4A8B-84FE-B308540A6F381500-2000mg/day1429ChemotherapyXelodaPROGRESSIONPOYES1152011,TCGA-A2-A0SX-R4026b73451cc-daa2-4f73-bf06-517ddecd777f213EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,746.0,WHITE,TCGA-BH-A0AU,BH,A0AU,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,H-Score 200,Allred score 5+3= 8,Left Upper Inner Quadrant,1.7712207031249918,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,left segmental mastectomy with sentinel node dissection,Infiltrating Ductal Carcinoma,Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Positive,0.263671875,0.0,170,Allred Score = 7,90-99%,Hercep Test  TM Dako,Dako Hercept test,110.3564453125,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,1.45,"LungBoneLiverOther, specifyskin",<10%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,185,3 Point Scale,1+,6thStage IIAT2N0M0,NO,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,7,2011,TCGA-BH-A0AU-F60769A74198DE-7ECF-4CBE-A42F-C8BB8ACFD761NOYESNOTUMOR FREEAlive1914NO1662014,1TCGA-E2-A156-D187879FA71240-8DEF-42FE-9235-91CC3980DDF71mg/day1mg/day119Hormone TherapyArimidexADJUVANTPOYES8112011,TCGA-BH-A0AU-R607831F29756B-02AC-49AA-BE44-BC4EDCEFBD8E65NOComplete Response1662014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,196.0,WHITE,TCGA-A7-A13F,A7,A13F,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,H-SCORE 300,Allred score 5+3 = 8,Right Upper Outer Quadrant,1.1,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Reexcision,Other,Excision,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Positive,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.6591796875,3.0,Allred Score 4,200,30-39%,ACIS,CAP SCORING GUIDELINE 2010,403.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe Kit,YES,NO,2.8,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.0,3 Point Scale,0,Stage IIIAT3N1aM0,NO,YES,YES994Distant MetastasisBoneNOYESYES,2,3,2011,TCGA-A7-A13F-F17799A1C9EECF-7FF9-4670-AF8A-053EE9F885D6Scheduled Follow-up SubmissionYESYESAlive387TUMOR FREENO25102011TCGA-A7-A13F-F39779C0C53386-68E4-4D29-ABF4-1C85462AE7DDNOYESYESTUMOR FREEAlive765NO122013,1TCGA-A7-A13F-D865916003a88-4c4e-4f56-ad98-b6e02346fe51798mg198-200mg4105175ChemotherapyDocetaxelADJUVANTIVNO1320111TCGA-A7-A13F-D8657ff50db3d-c7d9-4aca-8616-bd68d8d81157487mg121-123mg44991ChemotherapyDoxorubicinADJUVANTIVNO1320111TCGA-A7-A13F-D8658a3494e0e-47ac-4bf1-8911-42330fdda6fe4854mg1200-1230mg44991ChemotherapyCyclophosphamideADJUVANTIVNO1320111TCGA-A7-A13F-D1781322203C82-11A9-45F7-A172-B99BE2FC855D20mg179210Hormone TherapyTamoxifenADJUVANTPONO251020112TCGA-A7-A13F-D17801D0D604CB-1045-4D02-AC97-F5AE8513DA0F106mg1mg358Hormone TherapyArimidexADJUVANTPOYES25102011,TCGA-A7-A13F-R17800B1FB7AD8-B216-495A-9411-64F6A0D451E5211248EXTERNAL BEAM5040cGy28Primary Tumor FieldADJUVANTNO125102011TCGA-A7-A13F-R17807DB4D2F46-F9F4-4A31-92E4-B09C3567DBA0211246EXTERNAL BEAM4680cGy26Regional siteADJUVANTNO125102011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2365.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A04R,A2,A04R,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,1.0,H-Score 270,H-SCORE 210,Left Upper Inner Quadrant,1.1,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,Invasive mixed ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.0,0.0,Allred score 8,Allred Score 5,10-19%,ACIS,CAP scoring guideline 2010,63.8671875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,118,"Other, specifyaxilaary node negative but intrammary node positive",60-69%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,4.6,3 Point Scale,2+,6thStage IAT1N0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,8,10,2010,TCGA-A2-A04R-F932776955B11-9319-4621-99D7-823860110AD62499AliveTUMOR FREEYESYES2132010TCGA-A2-A04R-F59315C91D9225-7AD4-4F0C-9851-D37807AA970ANOYESYESTUMOR FREEAlive3709NO852014,2TCGA-A2-A04R-D255380d22cd5-ee42-4e09-b192-f6b2183cf0b34800mg1200mg4119184ChemotherapyCYTOXANADJUVANTIVNO121020103TCGA-A2-A04R-D2554575ace17-a333-4457-837f-9f4210296cb5480mg120mg4119184ChemotherapyAdriamycinADJUVANTIVNO121020105TCGA-A2-A04R-D2556258814a0-8e67-4ac2-84ec-1353588f2f9d1mg/day910Hormone TherapyAnastrozoleADJUVANTPOYES121020104TCGA-A2-A04R-D255559cf62c8-9052-43df-aefa-ea940996727a20mg/day399909Hormone TherapyTamoxifenADJUVANTPONO121020101TCGA-A2-A04R-D25527430b157-f641-4b64-86b4-38f47b845980354mg354mg14545ChemotherapyTAXOLADJUVANTIVNO12102010,TCGA-A2-A04R-R25577b76f4d4-65c9-4ff3-abef-09844e8fc56a300342EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112102010
TCGAFPPP,Breast,No,FEMALE,Dead,1642.0,820.8818359375,WHITE,TCGA-BH-A1FR,BH,A1FR,No,YES,C50.9,8523/3,C50.9,1997.0,WITH TUMOR,YES,10.0,H-SCORE 136,PR Negative H-Score 0,Right Upper Inner Quadrant,2.3146484374999905,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Right Breast reexcision,Modified radical mastectomy,segmental mastectomy with excision of mass on chest wall and axillary node dissection,"Other, specify",mixed idc and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Equivocal,1.3095703125,4.0,Allred Score 3,Moderate,90-99%,Hercep Test  TM Dako,Dako Hecept Test,164.904296875,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,54,BoneLiver,50-59%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,2.0495312500000025,1.57,3 Point Scale,2+,5thStage IIIBT4bN1aM0,NO,NO,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,8,9,2011,TCGA-BH-A0AU-F60769A74198DE-7ECF-4CBE-A42F-C8BB8ACFD761NOYESNOTUMOR FREEAlive1914NO1662014,2TCGA-AR-A24S-D31500D4ADA29C-A0D8-40B4-9BC1-5C021EE0D1CA25mg/day1291124Hormone TherapyExemestaneADJUVANTPONO4520121TCGA-AR-A24S-D31499F328D456-9B78-4357-99E0-40F41C3314CE1mg/day32126Hormone TherapyAnastrozoleADJUVANTPONO452012,"TCGA-EW-A1PE-R30266E51F4CA1-EFA3-4660-BE2F-4A2E464A2496208269EXTERNAL BEAM10,500cGy25Primary Tumor FieldADJUVANTNO1832012"
TCGAFPPP,Breast,No,FEMALE,Dead,2469.0,3663.9619140625,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0RL,B6,A0RL,No,YES,C50.9,8500/3,C50.9,1993.0,TUMOR FREE,YES,16.0,Image Analysis,Image Analysis,Left,1.9777929687499936,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Malignant Phyllodes Tumor,Peri (6-12 months since last menstrual period),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,"Biopsy, NOS",Positive,Positive,Equivocal,0.9697265625,0.0,Allred Score 6,270 H,10-19%,ACIS,DAKOHercepTest TM,257.400390625,Vysis AutoVysion System,PathVysion Her-2 DNA,NO,YES,1.78,BoneLiver,80-89%,70-79%,Negative,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,118,4 Point Scale,1+,4thStage IIAT2N0 (i-)M0,NO,NO,PositivePositiveNegativeNegative,2,11,2010,TCGA-B6-A0RL-F13796B2545806-EF62-435D-8C96-4BE1AFC4178EScheduled Follow-up SubmissionNOYESDead2469TUMOR FREENO1272011,1TCGA-AR-A0TU-D19570EFEB5E4B-A824-4B78-B373-603E8A1C7BBA4ChemotherapyDoxorubicinADJUVANTNO151220111TCGA-AR-A0TU-D19572EE4C23A8-EDAC-4DE6-9B48-CD0BCB2D99784ChemotherapyDocetaxelADJUVANTNO151220111TCGA-AR-A0TU-D195718B38DA0D-2D5D-4484-BC07-F2BF3584123C4ChemotherapyCytoxanADJUVANTNO15122011,TCGA-AO-A0JE-R3198a51218ad-d05c-4f75-9d0b-4a9a4bd51689202243EXTERNAL BEAM16000cGy30Primary Tumor FieldADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,107.0,WHITE,TCGA-EW-A1PE,EW,A1PE,No,YES,C50.9,8507/3,C50.9,2011.0,TUMOR FREE,YES,23.0,H-SCORE 260,H-SCORE 0,Left Upper Outer Quadrant,2.408281249999998,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Re-excision of the inferior margin,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Positive,Positive,Negative,0.224609375,1.0,Allred score 8,Moderate,<10%,CISH,Hercep Test TM DAKO,169.759765625,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,118,LungBone,90-99%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,105,3 Point Scale,3+,7thStage IIAT1cN1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-EW-A1PE-F2910824F4F0FF-7280-401C-AA8D-816162986D9BScheduled Follow-up SubmissionYESYESAlive320TUMOR FREENO832012,FEC then TTCGA-EW-A1PE-D302649419C58F-6F5C-443B-A471-E46D727005DE603mg200mg3132174ChemotherapyTaxotereADJUVANTIVNO832012FEC then TTCGA-EW-A1PE-D30263DD378684-5C18-47DC-902E-D3280283DAAB598mg200mg371111ChemotherapyFluorouracilADJUVANTIVNO832012FEC then TTCGA-EW-A1PE-D302629592447F-C6E8-43AF-8E6D-A30F6ED755442990mg1000mg371111ChemotherapyCyclophosphamideADJUVANTIVNO8320122TCGA-EW-A1PE-D307029A2FDA20-E99F-42D4-B233-C6EBD504545D25mg/day269Hormone TherapyExemestaneADJUVANTPOYES832012FEC then TTCGA-EW-A1PE-D3026112C9B1C5-FC49-432B-BDD4-5492291120CA2990mg1000mg371111ChemotherapyEpirubicinADJUVANTIVNO832012,"TCGA-EW-A1PE-R30266E51F4CA1-EFA3-4660-BE2F-4A2E464A2496208269EXTERNAL BEAM10,500cGy25Primary Tumor FieldADJUVANTNO1832012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,585.0,WHITE,TCGA-AO-A0J2,AO,A0J2,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.0,allred score 0 + 0 = 0,Allred score 2+2 = 4,Left Lower Inner QuadrantLeft,1.5,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Negative,Equivocal,0.0,0.0,Intensity=Weak,Intensity=Strong,30-39%,CISH,3+ POSITIVE,40.0,HER2 amplification - negative,RATIO > 2.2,NO,YES,2.4,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,3.5,3 Point Scale,2+,Stage IAT1cN0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,19,9,2010,TCGA-AO-A0J2-F3120E53098E7-BE78-4106-8496-E08E4D23D102585AliveTUMOR FREENOYES1992010TCGA-AO-A0J2-F1548104B90C44-B6F4-4F85-A233-052B0C12C62BScheduled Follow-up SubmissionNOYESAlive997TUMOR FREENO2282011,1TCGA-AO-A0J2-D312556624a3a-1602-438a-b089-4782c8fcbed61040mg175mg/m24120162ChemotherapyPACLITAXELADJUVANTIVNO19920101TCGA-AO-A0J2-D3122e2ba693c-5978-4227-b81a-4a4823d3ee843600mg600mg/m2464106ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO19920101TCGA-AO-A0J2-D3124ed9afd15-7930-40b7-808e-705182137410360mg60mg/m2464106ChemotherapyDOXORUBICINADJUVANTIVNO1992010,TCGA-A2-A04R-R25577b76f4d4-65c9-4ff3-abef-09844e8fc56a300342EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112102010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1966.0,BLACK OR AFRICAN AMERICAN,TCGA-AO-A0JE,AO,A0JE,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,29.0,H-SCORE 0,%IHC,Right Lower Outer QuadrantRight,3.8,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,3+,Negative,Positive,Core needle biopsy,stereotactic biopsy,Positive,Negative,Positive,0.0,8.0,Two-tier,Moderate,50-59%,CISH,3+ POSITIVE,33.0,HER2 amplification - negative,RATIO > = 2.0,NO,YES,71,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,269,3 Point Scale,2+,Stage IIIAT2N2aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,20,9,2010,TCGA-AO-A0JE-F31975076E01B-BDF8-4116-84A5-E432D1D45E3A1966AliveTUMOR FREEYESYES2092010TCGA-AO-A0JE-F15488975B8C53-2E18-4DBB-9A34-2DCCA4680406Scheduled Follow-up SubmissionYESYESAlive2335TUMOR FREENO2282011,1TCGA-AO-A0JE-D320233e32dbf-9c8e-4dff-b75b-c6342c56420a1220mg175mg/m24119161ChemotherapyPACLITAXELADJUVANTIVNO20920102TCGA-AO-A0JE-D32032806bb73-968f-4ce0-a287-e75f00b76f6d7869mg6mg/kg22119462Targeted Molecular therapyTRASTUZUMABADJUVANTIVNO20920101TCGA-AO-A0JE-D320050d69645-1eb9-4fa7-83c0-f6614085a07f428mg60mg/m2463105ChemotherapyDOXORUBICINADJUVANTIVNO20920101TCGA-AO-A0JE-D3199d2701b3c-2642-422e-afff-33ea4ef763594272mg600mg/m2463105ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO2092010,TCGA-AO-A0JE-R3198a51218ad-d05c-4f75-9d0b-4a9a4bd51689202243EXTERNAL BEAM16000cGy30Primary Tumor FieldADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,477.0,WHITE,TCGA-BH-A0E1,BH,A0E1,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,17.0,H-SCORE 180,H-SCORE 245,Left Upper Inner QuadrantLeft,1.69,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Right Breast reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,Ductal partially papillary,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.9794921875,2.0,H-SCORE,H-SCORE,30-39%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.0,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,1.67,"LungBoneLiverOther, specifyskin",70-79%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.81,3 Point Scale,3+,Stage IIBT2N1M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-BH-A0E1-F4631CFD1B195-8DD2-421F-B5EC-E88E05B12781477AliveTUMOR FREENOYES16112010,1TCGA-BH-A0E1-D4606F8C26458-97F0-4CF8-A153-FBA11A2229374140203ChemotherapyCYTOXANADJUVANTIVNO301120101TCGA-BH-A0E1-D460580A0A78F-619A-4E22-AFF1-7C0E3E08A26B4140203ChemotherapyADRIAMYCINADJUVANTIVNO301120101TCGA-BH-A0E1-D4630040CDDFF-2EDD-437D-AB7D-3C4C995301A312308596ChemotherapyTAXOTEREADJUVANTIVNO301120101TCGA-BH-A0E1-D460487AC4755-E995-47CF-90E0-FDD4084563871mg/day349Hormone TherapyARIMIDEXADJUVANTPOYES30112010,TCGA-A2-A0T0-R3435216a63e4-215a-4fc7-a5ea-e50076307b40262323EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12U,C8,A12U,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,H-SCORE 260,Allred score 4+3 = 7,Right,1.4133691406249944,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.0380859375,1.58203125,Allred Score 3,Allred Score 5,30-39%,Hercep Test  TM Dako,CAP scoring guideline 2010,105.4853515625,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,2.13,"Other, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,105,4 Point Scale,1+,6thStage IIBT2N1M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",13,4,2011,TCGA-C8-A12U-F2024906835152-B8AC-4FE9-A8E6-873E5B07FD48Scheduled Follow-up SubmissionNONOAlive385TUMOR FREENO912012,TCGA-EW-A1J6-D21611DE34FA0A-12BB-466B-9E7B-053B947EC6962.5mg/day111Hormone TherapyFemaraADJUVANTPOYES1622012,TCGA-A2-A0SX-R4026b73451cc-daa2-4f73-bf06-517ddecd777f213EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,Yes,FEMALE,Dead,883.0,218.8583984375,WHITE,TCGA-A8-A06U,A8,A06U,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,14.5576171875,CAP SCORING GUIDELINE 2010,H-SCORE 150,Right Upper Outer Quadrant,1.7755371093749954,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Positive,Positive,Positive,0.3173828125,1.46484375,Allred Score 5,STRONG,10-19%,Hercep Test  TM Dako,Dako Hercept test,135.7685546875,HER2 amplification - negative,PathVysion,NO,YES,1.57,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,59,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,27,5,2011,TCGA-A8-A06U-F40817B73596BB-A8E2-4419-A10A-5FB43A34299BNONOTUMOR FREEDead883232013,1TCGA-E2-A156-D187879FA71240-8DEF-42FE-9235-91CC3980DDF71mg/day1mg/day119Hormone TherapyArimidexADJUVANTPOYES8112011,TCGA-AO-A126-R5877a3a403cf-f4f1-46ae-a7b9-d614b4e1266c384421EXTERNAL BEAM10000cGy25Local RecurrenceRECURRENCENO17122010
TCGAFPPP,Breast,No,FEMALE,Dead,1272.0,1300.3525390625,WHITE,TCGA-AR-A1AT,AR,A1AT,No,YES,C50.9,8520/3,C50.9,2007.0,WITH TUMOR,YES,3.0,H-Score 150,IHC,Left Upper Outer Quadrant,3.0566113281249807,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Re-excision of the inferior margin,Other,Wide local excision,Infiltrating Lobular Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,3+,Positive,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Positive,0.0087890625,1.0,Allred score = 0,H-Score,30-39%,Hercep Test  TM Dako,+ or -,101.228515625,HER2 amplification - negative,PathVysion,NO,YES,54,"Other, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,71,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,NONO,14,6,2011,TCGA-AR-A1AT-F22148D7B56DE8-A5E4-4524-80B2-C2260F0A0054Scheduled Follow-up SubmissionYESYESDead1272NO132012,3TCGA-AR-A1AT-D2215346749B9C-613A-40A5-B0CB-44978EEF1A911mg/day1741272Hormone TherapyAnastrozoleADJUVANTPONO1320122TCGA-AR-A1AT-D22152022F99BE-9A3B-44EF-94DE-B304CF259B65ImmunotherapyTrastuzumabADJUVANTNO1320121TCGA-AR-A1AT-D2215063B8C39E-9EA4-4B8E-9431-A97DAA709EB4ChemotherapyNot otherwise specifiedADJUVANTNO132012,TCGA-AR-A1AT-R2214953C226CF-2609-447A-8D85-B49B4E12C7EDNO132012
TCGAFPPP,Breast,No,FEMALE,Dead,3126.0,4358.751953125,WHITE,TCGA-B6-A0RP,B6,A0RP,No,YES,C50.9,8522/3,C50.9,1994.0,WITH TUMOR,YES,15.0,Image Analysis,Image Analysis,Left Upper Outer QuadrantLeft,1.8636035156249973,Axillary lymph node dissection alone,axillary ultrasound,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,bilateral total mastectomies with right sentinel node biopsy,Mixed Histology (please specify),ductal/lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,4+,2+,Negative,Positive,"Other method, specify:","Biopsy, NOS",Negative,Positive,Equivocal,0.857421875,2.0,Allred score 7 per outside facility report,H score,10-19%,ACIS,Hecep Test TM DAKO,161.5078125,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,NO,YES,54,BoneLiver,80-89%,10-19%,Negative,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,2.3,4 Point Scale,1+,4thT2N1bM0,YES,NO,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,2,11,2010,TCGA-B6-A0RP-F137863A57F47C-7FC0-48B0-9F95-B5C63CEC73BEScheduled Follow-up SubmissionNOYESDead3126WITH TUMORYES2787Distant MetastasisBoneNONOYES1272011,TCGA-E9-A1RB-D30858ED42B1AF-E7F0-4598-9EFE-12B6AEA180C320mg/day15Hormone TherapyTamoxifenADJUVANTPOYES1742012TCGA-E9-A1RB-D3085625429B7D-51F9-4C70-AC60-B8148B735388500mg100mg511107ChemotherapyMethotrexateADJUVANTIVNO1742012TCGA-E9-A1RB-D308575E138DC3-70C8-4195-8DF7-2EFC4FA2740710000mg2000mg511107Chemotherapy5-FluorouracilADJUVANTIVNO1742012TCGA-E9-A1RB-D3085927022DC0-5FA3-4EB4-B968-C35A4655475D10000mg2000mg511107ChemotherapyCyclophosphamideADJUVANTIVNO1742012,TCGA-AO-A0JF-R3205605f8f77-3566-431e-93ae-33ec0b26904a299328EXTERNAL BEAM5272cGy21Primary Tumor FieldADJUVANTNO1692010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,316.0,WHITE,TCGA-E2-A15D,E2,A15D,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.0,dextran coated charcoal,Allred score 2+2 = 4,Right,1.1,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Equivocal,0.345703125,0.0,Allred score = 8,Allred score = 8,90-99%,Dako,Venten,70.5888671875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,66,"Other, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,PositivePositiveNegativeNegative1.09,13,4,2011,TCGA-E2-A15D-F187833C9904FC-1B91-4FBD-B16D-F2FBBAE64A14Scheduled Follow-up SubmissionYESYESAlive526TUMOR FREENO9112011,1TCGA-E2-A15D-D1878439818837-2CB1-402D-AEE7-456C52833C474100mg20mg111316Hormone TherapyTamoxifenADJUVANTPONO9112011,TCGA-E2-A15D-R1878536563FC0-3E99-4312-B812-D3595CDCFEE461106EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO19112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,911.0,WHITE,TCGA-E2-A1B4,E2,A1B4,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.0,Allred score 5+3 = 8,Allred score 5+3 = 8,Left Upper Inner Quadrant,1.1656347656249997,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.3427734375,3.0,Allred score = 8,Allred score = 8,10-19%,Hercep Test  TM Dako,Dako Hercept test,110.6044921875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.5,"Other, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,145,3 Point Scale,2+,6thStage IIIAT1cN2aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",25,4,2011,TCGA-E2-A1B4-F19443C0578C7E-FCF4-4943-8D39-E0350CDF44D3Scheduled Follow-up SubmissionYESYESDead1004TUMOR FREENO8122011,1TCGA-E2-A1B4-D19444A6C154F3-9CE0-4FC3-943B-640A43ADC915828mg1mg/day1761004Hormone TherapyarimidexADJUVANTPONO8122011,TCGA-E2-A1B4-R19446BD169F79-61EA-4201-866C-A99BFEB0CFC483187EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO18122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,28.0,WHITE,TCGA-AC-A2QI,AC,A2QI,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,2.0,H-Score 150,IHC,Right,1.4307714843750052,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Right Breast reexcision,Modified radical mastectomy,Total Mastectomy,Infiltrating Lobular Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.07421875,2.0,allred score = 6,0%,<10%,ACIS,Hercep Test  TM Dako,57.4296875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,1.0,"Other, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.80,3 Point Scale,3+,7thStage IIIAT3N1aMX,YES,NO,YES994Distant MetastasisBoneNOYESYES,18,10,2011,TCGA-AC-A2QI-F570476AA0381B-1A09-4E7E-A968-8065C44EB313NOYESYESTUMOR FREEAlive588NO2822014,NOTCGA-AC-A2QI-D570497AE4D249-9E5B-463E-9352-BB540E0FD3AB100275ChemotherapyCytoxanNOComplete Response2822014NOTCGA-AC-A2QI-D57050811FCC91-6880-400D-B7BB-C848DF5A5C23100275Chemotherapy5-FUNOComplete Response2822014NOTCGA-AC-A2QI-D57051ED0E149B-307C-4202-9AD7-09B21CE8FAB9100275ChemotherapyMethotrexateNOComplete Response2822014,TCGA-AC-A2QI-R5704867D9DBB7-C7EE-49D0-9D87-3DA5AD405CFF309355External6040cGy33Primary Tumor FieldNOComplete Response2822014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,61.0,WHITE,TCGA-BH-A18G,BH,A18G,No,YES,C50.5,8500/3,C50.5,2010.0,TUMOR FREE,YES,3.0,Allread score 5+3 = 8,Allred score 7 per outside facility report,Right,2.4388085937499966,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Other,Right Breast reexcision,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, classical type, focal pleomorphic type",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,4 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Equivocal,Negative,Negative,1.546875,0.0,Allred Score 4,250,10-19%,ACIS,Hercep Test  TM Dako,125.1171875,HER2 amplification - negative,Positive >2.2,NO,YES,3.1,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,60-69%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,<4.0,4 Point Scale,1+,Stage IAT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,1,6,2011,TCGA-BH-A18G-F64216112BA8BF-77D2-4E83-AAFE-9FABF7EC76CANOYESNOTUMOR FREEAlive149NO2782014,NOTCGA-EW-A2FV-D32327A38929AB-8A68-468D-ADE5-A9CA41F35D39141246ChemotherapyDocetaxelNO2352012NOTCGA-EW-A2FV-D323281E9A1A88-0C4F-4990-8144-7C1499F9CFE3141246ChemotherapyDoxorubicinNO2352012NOTCGA-EW-A2FV-D32329B03E11F1-B000-4AF8-867B-BBAA82017EFD141246ChemotherapyCyclophosphamideNO2352012NOTCGA-EW-A2FV-D32330A6AB155D-A721-4195-B5D4-0D2C98677EBE268Hormone TherapyTamoxifenYES2352012NOTCGA-EW-A2FV-D32331A0359D0A-8675-430D-B394-9D12D035767C268Hormone TherapyGoserelinYES2352012,TCGA-BH-A18G-R64217911630F0-5BE2-4E57-8DB4-987BF400F086103149External6000cGy25Primary Tumor FieldNOComplete Response2782014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,105.0,WHITE,TCGA-D8-A1JS,D8,A1JS,No,YES,C50.9,8503/3,C50.9,2010.0,TUMOR FREE,YES,13.0,manual counting,manual counting,Right Upper Outer Quadrant,1.0152929687500016,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,breast conserving therapy,"Other, specify",papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Positive,Negative,0.298828125,0.0,>75%,>75%,30-39%,Dako,Hecep Test TM DAKO,193.7119140625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.7,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.2,3 Point Scale,2+,7thStage IAT1cN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,3,2011,TCGA-D8-A1JS-F1405107528AAE-783F-405C-92D4-AE19620D76CBScheduled Follow-up SubmissionNOYESAlive371TUMOR FREENO1872011,hormone therapyTCGA-D8-A1JS-D140528318EC65-2D4F-490D-9C42-264220D999DAmg/day20mg/day14Hormone TherapyTamoxifenADJUVANTPOYES1872011,TCGA-A8-A06X-R381790E1337C9-4541-4CCF-B78A-A3CF4F763A066192External52GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3120.0,WHITE,TCGA-AO-A124,AO,A124,No,YES,C50.9,8523/3,C50.9,2002.0,TUMOR FREE,YES,18.0,Allred 0 = 0+0,Allred score 0+0 = 0,Left,1.5228808593749958,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,surgical resection,"Other, specify",mucinous & Ductal,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,0,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.0,0.0,Allred score = 5,Allred score = 7,<10%,CISH,3+ Positive,73.5390625,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,1.78,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,<4.0,3 Point Scale,1+,5thStage IIAT2N0 (i-)M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,12,2010,TCGA-AO-A124-F5872F53CE454-A59B-4F2B-A928-96D5BEEDECDC3120AliveTUMOR FREENOYES7122010TCGA-AO-A124-F193954C248C62-B6C3-4222-AA49-AF4679BD9264Scheduled Follow-up SubmissionNOYESAlive3506NO12122011,1TCGA-AO-A124-D59327bd8d7d3-3c72-4d00-9efb-7b5cc816aae9424mg60mg/m2460126ChemotherapyDoxorubicinADJUVANTIVNO10120111TCGA-AO-A124-D593402906cd5-712c-423b-8684-6830cf1a7c7e1600mg175mg/m25147238ChemotherapyPaclitaxelADJUVANTIVNO10120111TCGA-AO-A124-D5933c107f6da-b6fa-47ff-b3a3-d6edac66e0f44240mg600mg/m2460126ChemotherapyCyclophosphamideADJUVANTIVNO1012011,TCGA-A8-A08L-R38161D73DFE9C-A7EF-4DD0-8879-04052984D07D3030External45GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,337.0,WHITE,TCGA-A2-A0T0,A2,A0T0,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,14.0,H-SCORE 140,H-Score 160,Left Lower Outer Quadrant,1.8481152343749965,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Apocrine,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,1+,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.0419921875,2.0,Allred score = 4,Allred score 8,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,42.8701171875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,4,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,3.65,3 Point Scale,0,6thStage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,12,11,2010,TCGA-A2-A0T0-F13944B0DC7631-8558-431C-B56D-B8C9C74C29F5Scheduled Follow-up SubmissionYESYESAlive533TUMOR FREENO1872011,1TCGA-A2-A0T0-D34307b30d8b7-1a91-4f14-93d1-1d690c083a3amgmg50234ChemotherapyTaxotereADJUVANTIVNO121120103TCGA-A2-A0T0-D3434d86d4e6c-4305-493c-b8bf-968971f358c9mgmg50234ChemotherapyCytoxanADJUVANTIVNO121120102TCGA-A2-A0T0-D3432e011bb8b-77b8-4daa-9bea-75f9c039e676mgmg50234ChemotherapyAdriamycinADJUVANTIVNO12112010,TCGA-A2-A0T0-R3435216a63e4-215a-4fc7-a5ea-e50076307b40262323EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,239.0,WHITE,TCGA-EW-A2FV,EW,A2FV,No,YES,C50.9,8507/3,C50.9,2011.0,TUMOR FREE,YES,32.0,H-SCORE 260,IHC,Left Upper Inner Quadrant,1.273681640625005,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Fine Needle aspiration biopsy,"Other, specify",invasive micropapillary ductal carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Excisional Biopsy,Lumpectomy,Negative,Positive,Negative,0.3193359375,29.0,8,8,<10%,CISH,Dako Hercept test,73.625,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,2.6,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,816,3 Point Scale,3+,7thStage IIICT3N3aMX,NO,YES,YES994Distant MetastasisBoneNOYESYES,5,10,2011,TCGA-EW-A2FV-F32324A772DDD5-FD35-4692-BB42-38E76B8D5016Scheduled Follow-up SubmissionYESYESAlive428TUMOR FREENO2352012TCGA-EW-A2FV-F4206554F63442-7AE5-4512-B4D8-853D2F27707ANOYESYESTUMOR FREEAlive788NO1042013,NOTCGA-EW-A2FV-D32327A38929AB-8A68-468D-ADE5-A9CA41F35D39141246ChemotherapyDocetaxelNO2352012NOTCGA-EW-A2FV-D323281E9A1A88-0C4F-4990-8144-7C1499F9CFE3141246ChemotherapyDoxorubicinNO2352012NOTCGA-EW-A2FV-D32329B03E11F1-B000-4AF8-867B-BBAA82017EFD141246ChemotherapyCyclophosphamideNO2352012NOTCGA-EW-A2FV-D32330A6AB155D-A721-4195-B5D4-0D2C98677EBE268Hormone TherapyTamoxifenYES2352012NOTCGA-EW-A2FV-D32331A0359D0A-8675-430D-B394-9D12D035767C268Hormone TherapyGoserelinYES2352012,TCGA-EW-A2FV-R32325F344EF8E-08CC-4FBD-B10F-ED74909B2EDD329391EXTERNAL BEAM9700cGy30Primary Tumor FieldADJUVANTNO12352012
TCGAFPPP,Breast,No,FEMALE,Dead,160.0,1284.3232421875,WHITE,TCGA-AR-A0TR,AR,A0TR,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,27.0,Allred score 5+3 = 8,Image Analysis,Left,1.485478515624998,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Biopsy not specified,Negative,Positive,Equivocal,0.2607421875,1.0,10-75%,Allred Score 8,30-39%,Dako,CAP SCORING GUIDELINE 2010,161.265625,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,54,"Other, specifyskin",80-89%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,60,3 Point Scale,0,Stage IIBT2N1M0,YES,YES,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,8,3,2011,TCGA-AR-A0TR-F18771C7428C57-68C1-4574-81BA-167AAA258024Scheduled Follow-up SubmissionNOYESDead160NO12122011,1TCGA-AR-A0TR-D193701D3E42DF-081F-4DA4-927E-03701EF9B27020mg/dL25160Hormone TherapyTamoxifenADJUVANTPONO12122011,TCGA-AC-A3TN-R60191F59786E2-ADDA-4D6F-AD25-572BB54CEA1E96144External6040cGyPrimary Tumor FieldNOComplete Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1471.0,WHITE,TCGA-AO-A12F,AO,A12F,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,17.0,ER Positive H-Score 95,H-Score 15,Right Upper Outer QuadrantRight,1.2904687500000018,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast reexcision,Modified radical mastectomy,Wide Local Excision,Infiltrating Ductal Carcinoma,Mixed infiltrating lobular and grade 1 ductal carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.0,0.0,<10%,STRONG,<10%,CISH,3+ Positive,31.9638671875,Vysis AutoVysion System,Path Vysion HER2 DNA Probe Kit,NO,YES,50,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.67,3 Point Scale,0,6thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,8,12,2010,TCGA-AO-A12F-F5899D78677C1-3F45-44EB-B8B7-0DCE0D11019D1471AliveTUMOR FREEYESYES8122010TCGA-AO-A12F-F1943420F415F8-AAC1-42CF-B61F-F8035EAD23B8Scheduled Follow-up SubmissionYESYESAlive1842TUMOR FREENO12122011,1TCGA-AO-A12F-D5981272961f9-9281-4a6c-81c0-f2052b56f0e1175mg/m2463189ChemotherapyPaclitaxelADJUVANTIVNO10120111TCGA-AO-A12F-D5979c34652a1-fcbd-42e8-9bfb-991088feb8bd600mg/m2463189ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A12F-D5980694d184f-3285-46a6-904c-6c2136c0e92d60mg/m2463189ChemotherapyDoxorubicinADJUVANTIVNO1012011,TCGA-AO-A12F-R5904d6634ff1-45f7-48bb-9b16-7b9d2f69a6db220254EXTERNAL BEAM5000cGy25Regional siteADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2352.0,WHITE,TCGA-GM-A2DN,GM,A2DN,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,9.0,H-SCORE 190,Allred score 7 per outside facility report,Left Upper Outer Quadrant,2.61942382812499,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,right segmental mastectomy,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Positive,Positive,Negative,0.0,0.0,8,8,10-19%,0,Dako Hecept Test,72.685546875,HER2 amplification - negative,Ratio >=2.0,NO,YES,67,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,47,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,30,9,2011,TCGA-GM-A2DN-F471248C417396-011E-4C2E-B08C-42A8A47EA1D7NONOYESTUMOR FREEAlive3091NO2282013,YESTCGA-GM-A2DN-D471262F3C7A0D-A528-4393-8A8C-E4BA2A55F39A167244ChemotherapyTaxolNOComplete Response2282013YESTCGA-GM-A2DN-D4712723F229E0-8687-49C9-A84B-FF6D954A025E251314ChemotherapyFluorouracilNOComplete Response2282013YESTCGA-GM-A2DN-D47128F64D6F34-B6B3-4B1A-88DE-96B8C8A07835251314ChemotherapyEpirubicinNOComplete Response2282013YESTCGA-GM-A2DN-D471299CB21DFD-9BDD-4A32-A8A7-1E5F2519AC34251314ChemotherapyCytoxanNOComplete Response2282013NOTCGA-GM-A2DN-D47130F102C2E8-AC64-42D3-8420-DD1DF9F856C03351063Hormone TherapyArimidexNOComplete Response2282013,TCGA-AO-A1KT-R9906e031925b-8fc6-4d32-9a26-d3fdf0ae7662238280EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1142011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1363.0,WHITE,TCGA-BH-A0E7,BH,A0E7,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,17.0,H-SCORE 136,H-Score-230,Left Upper Outer QuadrantLeft,2.149990234375004,Axillary lymph node dissection alone,axillary ultrasound,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive mixed ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Excisional Biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.37109375,1.0,Allred score = 0,Strong,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.3515625,HER2 amplification - negative,Ratio >=2.0,NO,YES,118,"LungBoneLiverOther, specifyskin",50-59%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,1.98,3 Point Scale,3+,Stage IIBT2N1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-BH-A0E7-F4656C4793CFE-2B14-4704-BEC5-5E9961E516CD1363AliveTUMOR FREEYESYESNONONONO16112010,1TCGA-BH-A0E7-D46537F0147D6-EB47-47CD-A3B8-E8B645FAB5171mg/day26Hormone TherapyARIMIDEXADJUVANTPOYES17112010,TCGA-BH-A0E7-R46558916C7B7-CD5F-4704-A422-9233DB47C9AA74124EXTERNAL BEAM5940cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,35.0,WHITE,TCGA-E9-A1RG,E9,A1RG,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,% IHC,Image Analysis,Right Upper Outer Quadrant,1.3380468750000047,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.82421875,4.0,allred score = 6,allred score = 0,<10%,ACIS,Dako Hecept Test,183.3955078125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,1.67,"Other, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.9,4 Point Scale,1+,7thStage IIIAT1cN2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,2,8,2011,TCGA-E9-A1RG-F3064289106DE0-F716-4415-8769-8B80305655DAScheduled Follow-up SubmissionYESYESAlive647TUMOR FREENO2412014TCGA-E9-A1RG-F395348AF68D77-E97C-4EA0-9609-FE1BC59C0186YESYESYESTUMOR FREEAlive647NO2412013,TCGA-E9-A1RG-D30645F5810F71-8A39-45E8-B825-FFD43A8B53F6200mg100mg232200ChemotherapyMethotrexateADJUVANTIVNO1342012TCGA-E9-A1RG-D3065117A6D8A3-3C52-47CE-9472-6B5586F2A6924000mg1000mg432200ChemotherapyCyclophosphamideADJUVANTIVNO1342012TCGA-E9-A1RG-D306447AAD1A06-8D8C-4EF1-8A1A-EF566C06B16B4000mg1000mg432200Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RG-D306469DC27C00-1D63-4E9D-A801-199B11EBABFF140mg70mg232200ChemotherapyMethotrexateADJUVANTIVNO1342012TCGA-E9-A1RG-D306496E4EA79B-DDD5-42BE-A154-8BD0E469C04B2000mg2000mg132200ChemotherapyCyclophosphamideADJUVANTIVNO1342012TCGA-E9-A1RG-D306475BFAE4C4-9F95-4703-828F-E55740F9BD7A100mg50mg232200ChemotherapyMethotrexateADJUVANTIVNO1342012TCGA-E9-A1RG-D30652679A17F2-BFCD-4260-AE16-9D5E95B41D3A20mg/day31Hormone TherapyTamoxifenADJUVANTPOYES1342012TCGA-E9-A1RG-D30643AD8B41A3-608E-459B-8F60-B4B6009218604000mg2000mg232200Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RG-D30650E1E678C3-0EE1-4950-BB4A-001B9FD2F4B91600mg1600mg132200ChemotherapyCyclophosphamideADJUVANTIVNO1342012,TCGA-E9-A1RG-R30653E189A27D-B536-4D3F-A1D3-7E38373AB1A7149177EXTERNAL BEAM9000cGy45Regional siteADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1620.0,WHITE,TCGA-AR-A24T,AR,A24T,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,17.0,Image Analysis,manual counting,Right Upper Outer Quadrant,1.4306152343750025,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Modified Radical Masectomy,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,0.185546875,15.0,0,0,<10%,Hercep Test  TM Dako,Dako Hercept test,72.767578125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,1.57,"Other, specifyaxilaary node negative but intrammary node positive",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.80,3 Point Scale,2+,6thStage IIICT3N3M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",30,8,2011,TCGA-AR-A24T-F315035DD029D1-BE31-4AA9-AA4E-CA2D73E449D0Scheduled Follow-up SubmissionYESYESAlive1620NO452012TCGA-AR-A24T-F4946371B7C342-2D87-4E59-B1DA-18539B19FA10YESYESTUMOR FREEAlive2312NO2102013TCGA-AR-A24T-F7172837FE3D8F-859F-4A8D-9AA3-443C80674854NOYESYESTUMOR FREEAlive3202NO3032015,3TCGA-AR-A24T-D315121CAF26F7-14B5-441D-B185-4B37F4059B932.5mg/day1995Hormone TherapyLetrozoleADJUVANTPOYES4520121TCGA-AR-A24T-D3150700300D73-B562-4EE9-A8D4-27E5B97AE5014270mg600mg/m243880ChemotherapyCytoxanADJUVANTIVNO4520121TCGA-AR-A24T-D31505E38D1685-E03E-45B3-B2E3-14C26D6034CB420mg60mg/m243880ChemotherapyDoxorubicinADJUVANTIVNO4520121TCGA-AR-A24T-D315086582CFB0-38DB-40AA-B9DB-3E4241EE51EF1260mg175mg/m2494157ChemotherapyPaclitaxelADJUVANTIVNO4520122TCGA-AR-A24T-D315104564981E-0469-40CD-A0F1-7EA3750491FF20mg/day1891864Hormone TherapyTamoxifenADJUVANTPONO452012,TCGA-AR-A24T-R315046E123228-9066-4185-98D4-BF4F80D1BE4A189225EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1452012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,421.0,WHITE,TCGA-A7-A26E,A7,A26E,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,16.0,H-SCORE 190,Allred (Biocare),Left,1.5082324218750025,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Other,Excision,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.1298828125,0.0,Allred score = 7,Allred Score 5,10-19%,CISH,Hercep Test TM DAKO,132.142578125,HER2 amplification - negative,Ratio >=2.0,YES,NO,78,"LungBoneLiverOther, specifyskin",90-99%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,21,3 Point Scale,3+,7thStage IIIAT3N1aMX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,7,2011,TCGA-A7-A26E-F14328F9E29A3B-E71E-4720-B9B3-C9E1DA264FDAScheduled Follow-up SubmissionYESYESAlive421TUMOR FREENO2872011TCGA-A7-A26E-F397923EB59670-FB49-4558-A017-3800A97063FBNOYESYESTUMOR FREEAlive954NO122013,1TCGA-A7-A26E-D143340C2B9A8F-545C-48C7-A411-6086687670A8mg1mg174247Hormone TherapyArimidexADJUVANTPOYES28720111TCGA-A7-A26E-D14322C7645868-53FA-4051-9EEE-5F7F6FD7DEB54000mg1000mg4101164ChemotherapyCytoxanADJUVANTIVNO28720111TCGA-A7-A26E-D14323BFCADEC4-0E84-4052-BA0C-C5F91DCDE496520mg130mg4101164ChemotherapyTaxotereADJUVANTIVNO2872011,TCGA-A7-A26E-R143251308CF80-262B-4503-AA14-B83907126CA2205246EXTERNAL BEAM9720cGy54Primary Tumor FieldADJUVANTNO12872011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,177.0,WHITE,TCGA-D8-A1XQ,D8,A1XQ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,% IHC,IHC,Right Upper Outer Quadrant,2.078574218749988,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,partial mastectomy,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Negative,Negative,0.0,0.0,H-SCORE,0%,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,76.7353515625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.38,"Other, specifyskin",70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,4.70,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,16,5,2011,TCGA-D8-A1XQ-F29449E3365AFC-09F9-4524-A456-5208C249283DScheduled Follow-up SubmissionNONOAlive499TUMOR FREENO2632012,NOTCGA-BH-A0C3-D635404DF39809-E3F7-4075-A18D-2883605F6B37109209ChemotherapyAdriamycinNOClinical Progressive Disease1282014NOTCGA-BH-A0C3-D635410540668E-ECBB-43B1-AEE3-51C9F20C42B1109209ChemotherapyCytoxanNOClinical Progressive Disease1282014,TCGA-A8-A06R-R381723F996702-1D58-4178-BBF8-51E62724C215181212External60GyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,182.0,WHITE,TCGA-D8-A27E,D8,A27E,No,YES,C50.9,8523/3,C50.9,2010.0,TUMOR FREE,YES,1.0,manual counting,manual counting,Left Upper Inner Quadrant,1.2927929687499986,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast reexcision,Other,quadrantectomy,"Other, specify",infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.00390625,0.0,Allred score = 0,>75%,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,119.76953125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,4,"Other, specifyskin",70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.5,3 Point Scale,2+,7thStage IAT1cN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,7,2011,TCGA-D8-A27E-F30112AB1218C8-CF64-40A3-80A9-654B1A5A0BD3Scheduled Follow-up SubmissionYESYESAlive530TUMOR FREENO242012,TCGA-D8-A27E-D301133D420476-7EB9-4632-B3F8-3BB85B979A0Dmg20+1mg/day125Hormone Therapytamoxiphen+anastrazolumADJUVANTPOYES242012,TCGA-D8-A27E-R301148DF3C173-15EF-461F-BF7E-D5D973330EF59095RADIOISOTOPE3400cGy10Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,29.0,WHITE,TCGA-E9-A249,E9,A249,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,Allred 0 = 0+0,H-SCORE 0,Left Upper Outer Quadrant,2.119511718749994,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Positive,Positive,Equivocal,0.0224609375,0.0,Allred Score 6,180,30-39%,Dako,Dako Hercept test,178.6318359375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,1.45,"Other, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,60,3 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,22,3,2011,TCGA-E9-A249-F31245EC37D95B-4379-46EA-A8F9-E46E14298215Scheduled Follow-up SubmissionYESYESAlive217TUMOR FREENO2542012TCGA-E9-A249-F491087E07DC42-0F43-488D-9ED8-EBA590B0B5FCYESYESYESTUMOR FREEAlive217NO2592013,TCGA-E9-A249-D31246A0F0004B-8C6B-4412-B770-39EB7B0401E61200mg1200mg128100ChemotherapyCyclophosphamideADJUVANTIVNO2542012TCGA-E9-A249-D31248ECDD44B4-F229-4DD5-80B7-0AF3F66BE1EC3000mg1000mg328100ChemotherapyCyclophosphamideADJUVANTIVNO2542012TCGA-E9-A249-D312497A8EA282-7B3B-4CB3-9B6F-F35946CED74A20mg/day28Hormone TherapyTamoxifenADJUVANTPOYES2542012NOTCGA-E9-A249-D39725877690E5-008F-454B-9C29-5210E3FCA33828100ChemotherapyDoxorubicinNO3112013,TCGA-E9-A249-R312501F1A22C3-9307-4C5F-8EA2-A29C7D429E58128155EXTERNAL BEAM13500cGyRegional siteADJUVANTNO12542012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,344.0,WHITE,TCGA-D8-A146,D8,A146,Yes,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,manual counting,manual counting,Right Upper Outer QuadrantRight,1.1419824218750003,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,segmental mastectomy with sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Negative,0.0966796875,0.0,>75%,>75%,30-39%,Dako,DAKO Hercep Test TM,96.91015625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,160,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.8,3 Point Scale,2+,7thStage IIAT2N0MX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",30,3,2011,TCGA-D8-A146-F2075033ECAE33-7777-48D5-BE7F-83396199B0FCScheduled Follow-up SubmissionNOYESAlive643TUMOR FREENO1512012,1TCGA-AO-A0JJ-D2972d0f2f580-2076-4fcd-9849-8a81d7f2032c1280mg200mg/m23126154ChemotherapyAbraxaneADJUVANTIVNO20920101TCGA-AO-A0JJ-D2968099545fb-d2c8-42e3-8f4a-7757316b4d864800mg600mg/m245698ChemotherapyCyclophospamideADJUVANTIVNO20920102TCGA-AO-A0JJ-D29749b8965e1-1b43-431d-9e0a-34e799297fae2.5mg/day154Hormone TherapyLetrozole (Femara)ADJUVANTPOYES20920101TCGA-AO-A0JJ-D2969d4c6bfa5-ed26-40c9-b7df-6e754510d790480mg60mg/m245698ChemotherapyDoxorubicinADJUVANTIVNO20920101TCGA-AO-A0JJ-D2971c14cd41b-9bac-4238-b267-0ccf43eae566350mg175mg/m21112112ChemotherapyPaclitaxelADJUVANTIVNO2092010,TCGA-D8-A27E-R301148DF3C173-15EF-461F-BF7E-D5D973330EF59095RADIOISOTOPE3400cGy10Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,319.0,WHITE,TCGA-D8-A1XL,D8,A1XL,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,13.0,manual counting,manual counting,Left Upper Outer Quadrant,1.3707714843750023,Axillary lymph node dissection alone,axillary ultrasound,Lumpectomy,Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.40234375,2.0,>75%,>75%,10-19%,Hercep Test  TM Dako,HercepTest TM Dako,86.0390625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,54,"Other, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.9,3 Point Scale,2+,7thStage IIBT2N1aMX,YES,YES,YES994Distant MetastasisBoneNOYESYES,9,6,2011,TCGA-D8-A1XL-F29990A52FC449-F807-4D82-AB8E-CDCF9B2484D4Scheduled Follow-up SubmissionYESYESAlive606TUMOR FREENO3132012,TCGA-D8-A1XL-D2999299E79238-A6D7-4960-8534-AC4370815F98mg20+11.25+10.8mg/day250Hormone Therapytamoxiphene+leuporeline+goserelineADJUVANTPOYES3132012TCGA-D8-A1XL-D29991A6E0C004-801E-45BB-AC10-CCEC1557F108403.2+4032mg100.8+1000.8mg/day465128Chemotherapydoxorubicine+cyclophosphamide+tamoxifenADJUVANTIVNO3132012,TCGA-D8-A1XL-R299930F71B55C-E625-4828-9275-B75E1E186FF7211249EXTERNAL BEAM11000cGy55Primary Tumor FieldADJUVANTNO3132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,786.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3XY,A2,A3XY,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,16.0,>10% STAINING = POSITIVE,allred score 2+2 = 4,Left Upper Outer Quadrant,1.13,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0087890625,3.0,240 H,Moderate,10-19%,Hercep Test  TM Dako,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,64.63671875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,2.13,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.73,3 Point Scale,1+,7thStage IIBT2N1aM0,YES,YES,NO,14,8,2012,"TCGA-A2-A3XY-F4331102379C43-DB21-44A9-AE3C-0A268B0FAB40NOYESYESWITH TUMORAlive1064YES802Distant MetastasisLungNONOYES813Locoregional RecurrenceOther, specifyMediastinal and Supraclavicular Lymph NodesNONOYES1652013TCGA-A2-A3XY-F558369C95F754-39EE-4F59-AF2D-7F215716D933NOYESYESWITH TUMORDead1093YES1072Distant MetastasisBrainNOYESNO1612014",YESTCGA-A2-A3XY-D34406CBE5F428-42AB-4719-A28B-3D8E9903B59686149ChemotherapyAdriamycinNOComplete Response1482012YESTCGA-A2-A3XY-D34407E7F46F97-06FB-49A1-B9B2-DC0F211325DC86149ChemotherapyCyclophosphamideNOComplete Response1482012YESTCGA-A2-A3XY-D344082BB3150F-2130-4FA5-9E80-A2F76E236D3C170170ChemotherapyAdriamycinNOComplete Response1482012YESTCGA-A2-A3XY-D34409385416B0-05A4-45C0-A807-DDFFE65C59EE170170ChemotherapyCyclophosphamideNOComplete Response1482012YESTCGA-A2-A3XY-D344116B22D335-A270-451A-93F4-A11F8A4875A6184254ChemotherapyPaclitaxelNOComplete Response1482012NOTCGA-A2-A3XY-D433124620C49F-B2FE-4FBD-8CD3-C2CAFBD9EEA4816913ChemotherapyCarboplatinNOClinical Progressive Disease1652013NOTCGA-A2-A3XY-D4331389205666-328A-4D84-8355-E8627C761EC58161019ChemotherapyGemcitabineNOClinical Progressive Disease1652013NOTCGA-A2-A3XY-D43314D2AD9346-11EA-432E-94D0-DC4429648DC110401061ChemotherapyDocetaxelNOClinical Progressive Disease1652013NOTCGA-A2-A3XY-D43315D420260B-7367-4532-AC11-A5A0966EBCBC8161058AncillaryDenosumabNOClinical Progressive Disease1652013,TCGA-A2-A3XY-R344057A7E240A-DBB4-4389-ABD4-1836FA872FF7366ExternalNOComplete Response1482012TCGA-A2-A3XY-R558370F6362E1-CAE1-405E-9935-8D0EB86AF3EF10741082External1800cGy6Distant siteNORadiographic Progressive Disease1612014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,418.0,WHITE,TCGA-E2-A10E,E2,A10E,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,21.0,Allred score 5+3=8,Allred score 3+2=5,Left,1.07,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.427734375,2.0,Allred score 5,Allred score 8,40-49%,Dako,CAP SCORING GUIDELINE 2010,227.1513671875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.13,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5,3 Point Scale,2+,6thStage IIAT1cN1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,11,2,2011,TCGA-E2-A10E-F17248B250E415-A582-4263-A230-F81B31F7F5F5Scheduled Follow-up SubmissionYESYESAlive865TUMOR FREENO2692011,1TCGA-E2-A10E-D7737bd0584f4-ee79-49a0-9ade-0ad380645278460123ChemotherapyCytoxan and TaxotereADJUVANTIVNO14220112TCGA-E2-A10E-D77397ec81080-5df3-4dc4-8ec6-5e0ea241af2e1mg/day1mg/day217Hormone TherapyArimidexADJUVANTPOYES14220111TCGA-E2-A10E-D1735400E33CEE-3545-4F64-BF71-25DC3724D422460mg115mg460123ChemotherapyDocetaxelADJUVANTIVNO26920111TCGA-E2-A10E-D17356299A38EF-5935-4D67-8EF7-C7BCE9FF5DCC3672mg918mg460123ChemotherapyCyclophosphamideADJUVANTIVNO2692011,TCGA-E2-A10E-R77345ff50f19-2a03-46b9-bc52-f3a402b02e14173218EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO11422011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,215.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A400,B6,A400,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.0,H-SCORE 300,Allred score 0+0=0,Left Upper Outer Quadrant,1.7601464843750032,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,4 Point Scale,1+,1+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Negative,Negative,0.064453125,4.0,Allred score = 5,250,<10%,Hercep Test  TM Dako,+ or -,70.1845703125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.1,"Other, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.58,4 Point Scale,1+,6thStage IIIAT2N2aM0,YES,YES,NO,20,9,2012,TCGA-B6-A400-F5965559780D28-66A6-427C-9E17-691B40C10281YESYESYESAlive215NO362014,1TCGA-A7-A26E-D143340C2B9A8F-545C-48C7-A411-6086687670A8mg1mg174247Hormone TherapyArimidexADJUVANTPOYES28720111TCGA-A7-A26E-D14322C7645868-53FA-4051-9EEE-5F7F6FD7DEB54000mg1000mg4101164ChemotherapyCytoxanADJUVANTIVNO28720111TCGA-A7-A26E-D14323BFCADEC4-0E84-4052-BA0C-C5F91DCDE496520mg130mg4101164ChemotherapyTaxotereADJUVANTIVNO2872011,TCGA-E9-A249-R312501F1A22C3-9307-4C5F-8EA2-A29C7D429E58128155EXTERNAL BEAM13500cGyRegional siteADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,90.0,WHITE,TCGA-AN-A04A,AN,A04A,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,7.0,Allred (Biocare),Allred (Biocare),Left Lower Inner QuadrantLeft Lower Outer Quadrant,3.3133691406250088,No axillary staging,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Modified radical mastectomy,Wide Local Excision,Infiltrating Ductal Carcinoma,secretory,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,0,Negative,Positive,Tumor resection,Ultrasound-guided biopsy,Positive,Positive,Negative,0.0,4.0,87,112,30-39%,0,Dako Hercept test,59.0576171875,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.0,LungBone,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.57,3 Point Scale,1+,7thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,29,12,2010,TCGA-AN-A04A-F689737C41E6F7-07DD-4DFA-8EBB-82C1546E7788YESTUMOR FREEAlive9024122014,NOTCGA-EW-A2FV-D32327A38929AB-8A68-468D-ADE5-A9CA41F35D39141246ChemotherapyDocetaxelNO2352012NOTCGA-EW-A2FV-D323281E9A1A88-0C4F-4990-8144-7C1499F9CFE3141246ChemotherapyDoxorubicinNO2352012NOTCGA-EW-A2FV-D32329B03E11F1-B000-4AF8-867B-BBAA82017EFD141246ChemotherapyCyclophosphamideNO2352012NOTCGA-EW-A2FV-D32330A6AB155D-A721-4195-B5D4-0D2C98677EBE268Hormone TherapyTamoxifenYES2352012NOTCGA-EW-A2FV-D32331A0359D0A-8675-430D-B394-9D12D035767C268Hormone TherapyGoserelinYES2352012,TCGA-D8-A1XK-R300734AF40BF7-8C93-4618-8EA8-7F5FAAC782D9253281EXTERNAL BEAM9000cGy45Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,151.0,WHITE,TCGA-A7-A3IY,A7,A3IY,No,YES,C50.9,8480/3,C50.9,2011.0,TUMOR FREE,YES,1.0,H-SCORE 190,allred score 5+3+8,Right Upper Outer Quadrant,1.338056640624994,Sentinel node biopsy alone,SN+1 non sentinel node,Lumpectomy,Right Breast reexcision,Lumpectomy,Fine Needle aspiration biopsy,Mucinous Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Close,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.708984375,0.0,allred score = 4,moderate,90-99%,CISH,CAP SCORING GUIDELINE 2010,353.7509765625,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,1.78,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5,3 Point Scale,2+,7thStage IT1cN0M0,YES,YES,PositiveNegative,19,3,2012,TCGA-A7-A3IY-F33856BC3680DF-06D0-4445-9DB2-63B4EC299C1CScheduled Follow-up SubmissionYESYESAlive345TUMOR FREENO2072012,NOTCGA-A7-A3IY-D33857C48F9151-4B8D-4590-AE3F-C0FD5C568755151Hormone TherapyAnastrozoleYES2072012,TCGA-A7-A3IY-R29468E359F454-990F-4308-983F-6F88ECAB2FF370116EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO11932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,160.0,WHITE,TCGA-A7-A0D9,A7,A0D9,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,H-Score 150,Allred score 2+2 = 4,Left Upper Outer QuadrantLeft,1.2529492187500002,Axillary lymph node dissection alone,axillary ultrasound,Simple Mastectomy,Reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,pleomorphic infiltrating lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,<10%,Two-tier,10-19%,0,dextran coated charcoal,67.447265625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,54,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,47,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,4,10,2010,TCGA-A7-A0D9-F2920CC7279B1-E6EC-4C7C-B5D3-1FB6ABFAA9BC273AliveTUMOR FREENOYES4112010TCGA-A7-A0D9-F397715570A0D0-8B4A-4607-B2AF-33D1B4A7EAF9NONOYESTUMOR FREEAlive1139NO122013,1TCGA-A7-A0D9-D29122a6eeaea-d6cf-4c0b-a97f-8dd3dd922972560mg140mg462125ChemotherapyTaxotereADJUVANTIVNO41120101TCGA-A7-A0D9-D291657f1f05f-cb78-4305-9469-fe76399db9124140mg20mg157Hormone TherapyTamoxifenADJUVANTPOYES41120101TCGA-A7-A0D9-D290780d0a61f-a26b-46d4-91b4-5028df32c9cb4320mg1080mg462125ChemotherapyCytoxanADJUVANTIVNO4112010,TCGA-E2-A15F-R18908D9E37765-4428-4C8E-A7D0-6C851A7C95FF4286EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO110112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1481.0,WHITE,TCGA-BH-A0BP,BH,A0BP,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,3.0,ER Positive H-Score 95,H-SCORE 290,Left Upper Outer Quadrant,2.0417480468750058,Sentinel node biopsy alone,axillary ultrasound,Other,Re-excision of the inferior margin,Modified radical mastectomy,Segmental mastectomy,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.212890625,0.0,Allred Score 5,STRONG,10-19%,Hercep Test  TM Dako,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,76.740234375,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.38,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,42,3 Point Scale,1+,6thStage IT1cN0M0,NO,YES,YES994Distant MetastasisBoneNOYESYES,9,8,2011,TCGA-BH-A0BP-F59122A6C7E31C-28D6-4762-AC61-52999F2DFB05NOYESNOTUMOR FREEDead2296NO152014,YESTCGA-GM-A2DN-D471262F3C7A0D-A528-4393-8A8C-E4BA2A55F39A167244ChemotherapyTaxolNOComplete Response2282013YESTCGA-GM-A2DN-D4712723F229E0-8687-49C9-A84B-FF6D954A025E251314ChemotherapyFluorouracilNOComplete Response2282013YESTCGA-GM-A2DN-D47128F64D6F34-B6B3-4B1A-88DE-96B8C8A07835251314ChemotherapyEpirubicinNOComplete Response2282013YESTCGA-GM-A2DN-D471299CB21DFD-9BDD-4A32-A8A7-1E5F2519AC34251314ChemotherapyCytoxanNOComplete Response2282013NOTCGA-GM-A2DN-D47130F102C2E8-AC64-42D3-8420-DD1DF9F856C03351063Hormone TherapyArimidexNOComplete Response2282013,TCGA-BH-A0BP-R59124F27E0482-22DF-4596-9362-2054248AF498124153External5000cGy33Primary Tumor FieldNOComplete Response152014TCGA-BH-A0BP-R591253F5C1BF6-607D-47CE-BCE8-FA3A3A183E79162162External1600cGyPrimary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,987.0,WHITE,TCGA-EW-A1P3,EW,A1P3,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.0,H-Score 150,IHC,Right Lower Outer Quadrant,1.1848828125000022,Other (specify),SN+1 non sentinel node,Simple Mastectomy,Reexcision,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,allred score =  8,Intensity=Strong,<10%,CISH,Dako Hecept Test,42.9208984375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,54,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,<4.0,3 Point Scale,3+,6thStage IIAT2N0MX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",10,6,2011,TCGA-EW-A1P3-F32277EDE411CE-6185-490D-B7D9-9B2FCBE02D96Scheduled Follow-up SubmissionNOYESAlive1260TUMOR FREENO1552012TCGA-EW-A1P3-F41142C361F496-F694-4201-844C-066F444499C3NONOYESTUMOR FREEAlive1611NO1232013,NOTCGA-EW-A1P3-D32283ADEE31EE-3558-4B60-9FB9-AE7031EEA45D2611175Hormone TherapyTamoxifenNOStable Disease2352012NOTCGA-EW-A1P3-D322842DF181FE-A297-4584-BC96-62221AB5790D1181Hormone TherapyFemaraYES2352012NOTCGA-EW-A1P3-D32279E96674F2-DD8B-48F7-A5FF-D00715D4FC07105147ChemotherapyFluorouracilNO3052012NOTCGA-EW-A1P3-D322807C343140-68DC-4876-A592-603D0A985E0E105147ChemotherapyEpirubicinNO3052012NOTCGA-EW-A1P3-D3228183B4A268-34F3-48DE-8F37-38D69F993505105147ChemotherapyCyclophosphamideNO3052012NOTCGA-EW-A1P3-D322820E200A24-933F-4B50-8382-45D54BFC5B59167233ChemotherapyPaclitaxelNOStable Disease3052012,TCGA-A2-A3XY-R344057A7E240A-DBB4-4389-ABD4-1836FA872FF7366ExternalNOComplete Response1482012TCGA-A2-A3XY-R558370F6362E1-CAE1-405E-9935-8D0EB86AF3EF10741082External1800cGy6Distant siteNORadiographic Progressive Disease1612014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1512.0,WHITE,TCGA-AO-A0JJ,AO,A0JJ,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,44.0,H-SCORE 280,Allred score 2+2 = 4,Left Upper Outer QuadrantLeft,1.607011718750002,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Lobular Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,0,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.1552734375,2.0,Intensity=Weak,STRONG,<10%,CISH,3+ POSITIVE,28.3046875,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.4,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.85,3 Point Scale,3+,Stage IIBT2N1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,20,9,2010,TCGA-AO-A0JJ-F2962C94CDE29-C7A4-459A-872E-6704D8598DB01512AliveTUMOR FREEYESYES2092010TCGA-AO-A0JJ-F154930466F12C-73BA-4B3A-9794-698974812CF6Scheduled Follow-up SubmissionYESYESAlive1887TUMOR FREENO2282011,1TCGA-AO-A0JJ-D2972d0f2f580-2076-4fcd-9849-8a81d7f2032c1280mg200mg/m23126154ChemotherapyAbraxaneADJUVANTIVNO20920101TCGA-AO-A0JJ-D2968099545fb-d2c8-42e3-8f4a-7757316b4d864800mg600mg/m245698ChemotherapyCyclophospamideADJUVANTIVNO20920102TCGA-AO-A0JJ-D29749b8965e1-1b43-431d-9e0a-34e799297fae2.5mg/day154Hormone TherapyLetrozole (Femara)ADJUVANTPOYES20920101TCGA-AO-A0JJ-D2969d4c6bfa5-ed26-40c9-b7df-6e754510d790480mg60mg/m245698ChemotherapyDoxorubicinADJUVANTIVNO20920101TCGA-AO-A0JJ-D2971c14cd41b-9bac-4238-b267-0ccf43eae566350mg175mg/m21112112ChemotherapyPaclitaxelADJUVANTIVNO2092010,TCGA-AO-A0JJ-R2967dbd25158-9d0f-4bfc-aa40-b2b6ac9685ea217256EXTERNAL BEAM10000cGy25Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,392.0,WHITE,TCGA-BH-A0HU,BH,A0HU,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,H-Score 140,H-Score 140,Right Upper Outer QuadrantRight,1.47816406250001,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/cribiform,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.3515625,0.0,H-Score,H-Score,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.5859375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.57,"LungBoneLiverOther, specifyskin",40-49%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,68,3 Point Scale,2+,Stage IAT1cN0 (i-)M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,11,11,2010,TCGA-BH-A0HU-F481340F5F2C3-261E-4B28-ACD9-B4999AFB0205392AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0HU-D48016D4CA4CC-7926-4E56-B25B-F27500BD827C20mg/day110Hormone TherapyTamoxifenADJUVANTPOYES171120101TCGA-BH-A0HU-D480326626424-B305-42C3-A6BD-086F573FE20B684mg170mg447110ChemotherapyDocetaxelADJUVANTIVNO181120101TCGA-BH-A0HU-D48025F867E23-30D8-48D8-B2D0-B005C681645F5472mg1362mg447110ChemotherapyCyclophosphamideADJUVANTIVNO18112010,TCGA-BH-A0HU-R48043BA2AF28-AFDF-46E2-A50D-AB7322DF428C155196EXTERNAL BEAM5750cGy30Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,834.0,WHITE,TCGA-E2-A14S,E2,A14S,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,Allred score 5+3 = 8,Allred score 4+3 = 7,Left Lower Outer Quadrant,1.04,Sentinel node biopsy alone,Pateys surgery,Lumpectomy,Reexcision,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.3408203125,0.0,Allred score = 7,Allred score = 8,90-99%,Dako,CAP SCORING GUIDELINE 2010,61.1318359375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.8,"Other, specifyaxilaary node negative but intrammary node positive",<10%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,5,3 Point Scale,2+,6thStage IT1cN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,6,4,2011,TCGA-E2-A14S-F18831BA1A9FEA-BC27-4CF3-95A9-65E53B46B582Scheduled Follow-up SubmissionYESYESAlive1009TUMOR FREENO3112011,2TCGA-E2-A14S-D1883637A94E43-59E6-49FE-BC0D-AB11CA6B313025mg/day25mg/day147Hormone TherapyAromasinADJUVANTPOYES31120111TCGA-E2-A14S-D18832DFE33AFA-BE0A-47EB-AA3E-07745099111C4728mg1182mg450119ChemotherapyCytoxanADJUVANTIVNO31120111TCGA-E2-A14S-D188343CD785FB-FFD4-4BC9-8B61-5CDF4C3205F4592mg148mg450119ChemotherapyTaxotereADJUVANTIVNO3112011,TCGA-E2-A14S-R188374A373E26-3FEB-48D8-B451-FAD04381BE4F160212EXTERNAL BEAM6280cGy34Primary Tumor FieldADJUVANTNO13112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,372.0,WHITE,TCGA-BH-A0WA,BH,A0WA,No,YES,C50.9,8575/3,C50.9,2008.0,TUMOR FREE,YES,3.0,H-Score 200,Allred score 5+3= 8,Right Upper Outer Quadrant,1.6788183593750017,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,segmental mastectomy,Mucinous Carcinoma,"Invasive lobular carcinoma, classical type, focal pleomorphic type",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Negative,Negative,0.4814453125,0.0,240 H,Two-tier,30-39%,Dako,Venten,225.1865234375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.9,3 Point Scale,2+,6thStage IT1cN0 (i-)M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,16,2,2011,TCGA-BH-A0WA-F34068B26AA90B-6D51-4807-902F-8E6B2E695140Scheduled Follow-up SubmissionNONOAlive701TUMOR FREENO2972012,1TCGA-AO-A12F-D5981272961f9-9281-4a6c-81c0-f2052b56f0e1175mg/m2463189ChemotherapyPaclitaxelADJUVANTIVNO10120111TCGA-AO-A12F-D5979c34652a1-fcbd-42e8-9bfb-991088feb8bd600mg/m2463189ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A12F-D5980694d184f-3285-46a6-904c-6c2136c0e92d60mg/m2463189ChemotherapyDoxorubicinADJUVANTIVNO1012011,TCGA-AO-A0JJ-R2967dbd25158-9d0f-4bfc-aa40-b2b6ac9685ea217256EXTERNAL BEAM10000cGy25Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,170.0,WHITE,TCGA-BH-A0RX,BH,A0RX,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,3.0,H-Score 0,H-Score 0,Left Upper Outer QuadrantLeft,2.0207519531250075,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,0,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.3037109375,0.0,H-Score,H-Score,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.5185546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,118,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,3.65,3 Point Scale,0,Stage IIAT2N0 (i-)M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,11,11,2010,TCGA-BH-A0RX-F48754CFEECD1-12BC-496C-9B8E-2E006F072A1E170AliveTUMOR FREEYESYESYES16112010,1TCGA-BH-A0RX-D48735D132A06-F3D4-4E01-ACBA-37EBA9BACD226808mg1122mg650155ChemotherapyFluorouracilADJUVANTIVNO181120101TCGA-BH-A0RX-D4872CBEF5FFD-0B68-4780-939F-C001E4A34CCB6808mg1122mg650155ChemotherapyCyclophosphamideADJUVANTIVNO181120101TCGA-BH-A0RX-D4874A90F4DFB-A730-4F63-B6A4-BDC3570C9474447mg75mg650155ChemotherapyMethotrexateADJUVANTIVNO18112010,TCGA-OL-A66N-R64494329248C5-412D-40AF-BC3D-5C54F1C54EB9374412External5040cGyPrimary Tumor FieldNOComplete Response1292014
TCGAFPPP,Breast,No,FEMALE,Dead,2192.0,881.7919921875,WHITE,TCGA-BH-A1FN,BH,A1FN,No,YES,C50.9,8500/3,C50.9,1997.0,WITH TUMOR,YES,29.0,H-Score 295,H-Score 15,Right Upper Outer Quadrant,2.3319726562499983,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Right Breast reexcision,Other,segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Apocrine,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Biopsy not specified,Negative,Positive,Negative,0.4482421875,0.0,MODERATE,8,<10%,Hercep Test  TM Dako,Dako Hercept test,57.6279296875,HER2 amplification - negative,Positive >2.2,NO,YES,1.57,"Other, specifyskin",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,3.65,3 Point Scale,2+,5thStage IIAT2N0M0,NO,YES,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,8,9,2011,TCGA-AN-A04A-F689737C41E6F7-07DD-4DFA-8EBB-82C1546E7788YESTUMOR FREEAlive9024122014,NOTCGA-EW-A2FV-D32327A38929AB-8A68-468D-ADE5-A9CA41F35D39141246ChemotherapyDocetaxelNO2352012NOTCGA-EW-A2FV-D323281E9A1A88-0C4F-4990-8144-7C1499F9CFE3141246ChemotherapyDoxorubicinNO2352012NOTCGA-EW-A2FV-D32329B03E11F1-B000-4AF8-867B-BBAA82017EFD141246ChemotherapyCyclophosphamideNO2352012NOTCGA-EW-A2FV-D32330A6AB155D-A721-4195-B5D4-0D2C98677EBE268Hormone TherapyTamoxifenYES2352012NOTCGA-EW-A2FV-D32331A0359D0A-8675-430D-B394-9D12D035767C268Hormone TherapyGoserelinYES2352012,TCGA-AO-A0JF-R3205605f8f77-3566-431e-93ae-33ec0b26904a299328EXTERNAL BEAM5272cGy21Primary Tumor FieldADJUVANTNO1692010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,973.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3XZ,A2,A3XZ,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,3.0,>10% STAINING = POSITIVE,allred score 2+2 = 4,Left Upper Inner QuadrantLeft Upper Outer Quadrant,2.540917968749988,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Margin resection,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Positive,0.0,0.0,200,250,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,89.1376953125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.38,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,42,3 Point Scale,1+,6thStage IT1cN0M0,YES,NO,NO,21,8,2012,TCGA-A2-A3XZ-F4330724F38B79-CE2B-497E-A800-AAD515C7A2B1NONOYESTUMOR FREEAlive1165NO1752013TCGA-A2-A3XZ-F5892416A1FC59-6B05-472B-A7F8-427B5324C1A5NONOYESTUMOR FREEAlive1532NO2842014,NOTCGA-A2-A3XZ-D34516EC157BD8-01E2-4587-87D0-ED9A7863A13697202ChemotherapyCarboplatinNOComplete Response2182012NOTCGA-A2-A3XZ-D345179E6E1263-16AB-4E0E-8C59-14347BB6F50C97202ChemotherapyDocetaxelNOComplete Response2182012NOTCGA-A2-A3XZ-D345183F688A9E-5E71-4676-BA57-190015FED40097423Targeted Molecular therapyTrastuzumabNOComplete Response2182012,TCGA-E9-A249-R312501F1A22C3-9307-4C5F-8EA2-A29C7D429E58128155EXTERNAL BEAM13500cGyRegional siteADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,437.0,WHITE,TCGA-A1-A0SD,A1,A0SD,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,3.0,H-SCORE 260,Allred score 4+3 = 7,Left,1.5820898437500008,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Lumpectomy,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.0,0.0,allred score = 6,80,30-39%,CISH,Dako Hecept Test,102.4375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.13,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,816,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,7,9,2011,TCGA-GM-A2DH-F4708142FCC169-41BB-48F3-BB58-86689559BD62NONOYESTUMOR FREEAlive2193NO2282013,NOTCGA-AC-A2FK-D66198A85E31F8-6790-4964-AC1A-C6253F9E413D51174ChemotherapyCytoxanNOComplete Response3102014NOTCGA-AC-A2FK-D66199118A7D45-089C-4980-B978-FD970C00090551174ChemotherapyAdriamycinNOComplete Response3102014NOTCGA-AC-A2FK-D6620096CBB13E-8C96-4CE4-B4FE-2FC707EC8044294Hormone TherapyFemaraNOComplete Response3102014NOTCGA-AC-A2FK-D6620167C16321-C0D6-4EE5-AA5C-25C290914D9E51174ChemotherapyTaxotereNOComplete Response3102014,"TCGA-EW-A1P1-R29236A05C32BB-CE32-45B3-88F1-10EE839FC231281322EXTERNAL BEAM11,000cGyPrimary Tumor FieldADJUVANTNO11232012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,169.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A6VX,A7,A6VX,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,2.0,Immune Stain by GenPath,Immune stain by GenPath,LeftLeft Upper Outer Quadrant,2.1469335937499885,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.2607421875,0.0,Moderate,Intensity=Strong,10-19%,CISH,Hercep Test  TM Dako,57.01171875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,1.73,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,47,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,NO,29,10,2013,TCGA-A7-A6VX-F57518447123BC-55E4-401F-9F3E-452E63FAED88NOYESYESTUMOR FREEAlive317NO1332014,NOTCGA-A7-A6VX-D50834660703C0-DE54-4AB9-A7E1-9AC73C6D7D7579142ChemotherapyDocetaxelNOComplete Response31102013NOTCGA-A7-A6VX-D508367F01C477-E69D-4E9E-81AB-2DB85686C1D279142ChemotherapyCyclophosphamideNOComplete Response31102013NOTCGA-A7-A6VX-D57517699D81B9-5EC8-4E6A-AE3A-3C9AD9B40B98230Hormone TherapyAnastrazoleYES1332014,TCGA-A7-A6VX-R57519717DF965-D0A9-459A-8C2F-BDB9C73B25D6170204External4500cGy25Primary Tumor FieldNOComplete Response1432014TCGA-A7-A6VX-R5753177DBF440-49CC-420D-B998-91FAAED0B34A206220External2000cGy10Primary Tumor FieldNOComplete Response1432014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,945.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A66L,OL,A66L,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,H-SCORE 280,Allred score 2+3 = 5,Right Lower Inner Quadrant,1.1,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,SKIN SPARING RADICAL MASTECTOMY,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.1630859375,1.7041015625,allred score =  8,Two-tier,90-99%,CISH,Hercep Test  TM Dako,38.1328125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,74,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1.66,3 Point Scale,3+,7thStage IAT1cN0MX,NO,YES,NO,11,6,2013,TCGA-OL-A66L-F5849343834AEE-2446-4577-8539-711FEA80E30FNOYESNOTUMOR FREEAlive1301NO1142014,1TCGA-AO-A0J8-D31377b8d5881-41d9-4c7b-ad68-60ae52734e668800mg600mg/m2863224ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO6920102TCGA-AO-A0J8-D31389b5ca20e-c9f2-4b98-be3a-d7ddacbf83291mg/day277Hormone TherapyANASTROZOLE (ARIMIDEX)ADJUVANTPOYES19920101TCGA-AO-A0J8-D3136082d6734-1bb5-4efc-90a5-d63188cb7651560mg40mg/m2863224ChemotherapyMETHOTREXATEADJUVANTIVNO19920101TCGA-AO-A0J8-D3131101e4937-20c7-461a-a4ce-a2e0b03c5f2d8800mg600mg/m2863224ChemotherapyFluorouracilADJUVANTIVNO1992010,TCGA-OL-A66L-R46789A689A4CE-EE17-4BFB-B69D-86DDFF35870F71120External6080cGyPrimary Tumor FieldNOComplete Response1292014
TCGAFPPP,Breast,No,FEMALE,Dead,1781.0,1781.41015625,WHITE,TCGA-B6-A0X7,B6,A0X7,No,YES,C50.9,8500/3,C50.9,1994.0,WITH TUMOR,YES,0.0,Image Analysis,Image Analysis,Right,1.3448925781250012,No axillary staging,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Right Breast reexcision,Modified radical mastectomy,EXCISION WITH NEEDLE WIRE LOCALIZATION,Mixed Histology (please specify),Ductal/Lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,4+,3+,Negative,Negative,Excisional Biopsy,intraoperative examination,Negative,Positive,Equivocal,0.7861328125,4.0322265625,Allred score = 5,190,10-19%,ACIS,DAKOHercepTest TM,73.8203125,HER2 amplification - negative,Positive >2.2,NO,YES,50,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,47,4 Point Scale,1+,4thStage XT1cNXMX,YES,NO,PositiveNegative1+,14,12,2010,"TCGA-B6-A0X7-F15714407D3BEE-E689-48D3-BD64-8C07564E2AD9Scheduled Follow-up SubmissionYESYESDead1781TUMOR FREEYES1104New Primary TumorOther, specifycolonYES1104NONO2982011",1TCGA-BH-A0B3-D1542013E5B5DC-2CA1-474B-A21D-B7AD5884839B4540mg1128mg452115ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO31120101TCGA-BH-A0B3-D1541949AB6F59-1B1E-4B04-914E-82339768A10C454mg113mg452115ChemotherapyDoxorubicinADJUVANTIVNO31120101TCGA-BH-A0B3-D15421E89062E2-7543-4BBA-9DA0-D4F6C81279C61873mg154mg12136213ChemotherapyPaclitaxelADJUVANTIVNO3112010,TCGA-AO-A0JJ-R2967dbd25158-9d0f-4bfc-aa40-b2b6ac9685ea217256EXTERNAL BEAM10000cGy25Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,8.0,BLACK OR AFRICAN AMERICAN,TCGA-PL-A8LY,PL,A8LY,No,YES,C50.9,8500/3,C50.9,2013.0,WITH TUMOR,NO,11.3369140625,H-Score 150,H-Score 290,RightRight Upper Outer Quadrant,1.8646289062500088,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Other,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,0.0576171875,3.634765625,108,130,90-99%,CISH,Hercep Test  TM Dako,54.158203125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,1.45,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,52,3 Point Scale,2+,7thStage IIBT3N0M0,NO,NO,NO,26,3,2014,TCGA-PL-A8LY-F64851D22A3C5D-4EAD-4A4B-ACAF-158F43785286YESNONOWITH TUMORAlive817102014,4TCGA-A2-A0EW-D679729e822b5-c5e4-453f-9c1b-a7e30508d9e21mg221812Hormone TherapyArimidexADJUVANTPONO6120092TCGA-A2-A0EW-D6794fd289cfd-fcaf-4acb-8fc0-5ca6b1ab340b463mg115-116mg485127ChemotherapyAdriamycinADJUVANTIVNO6120111TCGA-A2-A0EW-D6754e9277ae6-b3a0-4b3b-a966-f019eda5e0354632mg1158mg485127ChemotherapyCytoxanADJUVANTIVNO6120113TCGA-A2-A0EW-D6795d456b88f-f515-4180-8cd6-ff63d245e1981344mg334-338mg4141184ChemotherapyTaxolADJUVANTIVNO612011NOTCGA-A2-A0EW-D59516435F5BFB-5046-4569-B0B6-57857326B73A813903Hormone TherapyLetrozoleNOComplete Response1452014NOTCGA-A2-A0EW-D595179978CD5C-428A-4871-B65B-A055D93259559041001Hormone TherapyArimidexNOComplete Response1452014NOTCGA-A2-A0EW-D59518086CE23B-765A-4665-BD7E-9CD16396B4B910021365Hormone TherapyExemestaneNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D5951969429F28-2A38-4B0B-9306-59A9133230D711581422AncillaryZoledronic AcidNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D595201071A37F-0128-473D-8BA3-2DBF3AD5953E13661562Hormone TherapyFulvestrantNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D5952101259757-DD3D-4DF9-9686-9CB07AE8A15014251718AncillaryDenosumabNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D59522C89E1F88-A478-4697-9540-2AC63A29574716181722Hormone TherapyTamoxifenNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D595239FAAE45E-9014-4CD8-BBBA-F327C60E65D716961787ChemotherapyDoxorubicin LiposomeNOClinical Progressive Disease1452014,TCGA-A2-A0EQ-R1959ea9bcf48-3312-4c01-a03d-8628ec8b301d203251EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11282010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2053.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A0EQ,A2,A0EQ,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,2.0,H-Score-190,Allred score 4+3 = 7,Left,1.1,Other (specify),Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Lumpectomy,L Total Mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, classical type, focal pleomorphic type",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,0,3+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Positive,0.0,0.0,Allred score = 7,10-75%,<10%,Hercep Test  TM Dako,Dako Hercept test,74.544921875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,33,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,6.4,3 Point Scale,0,6thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,11,8,2010,TCGA-A2-A0EQ-F137200D4DC400-90B0-4475-AECB-5547B6CA8BFFScheduled Follow-up SubmissionYESYESAlive2426TUMOR FREENO1362011,"1TCGA-A2-A0EQ-D195451e8ec2a-d6cf-441c-9bbb-e3cc24771544488mg122mg484146ChemotherapyAdriamycinADJUVANTIVNO12820104TCGA-A2-A0EQ-D195768372627-8263-45a3-8639-655764fcb57610543mg195-594mg22229586Targeted Molecular therapyHerceptinADJUVANTIVNO12820102TCGA-A2-A0EQ-D195556d1ca0d-0923-4f84-9ede-e315f87f16484872mg1218mg484146ChemotherapyCytoxanADJUVANTIVNO12820103TCGA-A2-A0EQ-D1956f5f84132-0ffb-472d-bf1d-c1d076a7708b355mg355mg1167167ChemotherapyPaclitaxelADJUVANTIVNO12820105TCGA-A2-A0EQ-D19585dc02798-980f-40ea-b086-988e10bfba6d3000ug500ug6679796ImmunotherapyAE-37OTHER, SPECIFY IN NOTESCancer Vaccine TrialNO992010",TCGA-A2-A0EQ-R1959ea9bcf48-3312-4c01-a03d-8628ec8b301d203251EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11282010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1304.0,WHITE,TCGA-AR-A2LK,AR,A2LK,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,18.0,Allred score 5+3=8,Allred (Biocare),Right Upper Outer QuadrantRight Lower Outer Quadrant,2.9718359374999865,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Margin resection,Mastectomy NOS,Wide local excision,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Positive,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.54296875,5.0,allred score = 6,Allred Score 5,30-39%,Dako,CAP SCORING GUIDELINE 2010,358.537109375,HER2 amplification - negative,PathVysion,NO,YES,33,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,10-19%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,2+,Negative,1.8985937499999987,71,3 Point Scale,2+,6thStage IIIT3N2M0,YES,NO,PositivePositiveNegative,25,1,2012,TCGA-AR-A2LK-F3520301404DEF-ED7D-4186-9DC8-5FE8C812821BNOYESYESDead1649YES1304Distant MetastasisBonePositivePositiveNegative6122012,NOTCGA-AR-A2LK-D3726880FE69D1-54B5-44CA-8D96-AFF0EC366BB2ChemotherapyAdriamycinNO6122012NOTCGA-AR-A2LK-D37269C8B24AF7-897D-4A58-9CF0-393DEB02542CChemotherapyCytoxanNO6122012NOTCGA-AR-A2LK-D37270873DD1AD-E816-474B-AE05-EB495268C779ChemotherapyPaclitaxelNO6122012NOTCGA-AR-A2LK-D37735F52A9E2B-71AB-4E83-826D-E7307A8EE0042631310Hormone TherapyAnastrozoleNO6122012,TCGA-AR-A2LK-R37267B628417D-C4BC-45CE-968F-80AAE78899EB218262External6100cGy33Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,770.0,WHITE,TCGA-A2-A0EW,A2,A0EW,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,15.2998046875,H-Score 295,H-Score 15,Right Lower Outer Quadrant,1.33,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Margin resection,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Lobular Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,0,Negative,Positive,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,26.0,allred score = 8,120,20-29%,Hercep Test  TM Dako,Venten,312.9267578125,HER2 amplification - negative,Positive >2.2,NO,YES,54,"Other, specifyskin",90-99%,10-19%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.7867382812499957,816,3 Point Scale,2+,6thStage IIICT1bN3aM0,YES,YES,YES275Distant MetastasisLung,5,1,2011,TCGA-A2-A0EW-F1372409B81A25-DC34-48EB-9651-B0ACA113E04DScheduled Follow-up SubmissionNOYESAlive905TUMOR FREENO1062011TCGA-A2-A0EW-F59511195DBE0F-C593-40A4-A0EC-3B0CCBD34DE5NOYESYESWITH TUMORDead1884YES1353Distant MetastasisBoneNOYESYES1452014,4TCGA-A2-A0EW-D679729e822b5-c5e4-453f-9c1b-a7e30508d9e21mg221812Hormone TherapyArimidexADJUVANTPONO6120092TCGA-A2-A0EW-D6794fd289cfd-fcaf-4acb-8fc0-5ca6b1ab340b463mg115-116mg485127ChemotherapyAdriamycinADJUVANTIVNO6120111TCGA-A2-A0EW-D6754e9277ae6-b3a0-4b3b-a966-f019eda5e0354632mg1158mg485127ChemotherapyCytoxanADJUVANTIVNO6120113TCGA-A2-A0EW-D6795d456b88f-f515-4180-8cd6-ff63d245e1981344mg334-338mg4141184ChemotherapyTaxolADJUVANTIVNO612011NOTCGA-A2-A0EW-D59516435F5BFB-5046-4569-B0B6-57857326B73A813903Hormone TherapyLetrozoleNOComplete Response1452014NOTCGA-A2-A0EW-D595179978CD5C-428A-4871-B65B-A055D93259559041001Hormone TherapyArimidexNOComplete Response1452014NOTCGA-A2-A0EW-D59518086CE23B-765A-4665-BD7E-9CD16396B4B910021365Hormone TherapyExemestaneNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D5951969429F28-2A38-4B0B-9306-59A9133230D711581422AncillaryZoledronic AcidNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D595201071A37F-0128-473D-8BA3-2DBF3AD5953E13661562Hormone TherapyFulvestrantNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D5952101259757-DD3D-4DF9-9686-9CB07AE8A15014251718AncillaryDenosumabNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D59522C89E1F88-A478-4697-9540-2AC63A29574716181722Hormone TherapyTamoxifenNOClinical Progressive Disease1452014NOTCGA-A2-A0EW-D595239FAAE45E-9014-4CD8-BBBA-F327C60E65D716961787ChemotherapyDoxorubicin LiposomeNOClinical Progressive Disease1452014,TCGA-A2-A0EW-R59512F5F06A88-0642-4AA7-B9EF-9BA4A71E0677211249External5040cGyPrimary Tumor FieldNOComplete Response1452014TCGA-A2-A0EW-R59513221162DC-64B5-485A-98E8-BA764D594EE0211246External4500cGyRegional siteNOComplete Response1452014TCGA-A2-A0EW-R59514970E4073-9905-472F-B638-04E9643AA8B2252256External1000Primary Tumor FieldNOComplete Response1452014TCGA-A2-A0EW-R595151208B130-7049-48E8-9340-9D4B26754D0314661480External3000cGyDistant siteNORadiographic Progressive Disease1452014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,277.0,WHITE,TCGA-AO-A0J8,AO,A0J8,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,2.0,H-SCORE 190,%IHC,Right Upper Outer QuadrantRight,1.472236328125003,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Margin resection,Modified radical mastectomy,right segmental mastectomy,Infiltrating Lobular Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,1.0,0.0,H score,Allred Score 5,<10%,CISH,3+ POSITIVE,30.73828125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,127,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,>6.0,3 Point Scale,3+,Stage IIAT2N0 (i+)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,19,9,2010,TCGA-AO-A0J8-F3127BF41498F-03CE-41C2-86E8-B2A26D89DA67277AliveTUMOR FREEYESYES1992010TCGA-AO-A0J8-F154827F5BA75D-9EB6-4BD5-AC2E-101D65FBEB78Scheduled Follow-up SubmissionYESYESAlive680TUMOR FREENO2282011,1TCGA-AO-A0J8-D31377b8d5881-41d9-4c7b-ad68-60ae52734e668800mg600mg/m2863224ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO6920102TCGA-AO-A0J8-D31389b5ca20e-c9f2-4b98-be3a-d7ddacbf83291mg/day277Hormone TherapyANASTROZOLE (ARIMIDEX)ADJUVANTPOYES19920101TCGA-AO-A0J8-D3136082d6734-1bb5-4efc-90a5-d63188cb7651560mg40mg/m2863224ChemotherapyMETHOTREXATEADJUVANTIVNO19920101TCGA-AO-A0J8-D3131101e4937-20c7-461a-a4ce-a2e0b03c5f2d8800mg600mg/m2863224ChemotherapyFluorouracilADJUVANTIVNO1992010,TCGA-AO-A0J8-R31297699227a-2529-4bd0-bb64-08d7ffbe4aad252281EXTERNAL BEAM5240cGy21Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,658.0,WHITE,TCGA-E2-A1IH,E2,A1IH,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,2.0,allred score 5+3=8,allred score 5+3+8,Right Upper Inner Quadrant,0.9738769531250032,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Other,L Total Mastectomy,Infiltrating Lobular Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Equivocal,0.2421875,0.0,allred score = 8,allred score = 8,20-29%,Dako,CAP scoring guideline 2010,113.396484375,HER2 amplification - negative,Ratio >=2.0,NO,YES,118,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,71,3 Point Scale,2+,6thStage IT1cN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,4,2011,TCGA-E2-A1IH-F1996065E9B5ED-CC0C-41F6-8985-1A9D0EF1712DScheduled Follow-up SubmissionNOYESAlive1026TUMOR FREENO21122011,1TCGA-E2-A1IH-D19961ADCF42F6-D220-4FED-B497-03BA85C4304D25mg/day25mg/day32Hormone TherapyAromasinADJUVANTPOYES21122011,TCGA-A2-A0EQ-R1959ea9bcf48-3312-4c01-a03d-8628ec8b301d203251EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11282010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,974.0,WHITE,TCGA-BH-A0BC,BH,A0BC,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,18.0,H-Score 295,Allred score = 8,Right Upper Inner QuadrantRight Upper Outer QuadrantRight,1.8296972656250048,Sentinel lymph node biopsy plus axillary dissection,Pateys surgery,Other,Margin resection,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Mixed infiltrating lobular and grade 1 ductal carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.4580078125,12.0,0,0,<10%,ACIS,CAP scoring guideline 2010,56.578125,Vysis AutoVysion System,Positive >2.2,NO,YES,40,"LungBoneLiverOther, specifyskin",90-99%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,68,3 Point Scale,1+,Stage IIICT2N3M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",4,11,2010,TCGA-BH-A0BC-F44874825C6EA-F0A2-4F0C-9BF7-ABE3F09863B9974AliveTUMOR FREEYESYES4112010,1TCGA-BH-A0BC-D1540925DE46D5-5A3F-4DAC-A98E-5BFE3430C05F495mg124mg4106169ChemotherapyDoxorubicinADJUVANTIVNO41120101TCGA-BH-A0BC-D15413EA6A86CD-D2D8-4A14-BF9C-4D1918CABE51785mg130mg6795900ChemotherapyDocetaxelADJUVANTIVNO41120101TCGA-BH-A0BC-D154114D2FEA19-8DBD-4372-B1A8-4A983BB9D9014944mg1236mg4106169ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO41120101TCGA-BH-A0BC-D15408748DA09C-F045-4030-9629-73419051E23E1mg/day106Hormone TherapyArimidexADJUVANTPOYES41120101TCGA-BH-A0BC-D15412599CEF77-9455-48E3-9C50-7119D3A37F581264mg164mg12190239ChemotherapyPaclitaxelADJUVANTIVNO4112010,TCGA-BH-A0BC-R154143B79C753-1212-4F23-BC19-498992CDF995312361EXTERNAL BEAM6640cGy32Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,23.0,WHITE,TCGA-E9-A2JT,E9,A2JT,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,10.0,H-SCORE 260,Allred score 2+3 = 5,Left Upper Outer Quadrant,1.816591796874996,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Lumpectomy,Right Breast reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Positive,Positive,Equivocal,0.0263671875,0.0,230,270 H,10-19%,Hercep Test  TM Dako,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,70.3447265625,HER2 amplification - negative,Ratio >=2.0,YES,NO,1.5,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,<4.0,4 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,20,12,2011,TCGA-E9-A2JT-F34097BD6E3218-FD63-434B-8453-99FC7DC05314Scheduled Follow-up SubmissionYESYESAlive261TUMOR FREENO3072012TCGA-E9-A2JT-F402921B8BFE3C-EFD6-44EC-83E7-D91CA4678C10YESYESYESTUMOR FREEAlive288NO1522013,NOTCGA-E9-A2JT-D340989899A8BD-E368-4788-944F-E1685DA002C627Hormone TherapyTamoxifenYES3072012,TCGA-E9-A2JT-R340990BD58064-0B71-450B-9DF6-ECD92445BE835887External46Gy23Primary Tumor FieldNOComplete Response3072012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1203.0,WHITE,TCGA-BH-A0B3,BH,A0B3,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,29.0,Allread score 5+3 = 8,Allred score 3+3=6,Right Upper Inner QuadrantRight Upper Outer QuadrantRight,1.6149804687500058,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,0,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.376953125,2.0,0,allred score = 8,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,57.1005859375,Vysis AutoVysion System,Path Vysion HER-2 DNA probe kit,NO,YES,2.6,"LungBoneLiverOther, specifyskin",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,5.8,3 Point Scale,0,Stage IIBT2N1aM0,NO,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",3,11,2010,TCGA-BH-A0B3-F15418493B0584-FAA6-475F-97F9-CFE0524DF460Scheduled Follow-up SubmissionYESYESAlive1203TUMOR FREENO3112010,1TCGA-BH-A0B3-D1542013E5B5DC-2CA1-474B-A21D-B7AD5884839B4540mg1128mg452115ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO31120101TCGA-BH-A0B3-D1541949AB6F59-1B1E-4B04-914E-82339768A10C454mg113mg452115ChemotherapyDoxorubicinADJUVANTIVNO31120101TCGA-BH-A0B3-D15421E89062E2-7543-4BBA-9DA0-D4F6C81279C61873mg154mg12136213ChemotherapyPaclitaxelADJUVANTIVNO3112010,TCGA-BH-A0B3-R15422F9F1D8C1-B2FA-4516-B98F-D50ACCB6C8C62472EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,45.0,WHITE,TCGA-AC-A2B8,AC,A2B8,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,1.0,H-SCORE 300,Image Analysis,Right,1.6520214843749974,Axillary lymph node dissection alone,SN+1 non sentinel node,Simple Mastectomy,Right Breast reexcision,Modified radical mastectomy,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, classical type, focal pleomorphic type",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0,0.0,Two-tier,Allred score = 7,<10%,ACIS,Hercep Test  TM Dako,58.611328125,HER2 amplification - negative,PathVysion Her-2 DNA,YES,NO,3.0,BoneLiver,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.85,3 Point Scale,2+,7thStage IIBT3N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,12,9,2011,"TCGA-AC-A2B8-F43210E01D57EB-5162-4BCE-8AC8-D37DDBE74B3CNOYESYESTUMOR FREEAlive677YES654New Primary TumorOther, specifyRectumYES672YESNO1552013","NOTCGA-AC-A2B8-D4321201CD233B-B68C-458C-932F-5FD7F87DCB3F135ChemotherapyChemo, NOSNOComplete Response1552013NOTCGA-AC-A2B8-D43213FE83C33F-CAF2-4C0F-8447-2905F8864C89Hormone TherapyArimidexYES1552013",TCGA-AC-A2B8-R43215DAB5FC3E-2668-4D3F-B2AD-9411CCACBF9C80122ExternalPrimary Tumor FieldNOComplete Response1552013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1321.0,WHITE,TCGA-A1-A0SE,A1,A0SE,No,YES,C50.9,8522/3,C50.9,2005.0,TUMOR FREE,YES,8.0,H-SCORE 0,Allred score 5+3=8,Left Upper Outer Quadrant,1.0,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Nipple Sparing Total Mastectomy,Mixed Histology (please specify),invasive ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.0146484375,0.0,Allred score 7 per outside facility report,Two-tier,30-39%,0,Dako Hercept test,134.6171875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2,"LungBoneLiverOther, specifyskin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2,3 Point Scale,3+,6thStage IT1cN0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",6,12,2010,TCGA-E2-A1B0-F1946014D44CAA-26DC-4B41-B2A0-DC4A8A58BED3Scheduled Follow-up SubmissionYESYESAlive1631TUMOR FREENO7122011,TCGA-D8-A1JP-D20741E016C444-DD80-48AC-83D9-42A76BE1486020mg/day68Hormone TherapyTAMOXIFENADJUVANTPOYES1512012,TCGA-AO-A0J8-R31297699227a-2529-4bd0-bb64-08d7ffbe4aad252281EXTERNAL BEAM5240cGy21Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1658.0,WHITE,TCGA-OL-A66J,OL,A66J,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,4.0,H-SCORE 0,H-SCORE 280,Right Upper Outer Quadrant,1.5,Sentinel node biopsy alone,SN+1 non sentinel node,Lumpectomy,Right Breast reexcision,Other,Segmental mastectomy with sentinel axillary lymph node biopsy,Infiltrating Lobular Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.8857421875,0.0,230,Intensity=Strong,90-99%,CISH,Dako Hecept Test,89.515625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,1.9,"Other, specifyskin",90-99%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,<4.0,3 Point Scale,3+,6thStage IT1cN0MX,NO,YES,NO,11,6,2013,TCGA-OL-A66J-F58495D190CA5D-31E1-4E9F-A6DF-042F0D7D982ENOYESNOTUMOR FREEAlive1996NO1142014,NOTCGA-E9-A2JT-D340989899A8BD-E368-4788-944F-E1685DA002C627Hormone TherapyTamoxifenYES3072012,TCGA-A2-A0EW-R59512F5F06A88-0642-4AA7-B9EF-9BA4A71E0677211249External5040cGyPrimary Tumor FieldNOComplete Response1452014TCGA-A2-A0EW-R59513221162DC-64B5-485A-98E8-BA764D594EE0211246External4500cGyRegional siteNOComplete Response1452014TCGA-A2-A0EW-R59514970E4073-9905-472F-B638-04E9643AA8B2252256External1000Primary Tumor FieldNOComplete Response1452014TCGA-A2-A0EW-R595151208B130-7049-48E8-9340-9D4B26754D0314661480External3000cGyDistant siteNORadiographic Progressive Disease1452014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1733.0,WHITE,TCGA-BH-A0B7,BH,A0B7,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,17.0,allred score 0 + 0 = 0,Allred score 7 per outside facility report,Right,2.1248437499999997,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Reexcision,Other,right total mastectomy with sentinel lymph node dissection right reconstruction with TRAMP,Infiltrating Ductal Carcinoma,tubular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,0.1875,1.0,MODERATE,Strong,<10%,ACIS,Dako Hercept test,111.466796875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,3.1,"Other, specifyskin",<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.58,3 Point Scale,2+,6thStage IIBT2N1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,4,8,2011,TCGA-BH-A0B7-F587179C4412C3-9117-491D-9B4E-9579762E7EF3NOYESYESTUMOR FREEAlive2559NO2242014,NOTCGA-BH-A0B7-D58721341C74D1-788A-4312-A88D-96B3FAAB73CE105168ChemotherapyAdriamycinNOComplete Response2242014NOTCGA-BH-A0B7-D587224F4B553E-E1BA-43B5-AA88-811D9E6FE6A1196378ChemotherapyTaxolNOComplete Response2242014,TCGA-BH-A0B7-R5871850A9D3AB-1FDB-404E-94D5-6CEEA124DF29305356External5040cGy28Primary Tumor FieldNOComplete Response2242014TCGA-BH-A0B7-R58720F586906B-024C-452A-9A32-350AFD7F2932305356External4860cGy27Regional siteNOComplete Response2242014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,31.0,WHITE,TCGA-E9-A3Q9,E9,A3Q9,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,22.0,CAP scoring guideline 2010,allred score 5+3+8,Right Lower Inner Quadrant,1.3435644531250004,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Margin resection,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Indeterminate,0.0,22.0,8,8,<10%,Dako,Dako Hercept test,109.4091796875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,50,"LungBoneLiverOther, specifyskin",40-49%,40-49%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,1,3 Point Scale,2+,7thStage IIICT3N3M0,YES,NO,PositiveNegative,30,4,2012,TCGA-E9-A3Q9-F40589685D54DA-6242-4E70-A7EA-0C22A6BA84B3NONOYESTUMOR FREEAlive560NO2522013TCGA-E9-A3Q9-F597410902FC35-0AAF-4110-9F64-887922B8B914NONOYESTUMOR FREEAlive1001NO2052014,NOTCGA-E9-A3Q9-D405911D3313F6-A11D-433B-9DE9-C6710E7269052851ChemotherapyCyclophosphaneNOComplete Response2522013NOTCGA-E9-A3Q9-D40592EE1ADBED-9135-4EE3-84F2-42AB43FA667F2851ChemotherapyMitoxantroneNOComplete Response2522013NOTCGA-E9-A3Q9-D40593E7C7F8BC-C6B2-4F17-9D8B-484C4B9037462851Chemotherapy5-FluorouracilNOComplete Response2522013NOTCGA-E9-A3Q9-D405948925146E-CA92-4C23-9610-AA8FAADEC1D3108Hormone TherapyTamoxifenYES2522013,TCGA-BH-A0BC-R154143B79C753-1212-4F23-BC19-498992CDF995312361EXTERNAL BEAM6640cGy32Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1080.0,WHITE,TCGA-BH-A0H5,BH,A0H5,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,1.0,H-Score-190,H-Score 290,Right Upper Outer Quadrant,2.2007324218749984,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Other,Reexcision,Other,Right total mastectomy with lymph node left axillary lymph node excision,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.353515625,0.0,Allred Score 5,10-75%,<10%,Hercep Test  TM Dako,Dako Hercept test,55.4599609375,HER2 amplification - negative,Ratio >=2.0,NO,YES,4,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5.8,3 Point Scale,1+,6thStage IT1cN0 (i-)M0,NO,YES,YES994Distant MetastasisBoneNOYESYES,12,8,2011,TCGA-BH-A0H5-F587276C579D1F-0A86-4BC6-9C10-E56A23CDE9FBNONOYESTUMOR FREEAlive1620NO2242014,NOTCGA-BH-A0H5-D58731AE71C06F-4D9D-4EE7-B6D1-14FF06F8C6E8174ChemotherapyCytoxanNOComplete Response2242014NOTCGA-BH-A0H5-D58732C099D047-9A31-4CB6-8F0B-FEAF89B6F351174ChemotherapyTaxotereNOComplete Response2242014,TCGA-BH-A0B3-R15422F9F1D8C1-B2FA-4516-B98F-D50ACCB6C8C62472EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,127.0,WHITE,TCGA-E2-A1IU,E2,A1IU,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,H-SCORE 260,H-Score 0,Right Upper Outer Quadrant,1.317871093749995,Sentinel node biopsy alone,SN+1 non sentinel node,Simple Mastectomy,Right Breast reexcision,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.5732421875,0.0,Allred Score 8,0,90-99%,Dako,CAP scoring guideline 2010,127.900390625,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,4.43,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Negative,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.62,3 Point Scale,2+,7thStage IAT1cN0 (mol+)M0,YES,NO,YES275Distant MetastasisLung,29,4,2011,TCGA-E2-A1IU-F1997424CBF8D6-4B40-4569-A40F-F3C906BEEA9DScheduled Follow-up SubmissionNOYESAlive337TUMOR FREENO412012,1TCGA-E2-A1IU-D199756BB85C8B-BED1-4F0D-B330-2307404DA3141mg/day1mg/day36Hormone TherapyArimidexADJUVANTPOYES412012,TCGA-AC-A2B8-R43215DAB5FC3E-2668-4D3F-B2AD-9411CCACBF9C80122ExternalPrimary Tumor FieldNOComplete Response1552013
TCGAFPPP,Breast,No,FEMALE,Dead,577.0,763.6240234375,WHITE,TCGA-BH-A1FG,BH,A1FG,No,YES,C50.9,8500/3,C50.9,1998.0,WITH TUMOR,YES,11.1181640625,H-Score 150,Allred score 7 per outside facility report,Left,2.458740234374985,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Right Breast reexcision,Modified radical mastectomy,segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive mixed ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,1.4091796875,4.173828125,Allred Score 3,Moderate,10-19%,ACIS,Dako Hecept Test,83.931640625,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,NO,YES,1.78,BoneLiver,10-19%,60-69%,Negative,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,68,3 Point Scale,2+,5thStage IT1cNXM0,NO,YES,NONO,8,9,2011,TCGA-E2-A1B0-F1946014D44CAA-26DC-4B41-B2A0-DC4A8A58BED3Scheduled Follow-up SubmissionYESYESAlive1631TUMOR FREENO7122011,NOTCGA-C8-A278-D70993C2C73BBA-5B7A-4D5E-9026-7C416C68754A23Hormone TherapyTamoxifenYES1232015,TCGA-BH-A0B3-R15422F9F1D8C1-B2FA-4516-B98F-D50ACCB6C8C62472EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1271.0,WHITE,TCGA-E2-A1B0,E2,A1B0,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,28.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Left Upper Outer Quadrant,2.732158203124994,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Positive,Negative,Positive,0.5791015625,6.0,Allred score = 0,Allred score = 0,90-99%,Dako,Hercep Test  TM Dako,104.439453125,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.57,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.83,3 Point Scale,2+,6thStage IIIAT2N2M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",25,4,2011,TCGA-E2-A1B0-F1946014D44CAA-26DC-4B41-B2A0-DC4A8A58BED3Scheduled Follow-up SubmissionYESYESAlive1631TUMOR FREENO7122011,1TCGA-E2-A1B0-D19464A0811C15-BA7F-4042-8E8C-0C3BA33C8A897560mg1260mg635119ChemotherapycytoxanADJUVANTIVNO71220113TCGA-E2-A1B0-D19480B08E096E-EE65-42AA-B000-0198892EB17B8720mg545mg16231557ChemotherapyherceptinADJUVANTIVNO71220112TCGA-E2-A1B0-D19466F6516BAA-1825-4C57-824A-D8EE3A2497D81920mg160mg6140217ChemotherapytaxolADJUVANTIVNO71220111TCGA-E2-A1B0-D194635806DC75-529D-450D-952E-3AEA4294E6CB756mg126mg635119ChemotherapyadriamycinADJUVANTIVNO7122011,TCGA-E2-A1B0-R1946107FCCE4F-84AC-4AC3-A6BE-A677BDAD8EF3257300EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO17122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,9.0,ASIAN,TCGA-C8-A278,C8,A278,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,11.3251953125,CAP scoring guideline 2010,Allred score 5+3 = 8,Left,1.5503027343749982,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Negative,Positive,0.486328125,3.8720703125,Strong,0,90-99%,ACIS,Dako Hercept test,101.28125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,1.45,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.85,4 Point Scale,2+,6thStage IIIAT2N2M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,7,2011,TCGA-C8-A278-F20278C06E117F-44A5-4CD4-8B4B-0149099DECE2Scheduled Follow-up SubmissionNOYESAlive297NO912012,NOTCGA-C8-A278-D70993C2C73BBA-5B7A-4D5E-9026-7C416C68754A23Hormone TherapyTamoxifenYES1232015,TCGA-BH-A0B7-R5871850A9D3AB-1FDB-404E-94D5-6CEEA124DF29305356External5040cGy28Primary Tumor FieldNOComplete Response2242014TCGA-BH-A0B7-R58720F586906B-024C-452A-9A32-350AFD7F2932305356External4860cGy27Regional siteNOComplete Response2242014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,763.0,WHITE,TCGA-E2-A107,E2,A107,No,YES,C50.9,8520/3,C50.9,2008.0,WITH TUMOR,YES,27.0,Allred score 5+3=8,Allred score 0+0=0,Right Upper Inner Quadrant,1.2,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Simple Mastectomy,Margin resection,Other,Wide Local Excision,Infiltrating Lobular Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.4697265625,4.0,Allred score 0,Allred score 8,20-29%,Dako,Venten,161.94140625,HER2 amplification - negative,Ratio >=2.0,NO,YES,40,"Other, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.9215039062499983,52,3 Point Scale,2+,6thStage IIIAT3N2aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",11,2,2011,TCGA-E2-A107-F17173C7D2518B-F2DE-4B90-93B3-EA2F681E4044Scheduled Follow-up SubmissionYESYESAlive1047TUMOR FREENO2892011,"2TCGA-E2-A107-D775794caf20f-89a4-438f-919c-b340c5ce246913845mg1065mg13165333ChemotherapyAvastinADJUVANTIVNO14220112TCGA-E2-A107-D7756c58484ad-b8a7-4f27-9386-eecae3edc98a140mg/wk80mg/m2/wk12165242ChemotherapyTaxolADJUVANTIVNO14220114TCGA-E2-A107-D7759defcd3cc-c0c4-4a02-9921-4c97f1ab4e62459Hormone TherapyTamoxifenADJUVANTPOYES14220113TCGA-E2-A107-D775832e23773-9014-438f-887b-f921486a2877305355Hormone TherapyArimidexADJUVANTPONO14220111TCGA-E2-A107-D7755a7e00902-e7a5-4186-af3b-ad72c543f90a4109151ChemotherapyAdriamycin, cytoxan, avastinADJUVANTIVNO14220111TCGA-E2-A107-D1717446E34570-DA26-49E6-9564-CD69C9A9ECE64200mg1050mg4109151ChemotherapyCyclophosphamideADJUVANTIVNO28920111TCGA-E2-A107-D1781801B8342F-2262-4BEE-8828-DD3CC79BA416420mg105mg4109151ChemotherapyDoxorubicinADJUVANTIVNO28920115TCGA-E2-A107-D17179F8A4A3FF-59B7-45D2-93E6-AB8090FD077D397417Hormone TherapyAromasinADJUVANTPONO28920113TCGA-E2-A107-D17823B6BDB863-8723-4E39-981C-050BD35D21534196mg1049mg4249333ChemotherapyBevacizumabADJUVANTIVNO28920116TCGA-E2-A107-D17180B2F276EF-9F6D-4748-B73C-14E98959428A20mg459Hormone TherapyTamoxifenADJUVANTPOYES28920112TCGA-E2-A107-D17821154B47FC-B1D3-491D-9EA5-29AF63F4E1601680mg140mg12165242ChemotherapyPaclitaxelADJUVANTIVNO2892011",TCGA-E2-A107-R77541241840c-6acc-43d3-8ca1-58be8ecb2824279326EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO11422011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,635.0,WHITE,TCGA-A1-A0SI,A1,A0SI,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,23.0,allred score 5 + 3 = 8,CAP SCORING GUIDELINE 2010,Right,1.4237792968749967,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Positive,Positive,Negative,0.02734375,1.0,Two-tier,Allred Score 6,<10%,0,Hercep Test  TM Dako,109.0166015625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,1.5,"LungBoneLiverOther, specifyskin",50-59%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,4.70,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",30,6,2011,TCGA-D8-A1JP-F20740F5A697E5-7254-4E78-99D2-2C0D8F8C5549Scheduled Follow-up SubmissionNOYESAlive639TUMOR FREENO1512012,"2TCGA-E2-A107-D775794caf20f-89a4-438f-919c-b340c5ce246913845mg1065mg13165333ChemotherapyAvastinADJUVANTIVNO14220112TCGA-E2-A107-D7756c58484ad-b8a7-4f27-9386-eecae3edc98a140mg/wk80mg/m2/wk12165242ChemotherapyTaxolADJUVANTIVNO14220114TCGA-E2-A107-D7759defcd3cc-c0c4-4a02-9921-4c97f1ab4e62459Hormone TherapyTamoxifenADJUVANTPOYES14220113TCGA-E2-A107-D775832e23773-9014-438f-887b-f921486a2877305355Hormone TherapyArimidexADJUVANTPONO14220111TCGA-E2-A107-D7755a7e00902-e7a5-4186-af3b-ad72c543f90a4109151ChemotherapyAdriamycin, cytoxan, avastinADJUVANTIVNO14220111TCGA-E2-A107-D1717446E34570-DA26-49E6-9564-CD69C9A9ECE64200mg1050mg4109151ChemotherapyCyclophosphamideADJUVANTIVNO28920111TCGA-E2-A107-D1781801B8342F-2262-4BEE-8828-DD3CC79BA416420mg105mg4109151ChemotherapyDoxorubicinADJUVANTIVNO28920115TCGA-E2-A107-D17179F8A4A3FF-59B7-45D2-93E6-AB8090FD077D397417Hormone TherapyAromasinADJUVANTPONO28920113TCGA-E2-A107-D17823B6BDB863-8723-4E39-981C-050BD35D21534196mg1049mg4249333ChemotherapyBevacizumabADJUVANTIVNO28920116TCGA-E2-A107-D17180B2F276EF-9F6D-4748-B73C-14E98959428A20mg459Hormone TherapyTamoxifenADJUVANTPOYES28920112TCGA-E2-A107-D17821154B47FC-B1D3-491D-9EA5-29AF63F4E1601680mg140mg12165242ChemotherapyPaclitaxelADJUVANTIVNO2892011",TCGA-AC-A2B8-R43215DAB5FC3E-2668-4D3F-B2AD-9411CCACBF9C80122ExternalPrimary Tumor FieldNOComplete Response1552013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,167.0,WHITE,TCGA-D8-A1JP,D8,A1JP,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,manual counting,manual counting,Left Upper Inner Quadrant,0.8744335937500004,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast reexcision,Mastectomy NOS,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.0439453125,0.1708984375,H-Score,>75%,30-39%,Dako,DAKOHercepTest TM,105.791015625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,2.7,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.9,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",29,3,2011,TCGA-D8-A1JP-F20740F5A697E5-7254-4E78-99D2-2C0D8F8C5549Scheduled Follow-up SubmissionNOYESAlive639TUMOR FREENO1512012,TCGA-D8-A1JP-D20741E016C444-DD80-48AC-83D9-42A76BE1486020mg/day68Hormone TherapyTAMOXIFENADJUVANTPOYES1512012,TCGA-AC-A2B8-R43215DAB5FC3E-2668-4D3F-B2AD-9411CCACBF9C80122ExternalPrimary Tumor FieldNOComplete Response1552013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,17.0,WHITE,TCGA-AC-A3EH,AC,A3EH,No,YES,C50.9,8022/3,C50.9,2011.0,TUMOR FREE,YES,12.0,H-SCORE 0,H-SCORE 0,Right,1.686191406250012,Axillary lymph node dissection alone,SN+1 non sentinel node,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,Segmental Mastectomy,Infiltrating Lobular Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Excisional Biopsy,Lumpectomy,Negative,Positive,Negative,1.0029296875,12.0,8,Moderate,10-19%,ACIS,CAP SCORING GUIDELINE 2010,102.255859375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,2.6,"Other, specifyskin",<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.83,3 Point Scale,2+,7thStage IIICT3N3M0,YES,NO,NO,24,9,2012,TCGA-AC-A3EH-F65834040824B3-8139-4984-8578-00C653C57223NONOYESTUMOR FREEDead197NO3092014,"2TCGA-E2-A107-D775794caf20f-89a4-438f-919c-b340c5ce246913845mg1065mg13165333ChemotherapyAvastinADJUVANTIVNO14220112TCGA-E2-A107-D7756c58484ad-b8a7-4f27-9386-eecae3edc98a140mg/wk80mg/m2/wk12165242ChemotherapyTaxolADJUVANTIVNO14220114TCGA-E2-A107-D7759defcd3cc-c0c4-4a02-9921-4c97f1ab4e62459Hormone TherapyTamoxifenADJUVANTPOYES14220113TCGA-E2-A107-D775832e23773-9014-438f-887b-f921486a2877305355Hormone TherapyArimidexADJUVANTPONO14220111TCGA-E2-A107-D7755a7e00902-e7a5-4186-af3b-ad72c543f90a4109151ChemotherapyAdriamycin, cytoxan, avastinADJUVANTIVNO14220111TCGA-E2-A107-D1717446E34570-DA26-49E6-9564-CD69C9A9ECE64200mg1050mg4109151ChemotherapyCyclophosphamideADJUVANTIVNO28920111TCGA-E2-A107-D1781801B8342F-2262-4BEE-8828-DD3CC79BA416420mg105mg4109151ChemotherapyDoxorubicinADJUVANTIVNO28920115TCGA-E2-A107-D17179F8A4A3FF-59B7-45D2-93E6-AB8090FD077D397417Hormone TherapyAromasinADJUVANTPONO28920113TCGA-E2-A107-D17823B6BDB863-8723-4E39-981C-050BD35D21534196mg1049mg4249333ChemotherapyBevacizumabADJUVANTIVNO28920116TCGA-E2-A107-D17180B2F276EF-9F6D-4748-B73C-14E98959428A20mg459Hormone TherapyTamoxifenADJUVANTPOYES28920112TCGA-E2-A107-D17821154B47FC-B1D3-491D-9EA5-29AF63F4E1601680mg140mg12165242ChemotherapyPaclitaxelADJUVANTIVNO2892011",TCGA-AO-A0J8-R31297699227a-2529-4bd0-bb64-08d7ffbe4aad252281EXTERNAL BEAM5240cGy21Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Dead,571.0,3719.416015625,WHITE,TCGA-B6-A0IK,B6,A0IK,No,YES,C50.9,8500/3,C50.9,1994.0,WITH TUMOR,YES,14.0,Image Analysis,Image Analysis,Left,1.9707226562499889,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,IDC+ mucinous carcinoma,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,2+,2+,Negative,Positive,"Other method, specify:","Biopsy, NOS",Positive,Negative,Equivocal,0.9033203125,1.0,allred score = 4,270 H,<10%,ACIS,DAKOHercepTest TM,215.1005859375,Vysis AutoVysion System,CAP SCORING GUIDELINE 2007,NO,YES,2.8,BoneLiver,70-79%,70-79%,Negative,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,5.8,4 Point Scale,1+,4thStage IIIBT4N1M0,YES,YES,NONO,2,11,2010,TCGA-B6-A0IK-F126215C061F46-F69E-458A-A125-056C62D4E583Scheduled Follow-up SubmissionNOYESDead571WITH TUMORYES489Distant MetastasisBrainYES489YESYES262011,1TCGA-BH-A0RX-D48735D132A06-F3D4-4E01-ACBA-37EBA9BACD226808mg1122mg650155ChemotherapyFluorouracilADJUVANTIVNO181120101TCGA-BH-A0RX-D4872CBEF5FFD-0B68-4780-939F-C001E4A34CCB6808mg1122mg650155ChemotherapyCyclophosphamideADJUVANTIVNO181120101TCGA-BH-A0RX-D4874A90F4DFB-A730-4F63-B6A4-BDC3570C9474447mg75mg650155ChemotherapyMethotrexateADJUVANTIVNO18112010,TCGA-A2-A0EQ-R1959ea9bcf48-3312-4c01-a03d-8628ec8b301d203251EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11282010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,373.0,WHITE,TCGA-A7-A0DA,A7,A0DA,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,H-SCORE 280,image cytometry,Left Lower Outer Quadrant,1.3726660156249897,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Negative,Negative,0.037109375,0.0,Allred score = 2,190,90-99%,CISH,DAKOHercepTest TM,98.4912109375,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,2.13,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.8985937499999987,145,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",10,1,2011,TCGA-A7-A0DA-F6131528F3E9A-532F-464C-944C-2B0B7952D753373AliveTUMOR FREEYESYES1312011TCGA-A7-A0DA-F38487492F04DA-FBF7-48D8-99A9-9F4490E79F21NOYESYESTUMOR FREEAlive1085NO14122012,1TCGA-A7-A0DA-D6123848337bd-29ff-4b6c-8710-4bb3ac828398400mg100mg465107ChemotherapyAdriamycinADJUVANTIVNO13120111TCGA-A7-A0DA-D612584e6d642-6da6-4216-a376-2077ac9694423990mg990-1000mg465107ChemotherapyCytoxanADJUVANTIVNO13120111TCGA-A7-A0DA-D61261b1e115e-9a35-4b44-a883-94573341a8931435mg90-130mg12122199ChemotherapyTaxolADJUVANTIVNO1312011,TCGA-A7-A0DA-R595343ddf4b7-e2e9-4629-9fbc-01598b2cb8aa226274EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO11012011
TCGAFPPP,Breast,No,FEMALE,Dead,825.0,1301.4921875,WHITE,TCGA-A2-A0SV,A2,A0SV,No,YES,C50.9,8500/3,C50.9,2006.0,WITH TUMOR,YES,9.0,IMAGE ANALYSIS,Allred score 4+3 = 7,Right,1.0,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast reexcision,Modified radical mastectomy,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.7138671875,8.0,Strong,Strong,<10%,ACIS,Venten,115.2861328125,Vysis AutoVysion System,> = 2.0,NO,YES,2.13,Bone,90-99%,10-19%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,1.98,3 Point Scale,2+,6thStage IVT2N2aM1,YES,NO,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,15,11,2010,TCGA-A2-A0SV-F375594723553-D507-4FCD-98BB-176F2233F930DeadWITH TUMOR825YESYESNONOYES22112010,"1TCGA-A2-A0SV-D3723dffb0d8f-27a1-4dc6-855e-0fb99d5c458416mg4mg765253Other, specify in notesBisphosphonate therapyZometaADJUVANTIVNO151120102TCGA-A2-A0SV-D37245207293a-a541-4268-9200-ec61f261433fmg1mg/day79168Hormone TherapyArimidexADJUVANTPONO151120103TCGA-A2-A0SV-D3725ff55eeb9-fb43-4b8c-915b-c74dc4195ffe1250mg250-500mg5170223Hormone TherapyFulvestrantADJUVANTIMNO151120104TCGA-A2-A0SV-D372693f9d2f6-5376-40a2-b368-fc89e4e8650cmg3000mg/day304ChemotherapyXelodaPROGRESSIONPONO15112010",TCGA-A2-A0SV-R3727e12b8a6f-2881-4d70-8abb-c5f2944d4ae7108141EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO115112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,396.0,WHITE,TCGA-A8-A09D,A8,A09D,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,8.921875,Allred score 5+3=8,H-SCORE 0,Right Lower Outer Quadrant,1.6281249999999954,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Margin resection,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.5390625,2.3349609375,0%,H-Score,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,109.236328125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,160,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,59,3 Point Scale,3+,5thStage IIBT2N1M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A09D-F40549A2B31F29-0E1F-4F7F-B705-1B6F0312A9F4NOYESYESTUMOR FREEAlive1522NO2322013,NOTCGA-A8-A09D-D377637501154C-AB3E-4BCF-8170-83C79CD130EF092ChemotherapyDoxorubicinn/aNOComplete Response6122012NOTCGA-A8-A09D-D377642832D3CB-D8F2-4D5E-BCF9-1352FF358AE8092ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A09D-D3776558419487-BBD7-4BC3-A34A-1791CFFDFD0592153ChemotherapyPaclitaxeln/aNOComplete Response6122012NOTCGA-A8-A09D-D37766B4C8E610-F345-484B-BC53-E1B72842ABE22741400Hormone TherapyTamoxifenn/aNOComplete Response6122012NOTCGA-A8-A09D-D377673CE1FDD7-6CB8-4FEB-9A0A-D9C352B117AF1400Hormone TherapyAnastrozolen/aYES6122012,TCGA-A8-A09D-R3815731E1897B-65F4-4842-8B8A-B76F8482942E214274External67GyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Dead,3959.0,866.720703125,BLACK OR AFRICAN AMERICAN,TCGA-BH-A209,BH,A209,No,YES,C50.9,8510/3,C50.9,1996.0,TUMOR FREE,YES,12.0,H-Score 295,Allred score = 8,Left Upper Outer Quadrant,2.3135253906249904,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Reexcision,Other,Left segmental mastectomy with left axillary lymph node dissection,Medullary Carcinoma,pleomorphic infiltrating lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.876953125,0.0,Strong,8,90-99%,ACIS,Dako Hecept Test,91.8125,HER2 amplification - negative,Positive >2.2,NO,YES,4,"Other, specifyskin",80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,21,3 Point Scale,2+,5thStage IT1cN0M0,NO,NO,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,8,9,2011,TCGA-A7-A0DA-F6131528F3E9A-532F-464C-944C-2B0B7952D753373AliveTUMOR FREEYESYES1312011TCGA-A7-A0DA-F38487492F04DA-FBF7-48D8-99A9-9F4490E79F21NOYESYESTUMOR FREEAlive1085NO14122012,NOTCGA-EW-A2FV-D32327A38929AB-8A68-468D-ADE5-A9CA41F35D39141246ChemotherapyDocetaxelNO2352012NOTCGA-EW-A2FV-D323281E9A1A88-0C4F-4990-8144-7C1499F9CFE3141246ChemotherapyDoxorubicinNO2352012NOTCGA-EW-A2FV-D32329B03E11F1-B000-4AF8-867B-BBAA82017EFD141246ChemotherapyCyclophosphamideNO2352012NOTCGA-EW-A2FV-D32330A6AB155D-A721-4195-B5D4-0D2C98677EBE268Hormone TherapyTamoxifenYES2352012NOTCGA-EW-A2FV-D32331A0359D0A-8675-430D-B394-9D12D035767C268Hormone TherapyGoserelinYES2352012,TCGA-AR-A2LK-R37267B628417D-C4BC-45CE-968F-80AAE78899EB218262External6100cGy33Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Dead,1388.0,850.984375,WHITE,TCGA-BH-A1FM,BH,A1FM,No,YES,C50.9,8500/3,C50.9,1998.0,WITH TUMOR,YES,10.0,Allred score = 8,H-Score-230,Right Upper Outer Quadrant,2.447812499999988,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,total mastectomy with sentinel lymph node biopsy with tissue reconstruction,Infiltrating Ductal Carcinoma,Invasive mixed ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,1.1708984375,8.0,Allred score 8,Allred Score 5,10-19%,ACIS,Dako Hecept Test,87.099609375,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,NO,YES,1.78,BoneLiver,50-59%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,3.65,3 Point Scale,2+,5thStage IIIAT2N2M0,NO,YES,NONO,8,9,2011,TCGA-B6-A0WX-F15729BA8B9EFE-3133-40B3-9336-0CD5C63B5D0AScheduled Follow-up SubmissionNOYESDead639WITH TUMORYES563Distant MetastasisBoneNONONO2982011,hormone therapyTCGA-D8-A1JS-D140528318EC65-2D4F-490D-9C42-264220D999DAmg/day20mg/day14Hormone TherapyTamoxifenADJUVANTPOYES1872011,TCGA-E2-A10E-R77345ff50f19-2a03-46b9-bc52-f3a402b02e14173218EXTERNAL BEAM6000cGy30Regional siteADJUVANTNO11422011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,252.0,WHITE,TCGA-LD-A66U,LD,A66U,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,15.0,H-Score 300,H-Score 290,Right Upper Outer Quadrant,1.830742187500008,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.3798828125,2.0,Allred score 0,250,<10%,CISH,Hercep Test TM DAKO,123.73046875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,1.45,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,52,3 Point Scale,3+,7thStage IIBT2N1miMX,YES,YES,NO,27,6,2013,TCGA-LD-A66U-F5844590F609AB-BB7D-47BD-B55F-10F4F655C783NOYESYESTUMOR FREEAlive422NO1042014TCGA-LD-A66U-F630676AA69A72-7696-47F4-B184-4F5F74969DDDNOYESYESTUMOR FREEAlive646NO3072014,NOTCGA-LD-A66U-D4482626C2F6EB-DFF2-4C2A-A095-98A2434C36EF141183ChemotherapyTaxolNO2762013NOTCGA-LD-A66U-D447847A18D472-645D-49A3-B32B-E960EF3D6FC185127ChemotherapyAdriamycinNO2762013NOTCGA-LD-A66U-D448240938D350-5A79-457E-B8EA-2BCF27413DDE85127ChemotherapyCytoxanNO2762013NOTCGA-LD-A66U-D58447F33118FA-3D18-420A-8F4A-2B5ECD06BE24278Hormone TherapyTamoxifenYES1042014,TCGA-LD-A66U-R44783EF712C6A-231E-4FEA-B371-DFBEF41B049B231External4680cGy28Primary Tumor FieldYES2662013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,261.0,WHITE,TCGA-AO-A0J7,AO,A0J7,No,YES,C50.9,8523/3,C50.9,2009.0,TUMOR FREE,YES,11.0,allred score 0 + 0 = 0,Allred score 2+2 = 4,Left Upper Inner QuadrantLeft Lower Inner QuadrantLeft,2.476728515625,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,right segmental mastectomy,"Other, specify",Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,3.0,90 H,Allred Score 6,<10%,CISH,3+ POSITIVE,33.09375,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,118,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,185,3 Point Scale,2+,Stage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,19,9,2010,TCGA-AO-A0J7-F3109A6013BFD-2B91-4245-90CB-81BED5DF1764261AliveTUMOR FREEYESYES1992010TCGA-AO-A0J7-F1548039B5539A-E3E4-4585-9081-D1FDC294262FYESYESAlive618TUMOR FREENO2282011,1TCGA-AO-A0J7-D3114304050e5-dfd9-48ce-aab0-49d8d7f731a0440mg60mg/m2497140ChemotherapyDOXORUBICINADJUVANTIVNO19920102TCGA-AO-A0J7-D3118926f18ae-e779-45e5-b100-5edfc2e971331mg/day202Hormone TherapyANASTROZOLE (ARIMIDEX)ADJUVANTPOYES19920101TCGA-AO-A0J7-D3113c6d2fa6c-c6bb-4696-9ffd-3cada015a6244400mg600mg/m2497140ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO19920101TCGA-AO-A0J7-D311699f7ae0d-d072-40fc-be36-42be73a600e51280mg175mg/m24154195ChemotherapyPACLITAXELADJUVANTIVNO1992010,TCGA-AO-A0J7-R31112efb0bf7-1bbb-4da2-a353-3eef4c2f4b18258EXTERNAL BEAM3060cGy17Regional siteADJUVANTYES11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1464.0,WHITE,TCGA-BH-A0C3,BH,A0C3,No,YES,C50.9,8522/3,C50.9,2006.0,TUMOR FREE,YES,4.0,H-Score 200,PR Negative H-Score 0,Left,1.925390625000002,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Re-excision of the inferior margin,Other,Segmental mastectomy with sentinel node biopsy,Mixed Histology (please specify),with ductal and lobular phenotypes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.326171875,0.0,Allred score = 7,STRONG,90-99%,Hercep Test  TM Dako,+ or -,68.9326171875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.6,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,21,3 Point Scale,2+,6thStage IT1cN0M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,11,8,2011,TCGA-BH-A0C3-F63533823D487F-FD80-4797-A129-C63FDF8002BCNOYESYESWITH TUMORAlive2709YES2674Distant MetastasisBone1282014,NOTCGA-BH-A0C3-D635404DF39809-E3F7-4075-A18D-2883605F6B37109209ChemotherapyAdriamycinNOClinical Progressive Disease1282014NOTCGA-BH-A0C3-D635410540668E-ECBB-43B1-AEE3-51C9F20C42B1109209ChemotherapyCytoxanNOClinical Progressive Disease1282014,TCGA-BH-A0C3-R6354222C40DCA-0F16-42B4-A28F-29FEAC78B565209262External6640cGy34Primary Tumor FieldNORadiographic Progressive Disease1282014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,365.0,WHITE,TCGA-D8-A1JB,D8,A1JB,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,8.0,manual counting,manual counting,Right Upper Outer Quadrant,1.0285156250000018,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Positive,Positive,Equivocal,0.0634765625,1.0,10-75%,>75%,30-39%,Dako,Hecep Test TM DAKO,180.1435546875,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,1.1,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,not amplified,3 Point Scale,1+,7thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",29,3,2011,TCGA-D8-A1JB-F20852B676086B-3785-49BA-BD79-4DE804A29EA2Scheduled Follow-up SubmissionYESYESAlive569TUMOR FREENO1912012TCGA-D8-A1JB-F722098A90816F-786C-42BC-A9D7-81292956CE90NOYESYESTUMOR FREEAlive1688NO2942015,TCGA-D8-A1JB-D20850169E2D43-D1E5-42FF-AA6C-DB036D823477240mg60mg/m2451111ChemotherapyadriamycinADJUVANTIVNO1912012NOTCGA-D8-A1JB-D6531831DE8E14-409E-43CB-96CD-369FD9AF142F51111ChemotherapycyclophosphamideNO2292014,TCGA-D8-A1JB-R208518B735435-06BF-4F0A-880B-532D5CA6D853532554EXTERNAL BEAM4500cGyPrimary Tumor FieldADJUVANTNO1912012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,1477.0,WHITE,TCGA-5L-AAT0,5L,AAT0,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,8.0,H-SCORE 190,Allred score 7 per outside facility report,RightRight Lower Outer Quadrant,2.0149121093750035,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,biopsy,Infiltrating Lobular Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Positive,Incisional Biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,moderately to strongly,H score,30-39%,CISH,Dako Hecept Test,37.998046875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,50,"Other, specifyskin",70-79%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,172,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,NO,15,8,2014,TCGA-BH-A0RX-F48754CFEECD1-12BC-496C-9B8E-2E006F072A1E170AliveTUMOR FREEYESYESYES16112010,NOTCGA-5L-AAT0-D63723BCA5B47A-BE3A-4258-8A17-692D7DFDDF87322Hormone TherapyTamoxifenYES1582014,TCGA-5L-AAT0-R63722F11A131E-E0C5-4BCE-A06B-BFEB0058AEDD371411External5000cGy25Primary Tumor FieldNO1582014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,448.0,WHITE,TCGA-AO-A1KO,AO,A1KO,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,19.0,H-Score 300,%IHC,Left Upper Outer QuadrantLeft Lower Outer QuadrantLeft,1.496376953125002,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Lobular Carcinoma,Ductal partially papillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,4 Point Scale,4+,1+,Negative,Negative,Excisional Biopsy,Modified Radical Masectomy,Positive,Positive,Negative,1.0,0.0,Two-tier,205,<10%,ACIS,CAP SCORING GUIDELINE 2010,51.708984375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,69,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,3.3,4 Point Scale,4+,6thStage IIBT3N0 (i+)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,1,4,2011,TCGA-AO-A1KO-F9898DA36CD69-A4AD-4365-8E14-29AAC2D9783B448AliveTUMOR FREENOYES142011TCGA-AO-A1KO-F20630345F758B-4506-48DC-87A7-25B67862B7DCScheduled Follow-up SubmissionNOYESAlive622NO2022012,1TCGA-AO-A1KO-D99026524d129-d2a8-47ca-8d86-a659d0f1289b175mg/m2470160ChemotherapyPaclitaxelADJUVANTIVNO1420111TCGA-AO-A1KO-D990020a6f8cb-e82a-4275-99dd-c1dec8bbf00b600mg/m2470160ChemotherapyCyclophosphamideADJUVANTIVNO1420111TCGA-AO-A1KO-D9903994fc070-2c81-4aec-ad37-86de8d038e4a20mg/day231Hormone TherapyTamoxifenADJUVANTPOYES1420111TCGA-AO-A1KO-D9901fdaf8481-4ae7-4917-a33f-7f4624338ea860mg/m2470160ChemotherapyDoxorubicinADJUVANTIVNO142011,TCGA-D8-A1XK-R300734AF40BF7-8C93-4618-8EA8-7F5FAAC782D9253281EXTERNAL BEAM9000cGy45Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,326.0,WHITE,TCGA-D8-A1XK,D8,A1XK,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,18.0,manual counting,manual counting,Left Lower Inner Quadrant,1.5166210937499975,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision,Other,Partial Mastectomy,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Negative,Negative,Negative,0.37109375,3.0,H-SCORE,H-SCORE,10-19%,Hercep Test  TM Dako,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,55.4501953125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.13,"Other, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.83,3 Point Scale,2+,7thStage IIBT2N1aMX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",9,6,2011,TCGA-D8-A1XK-F300746E9797E4-9661-4BDD-9F1E-1EC2D1DB381BScheduled Follow-up SubmissionYESYESAlive441TUMOR FREENO422012,TCGA-D8-A1XK-D30075A849F857-16FA-41BF-8358-A98B7681F21B1560mg80mg/m2/day12149233ChemotherapypaclitaxelumADJUVANTIVNO422012TCGA-D8-A1XK-D3007625913AF2-0E2D-4199-A59A-8CB451696BDF388.8+3888mg97.2+972mg/day465128Chemotherapydoxorubicine+cyclophosphamideADJUVANTIVNO242012,TCGA-D8-A1XK-R300734AF40BF7-8C93-4618-8EA8-7F5FAAC782D9253281EXTERNAL BEAM9000cGy45Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A8-A090,A8,A090,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.4375,Allred score 5+3=8,allred score 5+3+8,Right,1.854111328124989,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.3173828125,0.0,Allred Score 8,H-Score,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,117.6171875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,1.45,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,21,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A06R-F40815AB298BD7-3CA2-44B2-8FA0-1DB436A3375FNOYESYESTUMOR FREEAlive547NO232013,TCGA-D8-A1XK-D30075A849F857-16FA-41BF-8358-A98B7681F21B1560mg80mg/m2/day12149233ChemotherapypaclitaxelumADJUVANTIVNO422012TCGA-D8-A1XK-D3007625913AF2-0E2D-4199-A59A-8CB451696BDF388.8+3888mg97.2+972mg/day465128Chemotherapydoxorubicine+cyclophosphamideADJUVANTIVNO242012,TCGA-AO-A128-R5880a8fd3954-09d3-4dd2-8fa4-4e734dc2918b263308EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO17122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,886.0,WHITE,TCGA-AO-A03V,AO,A03V,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,H-SCORE 255,Allred (Biocare),Left Upper Inner QuadrantLeft,1.551328124999988,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Reexcision,Other,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Peri (6-12 months since last menstrual period),Positive,YES,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,200,250,<10%,ACIS,3+ Positive,97.658203125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,3.1,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,80-89%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.8985937499999987,52,3 Point Scale,2+,6thStage IT1cN0 (i-)M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",9,1,2011,TCGA-AO-A03V-F58650B379E3A-D581-4E7E-87DB-950BA57BA1BE886AliveTUMOR FREENOYES912011TCGA-AO-A03V-F20912DB9D76BF-ADFA-4518-ADEC-B8FE3E187699Scheduled Follow-up SubmissionNOYESAlive1351NO2412012,1TCGA-AO-A03V-D60017a86ed9d-040d-497b-b401-e175e0ad50248800mg600mg/m28102200ChemotherapyFluorouracilADJUVANTIVNO10120111TCGA-AO-A03V-D59986b741be6-03f1-4acd-b9c2-4b38fa485a528800mg600mg/m28102200ChemotherapyCyclophosphamideADJUVANTIVNO10120112TCGA-AO-A03V-D6002a7b71a1a-29a2-4ced-9a77-1b29bf37f48a20mg/day200735Hormone TherapyTamoxifenADJUVANTPONO10120112TCGA-AO-A03V-D60043d49c566-fdcb-4849-9312-d27620f772f41mg/day753Hormone TherapyArimidexADJUVANTPOYES10120111TCGA-AO-A03V-D599954c7a76e-7409-4470-9021-6b209c2c9b7b600mg40mg/m28102200ChemotherapyMethotrexateADJUVANTIVNO1012011,TCGA-D8-A1JB-R208518B735435-06BF-4F0A-880B-532D5CA6D853532554EXTERNAL BEAM4500cGyPrimary Tumor FieldADJUVANTNO1912012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,2.0,ASIAN,TCGA-C8-A1HL,C8,A1HL,No,YES,C50.9,8480/3,C50.9,2010.0,TUMOR FREE,YES,9.0,% IHC,Image Analysis,Left,1.6135742187500026,Axillary lymph node dissection alone,Pateys surgery,Other,Re-excision of the inferior margin,Other,Patey's Surgery,"Other, specify",Infiltrating Mucinous-papillary ductal carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Equivocal,0.5087890625,2.5927734375,Strong,Allred Score 8,90-99%,ACIS,Hercep Test TM DAKO,202.5078125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,1.67,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,71,4 Point Scale,1+,6thStage IIIAT3N1M0,NO,YES,YES994Distant MetastasisBoneNOYESYES,2,6,2011,TCGA-C8-A1HL-F20266FC4E3C55-61FA-44EF-83CE-5A7BEEC6B79DScheduled Follow-up SubmissionNONOAlive317TUMOR FREENO912012,1TCGA-BH-A0B4-D15436E5C444DF-3662-4062-B553-FB8DE188EE81785mg130mg6692797ChemotherapyDocetaxelADJUVANTIVNO41120101TCGA-BH-A0B4-D15437E2E65D25-78D3-4CEC-B111-4B60F152B12820mg/day211Hormone TherapyTamoxifenADJUVANTPOYES4112010,TCGA-A1-A0SP-R42235E22E8A7-7CD2-4DED-A532-43CB2DEF4F91215259EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO7122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,515.0,WHITE,TCGA-E2-A159,E2,A159,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Left Lower Outer Quadrant,1.296865234374995,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Equivocal,0.33984375,0.0,Allred score = 0,Allred score = 0,90-99%,Dako,Venten,54.0986328125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.78,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,52,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,7,4,2011,TCGA-E2-A159-F191150C4FDB82-9EF8-4D7E-9A24-4B151317F7F1Scheduled Follow-up SubmissionYESYESAlive762TUMOR FREENO8112011,1TCGA-E2-A159-D1911657830A90-A8C2-4396-977D-CC41223CD5E35088mg1272mg45091ChemotherapyCyclophosphamideADJUVANTIVNO81120112TCGA-E2-A159-D1911910D6AF3A-547A-4172-A1AA-9C9266122BEF1134mg378mg3113141ChemotherapyPaclitaxel (Protein-Bound)ADJUVANTIVNO81120111TCGA-E2-A159-D19118E04BF780-9220-4AB5-9C43-2472BB5FBFD6508mg127mg45091ChemotherapyDoxorubicinADJUVANTIVNO8112011,TCGA-E2-A159-R19120ABEB4CB1-0F56-4D55-8796-EF6EF74DD791165215EXTERNAL BEAM6240cGy34Primary Tumor FieldADJUVANTNO18112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,518.0,WHITE,TCGA-A8-A075,A8,A075,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,13.2080078125,image cytometry,Allred score 4+3 = 7,Left Upper Outer Quadrant,2.96041992187499,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.296875,1.578125,MODERATE,Strong,10-19%,Hercep Test  TM Dako,Dako Hecept Test,95.2666015625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.1,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.80,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A075-F40820030338FD-A8B6-40FA-B40C-D31ECB4B3CD2NOYESYESTUMOR FREEAlive518NO232013,NOTCGA-A8-A075-D3784601EB4E82-BDB4-4A0D-AE50-BE001501E91831122ChemotherapyEpirubicoinn/aNOComplete Response6122012NOTCGA-A8-A075-D378474F50CB8E-0F25-40D0-A2A9-E840A63A515831122ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A075-D378483B670A10-80C3-4879-BC47-89AD2311D0CA122214ChemotherapyDocetaxeln/aNOComplete Response6122012NOTCGA-A8-A075-D37849BEDE978F-31C6-4E5C-98AE-D4AE802920F2275Hormone TherapyTamoxifenn/aYES6122012NOTCGA-A8-A075-D3785002D06787-6B7F-42B2-BEB7-F10802F43C59214AncillaryZoledronic acidn/aYES6122012,TCGA-A8-A075-R381777D9218C9-489E-4C64-9C92-7EE1AEB9C75E214275ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,948.0,WHITE,TCGA-BH-A0DE,BH,A0DE,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,2.0,H-Score 200,H-Score 190,Left Upper Outer Quadrant,3.154658203124977,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Re-excision of the inferior margin,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.291015625,0.0,Allred score = 7,80,90-99%,Hercep Test  TM Dako,+ or -,82.5634765625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.6,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,47,3 Point Scale,1+,6thStage IIAT2N0M0,NO,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",11,8,2011,TCGA-BH-A0DE-F63543BC05D1FA-6912-499B-8634-5B1EBA26C03ANOYESNOTUMOR FREEAlive2372NO1282014,1TCGA-BH-A0B4-D15436E5C444DF-3662-4062-B553-FB8DE188EE81785mg130mg6692797ChemotherapyDocetaxelADJUVANTIVNO41120101TCGA-BH-A0B4-D15437E2E65D25-78D3-4CEC-B111-4B60F152B12820mg/day211Hormone TherapyTamoxifenADJUVANTPOYES4112010,TCGA-BH-A0DE-R6354453372D2F-D9F7-48BC-8E09-94CF40CC253F105149External6040cGy33Primary Tumor FieldNOComplete Response1282014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1270.0,WHITE,TCGA-BH-A0C0,BH,A0C0,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,35.0,H-Score 295,H-SCORE 120,Left Upper Outer QuadrantLeft,4.7,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Other,Right Breast reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Malignant Phyllodes Tumor,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Equivocal,0.521484375,1.0,0,80,10-19%,ACIS,CAP scoring guideline 2010,40.0,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.65,"LungBoneLiverOther, specifyskin",90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,12.45,3 Point Scale,2+,Stage IIAT1cN1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,8,11,2010,TCGA-BH-A0C0-F4518C4A30038-2C06-4BBC-B071-677AEB2DD3591270AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0C0-D45147E66711C-BC10-4345-92B8-220DF4EE8F191mg/day158Hormone TherapyARIMIDEXADJUVANTPOYES161120101TCGA-BH-A0C0-D4515A22F23D5-AC34-48AE-85C2-6EE1B5E65A0C3740mg/day620mg/day657162ChemotherapyCARBOPLATINADJUVANTIVNO161120101TCGA-BH-A0C0-D4516D15BAC27-4BE3-4929-8B32-41DCA93AC97F710mg116mg657162ChemotherapyDOCETAXELADJUVANTIVNO16112010,TCGA-BH-A0C0-R4517E34524B4-285D-4250-BFF1-FC7F8FB4999D204249EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO116112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,189.0,WHITE,TCGA-A7-A0CJ,A7,A0CJ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,H-SCORE 260,Allred score 2+2 = 4,Left,1.3977539062500002,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-excision of the inferior margin,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Ductal/cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,1+,Negative,Positive,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,Allred score 8,Allred Score 5,<10%,0,CAP SCORING GUIDELINE 2010,139.8134765625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,54,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.98,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,10,2010,TCGA-A7-A0CJ-F29583ABA56D3-D1C1-468E-B5D7-33748980F487410AliveTUMOR FREEYESYES2062011TCGA-A7-A0CJ-F3974050209FC0-82C7-48DE-8CD9-0F33E8125B0ENOYESYESTUMOR FREEAlive931NO3112013,1TCGA-A7-A0CJ-D294012be856f-cc3d-4090-844e-bddee5eda9d44320mg1080mg461124ChemotherapyCytoxanADJUVANTIVNO51120101TCGA-A7-A0CJ-D2941cde6bb96-e9e1-4308-9aed-0d9eadef467f560mg140mg461124ChemotherapyTaxotereADJUVANTIVNO51120101TCGA-A7-A0CJ-D1315003D86C19-07DE-41C5-8A27-A742EA3E7D3Dmg1mg208203Hormone TherapyArimidexADJUVANTPOYES2062011,TCGA-A7-A0CJ-R293706bbdff4-295e-481d-90e9-5038ee936ce3152202EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO15112010
TCGAFPPP,Breast,No,MALE,Alive,0.0,1191.0,WHITE,TCGA-BH-A0B4,BH,A0B4,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,10.0,Allred score = 8,PR Negative H-Score 0,Left,2.83,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,mixed idc and mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Equivocal,0.4091796875,6.0,Allred Score 7,10-75%,10-19%,ACIS,Dako Hecept Test,40.0,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2.0,"LungBoneLiverOther, specifyskin",80-89%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5.65,3 Point Scale,3+,Stage IIIAT2N2M0,NO,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",4,11,2010,TCGA-BH-A0B4-F15435AE2D2C86-0F6F-4CD9-9D52-361A471B6676Scheduled Follow-up SubmissionYESYESAlive1191TUMOR FREENO4112010,1TCGA-BH-A0B4-D15436E5C444DF-3662-4062-B553-FB8DE188EE81785mg130mg6692797ChemotherapyDocetaxelADJUVANTIVNO41120101TCGA-BH-A0B4-D15437E2E65D25-78D3-4CEC-B111-4B60F152B12820mg/day211Hormone TherapyTamoxifenADJUVANTPOYES4112010,TCGA-BH-A0C0-R4517E34524B4-285D-4250-BFF1-FC7F8FB4999D204249EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO116112010
TCGAFPPP,Breast,No,MALE,Alive,0.0,175.0,WHITE,TCGA-EW-A1PD,EW,A1PD,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,H-SCORE 280,Allred score 2+2 = 4,Right,2.2,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Modified Radical Mastectomy,Reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Positive,Positive,Equivocal,0.0458984375,2.0,Allred Score,Allred Score 5,20-29%,CISH,Dako Hecept Test,62.4462890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.45,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,>6.0,3 Point Scale,3+,7thStage IIAT1cN1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",18,5,2011,TCGA-EW-A1PD-F29106AEB2D7F0-8756-4DE0-9278-64F6193B5284Scheduled Follow-up SubmissionNOYESAlive424TUMOR FREENO832012,1TCGA-EW-A1PD-D302901681B955-E38A-4793-BD18-B508BA3EC40A872mg145mg6112217ChemotherapyDocetaxelADJUVANTIVNO8320121TCGA-EW-A1PD-D3028987DA1EC9-4D7A-47A4-8455-BB95C304B65C7007mg500mg14112405ChemotherapyTrastuzumabADJUVANTIVNO8320121TCGA-EW-A1PD-D30291FD142565-E97D-46EE-AB46-9AB855E32A3B3933mg669mg6112217ChemotherapyCarboplatinADJUVANTIVNO832012,TCGA-E2-A154-R189430161D7CC-AED1-4B99-B6DC-36967E820C263277EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO18112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,423.0,WHITE,TCGA-BH-A0DK,BH,A0DK,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,3.0,H-SCORE 260,H-SCORE 120,Left Upper Outer QuadrantLeft,2.458906249999995,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Ductal/cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,0,Negative,Negative,Excisional Biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.177734375,0.0,H-SCORE,H-SCORE,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.7451171875,HER2 amplification - negative,Ratio >=2.0,NO,YES,118,"LungBoneLiverOther, specifyskin",<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,68,3 Point Scale,1+,Stage IIAT2N0 (i-)M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,8,11,2010,TCGA-BH-A0DK-F453200ADA7FD-4CEC-4D7C-A86A-BAFE4B35FEE2423AliveTUMOR FREENOYES16112010,1TCGA-BH-A0DK-D4531F66FFF44-E13B-490E-B862-8317DB18575220mg/day112Hormone TherapyTAMOXIFENADJUVANTPOYES17112010,TCGA-D8-A1XK-R300734AF40BF7-8C93-4618-8EA8-7F5FAAC782D9253281EXTERNAL BEAM9000cGy45Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1163.0,WHITE,TCGA-E2-A105,E2,A105,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,1.0,Allred score 3 + 2 = 5,Allred score 3 + 2 = 5,Left Upper Inner Quadrant,1.3485546875000032,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.353515625,0.0,Allred score 5,Allred score 5,70-79%,Dako,Venten,109.7333984375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.13,"Other, specifyaxilaary node negative but intrammary node positive",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,60,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,11,2,2011,TCGA-E2-A105-F1743198CF51C1-3D09-49B5-A0F2-BD06DB419082Scheduled Follow-up SubmissionYESYESAlive1308TUMOR FREENO992011,1TCGA-E2-A105-D7696e88c01a6-d3d9-48bf-8e5e-929c0c0c7d9a1mg/day1mg/day65Hormone TherapyArimidexADJUVANTPOYES1422011,TCGA-E2-A105-R7695686c1c4e-ee34-4e9d-adfb-82306b6becf261122EXTERNAL BEAM6000cGyPrimary Tumor FieldADJUVANTNO11422011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,4929.0,WHITE,TCGA-B6-A0RO,B6,A0RO,No,YES,C50.9,8500/3,C50.9,1993.0,TUMOR FREE,YES,17.0,Image Analysis,Image Analysis,Right,2.0520312499999944,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,IDC+ mucinous carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Positive,Positive,Equivocal,0.724609375,2.0,Two-tier,H score,10-19%,ACIS,CAP scoring guideline 2010,184.3662109375,Vysis AutoVysion System,PathVysion Her-2 DNA,NO,YES,3.0,BoneLiver,70-79%,70-79%,Negative,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,68,4 Point Scale,1+,4thStage IIIBT4N1aM0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,2,11,2010,TCGA-B6-A0RO-F137999A962820-D315-4506-9994-96C7C5A52C5FScheduled Follow-up SubmissionNOYESAlive4929TUMOR FREENO1272011,NOTCGA-A8-A075-D3784601EB4E82-BDB4-4A0D-AE50-BE001501E91831122ChemotherapyEpirubicoinn/aNOComplete Response6122012NOTCGA-A8-A075-D378474F50CB8E-0F25-40D0-A2A9-E840A63A515831122ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A075-D378483B670A10-80C3-4879-BC47-89AD2311D0CA122214ChemotherapyDocetaxeln/aNOComplete Response6122012NOTCGA-A8-A075-D37849BEDE978F-31C6-4E5C-98AE-D4AE802920F2275Hormone TherapyTamoxifenn/aYES6122012NOTCGA-A8-A075-D3785002D06787-6B7F-42B2-BEB7-F10802F43C59214AncillaryZoledronic acidn/aYES6122012,TCGA-E2-A154-R189430161D7CC-AED1-4B99-B6DC-36967E820C263277EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO18112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0FV,AN,A0FV,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,12.0,Allred (Biocare),H-Score 290,Right Upper Outer Quadrant,2.324570312499992,No axillary staging,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,surgical resection,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,3+,Negative,Negative,Tumor resection,stereotactic biopsy,Positive,Negative,Positive,0.0,0.0,0,0,20-29%,0,Venten,133.9140625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,58,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5.8,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,28,12,2010,TCGA-AN-A0FV-F68965B6FDCFD2-3073-48EF-8C35-A799915D4467YESNONOTUMOR FREEAlive1024122014,1TCGA-EW-A1PD-D302901681B955-E38A-4793-BD18-B508BA3EC40A872mg145mg6112217ChemotherapyDocetaxelADJUVANTIVNO8320121TCGA-EW-A1PD-D3028987DA1EC9-4D7A-47A4-8455-BB95C304B65C7007mg500mg14112405ChemotherapyTrastuzumabADJUVANTIVNO8320121TCGA-EW-A1PD-D30291FD142565-E97D-46EE-AB46-9AB855E32A3B3933mg669mg6112217ChemotherapyCarboplatinADJUVANTIVNO832012,"TCGA-EW-A1P1-R29236A05C32BB-CE32-45B3-88F1-10EE839FC231281322EXTERNAL BEAM11,000cGyPrimary Tumor FieldADJUVANTNO11232012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5.0,WHITE,TCGA-AN-A0AM,AN,A0AM,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,20.0,allred score 5+3=8,IHC,Left Upper Outer Quadrant,2.391943359374997,No axillary staging,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,3+,Negative,Negative,Tumor resection,stereotactic biopsy,Positive,Positive,Negative,0.0,0.0,0,205,40-49%,0,Hercep Test  TM Dako,123.51171875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,125,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,149,3 Point Scale,1+,Stage IIAT2N0M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,28,12,2010,TCGA-AN-A0AM-F68945CCD98B71-7FC0-4FB5-9595-B9E2959A20F0YESNONOTUMOR FREEAlive523122014,1TCGA-E2-A154-D18941A19AD7AA-E6A9-40A8-A357-65677967265C1mg/day325Hormone TherapyarimidexADJUVANTPOYES8112011,"TCGA-EW-A1P1-R29236A05C32BB-CE32-45B3-88F1-10EE839FC231281322EXTERNAL BEAM11,000cGyPrimary Tumor FieldADJUVANTNO11232012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,199.0,WHITE,TCGA-BH-A8G0,BH,A8G0,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,3.0,H-Score 200,Allred score 5+3= 8,Left,1.3823925781250004,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Lobular Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Negative,0.484375,3.0,10,"Moderate using the scale of Weak, Moderate, Strong",30-39%,Dako,CAP SCORING GUIDELINE 2010,182.181640625,HER2 amplification - negative,Ratio >=2.0,YES,NO,50,"LungBoneLiverOther, specifyskin",<10%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,61,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,NO,26,3,2014,TCGA-BH-A8G0-F6420010DA390E-2291-419B-8B1D-56CD9274E316NONOYESTUMOR FREEAlive662NO2782014,YESTCGA-BH-A8G0-D57780D9246CEE-989C-4F55-8C8E-F44C20C26427155267ChemotherapyTaxotereNOComplete Response2632014YESTCGA-BH-A8G0-D577811554145F-6AD9-4A57-92CC-2C65179DF840155267ChemotherapyCytoxanNOComplete Response2632014,TCGA-BH-A5IZ-R5658422DA154D-0940-4F18-A8C1-18FA728B21F1280323NOComplete Response1322014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,325.0,WHITE,TCGA-E2-A154,E2,A154,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,allred score 5+3=8,H-Score 0,Left Upper Outer Quadrant,2.0078222656249918,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Re-excision of the inferior margin,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.34765625,0.0,Allred score = 4,230,90-99%,Dako,Hercep Test  TM Dako,85.75390625,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.8,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,90-99%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1,3 Point Scale,1+,6thStage IT1cN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,7,4,2011,TCGA-E2-A154-F18940640B6B5F-8868-48C5-BB54-8BCAD1124002Scheduled Follow-up SubmissionYESYESAlive591TUMOR FREENO8112011,1TCGA-E2-A154-D18941A19AD7AA-E6A9-40A8-A357-65677967265C1mg/day325Hormone TherapyarimidexADJUVANTPOYES8112011,TCGA-E2-A154-R189430161D7CC-AED1-4B99-B6DC-36967E820C263277EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO18112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1305.0,WHITE,TCGA-BH-A0C7,BH,A0C7,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,18.0,H-Score 200,H-SCORE 120,Left,2.229931640625003,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,pleomorphic infiltrating lobular carcinoma,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.546875,1.0,allred score = 8,Allred Score 5,10-19%,Hercep Test  TM Dako,CISH,55.583984375,HER2 amplification - negative,Ratio >=2.0,NO,YES,40,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.65,3 Point Scale,2+,6thStage IIBT2N1miM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,11,8,2011,TCGA-BH-A0C7-F59178DE59E19C-C2B2-44A8-A313-696DFCDB91EENONOYESTUMOR FREEAlive2767NO252014,NOTCGA-BH-A0C7-D59179716C77CF-18B0-4B77-BE11-C5B4B61DFCED50113ChemotherapyAdriamycinNOComplete Response252014NOTCGA-BH-A0C7-D5918034A1744E-AFE4-4ECB-A86D-0AA9F44D0ABF50113ChemotherapyCytoxanNOComplete Response252014NOTCGA-BH-A0C7-D5918104AB53D8-4D37-4845-B139-414A9D08CFC350113ChemotherapyTaxolNOComplete Response252014,TCGA-AO-A0JF-R3205605f8f77-3566-431e-93ae-33ec0b26904a299328EXTERNAL BEAM5272cGy21Primary Tumor FieldADJUVANTNO1692010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,920.0,WHITE,TCGA-EW-A1P1,EW,A1P1,No,YES,C50.9,8500/3,C50.9,2008.0,WITH TUMOR,YES,32.0,H-SCORE 0,CAP scoring guideline 2010,Right Upper Outer Quadrant,1.8,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Lumpectomy,Reexcision,Modified radical mastectomy,Excisional biopsy,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Equivocal,0.6064453125,11.0,allred score = 6,Allred Score 5,<10%,CISH,Dako Hercept test,116.8837890625,HER2 amplification - negative,PathVysion,NO,YES,33,Lung,<10%,<10%,Negative,<10%,3+,Negative,Equivocal,<10%,1+,<10%,1+,Negative,1.924199218749999,1.85,3 Point Scale,3+,6thStage IIICT2N3bMX,YES,NO,Negative<10%3 Point ScaleNegative<10%3 Point ScaleEquivocal<10%1+,27,5,2011,TCGA-EW-A1P1-F291151B13E198-7074-4211-9F1F-EDBD860D6F76Scheduled Follow-up SubmissionYESYESAlive1210TUMOR FREEYES1014Distant MetastasisLungYES1200NONONegativeNegative832012,TCGA-EW-A1P1-D2923448C077A1-8D4D-4F04-9651-C690CC977963288mg144mg2140147ChemotherapyTaxolADJUVANTIVNO1232012TACTCGA-EW-A1P1-D292334741983E-274B-433C-B89D-5BEAE68D4803377mg131mg377119ChemotherapyTaxotereADJUVANTIVNO1232012ACTCGA-EW-A1P1-D29235F27A496D-E750-4C38-8AB0-8E9458182736217mg108mg2157178ChemotherapyAdriamycinADJUVANTIVNO1232012TACTCGA-EW-A1P1-D292751C58018D-9EDE-4229-BE75-BAF2AE767EB52515mg875mg377119ChemotherapyCyclophosphamideADJUVANTIVNO1332012TACTCGA-EW-A1P1-D29274409B60F9-D4ED-4733-A1F0-318ED27B2FA3252mg88mg377119ChemotherapyAdriamycinADJUVANTIVNO1332012TCGA-EW-A1P1-D292768A876DD1-A78D-4A4E-ABE0-48E9D87B50182172mg1080mg2157178ChemotherapyCyclophosphamideADJUVANTIVNO1332012,"TCGA-EW-A1P1-R29236A05C32BB-CE32-45B3-88F1-10EE839FC231281322EXTERNAL BEAM11,000cGyPrimary Tumor FieldADJUVANTNO11232012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1550.0,WHITE,TCGA-AR-A24W,AR,A24W,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,22.0,allred score 5 + 3 = 8,image cytometry,Right Lower Inner Quadrant,1.5548828125000012,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Reexcision,Modified radical mastectomy,Total Mastectomy,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.1787109375,3.0,Allred score = 0,Allred score 8,10-19%,Hercep Test  TM Dako,Dako Hercept test,49.6455078125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,50,"Other, specifyskin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,>6.0,4 Point Scale,1+,6thStage IIBT2N1M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,10,11,2011,TCGA-AR-A24W-F31634E65CA6F6-4AD9-411B-B4F6-A3F3C34F1DBAScheduled Follow-up SubmissionNOYESAlive1550NO752012TCGA-AR-A24W-F494767B6E8320-51FE-49BF-A68A-6AB693D91DD2NOYESTUMOR FREEAlive991NO2102013,NOTCGA-AR-A24W-D316351CD0389E-EE24-475D-B7C2-4004B7E66425ChemotherapyDoxorubicinNO2152012NOTCGA-AR-A24W-D31637B02CD97F-591A-4C8A-ADBE-EDE8209C6296ChemotherapyCytoxanNO2152012NOTCGA-AR-A24W-D31640567A9E78-2614-4140-A312-1D519B05A899ChemotherapyPaclitaxelNO2152012NOTCGA-AR-A24W-D31641B0D36A62-52F5-4332-A90A-58BBBE026CE6164345Hormone TherapyLetrozoleNO2152012NOTCGA-AR-A24W-D316421C382941-469A-4FBC-BBFC-AECC59416F32345Hormone TherapyAnastrozoleYES2152012,TCGA-BH-A0BG-R58616FBA2D677-DEA7-483C-AA88-82D4D14CB64484131External5040cGy28Primary Tumor FieldNOComplete Response1642014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,54.0,WHITE,TCGA-A7-A3RF,A7,A3RF,No,YES,C50.9,8480/3,C50.9,2012.0,TUMOR FREE,YES,2.0,Allread score 5+3 = 8,allred score 5 + 3 = 8,Left Upper Outer Quadrant,3.416728515624965,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Left breast reexcision,Other,Segmental Mastectomy,Mucinous Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.2734375,0.0,Allred Score 5,Allred score 7 (per outside facility),30-39%,CISH,Hercep Test TM DAKO,284.3125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,74,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,71,3 Point Scale,2+,7thStage IIAT2N0M0,NO,NO,Positive70-79%Positive<10%Negative1+,3,5,2012,TCGA-A7-A3RF-F40413AC15B3B7-EBCC-4CCB-9491-7D2BA72CF137NOYESYESWITH TUMORAlive408YES174Distant MetastasisBoneNONONO192Distant MetastasisLiverNONONO1922013,NOTCGA-A7-A3RF-D40414C60A018E-A8EC-4C00-AB28-40901C23F33E137Hormone TherapyAnastrozoleYESClinical Progressive Disease1922013,TCGA-A7-A3RF-R40415D04B5775-2ABC-484C-A0AC-0B1AE645EFAE88136External6280cGy34Primary Tumor FieldNORadiographic Progressive Disease1922013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,756.0,WHITE,TCGA-BH-A0BG,BH,A0BG,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,1.0,H-SCORE 255,H-SCORE 120,Left Lower Outer Quadrant,2.3444140624999967,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Reexcision,Other,Segmental mastectomy with sentinel axillary lymph node biopsy,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.2138671875,0.0,Allred Score,Allred Score 5,10-19%,Hercep Test  TM Dako,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,45.982421875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,40,"Other, specifyskin",80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,47,3 Point Scale,2+,6thStage IT1N0M0,NO,NO,YES994Distant MetastasisBoneNOYESYES,8,8,2011,TCGA-BH-A0BG-F58615C970540D-F1A7-425C-BEF1-2AD70CD6AD13NOYESNOTUMOR FREEAlive1871NO1642014,NOTCGA-AR-A24W-D316351CD0389E-EE24-475D-B7C2-4004B7E66425ChemotherapyDoxorubicinNO2152012NOTCGA-AR-A24W-D31637B02CD97F-591A-4C8A-ADBE-EDE8209C6296ChemotherapyCytoxanNO2152012NOTCGA-AR-A24W-D31640567A9E78-2614-4140-A312-1D519B05A899ChemotherapyPaclitaxelNO2152012NOTCGA-AR-A24W-D31641B0D36A62-52F5-4332-A90A-58BBBE026CE6164345Hormone TherapyLetrozoleNO2152012NOTCGA-AR-A24W-D316421C382941-469A-4FBC-BBFC-AECC59416F32345Hormone TherapyAnastrozoleYES2152012,TCGA-BH-A0BG-R58616FBA2D677-DEA7-483C-AA88-82D4D14CB64484131External5040cGy28Primary Tumor FieldNOComplete Response1642014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,354.0,WHITE,TCGA-AO-A0JF,AO,A0JF,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,14.0,Allred 0 = 0+0,%IHC,Left Upper Outer QuadrantLeft,1.8460351562500037,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast reexcision,Modified radical mastectomy,right segmental mastectomy,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,2.0,Allred Score 6,10-75%,<10%,CISH,3+ POSITIVE,28.0693359375,HER2 amplification - negative,>= 2.0 Positive,NO,YES,127,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,21.0,3 Point Scale,2+,Stage IIAT1cN1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",20,9,2010,TCGA-AO-A0JF-F32049B204717-E586-4156-B08E-25167DC424C9354AliveTUMOR FREEYESYES2092010TCGA-AO-A0JF-F15489AC690AA5-8AC7-4FCD-8B92-2A1010CCFB53Scheduled Follow-up SubmissionYESYESAlive650TUMOR FREENO2282011TCGA-AO-A0JF-F72115704FB623-3791-4E9D-8194-3C9B34439C3BNOYESYESTUMOR FREEAlive1980NO1542015,1TCGA-AO-A0JF-D3207c6fe7b1e-7d43-4f33-add3-cb45112a5a0b480mg60mg/m24105155ChemotherapyDOXORUBICINADJUVANTIVNO20920101TCGA-AO-A0JF-D3208957365be-dbc2-4492-98f7-f7125cb4700c1920mg80mg/m212172256ChemotherapyPACLITAXELADJUVANTIVNO20920102TCGA-AO-A0JF-D32093f8e0a6f-72a8-4d35-84bf-ed2c931be8321mg/day336353Hormone TherapyANASTROZOLE (ARIMIDEX)ADJUVANTPONO20920102TCGA-AO-A0JF-D32110e86b873-98ca-4bc2-83b4-9acfddbb62a42.5mg/day356Hormone TherapyLETROZOLE (FEMARA)ADJUVANTPOYES20920101TCGA-AO-A0JF-D320669646598-6e7b-4f0c-a0e9-601b648159df4800mg600mg/m24105155ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO2092010,TCGA-AO-A0JF-R3205605f8f77-3566-431e-93ae-33ec0b26904a299328EXTERNAL BEAM5272cGy21Primary Tumor FieldADJUVANTNO1692010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,876.0,WHITE,TCGA-EW-A1PG,EW,A1PG,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,25.0,H-SCORE 260,IHC,Left Lower Inner QuadrantLeft Lower Outer Quadrant,1.8,Sentinel lymph node biopsy plus axillary dissection,SN+1 non sentinel node,Modified Radical Mastectomy,Right Breast reexcision,Other,Excision,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,1.0,1.0,Allred Score 6,130,10-19%,CISH,Dako Hecept Test,38.8125,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,1.45,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,<4.0,3 Point Scale,3+,6thStage IIBT2N1aMX,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",18,5,2011,TCGA-EW-A1PG-F291038BA6C3BB-BF54-4173-8FD5-BD3A864EA6ECScheduled Follow-up SubmissionNOYESAlive1051TUMOR FREENO832012,FEC x3 then T x3TCGA-EW-A1PG-D29645A507200D-0651-4B04-951A-3B520607A972546mg182mg3157262ChemotherapyDocetaxelADJUVANTIVNO832012FEC x3 then T x3TCGA-EW-A1PG-D29104252A2A60-D59F-40FC-B2AF-72551B1D46F12730mg910mg3157262ChemotherapyFluorouracilADJUVANTIVNO832012FEC X3 THEN T X3TCGA-EW-A1PG-D296425649EFA1-DE70-4DC9-AC8B-3770FB06A63D2730mg910mg3157262ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO832012FEC x3 then T x3TCGA-EW-A1PG-D29639AC1801E0-6BCE-4E2E-9CAC-53852EAA2C9C546mg182mg3157262ChemotherapyEpirubicinADJUVANTIVNO832012TCGA-EW-A1PG-D29649DA69487C-E853-43D8-8FE8-325C97F99CB625mg/day263Hormone TherapyAromasinADJUVANTPOYES832012,TCGA-E2-A14N-R191827722E80A-C0A5-4B7D-95C4-6BBF762D55DD181236EXTERNAL BEAM5040cGy28Regional siteADJUVANTNO117112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1162.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A2BM,AC,A2BM,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,13.0,H-SCORE 300,Image Analysis,Left Upper Inner Quadrant,1.4510644531250003,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,ductal and papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,1.0,1.0,Allred Score 5,Allred score = 7,10-19%,ACIS,Dako Hercept test,50.2333984375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,40,BoneLiver,60-69%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.65,3 Point Scale,2+,6thStage IIBT2N1aMX,YES,NO,YES994Distant MetastasisBoneNOYESYES,12,9,2011,TCGA-AC-A2BM-F66202DD44274C-674F-4906-827E-1411F9F99094NONONOTUMOR FREEAlive3022NO3102014,NOTCGA-AR-A24W-D316351CD0389E-EE24-475D-B7C2-4004B7E66425ChemotherapyDoxorubicinNO2152012NOTCGA-AR-A24W-D31637B02CD97F-591A-4C8A-ADBE-EDE8209C6296ChemotherapyCytoxanNO2152012NOTCGA-AR-A24W-D31640567A9E78-2614-4140-A312-1D519B05A899ChemotherapyPaclitaxelNO2152012NOTCGA-AR-A24W-D31641B0D36A62-52F5-4332-A90A-58BBBE026CE6164345Hormone TherapyLetrozoleNO2152012NOTCGA-AR-A24W-D316421C382941-469A-4FBC-BBFC-AECC59416F32345Hormone TherapyAnastrozoleYES2152012,TCGA-E9-A1RG-R30653E189A27D-B536-4D3F-A1D3-7E38373AB1A7149177EXTERNAL BEAM9000cGy45Regional siteADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Dead,224.0,743.8095703125,WHITE,TCGA-BH-A18T,BH,A18T,No,YES,C50.9,8500/3,C50.9,2003.0,WITH TUMOR,YES,3.625,ER Positive H-Score 95,H-SCORE 150,Right Upper Outer Quadrant,2.322529296874992,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Re-excision of the inferior margin,Other,segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Negative,Negative,Positive,0.21875,0.6181640625,allred score = 7,8,90-99%,Hercep Test  TM Dako,Dako Hecept Test,218.041015625,HER2 amplification - negative,Positive >2.2,NO,YES,3.1,"Other, specifyskin",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,441,3 Point Scale,1+,6thStage IIAT2N0M0,NO,NO,PositivePositiveNegativeNegative,2,7,2011,TCGA-AC-A2QI-F570476AA0381B-1A09-4E7E-A968-8065C44EB313NOYESYESTUMOR FREEAlive588NO2822014,NOTCGA-A7-A3RF-D40414C60A018E-A8EC-4C00-AB28-40901C23F33E137Hormone TherapyAnastrozoleYESClinical Progressive Disease1922013,TCGA-EW-A1P5-R32257ABC06C94-9A7F-4CD6-B371-E40477EF4EBC124185EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO11552012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,98.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A5IZ,BH,A5IZ,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,6.0,Allred 7 = 5+2,Allred score 5+3= 8,Left,1.8992382812500044,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,Pateys surgery,Infiltrating Ductal Carcinoma,pleomorphic infiltrating lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.990234375,1.0,Intensity=Strong,Moderate to strong,20-29%,Hercep Test  TM Dako,Hercep Test  TM Dako,406.2822265625,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,2.13,"Other, specifyskin",70-79%,40-49%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1,3 Point Scale,2+,7thStage IIBT2N1acM0 (i+),YES,YES,NO,13,2,2014,TCGA-BH-A5IZ-F63663FAADBA23-9D4F-4AC4-ADB7-5E0F9CC3FF01NOYESYESTUMOR FREEAlive567NO1482014,NOTCGA-BH-A5IZ-D56581EB4E7F2F-14F6-4609-94C9-937F41DF852177140ChemotherapyAdriamycinNOComplete Response1322014NOTCGA-BH-A5IZ-D565823B0DE458-656A-4A35-8FC0-B76E3C7A33E1161161ChemotherapyTaxotereNOComplete Response1322014NOTCGA-BH-A5IZ-D66934E11C1618-C47C-4EA9-8EC5-B0D84CC12E5377140ChemotherapyCyclophosphamideNOComplete Response28102014,TCGA-BH-A5IZ-R5658422DA154D-0940-4F18-A8C1-18FA728B21F1280323NOComplete Response1322014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,464.0,WHITE,TCGA-E2-A15J,E2,A15J,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,12.0,Allred score 5+3=8,Allred score 2+3 = 5,Left Upper Outer Quadrant,2.0467968750000027,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Reexcision,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.328125,0.0,Allred score = 8,Allred score = 7,90-99%,Dako,Dako Hercept test,66.54296875,HER2 amplification - negative,Ratio >=2.0,NO,YES,54,"Other, specifyaxilaary node negative but intrammary node positive",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,105,3 Point Scale,2+,6thStage IT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,13,4,2011,TCGA-E2-A15J-F18892AA79264E-5F95-4C32-80C4-910248E78E0DScheduled Follow-up SubmissionNOYESAlive590TUMOR FREENO15112011TCGA-E2-A15J-F70020EA54E7E2-D8FF-48C4-8B88-F15C664136DFNONOYESTUMOR FREEAlive1640NO922015,1TCGA-E2-A15J-D18893A6C43C80-32E8-4A0D-A6C0-6332C91C8B32504mg126mg465128ChemotherapyDocetaxelADJUVANTIVNO151120112TCGA-E2-A15J-D18896E6213072-8B49-4836-BAAF-DE468501668520mg/day20mg/day151Hormone TherapyTamoxifenADJUVANTPOYES151120111TCGA-E2-A15J-D18895D882E0A2-E3B4-4D0A-ADB8-9D48507E0D7B4032mg1008mg465128ChemotherapyCyclophosphamideADJUVANTIVNO15112011,TCGA-A2-A3XY-R344057A7E240A-DBB4-4389-ABD4-1836FA872FF7366ExternalNOComplete Response1482012TCGA-A2-A3XY-R558370F6362E1-CAE1-405E-9935-8D0EB86AF3EF10741082External1800cGy6Distant siteNORadiographic Progressive Disease1612014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,519.0,WHITE,TCGA-E2-A1IK,E2,A1IK,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,6.0,dextran coated charcoal,Allred score 0+0=0,Left,1.911171874999994,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.6953125,1.0,Allred Score 7,Allred score 8,10-19%,Hercep Test  TM Dako,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,55.0830078125,HER2 amplification - negative,Ratio >=2.0,NO,YES,4,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.80,3 Point Scale,3+,6thStage IIAT1cN1miM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,17,5,2011,TCGA-E2-A1IK-F199760E98A0A0-78D3-4D4F-AA64-BA761C736E42Scheduled Follow-up SubmissionNOYESAlive689TUMOR FREENO312012TCGA-E2-A1IK-F70395C706AB33-CD90-495B-AD28-271551DB85A8NONOYESTUMOR FREEAlive1800NO1732015,1TCGA-E2-A1IK-D1997711888A89-B610-43B7-9103-C695EDAB93321mg/day1mg/day92Hormone TherapyArimidexADJUVANTPOYES312012,TCGA-AR-A24M-R31289993D8611-83E6-452A-8153-DD07E97149A3172221EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO12742012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A8-A09Z,A8,A09Z,No,YES,C50.9,8520/3,C50.9,2008.0,WITH TUMOR,YES,9.4091796875,allred score 5+3=8,H-SCORE 280,Right,1.6346972656250005,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Surgical Resection,Infiltrating Lobular Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Positive,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.2783203125,3.8349609375,Allred Score 8,0,10-19%,Hercep Test  TM Dako,Dako Hecept Test,118.2958984375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.73,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.3,3 Point Scale,3+,6thStage IIBT3N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-AO-A0J3-F295726278313-311F-4604-93D1-B6D087933874302AliveTUMOR FREEYESYES1992010TCGA-AO-A0J3-F154779F50DC63-8F33-4824-9078-B96B2188703DScheduled Follow-up SubmissionYESYESAlive651TUMOR FREENO2282011,1TCGA-A7-A0DA-D6123848337bd-29ff-4b6c-8710-4bb3ac828398400mg100mg465107ChemotherapyAdriamycinADJUVANTIVNO13120111TCGA-A7-A0DA-D612584e6d642-6da6-4216-a376-2077ac9694423990mg990-1000mg465107ChemotherapyCytoxanADJUVANTIVNO13120111TCGA-A7-A0DA-D61261b1e115e-9a35-4b44-a883-94573341a8931435mg90-130mg12122199ChemotherapyTaxolADJUVANTIVNO1312011,TCGA-AR-A24T-R315046E123228-9066-4185-98D4-BF4F80D1BE4A189225EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1452012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,365.0,WHITE,TCGA-A8-A0A1,A8,A0A1,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,5.615234375,CAP scoring guideline 2010,Allred score 0+0=0,Right,1.786884765624993,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Surgical Resection,Infiltrating Lobular Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.26953125,0.0,allred score = 7,Allred Score 8,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,127.2705078125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,172,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,PositivePositiveNegativeNegative1.09,27,5,2011,TCGA-A2-A3KC-F373406468BE4A-4E05-4B7F-93C7-642E6C1FD9E5NOYESYESTUMOR FREEAlive635NO3122012TCGA-A2-A3KC-F59210471ED8F4-04BC-465A-A8E7-C1D948B5CBAANOYESYESTUMOR FREEAlive1102NO552014,NOTCGA-A8-A0A1-D37902A7EE46AB-50EC-4F0E-9E46-F0C31EC1420431Hormone TherapyTamoxifenYES6122012,TCGA-AR-A24M-R31289993D8611-83E6-452A-8153-DD07E97149A3172221EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO12742012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1492.0,WHITE,TCGA-BH-A0BZ,BH,A0BZ,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,23.0,ER Positive H-Score 95,H-SCORE 140,Left,2.284814453124997,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,pleomorphic infiltrating lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.5234375,1.0,allred score = 7,10-75%,10-19%,Hercep Test  TM Dako,+ or -,56.0048828125,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.45,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,>6.0,3 Point Scale,2+,6thStage IIIAT3N1aM0,NO,YES,YES994Distant MetastasisBoneNOYESYES,10,8,2011,TCGA-BH-A0BZ-F586835A5736DB-EA1E-47C5-8CDB-335A2A0274ADNOYESYESTUMOR FREEAlive2255NO2142014,NOTCGA-BH-A0BZ-D58689B11042C3-48A4-4427-AD8F-54AE2DE97D0076167ChemotherapyDoxorubicinNOComplete Response2242014NOTCGA-BH-A0BZ-D58690025FAF2B-F67F-42A2-86B3-DFC2BBB2148776167ChemotherapyCyclophosphamideNOComplete Response2242014NOTCGA-BH-A0BZ-D5869127F92F87-436A-44BE-A7AE-0AE19498D67C167197ChemotherapyAbraxaneNOComplete Response2242014,TCGA-BH-A0BZ-R5868472F11767-FAE3-406C-9239-648AC9322232257293External50Gy25Primary Tumor FieldNOComplete Response2142014TCGA-BH-A0BZ-R586856883F907-24F3-4229-B29A-0DCE18F291CA257293External50Gy25Primary Tumor FieldNOComplete Response2142014TCGA-BH-A0BZ-R58687D0470E61-8557-41E7-BDD8-97D0B17E1D00257293External45Gy25Regional siteNOComplete Response2242014TCGA-BH-A0BZ-R58688D22DAA71-0A92-4F4F-A8DC-864A0863B07A294300External10GyPrimary Tumor FieldNOComplete Response2242014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,9.0,ASIAN,TCGA-C8-A8HQ,C8,A8HQ,No,YES,C50.9,8480/3,C50.9,2013.0,TUMOR FREE,YES,7.0,allred score 0 + 0 = 0,Allred score 7 per outside facility report,Left,2.193251953125,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node dissection,Mucinous Carcinoma,Infiltrating ductal & lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Positive,Positive,Negative,4.0,3.0,allred score = 6,Intensity=Strong,90-99%,ACIS,Dako Hecept Test,125.31640625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,1.73,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1,4 Point Scale,2+,7thStage IIBT2N1M0,NO,NO,NO,29,12,2014,TCGA-C8-A8HQ-F698794243CE27-CD57-4D7A-B76B-03869D2A4945NONONOTUMOR FREEAlive380NO2212015,NOTCGA-A8-A0A1-D37902A7EE46AB-50EC-4F0E-9E46-F0C31EC1420431Hormone TherapyTamoxifenYES6122012,TCGA-A1-A0SP-R42235E22E8A7-7CD2-4DED-A532-43CB2DEF4F91215259EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO7122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1350.0,WHITE,TCGA-E2-A14N,E2,A14N,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,38.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Right Upper Inner Quadrant,1.991201171874988,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Other,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,Lobular carcinoma with ductal features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Positive,Negative,Negative,0.37890625,1.0,Allred score = 0,Allred score = 0,<10%,Hercep Test  TM Dako,Dako Hercept test,111.7353515625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.57,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,21,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",31,5,2011,TCGA-E2-A14N-F19154374DA424-B865-46D4-A433-F702C840CF36Scheduled Follow-up SubmissionYESYESAlive1434TUMOR FREENO17112011,1TCGA-E2-A14N-D19160774B35C1-A2FE-4E38-9361-04E5C80ED9345444mg1100mg564148ChemotherapyCyclophosphamideADJUVANTIVNO171120112TCGA-E2-A14N-D1918117CBAB16-10F1-4630-8C6E-81E28038C433540mg135mg487148ChemotherapyDocetaxelADJUVANTIVNO171120111TCGA-E2-A14N-D191809E98636D-8BD0-483C-B86A-593FAEF2D5B4110mg110mg16464ChemotherapyDoxorubicinADJUVANTIVNO17112011,TCGA-E2-A14N-R191827722E80A-C0A5-4B7D-95C4-6BBF762D55DD181236EXTERNAL BEAM5040cGy28Regional siteADJUVANTNO117112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,487.0,WHITE,TCGA-A8-A092,A8,A092,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,16.6259765625,IHC,H-SCORE 280,Left,1.787880859374993,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.3740234375,4.376953125,Allred Score 8,H-Score,10-19%,Hercep Test  TM Dako,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,98.2919921875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.5,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,59,3 Point Scale,2+,6thStage IIIAT2N2aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A092-F4055608BBC200-9E93-4FC1-8382-1CBF2310477FNOYESYESTUMOR FREEAlive942NO2322013,NOTCGA-A8-A092-D377933BB14198-BDE6-4F06-85E6-41F6C1519A1E3091ChemotherapyPaclitaxeln/aNOComplete Response6122012NOTCGA-A8-A092-D377947DEE3F98-1E1E-41EF-A92F-77AE88709E2730153ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A092-D377955EC320E1-3655-436C-B8CC-5E65353FEC3430153ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A092-D377962E5FD555-117E-45B5-BD9D-9F6653236007181Hormone TherapyTamoxifenn/aYES6122012,TCGA-A8-A092-R38164CF613056-FC7D-4604-89E3-ABBBC28E70AD181273External60GyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,20.0,WHITE,TCGA-LL-A440,LL,A440,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,4.0,Allred (Biocare),Allred score 4+3 = 7,Left Upper Outer Quadrant,1.7,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Modified radical mastectomy,Wide Local Excision,Infiltrating Lobular Carcinoma,Lobular carcinoma with ductal features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.0,0.0,Allred score = 7,205,10-19%,CISH,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,20.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,46,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,79,3 Point Scale,3+,7thStage IAT1cN0 (i-)MX,NO,NO,NO,26,10,2012,TCGA-LL-A440-F463879524E6CE-345A-422C-963B-8ED916821299NONOYESTUMOR FREEAlive759NO782013,NOTCGA-LL-A440-D46388594D9D16-EBE5-48DB-8248-895F81E52C71200Hormone TherapyARIMIDEXYES782013NOTCGA-LL-A440-D46389DDE1F9CF-5FD6-44F3-A2FB-5DA0244330D460123ChemotherapyCYTOXANNOComplete Response782013NOTCGA-LL-A440-D4639033BE396B-855F-4092-A53F-628047C5B25B60123ChemotherapyTAXOTERENOComplete Response782013,TCGA-D8-A27F-R29517971EDB07-58FF-45DD-9E58-5B6F0310BF2A158182EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO2132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,363.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3KC,A2,A3KC,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,19.0,>10% STAINING = POSITIVE,H-SCORE 250,Right Lower Outer Quadrant,1.0,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast reexcision,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.0,2.0,Two-tier,120,30-39%,Dako,Venten,20.0,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,1.9,"Other, specifyskin",90-99%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,1.8,3 Point Scale,3+,7thStage IIBT2N1aM0,YES,NO,PositiveNegative,14,3,2012,TCGA-A2-A3KC-F373406468BE4A-4E05-4B7F-93C7-642E6C1FD9E5NOYESYESTUMOR FREEAlive635NO3122012TCGA-A2-A3KC-F59210471ED8F4-04BC-465A-A8E7-C1D948B5CBAANOYESYESTUMOR FREEAlive1102NO552014,2TCGA-A2-A3KC-D3012689F4A022-4646-4C62-92B2-D98CBA444FB0636mg106mg677182ChemotherapyAdriamycinADJUVANTIVNO14320121TCGA-A2-A3KC-D30125ABA4D3E6-1A06-465B-83A0-EF2E9F3BAA4A6360mg1060mg677182ChemotherapyCytoxanADJUVANTIVNO14320124TCGA-A2-A3KC-D3012816218EC6-7B12-489E-8AB0-BD5C8278E00F20mg/day2031101Hormone TherapyTamoxifenADJUVANTPONO14320123TCGA-A2-A3KC-D30127332AAD9D-0369-443A-B563-28B1E2B02E65954mg159mg677182ChemotherapyTaxotereADJUVANTIVNO1432012NOTCGA-A2-A3KC-D592097D787BBB-1268-4E08-9C9E-BFA413D22B041102Hormone TherapyArimidexYES552014,TCGA-A2-A3KC-R30129D4342F05-5278-45FA-BC38-987E587E740CEXTERNAL BEAMADJUVANTNO11232012
TCGAFPPP,Breast,No,FEMALE,Dead,558.0,3575.1728515625,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0WW,B6,A0WW,No,YES,C50.9,8500/3,C50.9,1997.0,WITH TUMOR,YES,18.0,Image Analysis,Image Analysis,Right Upper Inner QuadrantRight,1.6963476562499986,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node dissection,Infiltrating Ductal Carcinoma,IDC+ mucinous carcinoma,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,4+,2+,Negative,Negative,Incisional Biopsy,intraoperative examination,Negative,Positive,Equivocal,0.587890625,5.0,allred score = 4,H score,10-19%,ACIS,Hecep Test TM DAKO,148.3388671875,Vysis AutoVysion System,>=2.2 Positive,NO,YES,33,BoneLiver,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,42,4 Point Scale,2+,4thStage XT2N1bMX,YES,NO,NONO,14,12,2010,TCGA-B6-A0WW-F157348CBC2A93-DCB9-4AEF-9C63-54316907C361Scheduled Follow-up SubmissionYESNODead558WITH TUMORYES447Distant MetastasisLiverNONOYES2982011,2TCGA-A2-A3KC-D3012689F4A022-4646-4C62-92B2-D98CBA444FB0636mg106mg677182ChemotherapyAdriamycinADJUVANTIVNO14320121TCGA-A2-A3KC-D30125ABA4D3E6-1A06-465B-83A0-EF2E9F3BAA4A6360mg1060mg677182ChemotherapyCytoxanADJUVANTIVNO14320124TCGA-A2-A3KC-D3012816218EC6-7B12-489E-8AB0-BD5C8278E00F20mg/day2031101Hormone TherapyTamoxifenADJUVANTPONO14320123TCGA-A2-A3KC-D30127332AAD9D-0369-443A-B563-28B1E2B02E65954mg159mg677182ChemotherapyTaxotereADJUVANTIVNO1432012NOTCGA-A2-A3KC-D592097D787BBB-1268-4E08-9C9E-BFA413D22B041102Hormone TherapyArimidexYES552014,TCGA-A8-A06R-R381723F996702-1D58-4178-BBF8-51E62724C215181212External60GyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Dead,639.0,1691.7294921875,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0WX,B6,A0WX,No,YES,C50.9,8520/3,C50.9,1998.0,WITH TUMOR,YES,21.0,Image Analysis,Image Analysis,Left,1.4938574218750016,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,breast conserving therapy,"Other, specify",Pleomorphic/lobular,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,4 Point Scale,4+,3+,Negative,Negative,Excisional Biopsy,intraoperative examination,Negative,Negative,Equivocal,0.744140625,9.0,allred score = 6,270 H,10-19%,ACIS,Venten,61.4326171875,HER2 amplification - negative,Positive >2.2,NO,YES,4.43,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,2.9,4 Point Scale,2+,5thStage IIIAT3N1bM0,YES,NO,NONO,14,12,2010,TCGA-B6-A0WX-F15729BA8B9EFE-3133-40B3-9336-0CD5C63B5D0AScheduled Follow-up SubmissionNOYESDead639WITH TUMORYES563Distant MetastasisBoneNONONO2982011,TCGA-D8-A27F-D29516623BDB83-F7A0-4C0E-8D45-D2C8A45913FF360+3600mg60+600mg/m26379488Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO2132012,TCGA-D8-A27F-R29517971EDB07-58FF-45DD-9E58-5B6F0310BF2A158182EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO2132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,106.0,WHITE,TCGA-D8-A27F,D8,A27F,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,manual counting,dextran coated charcoal,Right Upper Outer Quadrant,1.4081738281249951,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,Ductal with mucinous features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,4+,1+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Negative,Negative,0.0,0.0,Allred score = 0,H-Score,90-99%,Hercep Test  TM Dako,Dako Hercept test,100.169921875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,50,"Other, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,131,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",18,7,2011,TCGA-D8-A27F-F2951557370D31-378D-4228-9DAA-39A366A418B6Scheduled Follow-up SubmissionYESYESAlive488TUMOR FREENO2132012,TCGA-D8-A27F-D29516623BDB83-F7A0-4C0E-8D45-D2C8A45913FF360+3600mg60+600mg/m26379488Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO2132012,TCGA-D8-A27F-R29517971EDB07-58FF-45DD-9E58-5B6F0310BF2A158182EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO2132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,52.0,WHITE,TCGA-AN-A04D,AN,A04D,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,15.0,Allred (Biocare),Allred (Biocare),Left Upper Outer Quadrant,2.1119140624999986,No axillary staging,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Modified radical mastectomy,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,0,0,Negative,Positive,Tumor resection,Patey's Suregery,Positive,Negative,Negative,0.0,2.0,0,0,40-49%,0,Dako Hercept Test,107.3056640625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,1.0,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,42,3 Point Scale,0,Stage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,20,12,2010,TCGA-AN-A04D-F68975EE0071B8-0C20-431B-8150-16603C61D46FYESTUMOR FREEAlive5224122014,TCGA-D8-A27F-D29516623BDB83-F7A0-4C0E-8D45-D2C8A45913FF360+3600mg60+600mg/m26379488Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO2132012,TCGA-D8-A27F-R29517971EDB07-58FF-45DD-9E58-5B6F0310BF2A158182EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO2132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1991.0,WHITE,TCGA-AR-A24M,AR,A24M,No,YES,C50.9,8522/3,C50.9,2005.0,TUMOR FREE,YES,28.0,dextran coated charcoal,Image Analysis,Left Upper Outer Quadrant,1.9401367187499972,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Re-excision of the inferior margin,Other,Wide local excision,Mixed Histology (please specify),Mixed invasive ductal and invasive lobular,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.4189453125,4.0,Allred score = 0,Allred score = 0,10-19%,Hercep Test  TM Dako,CISH,71.7119140625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.38,"Other, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,21,4 Point Scale,2+,6thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,12,8,2011,TCGA-AR-A24M-F31275177526AB-A3B2-4310-854F-D6AD40F55BA5Scheduled Follow-up SubmissionYESYESAlive1991NO2642012TCGA-AR-A24M-F49489F4C44AB5-CE2E-484C-8430-7CE5DC5486F4NOYESYESTUMOR FREEAlive2947NO2102013TCGA-AR-A24M-F71732D6CB81E1-AE9D-4A1C-8E40-6E68F4B6936BNOYESYESTUMOR FREEAlive3660NO3032015,1TCGA-AR-A24M-D313490CE63344-9846-491C-BB79-071A252824D64ChemotherapyCytoxanADJUVANTNO1520122TCGA-AR-A24M-D31351A56BF7ED-38FA-4172-BA59-B2E1B0FED60120mg/day171597Hormone TherapyTamoxifenADJUVANTPONO1520121TCGA-AR-A24M-D313503AAE3639-A0AE-48F7-81A2-C05BA2ED77824ChemotherapyPaclitaxelADJUVANTNO1520121TCGA-AR-A24M-D313476CF36578-40F0-4B65-B7A9-2E017552BF044ChemotherapyDoxorubicinADJUVANTNO1520123TCGA-AR-A24M-D313537600BF7D-7046-47BB-B302-45F9C1AD00022.5mg/day597Hormone TherapyLetrozoleADJUVANTPOYES152012,TCGA-AR-A24M-R31289993D8611-83E6-452A-8153-DD07E97149A3172221EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO12742012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,273.0,WHITE,TCGA-A8-A07R,A8,A07R,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,17.01171875,IHC,Allred score 2+3 = 5,Left Upper Outer Quadrant,2.5171093749999955,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Positive,Tumor resection,Lumpectomy,Negative,Negative,Positive,0.322265625,4.896484375,0%,0,10-19%,Hercep Test  TM Dako,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,85.6142578125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.5,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.66,3 Point Scale,2+,6thStage IIICT2N3aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-B6-A0RG-F1379381C89D48-283C-43B0-97AE-F30BB640272DScheduled Follow-up SubmissionNOYESAlive2082TUMOR FREENO1272011,NOTCGA-A8-A07R-D37859405A82A8-7239-4AA4-9C46-4C081D26D8E4181AncillaryZoledronic acidn/aYES6122012,TCGA-A8-A07R-R3818279E24A2B-F8AD-4310-8924-83117D9C4CC3120151ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,439.0,WHITE,TCGA-AR-A5QP,AR,A5QP,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,40.0,H-SCORE 0,Allred score 0+0=0,Left,2.9058984375000017,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision,Other,total mastectomy with sentinel lymph node biopsy with tissue reconstruction,Infiltrating Lobular Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.4912109375,1.0,Allred score = 8,Allred score = 7,10-19%,Hercep Test  TM Dako,Hercep Test TM DAKO,82.4541015625,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.8,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,816,3 Point Scale,3+,7thStage IIBT2N1M0,YES,YES,NO,15,5,2013,TCGA-AR-A5QP-F438758273D0A2-FA6A-44B5-B288-5F1049F5C9E5NOYESYESTUMOR FREEAlive622NO1062013TCGA-AR-A5QP-F69266E98992F8-020A-46A2-A019-DC50F9C178C3NOYESYESTUMOR FREEAlive1185NO31122014,NOTCGA-AR-A5QP-D439148150DA11-23B1-4826-AD05-FFB7FBE8410D46Hormone TherapyTamoxifenYES1062013,TCGA-AR-A5QP-R43913CF61419A-FE99-4501-84F5-3EAFB9324AFB4270External5256cGy20Primary Tumor FieldNO1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,547.0,WHITE,TCGA-A8-A06R,A8,A06R,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,13.4296875,CAP scoring guideline 2010,Allred score 0+0=0,Right Upper Outer Quadrant,1.6635546874999954,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Right Breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.3115234375,4.0810546875,Allred score = 4,Allred Score 8,10-19%,ACIS,Dako Hercept test,86.154296875,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,NO,YES,160,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,441,3 Point Scale,3+,5thStage IIBT2N1aM0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A06R-F40815AB298BD7-3CA2-44B2-8FA0-1DB436A3375FNOYESYESTUMOR FREEAlive547NO232013,NOTCGA-A8-A06R-D37825D8FE6469-6DAB-4BCB-9DF8-8AD53DF522F259151Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A06R-D3782602116C14-0DE0-40A5-9224-0A2BBC4D0DEB59151ChemotherapyDoxorubicinn/aNOComplete Response6122012NOTCGA-A8-A06R-D3782724AF886F-B700-4E8D-91FA-5A62222090E459151ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A06R-D37828A8ADA003-4EDE-4F08-BD6D-033E139A8077243334Hormone TherapyTamoxifenn/aNOComplete Response6122012,TCGA-A8-A06R-R381723F996702-1D58-4178-BBF8-51E62724C215181212External60GyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Dead,1920.0,1467.6875,WHITE,TCGA-A2-A04V,A2,A04V,No,YES,C50.9,8500/3,C50.9,2005.0,WITH TUMOR,YES,2.0,Allred score 3+2 = 5,Allred score 5+3= 8,Right Lower Outer QuadrantRight,1.1,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,Infiltrating ductal & lobular,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,1+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.0,0.0,MODERATE,STRONG,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,43.5517578125,Vysis AutoVysion System,Positive >2.2,NO,YES,33,"LungBoneLiverOther, specifyskin",90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0495312500000025,1.67,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,PositivePositiveNegative,10,8,2010,TCGA-A2-A04V-F102738A12F731-0D21-451D-AED9-2677F2356DE2DeadWITH TUMOR1920NOYES1470NONONOYES1832011,1TCGA-A2-A04V-D2667e691b7e7-6b22-430c-9b18-b7f08912f85a4584mg1146mg45092ChemotherapyCYTOXANADJUVANTIVNO11820104TCGA-A2-A04V-D267341160c56-81c5-42b7-83b8-cc0018073cac25mg1452Hormone TherapyEXEMESTANEADJUVANTPONO11820103TCGA-A2-A04V-D2672c1e949b8-77cf-4bbb-b6f2-a74ede20457a20mg1071258Hormone TherapyTAMOXIFENADJUVANTPONO11820106TCGA-A2-A04V-D27684de0e435-5d29-44a0-a877-986681b96a3b2.5mg12691439Hormone TherapyLETROZOLEADJUVANTPONO11820105TCGA-A2-A04V-D2674a2308b51-8301-425e-b065-0be458fe16721577ChemotherapyXELODARECURRENCEPONO11820102TCGA-A2-A04V-D26688e869f6b-ed8a-4174-ad9e-fff54d6496cc460mg115mg45092ChemotherapyADRIAMYCINADJUVANTIVNO1182010,TCGA-BH-A0E9-R59108D79458CD-6078-486D-8B25-624CA0AF0452150189External5040cGy28Primary Tumor FieldNOComplete Response152014TCGA-BH-A0E9-R59109F5797B5C-F9B3-4797-9DE9-0A5DEACCBF3C192201External1400cGy7Primary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,58.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A66P,OL,A66P,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,2.0,H-Score 150,Allred score 2+3 = 5,Right,1.13,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Re-excision of the inferior margin,Other,SKIN SPARING RADICAL MASTECTOMY,Infiltrating Ductal Carcinoma,Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.234375,0.0078125,Allred score 0,Intensity=Strong,30-39%,0,Hercep Test TM DAKO,77.8876953125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.8,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.80,3 Point Scale,3+,7thStage IIAT2N0MX,YES,NO,NO,11,6,2013,TCGA-OL-A66P-F5849409B7FC8E-A0C0-4ECB-B6D4-A185043F7DAFNONOYESTUMOR FREEAlive428NO1142014,NOTCGA-OL-A66P-D644931BB36628-3326-4CF1-B898-053AE55A2C1071162ChemotherapyCytoxanNOComplete Response2492014NOTCGA-OL-A66P-D65245D827B0B7-5809-4FDC-BA64-92F84625B85571162ChemotherapyTaxotereNOComplete Response2492014,TCGA-AC-A2BK-R439895F23873B-7D5F-43C9-86F1-820C26351615203254External6000cGy25Primary Tumor FieldNOComplete Response1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,210.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A26G,A7,A26G,No,YES,C50.9,8575/3,C50.9,2010.0,TUMOR FREE,YES,2.0,H-SCORE 300,Allred score 5+3 = 8,Right,1.1807128906250042,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Reexcision,Modified radical mastectomy,Total Mastectomy,"Other, specify",Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Negative,Negative,0.841796875,0.0,Allred score = 7,Allred Score 5,10-19%,CISH,Dako Hecept Test,127.8896484375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,3.1,"Other, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,816,3 Point Scale,2+,7thStage IIAT2N0 (i+)M0,NO,YES,YES994Distant MetastasisBoneNOYESYES,10,8,2011,TCGA-A7-A26G-F2941991E3B3A1-3446-4119-8A7F-2419BAEC4831Scheduled Follow-up SubmissionNOYESAlive334TUMOR FREENO1632012TCGA-A7-A26G-F390471C41020E-8C83-4C5D-8CB2-6926012E4ED9NONOYESTUMOR FREEAlive722NO912013,1TCGA-A7-A26G-D1490690ABBBFF-599A-4245-A3A3-FAFC37EEC924648mg160-168mg489152ChemotherapyTaxotereADJUVANTIVNO10820111TCGA-A7-A26G-D149087D7AE68F-EC3A-4BA6-A19A-4A4D2590CA7E5292mg1308-1344mg489152ChemotherapyCytoxanADJUVANTIVNO1082011,TCGA-BH-A0E9-R59108D79458CD-6078-486D-8B25-624CA0AF0452150189External5040cGy28Primary Tumor FieldNOComplete Response152014TCGA-BH-A0E9-R59109F5797B5C-F9B3-4797-9DE9-0A5DEACCBF3C192201External1400cGy7Primary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,584.0,WHITE,TCGA-A1-A0SP,A1,A0SP,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,3.0,Allred 0 = 0+0,allred score 4 + 3 = 7,Right,1.407587890625005,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-excision of the inferior margin,Modified radical mastectomy,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,pleomorphic infiltrating lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,4+,0,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Negative,Negative,Negative,0.0048828125,0.0,8,Moderate,30-39%,0,Venten,136.19140625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,35,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,71,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",6,12,2010,TCGA-A7-A26G-F2941991E3B3A1-3446-4119-8A7F-2419BAEC4831Scheduled Follow-up SubmissionNOYESAlive334TUMOR FREENO1632012TCGA-A7-A26G-F390471C41020E-8C83-4C5D-8CB2-6926012E4ED9NONOYESTUMOR FREEAlive722NO912013,TCGA-A1-A0SP-D4489D44AD8B4-4B21-4F10-A99A-EEB2C92222FD108173ChemotherapyADJUVANTIVNO7122010,TCGA-A1-A0SP-R42235E22E8A7-7CD2-4DED-A532-43CB2DEF4F91215259EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO7122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,185.0,WHITE,TCGA-BH-AB28,BH,AB28,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,20.0,Allred score 4+3=7,PR Negative H-Score 0,Left,1.8021386718750032,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision,Other,biopsy,Infiltrating Lobular Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Indeterminate,Positive,Negative,0.9658203125,3.0,108,190,90-99%,ACIS,Hercep Test TM DAKO,124.5810546875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,1.1,"LungBoneLiverOther, specifyskin",80-89%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,441,3 Point Scale,2+,7thStage IIIAT3N1aM0,YES,NO,NO,30,6,2014,TCGA-BH-AB28-F642096CB9D593-9190-4C31-968A-C9D75BC2480DNONOYESTUMOR FREEAlive287NO2522015,YESTCGA-BH-AB28-D6147354C265C0-9FA9-491F-BB0D-4D8AFD0AB2A4122ChemotherapyTaxotereYES3062014YESTCGA-BH-AB28-D614745A9C6B1E-27C2-496C-8266-4D565A27C07F122ChemotherapyCytoxanYES3062014,TCGA-OL-A66N-R64494329248C5-412D-40AF-BC3D-5C54F1C54EB9374412External5040cGyPrimary Tumor FieldNOComplete Response1292014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1172.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A2BK,AC,A2BK,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,23.0,Allred 0 = 0+0,Allred score 5+3 = 8,Left Upper Outer Quadrant,2.009648437499997,Axillary lymph node dissection alone,SN+1 non sentinel node,Modified Radical Mastectomy,Reexcision,Modified radical mastectomy,Wide Local Excision,Infiltrating Ductal Carcinoma,micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Negative,Negative,0.1806640625,6.0,allred score = 7,Strong,<10%,ACIS,Hercep Test TM DAKO,56.7900390625,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,3.1,BoneLiver,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,149,3 Point Scale,2+,6thStage IIIAT2N2aMX,YES,YES,YES994Distant MetastasisBoneNOYESYES,16,9,2011,TCGA-AC-A2BK-F43987256CE2CD-BE4C-49CD-8395-1A4991708D69NOYESYESTUMOR FREEAlive2222NO1062013,NOTCGA-AC-A2BK-D439889DE66FB7-BCEC-4B84-B97E-1A9F68D8E87A73136ChemotherapyCytoxanNOComplete Response1062013NOTCGA-AC-A2BK-D439901502DE28-84D8-4351-BCEE-9661DACD2B2173136ChemotherapyAdriamycinNOComplete Response1062013NOTCGA-AC-A2BK-D439914869DCB0-723E-46A0-AB90-3D5FF038203A149164ChemotherapyTaxolNOComplete Response1062013NOTCGA-AC-A2BK-D439928283B14A-D235-4D20-B272-9B4A8A095886149164ChemotherapyAvastinNOComplete Response1062013,TCGA-AC-A2BK-R439895F23873B-7D5F-43C9-86F1-820C26351615203254External6000cGy25Primary Tumor FieldNOComplete Response1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1180.0,WHITE,TCGA-AC-A2FK,AC,A2FK,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,3.0,H-SCORE 280,allred score 5+3+8,Left Upper Outer Quadrant,1.567089843750005,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-excision of the inferior margin,Modified radical mastectomy,Mastectomy,Infiltrating Lobular Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Negative,Positive,Negative,0.0703125,3.0,Allred Score 3,Allred score = 7,10-19%,ACIS,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,56.8623046875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,4.43,"Other, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.80,3 Point Scale,2+,6thStage IIICT2N3aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,13,9,2011,TCGA-AC-A2FK-F66196DD3AB466-3C36-42BB-8F4A-E288ED7C6078NOYESYESTUMOR FREEAlive2650NO3102014,NOTCGA-AC-A2FK-D66198A85E31F8-6790-4964-AC1A-C6253F9E413D51174ChemotherapyCytoxanNOComplete Response3102014NOTCGA-AC-A2FK-D66199118A7D45-089C-4980-B978-FD970C00090551174ChemotherapyAdriamycinNOComplete Response3102014NOTCGA-AC-A2FK-D6620096CBB13E-8C96-4CE4-B4FE-2FC707EC8044294Hormone TherapyFemaraNOComplete Response3102014NOTCGA-AC-A2FK-D6620167C16321-C0D6-4EE5-AA5C-25C290914D9E51174ChemotherapyTaxotereNOComplete Response3102014,TCGA-AC-A2FK-R66197C93A72D1-3D52-4D17-A14F-82E4B3670AE8243280External5040cGy28Primary Tumor FieldNOComplete Response3102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2877.0,WHITE,TCGA-AO-A128,AO,A128,No,YES,C50.9,8500/3,C50.9,2002.0,TUMOR FREE,YES,15.0,allred score 0 + 0 = 0,Allred score 2+2 = 4,Right Lower Outer QuadrantRight,1.0,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Ductal/cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,0,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Negative,Negative,0.0,0.0,100,Allred Score 5,<10%,CISH,3+ Positive,30.0,Vysis AutoVysion System,>=2.0 Positive,NO,YES,49,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,52,3 Point Scale,1+,Stage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,7,12,2010,TCGA-AO-A128-F58792A6DEEAE-C739-4E88-8095-431BF42899E32877AliveTUMOR FREEYESYES7122010TCGA-AO-A128-F19405CAAF9EFF-2A56-4182-A1F0-115AA2CDDAEDScheduled Follow-up SubmissionYESYESAlive3248TUMOR FREENO12122011,1TCGA-AO-A128-D5943e2154fbe-e02b-44f3-a61a-e08146c61db2480mg62mg/m2482124ChemotherapyDoxorubicinADJUVANTIVNO10120111TCGA-AO-A128-D594539C00F42-C756-42EC-98DC-BB6F6434718B1360mg175mg/m24160222ChemotherapyPaclitaxelADJUVANTIVNO10120111TCGA-AO-A128-D5942554dcbf2-b7a5-4237-9b68-7484e41a52ab4800mg619mg/m2482124ChemotherapyCyclophosphamideADJUVANTIVNO1012011,TCGA-AO-A128-R5880a8fd3954-09d3-4dd2-8fa4-4e734dc2918b263308EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO17122010
TCGAFPPP,Breast,No,FEMALE,Dead,2009.0,936.9775390625,WHITE,TCGA-BH-A18S,BH,A18S,No,YES,C50.3,8523/3,C50.3,2003.0,TUMOR FREE,YES,2.0,No value Given,PR Negative H-Score 0,Right Lower Inner Quadrant,1.7252734375000025,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Reexcision,Other,total mastectomy,Mucinous Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.6748046875,0.0,Allred Score 3,10-75%,30-39%,Hercep Test  TM Dako,Dako Hercept test,61.4423828125,HER2 amplification - negative,PathVysion,NO,YES,74,"Other, specifyskin",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0495312500000025,5,3 Point Scale,1+,6thStage IT1cN0M0,NO,NO,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,2,7,2011,TCGA-OL-A66P-F5849409B7FC8E-A0C0-4ECB-B6D4-A185043F7DAFNONOYESTUMOR FREEAlive428NO1142014,TCGA-A1-A0SP-D4489D44AD8B4-4B21-4F10-A99A-EEB2C92222FD108173ChemotherapyADJUVANTIVNO7122010,TCGA-D8-A1XK-R300734AF40BF7-8C93-4618-8EA8-7F5FAAC782D9253281EXTERNAL BEAM9000cGy45Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,413.0,WHITE,TCGA-OL-A66N,OL,A66N,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,15.0,H-SCORE 0,H-SCORE 280,Left,1.1,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision,Other,Segmental mastectomy with sentinel axillary lymph node biopsy,Infiltrating Lobular Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.953125,13.0,allred score = 6,Intensity=Strong,30-39%,CISH,+ or -,87.6044921875,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,35,"Other, specifyskin",80-89%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,3+,7thStage IIICT3N3MX,NO,YES,NO,11,6,2013,TCGA-OL-A66N-F5850050D68837-611C-4482-A388-7FDD9BE57607NOYESNOTUMOR FREEAlive792NO1142014,YESTCGA-BH-AB28-D6147354C265C0-9FA9-491F-BB0D-4D8AFD0AB2A4122ChemotherapyTaxotereYES3062014YESTCGA-BH-AB28-D614745A9C6B1E-27C2-496C-8266-4D565A27C07F122ChemotherapyCytoxanYES3062014,TCGA-OL-A66N-R64494329248C5-412D-40AF-BC3D-5C54F1C54EB9374412External5040cGyPrimary Tumor FieldNOComplete Response1292014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1405.0,WHITE,TCGA-BH-A0E9,BH,A0E9,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,12.0,Allred score 5+2 = 7,H-SCORE 250,Right,1.8281445312500055,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Lobular Carcinoma,"Adenocarcinoma with squamous differentiation, metaplastic",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.2900390625,3.0,Allred Score 5,Strong,10-19%,Hercep Test  TM Dako,Dako Hecept Test,67.982421875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.38,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.62,3 Point Scale,2+,6thStage IIBT2N1aM0,NO,NO,YES994Distant MetastasisBoneNOYESYES,11,8,2011,TCGA-BH-A0E9-F59107265B9809-54D2-4DF5-8DB0-4D44667B3A1ENOYESYESTUMOR FREEAlive2489NO152014,NOTCGA-BH-A0E9-D59110ED0808E6-A224-44C7-8353-2A9DF81486C596503ChemotherapyTaxotereNOComplete Response152014NOTCGA-BH-A0E9-D59111303A080F-9FE8-4C7A-B424-44DF8F97B57C96503ChemotherapyAdriamycinNOComplete Response152014NOTCGA-BH-A0E9-D59113D3529E84-7664-4493-AF4D-F8B121B6983B96503ChemotherapyCytoxanNOComplete Response152014,TCGA-BH-A0E9-R59108D79458CD-6078-486D-8B25-624CA0AF0452150189External5040cGy28Primary Tumor FieldNOComplete Response152014TCGA-BH-A0E9-R59109F5797B5C-F9B3-4797-9DE9-0A5DEACCBF3C192201External1400cGy7Primary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,15.0,WHITE,TCGA-D8-A27W,D8,A27W,No,YES,C50.9,8480/3,C50.9,2011.0,TUMOR FREE,YES,12.0,manual counting,manual counting,Right,1.4081738281250038,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast reexcision,Other,breast conserving therapy,Mucinous Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Positive,Positive,Equivocal,0.5537109375,0.0,>75%,>75%,90-99%,Hercep Test  TM Dako,Venten,127.4365234375,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,1.1,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.3,3 Point Scale,2+,7thStage IIIBT4bN0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",21,7,2011,TCGA-D8-A27W-F3010712E2DB12-F8A5-49D9-A51C-012731462DE5Scheduled Follow-up SubmissionYESYESAlive373TUMOR FREENO242012,TCGA-D8-A27W-D30108638ECF5D-30BB-4107-95B4-9347666BF398mgmg656162Chemotherapydoxorubicine+cyclophosphamideADJUVANTIVNO242012TCGA-D8-A27W-D301107E602CDB-4F73-4338-B776-1E33AC8151D9mg20mg/day226Hormone TherapyTamoxifenADJUVANTPOYES242012,TCGA-D8-A27W-R301094F59F468-DD4A-40AE-B63B-3DDEA2721CA1189221EXTERNAL BEAM5500cGy25Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1574.0,WHITE,TCGA-AR-A24Z,AR,A24Z,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,8.0,H-Score 300,Allred score 5+3 = 8,Left Upper Outer Quadrant,5.662548828124987,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Reexcision,Other,Total mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,1+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Positive,Positive,Negative,0.07421875,0.0,10-75%,230,10-19%,Hercep Test  TM Dako,Dako Hecept Test,105.1279296875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.1,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.3,3 Point Scale,0,6thStage IIAT2N0M0,YES,NO,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",30,8,2011,TCGA-AR-A24Z-F31664A77B894E-2A15-4FCD-8DDD-28769F257CE3Scheduled Follow-up SubmissionNOYESAlive1574NO852012TCGA-AR-A24Z-F49507DEBAA1B0-B174-41E1-BAE2-2B5E069C17E3NOYESTUMOR FREEAlive2403NO2102013TCGA-AR-A24Z-F717434F1B7892-51A0-4396-8B71-2847EE22CBEFNONOYESTUMOR FREEAlive3001NO3032015,NOTCGA-AR-A24Z-D3166524B6AA72-F2AB-4E43-84F8-C9EBEDE6978B4991ChemotherapyDoxorubicinNO2152012NOTCGA-AR-A24Z-D31668CEF63E08-B78B-4BE0-BD0B-1A62629A45AA4991ChemotherapyCytoxanNO2152012NOTCGA-AR-A24Z-D3166700E48087-B371-4EB8-93D4-4F9C4E366C281331912Hormone TherapyAnastrozoleNO2152012,TCGA-AC-A2BK-R439895F23873B-7D5F-43C9-86F1-820C26351615203254External6000cGy25Primary Tumor FieldNOComplete Response1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,81.0,WHITE,TCGA-D8-A1XY,D8,A1XY,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,3.0,manual counting,manual counting,Left Upper Outer Quadrant,1.3151855468750009,Axillary lymph node dissection alone,axillary ultrasound,Simple Mastectomy,Re-excision of the inferior margin,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Positive,Positive,0.0126953125,0.0,>75%,>75%,90-99%,Hercep Test  TM Dako,HerceptTest TM Dako,82.841796875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,1.78,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.9,3 Point Scale,2+,7thStage IIAT2N0MX,YES,YES,YES994Distant MetastasisBoneNOYESYES,9,6,2011,TCGA-D8-A1XY-F2999485C03FE0-C6F1-4428-A4D2-749634FC006DScheduled Follow-up SubmissionNOYESAlive503TUMOR FREENO3132012,TCGA-D8-A1XY-D299954983452A-0399-4CBE-BCDF-9F09A21FC698mg20mg/day421ChemotherapyTamoxifenADJUVANTPOYES3132012,TCGA-D8-A27W-R301094F59F468-DD4A-40AE-B63B-3DDEA2721CA1189221EXTERNAL BEAM5500cGy25Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12M,C8,A12M,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,H-SCORE 280,allred score 2+2 = 4,Left,1.7622363281249884,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Re-excision of the inferior margin,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Infiltrating papillary adenocarcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.0048828125,0.0009765625,Allred Score 5,Allred Score 8,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,66.625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,1.78,"Other, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,145,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,12,4,2011,TCGA-C8-A12M-F1909324695606-56F0-47DB-9B5E-AFBC4C80292DScheduled Follow-up SubmissionNOYESAlive358TUMOR FREENO2122011,TCGA-D8-A27N-D295957055CBBE-07D0-4F99-B7A5-FC251DAE2E28mg60+600mg/m268Chemotherapytaxol+adriamycin+cyclophosphamide+herceptinADJUVANTIVYES2632012,TCGA-E2-A159-R19120ABEB4CB1-0F56-4D55-8796-EF6EF74DD791165215EXTERNAL BEAM6240cGy34Primary Tumor FieldADJUVANTNO18112011
TCGAFPPP,Breast,No,FEMALE,Dead,2207.0,871.87109375,WHITE,TCGA-BH-A18M,BH,A18M,No,YES,C50.3,8500/3,C50.3,2001.0,WITH TUMOR,YES,6.0,H-Score-190,Allred 5 = 2+3,Left Upper Inner Quadrant,1.8386718749999984,Sentinel node biopsy alone,SN+1 non sentinel node,Modified Radical Mastectomy,Right Breast reexcision,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Positive,4.0,4.0,8,Intensity=Strong,10-19%,ACIS,CAP SCORING GUIDELINE 2010,153.9248046875,HER2 amplification - negative,>=2.2 Positive,NO,YES,40,BoneLiver,80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,816,3 Point Scale,2+,5thStage IIIAT3N1M0,NO,YES,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,15,6,2011,TCGA-BH-A0HO-F477158E9756A-3F14-478E-8CF9-BFFB2908910276AliveTUMOR FREEYESYES16112010,YESTCGA-BH-A0B0-D592057588271F-B241-4AE6-AE91-0065CCD2FE3782194ChemotherapyAdriamycinNOComplete Response252014YESTCGA-BH-A0B0-D592069A3AEC18-4AD6-47E3-B8CA-EA762943F95082194ChemotherapyCytoxanNOComplete Response252014,TCGA-GM-A2DK-R470950F34A3E2-169D-4D79-B883-9E14DADAF2DD93135External60Gy30Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Dead,2373.0,3483.2265625,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0RM,B6,A0RM,No,YES,C50.9,8500/3,C50.9,1993.0,TUMOR FREE,YES,0.0,Image Analysis,Image Analysis,Left,1.7828417968749897,No axillary staging,axillary ultrasound,Other,Left breast reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,invasive papillary carcinoma,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Positive,Positive,Equivocal,0.984375,3.716796875,moderately to strongly,moderate,10-19%,ACIS,DAKOHercepTest TM,224.2158203125,Vysis AutoVysion System,PathVysion Her-2 DNA,NO,YES,2.8,"Other, specifyskin",80-89%,90-99%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0522265625000027,1,4 Point Scale,1+,4thStage XTXNXMX,YES,YES,NONO,2,11,2010,TCGA-B6-A0RM-F13797FAE88C3C-4AE1-4274-B83F-EDF870D50E59Scheduled Follow-up SubmissionNONODead2373TUMOR FREENO1272011,1TCGA-A2-A0SW-D37025751c947-6519-4f54-b423-fda73bc2b43amg1mg/day85479Hormone TherapyArimidexADJUVANTPONO81120102TCGA-A2-A0SW-D37031e0659e4-5a29-4057-a83b-90e3e8f398eemg20mg/day4791365Hormone TherapyTamoxifenADJUVANTPONO8112010,TCGA-AR-A2LQ-R37595BC8640F7-F340-4B7A-8B3E-7FD66D6DA282201240External5040cGy28Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,469.0,WHITE,TCGA-E2-A15F,E2,A15F,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,3.0,CAP SCORING GUIDELINE 2010,Allred score 7 per outside facility report,Left Upper Outer Quadrant,1.388691406249991,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.736328125,0.0,allred score = 7,0,30-39%,Dako,Venten,83.0380859375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,33,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,131,3 Point Scale,3+,6thStage IT1cN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",13,4,2011,TCGA-E2-A15F-F18906B97A662C-1E3B-4E86-A42A-E23819047D85Scheduled Follow-up SubmissionYESYESAlive658TUMOR FREENO10112011,1TCGA-E2-A15F-D189071EAC6D1E-0E8F-4AD2-8571-21809FF6F41C1mg/day1mg/day87Hormone TherapyArimidexADJUVANTPOYES10112011,TCGA-E2-A15F-R18908D9E37765-4428-4C8E-A7D0-6C851A7C95FF4286EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO110112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,379.0,WHITE,TCGA-A2-A0YH,A2,A0YH,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,28.0,ER Positive H-Score 95,H-Score 15,Left Lower Outer Quadrant,1.1732421874999996,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Lumpectomy,Re-excision of the inferior margin,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.3515625,5.0,Allred score 8,Strong,<10%,ACIS,CAP scoring guideline 2010,40.28515625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,NO,YES,1.1,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,4.70,3 Point Scale,3+,Stage IIIAT2N2aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,14,12,2010,TCGA-A2-A0YH-F1675272D0FFE4-4FE3-4846-A658-E195AE00FAE0Scheduled Follow-up SubmissionYESYESAlive659TUMOR FREENO1692011,2TCGA-A2-A0YH-D543780f9e542-473a-4608-9e1c-491b215c50d7828mg138mg674179ChemotherapyTaxotereADJUVANTIVNO141220103TCGA-A2-A0YH-D5440599117f8-1d3d-4e44-bf96-83aaba1b8ca76600mg1100mg674179ChemotherapyCytoxanADJUVANTIVNO141220104TCGA-A2-A0YH-D5441cbf163a4-c78e-463e-8de3-c0981fefd6f9Hormone TherapyArimidexADJUVANTPOYES141220101TCGA-A2-A0YH-D5435e60cd9fa-5849-49a5-8bb1-69491f0379a116060ChemotherapyAdriamycinADJUVANTIVNO14122010,TCGA-A2-A0YH-R54427446a50c-47f9-4fab-84f9-78ee16a151d5214264EXTERNAL BEAM5940cGy33Primary Tumor FieldADJUVANTNO114122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2082.0,WHITE,TCGA-B6-A0RG,B6,A0RG,No,YES,C50.9,8500/3,C50.9,1991.0,TUMOR FREE,YES,19.0,IHC,IHC,Left,1.4176953125000011,Axillary lymph node dissection alone,Pateys surgery,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,partial mastectomy,Infiltrating Ductal Carcinoma,lobular/ductal,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,2+,3+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Negative,Equivocal,0.7236328125,0.0,Allred Score 4,250,10-19%,ACIS,DAKOHercepTest TM,228.9560546875,Vysis AutoVysion System,Ratio >=2.0,NO,YES,3.1,"Other, specifySkin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.5,4 Point Scale,1+,4thStage IIBT3N0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,2,11,2010,TCGA-B6-A0RG-F1379381C89D48-283C-43B0-97AE-F30BB640272DScheduled Follow-up SubmissionNOYESAlive2082TUMOR FREENO1272011,1TCGA-AQ-A04J-D10110D8796E39-CFDE-459F-9BCD-D002AFF025CF2400mg/m2600mg/m2461104ChemotherapyCytoxanADJUVANTIVNO7420111TCGA-AQ-A04J-D10098C6A8B218-BCD7-4F96-B5AB-9B20A7A0B735240mg/m260mg/m2461104ChemotherapyAdriamycinADJUVANTIVNO7420111TCGA-AQ-A04J-D101119826B415-20EE-4140-A2D8-EA39857695D9700mg/m2175mg/m24118160ChemotherapyTaxolADJUVANTIVNO742011,TCGA-BH-A8FZ-R57777A3520120-DE20-49A6-A0A8-DC098E7076DC81125External10Gy33Primary Tumor FieldNOComplete Response2632014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1NG,E9,A1NG,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,5.0,allred score 5 + 3 = 8,Allred (Biocare),Right Upper Outer Quadrant,1.523847656249992,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,Total Mastectomy,Infiltrating Ductal Carcinoma,Lobular/Ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.0,0.0,Allred Score 4,120,10-19%,Hercep Test  TM Dako,Venten,155.552734375,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,3.1,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.8,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,23,6,2011,TCGA-E9-A1NG-F29212CF8E81EE-644C-447C-8659-32AF571CBD47Scheduled Follow-up SubmissionNOYESAlive656TUMOR FREENO1232012TCGA-E9-A1NG-F39774B3EEEE00-5B8E-436F-80FE-7412C969BF0CNONOYESTUMOR FREEDead786NO122013,NOTCGA-E9-A1NG-D397760D22B7CA-FD4C-4FB1-BC8D-AC7B958AE6E634Hormone TherapyLetrozoleYES122013NOTCGA-E9-A1NG-D397778D15500A-996F-42AD-9B5C-4B59FBEB68D634786Hormone TherapyTamoxifenNOComplete Response122013,TCGA-E2-A1LI-R20626B73909E2-58E4-42C3-AFFF-2F8746177C50152194Primary Tumor FieldADJUVANTNO11212012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,4788.0,WHITE,TCGA-B6-A0RV,B6,A0RV,No,YES,C50.9,8522/3,C50.9,1996.0,TUMOR FREE,YES,10.0,Image Analysis,Image Analysis,Right,1.6208593749999975,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,surgical resection,Modified radical mastectomy,Partial Mastectomy,Mixed Histology (please specify),Lobular/Ductal,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,2+,3+,Negative,Negative,Incisional Biopsy,intraoperative examination,Positive,Positive,Equivocal,0.828125,5.0,60,moderate,10-19%,ACIS,Hecep Test TM DAKO,203.4521484375,Vysis AutoVysion System,CAP SCORING GUIDELINE 2010,NO,YES,3.1,"LungOther, specifyleft adrenal gland",10-19%,70-79%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,52,4 Point Scale,1+,4thStage IIIAT3N2M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",2,11,2010,TCGA-B6-A0RV-F137912950EE46-B267-4898-9ADF-B5B140CAD0A8Scheduled Follow-up SubmissionYESYESAlive5156TUMOR FREENO1272011,1TCGA-A7-A13G-D17698123A3E9A-D014-419E-93FC-E001C3B336B2376mg1mg33Hormone TherapyArimidexADJUVANTPOYES24102011NOTCGA-A7-A13G-D35038BEEDA94D-D6C3-4811-A18E-AA495A0EF9C333Hormone TherapyArimidexYES1492012,TCGA-A8-A09V-R3819319729E19-9B06-4822-85A2-5D7A869767643192ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,302.0,WHITE,TCGA-AO-A0J3,AO,A0J3,No,YES,C50.9,8523/3,C50.9,2009.0,TUMOR FREE,YES,36.0,H-SCORE 0,dextran coated charcoal,Right Upper Inner QuadrantRight Upper Outer QuadrantRight Lower Inner QuadrantRight Lower Outer QuadrantRight,0.9,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast Reexcision,Other,partial mastectomy,"Other, specify",neuroendocrine and ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.0,1.0,Allred Score 4,Moderate,10-19%,CISH,3+ Positive,40.0,Vysis AutoVysion System,Ratio >=2.2,NO,YES,2.6,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.4,3 Point Scale,4+,Stage IIBT2N1bM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",19,9,2010,TCGA-AO-A0J3-F295726278313-311F-4604-93D1-B6D087933874302AliveTUMOR FREEYESYES1992010TCGA-AO-A0J3-F154779F50DC63-8F33-4824-9078-B96B2188703DScheduled Follow-up SubmissionYESYESAlive651TUMOR FREENO2282011,1TCGA-AO-A0J3-D30512cba97f0-e44a-41cf-a5e6-96b637c1e453240mg40mg/m23149191ChemotherapyMETHOTREXATEADJUVANTIVNO19920101TCGA-AO-A0J3-D3044b66cb509-ac95-4cae-8fde-5fecc8d6d9a64700mg600mg/m2466107ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO19920101TCGA-AO-A0J3-D3050d78ab251-4543-49f7-b7a5-3dd2cbe6ff273600mg600mg/m23149191ChemotherapyFLOUROURACILADJUVANTIVNO19920101TCGA-AO-A0J3-D304204eb8d7b-e0fe-48f0-903f-0b0a03343d79470mg60mg/m2466107ChemotherapyDOXORUBICINADJUVANTIVNO19920101TCGA-AO-A0J3-D30544d690b3c-0e7e-4e46-91c4-a1405ba74fa13600mg600mg/m23149191ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO19920102TCGA-AO-A0J3-D3055514f9a1d-4c93-4657-9f68-4a5a83d645891mg/day245Hormone TherapyANASTROZOLE (ARIMIDEX)ADJUVANTPOYES19920101TCGA-AO-A0J3-D3047d0506624-2dd1-4f05-995e-fe7527c6ccaa340mg175mg/m21121121ChemotherapyPACLITAXELADJUVANTIVNO1992010,TCGA-AO-A0J3-R3040e7906fe2-660d-4ad4-ae6b-4b90b2eff3fa223263EXTERNAL BEAM10080cGy28Regional siteADJUVANTNO11992010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,1550.0,BLACK OR AFRICAN AMERICAN,TCGA-WT-AB41,WT,AB41,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,Left Upper Outer QuadrantLeft Lower Inner QuadrantLeft Lower Outer Quadrant,2.337714843749997,No axillary staging,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast Reexcision,Other,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,0.396484375,1.0,Allred Score 4,"Moderate using the scale of Weak, Moderate, Strong",10-19%,CISH,CAP SCORING GUIDELINE 2010,30.951171875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,69,LungBone,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.3,3 Point Scale,1+,7thStage IIBT2N1miMX,YES,NO,NO,16,7,2014,TCGA-WT-AB41-F66639BF795D81-B99B-4A0E-9A01-42FDB7F837BDNONOYESTUMOR FREEAlive1611NO21102014,NOTCGA-WT-AB41-D62422F3CB280B-1BAF-4C0D-AC67-5A602FB8F3BF181273Hormone TherapyArimidexNOComplete Response1672014NOTCGA-WT-AB41-D62423A0282F4E-3251-4690-9FC0-FC12FED22320273Hormone TherapyTamoxifenYES1672014NOTCGA-WT-AB41-D62424D3833BF8-80A4-48E5-B86D-8F75692C747289150ChemotherapyTaxotereNOComplete Response1672014NOTCGA-WT-AB41-D624251D21BF3A-67F1-4026-A0E6-739FCA50B55A89150ChemotherapyCytoxanNOComplete Response1672014,TCGA-AR-A2LH-R37176C1A492A6-382A-4863-9A54-E60996E31148214External5000Gy25Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1NF,E9,A1NF,No,YES,C50.9,8522/3,C50.9,2011.0,TUMOR FREE,YES,9.0,Allred (Biocare),H-SCORE 0,Right Upper Outer Quadrant,1.5063281249999991,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Surgical resection,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.0,0.0,Allred Score 4,120,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,161.0419921875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,74,LungBone,80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.8,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,23,6,2011,TCGA-E9-A1NF-F291687942FB91-56B2-43E4-AC0A-D312AB589118Scheduled Follow-up SubmissionNOYESAlive610WITH TUMORYES90Distant MetastasisLungNOYES2172014TCGA-E9-A1NF-F39778BF1ADCE9-14BB-4F7D-9B8D-DC8A5E3D824FNONOYESWITH TUMORDead1072NO122013,NOTCGA-E9-A1NF-D329199A0E9054-76D2-4DFA-B120-DA25523FEC812163ChemotherapyDoxorubicinNO1562012NOTCGA-E9-A1NF-D329203F6B874E-A4B8-460B-A135-C9AAF2975A262163ChemotherapyCyclophosphamideNO1562012NOTCGA-E9-A1NF-D3292112ABC791-CDA4-46C3-9913-518EEDEF203A2163Chemotherapy5-FluorouracilNO1562012NOTCGA-E9-A1NF-D329228B6A8702-47E0-4CFA-A700-8618FE4CA0B091178ChemotherapyVinorelbineNO1562012NOTCGA-E9-A1NF-D329238AE1CA3A-950C-45F8-A327-AD92398769BE91178ChemotherapyMitomycinNO1562012NOTCGA-E9-A1NF-D32924A11CB0B1-B0B0-4E89-8C87-63A0F6638B32280Hormone TherapyTamoxifenYES1562012,TCGA-LL-A7SZ-R669744C950E6E-B651-4FE5-842B-46976BEF8BC8239275External45Gy28Regional siteNOComplete Response29102014TCGA-LL-A7SZ-R6697573EF3361-48B3-4F10-A4CF-137ACCA6B8C8239275External50.4Gy28Primary Tumor FieldNOComplete Response29102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,160.0,WHITE,TCGA-AQ-A04J,AQ,A04J,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,20.0,CAP scoring guideline 2010,Allred score 5+3 = 8,Right Upper Outer Quadrant,1.989189453125001,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,right segmental mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,0,0,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,allred score = 7,allred score = 7,<10%,0,CAP scoring guideline 2010,76.4892578125,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,NO,YES,40,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,5,3 Point Scale,0,Stage IIAT2N0 (i+)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",15,10,2010,TCGA-AQ-A04J-F10104B746D98E-FBB4-4B00-9F7B-15D7187ED53D500AliveTUMOR FREENOYES742011TCGA-AQ-A04J-F2174009FC391F-4113-4C17-8BDA-25158626688EScheduled Follow-up SubmissionNOYESAlive819TUMOR FREENO2022012,1TCGA-AQ-A04J-D10110D8796E39-CFDE-459F-9BCD-D002AFF025CF2400mg/m2600mg/m2461104ChemotherapyCytoxanADJUVANTIVNO7420111TCGA-AQ-A04J-D10098C6A8B218-BCD7-4F96-B5AB-9B20A7A0B735240mg/m260mg/m2461104ChemotherapyAdriamycinADJUVANTIVNO7420111TCGA-AQ-A04J-D101119826B415-20EE-4140-A2D8-EA39857695D9700mg/m2175mg/m24118160ChemotherapyTaxolADJUVANTIVNO742011,TCGA-A8-A08G-R38174565C6FF1-BC4D-4E70-8DAC-BEC6DFF29A9F150212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,15.0,WHITE,TCGA-AR-A0TX,AR,A0TX,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,25.0,% IHC,Allred score 0+0 = 0,Left Upper Outer Quadrant,1.3013964843749908,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast Reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Positive,0.3603515625,3.0,10-75%,Allred Score 7,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,336.6923828125,Vysis AutoVysion System,Path Vysion HER-2 DNA probe kit,NO,YES,2.8,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,816,3 Point Scale,2+,Stage IIAT1N1M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",10,3,2011,TCGA-AR-A0TX-F187702209AE18-3C7D-4B37-B4E6-7AF69F83F2DEScheduled Follow-up SubmissionYESAlive1972NO16122011TCGA-AR-A0TX-F49468430C16CF-997B-4D57-9615-B27A264E0BEAYESTUMOR FREEAlive1972NO2102013TCGA-AR-A0TX-F6393925A1DB00-F68E-4BAB-BFFD-B8FF97587207NOYESTUMOR FREEAlive19722182014,NOTCGA-GM-A3XL-D35523E53B3221-61CB-48E0-A761-E99D86612033100163ChemotherapyFluorouracilNOComplete Response1102012NOTCGA-GM-A3XL-D355243C18A200-60E1-402E-B214-AE55C2033154100163ChemotherapyAdriamycinNOComplete Response1102012NOTCGA-GM-A3XL-D35525AC30090D-D89E-4942-B93B-C44B8BBA2641100163ChemotherapyCytoxanNOComplete Response1102012NOTCGA-GM-A3XL-D35526A7375485-9703-446C-A59F-3E2E7F2A3E83191248ChemotherapyPaclitaxelNOComplete Response1102012,TCGA-AR-A0TX-R19619BA27F3B1-95DB-46EC-A3DC-2BC907DF01CD16122011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,208.0,WHITE,TCGA-A7-A13G,A7,A13G,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,H-SCORE 300,CAP scoring guideline 2010,Left,1.9294824218749893,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast Reexcision,Other,Total mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0244140625,0.0,MODERATE,Allred score 7 (per outside facility),10-19%,CISH,Hercep Test  TM Dako,111.9970703125,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,YES,NO,1.78,Lung,90-99%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,3 Point Scale,2+,7thStage IIAT2N0MX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,5,2011,"TCGA-A7-A13G-F17696087E9825-65B1-4984-B360-0C86EA23E197Scheduled Follow-up SubmissionNOYESAlive348TUMOR FREENO24102011TCGA-A7-A13G-F3503925A9D546-BE0A-4F1D-BE67-D3D8653307F9NONOYESTUMOR FREEAlive718YES586New Primary TumorOther, specifySkin, right legYES586NONO1492012",1TCGA-A7-A13G-D17698123A3E9A-D014-419E-93FC-E001C3B336B2376mg1mg33Hormone TherapyArimidexADJUVANTPOYES24102011NOTCGA-A7-A13G-D35038BEEDA94D-D6C3-4811-A18E-AA495A0EF9C333Hormone TherapyArimidexYES1492012,TCGA-E2-A10F-R7744ddf6fed7-242c-4544-bb29-f2d335f2dcb7170216EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11422011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1717.0,BLACK OR AFRICAN AMERICAN,TCGA-GM-A3XL,GM,A3XL,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,4.0,H-SCORE 300,Allred score 2+3 = 5,RightRight Upper Outer Quadrant,0.99,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,surgical resection,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Negative,Negative,0.0,0.0,allred score = 4,Allred score 7 (per outside facility),90-99%,CISH,CAP SCORING GUIDELINE 2010,73.2412109375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.38,LungBone,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.62,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,YES,NO,1,10,2012,TCGA-GM-A3XL-F41970FD97C14F-E6E6-45D7-9912-84402AECAD79NOYESYESTUMOR FREEAlive2108NO842013,NOTCGA-GM-A3XL-D35523E53B3221-61CB-48E0-A761-E99D86612033100163ChemotherapyFluorouracilNOComplete Response1102012NOTCGA-GM-A3XL-D355243C18A200-60E1-402E-B214-AE55C2033154100163ChemotherapyAdriamycinNOComplete Response1102012NOTCGA-GM-A3XL-D35525AC30090D-D89E-4942-B93B-C44B8BBA2641100163ChemotherapyCytoxanNOComplete Response1102012NOTCGA-GM-A3XL-D35526A7375485-9703-446C-A59F-3E2E7F2A3E83191248ChemotherapyPaclitaxelNOComplete Response1102012,TCGA-GM-A3XL-R355225579FB1C-390D-4919-A4B9-138CA5AF97BB274315External60Gy30Primary Tumor FieldNOComplete Response1102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,125.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A6VY,A7,A6VY,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,14.0,H-Score 295,image cytometry,RightRight Upper Outer Quadrant,2.6381054687499907,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.4404296875,2.0,110,Allred score 7 (per outside facility),10-19%,0,Hercep Test  TM Dako,51.6494140625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,1.78,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,71,3 Point Scale,2+,7thStage IIBT2N1M0,YES,NO,NO,25,10,2013,TCGA-A7-A6VY-F5725711D83905-3096-497D-A947-096697D1CD40NOYESYESTUMOR FREEAlive266NO632014,NOTCGA-A7-A6VY-D572295D3D1784-E381-460E-B773-DE56BABA6BCF68111ChemotherapyCyclophosphamideNOComplete Response632014NOTCGA-A7-A6VY-D572302DB83098-CA32-424E-ACFA-3207D2899E9568111ChemotherapyDoxorubicinNOComplete Response632014NOTCGA-A7-A6VY-D572315D349A3C-E310-48A5-A0E1-248ABE65246D126167ChemotherapyPaclitaxelNOComplete Response632014,TCGA-A7-A6VY-R57255395D4E07-8431-402C-932F-61689DB69B9E211247External4500cGy25Primary Tumor FieldNOComplete Response632014TCGA-A7-A6VY-R57256E45FC357-F0D6-4CAF-A745-480BB0BD7C42251266External2000cGy10Primary Tumor FieldNOComplete Response632014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2763.0,WHITE,TCGA-GM-A2DL,GM,A2DL,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,2.0,allred score 5+3=8,Allred score 2+2 = 4,Left Upper Outer Quadrant,1.4813085937499864,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,partial mastectomy,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Peri (6-12 months since last menstrual period),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,Allred Score 4,Two-tier,<10%,0,Dako Hercept test,84.2109375,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,78,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.9,3 Point Scale,2+,6thStage IT1cN0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,9,2011,TCGA-GM-A2DL-F47098050D20E4-BB66-4D0F-B205-E99C63577775NOYESYESTUMOR FREEAlive3519NO2282013,NOTCGA-GM-A2DL-D4710064A06228-D44D-48D4-920A-2EF984608DE91581989Hormone TherapyTamoxifenNOComplete Response2282013NOTCGA-GM-A2DL-D47102C22DF452-BBBA-49F3-ACF1-E448627C6D681990Hormone TherapyArimidexYES2282013,TCGA-GM-A2DL-R470992E8B03A4-E42D-4861-97AC-4C1D485B6DE6110151External60Gy30Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A9RU,E2,A9RU,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,22.0,No value Given,H-Score 290,Right Lower Outer Quadrant,1.0,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.8876953125,12.0,Allred Score,Allred Score 6,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,74.873046875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.5,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,1.1,3 Point Scale,2+,7thStage IIICT2N3aMX,YES,YES,NO,16,6,2014,TCGA-E2-A9RU-F675780E1468D5-13FF-4DA9-B3E2-19E5F062869ANOYESYESTUMOR FREEAlive0NO6112014TCGA-E2-A9RU-F70313BF7D4093-2A5D-4A9B-A257-7303FD2DD6E5NOYESYESTUMOR FREEAlive0NO922015,NOTCGA-E2-A9RU-D60754E37A508B-E21A-488A-B8D1-9927AA86305A0Hormone TherapyArimidexYES1662014,TCGA-E2-A9RU-R6075597D7F63A-20AB-4935-8123-943CFF3853D200External50.4GyRegional siteNOComplete Response1662014TCGA-E2-A9RU-R607564068FAFC-865C-49DB-8D79-51CEA29F727F00External10Gy5Primary Tumor FieldNOComplete Response1662014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,126.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A73Y,LL,A73Y,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,1.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,RightRight Upper Inner Quadrant,3.5440039062499955,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast Reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Negative,0.0,0.0,allred score = 8,Allred Score 6,90-99%,0,CAP SCORING GUIDELINE 2010,25.3212890625,Vysis AutoVysion System,>= 2.0 Positive,YES,NO,1.78,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,172,3 Point Scale,3+,7thStage IAT1cN0MX,YES,NO,NO,12,11,2013,TCGA-LL-A73Y-F67099E9959843-2F90-4BF2-B36D-9C4F8836A0E1NONOYESTUMOR FREEAlive477NO30102014,NOTCGA-LL-A73Y-D51201F696F179-D694-412F-9044-A859E937178342126ChemotherapytaxotereNO12112013NOTCGA-LL-A73Y-D51202E1AF783B-A8A8-4502-92CE-C221FF5DE1BD42126ChemotherapycytoxanNO12112013,TCGA-GM-A3XN-R35530BEB66920-DAD1-453E-A0F4-9C99FAAFDF03359394External60Gy30Primary Tumor FieldNOComplete Response1102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,40.0,WHITE,TCGA-AC-A3YJ,AC,A3YJ,No,YES,C50.9,8050/3,C50.9,2012.0,TUMOR FREE,YES,1.0,H-SCORE 190,Allred score 2+2 = 4,Right,1.6417871093750085,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Modified Radical Masectomy,"Other, specify",Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Negative,Positive,Equivocal,0.0,0.0,Allred Score 4,8,10-19%,ACIS,Hercep Test  TM Dako,163.400390625,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,YES,NO,1.78,Lung,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,145,3 Point Scale,2+,7thStage IIAT2N0 (i-)MX,YES,YES,NO,3,10,2012,TCGA-AC-A3YJ-F60187F91129E1-94BA-4771-B7FA-4F07CA7CB24BNONOYESTUMOR FREEAlive754NO3152014,NOTCGA-AC-A3YJ-D60188C21296BA-1657-4E74-A813-2141490BA60962247Hormone TherapyArimidexNO3152014NOTCGA-AC-A3YJ-D60189DF2F7479-281D-48B4-AB92-DB37A062A978256Hormone TherapyFemaraYES3152014,TCGA-E2-A1LE-R2066573C4148D-EEC1-42AD-A3D6-67DE98AE432B101146EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO011812012
TCGAFPPP,Breast,No,MALE,Alive,0.0,50.0,WHITE,TCGA-D8-A1XS,D8,A1XS,No,YES,C50.9,8507/3,C50.9,2010.0,TUMOR FREE,YES,28.0,% IHC,%IHC,Left Upper Outer Quadrant,5.0058398437499925,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,right segmental mastectomy,"Other, specify",Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Positive,0.0,25.0,>75%,>75%,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,83.82421875,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,40,Lung,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.83,3 Point Scale,2+,7thStage IIICT2N3aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,5,2011,TCGA-D8-A1XS-F1213349FAF5EE-952C-4CBB-A2EF-E2E972F20185Scheduled Follow-up SubmissionYESYESAlive496TUMOR FREENO1932012,TCGA-D8-A1XS-D2945272D7E95D-A251-492A-ABBC-D296BC9871D3240+2400mg60+600mg/m2485548Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO1932012,TCGA-D8-A1XS-R294538FF615B0-8A31-4C2E-8FC3-C90949FBBD97218258EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,125.0,WHITE,TCGA-D8-A1Y3,D8,A1Y3,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,8.0,manual counting,manual counting,Right Upper Outer Quadrant,1.2334765624999977,Axillary lymph node dissection alone,Pateys surgery,Modified Radical Mastectomy,Right Breast Reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Indeterminate,0.10546875,5.0,>75%,>75%,10-19%,Hercep Test  TM Dako,Venten,83.8857421875,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,YES,NO,2.38,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.23,3 Point Scale,2+,7thStage IIIAT2N2aMX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,6,2011,TCGA-D8-A1Y3-F30088796131A4-3877-4190-8790-8A92DB48E978Scheduled Follow-up SubmissionYESYESAlive430TUMOR FREENO242012,TCGA-D8-A1Y3-D30089CD27D9E9-957F-4103-9146-BD4B8D8CCDBBmg20mg/day133Hormone TherapytamoxipheneADJUVANTPOYES242012TCGA-D8-A1Y3-D30090804ACAFF-8BBF-4830-B5D7-67949CD57F82427.2+4272mg106.8+1068mg/day462125Chemotherapydoxorubicine+cyclophosphamideADJUVANTIVNO242012,TCGA-D8-A1Y3-R30091A12F5CAC-72A2-430B-893C-10338084842F145169EXTERNAL BEAM9000cGy40Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Dead,991.0,4774.1787109375,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0I6,B6,A0I6,No,YES,C50.9,8500/3,C50.9,1990.0,WITH TUMOR,YES,32.0,% IHC,%IHC,Left Upper Outer QuadrantLeft,1.6605761718749976,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,surgical resection,Modified radical mastectomy,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,lobular/ductal,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,2+,3+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Negative,Equivocal,0.7998046875,6.0,Allred Score 6,H score,10-19%,ACIS,dextran coated charcoal,165.3896484375,Vysis AutoVysion System,CAP SCORING GUIDELINE 2010,NO,YES,54,Lung,10-19%,70-79%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.944414062499999,3.3,4 Point Scale,1+,3rdStage IIAT1cN1M0,YES,YES,PositivePositiveNegative,2,11,2010,"TCGA-B6-A0I6-F12605DCA585A3-16B1-4A99-9C5A-AEB6183E3C9EScheduled Follow-up SubmissionNOYESDead991WITH TUMORYES859Distant MetastasisOther, specifySkin and boneNONONO162011",3TCGA-AO-A1KR-D217723870F7E2-7A57-4F72-B49B-6234D97C5792658mg175mg/m24132174ChemotherapypaclitaxelADJUVANTIVNO20220122TCGA-AO-A1KR-D21771BC8E60BC-1325-4D58-8CFC-5647A26B66284512mg600mg/m2476118ChemotherapycyclophosphamideADJUVANTIVNO20220121TCGA-AO-A1KR-D217709814E3A1-23C9-4193-94E2-B1E096A02EA1452mg60mg/m2476118ChemotherapydoxorubicinADJUVANTIVNO2022012,TCGA-EW-A2FW-R323378048DA7B-76F8-45CF-8B2D-46D6509CF44F279329EXTERNAL BEAM6400cGy30Primary Tumor FieldADJUVANTNO12352012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2141.0,WHITE,TCGA-AO-A1KR,AO,A1KR,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,4.0,Allred score = 8,Allred 0 = 0+0,Right Upper Inner Quadrant,1.4136816406249928,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Total mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,4 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Negative,Negative,0.0,0.0,Intensity=Strong,0%,10-19%,CISH,Venten,54.8212890625,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,NO,YES,64,LungBone,<10%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,PositivePositiveNegativeNegative1.09,15,9,2011,TCGA-AO-A1KR-F2176872013907-4371-4723-AF90-55C5BC120D64Scheduled Follow-up SubmissionNOYESAlive2513TUMOR FREENO2152013,3TCGA-AO-A1KR-D217723870F7E2-7A57-4F72-B49B-6234D97C5792658mg175mg/m24132174ChemotherapypaclitaxelADJUVANTIVNO20220122TCGA-AO-A1KR-D21771BC8E60BC-1325-4D58-8CFC-5647A26B66284512mg600mg/m2476118ChemotherapycyclophosphamideADJUVANTIVNO20220121TCGA-AO-A1KR-D217709814E3A1-23C9-4193-94E2-B1E096A02EA1452mg60mg/m2476118ChemotherapydoxorubicinADJUVANTIVNO2022012,TCGA-E2-A56Z-R44510ED43F584-56B4-41B9-B645-3A751C3355FA84129External60.4Gy33Regional siteNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,227.0,WHITE,TCGA-EW-A1J5,EW,A1J5,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,1.0,H-SCORE 0,Allred score 5+3 = 8,Left,1.245410156249995,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,surgical resection,Modified radical mastectomy,total mastectomy,Infiltrating Lobular Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,allred score = 8,Allred score 7 (per outside facility),<10%,CISH,Dako Hercept test,95.0615234375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,3.2,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,79,3 Point Scale,3+,7thStage IIBT3N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",10,6,2011,TCGA-EW-A1J5-F21353B3590EA5-E070-473D-8CCB-BE97155CED82Scheduled Follow-up SubmissionNOYESAlive477TUMOR FREENO622012,AC then THTCGA-EW-A1J5-D213541371E038-0A59-4F41-BE94-3306DDF2A13D392mg98mg494247ChemotherapyAdriamycinADJUVANTIVNO622012AC then THTCGA-EW-A1J5-D29270A98E7CEA-1E32-4CF2-B77F-F32B2B286E903936mg984mg494247ChemotherapyCyclophosphamideADJUVANTIVNO1332012AC then THTCGA-EW-A1J5-D29271B9A4AECF-CCA5-44DA-A370-1F56723E07D11524mg127mg1294247ChemotherapyPaclitaxelADJUVANTIVNO1332012AC then THTCGA-EW-A1J5-D292726535FB84-2971-4559-BBB2-62715AD2E85F2832mg236mg1294247ChemotherapyHerceptinADJUVANTIVNO1332012,TCGA-D8-A1Y3-R30091A12F5CAC-72A2-430B-893C-10338084842F145169EXTERNAL BEAM9000cGy40Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,219.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A56Z,E2,A56Z,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,16.0,Allred 8 = 5+3,Allred 5 = 2+3,Right,1.5,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,1.4716796875,1.0,Allred Score,Allred Score,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,200.0,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.2,Lung,10-19%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.2,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,YES,NO,20,6,2013,TCGA-E2-A56Z-F675848EFC436C-C4BE-4ADF-8B69-B4055EE66553NOYESYESTUMOR FREEAlive2526112014,NOTCGA-E2-A56Z-D44509B6730BD0-5AB2-4AC6-A8F5-F2DFB0DDBAD9130Hormone TherapyArimidexYES2062013,TCGA-E2-A56Z-R44510ED43F584-56B4-41B9-B645-3A751C3355FA84129External60.4Gy33Regional siteNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2298.0,WHITE,TCGA-AR-A1AH,AR,A1AH,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,9.0,allred score 5+3=8,CAP scoring guideline 2010,Right Upper Inner Quadrant,1.3849218749999952,Axillary lymph node dissection alone,axillary ultrasound,Other,surgical resection,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0380859375,1.0,H-SCORE,0,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,67.2587890625,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,NO,YES,2.6,Lung,10-19%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.23,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",13,6,2011,"TCGA-AR-A1AH-F216954CD580BF-CBB7-45CB-A465-E287DDD6E4AAScheduled Follow-up SubmissionNOYESAlive2298TUMOR FREEYES1136New Primary TumorOther, specifyRenal2722012TCGA-AR-A1AH-F6926739F31D97-DBEF-45B5-BF5A-73B8859724B9NONOYESTUMOR FREEAlive3807NO31122014",1TCGA-AR-A1AH-D21706E17CEAC2-757D-453F-824F-D3835792B356ChemotherapyADJUVANTNO27220121TCGA-AR-A1AH-D2171237BF063D-A8DE-410C-991D-B2FD6B00EA102241Hormone TherapyTamoxifenADJUVANTPONO2722012,TCGA-AC-A23E-R432395D4AA189-74A9-4527-95E0-9CD8C7441796127158External6000cGyPrimary Tumor FieldNOComplete Response1552013
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,0.0,WHITE,TCGA-BH-A18H,BH,A18H,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,H-Score 295,Allred score 4+3 = 7,Right Upper Outer Quadrant,2.0941699218749976,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Other,surgical resection,Other,segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Equivocal,Positive,Positive,0.5654296875,0.0,allred score = 7,205,10-19%,ACIS,CAP SCORING GUIDELINE 2010,105.091796875,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.6,Lung,70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.5,3 Point Scale,2+,7thStage IAT1bN0M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",6,6,2011,TCGA-BH-A18H-F59198975B9460-CA44-4CE3-A700-C1FC9E8C97DENOYESYESTUMOR FREEAlive652NO252014,NOTCGA-BH-A18H-D5920179B05235-CBBB-4B01-819B-84C9483B56B734118ChemotherapyAdriamycinNOComplete Response252014NOTCGA-BH-A18H-D592020E5715EA-719D-42AE-8516-6AD9DA3F885F34118ChemotherapyCytoxanNOComplete Response252014NOTCGA-BH-A18H-D592038719BC2E-D714-4B56-8035-F3E2D07DD9CF118219ChemotherapyTaxotereNOComplete Response252014,TCGA-BH-A18H-R5919948AE0EED-8630-4FB3-B325-284F85E0652E219259External50.4Gy28Primary Tumor FieldNOComplete Response252014TCGA-BH-A18H-R59200874B4EE2-C5FA-4C67-B91A-FB143D18AE49260266External10Gy5Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,9.0,WHITE,TCGA-AN-A0XP,AN,A0XP,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,19.0,IHC,Allred score 5+3 = 8,Right Upper Inner Quadrant,1.1929296874999973,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,Mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Positive,0.2197265625,1.0,140,260,20-29%,CISH,CAP scoring guideline 2010,86.037109375,HER2 amplification - negative,RATIO > = 2.0,NO,YES,3.1,LungBone,<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.8,3 Point Scale,2+,7thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,25,3,2011,TCGA-AN-A0XP-F68958158CE98D-2791-4E1C-AC57-0A24BD75BEB7YESNONOTUMOR FREEAlive923122014,TCGA-D8-A1XS-D2945272D7E95D-A251-492A-ABBC-D296BC9871D3240+2400mg60+600mg/m2485548Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO1932012,TCGA-E2-A56Z-R44510ED43F584-56B4-41B9-B645-3A751C3355FA84129External60.4Gy33Regional siteNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1.0,ASIAN,TCGA-C8-A3M7,C8,A3M7,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,6.0,Allred score 5+3 = 8,CAP scoring guideline 2010,Left Upper Inner Quadrant,1.3128124999999975,Axillary lymph node dissection alone,Pateys surgery,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,right segmental mastectomy,Infiltrating Lobular Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Negative,Negative,0.828125,0.0,60,moderate,90-99%,Hercep Test  TM Dako,DAKOHercepTest TM,217.4375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,1.67,Lung,80-89%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.23,4 Point Scale,2+,7thStage IIIBT4bN0M0,YES,YES,NO,6,3,2012,TCGA-C8-A3M7-F70838BFE6A7FF-9238-485C-836E-9BE96855EF6DNOYESYESWITH TUMORDead1034YES1034Locoregional RecurrenceNONONO932015,TCGA-D8-A1XS-D2945272D7E95D-A251-492A-ABBC-D296BC9871D3240+2400mg60+600mg/m2485548Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO1932012,TCGA-BH-A18H-R5919948AE0EED-8630-4FB3-B325-284F85E0652E219259External50.4Gy28Primary Tumor FieldNOComplete Response252014TCGA-BH-A18H-R59200874B4EE2-C5FA-4C67-B91A-FB143D18AE49260266External10Gy5Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1021.0,WHITE,TCGA-OL-A66K,OL,A66K,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,2.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.23,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast Reexcision,Other,surgical resection,Infiltrating Lobular Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,0.212890625,0.0107421875,allred score = 6,Allred score 7 (per outside facility),30-39%,CISH,Dako Hecept Test,99.6826171875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.25,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.8,3 Point Scale,2+,7thStage IIAT2N0MX,NO,NO,NO,11,6,2013,TCGA-OL-A66K-F58498A7D35DF2-9B47-41B2-B62E-898F9B98D659NONONOTUMOR FREEDead1275NO1142014,NOTCGA-E2-A56Z-D44509B6730BD0-5AB2-4AC6-A8F5-F2DFB0DDBAD9130Hormone TherapyArimidexYES2062013,TCGA-E2-A56Z-R44510ED43F584-56B4-41B9-B645-3A751C3355FA84129External60.4Gy33Regional siteNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,72.0,WHITE,TCGA-AC-A23E,AC,A23E,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,H-SCORE 300,Allred score 0+0 = 0,Right,1.3453808593749983,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Total mastectomy,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,0.5078125,1.0,Allred Score 5,Allred Score 7,10-19%,ACIS,Venten,68.2236328125,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,NO,YES,2.6,Lung,30-39%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.23,3 Point Scale,2+,7thStage IIBT2N1MX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",18,7,2011,TCGA-AC-A23E-F432406B8CD25F-D9F0-46C3-AA28-66D68A889F91NOYESYESTUMOR FREEAlive698NO1552013,NOTCGA-AC-A23E-D43238D789C42F-8DB9-4956-B101-E5635D52C40D111Hormone TherapyTamoxifenYES1552013,TCGA-AC-A23E-R432395D4AA189-74A9-4527-95E0-9CD8C7441796127158External6000cGyPrimary Tumor FieldNOComplete Response1552013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,671.0,WHITE,TCGA-A2-A04U,A2,A04U,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,3.0,Allred score = 8,H-Score 160,Right,2.2,Sentinel node biopsy alone,SLN and non-SLN biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Surgical resection,Infiltrating Ductal Carcinoma,ductal/mucinous,Peri (6-12 months since last menstrual period),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Negative,Negative,1.0,0.0,Allred Score 4,Intensity=Strong,10-19%,Hercep Test  TM Dako,DAKOHercepTest TM,185.29296875,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,64,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.460605468749991,5,3 Point Scale,2+,6thStage IIAT2N0 (i+)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",5,1,2011,TCGA-A2-A04U-F933499826B0C-9A4E-43B0-9EF8-F52CF27DD53E1486AliveTUMOR FREENOYES1732011TCGA-A2-A04U-F59317022819FE-3C6C-4DDD-90FD-EBF7BD427042YESNOYESAlive2654852014,"1TCGA-A2-A04U-D66737c4f7833-834c-4045-b558-4a53c47aec04464mg116mg478120ChemotherapyAdriamycinADJUVANTIVNO7120114TCGA-A2-A04U-D668014adba24-28a7-4eac-bcdf-6542a26395b812mg4mg3481671Other, specify in notesBisphosphonateZometaADJUVANTIVNO7120112TCGA-A2-A04U-D667515e8f3ac-8410-402b-85c4-76caeb2422264640mg1160mg478120ChemotherapyCytoxanADJUVANTIVNO7120113TCGA-A2-A04U-D66790a1f5288-fb98-4a32-ab56-4dca69f8d629612mg140-192mg4134197ChemotherapyTaxotereADJUVANTIVNO712011",TCGA-D8-A1Y3-R30091A12F5CAC-72A2-430B-893C-10338084842F145169EXTERNAL BEAM9000cGy40Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,285.0,WHITE,TCGA-A2-A25C,A2,A25C,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,ER Positive H-Score 95,allred score 2+2 = 4,Left Lower Outer Quadrant,1.2912695312500002,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0048828125,3.0,Allred score = 7,80,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,47.337890625,Vysis AutoVysion System,>= 2.0 Positive,YES,NO,4.43,Lung,90-99%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,5,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",15,7,2011,TCGA-A2-A25C-F31282423BE0BB-3129-452B-8F97-BCEEB2820AB4Scheduled Follow-up SubmissionYESYESAlive523TUMOR FREENO1742012,3TCGA-A2-A25C-D14513789E3F3F-057D-41A2-BC01-3C6103E3A603650mg130mg5108193ChemotherapyTaxotereADJUVANTIVNO20620112TCGA-A2-A25C-D14512B0EDF6A8-BC7C-44F3-B9A2-4306EC1EDE95435mg87mg5108193ChemotherapyAdriamycinADJUVANTIVNO20620111TCGA-A2-A25C-D145119A192F59-CCEE-4DCF-97FD-152DA7203A624350mg870mg5108193ChemotherapyCytoxanADJUVANTIVNO20620114TCGA-A2-A25C-D14514164E441C-E2D3-4CDA-B591-397424B65942mg20mg/day292325Hormone TherapyTamoxifenADJUVANTPONO28720116TCGA-A2-A25C-D31284ED492381-E4FE-41BA-8ECB-CEC9010547CBmg25mg/day476Hormone TherapyAromasinADJUVANTPOYES17420125TCGA-A2-A25C-D3128377D6AC50-7A0B-4BB5-9FA8-BFECB11CDC34mg2.5mg/day325475Hormone TherapyFemaraADJUVANTPONO1742012,TCGA-A2-A25C-R14515223E00A3-9E87-41BF-98F5-2EF812DCFBF3276285EXTERNAL BEAM6000cGy33Primary Tumor FieldADJUVANTNO11572011TCGA-A2-A25C-R7068073455A7F-CA95-41DF-9E57-1EDB33FD89E1234287External5040cGy28Regional siteNOComplete Response232015TCGA-A2-A25C-R706810880198C-ED2F-4373-A920-AB4DDA7254AB234271External4500cGy25Regional siteNOComplete Response232015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,358.0,WHITE,TCGA-A2-A0YI,A2,A0YI,No,YES,C50.9,8522/3,C50.9,2009.0,TUMOR FREE,YES,3.0,ER Positive H-Score 95,H-Score 290,Right Upper Outer Quadrant,1.4999023437499994,Other (specify),Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,surgical resection,Other,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,1.0,0.0,MODERATE,Allred score = 7,10-19%,ACIS,Venten,66.248046875,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,40,LungBoneLiver,90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.5,3 Point Scale,2+,6thStage IT1cN0 (i+)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",14,12,2010,TCGA-A2-A0YI-F16751C6B5D502-E855-42FF-A1A1-54CED61329FFScheduled Follow-up SubmissionYESYESAlive441TUMOR FREENO1692011TCGA-A2-A0YI-F59386C56BF853-8F73-44A9-8701-42CCAFA4D028NOYESYESTUMOR FREEAlive1505NO1252014,1TCGA-A2-A0YI-D54469b1f4d69-c1f1-49a2-b010-51bdc29628faHormone TherapyFemaraADJUVANTPONO14122010,TCGA-A2-A0YI-R5445ed6b0c3f-eef8-4151-8920-2293436afc0c77116EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO114122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1468.0,WHITE,TCGA-A2-A0CO,A2,A0CO,No,YES,C50.9,8520/3,C50.9,2002.0,TUMOR FREE,YES,11.0,ER Positive H-Score 95,Allred 5 = 2+3,Right,1.1,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,Allred score 0,120,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,116.5673828125,HER2 amplification - negative,Ratio >=2.0,NO,YES,66,"LungOther, specifyleft adrenal gland",40-49%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,5,3 Point Scale,2+,7thStage IIBT3N0M0,YES,YES,NO,21,5,2012,TCGA-A2-A0CO-F42395D9046E4C-FEFF-41E2-BE64-6931E4173BA9NOYESYESTUMOR FREEDead1468NO1842013,NOTCGA-A2-A0CO-D3366380B1C97B-8D60-43C3-BDCE-AC0B58A1141984512Hormone TherapyTamoxifenNOComplete Response1272012NOTCGA-A2-A0CO-D3366468699598-6953-48BB-BD8B-76AC54625819513Hormone TherapyArimidex1272012,TCGA-A2-A0CO-R33659D2343CBD-DC2B-49BF-89D6-6D505002D4D293127External5000cGyPrimary Tumor FieldNOComplete Response1272012TCGA-A2-A0CO-R336608FD8C301-7FE0-4D3A-923B-6A5A1911E753128134External1000cGyPrimary Tumor FieldNOComplete Response1272012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,743.0,WHITE,TCGA-GM-A3NY,GM,A3NY,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,13.0,allred score 5 + 3 = 8,Allred 0 = 0+0,Left Upper Outer Quadrant,1.7251171874999942,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Lumpectomy,Right Breast Reexcision,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Lobular Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,1.0,Allred score = 5,H score,30-39%,CISH,Venten,251.75,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.38,LungBone,90-99%,20-29%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.5724609374999916,2.83,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,NO,3,1,2012,TCGA-GM-A3NY-F40403055BBB55-226C-4908-8773-39A4E65A9E37NOYESYESTUMOR FREEAlive1162NO1922013,NOTCGA-GM-A3NY-D40405907FA230-9311-4125-9C9D-FA54ED976D6C160Hormone TherapyArimidexYES1922013,TCGA-GM-A3NY-R404047B29BB47-1F8A-4F98-ADD3-B16DEDB079F682124External60Gy30Primary Tumor FieldNOStable Disease1922013
TCGAFPPP,Breast,No,FEMALE,Dead,1142.0,920.3837890625,WHITE,TCGA-BH-A18R,BH,A18R,No,YES,C50.9,8500/3,C50.9,2001.0,TUMOR FREE,YES,15.0,Allred score = 8,H-Score 290,Right Upper Outer Quadrant,2.1403613281249942,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,surgical resection,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Incisional Biopsy,Ultrasound-guided biopsy,Positive,Indeterminate,Positive,1.4150390625,10.0,Allred Score 3,8,90-99%,ACIS,CAP SCORING GUIDELINE 2010,240.1455078125,Vysis AutoVysion System,Positive >2.2,NO,YES,2.6,LungBone,20-29%,40-49%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,3.3,3 Point Scale,2+,Stage IIAT2bN1M0,NO,YES,NONO,3,7,2011,"TCGA-B6-A2IU-F3890763102408-1829-4144-8CE6-018FA7240B97NOYESYESWITH TUMORAlive5176YES4224New Primary TumorOther, specifyLungNOYESYES312013",AC then THTCGA-EW-A1J5-D213541371E038-0A59-4F41-BE94-3306DDF2A13D392mg98mg494247ChemotherapyAdriamycinADJUVANTIVNO622012AC then THTCGA-EW-A1J5-D29270A98E7CEA-1E32-4CF2-B77F-F32B2B286E903936mg984mg494247ChemotherapyCyclophosphamideADJUVANTIVNO1332012AC then THTCGA-EW-A1J5-D29271B9A4AECF-CCA5-44DA-A370-1F56723E07D11524mg127mg1294247ChemotherapyPaclitaxelADJUVANTIVNO1332012AC then THTCGA-EW-A1J5-D292726535FB84-2971-4559-BBB2-62715AD2E85F2832mg236mg1294247ChemotherapyHerceptinADJUVANTIVNO1332012,TCGA-AR-A255-R31919339C3612-78BA-4998-8944-2594F16E73154789EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO11152012
TCGAFPPP,Breast,No,MALE,Alive,0.0,1519.0,WHITE,TCGA-AO-A1KQ,AO,A1KQ,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,9.0,H-Score 300,Allred score 5+3 = 8,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft Lower Inner QuadrantLeft,4.916464843749978,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,surgical resection,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,4 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Positive,Positive,Negative,0.0,2.0,Allred score 5,Moderate,<10%,ACIS,CAP scoring guideline 2010,65.0009765625,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,2.8,Lung,90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.0,4 Point Scale,3+,6thStage IIIBT4N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",1,4,2011,TCGA-AO-A1KQ-F98838350EB70-2195-46FD-81B0-248546115C741519AliveTUMOR FREENOYES142011TCGA-AO-A1KQ-F21775DB04403E-1473-4BBC-B665-0103F9DB2608Scheduled Follow-up SubmissionNOYESAlive1882NO2022012,1TCGA-AO-A1KQ-D98840dd32c09-be32-467e-9a5b-83a6e7f6f71320mg/day49Hormone TherapyTamoxifenADJUVANTPOYES142011,TCGA-E2-A1LI-R20626B73909E2-58E4-42C3-AFFF-2F8746177C50152194Primary Tumor FieldADJUVANTNO11212012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0XN,AN,A0XN,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,15.0,IHC,Allred score 5+3 = 8,Right Upper Inner Quadrant,1.174941406249998,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,Mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Negative,0.216796875,1.0,170,0,20-29%,0,CAP scoring guideline 2010,85.408203125,HER2 amplification - negative,RATIO > = 2.0,NO,YES,74,LungBone,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.9,3 Point Scale,2+,7thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,25,3,2011,TCGA-AN-A0XN-F6895600AF090C-547A-493B-9220-2FEF43822FD0YESNONOTUMOR FREEAlive1023122014,1TCGA-AO-A03R-D2953ef4485c7-bf90-4b7a-a8db-28bc351ea4be424mg60mg/m2467109ChemotherapyDOXORUBICINADJUVANTIVNO19920102TCGA-AO-A03R-D29565ae7957b-39b0-45da-96ed-2c27dda3e59a2.5mg/day192Hormone TherapyLETROZOLE (FEMARA)ADJUVANTPOYES19920101TCGA-AO-A03R-D2955880fcfd1-ad27-4247-8df0-2518b514a93e1240mg175mg/m24123165ChemotherapyPACLITAXELADJUVANTIVNO19920101TCGA-AO-A03R-D29520484daf8-16e0-46d1-8655-ec65e9573fe04248mg600mg/m2467109ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO1992010,TCGA-D8-A27R-R297039A1612A4-80AF-4413-B95B-768251E6704D237262EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO2832012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,119.0,WHITE,TCGA-D8-A27K,D8,A27K,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,17.0,manual counting,manual counting,Left Upper Inner Quadrant,1.2882812500000018,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.0,2.0,>75%,>75%,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,69.7666015625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,40,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.8,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",18,7,2011,TCGA-D8-A27K-F29588060ACA7E-17C2-4C0F-893F-068B65ED5256Scheduled Follow-up SubmissionNOYESAlive287TUMOR FREENO2632012TCGA-D8-A27K-F72201A434782B-9E68-4CAB-9DC0-41AF7599933FNONOYESTUMOR FREEAlive1461NO2942015,TCGA-D8-A27K-D2958908CE6CE2-B1EE-4E48-AFCD-DF600C649E6E240+2400mg60+600mg/m2449117Chemotherapyadriamycin+cyclophosphamidADJUVANTIVNO2632012NOTCGA-D8-A27K-D72202B5F1746D-61A5-4826-81D4-303798C5688049Hormone TherapyTamoxifenYES2942015,TCGA-D8-A27R-R297039A1612A4-80AF-4413-B95B-768251E6704D237262EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO2832012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,97.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A5YO,LL,A5YO,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,1.0,image cytometry,CAP SCORING GUIDELINE 2010,Left Upper Outer Quadrant,3.1321582031250146,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Lumpectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Negative,0.0,0.0,Strong,120,30-39%,CISH,Hercep Test  TM Dako,117.193359375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.25,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,<4.0,3 Point Scale,2+,7thStage IAT1bN0MX,YES,NO,NO,8,5,2013,TCGA-LL-A5YO-F586388D9AF5E1-0A39-49CE-9F74-CB0D3A1E192ENOYESYESTUMOR FREEAlive440NO1742014,YESTCGA-LL-A5YO-D430172796DB97-696B-4A10-94A8-0596D8A2F43E56160ChemotherapyTAXOTERENOComplete Response852013YESTCGA-LL-A5YO-D430189E63512F-49BD-4691-8C4D-920BA81A33D756160ChemotherapyCYTOXANNOComplete Response852013,TCGA-LL-A5YO-R586424B671EF3-EA8C-45F5-9CCC-C2189FB3DF30192210External40/48Gy15Primary Tumor FieldNOComplete Response1742014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,259.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-AA12,S3,AA12,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,16.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,LeftLeft Upper Inner QuadrantLeft Lower Inner Quadrant,2.1446582031249983,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.0,2.0,MODERATE,MODERATE,10-19%,CISH,CAP SCORING GUIDELINE 2010,21.6767578125,HER2 amplification - negative,CAP SCORING GUIDELINE 2007,YES,NO,1.78,"LungOther, specifyleft adrenal gland",90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,145,3 Point Scale,2+,7thStage IIIAT3N1aMX,YES,NO,NO,18,4,2014,TCGA-S3-AA12-F6762051D6062C-FC35-4A9F-8888-CF19EC5BD0ACNONOYESTUMOR FREEAlive467NO7112014TCGA-S3-AA12-F70442C4900549-569B-42AF-A29A-0C7466A08071NONOYESTUMOR FREEAlive574NO2622015,NOTCGA-S3-AA12-D583681212862C-4FC4-424A-AE86-4464B10A60B158Hormone TherapyANASTROZOLEYES1842014,TCGA-E2-A574-R444924F7A8469-49C3-4615-884A-A4068C9C9597195246External6640cGy36Primary Tumor FieldNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,411.0,WHITE,TCGA-E2-A15I,E2,A15I,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.0,Allred score 5+3=8,Allred 0 = 0+0,Left Upper Outer QuadrantLeft Lower Outer Quadrant,1.04,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,surgical resection,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.8349609375,0.0,Strong,0,90-99%,Dako,CAP scoring guideline 2010,52.1826171875,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,40,"LungOther, specifyleft adrenal gland",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,1.9,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,13,4,2011,TCGA-E2-A15I-F18888FC992314-E382-422C-8DCB-0F5EA947DCD4Scheduled Follow-up SubmissionNOYESAlive530TUMOR FREENO14112011TCGA-E2-A15I-F700236FDF2BA1-9D26-4621-A9B4-D4CD25811DB6NONOYESTUMOR FREEAlive1692NO922015,1TCGA-E2-A15I-D18890F282FF05-35FC-48D3-B9BD-E0006F0F255D20mg/day20mg/day41Hormone TherapyTamoxifenADJUVANTPOYES14112011,TCGA-BH-A0BS-R633978727D0E4-840A-4524-962B-7AD1986FB858245302External6040cGy25Primary Tumor FieldNOComplete Response782014TCGA-BH-A0BS-R63398FB9FF030-2089-4C98-BB5C-D04016148325245302External46.8Gy26Regional siteNOComplete Response782014
TCGAFPPP,Breast,No,FEMALE,Dead,2798.0,1289.646484375,WHITE,TCGA-BH-A1EO,BH,A1EO,No,YES,C50.9,8522/3,C50.9,1999.0,TUMOR FREE,YES,15.0,Allred score = 8,allred score 4 + 3 = 7,Right,1.8989550781249984,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,surgical resection,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Mixed Histology (please specify),ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,Biopsy not specified,Positive,Positive,Negative,0.9521484375,1.0,Allred Score 3,Moderate,10-19%,ACIS,CAP SCORING GUIDELINE 2010,90.869140625,Vysis AutoVysion System,Positive >2.2,NO,YES,2.13,LungBone,10-19%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,5,3 Point Scale,2+,5thStage IIAT1cN1M0,NO,YES,PositivePositiveNegativeNegative,6,9,2011,TCGA-A2-A4RW-F5912333B06046-3374-42DE-8585-2C4E3130E18BYESTUMOR FREEAlive222152014,AC then THTCGA-EW-A1J5-D213541371E038-0A59-4F41-BE94-3306DDF2A13D392mg98mg494247ChemotherapyAdriamycinADJUVANTIVNO622012AC then THTCGA-EW-A1J5-D29270A98E7CEA-1E32-4CF2-B77F-F32B2B286E903936mg984mg494247ChemotherapyCyclophosphamideADJUVANTIVNO1332012AC then THTCGA-EW-A1J5-D29271B9A4AECF-CCA5-44DA-A370-1F56723E07D11524mg127mg1294247ChemotherapyPaclitaxelADJUVANTIVNO1332012AC then THTCGA-EW-A1J5-D292726535FB84-2971-4559-BBB2-62715AD2E85F2832mg236mg1294247ChemotherapyHerceptinADJUVANTIVNO1332012,TCGA-A7-A6VW-R5725375FCD986-D2B7-4F5B-B37A-FE0AF6FC2AC8285331External50.40Gy28Primary Tumor FieldNOComplete Response3132014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1339.0,WHITE,TCGA-BH-A0C1,BH,A0C1,No,YES,C50.9,8520/3,C50.9,2007.0,WITH TUMOR,YES,10.0,ER Positive H-Score 95,H-Score 290,Right,1.746875000000005,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,surgical resection,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.56640625,8.0,Allred Score 5,80,10-19%,ACIS,Hercep Test  TM Dako,66.025390625,Vysis AutoVysion System,Ratio >=2.0,NO,YES,4,Lung,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,5,3 Point Scale,2+,6thStage IIIAT3N2aM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,8,2011,TCGA-BH-A0C1-F63399CD476A7D-DDD8-4815-98A8-9F82F7F0D480NOYESYESWITH TUMORDead1411YES1123Distant MetastasisBone782014,NOTCGA-BH-A0C1-D6340161C5552F-F0F5-40A2-9749-2A2F13D9FFDA1191167ChemotherapyAdriamycinNOClinical Progressive Disease782014NOTCGA-BH-A0C1-D634025104D7EB-AA20-495D-B052-EA95B8DB96581191167ChemotherapyCytoxanNOClinical Progressive Disease782014,TCGA-BH-A0C1-R63403B71FD2B6-D242-4DE7-8DCC-A78C429010F184101External3500cGy14Distant RecurrenceNORadiographic Progressive Disease782014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12Y,C8,A12Y,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,9.0,H-SCORE 0,Allred score 0+0=0,Left,1.4518749999999885,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,Patey's Surgery,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Equivocal,0.0556640625,1.2529296875,MODERATE,Allred Score 7,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,90.9228515625,Vysis AutoVysion System,Path Vysion HER2 DNA Probe Kit,YES,NO,2.6,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",13,4,2011,TCGA-C8-A12Y-F70839BEEE8436-461C-4F8E-B7FC-6960B548AF37NOYESYESTUMOR FREEAlive1476NO932015,1TCGA-BH-A0E6-D4647066B8D3A-D2FB-4BC0-B6C5-9D06F6529B73458121ChemotherapyCYTOXANADJUVANTNO181120101TCGA-BH-A0E6-D464685D6AB5B-4057-4C31-B9B0-CF2D73E1CE93458121ChemotherapyTAXOTEREADJUVANTNO18112010,TCGA-BH-A18H-R5919948AE0EED-8630-4FB3-B325-284F85E0652E219259External50.4Gy28Primary Tumor FieldNOComplete Response252014TCGA-BH-A18H-R59200874B4EE2-C5FA-4C67-B91A-FB143D18AE49260266External10Gy5Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1707.0,WHITE,TCGA-AO-A03R,AO,A03R,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,26.0,H-Score 300,dextran coated charcoal,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft,1.5,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,0,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,3.0,Intensity=Strong,Allred Score 5,<10%,CISH,3+ POSITIVE,28.0,Vysis AutoVysion System,Ratio >=2.0,NO,YES,70,"LungOther, specifyleft adrenal gland",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,105,3 Point Scale,2+,Stage IIBT2N1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",19,9,2010,TCGA-AO-A03R-F294769B88C8B-A186-4D82-A8EB-6F8D0319FD931707AliveTUMOR FREEYESYES1992010TCGA-AO-A03R-F15469BCD222CA-5847-43C0-8BEA-028A0E76FA81Scheduled Follow-up SubmissionYESYESAlive2091TUMOR FREENO2282011,1TCGA-AO-A03R-D2953ef4485c7-bf90-4b7a-a8db-28bc351ea4be424mg60mg/m2467109ChemotherapyDOXORUBICINADJUVANTIVNO19920102TCGA-AO-A03R-D29565ae7957b-39b0-45da-96ed-2c27dda3e59a2.5mg/day192Hormone TherapyLETROZOLE (FEMARA)ADJUVANTPOYES19920101TCGA-AO-A03R-D2955880fcfd1-ad27-4247-8df0-2518b514a93e1240mg175mg/m24123165ChemotherapyPACLITAXELADJUVANTIVNO19920101TCGA-AO-A03R-D29520484daf8-16e0-46d1-8655-ec65e9573fe04248mg600mg/m2467109ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO1992010,TCGA-AO-A03R-R2949cb083b63-0f8b-4518-86d5-8c2675da9503200245EXTERNAL BEAM10540cGy23Regional siteADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,29.0,WHITE,TCGA-D8-A27R,D8,A27R,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,11.0,manual counting,manual counting,Right Upper Outer Quadrant,1.218105468749999,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,Partial Mastectomy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,0.0146484375,11.0,>75%,>75%,10-19%,Hercep Test  TM Dako,Venten,78.01953125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,polisomy,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,not amplified,3 Point Scale,2+,7thStage IIICT2N3aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,18,7,2011,TCGA-D8-A27R-F297006A541EC5-15E4-48FD-B3AA-B0EFBE8FDFDBScheduled Follow-up SubmissionYESYESAlive307TUMOR FREENO2832012TCGA-D8-A27R-F29701129D0E3E-3420-4E29-8434-91ECC7A3E6C3Scheduled Follow-up Submission2842012,TCGA-D8-A27R-D297028D2A839B-9923-4EDA-9E50-5BDA071574E2240+2400mg60+600mg/m2457218Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO2832012,TCGA-D8-A27R-R297039A1612A4-80AF-4413-B95B-768251E6704D237262EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO2832012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,413.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A66H,OL,A66H,No,YES,C50.9,8480/3,C50.9,2012.0,TUMOR FREE,YES,1.0,H-SCORE 300,Allred score 2+2 = 4,Right,1.03,Sentinel node biopsy alone,SN+1 non sentinel node,Lumpectomy,Right Breast Reexcision,Other,Segmental Mastectomy,Mucinous Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Fine needle aspiration biopsy,Biopsy not specified,Negative,Positive,Negative,0.96875,2.212890625,allred score = 6,Allred Score 6,90-99%,CISH,Dako Hercept test,102.71875,HER2 amplification - negative,Ratio >=2.0,NO,YES,1.7,Lung,90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.8,3 Point Scale,3+,7thStage IBT1cN1miMX,NO,YES,NO,11,6,2013,TCGA-OL-A66H-F584929696265B-08D0-4DF9-922E-7EF1C0281AD6NOYESNOTUMOR FREEAlive812NO1142014,CMFTCGA-D8-A142-D1381520BD3B94-30E2-4571-B116-A786A8D72633mg/m2100mg/m2661271ChemotherapycyclophosphamidADJUVANTIVNO2062011NOTCGA-D8-A142-D64906C9AD9634-5799-4DB1-B41C-28D2AB117AF261271ChemotherapymetotreksatNO1592014NOTCGA-D8-A142-D649083AB62920-B064-4CD7-9D3B-F002D10D66E561271ChemotherapyfluorouracilNO1592014,TCGA-OL-A66H-R648400C6BC7D3-CF64-40E8-AAB3-B75DA3F377A368105External5040cGyPrimary Tumor FieldNOComplete Response1292014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,61.0,WHITE,TCGA-D8-A142,D8,A142,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,Image Analysis,manual counting,Left Lower Outer QuadrantLeft,1.9022558593749923,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Negative,Equivocal,0.1083984375,0.0,allred score = 6,Allred Score 8,10-19%,FISH,CAP SCORING GUIDELINE 2010,135.61328125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,4.43,Lung,70-79%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.816386718749996,3.8,3 Point Scale,2+,7thStage IIBT3N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,25,2,2011,TCGA-D8-A142-F13813955192A4-D534-42D7-8A51-67D7446F1AE1Scheduled Follow-up SubmissionNOYESAlive425TUMOR FREENO2062011,CMFTCGA-D8-A142-D1381520BD3B94-30E2-4571-B116-A786A8D72633mg/m2100mg/m2661271ChemotherapycyclophosphamidADJUVANTIVNO2062011NOTCGA-D8-A142-D64906C9AD9634-5799-4DB1-B41C-28D2AB117AF261271ChemotherapymetotreksatNO1592014NOTCGA-D8-A142-D649083AB62920-B064-4CD7-9D3B-F002D10D66E561271ChemotherapyfluorouracilNO1592014,TCGA-E2-A1L9-R20602FB33C7DC-7439-4DE4-B8CE-2F122C0D2BB8140177EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11112012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3359.0,WHITE,TCGA-AQ-A04L,AQ,A04L,No,YES,C50.9,8500/3,C50.9,2001.0,TUMOR FREE,YES,2.0,CAP scoring guideline 2010,dextran coated charcoal,Right,2.0949121093750005,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Negative,Positive,Positive,0.7158203125,0.0,Allred Score 5,Allred score 7 (per outside facility),30-39%,0,DAKOHercepTest TM,103.3515625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.6,"LungOther, specifyleft adrenal gland",60-69%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,5,3 Point Scale,1+,5thStage IIAT2N0 (i-)MX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",15,12,2010,TCGA-AQ-A04L-F49083CE88760-4A4B-436E-87CE-465B430365BB3359AliveTUMOR FREENOYES15122010TCGA-AQ-A04L-F3532434C3837D-DC46-481C-B853-6E2BD80C7466NONOYESTUMOR FREEAlive3957NO2492012,1TCGA-AQ-A04L-D57778cfa2f3b-c536-46a5-ae5e-d9045e765e11404mg101mg448111ChemotherapyAdriamycinADJUVANTIVNO6120111TCGA-AQ-A04L-D5902d5c327db-f7d5-4cd6-b90d-ea1ac1999f6a11411957Hormone TherapyTamoxifenADJUVANTPONO10120111TCGA-AQ-A04L-D5900f935f513-a1e9-4ada-87c4-07d532acd7564056mg1014mg448111ChemotherapyCytoxanADJUVANTIVNO1012011,TCGA-D8-A1Y3-R30091A12F5CAC-72A2-430B-893C-10338084842F145169EXTERNAL BEAM9000cGy40Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,748.0,WHITE,TCGA-E2-A14V,E2,A14V,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,24.0,IHC,image cytometry,Left Lower Inner Quadrant,1.2870410156249923,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,Biopsy not specified,Negative,Positive,Positive,0.9189453125,3.0,0%,0,90-99%,Dako,CAP scoring guideline 2010,62.4296875,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,2.6,"LungOther, specifyleft adrenal gland",<10%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,1.9,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",6,4,2011,TCGA-E2-A14V-F18870FFA983CC-57D9-4557-B5BB-BCD3D09CB1CEScheduled Follow-up SubmissionYESYESAlive1042TUMOR FREENO4112011,1TCGA-E2-A14V-D18889AE8D09DE-A05B-4A3B-99CC-4CE7A88E8DF14512mg1128mg45597ChemotherapycyclophosphamideADJUVANTIVNO11120112TCGA-E2-A14V-D188913DFEAA7A-286F-4E35-840E-F22E6ABF302F1499mg152mg4118195ChemotherapypaclitaxelADJUVANTIVNO71120112TCGA-E2-A14V-D18914BB18FBCE-4921-4FD2-B7C0-CDA67CCD1AF5571500mg1500mg/day118468ChemotherapylapatinibADJUVANTPONO71120113TCGA-E2-A14V-D18872AF33F97A-5569-496E-8D09-EE256571D9C4mg1mg304Hormone TherapyarimidexADJUVANTPOYES71120111TCGA-E2-A14V-D18886A22C1AFA-B014-42F4-BAE1-B26AA885A2D4448mg112mg45597ChemotherapydoxorubicinADJUVANTIVNO7112011,TCGA-E2-A14V-R1891879735EF6-10DC-4DF6-B729-8C11B3A5D417253303EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO14112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,267.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A13D,A7,A13D,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,4.0,Allred (Biocare),CAP scoring guideline 2010,Right Upper Outer Quadrant,1.1,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Lumpectomy,Total mastectomy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Close,Core needle biopsy,stereotactic biopsy,Negative,Negative,Equivocal,0.009765625,0.0,230,Intensity=Strong,90-99%,CISH,DAKOHercepTest TM,197.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe Kit,YES,NO,1.8,Lung,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,23,2,2011,TCGA-A7-A13D-F82173D820843-BF50-4A74-8708-4B00899AF6D3267AliveTUMOR FREEYESYES2422011TCGA-A7-A13D-F397946E464627-70AF-44BE-8CCD-1AA8D584B152NOYESYESTUMOR FREEAlive965NO122013,1TCGA-A7-A13D-D8216c345ebac-a9ee-49bc-b310-9629cee338307104mg1410-1428mg571155ChemotherapyCytoxanADJUVANTIVNO23220111TCGA-A7-A13D-D8215559c6d67-c4d2-4b4d-bf0b-b13454988426889mg176-179mg571155ChemotherapyTaxotereADJUVANTIVNO2322011,TCGA-A7-A13D-R8218558c4f55-6729-4f9a-817b-ae35c1c3b2e2188237EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO12322011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3820.0,WHITE,TCGA-A2-A0CK,A2,A0CK,No,YES,C50.9,8520/3,C50.9,2001.0,TUMOR FREE,YES,20.0,ER Positive H-Score 95,allred score 4 + 3 = 7,Right,1.1,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Excisional Biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.734375,4.0,8,Intensity=Strong,10-19%,ACIS,CAP SCORING GUIDELINE 2010,122.744140625,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,2.6,Lung,40-49%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,5,3 Point Scale,3+,5thStage IIIAT3N2aM0,YES,YES,Positive70-79%Positive<10%Negative1+,21,5,2012,"TCGA-A2-A0CK-F423964AC2C5F2-CF56-492A-B095-C6D9640612E1NOYESYESTUMOR FREEAlive4159YES1364New Primary TumorOther, specifyLEFT BREASTYES1409NOYESPositive50-59%3 Point Scale2+Positive10-19%3 Point Scale1+NegativeNegative1.21842013",NOTCGA-A2-A0CK-D326549B39167B-12F1-4113-A4B9-6D87C0D579F0ChemotherapyAdriamycinNOComplete Response662012NOTCGA-A2-A0CK-D3265566EDDC61-9F6C-4BBA-A99E-BCD484A1A162ChemotherapyCytoxanNOComplete Response662012NOTCGA-A2-A0CK-D326569C6B9B44-4C5B-42CD-8AA6-38038395E117ChemotherapyTaxolNOComplete Response662012NOTCGA-A2-A0CK-D42397F5986AFE-856D-4225-B5CE-EA9C5922B67414511518ChemotherapyTaxotereNOComplete Response1842013NOTCGA-A2-A0CK-D42398DACB6594-4AB8-425A-8BF3-E16A2296F99E1569Hormone TherapyAnastrozoleYES1842013YESTCGA-A2-A0CK-D42399DB784ADC-6137-423C-8F1C-5832E32592E5VaccineE-75NO1842013,TCGA-A2-A0CK-R326474B8B651E-F54C-4EB0-AC3F-BFEFB8E3BF05243280External5040cGyRegional siteNOComplete Response562012TCGA-A2-A0CK-R3265357C35411-3766-4C37-B699-47F58743FD98243280External5040cGyRegional siteNOComplete Response662012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,42.0,WHITE,TCGA-E9-A1R5,E9,A1R5,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,IHC,dextran coated charcoal,Right Upper Outer Quadrant,1.3466699218749945,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,partial mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Negative,0.0,0.0,Allred score = 5,Intensity=Strong,10-19%,Hercep Test  TM Dako,Venten,134.8056640625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,33,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.0,3 Point Scale,1+,7thStage IAT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,28,7,2011,TCGA-E9-A1R5-F308400D7066DE-52E0-4A17-8F0F-17ADEF0BAE8CScheduled Follow-up SubmissionYESYESAlive92TUMOR FREENO1742012TCGA-E9-A1R5-F4870005A3A194-C053-42E5-BC72-38C2C5BFDD8DYES1992013,TCGA-E9-A1R5-D30843D4023E14-4199-48D4-A1ED-0B85D63C7BA420mg/day24Hormone TherapyTamoxifenADJUVANTPOYES1742012,TCGA-E9-A1R5-R3084598C41B70-3054-4029-8DA9-02E2B870A48C6592EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO11742012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,53.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A8OP,AC,A8OP,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,6.0,Allred score = 8,H-SCORE 0,Right Lower Inner Quadrant,1.298486328124996,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Indeterminate,0.0,0.0,240 H,180,10-19%,Hercep Test  TM Dako,Venten,126.443359375,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,74,Lung,90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.816386718749996,1.1,3 Point Scale,2+,7thStage IAT1cN0 (i-)MX,YES,NO,NO,26,2,2014,TCGA-AC-A8OP-F66027051ED97E-B012-42EF-BD2D-25AF9EE444F3NONOYESTUMOR FREEAlive614NO1102014,1TCGA-E2-A14V-D18889AE8D09DE-A05B-4A3B-99CC-4CE7A88E8DF14512mg1128mg45597ChemotherapycyclophosphamideADJUVANTIVNO11120112TCGA-E2-A14V-D188913DFEAA7A-286F-4E35-840E-F22E6ABF302F1499mg152mg4118195ChemotherapypaclitaxelADJUVANTIVNO71120112TCGA-E2-A14V-D18914BB18FBCE-4921-4FD2-B7C0-CDA67CCD1AF5571500mg1500mg/day118468ChemotherapylapatinibADJUVANTPONO71120113TCGA-E2-A14V-D18872AF33F97A-5569-496E-8D09-EE256571D9C4mg1mg304Hormone TherapyarimidexADJUVANTPOYES71120111TCGA-E2-A14V-D18886A22C1AFA-B014-42F4-BAE1-B26AA885A2D4448mg112mg45597ChemotherapydoxorubicinADJUVANTIVNO7112011,TCGA-D8-A27R-R297039A1612A4-80AF-4413-B95B-768251E6704D237262EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO2832012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,848.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A6VR,OL,A6VR,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,2.0,H-SCORE 300,Allred score 2+2 = 4,Right,1.23,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Right Breast Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.9970703125,0.0,allred score = 8,Allred Score 6,30-39%,CISH,CAP SCORING GUIDELINE 2010,125.712890625,HER2 amplification - negative,Ratio >=2.0,NO,YES,3.0,Lung,30-39%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,172,3 Point Scale,2+,7thStage IAT1bN0MX,NO,NO,NO,5,12,2013,TCGA-OL-A6VR-F59367FEC2BC26-90CA-4ACF-87BF-4F743CBDB5D4NONONOTUMOR FREEAlive1220NO1052014,NOTCGA-A2-A0CK-D326549B39167B-12F1-4113-A4B9-6D87C0D579F0ChemotherapyAdriamycinNOComplete Response662012NOTCGA-A2-A0CK-D3265566EDDC61-9F6C-4BBA-A99E-BCD484A1A162ChemotherapyCytoxanNOComplete Response662012NOTCGA-A2-A0CK-D326569C6B9B44-4C5B-42CD-8AA6-38038395E117ChemotherapyTaxolNOComplete Response662012NOTCGA-A2-A0CK-D42397F5986AFE-856D-4225-B5CE-EA9C5922B67414511518ChemotherapyTaxotereNOComplete Response1842013NOTCGA-A2-A0CK-D42398DACB6594-4AB8-425A-8BF3-E16A2296F99E1569Hormone TherapyAnastrozoleYES1842013YESTCGA-A2-A0CK-D42399DB784ADC-6137-423C-8F1C-5832E32592E5VaccineE-75NO1842013,TCGA-A2-A25C-R14515223E00A3-9E87-41BF-98F5-2EF812DCFBF3276285EXTERNAL BEAM6000cGy33Primary Tumor FieldADJUVANTNO11572011TCGA-A2-A25C-R7068073455A7F-CA95-41DF-9E57-1EDB33FD89E1234287External5040cGy28Regional siteNOComplete Response232015TCGA-A2-A25C-R706810880198C-ED2F-4373-A920-AB4DDA7254AB234271External4500cGy25Regional siteNOComplete Response232015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,35.0,WHITE,TCGA-AC-A3OD,AC,A3OD,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,3.0,Allred 0 = 0+0,CAP scoring guideline 2010,Left,1.3137792968749984,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast Reexcision,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.3642578125,1.0,allred score = 6,Allred Score 6,10-19%,Hercep Test  TM Dako,Venten,83.666015625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,69,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.8,3 Point Scale,2+,7thStage IIBT2N1miMX,YES,YES,NO,19,4,2012,TCGA-AC-A3OD-F455821C298E20-D286-4A08-9193-1AB7F91CC8BDNOYESNOTUMOR FREEAlive451NO1772013,1TCGA-A7-A13D-D8216c345ebac-a9ee-49bc-b310-9629cee338307104mg1410-1428mg571155ChemotherapyCytoxanADJUVANTIVNO23220111TCGA-A7-A13D-D8215559c6d67-c4d2-4b4d-bf0b-b13454988426889mg176-179mg571155ChemotherapyTaxotereADJUVANTIVNO2322011,TCGA-AC-A3OD-R45583976C8875-AC78-48C4-AD55-5DFCB541E56076120External6040cGy25Primary Tumor FieldNOComplete Response1772013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5261.0,WHITE,TCGA-B6-A0RN,B6,A0RN,No,YES,C50.9,8500/3,C50.9,1993.0,TUMOR FREE,YES,19.0,Image Analysis,Image Analysis,Right Upper Inner QuadrantRight,1.2912011718750025,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Excision,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,4 Point Scale,2+,3+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Negative,Equivocal,0.0478515625,0.0,110,moderate,<10%,Hercep Test  TM Dako,dextran coated charcoal,64.8994140625,Vysis AutoVysion System,Ratio >=2.0,NO,YES,2.13,"Other, specifySkin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,145,4 Point Scale,1+,Stage IAT1cN0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,11,2010,TCGA-B6-A0RN-F13798FF2B6C81-2139-42A0-AFCB-87293273EFA1Scheduled Follow-up SubmissionYESYESAlive5261TUMOR FREENO1272011TCGA-B6-A0RN-F71514268E69D6-E783-4413-9FC9-6D584E476CF4NOYESYESTUMOR FREEAlive8008NO2632015,NOTCGA-A2-A0CK-D326549B39167B-12F1-4113-A4B9-6D87C0D579F0ChemotherapyAdriamycinNOComplete Response662012NOTCGA-A2-A0CK-D3265566EDDC61-9F6C-4BBA-A99E-BCD484A1A162ChemotherapyCytoxanNOComplete Response662012NOTCGA-A2-A0CK-D326569C6B9B44-4C5B-42CD-8AA6-38038395E117ChemotherapyTaxolNOComplete Response662012NOTCGA-A2-A0CK-D42397F5986AFE-856D-4225-B5CE-EA9C5922B67414511518ChemotherapyTaxotereNOComplete Response1842013NOTCGA-A2-A0CK-D42398DACB6594-4AB8-425A-8BF3-E16A2296F99E1569Hormone TherapyAnastrozoleYES1842013YESTCGA-A2-A0CK-D42399DB784ADC-6137-423C-8F1C-5832E32592E5VaccineE-75NO1842013,TCGA-GM-A2DL-R470992E8B03A4-E42D-4861-97AC-4C1D485B6DE6110151External60Gy30Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,93.0,WHITE,TCGA-AC-A3TM,AC,A3TM,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,4.0,H-SCORE 190,CAP scoring guideline 2010,Right,1.9,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Lobular Carcinoma,lobular/ductal,Peri (6-12 months since last menstrual period),Positive,YES,4 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Equivocal,Positive,Equivocal,2.0,0.0,Allred score 0,8,10-19%,ACIS,CAP SCORING GUIDELINE 2010,60.0,Vysis AutoVysion System,Path Vysion HER-2 DNA probe kit,YES,NO,1.9,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.3,4 Point Scale,1+,7thStage IIIAT3N1miM0,YES,YES,NO,1,8,2012,TCGA-AC-A3TM-F6019356C9B648-1452-4AC4-BD75-E1EF3F85A933NOYESYESTUMOR FREEAlive762NO3152014,NOTCGA-AC-A3TM-D60195B113D625-D78D-45A4-ADD0-80AB8685389D132213ChemotherapyCytoxanNOComplete Response3152014NOTCGA-AC-A3TM-D60196B550D10F-C488-4B1D-9461-2F40087F552D132213ChemotherapyTaxotereNOComplete Response3152014YESTCGA-AC-A3TM-D60197EDF4E71D-99B4-4E19-AB96-9999AC773627132213ImmunotherapyBiological Therapy/Monoclonal AntibodyNOComplete Response3152014NOTCGA-AC-A3TM-D60198B38B327E-F854-4338-B383-77104EC6F403272Hormone TherapyArimidexYES3152014,TCGA-AC-A3TM-R60194CF6D6ED8-625C-463C-9639-3609DC5BB383219266External5040cGy33Primary Tumor FieldNOComplete Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7067.0,WHITE,TCGA-B6-A0RU,B6,A0RU,No,YES,C50.9,8523/3,C50.9,1990.0,TUMOR FREE,YES,15.0,Image Analysis,Image Analysis,Right,1.398076171874999,Axillary lymph node dissection alone,axillary ultrasound,Other,surgical resection,Modified radical mastectomy,Excisional biopsy,"Other, specify",Ductal/Metaplastic,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,2+,3+,Negative,Negative,Tumor resection,"Biopsy, NOS",Negative,Negative,Equivocal,0.59765625,0.0,Allred score = 5,moderate,10-19%,ACIS,Hecep Test TM DAKO,177.88671875,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,3.1,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,5,4 Point Scale,1+,3rdStage IAT1cN0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,11,2010,"TCGA-B6-A0RU-F137906251D894-D6C0-46A4-A938-1E5FA5D5E280Scheduled Follow-up SubmissionYESYESAlive7067TUMOR FREEYES3076New Primary TumorOther, specifyRight BreastYES30761272011TCGA-B6-A0RU-F71565C76B35D5-C269-4642-994F-7458C733F814NOYESYESTUMOR FREEAlive8605NO2632015",NOTCGA-AC-A3TM-D60195B113D625-D78D-45A4-ADD0-80AB8685389D132213ChemotherapyCytoxanNOComplete Response3152014NOTCGA-AC-A3TM-D60196B550D10F-C488-4B1D-9461-2F40087F552D132213ChemotherapyTaxotereNOComplete Response3152014YESTCGA-AC-A3TM-D60197EDF4E71D-99B4-4E19-AB96-9999AC773627132213ImmunotherapyBiological Therapy/Monoclonal AntibodyNOComplete Response3152014NOTCGA-AC-A3TM-D60198B38B327E-F854-4338-B383-77104EC6F403272Hormone TherapyArimidexYES3152014,TCGA-AR-A5QN-R4390112842F15-A078-4D68-BFED-ED9D6FA40DD3136173External5040cGy28Primary Tumor FieldNO1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,520.0,WHITE,TCGA-AR-A2LN,AR,A2LN,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,2.0,allred score 5 + 3 = 8,Allred score 2+2 = 4,Right Upper Outer Quadrant,4.708720703125012,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,surgical resection,Other,Mastectomy,Infiltrating Lobular Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.029296875,0.0,Strong,Moderate,90-99%,Dako,DAKOHercepTest TM,196.8310546875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.38,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.5724609374999916,3.0,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,Positive70-79%Positive<10%Negative1+,12,1,2012,TCGA-AR-A2LN-F3753731DA3189-1539-4BBF-8C9F-E5EB069F3D56NONOYESAlive997NO6122012TCGA-AR-A2LN-F49496E7D8079A-0AC5-4D0D-8B52-2FF1367C2892NOYESTUMOR FREEAlive1161NO2102013,NOTCGA-AR-A2LN-D37541CECA734C-34EE-4E7A-BE8F-82D7437D58FB15Hormone TherapyLetrozoleYES6122012,TCGA-E9-A1R5-R3084598C41B70-3054-4029-8DA9-02E2B870A48C6592EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO11742012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,195.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A97C,OL,A97C,No,YES,C50.9,9020/3,C50.9,2013.0,TUMOR FREE,YES,6.0,allred score 5 + 3 = 8,image cytometry,Left,1.5429394531249938,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,surgical resection,"Other, specify",malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,SKIN BIOPSY,Negative,Negative,Negative,0.1376953125,0.0,Allred Score 6,Allred score 7 (per outside facility),20-29%,ACIS,Venten,160.001953125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,74,LungBone,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,5,3 Point Scale,2+,7thStage IIBT3N0M0,YES,NO,YES275Distant MetastasisLung,18,3,2014,TCGA-OL-A97C-F66330A92B2964-F02C-4129-A664-4BBB320621E7NONOTUMOR FREEAlive271NO31102014,1TCGA-A7-A13D-D8216c345ebac-a9ee-49bc-b310-9629cee338307104mg1410-1428mg571155ChemotherapyCytoxanADJUVANTIVNO23220111TCGA-A7-A13D-D8215559c6d67-c4d2-4b4d-bf0b-b13454988426889mg176-179mg571155ChemotherapyTaxotereADJUVANTIVNO2322011,TCGA-A2-A25C-R14515223E00A3-9E87-41BF-98F5-2EF812DCFBF3276285EXTERNAL BEAM6000cGy33Primary Tumor FieldADJUVANTNO11572011TCGA-A2-A25C-R7068073455A7F-CA95-41DF-9E57-1EDB33FD89E1234287External5040cGy28Regional siteNOComplete Response232015TCGA-A2-A25C-R706810880198C-ED2F-4373-A920-AB4DDA7254AB234271External4500cGy25Regional siteNOComplete Response232015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,856.0,WHITE,TCGA-BH-A0HA,BH,A0HA,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.0,Allread score 5+3 = 8,Allred 5 = 2+3,Right,2.058720703125016,Sentinel lymph node biopsy plus axillary dissection,SLN and non-SLN biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.2919921875,0.0,Strong,Moderate,<10%,Hercep Test  TM Dako,Hercep Test  TM Dako,148.1123046875,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.38,Lung,70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,71,3 Point Scale,1+,6thStage IT1cN0 (i-)M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,8,2011,TCGA-BH-A0HA-F19337A2A6ED0E-CEB2-4245-A4A4-A8C2181645F4Scheduled Follow-up SubmissionNONOAlive856TUMOR FREENO8122011TCGA-BH-A0HA-F433203BFD818A-CF1F-4459-9B36-7CAD9D475D5BNONONOTUMOR FREEAlive1611NO1752013,NOTCGA-AC-A3TM-D60195B113D625-D78D-45A4-ADD0-80AB8685389D132213ChemotherapyCytoxanNOComplete Response3152014NOTCGA-AC-A3TM-D60196B550D10F-C488-4B1D-9461-2F40087F552D132213ChemotherapyTaxotereNOComplete Response3152014YESTCGA-AC-A3TM-D60197EDF4E71D-99B4-4E19-AB96-9999AC773627132213ImmunotherapyBiological Therapy/Monoclonal AntibodyNOComplete Response3152014NOTCGA-AC-A3TM-D60198B38B327E-F854-4338-B383-77104EC6F403272Hormone TherapyArimidexYES3152014,TCGA-AO-A03R-R2949cb083b63-0f8b-4518-86d5-8c2675da9503200245EXTERNAL BEAM10540cGy23Regional siteADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,114.0,WHITE,TCGA-A2-A25F,A2,A25F,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,2.0,H-SCORE 255,Allred score 7 per outside facility report,Right Upper Outer Quadrant,1.400449218749992,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Other,L Total Mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,240 H,Allred score 7 (per outside facility),<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,103.83203125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,118,Lung,70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.3,3 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,26,7,2011,TCGA-A2-A25F-F3119783BFBA11-0DA8-4A8E-8851-25F1414D2F33Scheduled Follow-up SubmissionYESYESAlive322TUMOR FREENO2342012,1TCGA-A2-A25F-D31195891B2981-580C-4A0A-9C41-BED150D2AEB8464212ChemotherapyTaxotereADJUVANTIVNO19420122TCGA-A2-A25F-D31196D5EBB6A6-DE10-4033-AB1F-6ADA8072684A464212ChemotherapyCytoxanADJUVANTIVNO1942012,TCGA-A2-A25F-R14509DAB357C0-A2D3-4540-9F13-FA24263D85AD3743EXTERNAL BEAM3400cGy10Primary Tumor FieldADJUVANTNO12672011
TCGAFPPP,Breast,No,FEMALE,Dead,1034.0,1004.4775390625,WHITE,TCGA-BH-A1FH,BH,A1FH,No,YES,C50.9,8500/3,C50.9,1998.0,WITH TUMOR,YES,13.0,allred score 0 + 0 = 0,allred score 4 + 3 = 7,Left Upper Outer Quadrant,1.776230468749991,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.806640625,8.0,allred score = 8,Intensity=Strong,10-19%,ACIS,Dako Hercept test,94.1396484375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,2.38,Bone,70-79%,40-49%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,1.80,3 Point Scale,2+,5thStage IVT2N1bM1,NO,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,8,9,2011,TCGA-AO-A1KR-F2176872013907-4371-4723-AF90-55C5BC120D64Scheduled Follow-up SubmissionNOYESAlive2513TUMOR FREENO2152013,1TCGA-AR-A1AH-D21706E17CEAC2-757D-453F-824F-D3835792B356ChemotherapyADJUVANTNO27220121TCGA-AR-A1AH-D2171237BF063D-A8DE-410C-991D-B2FD6B00EA102241Hormone TherapyTamoxifenADJUVANTPONO2722012,TCGA-A2-A0CO-R33659D2343CBD-DC2B-49BF-89D6-6D505002D4D293127External5000cGyPrimary Tumor FieldNOComplete Response1272012TCGA-A2-A0CO-R336608FD8C301-7FE0-4D3A-923B-6A5A1911E753128134External1000cGyPrimary Tumor FieldNOComplete Response1272012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,14.0,ASIAN,TCGA-C8-A134,C8,A134,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,H-Score 150,Allred score 0+0=0,Left,1.3374511718749873,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Surgery,Negative,Negative,Equivocal,0.0078125,0.0029296875,Allred score 8,230,10-19%,Dako,CAP scoring guideline 2010,88.93359375,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,YES,NO,1.78,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.1,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,15,4,2011,TCGA-C8-A134-F190843331DC24-D1D5-4123-9F7F-C2F9B5AA76A9Scheduled Follow-up SubmissionNOYESAlive34TUMOR FREENO2122011TCGA-C8-A134-F7082213F00B89-54AB-41DA-BBD2-02C3D6521CCBNONOYESTUMOR FREEAlive383NO932015,NOTCGA-C8-A134-D708231808C5EE-0291-4C9E-9F3F-50A3ECD730CE3841Chemotherapy5-FlourouracilNOComplete Response932015NOTCGA-C8-A134-D708243F5F3438-79BA-43E0-B135-7E37333FD8E23841ChemotherapyEpirubicinNOComplete Response932015NOTCGA-C8-A134-D70825BD0FF962-3C67-4CB2-880F-11E2B2F8EF7F3841ChemotherapyCyclophosphamideNOComplete Response932015,TCGA-E9-A1R5-R3084598C41B70-3054-4029-8DA9-02E2B870A48C6592EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO11742012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,852.0,WHITE,TCGA-A1-A0SO,A1,A0SO,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,9.0,allred score 5 + 3 = 8,allred score 5+3+8,Right,1.6,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,surgical resection,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,3+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Negative,Equivocal,0.080078125,1.0,Strong,8,30-39%,0,CAP scoring guideline 2010,144.103515625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,3.2,"Other, specifySkin",10-19%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,5,3 Point Scale,1+,6thStage IIBT2N1M0,YES,NO,YES766Distant MetastasisBoneNOYESNO,6,12,2010,TCGA-GM-A3XL-F41970FD97C14F-E6E6-45D7-9912-84402AECAD79NOYESYESTUMOR FREEAlive2108NO842013,TCGA-A1-A0SO-D444926D19DA7-541E-4272-8678-F08424C58A6361180ChemotherapyADJUVANTIVNO6122010,TCGA-A1-A0SO-R44488E839EE0-AABF-432E-B55A-BEAD9FC6A0FC205266EXTERNAL BEAMRegional siteADJUVANTNO16122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1548.0,WHITE,TCGA-AR-A24K,AR,A24K,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,2.0,No value Given,CAP scoring guideline 2010,Left Upper Outer Quadrant,3.744443359375024,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Right Breast Reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,0.0078125,0.0,Allred score = 0,H-Score,10-19%,Hercep Test  TM Dako,Dako Hercept test,104.447265625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.38,LungBone,10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.66,4 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,12,8,2011,TCGA-AR-A24K-F3125529310A70-EB33-495F-93E9-9687F4A26EBFScheduled Follow-up SubmissionYESYESAlive1548NO2542012TCGA-AR-A24K-F494854D12DA3E-BE3E-4324-A4D9-7006E014CA9ENOYESYESTUMOR FREEAlive1548NO2102013,1TCGA-AR-A24K-D31262CDC672D1-9D6E-4784-B377-5AE2546F2EDB4170ChemotherapyPaclitaxelADJUVANTNO25420121TCGA-AR-A24K-D31261CF20F7DD-121A-44A7-B932-B417039C45D54ChemotherapyCytoxanADJUVANTNO25420121TCGA-AR-A24K-D312603AFC8797-628E-464D-A40B-5D0B624E3B204ChemotherapyDoxorubicinADJUVANTNO2542012,TCGA-AR-A24K-R312597EBD9D8A-5AA6-452F-979A-3A3CDDA5B87F195241EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1216.0,WHITE,TCGA-AR-A1AP,AR,A1AP,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,1.0,Allred score 5+3 = 8,Image Analysis,Left Upper Outer Quadrant,1.2826953124999965,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Right Breast Reexcision,Mastectomy NOS,Wide local excision,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,0.0166015625,0.0,Allred score = 0,Allred Score 8,10-19%,Hercep Test  TM Dako,Dako Hercept test,90.5830078125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,66,LungBone,70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,<4.0,3 Point Scale,2+,6thStage IT1N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",13,6,2011,TCGA-AR-A1AP-F2179232110B06-10DD-4AF4-B907-6C6F3A6F6F90Scheduled Follow-up SubmissionNOYESAlive1216TUMOR FREENO2722012TCGA-AR-A1AP-F692757F6FFB16-466B-42BB-BFB6-05059B1C63F7NONOYESTUMOR FREEAlive2856NO31122014,1TCGA-AR-A1AP-D2179589F5BA7B-C2F4-41AC-84D2-4EC2FC5D6F021mg/day29Hormone TherapyAnastrozoleADJUVANTPOYES2722012,TCGA-D8-A1Y3-R30091A12F5CAC-72A2-430B-893C-10338084842F145169EXTERNAL BEAM9000cGy40Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0AR,AN,A0AR,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,17.0,dextran coated charcoal,dextran coated charcoal,Right Upper Inner Quadrant,2.4775585937499844,No axillary staging,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,0,0,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,0%,Allred score = 7,20-29%,0,dextran coated charcoal,71.603515625,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,NO,YES,2.7,"LungOther, specifyleft adrenal gland",<10%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,145,3 Point Scale,0,Stage IIAT2N0M0,YES,NO,YES766Distant MetastasisBoneNOYESNO,28,12,2010,TCGA-AN-A0AR-F6894607FE1A95-D842-4DF8-9EAA-36D34C7989DDYESNONOTUMOR FREEAlive1023122014,NOTCGA-GM-A2DL-D4710064A06228-D44D-48D4-920A-2EF984608DE91581989Hormone TherapyTamoxifenNOComplete Response2282013NOTCGA-GM-A2DL-D47102C22DF452-BBBA-49F3-ACF1-E448627C6D681990Hormone TherapyArimidexYES2282013,TCGA-D8-A1JC-R20849A9A5EA39-2CEF-4A69-A4C6-E072C872237D122147EXTERNAL BEAM4500cGyPrimary Tumor FieldADJUVANTNO1912012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,239.0,WHITE,TCGA-E2-A1LS,E2,A1LS,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,5.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Right Lower Outer Quadrant,1.2380371093749991,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Negative,0.779296875,0.0,Allred score = 0,Allred score = 0,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,70.71484375,Vysis AutoVysion System,Ratio >=2.0,NO,YES,2.8,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.0,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",3,6,2011,TCGA-E2-A1LS-F20603512AFC08-F4A9-4570-91A2-F8F491877292Scheduled Follow-up SubmissionNOYESAlive470TUMOR FREENO1712012TCGA-E2-A1LS-F70016D73A246D-93CE-4E3C-8364-A243EFA91C86NONOYESTUMOR FREEAlive1604NO922015,1TCGA-E2-A1LS-D20604225992D9-0568-4DD6-BF26-D1C6E065C3DE4112ChemotherapyCyclophosphamideADJUVANTNO17120121TCGA-E2-A1LS-D20606ECEACF6D-18C4-4309-8AA5-54E2B721DAFE4112ChemotherapyTaxotereADJUVANTNO1712012,TCGA-A2-A3XT-R344983FC8B1C4-9668-4CC8-B355-AF3B27746C49233275External5040cGy28Primary Tumor FieldNOComplete Response1782012TCGA-A2-A3XT-R344998749065D-442D-4F58-98EA-5CFEAC7F5AB3233275External5040cGy28Regional siteNOComplete Response1782012TCGA-A2-A3XT-R3450044C63D6A-9809-45D0-A622-FC1FFD502681233275External868cGy28Regional siteNOComplete Response1782012TCGA-A2-A3XT-R34501D6509E2C-F849-48E2-9026-A7B97686D7D7278282External1000cGy5Primary Tumor FieldNOComplete Response1782012
TCGAFPPP,Breast,No,FEMALE,Dead,3941.0,5347.1552734375,WHITE,TCGA-B6-A0IB,B6,A0IB,No,YES,C50.9,8500/3,C50.9,1992.0,WITH TUMOR,YES,15.0,IHC,IHC,Right Upper Inner QuadrantRight,2.034560546874994,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,surgical resection,Modified radical mastectomy,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,2+,3+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Positive,Equivocal,0.4853515625,8.0,Intensity=Strong,270 H,10-19%,ACIS,dextran coated charcoal,75.478515625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,2.6,"Other, specifySkin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.944414062499999,71,4 Point Scale,1+,3rdStage IVT3N3M1,YES,YES,PositivePositiveNegative,2,11,2010,"TCGA-B6-A0IB-F12612B3CE5BB9-A83F-46D9-B1B3-71711115FFF4Scheduled Follow-up SubmissionNOYESDead3941WITH TUMORYES2717Distant MetastasisOther, specifylung, bone, liverNOPositivefmol/mgimage cytometryPositivefmol/mgimage cytometry162011",1TCGA-A2-A0EM-D185674da4aa7-764e-4340-8062-1e2f5b8e547910 mg BIDmg75Hormone TherapyTamoxifenADJUVANTPONO2382010,TCGA-GM-A2DC-R4706262127898-C5DE-49F3-853B-892863D6FAD6236278External60Gy30Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,371.0,WHITE,TCGA-A2-A1G1,A2,A1G1,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,13.0,H-SCORE 255,Allred 5 = 2+3,Right Upper Outer Quadrant,16.3,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Negative,Equivocal,0.0107421875,1.0,Strong,80,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,30.0,Vysis AutoVysion System,>= 2.0 Positive,YES,NO,51,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,816,3 Point Scale,2+,7thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",12,5,2011,TCGA-A2-A1G1-F20808BF8ABE0A-8961-4EC0-9687-21F465824BF8Scheduled Follow-up SubmissionYESNOAlive584TUMOR FREENO1212012,NOTCGA-AR-A24V-D31619ECA738C2-9571-4A0C-A17D-D3A9713FC6005395ChemotherapyDoxorubicinNO2152012NOTCGA-AR-A24V-D31620076FC6CD-C7E1-47EF-A4D3-A1C9A5B32DB35395ChemotherapyCytoxanNO2152012NOTCGA-AR-A24V-D31622C613A54C-32DC-42A4-93AF-B9A4921BBF5D109151ChemotherapyPaclitaxelNO2152012NOTCGA-AR-A24V-D31623A9AD5C02-19DC-42F0-B096-8FA618C4F7D3109178ImmunotherapyBevacizumabNO2152012NOTCGA-AR-A24V-D3162422B76231-6512-4D60-8D8E-3E9413F870FA1931027Hormone TherapyTamoxifenNO2152012NOTCGA-AR-A24V-D31625B34AEFC3-E29F-4CBD-B443-2FEE1DB176651027Hormone TherapyAnastrozoleYES2152012,TCGA-A2-A1G1-R11798b0a03ce9-a77f-43d8-8c34-8f37099e453192143EXTERNAL BEAM6000cGy28Primary Tumor FieldADJUVANTNO11252011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1NA,E9,A1NA,No,YES,C50.9,8522/3,C50.9,2011.0,TUMOR FREE,YES,11.0,Allred (Biocare),H-SCORE 0,Left Lower Outer Quadrant,2.4162207031249885,Axillary lymph node dissection alone,axillary ultrasound,Other,Right Breast Reexcision,Other,Mastectomy,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Positive,0.0,0.0,230,Allred score 7 (per outside facility),90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,115.7607421875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,54,LungBone,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,79,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,23,6,2011,TCGA-E9-A1NA-F291590DA884CF-F3AE-4AD9-AEE0-EF79534486D5Scheduled Follow-up SubmissionYESYESAlive654TUMOR FREENO932012TCGA-E9-A1NA-F397827D959C11-6F61-40A8-B8E3-A80F62DFE74ANOYESYESTUMOR FREEAlive1112NO122013,NOTCGA-E9-A1NA-D32899728F3086-1CBF-46B3-8113-1355961E96B612148ChemotherapyCyclophosphamideNO1562012NOTCGA-E9-A1NA-D329002A162745-964D-4B44-90CE-6DA163CD3A0112148ChemotherapyCarboplatinNO1562012NOTCGA-E9-A1NA-D329012D437D87-3612-4B26-B16A-AF426B729C67206Hormone TherapyLetrozoleYES1562012,TCGA-E9-A1NA-R29161698F1492-8386-44E8-9271-29109BBA6FCC5895EXTERNAL BEAM4600cGy23Regional siteADJUVANTNO932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,643.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A0D0,A2,A0D0,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,8.0,No value Given,Allred score 7 per outside facility report,Left Upper Outer Quadrant,1.17,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,0,0,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,Allred score 0,205,10-19%,Hercep Test  TM Dako,Dako Hercept test,86.1201171875,Vysis AutoVysion System,Ratio >=2.0,NO,YES,1.1,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.9,3 Point Scale,0,6thStage IIAT2N0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,16,9,2010,TCGA-A2-A0D0-F137294F4DEDB3-173C-4B24-B46B-D1DDCB67A318Scheduled Follow-up SubmissionNOYESAlive643TUMOR FREENO962011TCGA-A2-A0D0-F59399D16C3023-B057-4408-8F50-C78DEA6876E1NONOYESAlive20481252014,1TCGA-A2-A0D0-D1851f423013c-d03a-46bf-9df8-4261396bdc994920mg1230mg462125ChemotherapyCytoxanADJUVANTIVNO16920102TCGA-A2-A0D0-D1852e74bfde2-3653-4de9-bff3-80e8d53d150d612mg153mg462125ChemotherapyDocetaxelADJUVANTIVNO1692010,TCGA-BH-A18H-R5919948AE0EED-8630-4FB3-B325-284F85E0652E219259External50.4Gy28Primary Tumor FieldNOComplete Response252014TCGA-BH-A18H-R59200874B4EE2-C5FA-4C67-B91A-FB143D18AE49260266External10Gy5Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1125.0,WHITE,TCGA-AC-A2FG,AC,A2FG,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,11.0,H-SCORE 300,IHC,Left Upper Outer Quadrant,1.7636816406249964,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Total mastectomy with sentinel lymph node biopsy,Infiltrating Lobular Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,1.0,1.0,Allred Score 5,Strong,10-19%,ACIS,Hercep Test  TM Dako,81.369140625,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,50,LungBone,90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.80,3 Point Scale,2+,6thStage IIBT2N1aMX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,9,2011,TCGA-AC-A2FG-F4322106360A31-72BE-4B48-BC93-870CEB0E9BEDNONOYESTUMOR FREEAlive1853NO1552013,NOTCGA-AC-A2FG-D432221263ADA3-9E75-48E3-AC3C-891A3C9AF9AB39Hormone TherapyArimidexComplete Response1552013,TCGA-AC-A23E-R432395D4AA189-74A9-4527-95E0-9CD8C7441796127158External6000cGyPrimary Tumor FieldNOComplete Response1552013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,725.0,WHITE,TCGA-E2-A1IJ,E2,A1IJ,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,3.0,allred score 5 + 3 = 8,Allred score 5+3=8,Right Upper Outer Quadrant,1.2,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Lobular Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Equivocal,0.69921875,0.0,Strong,Allred score = 7,30-39%,Dako,DAKOHercepTest TM,131.701171875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.6,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,61,3 Point Scale,2+,6thStage IT1cN0M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,4,2011,TCGA-E2-A1IJ-F19950410FB9DE-FA2F-41B4-9C9A-584E963EA019Scheduled Follow-up SubmissionYESYESAlive865TUMOR FREENO21122011,1TCGA-E2-A1IJ-D19952F81CA42B-439C-4C65-B16B-D4461F89A0021mg/day1mg/day48Hormone TherapyArimidexADJUVANTPOYES21122011,TCGA-E2-A1IJ-R199532BFADC86-259E-4148-BD17-F7BB8E92FE8853102EXTERNAL BEAM6440cGy33Primary Tumor FieldADJUVANTNO121122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,63.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A5EH,AC,A5EH,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,14.0,H-Score 300,CAP SCORING GUIDELINE 2010,Left Upper Outer Quadrant,4.077343750000018,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast Reexcision,Other,surgical resection,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.486328125,1.0,allred score = 8,Allred Score 5,10-19%,ACIS,Hercep Test  TM Dako,89.5908203125,Vysis AutoVysion System,>= 2.0 Positive,YES,NO,1.67,LungBone,20-29%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,185,3 Point Scale,2+,7thStage IIBT2N1miMX,YES,YES,NO,12,7,2013,TCGA-AC-A5EH-F601850BF107A0-50A7-481B-957D-E8F1C0A4D8F2NOYESNOTUMOR FREEAlive511NO3152014,1TCGA-E2-A1IJ-D19952F81CA42B-439C-4C65-B16B-D4461F89A0021mg/day1mg/day48Hormone TherapyArimidexADJUVANTPOYES21122011,TCGA-AC-A5EH-R60186982113B3-EE91-4E1A-8D9E-FBE98CA4B6B6163216External6040cGy33Primary Tumor FieldNOComplete Response3152014
TCGAFPPP,Breast,No,FEMALE,Dead,1.0,976.3330078125,WHITE,TCGA-BH-A1F8,BH,A1F8,No,YES,C50.9,8500/3,C50.9,1999.0,WITH TUMOR,YES,13.0,allred score 0 + 0 = 0,allred score 4 + 3 = 7,Left,2.1798144531249903,Sentinel node biopsy alone,axillary ultrasound,Modified Radical Mastectomy,surgical resection,Other,L Total Mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,0.837890625,12.0,Allred Score 3,205,10-19%,ACIS,Hercep Test  TM Dako,89.171875,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,2.6,LungBone,70-79%,40-49%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,3.3,3 Point Scale,2+,5thStage IIIBT4bN2M0,NO,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,7,9,2011,TCGA-D8-A1XT-F294541DBB325B-97FD-4160-A1DB-1849297B9592Scheduled Follow-up SubmissionNOYESAlive506TUMOR FREENO2632012,NOTCGA-A2-A3XX-D344389F081506-F377-47BB-8EE6-EDE38541E7B980129ChemotherapyCyclophosphamideNOComplete Response1582012NOTCGA-A2-A3XX-D34439588DB182-2F95-48D2-A365-0BDF34B3C1FB80129ChemotherapyAdriamycinNOComplete Response1582012NOTCGA-A2-A3XX-D34441B6FD1396-6FE8-44FF-A6AC-72B380261AD5143185ChemotherapyPaclitaxelNOComplete Response1582012,TCGA-D8-A1JD-R208461EE12D22-7FFD-4B4B-AB50-8F43C4E58C30151183EXTERNAL BEAM4500cGy20Primary Tumor FieldADJUVANTNO1912011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,273.0,WHITE,TCGA-D8-A1JD,D8,A1JD,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,manual counting,manual counting,Left Upper Outer Quadrant,1.9419824218749864,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0,3.0,10-75%,>75%,90-99%,Dako,Hecep Test TM DAKO,187.9658203125,Vysis AutoVysion System,>= 2.0 Positive,YES,NO,2.38,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1,3 Point Scale,1+,7thStage IIBT2N1aM0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,3,2011,TCGA-D8-A1JD-F20844D3EFEE22-D62C-42F4-B23C-E08897B69A53Scheduled Follow-up SubmissionYESYESAlive552TUMOR FREENO1912012,TCGA-D8-A1JD-D2084539C2C11A-3C77-464E-98F4-A7A7C922535A240mg60mg/m2450113ChemotherapyAdriamycinADJUVANTIVNO1912012NOTCGA-D8-A1JD-D6532132787263-6D4A-4283-B7C7-50D3650A330D50113ChemotherapycyclophosphamideNO2292014,TCGA-D8-A1JD-R208461EE12D22-7FFD-4B4B-AB50-8F43C4E58C30151183EXTERNAL BEAM4500cGy20Primary Tumor FieldADJUVANTNO1912011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1168.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3XX,A2,A3XX,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,No value Given,Allred score 7 per outside facility report,Left Lower Outer Quadrant,1.25,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Right Breast Reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,allred score = 8,STRONG,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,45.1103515625,Vysis AutoVysion System,>= 2.0 Positive,YES,NO,2.13,Lung,<10%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.3,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,Positive70-79%Positive<10%Negative1+,15,8,2012,TCGA-A2-A3XX-F43310F765B888-581A-4FC9-804A-2FD66F290AF9NONOYESTUMOR FREEDead1439NO1652013,NOTCGA-A2-A3XX-D344389F081506-F377-47BB-8EE6-EDE38541E7B980129ChemotherapyCyclophosphamideNOComplete Response1582012NOTCGA-A2-A3XX-D34439588DB182-2F95-48D2-A365-0BDF34B3C1FB80129ChemotherapyAdriamycinNOComplete Response1582012NOTCGA-A2-A3XX-D34441B6FD1396-6FE8-44FF-A6AC-72B380261AD5143185ChemotherapyPaclitaxelNOComplete Response1582012,TCGA-LL-A5YO-R586424B671EF3-EA8C-45F5-9CCC-C2189FB3DF30192210External40/48Gy15Primary Tumor FieldNOComplete Response1742014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,235.0,WHITE,TCGA-E2-A15M,E2,A15M,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,5.0,CAP scoring guideline 2010,allred score 5+3+8,Right Lower Outer Quadrant,1.265205078124993,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,surgical resection,Other,partial mastectomy,Infiltrating Lobular Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.68359375,0.0,Allred score = 8,Allred score = 8,30-39%,Dako,Venten,56.5927734375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.6,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,2.8,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",14,4,2011,TCGA-E2-A15M-F1885265D32D89-B105-414F-A57D-98CFB36F9863Scheduled Follow-up SubmissionYESYESDead336TUMOR FREENO15112011,1TCGA-E2-A15M-D188536085AD44-E291-473A-9D84-846B9D83A6A71mg/day1mg/day202Hormone TherapyArimidexADJUVANTPONO15112011,TCGA-E2-A15M-R1885585069D51-475A-4210-8DA5-3C2AF8E51324140211EXTERNAL BEAM6600cGyPrimary Tumor FieldADJUVANTNO115112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,222.0,WHITE,TCGA-A2-A4RW,A2,A4RW,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,27.0,No value Given,Allred 5 = 2+3,RightRight Upper Outer Quadrant,1.973349609374996,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.0,27.0,Allred score 7 per outside facility report,180,10-19%,Dako,CAP SCORING GUIDELINE 2010,139.1689453125,HER2 amplification - negative,Ratio >=2.0,YES,NO,2.6,Lung,80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.704531249999993,172,3 Point Scale,3+,7thStage IIICT2N3aM0,YES,NO,NO,27,2,2013,TCGA-A2-A4RW-F5912333B06046-3374-42DE-8585-2C4E3130E18BYESTUMOR FREEAlive222152014,NOTCGA-AC-A2QH-D6410235EB8EC6-E1A8-4C43-9FF1-8743A658A8F994208ChemotherapyCytoxanNOComplete Response2682014NOTCGA-AC-A2QH-D641035555AA7B-5597-4D92-BC2B-20E6EC3BB63094208ChemotherapyAdriamycinNOComplete Response2682014NOTCGA-AC-A2QH-D64104CFAD5F9E-8CC3-430E-A4BC-F6079D09BC8494208AncillaryAloxiNOComplete Response2682014,TCGA-A2-A0CP-R20012bd9726c-9c8e-4177-a060-ea91da683282163210EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11382010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,224.0,WHITE,TCGA-AN-A0AK,AN,A0AK,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,dextran coated charcoal,dextran coated charcoal,Left Upper Outer Quadrant,2.4871093749999917,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Positive,0.0,0.0,Allred Score 8,230,70-79%,0,CAP SCORING GUIDELINE 2010,149.958984375,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,1.1,"LungOther, specifyleft adrenal gland",80-89%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,<4.0,3 Point Scale,0,Stage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,12,2010,TCGA-AN-A0AK-F6894262A33B4D-8305-4A17-85E8-832C43A07ED5NONONOTUMOR FREEAlive224NO23122014,1TCGA-A7-A0CH-D29342daa89c3-a79e-4a11-9bd4-c2472930362c247mg1mg107Hormone TherapyArimidexADJUVANTPOYES5112010,TCGA-E2-A2P5-R335299D9DEECE-7130-4B3B-890A-CCBD6A3A989F98143External60.4Gy28Regional siteNOComplete Response572012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12X,C8,A12X,No,YES,C50.9,8480/3,C50.9,2010.0,TUMOR FREE,YES,6.0,H-SCORE 190,Allred 0 = 0+0,Left,1.5857324218749944,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,surgical resection,Other,Patey's Surgery,Mucinous Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.0859375,1.2841796875,Allred Score 7,Allred Score 8,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,97.34765625,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,YES,NO,54,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,4 Point Scale,2+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",13,4,2011,TCGA-C8-A12X-F1910272134208-F31F-470B-845A-66954265B46DScheduled Follow-up SubmissionNOYESAlive385TUMOR FREENO2122011,1TCGA-E2-A15M-D188536085AD44-E291-473A-9D84-846B9D83A6A71mg/day1mg/day202Hormone TherapyArimidexADJUVANTPONO15112011,TCGA-D8-A1XS-R294538FF615B0-8A31-4C2E-8FC3-C90949FBBD97218258EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,396.0,WHITE,TCGA-AR-A5QN,AR,A5QN,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,19.0,allred score 5+3=8,IHC,Left,2.610214843749993,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Mastectomy NOS,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Positive,0.54296875,10.0,Allred score = 8,230,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,85.998046875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,3.2,LungBone,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.1,3 Point Scale,2+,7thStage IIICT2N3M0,YES,YES,NO,15,5,2013,TCGA-AR-A5QN-F4386245449D22-C8F2-4781-B1E8-8413EBCC5A80NOYESYESTUMOR FREEAlive488NO1062013TCGA-AR-A5QN-F692651B86CEE2-9C01-4E9F-8083-A7E49604B86CNOYESYESTUMOR FREEAlive1013NO31122014,NOTCGA-AR-A5QN-D439021656A4E7-6208-4559-9005-FBD70C8A737539102ChemotherapyTaxotereNO1062013NOTCGA-AR-A5QN-D43903DC1B5976-040D-4E03-A09E-78DA087AAD5539102ChemotherapyCytoxanNO1062013NOTCGA-AR-A5QN-D439115153CC9B-8AD7-4DAA-8A6A-47C5B422CBBE128388Hormone TherapyAnastrozoleNO1062013NOTCGA-AR-A5QN-D439129033B921-AB35-4CBF-9362-256C58629822388Hormone TherapyExemestaneYES1062013,TCGA-AR-A5QN-R4390112842F15-A078-4D68-BFED-ED9D6FA40DD3136173External5040cGy28Primary Tumor FieldNO1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,640.0,WHITE,TCGA-A8-A0A6,A8,A0A6,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,15.1962890625,image cytometry,Allred 0 = 0+0,Left Upper Outer Quadrant,3.289316406249996,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,surgical resection,Infiltrating Lobular Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.69921875,9.0634765625,MODERATE,Allred score 8,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,111.2900390625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4.43,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,441,3 Point Scale,2+,6thStage IIICT2N3aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A0A6-F4032563860C23-6640-45E1-B9C8-1E420148833DNOYESYESTUMOR FREEAlive640NO1622013,NOTCGA-A8-A0A6-D377402FD51391-D472-472E-9309-A80A518724D161184ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A0A6-D37741B93873B4-2604-43FB-8AF4-C7BF99021F9A61184ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A0A6-D377420C70B64D-A56E-43D4-BC98-F0E21C22E396214245Hormone TherapyExemestanen/aNOComplete Response6122012NOTCGA-A8-A0A6-D37743524B50B7-2D72-437D-B997-68ACAEE9481B245Hormone TherapyAnastrozolen/aYES6122012NOTCGA-A8-A0A6-D3774481F60DB0-ED0A-47FB-8CCE-8848A03AB8F4306AncillaryZoledronic acidn/aYES6122012,TCGA-A8-A0A6-R38120B5A342AD-F331-44AF-8190-79467FA299ED214275ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1471.0,WHITE,TCGA-BH-A0B5,BH,A0B5,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,24.0,Allread score 5+3 = 8,allred score 4 + 3 = 7,Left,2.0135156250000086,Sentinel node biopsy alone,SLN and non-SLN biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.3623046875,5.0,allred score = 7,Intensity=Strong,10-19%,ACIS,Dako Hecept Test,231.2666015625,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,33,LungBone,70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,145,3 Point Scale,1+,6thStage IIIAT2N2aM0,NO,YES,YES766Distant MetastasisBoneNOYESNO,2,8,2011,TCGA-BH-A0B5-F59182994E9DC9-8CDF-461E-A2DB-C42A64512AE8NOYESYESTUMOR FREEAlive2136NO252014,NOTCGA-BH-A0B5-D5918317D3063F-CC13-421E-A738-803D7C55847563ChemotherapyAdriamycinNOComplete Response252014NOTCGA-BH-A0B5-D5918405D47456-5206-4EA3-A5A3-8CF061849DEF63ChemotherapyCytoxanNOComplete Response252014NOTCGA-BH-A0B5-D59185C9BF525E-EE34-4064-99CD-996F6EB4C09E257ChemotherapyTaxolNOComplete Response252014,TCGA-BH-A0B5-R591860B41A50F-764D-4D7C-BC17-E313C18AA5F6257302External5040cGy28Primary Tumor FieldNOComplete Response252014TCGA-BH-A0B5-R59187B7B2EE6E-695B-4760-8724-30655D22136D257302External5936cGy43Regional siteNOComplete Response252014TCGA-BH-A0B5-R59188814C435B-99BC-4D04-AD11-C90E47DEBE5F300304External100Gy6Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,890.0,WHITE,TCGA-E2-A14T,E2,A14T,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,7.0,Allred score 5+3 = 8,Allred score 2+2 = 4,Left Upper Inner Quadrant,1.29,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,surgical resection,Other,Surgical resection,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.7880859375,0.0,Allred score = 4,Allred score = 8,90-99%,Dako,CAP scoring guideline 2010,77.7919921875,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,74,Lung,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,61,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,PositivePositiveNegativeNegative1.09,6,4,2011,TCGA-E2-A14T-F1881457A9496F-A47A-430A-A574-AA4A953432BAScheduled Follow-up SubmissionNOYESAlive1013TUMOR FREENO3112011TCGA-E2-A14T-F70396A5C92857-ABED-45D2-8326-E7A5DFA71B1FNONOYESTUMOR FREEAlive2311NO1732015,3TCGA-E2-A14T-D18829A411020C-8212-4584-90F9-D797C7120B811mg/day1mg/day159Hormone TherapyArimidexADJUVANTPOYES71120112TCGA-E2-A14T-D1882688256CB4-C3CF-4406-866A-27621E1D10131428mg357mg4103145ChemotherapyPaclitaxelADJUVANTIVNO71120111TCGA-E2-A14T-D18818491C04CD-29DC-4BA7-AC0E-EB33E9119638496mg124mg44789ChemotherapyDoxorubicinADJUVANTIVNO71120111TCGA-E2-A14T-D188230EA62B2B-479A-481F-8E0A-271DDF8A22024968mg1242mg44789ChemotherapyCyclophosphamideADJUVANTIVNO7112011,TCGA-D8-A1XB-R294371BE82867-064E-46F8-940F-DFD8A3C0791174111EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3088.0,WHITE,TCGA-B6-A1KF,B6,A1KF,No,YES,C50.9,8500/3,C50.9,1998.0,TUMOR FREE,YES,14.0,Allred score 0+0 = 0,%IHC,Right Lower Outer Quadrant,1.1909765625000015,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Other,Right Breast Reexcision,Modified radical mastectomy,Excisional biopsy,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Negative,Equivocal,0.57421875,2.0,Allred Score 6,200,60-69%,Hercep Test  TM Dako,Venten,50.3134765625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.6,LungBone,80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.8,4 Point Scale,2+,5thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",19,7,2011,TCGA-B6-A1KF-F1573961E927F2-F19E-4BA3-8DF6-318C8BB8E3A5Scheduled Follow-up SubmissionYESYESAlive3088TUMOR FREENO2982011,NOTCGA-A2-A3XX-D344389F081506-F377-47BB-8EE6-EDE38541E7B980129ChemotherapyCyclophosphamideNOComplete Response1582012NOTCGA-A2-A3XX-D34439588DB182-2F95-48D2-A365-0BDF34B3C1FB80129ChemotherapyAdriamycinNOComplete Response1582012NOTCGA-A2-A3XX-D34441B6FD1396-6FE8-44FF-A6AC-72B380261AD5143185ChemotherapyPaclitaxelNOComplete Response1582012,TCGA-BH-A0HF-R473378BFE41B-F146-4BC6-9D8E-1A21BCB1599E64111EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,274.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A4RX,A2,A4RX,No,YES,C50.9,8575/3,C50.9,2012.0,TUMOR FREE,YES,3.0,ER Positive H-Score 95,H-Score 160,Right Lower Outer Quadrant,1.4195800781249983,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Wide re-excisional biopsy,Metaplastic Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,1+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,0.0,Allred Score 6,allred score = 0,90-99%,Dako,CAP scoring guideline 2010,123.3349609375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,33,Lung,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.704531249999993,60,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,NO,28,2,2013,TCGA-A2-A4RX-F5849195B990F4-B105-40DD-A286-0FC1AEB007FENOTUMOR FREEAlive742NO1142014,TCGA-D8-A1JD-D2084539C2C11A-3C77-464E-98F4-A7A7C922535A240mg60mg/m2450113ChemotherapyAdriamycinADJUVANTIVNO1912012NOTCGA-D8-A1JD-D6532132787263-6D4A-4283-B7C7-50D3650A330D50113ChemotherapycyclophosphamideNO2292014,TCGA-BH-A0BS-R633978727D0E4-840A-4524-962B-7AD1986FB858245302External6040cGy25Primary Tumor FieldNOComplete Response782014TCGA-BH-A0BS-R63398FB9FF030-2089-4C98-BB5C-D04016148325245302External46.8Gy26Regional siteNOComplete Response782014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,31.0,WHITE,TCGA-AC-A2QH,AC,A2QH,No,YES,C50.9,8575/3,C50.9,2011.0,TUMOR FREE,YES,22.0,Allred 0 = 0+0,%IHC,Right Upper Outer Quadrant,1.3218652343750017,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Total mastectomy with sentinel lymph node biopsy,Metaplastic Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Negative,Negative,0.0,0.0,Allred Score 5,Allred score = 7,10-19%,ACIS,Hercep Test  TM Dako,83.140625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,50,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.0,3 Point Scale,2+,7thStage IIBT3N0MX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",18,10,2011,TCGA-AC-A2QH-F6410091E76EF9-3B27-4249-8F36-04C648DEAA31NOYESYESTUMOR FREEAlive1005NO2682014,NOTCGA-AC-A2QH-D6410235EB8EC6-E1A8-4C43-9FF1-8743A658A8F994208ChemotherapyCytoxanNOComplete Response2682014NOTCGA-AC-A2QH-D641035555AA7B-5597-4D92-BC2B-20E6EC3BB63094208ChemotherapyAdriamycinNOComplete Response2682014NOTCGA-AC-A2QH-D64104CFAD5F9E-8CC3-430E-A4BC-F6079D09BC8494208AncillaryAloxiNOComplete Response2682014,TCGA-AC-A2QH-R64101731DA497-5254-41D5-A65B-F5F0222CE5A1246305External6040cGy33Primary Tumor FieldNOComplete Response2682014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,19.0,WHITE,TCGA-E9-A3QA,E9,A3QA,No,YES,C50.9,8510/3,C50.9,2011.0,TUMOR FREE,YES,14.0,image cytometry,Allred (Biocare),Left Lower Inner Quadrant,1.758964843750002,Axillary lymph node dissection alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,L Total Mastectomy,Medullary Carcinoma,secretory,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,stereotactic biopsy,Negative,Positive,Equivocal,0.25390625,0.0,230,120,90-99%,Dako,Hercep Test  TM Dako,100.25390625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,33,LungBone,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.9,3 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,NO,PositiveNegative,30,4,2012,TCGA-E9-A3QA-F6610032054674-B4A7-45C1-AF24-7707709AD516NONONOTUMOR FREEAlive918NO2102014,TCGA-D8-A1JD-D2084539C2C11A-3C77-464E-98F4-A7A7C922535A240mg60mg/m2450113ChemotherapyAdriamycinADJUVANTIVNO1912012NOTCGA-D8-A1JD-D6532132787263-6D4A-4283-B7C7-50D3650A330D50113ChemotherapycyclophosphamideNO2292014,TCGA-A2-A0EU-R1714bc456128-c77d-444f-a359-a200d25bf391116193EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11282010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,3042.0,WHITE,TCGA-Z7-A8R5,Z7,A8R5,No,YES,C50.9,8520/3,C50.9,2005.0,TUMOR FREE,YES,5.0,image cytometry,CAP SCORING GUIDELINE 2010,Left Upper Outer Quadrant,2.4663085937500004,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast Reexcision,Other,Segmental Mastectomy,Infiltrating Lobular Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,3.0,3.0,allred score = 6,190,30-39%,CISH,Dako Hecept Test,130.865234375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,3.0,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.83,4 Point Scale,1+,6thStage IIIAT3N1aMX,YES,NO,YES181Locoregional RecurrenceYES181NOYES,9,7,2014,TCGA-Z7-A8R5-F587639849E8B7-D2F4-4C6A-B5A4-06D7FB7212B0NONOYESWITH TUMORAlive3287YES3287Locoregional RecurrenceBone972014,NOTCGA-Z7-A8R5-D5875908450109-B43A-47C4-8D73-9711DF98344461181ChemotherapyAdriamycinNOStable Disease972014NOTCGA-Z7-A8R5-D587613B9407D6-8ECF-44E6-A3C8-821C5FF3B17A61181ChemotherapyCytoxanNOStable Disease972014NOTCGA-Z7-A8R5-D58762975E7C8D-AADD-4A83-8053-CDE2D86B1A5A61181TaxolNOStable Disease972014,TCGA-AR-A24R-R3146395453BBE-20F4-4F6E-9C53-6FC33C65D529249295EXTERNAL BEAM6240cGy34Primary Tumor FieldADJUVANTNO1352012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1326.0,WHITE,TCGA-B6-A1KC,B6,A1KC,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,2.0,image cytometry,image cytometry,Right Lower Outer Quadrant,1.373740234374999,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Other,Total mastectomy,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Negative,Positive,Negative,0.064453125,1.0,110,49 fmol/mg protein,30-39%,Hercep Test  TM Dako,Venten,50.61328125,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,NO,YES,2.13,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.9,4 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",19,7,2011,TCGA-B6-A1KC-F15740C4FFD639-1D13-4E8E-80DC-B8D3730D3F2FScheduled Follow-up SubmissionYESYESAlive1326TUMOR FREENO2982011,NOTCGA-Z7-A8R5-D5875908450109-B43A-47C4-8D73-9711DF98344461181ChemotherapyAdriamycinNOStable Disease972014NOTCGA-Z7-A8R5-D587613B9407D6-8ECF-44E6-A3C8-821C5FF3B17A61181ChemotherapyCytoxanNOStable Disease972014NOTCGA-Z7-A8R5-D58762975E7C8D-AADD-4A83-8053-CDE2D86B1A5A61181TaxolNOStable Disease972014,TCGA-A2-A3XT-R344983FC8B1C4-9668-4CC8-B355-AF3B27746C49233275External5040cGy28Primary Tumor FieldNOComplete Response1782012TCGA-A2-A3XT-R344998749065D-442D-4F58-98EA-5CFEAC7F5AB3233275External5040cGy28Regional siteNOComplete Response1782012TCGA-A2-A3XT-R3450044C63D6A-9809-45D0-A622-FC1FFD502681233275External868cGy28Regional siteNOComplete Response1782012TCGA-A2-A3XT-R34501D6509E2C-F849-48E2-9026-A7B97686D7D7278282External1000cGy5Primary Tumor FieldNOComplete Response1782012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0AS,AN,A0AS,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,9.0,IHC,CAP scoring guideline 2010,Left Upper Outer Quadrant,2.308496093749989,No axillary staging,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,0,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.0,4.0,0,190,20-29%,0,Venten,131.2734375,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,2.7,Lung,70-79%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.80,3 Point Scale,0,Stage IIIAT2N2M0,YES,NO,YES766Distant MetastasisBoneNOYESNO,28,12,2010,TCGA-AN-A0AS-F689476DA8757D-7D76-4A0B-B31F-24A36D38E1F8YESNONOTUMOR FREEAlive1023122014,NOTCGA-AR-A5QN-D439021656A4E7-6208-4559-9005-FBD70C8A737539102ChemotherapyTaxotereNO1062013NOTCGA-AR-A5QN-D43903DC1B5976-040D-4E03-A09E-78DA087AAD5539102ChemotherapyCytoxanNO1062013NOTCGA-AR-A5QN-D439115153CC9B-8AD7-4DAA-8A6A-47C5B422CBBE128388Hormone TherapyAnastrozoleNO1062013NOTCGA-AR-A5QN-D439129033B921-AB35-4CBF-9362-256C58629822388Hormone TherapyExemestaneYES1062013,TCGA-A2-A0EU-R1714bc456128-c77d-444f-a359-a200d25bf391116193EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11282010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A2-A25D,A2,A25D,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,24.0,No value Given,allred score 4 + 3 = 7,Right Upper Outer Quadrant,1.22,Axillary lymph node dissection alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Other,partial mastectomy,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,1+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0625,22.0,Allred score = 5,"Moderate using the scale of Weak, Moderate, Strong",90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,60.0,HER2 amplification - negative,Ratio >=2.0,YES,NO,118,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,145,3 Point Scale,3+,7thStage IIICT2N3aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,6,2011,TCGA-A2-A25D-F3093141B3DC6F-0AEF-40AE-966C-285FC8F9D38EScheduled Follow-up SubmissionYESYESAlive0TUMOR FREENO1942012,1TCGA-A2-A25D-D1449713453903-A47B-4D8A-9288-9EE9FE59622620mg/day0Hormone TherapyTamoxifenADJUVANTPOYES21720112TCGA-A2-A25D-D144984E0D9B7A-4FB4-4A35-92D4-B0CF3C369CEE25mg00Hormone TherapyExemestaneADJUVANTPONO21720113TCGA-A2-A25D-D14499A604328B-BACF-486C-9E11-4CEC7C695BC61mg00Hormone TherapyArimidexADJUVANTPONO2172011,TCGA-A2-A25D-R14500D849D0F0-0D55-4F6A-80A1-49A9EEDF0C2700EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO12172011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,243.0,WHITE,TCGA-A8-A07S,A8,A07S,No,YES,C50.9,8522/3,C50.9,2009.0,WITH TUMOR,YES,4.7900390625,Allred (Biocare),Allred 0 = 0+0,Left Upper Outer Quadrant,5.280117187500003,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Mixed Histology (please specify),lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Positive,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.7265625,0.0009765625,Strong,Allred Score,30-39%,Hercep Test  TM Dako,Hercep Test  TM Dako,141.416015625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.38,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.83,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A07S-F4083378B6AD18-7DC4-47A4-908E-5490DAE3A3B9NOYESYESWITH TUMORAlive243NO232013,NOTCGA-A8-A07S-D37858D07D6350-F930-4F58-9B82-9257EC76316B151Hormone TherapyTamoxifenn/aYES6122012,TCGA-A8-A07S-R38181DA0CEEAB-4453-45D1-810B-36039944F72C121151ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7.0,ASIAN,TCGA-C8-A138,C8,A138,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,dextran coated charcoal,dextran coated charcoal,Left,1.4121093749999896,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Negative,Positive,Equivocal,0.427734375,3.916015625,allred score = 7,Allred Score 5,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,86.478515625,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,YES,NO,74,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.8,4 Point Scale,2+,6thStage IIIAT2N2M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",15,4,2011,TCGA-C8-A138-F19085796DB5B0-AE4E-4BF6-BDBC-21E5E0EAD6B7Scheduled Follow-up SubmissionNONOAlive124TUMOR FREENO2122011TCGA-C8-A138-F71893CA8159BD-20C6-4347-8D27-78773527103DNONOYESTUMOR FREEAlive380NO3132015,YESTCGA-GM-A2DC-D47063679FB4FD-B762-4872-806F-4EE16E16D89D57119ChemotherapyXelodaNOComplete Response2282013YESTCGA-GM-A2DC-D470645E67582A-3CD1-4483-9C0E-C98EF42102E357119ChemotherapyTaxotereNOComplete Response2282013YESTCGA-GM-A2DC-D47065F653FE5D-76FD-4DD7-A553-952CA706E60F140208ChemotherapyNOComplete Response2282013YESTCGA-GM-A2DC-D470664D71435A-BF64-420E-BAAA-4892EADB051F140208ChemotherapyEpirubicinNOComplete Response2282013YESTCGA-GM-A2DC-D47067DD73F85B-7DFB-4F68-ACDB-DA28D8449C86140208ChemotherapyCytoxanNOComplete Response2282013NOTCGA-GM-A2DC-D470689A846B76-30FF-41CC-854D-8BFDBE8D172E294341Hormone TherapyLetrozoleNOComplete Response2282013NOTCGA-GM-A2DC-D4706901F8744B-71EA-4966-BDDF-8D9D5CFD632C355383Hormone TherapyArimidexNOComplete Response2282013,TCGA-A8-A0A9-R3819489CEC5DA-77F7-448B-9CC1-9A2DE6F37364123153ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1465.0,WHITE,TCGA-AR-A24X,AR,A24X,No,YES,C50.9,8522/3,C50.9,2006.0,TUMOR FREE,YES,7.0,H-SCORE 300,%IHC,Right Upper Inner Quadrant,1.4751171875000015,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Reexcision of segmental mastectomy,Other,TOTAL MASTECTOMY,Mixed Histology (please specify),Mixed invasive ductal and invasive lobular,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,0.107421875,0.0,10-75%,Allred Score 8,90-99%,Dako,CAP SCORING GUIDELINE 2010,100.388671875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.38,"LungBoneLiverOther, specifyskin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,172,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,PositivePositiveNegativeNegative1.09,30,8,2011,TCGA-AR-A24X-F31643D38579DD-B26E-4ACC-AD09-47DCCB6A47A4Scheduled Follow-up SubmissionNOYESAlive1465NO752012TCGA-AR-A24X-F495056283A368-C360-4D7E-B284-5AB8F0FE43D6NOYESTUMOR FREEAlive2548NO2102013TCGA-AR-A24X-F71741D8FB489C-76DF-4D1D-9D2A-3DB704F0E1E3NONOYESTUMOR FREEAlive3004NO3032015,NOTCGA-AR-A24X-D316444A49DB24-6D72-4CF9-A396-F9FEC2E3A3FFChemotherapyDoxorubicinNO2152012NOTCGA-AR-A24X-D31645D805353E-47A2-4282-9237-2CAC88D2665EChemotherapyCytoxanNO2152012NOTCGA-AR-A24X-D316465D4ED2DA-2DBA-474E-911D-6EFAE11A411B1301926Hormone TherapyTamoxifenNO2152012,TCGA-A8-A0A9-R3819489CEC5DA-77F7-448B-9CC1-9A2DE6F37364123153ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,635.0,WHITE,TCGA-EW-A1P7,EW,A1P7,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,H-SCORE 280,Allred 0 = 0+0,Right Upper Outer Quadrant,1.8,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Lumpectomy,Re-Excision of Superior Margin,Other,Mastectomy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Equivocal,0.0,0.0,Allred Score 3,Intensity=Strong,10-19%,CISH,Venten,81.408203125,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,NO,YES,1.78,LungBone,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.0,3 Point Scale,2+,6thStage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",18,5,2011,"TCGA-EW-A1P7-F2911819E7F481-84A1-4837-B990-B4172DE0DBD5Scheduled Follow-up SubmissionNOYESAlive915WITH TUMORYES729Distant MetastasisOther, specifymediastinal lymph nodesYES793NOYES832012",Carboplatin/TaxolTCGA-EW-A1P7-D2923802AB6152-BB5D-4E54-9189-8B1A5D581075550mg1293ChemotherapyCarboplatinADJUVANTIVYES1232012Carboplatin/TaxolTCGA-EW-A1P7-D2927397468A51-638F-48FB-B604-59FE79E75919234mg1293ChemotherapyTaxolADJUVANTIVYES1332012,TCGA-E2-A56Z-R44510ED43F584-56B4-41B9-B645-3A751C3355FA84129External60.4Gy33Regional siteNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2495.0,WHITE,TCGA-A2-A0CP,A2,A0CP,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,2.0,allred score 0 + 0 = 0,Allred 5 = 2+3,Right,1.402304687499996,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,MODERATE,205,<10%,ACIS,CAP SCORING GUIDELINE 2010,68.765625,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,50,"Other, specifySkin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.5,3 Point Scale,2+,6thStage IAT1cN0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,8,9,2010,TCGA-A2-A0CP-F137417BF10142-06B6-4D5A-BF38-AE1D5E2468DFScheduled Follow-up SubmissionYESYESAlive2813TUMOR FREENO1062011,3TCGA-A2-A0CP-D20046a6c88d1-1963-4a43-b81a-b46a280df51f1 mg dailymg2062043Hormone TherapyAnastrozoleADJUVANTPONO13820101TCGA-A2-A0CP-D2002f2a18707-8081-432a-ba13-4789e14d46c94236mg1056-1062mg470134ChemotherapyCytoxanADJUVANTIVNO13820102TCGA-A2-A0CP-D2003e1068c5e-35cf-4b45-9e78-0d8b415602e8424mg106mg470134ChemotherapyAdriamycinADJUVANTIVNO1382010,TCGA-A2-A0CP-R20012bd9726c-9c8e-4177-a060-ea91da683282163210EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11382010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A1HI,C8,A1HI,Yes,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,6.0,Allred score 5+3=8,Allred score 5+3 = 8,Right,1.4374804687500042,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,4 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",Patey's Surgery,Positive,Positive,Negative,0.53515625,3.8994140625,Allred Score 6,Allred Score 8,90-99%,ACIS,Venten,147.8291015625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,2.8,Lung,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,4 Point Scale,1+,6thStage IIIAT2N2M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",1,6,2011,TCGA-C8-A1HI-F1909941B909BA-C457-4643-9821-7881F6EA6087Scheduled Follow-up SubmissionNOYESAlive343TUMOR FREENO2122011,NOTCGA-BH-A0B5-D5918317D3063F-CC13-421E-A738-803D7C55847563ChemotherapyAdriamycinNOComplete Response252014NOTCGA-BH-A0B5-D5918405D47456-5206-4EA3-A5A3-8CF061849DEF63ChemotherapyCytoxanNOComplete Response252014NOTCGA-BH-A0B5-D59185C9BF525E-EE34-4064-99CD-996F6EB4C09E257ChemotherapyTaxolNOComplete Response252014,TCGA-A2-A25D-R14500D849D0F0-0D55-4F6A-80A1-49A9EEDF0C2700EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO12172011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,580.0,WHITE,TCGA-A8-A091,A8,A091,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.3544921875,image cytometry,Allred score 0+0=0,Right,3.83144531250002,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.72265625,0.0009765625,Allred score 8,Allred score 8,10-19%,Hercep Test  TM Dako,Venten,139.6201171875,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,NO,YES,54,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.9,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A091-F405575C002AE2-4733-487B-8827-5B108727F910NOYESYESTUMOR FREEAlive1004YES2432322013,NOTCGA-A8-A091-D37748BB7A58AA-67C4-4906-8662-C5ADC58A70E70123Chemotherapy5-Fluorouraciln/aNO6122012NOTCGA-A8-A091-D377498FDB6109-FEFD-4D8A-BD04-D88DE1852A870123ChemotherapyEpirubicinn/aNO6122012NOTCGA-A8-A091-D37750CAB281AD-1C82-4832-9982-1EC937E751870123ChemotherapyCyclophosphamiden/aNO6122012NOTCGA-A8-A091-D37751A318C975-5C70-465F-B50F-29E1A23C842A184639Hormone TherapyTamoxifenn/aNOStable Disease6122012NOTCGA-A8-A091-D37752F9769A43-9D9A-4A64-8ACF-0B51D8CDD614639Hormone TherapyLetrozolen/aYES6122012NOTCGA-A8-A091-D37753B4B5A2CC-1753-4C12-8472-45D92D2CF095700AncillaryZoledronic acidn/aYES6122012NOTCGA-A8-A091-D3775472915C6D-EEBE-4670-ABF0-E15D34050969580669AncillaryPamidronaten/aNOStable Disease6122012,TCGA-A8-A091-R38154B6AFE9FC-6769-4F5A-B728-625645B39410123184ExternalGyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,974.0,WHITE,TCGA-E2-A14Q,E2,A14Q,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,7.0,Allred score 5+3 = 8,Allred score 5+3 = 8,Left Upper Outer Quadrant,1.6723046874999914,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.7333984375,1.0,Allred score = 8,Allred score = 8,<10%,Dako,CAP scoring guideline 2010,198.150390625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,66,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,4.70,3 Point Scale,2+,6thStage IIBT2N1miM0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",31,3,2011,TCGA-E2-A14Q-F18800D5D37217-A5A0-4F1E-A521-F1E6125491B4Scheduled Follow-up SubmissionNOYESAlive1163TUMOR FREENO20102011,1TCGA-E2-A14Q-D1880138EC0589-8337-4CE8-B1F2-D4F29BB091A120mg/day20mg/day53Hormone TherapyTamoxifenADJUVANTPOYES20102011,TCGA-E9-A247-R3120726249F86-F8CF-4233-A328-0F7884EEB5A03364EXTERNAL BEAM4600cGy23Primary Tumor FieldADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,144.0,WHITE,TCGA-BH-A8FZ,BH,A8FZ,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,7.0,ER Positive H-Score 95,H-Score 290,Left,2.3294238281249933,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast Reexcision,Other,Segmental Mastectomy,Infiltrating Lobular Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Equivocal,1.0380859375,0.0,240 H,250,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,360.9716796875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,2.6,LungBone,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,172,3 Point Scale,2+,7thStage IAT1bN0M0,NO,YES,NO,25,3,2014,TCGA-BH-A8FZ-F6367911E8283A-157A-43A1-8DB4-8F21080D28C5NOYESNOTUMOR FREEAlive574NO2782014,NOTCGA-A8-A0A9-D379049728FE30-70C8-4399-84BC-DCE88562667E31Hormone TherapyAnastrozoleYES6122012,TCGA-BH-A8FZ-R57777A3520120-DE20-49A6-A0A8-DC098E7076DC81125External10Gy33Primary Tumor FieldNOComplete Response2632014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2513.0,WHITE,TCGA-AO-A1KP,AO,A1KP,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,9.0,H-SCORE 260,CAP scoring guideline 2010,Left Lower Inner QuadrantLeft Lower Outer QuadrantLeft,1.3,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Simple Mastectomy,Right Breast Reexcision,Other,Partial Mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,1.0,0.0,Allred score 5,8,<10%,ACIS,CAP scoring guideline 2010,42.796875,Vysis AutoVysion System,>=2.0 Positive,NO,YES,2.8,Lung,80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.9,4 Point Scale,4+,6thStage IIAT1N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",1,4,2011,TCGA-AO-A1KP-F9887AC4C4A60-0A25-4A0D-A0C2-8CA86319498B2513AliveTUMOR FREENOYES142011TCGA-AO-A1KP-F2177457BE50C2-0DB3-4688-8591-106B44818CA6Scheduled Follow-up SubmissionNOYESAlive2953NO2022012,1TCGA-AO-A1KP-D98886dbc8d44-d5cc-47ee-884f-abfb08b15c5c8064mg600mg/m2886237ChemotherapyFluorouracilADJUVANTIVNO1420111TCGA-AO-A1KP-D9891c40a1ef3-ee24-431c-bc24-3d0560dcebef8064mg600mg/m2886237ChemotherapyCyclophosphamideADJUVANTIVNO1420111TCGA-AO-A1KP-D9889756b07bd-7b7d-499b-a092-be8e6c7eab77320mg40mg/m2886237ChemotherapyMethotrexateADJUVANTIVNO1420111TCGA-AO-A1KP-D9893263a6dfb-0cbe-43e4-84ce-66714eb4fe981mg/day3352161Hormone TherapyArimidexADJUVANTPONO142011,TCGA-BH-A0HI-R475442D1C987-18FD-4ABB-A93D-5D836F4ED4C496141EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO122112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,388.0,WHITE,TCGA-E2-A1L9,E2,A1L9,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,CAP scoring guideline 2010,IHC,Right,1.2287207031249998,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,Surgical resection,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,1.2734375,1.0,allred score = 7,allred score = 7,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,87.599609375,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,2.13,"LungOther, specifyleft adrenal gland",80-89%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.1,3 Point Scale,2+,6thStage IIAT1cN1miM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,6,2011,TCGA-E2-A1L9-F205971D1EB5B9-2C8B-47F3-BBD6-E02A269BE683Scheduled Follow-up SubmissionYESYESAlive598TUMOR FREENO1112012,2TCGA-E2-A1L9-D20601EA86D6FC-965B-4DD5-BAA8-D08128E3B0F120mg/day20mg/day187Hormone TherapyTamoxifenADJUVANTPOYES11120121TCGA-E2-A1L9-D20600ACCE2AC2-3256-4F8C-B862-CA109FC03BA3456122ChemotherapyTaxotereADJUVANTNO11120121TCGA-E2-A1L9-D205984A43A807-30FB-4969-B77C-A3BC9D040351455122ChemotherapyCytoxanADJUVANTNO1112012,TCGA-E2-A1L9-R20602FB33C7DC-7439-4DE4-B8CE-2F122C0D2BB8140177EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11112012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,231.0,WHITE,TCGA-AN-A0FL,AN,A0FL,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,8.0,dextran coated charcoal,dextran coated charcoal,Left Upper Inner Quadrant,2.488339843749984,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Wide Local Excision,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,1+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Positive,0.0,0.0,Allred Score 8,0%,20-29%,0,dextran coated charcoal,78.869140625,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,NO,YES,2.7,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,145,3 Point Scale,1+,Stage IIAT2N0M0,YES,NO,YES766Distant MetastasisBoneNOYESNO,28,12,2010,TCGA-AN-A0FL-F68952240E4926-540A-4B61-A6CE-1A9793228A2BYESNONOTUMOR FREEAlive23123122014,1TCGA-A7-A0CH-D29342daa89c3-a79e-4a11-9bd4-c2472930362c247mg1mg107Hormone TherapyArimidexADJUVANTPOYES5112010,TCGA-AO-A0J5-R5870f3025f80-8525-4819-b6cc-e2b2cd2207ed336371EXTERNAL BEAM10625cGy25Regional sitePALLIATIVENO17122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0AT,AN,A0AT,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,dextran coated charcoal,dextran coated charcoal,Right Upper Inner Quadrant,2.4791601562499834,No axillary staging,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,1+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,0,0,20-29%,0,dextran coated charcoal,71.5849609375,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,NO,YES,2.7,"LungOther, specifyleft adrenal gland",<10%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,145,3 Point Scale,1+,Stage IIAT2N0M0,YES,NO,YES766Distant MetastasisBoneNOYESNO,28,12,2010,TCGA-AN-A0AT-F689486E5C0241-D8BE-4DB8-8893-0E939CCED8F6YESNONOTUMOR FREEAlive1023122014,1TCGA-A7-A0CH-D29342daa89c3-a79e-4a11-9bd4-c2472930362c247mg1mg107Hormone TherapyArimidexADJUVANTPOYES5112010,TCGA-AO-A0J5-R5870f3025f80-8525-4819-b6cc-e2b2cd2207ed336371EXTERNAL BEAM10625cGy25Regional sitePALLIATIVENO17122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1628.0,WHITE,TCGA-GM-A2DC,GM,A2DC,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,21.0,Allred score 5+3=8,CAP scoring guideline 2010,Right Upper Outer Quadrant,1.06,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,right segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,1.0,Allred Score 4,8,10-19%,0,CAP SCORING GUIDELINE 2010,60.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,4.43,LungBone,90-99%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,4.70,3 Point Scale,2+,6thStage IIAT1cN1aM0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,9,2011,TCGA-GM-A2DC-F470616AC27496-A61A-402E-BF63-5AF1D989727ENOYESYESTUMOR FREEAlive2535NO2282013,YESTCGA-GM-A2DC-D47063679FB4FD-B762-4872-806F-4EE16E16D89D57119ChemotherapyXelodaNOComplete Response2282013YESTCGA-GM-A2DC-D470645E67582A-3CD1-4483-9C0E-C98EF42102E357119ChemotherapyTaxotereNOComplete Response2282013YESTCGA-GM-A2DC-D47065F653FE5D-76FD-4DD7-A553-952CA706E60F140208ChemotherapyNOComplete Response2282013YESTCGA-GM-A2DC-D470664D71435A-BF64-420E-BAAA-4892EADB051F140208ChemotherapyEpirubicinNOComplete Response2282013YESTCGA-GM-A2DC-D47067DD73F85B-7DFB-4F68-ACDB-DA28D8449C86140208ChemotherapyCytoxanNOComplete Response2282013NOTCGA-GM-A2DC-D470689A846B76-30FF-41CC-854D-8BFDBE8D172E294341Hormone TherapyLetrozoleNOComplete Response2282013NOTCGA-GM-A2DC-D4706901F8744B-71EA-4966-BDDF-8D9D5CFD632C355383Hormone TherapyArimidexNOComplete Response2282013,TCGA-GM-A2DC-R4706262127898-C5DE-49F3-853B-892863D6FAD6236278External60Gy30Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Dead,2127.0,989.1787109375,WHITE,TCGA-BH-A1EN,BH,A1EN,No,YES,C50.9,8500/3,C50.9,1999.0,TUMOR FREE,YES,12.5927734375,Allred score = 8,Allred 5 = 2+3,Right,2.040615234375,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,surgical resection,Modified radical mastectomy,right segmental mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,Ultrasound-guided biopsy,Positive,Negative,Positive,0.9013671875,5.9755859375,Allred Score 3,205,10-19%,ACIS,CAP SCORING GUIDELINE 2010,173.1943359375,Vysis AutoVysion System,CAP SCORING GUIDELINE 2010,NO,YES,1.78,LungBone,80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,5,3 Point Scale,2+,5thStage IIAT2NXM0,NO,YES,PositivePositiveNegativeNegative,3,9,2011,TCGA-BH-A0BF-F59142F0AF0BD4-A367-46F9-8059-CBDFB34BE1B8NONONOTUMOR FREEDead1324NO152014,TCGA-D8-A1JD-D2084539C2C11A-3C77-464E-98F4-A7A7C922535A240mg60mg/m2450113ChemotherapyAdriamycinADJUVANTIVNO1912012NOTCGA-D8-A1JD-D6532132787263-6D4A-4283-B7C7-50D3650A330D50113ChemotherapycyclophosphamideNO2292014,TCGA-AO-A0J5-R5870f3025f80-8525-4819-b6cc-e2b2cd2207ed336371EXTERNAL BEAM10625cGy25Regional sitePALLIATIVENO17122010
TCGAFPPP,Breast,No,MALE,Alive,0.0,242.0,WHITE,TCGA-A1-A0SM,A1,A0SM,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,3.0,allred score 5 + 3 = 8,H-SCORE 280,Left,11.0,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,surgical resection,Modified radical mastectomy,Wide Local Excision,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,4+,3+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Positive,Positive,Positive,0.0078125,0.0,allred score = 7,Intensity=Strong,30-39%,0,CAP scoring guideline 2010,168.2001953125,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,2,"Other, specifySkin",20-29%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,21,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,YES766Distant MetastasisBoneNOYESNO,6,12,2010,TCGA-E2-A106-F17181453994A4-28A8-43A0-B4F2-4D4F5A37984AScheduled Follow-up SubmissionNOYESAlive1807TUMOR FREENO2892011TCGA-E2-A106-F7039786E020FA-8617-4BFB-855C-06DA3C5ECFD9NONOYESAlive2541NO1732015,NOTCGA-AC-A2FG-D432221263ADA3-9E75-48E3-AC3C-891A3C9AF9AB39Hormone TherapyArimidexComplete Response1552013,TCGA-BH-A0HF-R473378BFE41B-F146-4BC6-9D8E-1A21BCB1599E64111EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,782.0,WHITE,TCGA-BH-A0BF,BH,A0BF,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,3.0,Allred score = 8,allred score 4 + 3 = 7,Right Upper Outer Quadrant,2.116962890625006,Sentinel node biopsy alone,SLN and non-SLN biopsy,Other,Right Breast Reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.4052734375,1.0,allred score = 7,Allred Score 6,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,85.251953125,Vysis AutoVysion System,Ratio >=2.0,NO,YES,64,Lung,70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.5,3 Point Scale,2+,6thStage IIBT2N1miM0,NO,YES,YES766Distant MetastasisBoneNOYESNO,5,8,2011,TCGA-BH-A0BF-F59142F0AF0BD4-A367-46F9-8059-CBDFB34BE1B8NONONOTUMOR FREEDead1324NO152014,NOTCGA-AC-A2FG-D432221263ADA3-9E75-48E3-AC3C-891A3C9AF9AB39Hormone TherapyArimidexComplete Response1552013,TCGA-A2-A0EU-R1714bc456128-c77d-444f-a359-a200d25bf391116193EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11282010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,162.0,WHITE,TCGA-A7-A0CH,A7,A0CH,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,Allred 0 = 0+0,CAP scoring guideline 2010,Left Upper Outer QuadrantLeft,1.3437695312499978,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Negative,Negative,0.0,0.0,Allred score 7 per outside facility report,Two-tier,10-19%,0,3+ Positive,72.55078125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,74,"LungOther, specifyleft adrenal gland",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,52,3 Point Scale,1+,Stage IIAT2N0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,4,10,2010,TCGA-A7-A0CH-F293554F1C21B-1D60-4A2F-A2AF-52A73EE8DCFC233AliveTUMOR FREENOYES5112010TCGA-A7-A0CH-F3914870682038-C827-4F58-A9DC-8433BFCE1CF6NONOYESTUMOR FREEAlive1079NO1412013,1TCGA-A7-A0CH-D29342daa89c3-a79e-4a11-9bd4-c2472930362c247mg1mg107Hormone TherapyArimidexADJUVANTPOYES5112010,TCGA-E9-A247-R3120726249F86-F8CF-4233-A328-0F7884EEB5A03364EXTERNAL BEAM4600cGy23Primary Tumor FieldADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,116.0,WHITE,TCGA-D8-A1Y1,D8,A1Y1,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,22.0,manual counting,manual counting,Left Upper Inner QuadrantLeft Upper Outer Quadrant,1.1524414062500004,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,partial mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Negative,Positive,Negative,0.193359375,1.0,>75%,10-75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,53.3818359375,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,YES,NO,33,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.8,3 Point Scale,2+,7thStage IIIAT3N1aMX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,6,2011,TCGA-D8-A1Y1-F30084B147E8C4-F15B-4D80-98D2-281316F91CE1Scheduled Follow-up SubmissionNOYESDead302WITH TUMORNO242012,TCGA-D8-A1Y1-D300855389E215-9B46-4ED9-A3F2-0392ACD376A5mg20mg/day58302Hormone TherapyTamoxifenADJUVANTPONO242012,TCGA-A2-A0SW-R3704b82f6467-290c-4472-9248-1095701eaf2054EXTERNAL BEAM10680cGyPrimary Tumor FieldADJUVANTNO18112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,735.0,WHITE,TCGA-AO-A0J5,AO,A0J5,Yes,YES,C50.9,8523/3,C50.9,2008.0,WITH TUMOR,YES,2.0,Allred 0 = 0+0,dextran coated charcoal,Right Upper Inner QuadrantRight Upper Outer QuadrantRight Lower Inner QuadrantRight Lower Outer QuadrantRight,1.1,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,surgical resection,Other,Partial Mastectomy,"Other, specify",Ductal/micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,4+,2+,Negative,Close,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.29296875,2.0,Allred score = 7,80,10-19%,CISH,3+ Positive,25.0,>2.2 Positive,PathVision HER2 DNA Probe Kit,NO,YES,64,LungBoneLiver,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,71,3 Point Scale,1+,Stage IVT4N1aM1,YES,YES,YES766Distant MetastasisBoneNOYESNO,7,12,2010,TCGA-AO-A0J5-F5869DDACC35F-1160-48BC-B755-EC8F6E8C2537705AliveWITH TUMOR735YESYES7122010TCGA-AO-A0J5-F194079C35625C-89D6-48BA-AE91-2B8411B85217Scheduled Follow-up SubmissionYESYESDead792WITH TUMORNO12122011,"1TCGA-AO-A0J5-D60053daac793-eb29-42ea-8866-27b14eca58204mg-1Other, specify in notesBisphosphonateZoledronic AcidOTHER, SPECIFY IN NOTESNeo-adjuvantIVYES10120112TCGA-AO-A0J5-D6007effd840a-7e52-4422-a5e1-ad5c2f84aa8a1500mg/day422ChemotherapyXeloda (Capecitabine)PROGRESSIONPOYES10120111TCGA-AO-A0J5-D60062819fde9-35d0-4e7e-a9eb-da82637892232.5mg/day9422Hormone TherapyFemara (Letrozole)OTHER, SPECIFY IN NOTESNeo-AdjuvantPONO10120113TCGA-AO-A0J5-D6008272824b5-160a-4d48-8b48-bcaa074214bb250mg618Hormone TherapyFulvestrant (Faslodex)PROGRESSIONIMYES1012011",TCGA-AO-A0J5-R5870f3025f80-8525-4819-b6cc-e2b2cd2207ed336371EXTERNAL BEAM10625cGy25Regional sitePALLIATIVENO17122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,733.0,WHITE,TCGA-A2-A0EU,A2,A0EU,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,1.0,ER Positive H-Score 95,allred score 4 + 3 = 7,Right Lower Outer Quadrant,0.97,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Right Breast Reexcision,Lumpectomy,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,0,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,Intensity=Strong,Intensity=Strong,10-19%,ACIS,DAKOHercepTest TM,48.087890625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.45,"Other, specifySkin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.3,3 Point Scale,2+,6thStage IAT1cN0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,8,2010,TCGA-A2-A0EU-F13717FC478CCD-9561-4F06-81A2-F8BA25C5AF85Scheduled Follow-up SubmissionYESNOAlive1043TUMOR FREENO1062011,NOTCGA-C8-A26W-D707976FA5FD97-F91B-4EA5-8434-AD7296AE38C123193ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A26W-D70798C80FD468-DF82-483E-8999-EF2110391C9623193ChemotherapyCyclophosphamideNOComplete Response932015,TCGA-A2-A0EU-R1714bc456128-c77d-444f-a359-a200d25bf391116193EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11282010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1555.0,ASIAN,TCGA-E2-A106,E2,A106,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,16.0,allred score 0 + 0 = 0,allred score 4 + 3 = 7,Right Upper Outer Quadrant,1.05,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,inner-upper margin re-excision,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Close,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.3369140625,1.0,Allred score 5,H score,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,427.5537109375,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,3.1,"LungOther, specifyleft adrenal gland",90-99%,80-89%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.9,3 Point Scale,2+,Stage IBT1cN1miM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,2,2011,TCGA-E2-A106-F17181453994A4-28A8-43A0-B4F2-4D4F5A37984AScheduled Follow-up SubmissionNOYESAlive1807TUMOR FREENO2892011TCGA-E2-A106-F7039786E020FA-8617-4BFB-855C-06DA3C5ECFD9NONOYESAlive2541NO1732015,1TCGA-E2-A106-D7753d99bb0ba-6f4a-424f-ad5f-6ec86deec9b53.6mg3.6mg883Hormone TherapyZoladexADJUVANTSCYES14220111TCGA-E2-A106-D7751da3db900-ed98-41e6-9c1e-6cdde2b53b9120mg/day883Hormone TherapyTamoxifenADJUVANTPOYES1422011,TCGA-E9-A247-R3120726249F86-F8CF-4233-A328-0F7884EEB5A03364EXTERNAL BEAM4600cGy23Primary Tumor FieldADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,124.0,WHITE,TCGA-E2-A108,E2,A108,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,27.0,Allred score 7 (outside facility),Allred score 7 per outside facility report,Right Upper Outer Quadrant,1.2623828124999938,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Lumpectomy,surgical resection,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.86328125,4.0,Allred score 7 per outside facility report,Allred score 7 (per outside facility),10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,217.12890625,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,54,"LungOther, specifyleft adrenal gland",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.1,3 Point Scale,2+,6thStage IIIAT2N2aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,2,2011,TCGA-E2-A108-F17423A33B2D82-E56A-4069-9F2E-D9EED8EEAFBAScheduled Follow-up SubmissionYESYESAlive837WITH TUMORNO2892011,1TCGA-E2-A108-D7774b5112aa6-5ae8-4f62-9901-d9fb84775ddd4102144ChemotherapyAdriamycinADJUVANTIVNO14220112TCGA-E2-A108-D77760e5f203f-3c34-4cb7-be76-4901295154cf12151187ChemotherapyTaxolADJUVANTIVNO14220113TCGA-E2-A108-D17424D2DB5EB8-9FA3-4CF9-88B7-0FEEDE0C21222.5mg244Hormone TherapyFemaraADJUVANTPOYES28920111TCGA-E2-A108-D17915478FCF8A-98C5-4614-BAF3-0E937EBBF1C595ChemotherapyCytoxanADJUVANTIVNO27102011,TCGA-E2-A108-R174263898256B-7709-4AD8-A5F1-C015BE2F2D7C307313EXTERNAL BEAM1000cGy5Primary Tumor FieldADJUVANTNO22892011TCGA-E2-A108-R1742733202687-94BA-4A4A-840C-2AEEB9DBAABB266306EXTERNAL BEAM4860cGyPrimary Tumor FieldADJUVANTNO22892011TCGA-E2-A108-R17425D1EF94C7-3632-4BEA-A17F-C2AD0BD214B4264306EXTERNAL BEAM5040cGyPrimary Tumor FieldADJUVANTNO022892011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,850.0,WHITE,TCGA-E2-A1II,E2,A1II,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.0,allred score 0 + 0 = 0,allred score 2+2 = 4,Left,1.2262597656249985,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Negative,0.7216796875,0.0,allred score = 4,allred score = 0,<10%,Dako,DAKOHercepTest TM,129.9697265625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.6,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,61,3 Point Scale,2+,6thStage IT1cN0M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,4,2011,TCGA-E2-A1II-F1995427975FD4-6AE6-4CF8-B70D-97A5D77F33F1Scheduled Follow-up SubmissionYESYESAlive1025TUMOR FREENO21122011,2TCGA-E2-A1II-D19957E52E0CD6-6BA3-4B19-B9A1-B64D2D70C3331312mg328mg4129171ChemotherapyPaclitaxelADJUVANTIVNO211220111TCGA-E2-A1II-D1995532F5916B-52FE-4FD3-8F7D-FAFD84F63E02460mg116mg473115ChemotherapyDoxorubicinADJUVANTIVNO211220111TCGA-E2-A1II-D199567F620EE0-F7E5-41C9-9E7F-E47843DBB6EC4656mg1164mg473115ChemotherapyCyclophosphamideADJUVANTIVNO21122011,TCGA-E2-A1II-R199590C04CF63-CC3C-4E0B-A37F-CAF63097FBAB181236EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO121122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,ASIAN,TCGA-C8-A8HR,C8,A8HR,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,8.0,H-Score 300,H-SCORE 0,Right,1.4157910156250024,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Lobular Carcinoma,Invasive tubulolobular carcinoma,Peri (6-12 months since last menstrual period),Positive,NO,4 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,1.123046875,5.0,Allred score 5,8,10-19%,ACIS,Hercep Test  TM Dako,122.1015625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,2.6,Lung,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,5,4 Point Scale,2+,7thStage IIIAT3N2M0,NO,NO,NO,29,12,2014,TCGA-C8-A8HR-F6979633528C47-968B-492E-B86C-31DC1D52F0EDNONOYESTUMOR FREEAlive408NO2012015,NOTCGA-C8-A8HR-D69797AAB14121-BF30-4BA7-B0DE-7F26E3723D2443237Chemotherapy5 fluorouracilNOComplete Response2012015NOTCGA-C8-A8HR-D69798F6A77EA7-2ED3-4BFD-AC8F-21E9DE5FA24243237ChemotherapyEpirubicinNOComplete Response2012015NOTCGA-C8-A8HR-D6979933674CC5-6A4D-42DB-87A8-270B36FA897443237ChemotherapyCyclophosphamideNOComplete Response2012015,TCGA-E2-A108-R174263898256B-7709-4AD8-A5F1-C015BE2F2D7C307313EXTERNAL BEAM1000cGy5Primary Tumor FieldADJUVANTNO22892011TCGA-E2-A108-R1742733202687-94BA-4A4A-840C-2AEEB9DBAABB266306EXTERNAL BEAM4860cGyPrimary Tumor FieldADJUVANTNO22892011TCGA-E2-A108-R17425D1EF94C7-3632-4BEA-A17F-C2AD0BD214B4264306EXTERNAL BEAM5040cGyPrimary Tumor FieldADJUVANTNO022892011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,13.0,WHITE,TCGA-E9-A247,E9,A247,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,Allred score 0+0 = 0,%IHC,Left Upper Inner Quadrant,1.2770605468749976,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Lumpectomy,Negative,Positive,Equivocal,0.2744140625,0.0,Allred score 0,270 H,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,65.53125,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,YES,NO,3.1,LungBone,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,61,4 Point Scale,2+,7thStage IAT1cN0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",18,8,2011,TCGA-E9-A247-F312048BAC0FD9-1E30-4203-B0C7-0382C7E97B77Scheduled Follow-up SubmissionYESYESAlive463TUMOR FREENO2092013TCGA-E9-A247-F402401B31A774-A7D0-41F4-A4E0-B650129E3C2DNOYESYESTUMOR FREEAlive828NO1422013TCGA-E9-A247-F618748455B922-8FE0-4FB7-9DFB-3798FA5B1CB0NOYESYESTUMOR FREEAlive1186NO2372014,1TCGA-E9-A247-D312085A067FB7-4E61-4DD8-9DCF-061185296A1520mg/day10Hormone TherapyTamoxifenADJUVANTPOYES2542012,TCGA-E9-A247-R3120726249F86-F8CF-4233-A328-0F7884EEB5A03364EXTERNAL BEAM4600cGy23Primary Tumor FieldADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,727.0,WHITE,TCGA-BH-A0HF,BH,A0HF,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,H-Score 295,H-Score 15,Right Upper Outer QuadrantRight,1.475498046875008,Sentinel node biopsy alone,Pateys surgery,Other,Right Breast Reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.28125,0.0,H-Score,H-Score,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.8642578125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,50,"Other, specifySkin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,816,3 Point Scale,1+,Stage IAT1cN0 (i-)M0,NO,YES,YES766Distant MetastasisBoneNOYESNO,10,11,2010,TCGA-BH-A0HF-F473461BFA455-749F-42A0-9883-8ECFC203B71B727AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0HF-D473052CDAF4B-976B-48BE-B49F-DBC0DDD25B7A1mg/day34Hormone TherapyArimidexADJUVANTPOYES17112010,TCGA-BH-A0HF-R473378BFE41B-F146-4BC6-9D8E-1A21BCB1599E64111EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Dead,967.0,632.01171875,ASIAN,TCGA-A1-A0SK,A1,A0SK,No,YES,C50.9,8013/3,C50.9,2007.0,TUMOR FREE,YES,4.0,H-SCORE 190,Allred score 2+3 = 5,Right Upper Outer Quadrant,2.037958984374997,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Lumpectomy,surgical resection,Other,Modified Radical Masectomy,"Other, specify","Neuroendocrine carcinoma, large-cell type, high-grade",Indeterminate (neither Pre or Postmenopausal),Negative,YES,3 Point Scale,4+,0,Negative,Positive,Excisional Biopsy,Patey's Suregery,Negative,Negative,Negative,0.27734375,0.0,Allred score 5,205,30-39%,0,Venten,164.5888671875,Vysis AutoVysion System,Path Vysion HER-2 DNA probe kit,NO,YES,3.0,"Other, specifySkin",10-19%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.8352539062499968,4.70,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,Negative<10%3 Point ScaleNegative<10%3 Point ScaleEquivocal<10%1+,6,12,2010,TCGA-A1-A0SK-F159265F98C53B-5EE8-444C-9089-1E7EF433117DScheduled Follow-up SubmissionDead967WITH TUMOR792011,1TCGA-A2-A0EM-D185674da4aa7-764e-4340-8062-1e2f5b8e547910 mg BIDmg75Hormone TherapyTamoxifenADJUVANTPONO2382010,TCGA-D8-A1XZ-R30079C8844127-DA9B-42AF-8D57-3B1CE257E1A56993EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,121.0,WHITE,TCGA-D8-A1XZ,D8,A1XZ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,manual counting,manual counting,Right Lower Inner Quadrant,1.3352441406249984,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Right Breast Reexcision,Other,Excision,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Negative,Positive,Negative,0.2314453125,6.0,Allred score = 0,>75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,61.0009765625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,1.78,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.9,3 Point Scale,2+,7thStage IIIAT1cN2aMX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,6,2011,TCGA-D8-A1XZ-F300775898E4E8-0E20-482D-BF42-11B375146742Scheduled Follow-up SubmissionYESYESAlive466TUMOR FREENO242012,TCGA-D8-A1XZ-D300783B8B3BD1-028D-4001-B58C-D0CE9C68CF27mg20+1mg/day94Hormone Therapytamoxiphene+anastrozolumADJUVANTPOYES242012,TCGA-D8-A1XZ-R30079C8844127-DA9B-42AF-8D57-3B1CE257E1A56993EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,859.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3Y0,A2,A3Y0,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,39.0,No value Given,H-Score 160,Left Upper Outer Quadrant,2.5104296874999945,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,1+,Negative,Close,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,1.0,allred score = 4,Allred score 7 (per outside facility),10-19%,Hercep Test  TM Dako,Dako Hercept test,102.0048828125,Vysis AutoVysion System,Ratio >=2.0,NO,YES,66,LungBone,90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.85,3 Point Scale,1+,7thStage IIBT2N1aM0,YES,NO,NO,24,8,2012,TCGA-A2-A3Y0-F43305F0E5AA9E-2FA1-4CB2-A39C-EEFDECF50948NONOYESTUMOR FREEAlive1167NO1652013TCGA-A2-A3Y0-F591181EF24DD9-1163-4D9E-9C00-F0FD9BB65B89NONOYESTUMOR FREEAlive1546NO152014,NOTCGA-A2-A3Y0-D345709F7B7F8B-718E-4740-93BC-324EE04D01E874137ChemotherapyAdriamycinNOComplete Response2482012NOTCGA-A2-A3Y0-D34571FBC64FA5-C743-40B6-9565-79BFB168FF4E74137ChemotherapyCytoxanNOComplete Response2482012NOTCGA-A2-A3Y0-D3458727FAEC54-F24D-438B-8005-1AA132B3092A165247ChemotherapyDocetaxelNOComplete Response2482012NOTCGA-A2-A3Y0-D345888E48C12C-49AB-4BAE-A24E-F9DA45AAA81FHormone TherapyArimidexNOComplete Response2482012NOTCGA-A2-A3Y0-D345898A141947-57F7-47C1-9301-538DC497884BHormone TherapyFemaraNOComplete Response2482012NOTCGA-A2-A3Y0-D345907CD22268-A875-4227-AB7F-E16930C56DDCHormone TherapyTamoxifenYES2482012,TCGA-A8-A0A9-R3819489CEC5DA-77F7-448B-9CC1-9A2DE6F37364123153ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Dead,2534.0,860.23828125,WHITE,TCGA-BH-A204,BH,A204,No,YES,C50.9,8500/3,C50.9,1996.0,WITH TUMOR,YES,16.0,allred score 0 + 0 = 0,H-Score 160,Left,2.4583886718749905,Sentinel node biopsy alone,Pateys surgery,Modified Radical Mastectomy,Right Breast Reexcision,Other,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.55859375,2.0,Strong,Two-tier,10-19%,Hercep Test  TM Dako,Dako Hercept test,77.197265625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,4,LungBone,70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,71,3 Point Scale,2+,5thStage IIBT2N1bM0,NO,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,8,9,2011,TCGA-BH-A0HF-F473461BFA455-749F-42A0-9883-8ECFC203B71B727AliveTUMOR FREEYESYES16112010,1TCGA-AO-A0JG-D32170da9c957-0267-41cc-9517-ac96284494e91280mg175mg/m24136185ChemotherapyPACLITAXELADJUVANTIVNO20920101TCGA-AO-A0JG-D3216a33b3892-3e6b-4da6-9f8e-d172913aa440440mg60mg/m2480122ChemotherapyDOXORUBICINADJUVANTIVNO20920102TCGA-AO-A0JG-D32186c1bae55-7974-4d4d-b031-2e8c522b0a5d1mg/day197Hormone TherapyARIMIDEXADJUVANTPOYES20920101TCGA-AO-A0JG-D3215b263b426-435b-4224-a98e-8fb254f0a03a4400mg600mg/m2480122ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO2092010,TCGA-BH-A0HF-R473378BFE41B-F146-4BC6-9D8E-1A21BCB1599E64111EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,193.0,WHITE,TCGA-D8-A1XT,D8,A1XT,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,% IHC,%IHC,Right Upper Outer Quadrant,3.31913085937501,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,3+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Negative,Positive,0.0,3.0,0%,0%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,61.943359375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.38,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.23,3 Point Scale,2+,7thStage IIAT1cN1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,5,2011,TCGA-D8-A1XT-F294541DBB325B-97FD-4160-A1DB-1849297B9592Scheduled Follow-up SubmissionNOYESAlive506TUMOR FREENO2632012,TCGA-D8-A1XT-D29455BA9F76EC-158B-4252-8921-AF7A7755CEAB360+3600mg60+600mg/m2674228Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO1932012,TCGA-AO-A0JL-R3221d709ea17-69fa-422f-ad04-a50953144eb1192240EXTERNAL BEAM10776cGy45Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1641.0,WHITE,TCGA-BH-A0BS,BH,A0BS,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,11.0,ER Positive H-Score 95,allred score 4 + 3 = 7,Left,1.996083984374993,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.736328125,0.0,Allred Score 4,Allred Score 6,10-19%,ACIS,Hercep Test  TM Dako,82.98828125,Vysis AutoVysion System,Path Vysion HER-2 DNA probe kit,NO,YES,64,LungBone,<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.3,3 Point Scale,2+,6thStage IIIAT3N1cM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",18,8,2011,TCGA-BH-A0BS-F619557D2BC44D-7ED6-4B0D-84B9-31E38397201FNOYESYESTUMOR FREEAlive2612NO782014,NOTCGA-BH-A0BS-D63392FCDA8776-2D25-4001-B9CC-956E0043F6A844207ChemotherapyAdriamycinNOComplete Response782014NOTCGA-BH-A0BS-D63400993049EF-D3F7-4F12-B97F-3D6AE402349844207ChemotherapyCytoxanNOComplete Response782014,TCGA-BH-A0BS-R633978727D0E4-840A-4524-962B-7AD1986FB858245302External6040cGy25Primary Tumor FieldNOComplete Response782014TCGA-BH-A0BS-R63398FB9FF030-2089-4C98-BB5C-D04016148325245302External46.8Gy26Regional siteNOComplete Response782014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7.0,ASIAN,TCGA-C8-A26W,C8,A26W,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,5.4912109375,Allred 0 = 0+0,allred score 5+3+8,Left Upper Outer Quadrant,4.511767578125,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Mixed invasive ductal and invasive lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Tumor resection,Patey's Surgery,Negative,Positive,Equivocal,0.046875,1.189453125,Allred Score 8,Allred Score 8,90-99%,ACIS,Hercep Test  TM Dako,141.92578125,Vysis AutoVysion System,>= 2.0 Positive,YES,NO,54,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.66,4 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,7,2011,TCGA-C8-A26W-F707960471D048-FE29-4B0C-AC3B-79C58867B410NONOYESTUMOR FREEAlive381NO932015,NOTCGA-C8-A26W-D707976FA5FD97-F91B-4EA5-8434-AD7296AE38C123193ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A26W-D70798C80FD468-DF82-483E-8999-EF2110391C9623193ChemotherapyCyclophosphamideNOComplete Response932015,TCGA-D8-A1JC-R20849A9A5EA39-2CEF-4A69-A4C6-E072C872237D122147EXTERNAL BEAM4500cGyPrimary Tumor FieldADJUVANTNO1912012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2830.0,WHITE,TCGA-A8-A08T,A8,A08T,No,YES,C50.9,8500/3,C50.9,2002.0,WITH TUMOR,YES,10.6708984375,CAP SCORING GUIDELINE 2010,Allred 0 = 0+0,Right,2.7997949218749936,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Tumor resection,Lumpectomy,Positive,Positive,Positive,0.4013671875,1.6474609375,allred score = 7,Allred score = 7,10-19%,ACIS,CAP SCORING GUIDELINE 2010,134.6806640625,HER2 amplification - negative,Ratio >=2.0,NO,YES,54,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.1,3 Point Scale,3+,6thStage IVT2N1aM1,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A08T-F40559643ED7A2-6EA2-4E09-A96E-6C6D54CFBEF0NONOWITH TUMORDead3409YES25572422013,NOTCGA-AR-A24V-D31619ECA738C2-9571-4A0C-A17D-D3A9713FC6005395ChemotherapyDoxorubicinNO2152012NOTCGA-AR-A24V-D31620076FC6CD-C7E1-47EF-A4D3-A1C9A5B32DB35395ChemotherapyCytoxanNO2152012NOTCGA-AR-A24V-D31622C613A54C-32DC-42A4-93AF-B9A4921BBF5D109151ChemotherapyPaclitaxelNO2152012NOTCGA-AR-A24V-D31623A9AD5C02-19DC-42F0-B096-8FA618C4F7D3109178ImmunotherapyBevacizumabNO2152012NOTCGA-AR-A24V-D3162422B76231-6512-4D60-8D8E-3E9413F870FA1931027Hormone TherapyTamoxifenNO2152012NOTCGA-AR-A24V-D31625B34AEFC3-E29F-4CBD-B443-2FEE1DB176651027Hormone TherapyAnastrozoleYES2152012,TCGA-D8-A1XZ-R30079C8844127-DA9B-42AF-8D57-3B1CE257E1A56993EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1319.0,WHITE,TCGA-AO-A0JL,AO,A0JL,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,26.0,Allred 0 = 0+0,%IHC,Left Upper Outer QuadrantLeft Lower Outer QuadrantLeft,2.6,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,Total mastectomy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Positive,Negative,Negative,0.0771484375,7.0,Allred score = 7,80,<10%,CISH,3+ POSITIVE,21.0,Vysis AutoVysion System,RATIO > = 2.0,NO,YES,50,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,131,3 Point Scale,2+,Stage IIIAT2N2aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",20,9,2010,TCGA-AO-A0JL-F3220DD0750D5-100B-40A1-9393-C49DA44B5F661319AliveTUMOR FREEYESYES2092010TCGA-AO-A0JL-F154952DA970A3-1C67-4AE5-BAC4-13FDE30BD4D0Scheduled Follow-up SubmissionYESYESAlive1683TUMOR FREENO2282011,1TCGA-AO-A0JL-D32248dcbe4a5-051a-4efa-8075-bd9b1286cb99488mg60mg/m2480122ChemotherapyDOXORUBICINADJUVANTIVNO20920102TCGA-AO-A0JL-D3226159bd986-fd08-4ac4-bca0-67dfa5bdf56f9476mg6mg/kg22136493Targeted Molecular therapyTRASTUZUMABADJUVANTIVNO20920101TCGA-AO-A0JL-D3223b9f318a5-5322-4ead-a810-926101586b5e4872mg600mg/m2480122ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO20920101TCGA-AO-A0JL-D3225e91e3c59-4d69-4fa4-8fdb-3221b74de9a21372mg175mg/m24136178ChemotherapyPACLITAXELADJUVANTIVNO2092010,TCGA-AO-A0JL-R3221d709ea17-69fa-422f-ad04-a50953144eb1192240EXTERNAL BEAM10776cGy45Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,396.0,WHITE,TCGA-A8-A0A9,A8,A0A9,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.6875,Allred (Biocare),Allred 0 = 0+0,Left Upper Outer Quadrant,6.196396484375024,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.703125,0.001953125,Allred Score 3,Allred Score,30-39%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,134.5771484375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.6,LungBone,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,59,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A0A9-F403232268A2C4-38E4-4EAA-AE4D-4454ED86BB07NOYESYESTUMOR FREEAlive822NO1622013,NOTCGA-A8-A0A9-D379049728FE30-70C8-4399-84BC-DCE88562667E31Hormone TherapyAnastrozoleYES6122012,TCGA-A8-A0A9-R3819489CEC5DA-77F7-448B-9CC1-9A2DE6F37364123153ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1746.0,WHITE,TCGA-AR-A24R,AR,A24R,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,28.0,Image Analysis,manual counting,Right Upper Inner QuadrantRight Upper Outer Quadrant,2.526894531249991,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast Reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,lobular/ductal,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.1357421875,6.0,10-75%,Allred score 8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,89.4423828125,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,2.6,LungBone,10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,172,3 Point Scale,1+,6thStage IIIAT1N2M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",26,8,2011,TCGA-AR-A24R-F31462B874C101-A757-4D0F-9AB6-D5BC0F444BB6Scheduled Follow-up SubmissionYESYESAlive1746NO352012TCGA-AR-A24R-F494997FD6DCC3-94BA-40B7-8949-A360B92F61D9NOYESYESTUMOR FREEAlive2653NO2102013TCGA-AR-A24R-F7173120CD927D-EA75-4B4E-9695-06932A02A418NOYESYESTUMOR FREEAlive3430NO3032015,NOTCGA-AR-A24R-D320532D99DA1B-9B2A-4ECA-AE32-B72EA98D544B1969Hormone TherapyLetrozoleYES15520121TCGA-AR-A24R-D314662C100981-948D-403E-AD66-4E1C0D27C49810500mg60mg/m2/day553157ChemotherapyCytoxanADJUVANTPONO3520121TCGA-AR-A24R-D31468A5F6149E-F23B-460C-976E-013FB96B1C921200mg175mg/m24172214ChemotherapyPaclitaxelADJUVANTIVNO3520121TCGA-AR-A24R-D31464CCA3DC0B-E23D-40B1-9E84-27AA4E047FF8600mg24mg/m2553151ChemotherapyDoxorubicinADJUVANTIVNO3520122TCGA-AR-A24R-D314958ABD8AA5-234C-4EE7-8757-5E4639897AF320mg/day2281904Hormone TherapyTamoxifenADJUVANTPONO452012,TCGA-AR-A24R-R3146395453BBE-20F4-4F6E-9C53-6FC33C65D529249295EXTERNAL BEAM6240cGy34Primary Tumor FieldADJUVANTNO1352012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1648.0,WHITE,TCGA-AR-A24V,AR,A24V,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,2.0,CAP scoring guideline 2010,%IHC,Right Upper Outer Quadrant,2.3812988281249825,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Peri (6-12 months since last menstrual period),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0703125,1.0,Allred score = 4,Allred Score 7,10-19%,Hercep Test  TM Dako,Venten,126.8212890625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.13,LungBone,80-89%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,52,3 Point Scale,1+,6thStage IIBT2N1M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,8,2011,TCGA-AR-A24V-F31614C1FEBD32-0A27-497D-A3F5-150E6557CF31Scheduled Follow-up SubmissionYESYESAlive1648NO752012TCGA-AR-A24V-F494795C983853-8BE4-4FDF-8D26-55D45483BB03YESYESTUMOR FREEAlive2596NO2102013TCGA-AR-A24V-F717405447AFA3-8009-4D99-80F1-BD69E437431FNOYESYESTUMOR FREEAlive3203NO3032015,NOTCGA-AR-A24V-D31619ECA738C2-9571-4A0C-A17D-D3A9713FC6005395ChemotherapyDoxorubicinNO2152012NOTCGA-AR-A24V-D31620076FC6CD-C7E1-47EF-A4D3-A1C9A5B32DB35395ChemotherapyCytoxanNO2152012NOTCGA-AR-A24V-D31622C613A54C-32DC-42A4-93AF-B9A4921BBF5D109151ChemotherapyPaclitaxelNO2152012NOTCGA-AR-A24V-D31623A9AD5C02-19DC-42F0-B096-8FA618C4F7D3109178ImmunotherapyBevacizumabNO2152012NOTCGA-AR-A24V-D3162422B76231-6512-4D60-8D8E-3E9413F870FA1931027Hormone TherapyTamoxifenNO2152012NOTCGA-AR-A24V-D31625B34AEFC3-E29F-4CBD-B443-2FEE1DB176651027Hormone TherapyAnastrozoleYES2152012,TCGA-AR-A24V-R3161738CC31C7-2363-4444-953E-DDAAFB7098AA200248EXTERNAL BEAM6600cGy33ADJUVANTNO1752012
TCGAFPPP,Breast,No,FEMALE,Dead,879.0,493.0771484375,WHITE,TCGA-E2-A1LE,E2,A1LE,No,YES,C50.9,8500/3,C50.9,2008.0,WITH TUMOR,YES,28.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Right Upper Inner QuadrantRight Lower Inner Quadrant,1.4767382812499965,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,Biopsy not specified,Negative,Negative,Positive,1.015625,27.0,Allred score = 0,Allred score = 0,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,54.0185546875,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,2.6,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.8325585937499964,1.1,3 Point Scale,2+,6thStage IIICT2N3aM0,YES,YES,PositivePositiveNegative,7,6,2011,TCGA-E2-A1LE-F206574AB0B560-C397-4945-A69B-2DC2A6437160Scheduled Follow-up SubmissionYESYESDead879WITH TUMORYES361Distant MetastasisLungNONOYES1812012,1TCGA-E2-A1LE-D2066019196460-368E-41C9-B27F-4DB7C615B079635mg635mg15454ChemotherapyherceptinADJUVANTIVNO18120121TCGA-E2-A1LE-D20658E1057F1C-5208-4158-B2EA-5017FB560FF6134mg134mg15454ChemotherapydocetaxelADJUVANTIVNO18120121TCGA-E2-A1LE-D20661522A5688-06F7-4DE2-AAB5-1A7CFA4286A11074mg1074mg15454ChemotherapycyclophosphamideADJUVANTIVNO18120122TCGA-E2-A1LE-D206647BC50522-B439-499F-88CC-E549DC5D26A63468530ChemotherapygemcitabineRECURRENCEIVNO1812012,TCGA-E2-A1LE-R2066573C4148D-EEC1-42AD-A3D6-67DE98AE432B101146EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO011812012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2238.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3XT,A2,A3XT,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,13.0,No value Given,H-Score 160,Left,1.13,Other (specify),FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Excisional Biopsy,Patey's Suregery,Negative,Negative,Negative,0.03125,1.0,Allred Score 4,205,<10%,Hercep Test  TM Dako,Dako Hercept test,90.6767578125,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,40,"LungOther, specifyleft adrenal gland",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,145,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,YES,NO,17,8,2012,TCGA-A2-A3XT-F4330932EAD95B-751B-4BFD-BE2E-908EA3CE2617NOYESYESTUMOR FREEAlive2525NO1652013TCGA-A2-A3XT-F5584160EA646B-4B74-49E4-8493-AE2DA1AF4BFANOYESYESTUMOR FREEAlive2770NO1612014,NOTCGA-A2-A3XT-D34495C93B9D6C-DE38-4B66-AA69-C788731E6DA23583ChemotherapyCyclophosphamideNOPartial Response1782012NOTCGA-A2-A3XT-D34496314F8E23-81C1-41B5-BB1D-78A78525EE503583ChemotherapyDoxorubicinNOPartial Response1782012NOTCGA-A2-A3XT-D344973E9B81CF-BFAD-4C78-AC24-32461C48569297161ChemotherapyDocetaxelNOPartial Response1782012,TCGA-A2-A3XT-R344983FC8B1C4-9668-4CC8-B355-AF3B27746C49233275External5040cGy28Primary Tumor FieldNOComplete Response1782012TCGA-A2-A3XT-R344998749065D-442D-4F58-98EA-5CFEAC7F5AB3233275External5040cGy28Regional siteNOComplete Response1782012TCGA-A2-A3XT-R3450044C63D6A-9809-45D0-A622-FC1FFD502681233275External868cGy28Regional siteNOComplete Response1782012TCGA-A2-A3XT-R34501D6509E2C-F849-48E2-9026-A7B97686D7D7278282External1000cGy5Primary Tumor FieldNOComplete Response1782012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2758.0,WHITE,TCGA-A2-A0EM,A2,A0EM,No,YES,C50.9,8500/3,C50.9,2002.0,TUMOR FREE,YES,1.0,Allred score = 8,Allred 5 = 2+3,Right Upper Inner Quadrant,1.3,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,surgical resection,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.0,0.0,Allred Score 3,Moderate,<10%,Hercep Test  TM Dako,DAKOHercepTest TM,78.419921875,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,33,LungBoneLiver,<10%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,5,3 Point Scale,1+,5thStage IAT1N0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,6,9,2010,TCGA-A2-A0EM-F13714B2013AC6-E2F9-4125-9F5F-459BAE754700Scheduled Follow-up SubmissionYESYESAlive3094TUMOR FREENO962011,1TCGA-A2-A0EM-D185674da4aa7-764e-4340-8062-1e2f5b8e547910 mg BIDmg75Hormone TherapyTamoxifenADJUVANTPONO2382010,TCGA-A2-A0EM-R1857dc50a49e-3060-45e5-b116-412aadc8f49772119EXTERNAL BEAM6060cGy33Primary Tumor FieldADJUVANTNO12382010
TCGAFPPP,Breast,No,FEMALE,Dead,3462.0,1159.060546875,WHITE,TCGA-BH-A1ES,BH,A1ES,No,YES,C50.9,8500/3,C50.9,1999.0,WITH TUMOR,YES,4.0,H-Score 295,allred score 4 + 3 = 7,Right Upper Inner Quadrant,1.9700781249999992,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.4521484375,1.0,Allred Score 3,8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,65.46484375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,40,Lung,70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.8325585937499964,52,3 Point Scale,2+,5thStage IIBT2N1aM0,NO,YES,PositivePositiveNegative,6,9,2011,TCGA-C8-A134-F190843331DC24-D1D5-4123-9F7F-C2F9B5AA76A9Scheduled Follow-up SubmissionNOYESAlive34TUMOR FREENO2122011TCGA-C8-A134-F7082213F00B89-54AB-41DA-BBD2-02C3D6521CCBNONOYESTUMOR FREEAlive383NO932015,1TCGA-E2-A1LS-D20604225992D9-0568-4DD6-BF26-D1C6E065C3DE4112ChemotherapyCyclophosphamideADJUVANTNO17120121TCGA-E2-A1LS-D20606ECEACF6D-18C4-4309-8AA5-54E2B721DAFE4112ChemotherapyTaxotereADJUVANTNO1712012,TCGA-BH-A0BT-R591449C01B233-7499-4880-BDBF-74AE44ED26D6167227External66.4Gy36Primary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,853.0,WHITE,TCGA-A8-A07Z,A8,A07Z,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.4541015625,Allred (Biocare),allred score 2+2 = 4,Left,2.1857421874999905,Sentinel node biopsy alone,axillary ultrasound,Other,Right Breast Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.720703125,0.0078125,allred score = 6,Allred score 8,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,140.7802734375,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.6,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,61,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,YES275Distant MetastasisLung,27,5,2011,TCGA-A8-A07Z-F40836517EFC98-3027-495D-88B5-D50994A0F178NONOYESTUMOR FREEAlive1371NO232013,NOTCGA-A8-A07Z-D378937451614E-5AF0-44F4-8C54-978B7E546B5DHormone TherapyExemestaneYES6122012,TCGA-OL-A5RV-R6525709E25775-2A38-48D7-8505-A90B508ACD39202249External5040cGyRegional siteNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,449.0,WHITE,TCGA-AO-A0JG,AO,A0JG,No,YES,C50.9,8523/3,C50.9,2009.0,TUMOR FREE,YES,19.0,Allred 0 = 0+0,%IHC,Right Lower Outer QuadrantRight,2.451152343749985,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,Excision,"Other, specify",Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Close,Core needle biopsy,stereotactic biopsy,Positive,Positive,Negative,0.0,4.0,allred score = 6,STRONG,<10%,CISH,3+ POSITIVE,34.083984375,Vysis AutoVysion System,Ratio >=2.0,NO,YES,118,"LungOther, specifyleft adrenal gland",90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,52,3 Point Scale,3+,Stage IIIAT2N2aM0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",20,9,2010,TCGA-AO-A0JG-F321270C0FC3F-1AC8-4DF6-A1A2-1DAC1F7A195A449AliveTUMOR FREEYESYES2092010TCGA-AO-A0JG-F15492B37C0A82-E26C-40E9-AC60-492996CD6E5EScheduled Follow-up SubmissionYESYESAlive798TUMOR FREENO2282011,1TCGA-AO-A0JG-D32170da9c957-0267-41cc-9517-ac96284494e91280mg175mg/m24136185ChemotherapyPACLITAXELADJUVANTIVNO20920101TCGA-AO-A0JG-D3216a33b3892-3e6b-4da6-9f8e-d172913aa440440mg60mg/m2480122ChemotherapyDOXORUBICINADJUVANTIVNO20920102TCGA-AO-A0JG-D32186c1bae55-7974-4d4d-b031-2e8c522b0a5d1mg/day197Hormone TherapyARIMIDEXADJUVANTPOYES20920101TCGA-AO-A0JG-D3215b263b426-435b-4224-a98e-8fb254f0a03a4400mg600mg/m2480122ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO2092010,TCGA-AO-A0JG-R32146e8b98b1-8cb9-4b43-b0cd-fcac615f65a2238273EXTERNAL BEAM11400cGy25Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,178.0,WHITE,TCGA-D8-A1JC,D8,A1JC,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,Image Analysis,Image Analysis,Left Upper Outer Quadrant,1.524423828124994,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,breast conserving therapy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Positive,Negative,0.2001953125,4.0,>75%,>75%,90-99%,Dako,Hecep Test TM DAKO,233.9658203125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,4.43,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1,3 Point Scale,1+,7thStage IIIAT2N2aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,29,3,2011,TCGA-D8-A1JC-F208476E9DB5EF-A97B-4101-B6FB-344C19F675D5Scheduled Follow-up SubmissionYESYESAlive480TUMOR FREENO1912012,TCGA-D8-A1JC-D2084804150296-7BAD-4DD4-8B28-C14FCB79BD22240mg60mg/m242487ChemotherapyadriamycinADJUVANTIVNO1912012NOTCGA-D8-A1JC-D65319FECB156F-3FF8-4A4B-B968-896FD08938682487ChemotherapycyclophosphamideNO2292014,TCGA-D8-A1JC-R20849A9A5EA39-2CEF-4A69-A4C6-E072C872237D122147EXTERNAL BEAM4500cGyPrimary Tumor FieldADJUVANTNO1912012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,201.0,WHITE,TCGA-D8-A1XB,D8,A1XB,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,% IHC,%IHC,Right Upper Outer Quadrant,2.4456738281250057,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,Total mastectomy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0,1.0,>75%,>75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,76.892578125,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,33,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.8,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,16,5,2011,TCGA-D8-A1XB-F29436D58EE9E5-C9D2-46A5-B0D5-4DE2A638DE07Scheduled Follow-up SubmissionYESNOAlive552TUMOR FREENO1932012,1TCGA-A2-A0D0-D1851f423013c-d03a-46bf-9df8-4261396bdc994920mg1230mg462125ChemotherapyCytoxanADJUVANTIVNO16920102TCGA-A2-A0D0-D1852e74bfde2-3653-4de9-bff3-80e8d53d150d612mg153mg462125ChemotherapyDocetaxelADJUVANTIVNO1692010,TCGA-D8-A1XB-R294371BE82867-064E-46F8-940F-DFD8A3C0791174111EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,293.0,WHITE,TCGA-BH-A0E6,BH,A0E6,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,H-SCORE 0,H-SCORE 0,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft,1.19,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,0,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Equivocal,0.314453125,0.0,H-SCORE,H-SCORE,<10%,Hercep Test  TM Dako,DAKOHercepTest TM,40.0,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,2.38,"LungOther, specifyleft adrenal gland",<10%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,2.83,3 Point Scale,0,Stage IAT1cN0 (i-)M0,NO,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,11,2010,TCGA-BH-A0E6-F465057382918-996B-4452-A6EC-6520C9719E12293AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0E6-D4647066B8D3A-D2FB-4BC0-B6C5-9D06F6529B73458121ChemotherapyCYTOXANADJUVANTNO181120101TCGA-BH-A0E6-D464685D6AB5B-4057-4C31-B9B0-CF2D73E1CE93458121ChemotherapyTAXOTEREADJUVANTNO18112010,TCGA-BH-A0E6-R46496D6BDE4C-3E32-4C6A-9BBA-B937678BBDE3145191EXTERNAL BEAM5860cGy32Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,326.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A2P5,E2,A2P5,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,25.0,Allred score = 8,Allred score = 8,Left,1.0,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,surgical resection,Infiltrating Lobular Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.712890625,21.0,Allred score = 8,Allred score = 8,10-19%,ACIS,Dako Hecept Test,81.32421875,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,118,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.5,3 Point Scale,2+,7thStage IIICT2N3M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",19,12,2011,TCGA-E2-A2P5-F33516DC06A07E-55FC-4C89-B724-15DA57A30FF9Scheduled Follow-up SubmissionYESYESAlive515TUMOR FREENO2962012TCGA-E2-A2P5-F6857576F6E0C5-BD3F-4008-AA91-1E51F54AF7DFNOYESYESWITH TUMORDead821YES597Distant MetastasisBoneNONOYES26112014,NOTCGA-E2-A2P5-D33517BB98F3FD-3E77-42DE-B60F-4556F6BBDBEF163Hormone TherapyArimidexYES572012,TCGA-E2-A2P5-R335299D9DEECE-7130-4B3B-890A-CCBD6A3A989F98143External60.4Gy28Regional siteNOComplete Response572012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,501.0,WHITE,TCGA-EW-A1P4,EW,A1P4,No,YES,C50.9,8510/3,C50.9,2009.0,TUMOR FREE,YES,3.0,H-Score 295,allred score 4 + 3 = 7,Left Upper Outer Quadrant,2.2310839843749948,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast Reexcision,Other,Excisional biopsy,Medullary Carcinoma,Ductal/Metaplastic,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.0,0.0,Strong,Allred Score 6,<10%,CISH,Dako Hercept test,92.791015625,Vysis AutoVysion System,Path Vysion HER2 DNA Probe Kit,NO,YES,54,LungBone,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,21,3 Point Scale,2+,6thStage IIAT2N0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,5,2011,TCGA-EW-A1P4-F2968445EAB7C6-BFBF-48EC-B18C-19642B61C70EScheduled Follow-up SubmissionYESYESAlive907TUMOR FREENO2632012,TCTCGA-EW-A1P4-D2968779E0A6AE-A364-45A1-9ED5-E0FBDD00DAA975mg/m2473144ChemotherapyDocetaxelADJUVANTIVNO2632012TCTCGA-EW-A1P4-D29689E8073733-F67A-40F9-88DA-22013C8ED597600mg/m2473144ChemotherapyCyclophosphamideADJUVANTIVNO2632012,"TCGA-EW-A1P4-R296851B09106F-D19A-436A-AE7E-6DE51BA1A9B4208263EXTERNAL BEAM15,900cGyPrimary Tumor FieldADJUVANTNO12632012"
TCGAFPPP,Breast,No,MALE,Alive,0.0,1124.0,WHITE,TCGA-A8-A085,A8,A085,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,15.591796875,H-SCORE 0,H-Score 15,Left,5.8220214843749964,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.71875,1.369140625,Allred Score 4,230,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,127.4111328125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,66,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,60,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A085-F408399130CB27-2E3C-4E79-B685-4C2367ADFD41NONOYESTUMOR FREEAlive1124NO232013,NOTCGA-A8-A085-D37772DA0D6313-0886-4A80-817A-6FDF72104A27394Hormone TherapyTamoxifenn/aYES6122012,TCGA-E2-A9RU-R6075597D7F63A-20AB-4935-8123-943CFF3853D200External50.4GyRegional siteNOComplete Response1662014TCGA-E2-A9RU-R607564068FAFC-865C-49DB-8D79-51CEA29F727F00External10Gy5Primary Tumor FieldNOComplete Response1662014
TCGAFPPP,Breast,No,FEMALE,Dead,1759.0,805.40625,WHITE,TCGA-BH-A208,BH,A208,No,YES,C50.9,8500/3,C50.9,1995.0,TUMOR FREE,YES,15.0,Allred score 7 (outside facility),Allred score 7 per outside facility report,Left,1.9984863281250107,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.591796875,3.0,allred score = 8,205,10-19%,Hercep Test  TM Dako,Dako Hercept test,86.751953125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,1.1,LungBone,70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,3.3,3 Point Scale,1+,5thStage IIBT2N1bM0,NO,NO,PositivePositiveNegativeNegative,8,9,2011,TCGA-E9-A1NI-F2921325652B21-898C-410A-A0C0-2CD806632066Scheduled Follow-up SubmissionNOYESAlive300TUMOR FREENO1232012TCGA-E9-A1NI-F520564876BC0D-F943-41B2-8EE0-FAF3D05A3FCEYES27112013,3TCGA-E2-A158-D18963B94489C2-71D2-40FE-86DD-A3E999BF3373mg1mg450ChemotherapyarimidexADJUVANTPOYES81120111TCGA-E2-A158-D18958A3051694-896A-4A9D-9178-CA248163F114228ChemotherapydoxorubicinADJUVANTNO81120111TCGA-E2-A158-D189608C16F7B2-EFBC-4B7E-AA40-8A152D0E4F0F228ChemotherapycytoxanADJUVANTNO81120112TCGA-E2-A158-D1896167C4C12D-8CB3-4ED8-8913-666D05A6057D228ChemotherapyTaxaneADJUVANTNO8112011,TCGA-E2-A15M-R1885585069D51-475A-4210-8DA5-3C2AF8E51324140211EXTERNAL BEAM6600cGyPrimary Tumor FieldADJUVANTNO115112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1173.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A2FS,EW,A2FS,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,8.0,H-SCORE 190,CAP scoring guideline 2010,Left Upper Outer Quadrant,3.272128906250011,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,right segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.388671875,1.0,allred score = 7,80,<10%,CISH,Dako Hercept test,86.064453125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,54,LungBone,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,441,3 Point Scale,1+,6thStage IIBT2N1miMX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",12,10,2011,TCGA-EW-A2FS-F322870057B553-0157-425E-9511-8FA81FBAC25AScheduled Follow-up SubmissionYESYESAlive1422TUMOR FREENO2352012TCGA-EW-A2FS-F4206107000F6B-F69E-4B6B-AB76-A744BB203540NOYESYESTUMOR FREEAlive1604NO1042013,NOTCGA-EW-A2FS-D32290E4D5F98B-9912-459A-AC81-4DEAF3FBE3C1343Hormone TherapyTamoxifenYES2352012NOTCGA-EW-A2FS-D322919720934C-6807-40ED-95F9-E25B66C9BF521401166Hormone TherapyGoserelinNOStable Disease2352012YESTCGA-EW-A2FS-D322925752A032-5B94-483E-B22A-0927779121F1164227ChemotherapyDoxorubicinNO2352012YESTCGA-EW-A2FS-D32293886177D2-3C39-40AC-B112-79B370B885AA164227ChemotherapyCyclophosphamideNO2352012YESTCGA-EW-A2FS-D322940CC44FB4-CCFA-4BF7-A1E7-281CA65EFE4A164318ChemotherapyBevacizumabNO2352012YESTCGA-EW-A2FS-D32295E518AF83-5C33-4071-BCE1-1E37F303A078248332ChemotherapyPaclitaxelNO2352012,TCGA-EW-A2FS-R322880AB7DA2D-C868-42CA-9C7C-A4C0DAD3EC9E394439EXTERNAL BEAM6400cGyPrimary Tumor FieldADJUVANTNO12352012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3019.0,BLACK OR AFRICAN AMERICAN,TCGA-AO-A125,AO,A125,No,YES,C50.9,8050/3,C50.9,2002.0,TUMOR FREE,YES,5.0,Allred 0 = 0+0,%IHC,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft,1.0,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast Reexcision,Other,Wide Local Excision,"Other, specify",Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,allred score = 6,STRONG,<10%,CISH,3+ Positive,46.671875,Vysis AutoVysion System,>=2.0 Positive,NO,YES,40,"Other, specifySkin",50-59%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1,3 Point Scale,4+,5thStage IIAT2N0 (i-)M0,NO,NO,YES766Distant MetastasisBoneNOYESNO,7,12,2010,TCGA-AO-A125-F58743C85C98F-2012-40C5-A235-01C28ED1A9543019AliveTUMOR FREENOYES7122010TCGA-AO-A125-F19398EB7A61A5-3724-4055-9588-907D177D46E0Scheduled Follow-up SubmissionNOYESAlive3456TUMOR FREENO12122011,1TCGA-AO-A125-D5936aa4b5228-8d3d-41fc-8036-e1dd449ea17525mg/day7992535Hormone TherapyAromasin (Exemestane)ADJUVANTPONO10120111TCGA-AO-A125-D59353c07a95a-8689-4e1c-8302-8af9978b4c0d20mg/day129799Hormone TherapyTamoxifenADJUVANTPONO1012011,TCGA-E2-A1IE-R1997203BCA171-2C59-4E91-93E2-0BCEBAD1E9F7200251EXTERNAL BEAM6080cGy33Regional siteADJUVANTNO121122011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,182.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A2KD,A7,A2KD,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,H-SCORE 300,CAP scoring guideline 2010,Right,1.2029785156249972,No axillary staging,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,partial mastectomy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Positive,0.0,8.0,Allred Score 3,80,10-19%,CISH,CAP SCORING GUIDELINE 2010,105.3154296875,Vysis AutoVysion System,PathVysion HER-2 DNA probe kit.,YES,NO,4.43,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,60,3 Point Scale,3+,7thStage IIIAT2N2aMX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,10,2011,TCGA-A7-A2KD-F3112303DDE331-432A-47B9-9D76-DF24C97ECD3BScheduled Follow-up SubmissionYESYESAlive391TUMOR FREENO2442012TCGA-A7-A2KD-F397830D8A8821-9994-454A-BB39-BADC6341A20ENOYESYESTUMOR FREEAlive679NO122013,1TCGA-A7-A2KD-D31129D27EB374-1499-4A17-9A6F-D6EF17DF32D04110mg1370mg35797ChemotherapyCytoxanADJUVANTIVNO24420121TCGA-A7-A2KD-D31143A86965D9-33B4-40A5-B803-EBD8F3205AA31020mg170mg657161ChemotherapyTaxotereADJUVANTIVNO24420121TCGA-A7-A2KD-D31144037E9933-2221-4B0E-B8CA-1397B14B65232430mg810mg3118161ChemotherapyCarboplatinADJUVANTIVNO2442012NOTCGA-A7-A2KD-D32490A17F619D-81A6-4A7B-BEB1-20FA1C82884357435Targeted Molecular therapyHerceptinNOComplete Response3052012,TCGA-A7-A2KD-R3115889DD7D0D-FD33-4ABE-AEBB-2355F247846D196235EXTERNAL BEAM5040cGy28Regional siteADJUVANTNO12442012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,713.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A0DG,BH,A0DG,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,3.0,Allred score = 8,Allred score 7 per outside facility report,Right Upper Outer Quadrant,2.1231054687500066,Sentinel node biopsy alone,SLN and non-SLN biopsy,Other,surgical resection,Modified radical mastectomy,Total mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.2607421875,0.0,Allred Score 5,80,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,245.67578125,Vysis AutoVysion System,Ratio >=2.0,NO,YES,33,LungBone,<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,71,3 Point Scale,1+,6thStage IIAT2N0M0,NO,NO,PositivePositiveNegativeNegative1.09,2,8,2011,TCGA-BH-A0DG-F636588C3A54AE-5BD9-4011-ACE6-99D5A1D02FE2NOYESYESTUMOR FREEAlive2041NO1482014,NOTCGA-BH-A0DG-D636599B494472-AB4F-4900-8EA9-FBFB49E1C6A948166ChemotherapyTaxotereNOComplete Response1482014NOTCGA-BH-A0DG-D636603BDFD427-B336-4AB3-A362-7E6587C297E748166ChemotherapyAdriamycinNOComplete Response1482014NOTCGA-BH-A0DG-D63661B7B05AD1-68C3-489B-A7EB-F57176297F1B48166ChemotherapyCytoxanNOComplete Response1482014,TCGA-BH-A0DG-R6366216BBF746-9D23-4F90-94B5-7C620BC39CFA166181External6000cGy30Primary Tumor FieldNOComplete Response1482014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,19.0,WHITE,TCGA-E9-A3HO,E9,A3HO,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,10.0,Allred (Biocare),allred score 5+3+8,Left Upper Outer Quadrant,1.4302441406249908,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,Modified Radical Masectomy,Infiltrating Lobular Carcinoma,Invasive tubulolobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Modified Radical Masectomy,Negative,Positive,Equivocal,0.0380859375,0.0,240 H,270 H,10-19%,Dako,Venten,230.3291015625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.38,LungBone,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1,3 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,YES,NO,20,2,2012,TCGA-E9-A3HO-F34119790B0540-C4A2-480F-BC85-F2021B89FE54Scheduled Follow-up SubmissionNOYESAlive337TUMOR FREENO3072012TCGA-E9-A3HO-F402892F7EA195-DA67-4B9A-B5E2-F2E1E7723756NONOYESTUMOR FREEAlive793NO1522013TCGA-E9-A3HO-F61875A4391DDE-1085-446A-9A5D-93492906AD7DNONOYESTUMOR FREEAlive1158NO972014,NOTCGA-E9-A3HO-D34120D0C4B016-5BD8-4E67-A168-03CBC0840AD82626ChemotherapyCyclophosphamideNOComplete Response3072012NOTCGA-E9-A3HO-D34121E5BBB372-92D7-41A2-8819-BFEBB1F526B32626Chemotherapy5-FluorouracilNOComplete Response3072012NOTCGA-E9-A3HO-D34122B87D3CDD-0D31-4353-9E68-879DB3A804D42626ChemotherapyMethotrexateNOComplete Response3072012NOTCGA-E9-A3HO-D341236B7696A0-95DC-48FD-BC5E-F5D77A8E683E28Hormone TherapyTamoxifenYES3072012NOTCGA-E9-A3HO-D40290B80F3DF7-5616-4DEB-B5B1-9AFD2E7A34EA313337Hormone TherapyLeuprorelinNOComplete Response1522013NOTCGA-E9-A3HO-D40291FC15DB60-9371-4C3A-8C2C-34D254C7B2646164Hormone TherapyZoladexNOComplete Response1522013,TCGA-BH-A0BS-R633978727D0E4-840A-4524-962B-7AD1986FB858245302External6040cGy25Primary Tumor FieldNOComplete Response782014TCGA-BH-A0BS-R63398FB9FF030-2089-4C98-BB5C-D04016148325245302External46.8Gy26Regional siteNOComplete Response782014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1138.0,WHITE,TCGA-AR-A0TS,AR,A0TS,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,16.0,image cytometry,IHC,Right,1.3826660156249937,Sentinel lymph node biopsy plus axillary dissection,Pateys surgery,Lumpectomy,Right Breast Reexcision,Other,Excisional biopsy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.0625,2.0,10-75%,Allred score 8,30-39%,Dako,DAKOHercepTest TM,113.5927734375,Vysis AutoVysion System,RATIO > = 2.0,NO,YES,2.38,LungBone,80-89%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.8,3 Point Scale,0,6thStage IIBT2N1M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,3,2011,TCGA-AR-A0TS-F18644DDE2E871-EE01-4B9E-B31D-D5BB5687213AScheduled Follow-up SubmissionYESYESAlive1138NO12122011TCGA-AR-A0TS-F495164ABA8613-33A6-4918-9B4F-8315C2EDA06AYESYESTUMOR FREEAlive2275NO2102013TCGA-AR-A0TS-F7173094425F1E-C3C6-4EF7-B1CD-AA1FBAF14FBENOYESYESTUMOR FREEAlive2558NO3032015,1TCGA-AR-A0TS-D191896DDD0B18-B972-42FE-81B7-F4D84C27F23E460mg60mg/m2461100ChemotherapyDoxorubicinADJUVANTIVNO121220111TCGA-AR-A0TS-D191943B977891-44ED-474F-973E-0BB631AA37E41320mg175mg/m24114156ChemotherapyPaclitaxelADJUVANTIVNO121220111TCGA-AR-A0TS-D19193674B9434-AFDB-4831-BF85-31EAEBAB94D14600mg600mg/m2461100ChemotherapyCytoxanADJUVANTIVNO12122011,TCGA-AR-A0TS-R18646B5DA5037-58AA-4B53-B86A-0C254CBEECE0185228EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO112122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,-7.0,WHITE,TCGA-E9-A1NI,E9,A1NI,No,YES,C50.9,8522/3,C50.9,2011.0,TUMOR FREE,YES,4.0,H-SCORE 190,H-Score 0,Left Upper Outer Quadrant,3.6229492187499854,Axillary lymph node dissection alone,axillary ultrasound,Other,Right Breast Reexcision,Other,Mastectomy,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.0,0.0,8,120,90-99%,Hercep Test  TM Dako,Dako Hercept test,160.826171875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,33,LungBone,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,131,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,23,6,2011,TCGA-E9-A1NI-F2921325652B21-898C-410A-A0C0-2CD806632066Scheduled Follow-up SubmissionNOYESAlive300TUMOR FREENO1232012TCGA-E9-A1NI-F520564876BC0D-F943-41B2-8EE0-FAF3D05A3FCEYES27112013,NOTCGA-E9-A1NI-D350229DFDBBC7-631F-4C94-A923-948195F59A36080ChemotherapyDoxorubicinNOComplete Response1392012NOTCGA-E9-A1NI-D35023FD81C1FD-32D3-41C2-91E3-B62B8B916AE7080ChemotherapyCyclophosphaneNOComplete Response1392012NOTCGA-E9-A1NI-D35027216067BB-58F6-4991-9A18-2FCE36C80910080Chemotherapy5-FluorouracilNOComplete Response1392012NOTCGA-E9-A1NI-D35028D4990B88-4B53-4E5A-A245-788D6F0CB83186Hormone TherapyTamoxifenYES1392012,TCGA-E2-A15M-R1885585069D51-475A-4210-8DA5-3C2AF8E51324140211EXTERNAL BEAM6600cGyPrimary Tumor FieldADJUVANTNO115112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,258.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A25B,A2,A25B,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,8.0,H-SCORE 255,H-Score 160,Left Upper Outer Quadrant,0.93,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Right Breast Reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Close,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.01171875,2.0,Intensity=Strong,80,90-99%,Hercep Test  TM Dako,Dako Hercept test,81.9970703125,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,YES,NO,2.7,Lung,90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.85,3 Point Scale,1+,7thStage IIBT2N1M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",15,7,2011,TCGA-A2-A25B-F3126746B9BB2E-82B1-4C6A-B19F-E791DEBBF004Scheduled Follow-up SubmissionYESYESAlive496TUMOR FREENO1642012TCGA-A2-A25B-F7067981C18AFE-BEA7-4D08-875B-339FFEA2E95DNOYESYESWITH TUMORAlive1291YES1290Distant MetastasisBoneNOPositive232015,1TCGA-A2-A25B-D145025CA1AA16-D037-4F6E-8F7B-46F0BFB54F17745mg148-150mg564148ChemotherapyTaxotereADJUVANTIVNO20620113TCGA-A2-A25B-D145054DB7724B-1C49-4082-A477-83CAA3AD9A6D4965mg985-1000mg564148ChemotherapyCytoxanADJUVANTIVNO20620112TCGA-A2-A25B-D14504E1774708-5D16-4022-9B47-09313FA0BF3F498mg99-100mg564148ChemotherapyAdriamycinADJUVANTIVNO20620114TCGA-A2-A25B-D3126405A1B7D2-5DCF-454F-9FE4-33CA8289D1B2mg20mg/day293Hormone TherapyTamoxifenADJUVANTPOYES1742012,TCGA-A2-A25B-R1450645D50414-CE7E-456B-BB0F-D49E70BB491D188ADJUVANTYES11572011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1561.0,ASIAN,TCGA-BH-A0HW,BH,A0HW,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,2.0,H-SCORE 136,H-Score 290,Left Lower Inner QuadrantLeft Lower Outer QuadrantLeft,1.6,Sentinel node biopsy alone,Pateys surgery,Other,Right Breast Reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.9755859375,0.0,10-75%,H-Score,<10%,Hercep Test  TM Dako,DAKOHercepTest TM,40.7451171875,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,66,"Other, specifySkin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,816,3 Point Scale,0,Stage IAT1cN0 (i-)M0,NO,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,11,2010,TCGA-BH-A0HW-F4827D8AD2E6A-F00C-40B6-A939-5FD2230FABA91561AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0HW-D48192F384DC7-D076-4C3E-AD10-C21C91BE07A41mg/day223Hormone TherapyArimidexADJUVANTPOYES171120101TCGA-BH-A0HW-D48243AA2DD0F-A104-4DAD-91CC-8DCC9A958CAD356mg90mg472135ChemotherapyDoxorubicinADJUVANTIVNO181120101TCGA-BH-A0HW-D4822DA8527E8-79FA-4F17-8B5C-FA1FA0A3E3773564mg900mg472135ChemotherapyCyclophosphamideADJUVANTIVNO18112010,TCGA-BH-A0HW-R48264853EDD3-68CE-4693-B548-7B20BF2B0E2F166212EXTERNAL BEAM6240cGy34Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1149.0,WHITE,TCGA-BH-A0H3,BH,A0H3,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,H-SCORE 255,Allred score 7 per outside facility report,Left Upper Outer Quadrant,1.6099902343750063,Sentinel node biopsy alone,axillary ultrasound,Other,Right Breast Reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.3310546875,0.0,Allred score 5,STRONG,10-19%,Hercep Test  TM Dako,Dako Hercept test,86.587890625,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,1.45,LungBone,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,125,3 Point Scale,1+,6thStage IT1cN0M0,NO,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,8,2011,TCGA-BH-A0H3-F5859922CC69F7-3445-4524-A216-80F457933E1ANOYESNOTUMOR FREEAlive1928NO1542014,TCGA-E9-A1RE-D3062988021F1F-6F05-49C2-974E-C81F92FBF7E1100mg100mg150145ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RE-D306257DC35BFA-9C80-4F0C-91E8-F45010BFF3A16000mg2000mg350145Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RE-D30626BC07A0C3-99D7-49FA-8CDA-8BDC0A5B3CFE1500mg1500mg150145Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RE-D306281955E286-AE41-4016-95CE-453A407709C080mg80mg150145ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RE-D30627E75E0ABA-5130-4FBE-B9D7-44081F1FF713120mg60mg250145ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RE-D30630AB669FF9-A215-4611-851F-9CF3F1DB948C6400mg1600mg450145ChemotherapyCyclophosphamideADJUVANTIVNO1342012TCGA-E9-A1RE-D306317E328C05-236F-4222-82CC-33615BDF912420mg/day39Hormone TherapyTamoxifenADJUVANTPOYES1342012,TCGA-BH-A0H3-R58600C0B72A02-DD39-4927-8682-60DBA02D627977115External5040cGy28Regional siteNOComplete Response1542014TCGA-BH-A0H3-R58601091A7641-7710-4553-8542-90FDEBEFA4AF118126External14Gy7Primary Tumor FieldNOComplete Response1542014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,229.0,WHITE,TCGA-OL-A6VQ,OL,A6VQ,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,1.0,Allred 0 = 0+0,CAP SCORING GUIDELINE 2010,Right,1.05,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Mastectomy NOS,Segmental Mastectomy,Infiltrating Lobular Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Positive,Tumor resection,SKIN BIOPSY,Negative,Positive,Equivocal,0.0517578125,0.0,allred score = 4,allred score = 7,20-29%,CISH,Venten,146.5751953125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.13,Lung,90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.0,3 Point Scale,2+,7thStage IIAT2N0MX,YES,NO,NO,20,2,2014,TCGA-OL-A6VQ-F593667EB828D6-D22B-42FC-B51A-FE00B3181056NONONOTUMOR FREEAlive600NO1052014,TCGA-D8-A141-D20735A15AAA0F-A203-4D17-AC59-C7871CF733F8405.6mg/m2101.4mg/m2450113ChemotherapydoxorubicineADJUVANTIVNO1412012NOTCGA-D8-A141-D64903F8D4FFC9-CAC1-4BF7-8524-0962257D22E050113ChemotherapycyclophosphamideNO1592014NOTCGA-D8-A141-D64904885E2338-5CEA-43F7-A449-B6C3AB63616550113Hormone TherapytamoxifenNO1592014,TCGA-E2-A572-R482486AF2B719-A8B2-4E95-BAF5-C4FAFA2FF01A19626360.4Gy28Primary Tumor FieldNOComplete Response1092013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,40.0,WHITE,TCGA-AC-A8OR,AC,A8OR,No,YES,C50.9,8480/3,C50.9,2013.0,TUMOR FREE,YES,2.0,Allred score 7 (outside facility),allred score 5+3+8,Left,1.2669042968749955,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node excision and biopsy,Mucinous Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,Allred Score 6,allred score = 0,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,276.923828125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,54,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.1,3 Point Scale,2+,7thStage IAT1cN0 (i-)MX,YES,YES,NO,26,2,2014,TCGA-BH-A5J0-F6366410B16ACD-2E32-4414-99E9-3838D5692CFBNONONOTUMOR FREEAlive715NO1482014,TCGA-D8-A141-D20735A15AAA0F-A203-4D17-AC59-C7871CF733F8405.6mg/m2101.4mg/m2450113ChemotherapydoxorubicineADJUVANTIVNO1412012NOTCGA-D8-A141-D64903F8D4FFC9-CAC1-4BF7-8524-0962257D22E050113ChemotherapycyclophosphamideNO1592014NOTCGA-D8-A141-D64904885E2338-5CEA-43F7-A449-B6C3AB63616550113Hormone TherapytamoxifenNO1592014,TCGA-BH-A0DP-R453761E05A64-548D-49A2-82C0-BD15A10024CD136180EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,34.0,WHITE,TCGA-AC-A3QQ,AC,A3QQ,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,5.0,H-SCORE 190,Allred score 2+2 = 4,Right,1.2167773437499976,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Right Breast Reexcision,Modified radical mastectomy,Nipple Sparing Total Mastectomy,Infiltrating Lobular Carcinoma,lobular/ductal,Peri (6-12 months since last menstrual period),Positive,YES,3 Point Scale,3+,3+,Negative,Close,Core needle biopsy,"Biopsy, NOS",Negative,Positive,Positive,0.0,0.0,8,8,10-19%,ACIS,Hercep Test  TM Dako,174.5390625,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,YES,NO,2.13,"LungOther, specifyleft adrenal gland",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,5,3 Point Scale,3+,7thStage IAT1cN0 (i-)MX,YES,YES,NO,3,12,2012,TCGA-AC-A3QQ-F66024FC62B467-765C-4836-B773-C315DE7A3049NONONOTUMOR FREEAlive734NO1102014,1TCGA-BH-A0HW-D48192F384DC7-D076-4C3E-AD10-C21C91BE07A41mg/day223Hormone TherapyArimidexADJUVANTPOYES171120101TCGA-BH-A0HW-D48243AA2DD0F-A104-4DAD-91CC-8DCC9A958CAD356mg90mg472135ChemotherapyDoxorubicinADJUVANTIVNO181120101TCGA-BH-A0HW-D4822DA8527E8-79FA-4F17-8B5C-FA1FA0A3E3773564mg900mg472135ChemotherapyCyclophosphamideADJUVANTIVNO18112010,TCGA-LL-A5YM-R5754390327544-390D-4E11-88EB-FCDB0ABD67FA307339External50Gy20Local RecurrenceNOPartial Response1432014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,225.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A5J0,BH,A5J0,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,5.0,No value Given,Allred score 7 per outside facility report,Left,1.8995605468750028,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Right Breast Reexcision,Other,L Total Mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.8466796875,0.0,Two-tier,180,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,200.0556640625,Vysis AutoVysion System,>= 2.0 Positive,YES,NO,50,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,816,3 Point Scale,2+,7thStage IAT1cN0M0,NO,NO,NO,13,2,2014,TCGA-BH-A5J0-F6366410B16ACD-2E32-4414-99E9-3838D5692CFBNONONOTUMOR FREEAlive715NO1482014,NOTCGA-A8-A09M-D37785C1C79A95-B5D8-45E8-8FE0-B54E7E43563431184ChemotherapyPaclitaxeln/aNOComplete Response6122012NOTCGA-A8-A09M-D3778609FBDD53-0E66-4D9E-AACA-888BC15FA3CF276Hormone TherapyExemestanen/aYES6122012,TCGA-E2-A572-R482486AF2B719-A8B2-4E95-BAF5-C4FAFA2FF01A19626360.4Gy28Primary Tumor FieldNOComplete Response1092013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,126.0,WHITE,TCGA-D8-A27L,D8,A27L,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,16.0,manual counting,manual counting,Right Upper Inner Quadrant,1.208085937499998,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0478515625,2.0,>75%,>75%,90-99%,Hercep Test  TM Dako,Venten,65.6455078125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,1.1,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.8,3 Point Scale,2+,7thStage IIIAT1cN2aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,18,7,2011,TCGA-D8-A27L-F29590F7C1DB5B-81CE-49D1-89AE-3C672EAE8635Scheduled Follow-up SubmissionNOYESAlive499TUMOR FREENO2662012,TCGA-D8-A27L-D2959153DEB285-A9E3-4877-A72F-64441D85E4F9240+2400mg60+600mg/m24100238Chemotherapyadriamycin+cuclophosphamideADJUVANTIVNO2632012,TCGA-AR-A2LE-R3719056389EF6-0220-40E9-B0B0-1CAB2EDF58DB4284External6000cGy30Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,369.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A4SF,A7,A4SF,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,2.0,Allred score = 8,Allred score 0+0=0,Right,1.3325976562499893,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,3+,Positive,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,0.0,0.0,Allred score 7 per outside facility report,allred score = 7,90-99%,ACIS,CAP scoring guideline 2010,149.05859375,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,2.6,Lung,90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,60,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,NO,25,2,2013,TCGA-A7-A4SF-F49721FBC837B9-2100-498A-9BB9-BAEFE1F2EEB5NOYESYESTUMOR FREEAlive545NO9102013,NOTCGA-A7-A4SF-D40583308EA6ED-2B83-4B5B-95E0-CBDEF48D790989202ChemotherapyCarboplatinNOComplete Response2522013NOTCGA-A7-A4SF-D4058468535884-BA16-4956-99F0-FB17F5DE630D89202ChemotherapyDocetaxelNOComplete Response2522013NOTCGA-A7-A4SF-D405851A67FA24-FD67-47D8-A0B6-75D33DABFB3A89453Targeted Molecular therapyTrastuzumabNOComplete Response2522013NOTCGA-A7-A4SF-D405860F0BE62E-9086-4B0B-9D8A-0D6DE8B921E5306Hormone TherapyAnastrozoleYES2522013,TCGA-A7-A4SF-R40587305434B5-E683-4AEB-AA5E-B6BF6E111BA7232279External6100cGy33Primary Tumor FieldNOComplete Response2522013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,326.0,WHITE,TCGA-A2-A0YJ,A2,A0YJ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,18.0,ER Positive H-Score 95,allred score 4 + 3 = 7,Left,2.2537011718750017,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,L Total Mastectomy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,1+,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.2265625,5.0,Allred score 5,Moderate,10-19%,ACIS,Venten,93.283203125,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,1.57,LungBoneLiver,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,105,3 Point Scale,0,Stage IIIAT3N2aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,12,2010,"TCGA-A2-A0YJ-F16756717318E8-D1B6-4D8D-8FFC-BBA23E110C17Scheduled Follow-up SubmissionYESYESAlive566WITH TUMORYES559Distant MetastasisOther, specifyLeft Cervical Lymph NodeYES559NONONegativeNegativeNegative<10%1+1692011",2TCGA-A2-A0YJ-D582154cf26b3-3b56-440e-9d2e-6c4df631992b646150ChemotherapyCytoxanADJUVANTIVNO281220101TCGA-A2-A0YJ-D58203d201259-de17-489f-89f8-f605fa43fe37646150ChemotherapyTaxotereADJUVANTIVNO28122010,TCGA-A2-A0YJ-R581999d00471-4902-455d-8eaf-2b4ee63fb7dc180223EXTERNAL BEAM6000cGyPrimary Tumor FieldADJUVANTNO128122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,113.0,WHITE,TCGA-D8-A141,D8,A141,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,15.0,manual counting,manual counting,Right,1.1859960937499925,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,Surgical resection,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Indeterminate (neither Pre or Postmenopausal),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.2431640625,1.0,>75%,>75%,90-99%,Hercep Test  TM Dako,Venten,423.7138671875,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,YES,NO,2.6,"Other, specifySkin",70-79%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.8,3 Point Scale,2+,7thT1cN1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,2,2011,TCGA-D8-A141-F207343A9C552D-4EB1-455F-A421-E364643E5041Scheduled Follow-up SubmissionNOYESAlive626TUMOR FREENO1412012,TCGA-D8-A141-D20735A15AAA0F-A203-4D17-AC59-C7871CF733F8405.6mg/m2101.4mg/m2450113ChemotherapydoxorubicineADJUVANTIVNO1412012NOTCGA-D8-A141-D64903F8D4FFC9-CAC1-4BF7-8524-0962257D22E050113ChemotherapycyclophosphamideNO1592014NOTCGA-D8-A141-D64904885E2338-5CEA-43F7-A449-B6C3AB63616550113Hormone TherapytamoxifenNO1592014,TCGA-A8-A09M-R381625ACACE6F-008C-433C-9F3C-EED2853291D8214276ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,36.0,WHITE,TCGA-AC-A6IV,AC,A6IV,No,YES,C50.9,8524/3,C50.9,2012.0,TUMOR FREE,YES,1.0,Allred score 7 (outside facility),Allred score 2+2 = 4,Right,1.175341796874998,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast Reexcision,Other,surgical resection,Infiltrating Lobular Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,1.0,1.0,8,205,10-19%,ACIS,CAP SCORING GUIDELINE 2010,88.2900390625,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,YES,NO,74,Lung,90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,3 Point Scale,2+,7thStage IIBT2N1MX,YES,YES,NO,19,9,2013,TCGA-AC-A6IV-F6602341FE4D10-71F7-4A3D-99B6-8759A24B835ANOYESYESTUMOR FREEAlive568NO1102014,2TCGA-A2-A0YJ-D582154cf26b3-3b56-440e-9d2e-6c4df631992b646150ChemotherapyCytoxanADJUVANTIVNO281220101TCGA-A2-A0YJ-D58203d201259-de17-489f-89f8-f605fa43fe37646150ChemotherapyTaxotereADJUVANTIVNO28122010,TCGA-LL-A5YM-R5754390327544-390D-4E11-88EB-FCDB0ABD67FA307339External50Gy20Local RecurrenceNOPartial Response1432014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1082.0,ASIAN,TCGA-EW-A1IX,EW,A1IX,No,YES,C50.9,8524/3,C50.9,2008.0,TUMOR FREE,YES,27.0,H-SCORE 0,Allred score 5+3 = 8,Right Upper Outer Quadrant,1.1501953124999944,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node and non-sentinel lymph node biopsy,Other,surgical resection,Modified radical mastectomy,total mastectomy,"Other, specify",Invasive tubulolobular carcinoma,Peri (6-12 months since last menstrual period),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,1.0,1.0,Allred score = 7,205,<10%,CISH,Hercep Test  TM Dako,125.5185546875,Vysis AutoVysion System,Ratio >=2.0,NO,YES,69,"LungOther, specifyleft adrenal gland",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.23,3 Point Scale,3+,6thStage IIAT1bN1aMX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",10,6,2011,TCGA-EW-A1IX-F215420ACED877-3F0E-4050-A7E1-6CCFE9AEBEA3Scheduled Follow-up SubmissionNOYESAlive1208TUMOR FREENO622012,TCGA-EW-A1IX-D216099F1CC0D6-E9B7-4875-9B34-DC146AFDC9822.5mg/day871Hormone TherapyFemaraADJUVANTPOYES1622012,TCGA-E2-A572-R482486AF2B719-A8B2-4E95-BAF5-C4FAFA2FF01A19626360.4Gy28Primary Tumor FieldNOComplete Response1092013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,545.0,WHITE,TCGA-A2-A0EV,A2,A0EV,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,6.0,No value Given,Allred 5 = 2+3,Left,1.4,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,Allred score = 7,80,<10%,ACIS,Hercep Test  TM Dako,78.685546875,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,4,LungBoneLiver,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,71,3 Point Scale,1+,6thStage IAT1cN0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,8,2010,TCGA-A2-A0EV-F13712785B386C-75E3-49AA-A871-A8DD80C39466Scheduled Follow-up SubmissionNONOAlive968TUMOR FREENO1062011,2TCGA-AO-A12D-D59749e959e52-721e-4948-8ebb-0b025e5cf4a56mg/kg17170503Targeted Molecular therapyTrastuzumabADJUVANTIVNO10120111TCGA-AO-A12D-D597367744251-ab75-4c28-8782-6df6f473f4ed1728mg200mg/m24149212ChemotherapyAlbumin-Bound PaclitaxelADJUVANTIVNO10120111TCGA-AO-A12D-D5971cc8a523b-e65b-4413-95b9-ee3bb5e88e413984mg600mg/m2465128ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A12D-D59726c48065e-2a03-4fe6-a4d7-d5ceaba2cc5f400mg60mg/m2465128ChemotherapyDoxorubicinADJUVANTIVNO1012011,TCGA-D8-A1X9-R29433104383D3-283E-4D53-AAA0-4A610BB320E7320350EXTERNAL BEAM4500cGy20Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,MALE,Alive,0.0,1295.0,WHITE,TCGA-AR-A1AV,AR,A1AV,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,25.0,image cytometry,IHC,Left,5.6235449218749824,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,surgical resection,Other,Excisional biopsy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.037109375,1.0,Allred score = 0,H-Score,90-99%,Hercep Test  TM Dako,Dako Hercept test,109.6640625,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,2.6,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.1,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",14,6,2011,TCGA-AR-A1AV-F221002DF4BBA4-58D6-4FCE-A872-7337B1BC83ACScheduled Follow-up SubmissionYESYESAlive1295NO2922012TCGA-AR-A1AV-F4947512EE7C6D-9BA2-461A-BD10-888FCEFE23B5NOYESYESTUMOR FREEAlive1864NO2102013,2TCGA-AR-A1AV-D22108828B60C5-30E1-454A-BF7D-B31D23ED13CB20mg/day175Hormone TherapyTamoxifenADJUVANTPOYES29220121TCGA-AR-A1AV-D221052A341311-F186-4BB2-9C3B-77EA76B9B7AE5080mg600mg/m2450105ChemotherapyCytoxanADJUVANTIVNO29220121TCGA-AR-A1AV-D22104E8AA4773-70EB-4FBD-AE3E-8881E5D8E348505mg60mg/m2450105ChemotherapyDoxorubicinADJUVANTIVNO29220121TCGA-AR-A1AV-D221070635BAEF-1285-40DC-820E-8805EC2E3F111450mg175mg/m24126170ChemotherapyPaclitaxelADJUVANTIVNO2922012,TCGA-AR-A1AV-R22101CE98B1FF-7DB1-4336-AA1A-8BB3B2510D22194239EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO12922012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3941.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0WZ,B6,A0WZ,No,YES,C50.9,8500/3,C50.9,1996.0,TUMOR FREE,YES,21.0,Image Analysis,Image Analysis,Right Upper Inner QuadrantRight,1.385703125000003,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Other,Right Breast Reexcision,Modified radical mastectomy,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,4+,3+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Equivocal,0.1083984375,11.0,Allred score 0,moderate,10-19%,ACIS,dextran coated charcoal,47.060546875,Vysis AutoVysion System,Ratio >=2.0,NO,YES,33,"LungOther, specifyleft adrenal gland",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.5,4 Point Scale,1+,4thStage IIT2N1bM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",14,12,2010,TCGA-B6-A0WZ-F15735E49207CE-142F-4C8D-8EC5-94BD6AE7B23DScheduled Follow-up SubmissionYESYESAlive3941TUMOR FREENO2982011TCGA-B6-A0WZ-F71575B36349B9-27D9-4343-9447-A347465484A3NOYESYESTUMOR FREEAlive6292YES5117New Primary TumorBoneYES51173032015,TCTCGA-EW-A1P4-D2968779E0A6AE-A364-45A1-9ED5-E0FBDD00DAA975mg/m2473144ChemotherapyDocetaxelADJUVANTIVNO2632012TCTCGA-EW-A1P4-D29689E8073733-F67A-40F9-88DA-22013C8ED597600mg/m2473144ChemotherapyCyclophosphamideADJUVANTIVNO2632012,TCGA-A2-A0YJ-R581999d00471-4902-455d-8eaf-2b4ee63fb7dc180223EXTERNAL BEAM6000cGyPrimary Tumor FieldADJUVANTNO128122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,210.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A5ZV,A7,A5ZV,No,YES,C50.9,8010/3,C50.9,2012.0,TUMOR FREE,YES,2.0,H-SCORE 260,H-Score 0,Left,1.5,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Carcinoma NOS,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Equivocal,0.1240234375,0.0,allred score = 8,Intensity=Strong,10-19%,CISH,Dako Hercept test,40.0,Vysis AutoVysion System,PathVysion HER-2 DNA Probe Kit,YES,NO,2.5,LungBone,<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.8,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,NO,14,5,2013,TCGA-A7-A5ZV-F51143135338BE-7C95-4141-AF1A-A7515A8E065DNOYESYESTUMOR FREEAlive368NO8112013,YESTCGA-A7-A5ZV-D431788F1125F3-DBBB-47BC-BACF-5CE4963DC96695137ChemotherapyDoxorubicinNOComplete Response1452013YESTCGA-A7-A5ZV-D43179EADD43A7-E14F-4643-A3BE-C251663F4AA095137ChemotherapyCyclophosphamideNOComplete Response1452013YESTCGA-A7-A5ZV-D4318052DC65F2-30C0-4BDD-89AC-641853A9E429151193ChemotherapyPaclitaxelNOComplete Response1452013,TCGA-A7-A5ZV-R51144D208F7C1-8594-4935-AAA9-D798639B925F270316External6100cGy33Primary Tumor FieldNOComplete Response8112013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5.0,BLACK OR AFRICAN AMERICAN,TCGA-PL-A8LX,PL,A8LX,No,YES,C50.9,8500/3,C50.9,2013.0,WITH TUMOR,YES,10.8681640625,Allred (Biocare),image cytometry,LeftLeft Upper Outer Quadrant,1.8559960937500013,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,0.9287109375,7.802734375,230,190,20-29%,CISH,Venten,230.6865234375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,1.78,BoneLiver,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,5,3 Point Scale,2+,7thStage IVT4N1aM1,NO,NO,NO,25,3,2014,TCGA-PL-A8LX-F648520E44B46C-87DA-4980-8CD3-F0E13C3681B0YESNONOWITH TUMORAlive517102014,1TCGA-A2-A0D2-D18220b7ae681-1762-4598-b9c5-79d77a5f208a435mg108-109mg474123ChemotherapyAdriamycinADJUVANTIVNO17920102TCGA-A2-A0D2-D1823956680fa-6dc8-437e-8529-32d884b2e5724344mg1086mg474123ChemotherapyCytoxanADJUVANTIVNO17920103TCGA-A2-A0D2-D1824ef46d977-60f0-4915-9438-4c3e9c7e66d81308mg325-329mg4137179ChemotherapyTaxolADJUVANTIVNO1792010,TCGA-E9-A2JS-R3410774963151-D7B0-4C4B-8806-0961A312E981105133External45GyPrimary Tumor FieldNOComplete Response3072012TCGA-E9-A2JS-R55891E02F523B-959F-4754-B3BF-54778A1970F7105133External41GyRegional siteNOComplete Response1712014TCGA-E9-A2JS-R558924030FD77-DBC6-4EA9-8695-C17F48881165105133External38GyRegional siteNOComplete Response1712014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A1HF,C8,A1HF,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,12.0,H-SCORE 190,H-SCORE 0,Left,2.1021679687499923,Axillary lymph node dissection alone,axillary ultrasound,Other,Right Breast Reexcision,Modified radical mastectomy,Patey's Surgery,Infiltrating Ductal Carcinoma,Mixed invasive ductal and invasive lobular,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Negative,Positive,0.0234375,0.001953125,Allred Score 3,Allred Score 7,90-99%,Hercep Test  TM Dako,Venten,136.7578125,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,2.13,LungBone,10-19%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,61,3 Point Scale,1+,6thStage IIAT2N0M0,YES,NO,YES275Distant MetastasisLung,24,5,2011,TCGA-C8-A1HF-F19092437A6D3E-663B-42B1-840D-510BF0CA88B9Scheduled Follow-up SubmissionNOYESAlive332TUMOR FREENO2122011,1TCGA-A2-A0D2-D18220b7ae681-1762-4598-b9c5-79d77a5f208a435mg108-109mg474123ChemotherapyAdriamycinADJUVANTIVNO17920102TCGA-A2-A0D2-D1823956680fa-6dc8-437e-8529-32d884b2e5724344mg1086mg474123ChemotherapyCytoxanADJUVANTIVNO17920103TCGA-A2-A0D2-D1824ef46d977-60f0-4915-9438-4c3e9c7e66d81308mg325-329mg4137179ChemotherapyTaxolADJUVANTIVNO1792010,TCGA-B6-A40C-R410442765DB95-8665-4445-B94B-390902724055218254ExternalPrimary Tumor FieldNO1132013
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,304.0,WHITE,TCGA-AQ-A7U7,AQ,A7U7,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,14.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,Left,2.422158203125,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Other,Right Breast Reexcision,Other,L Total Mastectomy,Infiltrating Lobular Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.0,4.0,Allred score 5,allred score = 0,30-39%,CISH,Hercep Test TM DAKO,97.724609375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,33,LungBone,80-89%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,60,3 Point Scale,2+,7thStage IIIAT2N2aM0,YES,YES,NO,18,12,2013,TCGA-AQ-A7U7-F68763394E58E9-4FB5-4EAD-954C-DDB7179F6E8ENOYESYESTUMOR FREEDead584NO15122014,NOTCGA-AQ-A7U7-D54378F857DE6F-EDB7-4A82-8BE1-58094AF4D53A123193ImmunotherapyRituximabNOComplete Response18122013NOTCGA-AQ-A7U7-D54381EBE759A2-2DF0-4B0B-B155-47E54A053E90123193ChemotherapyCyclophosphamideNOComplete Response18122013NOTCGA-AQ-A7U7-D543825AC8BA1D-DEBC-48E8-83C5-2866BCF86F9B123193ChemotherapyDoxorubicinNOComplete Response18122013NOTCGA-AQ-A7U7-D54385894571F0-1421-4634-8EF3-350800E2C13A123165ChemotherapyVincristineNOComplete Response18122013NOTCGA-AQ-A7U7-D54386F2C99A5C-0BC4-4921-952F-76BF03F2B539123193Hormone TherapyPrednisoneNOComplete Response18122013NOTCGA-AQ-A7U7-D54387CCBE1A5B-B0E1-430F-9221-C2B446502EEC296Hormone TherapyLetrozoleYES18122013,TCGA-AQ-A7U7-R54388E8D0BC37-34EF-4639-B2AC-10DA059F3B08236278External6000cGy30Primary Tumor FieldNOComplete Response18122013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,365.0,BLACK OR AFRICAN AMERICAN,TCGA-A8-A07J,A8,A07J,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,15.0478515625,Allred 0 = 0+0,H-Score 15,Right Upper Outer Quadrant,2.5077343749999947,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.734375,2.71875,allred score = 6,Allred score 8,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,124.8623046875,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,NO,YES,66,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,61,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A07J-F4082917B903FF-A6D0-49CC-A697-C524DE70E422NOYESYESTUMOR FREEAlive365NO232013,NOTCGA-A8-A07J-D3786830FC02A5-ACD9-4CE4-A312-69CCBD6291A63192Chemotherapy5-FluorouracilNOComplete Response6122012NOTCGA-A8-A07J-D3786967EB5A96-AE11-405C-854F-6ABAE77D78A23192ChemotherapyEpirubicinNOComplete Response6122012NOTCGA-A8-A07J-D37870042C8BB6-D133-47F7-86D9-C19D091DC8593192ChemotherapyCyclophosphamideNOComplete Response6122012NOTCGA-A8-A07J-D378714D185435-8F11-4933-9616-FE908DBDF03F92153ChemotherapyDocetaxelNOComplete Response6122012NOTCGA-A8-A07J-D378723048378F-307F-4B1C-8A8E-286754868C32184Hormone TherapyTamoxifenYES6122012,TCGA-A8-A07J-R38186D420AEC4-2B57-4231-822E-611BDD49C141153184ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,-7.0,BLACK OR AFRICAN AMERICAN,TCGA-PL-A8LV,PL,A8LV,No,YES,C50.9,8510/3,C50.9,2013.0,WITH TUMOR,NO,12.39453125,Allred (Biocare),image cytometry,RightRight Upper Outer Quadrant,2.4804199218749927,No axillary staging,FNA plus axillary lymph node dissection,Lumpectomy,Right Breast Reexcision,Other,Left segmental mastectomy with axillary lymph node dissection,Medullary Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,0.58203125,6.73828125,allred score = 4,190,30-39%,CISH,CAP SCORING GUIDELINE 2010,225.517578125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,1.78,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,172,3 Point Scale,2+,7thStage IIIBT4N0M0,YES,NO,Positive70-79%Positive<10%Negative1+,25,3,2014,TCGA-PL-A8LV-F648494E70ED42-A1AA-48DD-81F7-E7153F19F679YESAlive-717102014,NOTCGA-E9-A3HO-D34120D0C4B016-5BD8-4E67-A168-03CBC0840AD82626ChemotherapyCyclophosphamideNOComplete Response3072012NOTCGA-E9-A3HO-D34121E5BBB372-92D7-41A2-8819-BFEBB1F526B32626Chemotherapy5-FluorouracilNOComplete Response3072012NOTCGA-E9-A3HO-D34122B87D3CDD-0D31-4353-9E68-879DB3A804D42626ChemotherapyMethotrexateNOComplete Response3072012NOTCGA-E9-A3HO-D341236B7696A0-95DC-48FD-BC5E-F5D77A8E683E28Hormone TherapyTamoxifenYES3072012NOTCGA-E9-A3HO-D40290B80F3DF7-5616-4DEB-B5B1-9AFD2E7A34EA313337Hormone TherapyLeuprorelinNOComplete Response1522013NOTCGA-E9-A3HO-D40291FC15DB60-9371-4C3A-8C2C-34D254C7B2646164Hormone TherapyZoladexNOComplete Response1522013,TCGA-S3-AA15-R67624FE3E452E-46DC-46B1-9014-9F6A43D28C78286359External114Gy57Primary Tumor FieldNOComplete Response7112014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1870.0,ASIAN,TCGA-A2-A0CV,A2,A0CV,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,18.0,No value Given,Allred score 7 per outside facility report,Left Lower Outer Quadrant,1.1,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,breast conserving therapy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,4.0,240 H,8,90-99%,Dako,DAKOHercepTest TM,126.7158203125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,4.43,Lung,90-99%,90-99%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,2+,Negative,1.5697656249999916,5,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,28,1,2011,TCGA-A2-A0CV-F137221CE47479-972B-4A3C-8A13-0093B066DBFAScheduled Follow-up SubmissionYESYESAlive1930TUMOR FREENO1362011TCGA-A2-A0CV-F5932170EFBD77-D291-4618-84F9-617087564F77NOYESYESTUMOR FREEAlive3011NO852014,4TCGA-A2-A0CV-D7432546eb18e-fefa-41d3-a86b-bef28743095c10mg274Hormone TherapyTamoxifenADJUVANTPOYES1220113TCGA-A2-A0CV-D7431c7ce28fd-8d85-4a62-949f-f363253334651104mg276mg4120176ChemotherapyTaxolADJUVANTIVNO1220112TCGA-A2-A0CV-D7430f6b8fbb1-9792-48f4-ad8f-0f6490d403ae3800mg950mg464106ChemotherapyCytoxanADJUVANTIVNO1220111TCGA-A2-A0CV-D74280fecbde9-3113-43c9-9873-5c3dc1c9158c380mg95mg464106ChemotherapyAdriamycinADJUVANTIVNO122011,TCGA-A2-A0CV-R7434ae409847-2014-463b-b89a-9b5c9ed32bb7229263EXTERNAL BEAMcGyPrimary Tumor FieldADJUVANTNO1922011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1948.0,WHITE,TCGA-AO-A12D,AO,A12D,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,16.0,H-SCORE 190,CAP scoring guideline 2010,Left Upper Outer QuadrantLeft,6.7,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Wide Local Excision,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,4+,3+,Negative,Negative,Core needle biopsy,Lumpectomy,Positive,Negative,Positive,0.0,1.0,Allred score 7 per outside facility report,80,90-99%,CISH,3+ Positive,32.0,Vysis AutoVysion System,>=2.0 Positive,NO,YES,66,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,441,3 Point Scale,1+,6thStage IIAT1cN1aM0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,12,2010,TCGA-AO-A12D-F58924E3E7D26-A688-4A6A-9F05-FDD4D6B7978B1948AliveTUMOR FREEYESYES8122010TCGA-AO-A12D-F19429357AAC1A-1D70-4199-85AD-44F31A28AEFBScheduled Follow-up SubmissionYESYESAlive2151NO12122011TCGA-AO-A12D-F43438497D877B-0253-4505-92FD-BD836D1444F6NOYESYESTUMOR FREEAlive2515NO2152013,2TCGA-AO-A12D-D59749e959e52-721e-4948-8ebb-0b025e5cf4a56mg/kg17170503Targeted Molecular therapyTrastuzumabADJUVANTIVNO10120111TCGA-AO-A12D-D597367744251-ab75-4c28-8782-6df6f473f4ed1728mg200mg/m24149212ChemotherapyAlbumin-Bound PaclitaxelADJUVANTIVNO10120111TCGA-AO-A12D-D5971cc8a523b-e65b-4413-95b9-ee3bb5e88e413984mg600mg/m2465128ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A12D-D59726c48065e-2a03-4fe6-a4d7-d5ceaba2cc5f400mg60mg/m2465128ChemotherapyDoxorubicinADJUVANTIVNO1012011,TCGA-AO-A12D-R5893be918525-d872-4c32-9a3b-104e79637323282316EXTERNAL BEAM10000cGy25Regional siteADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1673.0,WHITE,TCGA-B6-A40C,B6,A40C,No,YES,C50.9,8520/3,C50.9,2005.0,TUMOR FREE,YES,3.0,image cytometry,image cytometry,Left Upper Outer Quadrant,2.3139160156249994,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Lobular Carcinoma,Mixed invasive ductal and invasive lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0,0.0,Allred score = 5,allred score = 7,<10%,Hercep Test  TM Dako,Dako Hercept test,110.65625,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,2.6,LungBone,50-59%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.83,4 Point Scale,3+,6thStage IIBT3N0 (i-)M0,YES,YES,NO,20,9,2012,TCGA-B6-A40C-F596603C1BA7E3-2F4E-4FE3-B558-91284B51CC4ENOYESYESTUMOR FREEAlive2164NO362014,NOTCGA-B6-A40C-D410400EE50169-85A2-4749-923E-DC70257C063A37107Hormone TherapyCyclophosphamideNO1132013NOTCGA-B6-A40C-D41041AF65E574-4989-44B0-B73C-85E950DF1BC637107ChemotherapyDoxorubicinNO1132013NOTCGA-B6-A40C-D4104393C4C94A-4713-49E3-85A0-2D02AF47B8E8128170ChemotherapyPaclitaxelNO1132013,TCGA-B6-A40C-R410442765DB95-8665-4445-B94B-390902724055218254ExternalPrimary Tumor FieldNO1132013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1N9,E9,A1N9,No,YES,C50.9,8522/3,C50.9,2011.0,TUMOR FREE,YES,8.0,Allred (Biocare),H-SCORE 0,Right Lower Outer Quadrant,1.9659472656249943,Axillary lymph node dissection alone,axillary ultrasound,Other,Right Breast Reexcision,Modified radical mastectomy,Surgical resection,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Negative,Positive,0.0,0.0,240 H,Allred score 7 (per outside facility),30-39%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,122.05859375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.38,LungBone,50-59%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,79,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,23,6,2011,TCGA-E9-A1N9-F2915754014DFF-CDF9-49F0-B5A6-6F722416420BScheduled Follow-up SubmissionNOYESAlive399TUMOR FREENO932012TCGA-E9-A1N9-F5837307EB2A9C-A934-44A1-9FD2-C1580160C002NONOYESTUMOR FREEAlive1101NO842014,NOTCGA-E9-A1N9-D32897D16DD4A4-E874-49EE-82FB-2A247DCE61BD1491ChemotherapyDoxorubicinNO1562012NOTCGA-E9-A1N9-D32898378CC11C-A4AA-4803-B2C1-FD7C98CB5DAA119Hormone TherapyTamoxifenYES1562012,TCGA-AQ-A1H2-R19901DB2A4469-F942-4E92-90EE-E8434E806487208246EXTERNAL BEAM5900cGy28Primary Tumor FieldADJUVANTNO1412012TCGA-AQ-A1H2-R19902D33D7E94-096B-44C0-BFB7-7CCA8794CE55208243EXTERNAL BEAM5000cGy25Regional siteADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A8-A06N,A8,A06N,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,13.24609375,H-SCORE 0,allred score 2+2 = 4,Left,1.9796582031249972,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Right Breast Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,0,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.4638671875,7.927734375,Allred score 5,230,90-99%,ACIS,CAP SCORING GUIDELINE 2010,132.671875,Vysis AutoVysion System,Ratio >=2.0,NO,YES,2.38,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.0,3 Point Scale,2+,6thStage IIIBT4bN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A06O-F408069AAAC44E-7751-40C8-84B7-D95B4899BABFNONOYESTUMOR FREEAlive396NO132013,YESTCGA-BH-A0HY-D433177EC3CB4B-FC47-4903-8C56-460C10384B0888190Hormone TherapyTaxotereNOComplete Response1652013YESTCGA-BH-A0HY-D43318136D0D8F-953A-40A9-AB68-828686DD333B88190ChemotherapyCarboplatinNOComplete Response1652013YESTCGA-BH-A0HY-D433196C77D915-C2F7-4ED7-A3BE-5658AA5B858088427ChemotherapyHerceptinNOComplete Response1652013,TCGA-E2-A14R-R1884371319FB6-5CE9-4A19-8D5C-34C64A295435210259EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO124102011TCGA-E2-A14R-R188450DD87532-955B-43DE-A40E-7952D899390810261061EXTERNAL BEAM4500cGy25Regional siteADJUVANTNO224102011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,209.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-AA15,S3,AA15,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,13.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,RightRight Upper Inner Quadrant,2.378652343750003,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast Reexcision,Other,L Total Mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Negative,Negative,0.0,2.0,allred score = 8,250,30-39%,CISH,CAP SCORING GUIDELINE 2010,33.3681640625,HER2 amplification - negative,Ratio >=2.0,YES,NO,74,LungBone,<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.5,3 Point Scale,2+,7thStage IIBT2N1acM0 (i+),YES,NO,NO,18,4,2014,TCGA-S3-AA15-F67625516DF8F3-0887-44F0-B851-A01356DE4536NOYESYESTUMOR FREEAlive421NO7112014TCGA-S3-AA15-F704450C3A9677-3AAE-427C-836E-B83B55F9497ANOYESYESTUMOR FREEAlive509NO2622015TCGA-S3-AA15-F7209890913D52-D037-495E-ADB9-41512D877984NOYESYESTUMOR FREEAlive525NO1042015,NOTCGA-S3-AA15-D583800B7D016E-CC28-4274-BF66-92AC08BD4CCD82125ChemotherapyADRIAMYCINNOComplete Response1842014NOTCGA-S3-AA15-D58381CD0DBE0D-1FF4-4A8C-A3EF-5397C30A382A82125ChemotherapyCYTOXANNOComplete Response1842014NOTCGA-S3-AA15-D583824ACE7463-6DB8-42D6-93B0-327859CD747E82125AncillaryNEULASTANOComplete Response1842014NOTCGA-S3-AA15-D58383B4C53B22-0A11-4216-A8A3-EE51B419C715138236ChemotherapyTAXOLNOComplete Response1842014,TCGA-S3-AA15-R67624FE3E452E-46DC-46B1-9014-9F6A43D28C78286359External114Gy57Primary Tumor FieldNOComplete Response7112014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,761.0,WHITE,TCGA-A2-A0D2,A2,A0D2,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.0,H-Score 270,Allred 5 = 2+3,Left Lower Outer Quadrant,1.05,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,4 Point Scale,0,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,4.0,0.0,Allred score 0,Moderate,10-19%,Hercep Test  TM Dako,DAKOHercepTest TM,42.6943359375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,160,"Other, specifySkin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.3,3 Point Scale,0,6thStage IIAT2N0 (i+)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,9,2010,TCGA-A2-A0D2-F1445876B9C470-A143-4376-92CB-58317C2C3764Scheduled Follow-up SubmissionYESYESAlive1027TUMOR FREENO962011,1TCGA-A2-A0D2-D18220b7ae681-1762-4598-b9c5-79d77a5f208a435mg108-109mg474123ChemotherapyAdriamycinADJUVANTIVNO17920102TCGA-A2-A0D2-D1823956680fa-6dc8-437e-8529-32d884b2e5724344mg1086mg474123ChemotherapyCytoxanADJUVANTIVNO17920103TCGA-A2-A0D2-D1824ef46d977-60f0-4915-9438-4c3e9c7e66d81308mg325-329mg4137179ChemotherapyTaxolADJUVANTIVNO1792010,TCGA-A2-A0D2-R1825a912f4e0-99c5-408c-b321-73e7f5d077e0230270EXTERNAL BEAM5040cGy28Regional siteADJUVANTNO11792010TCGA-A2-A0D2-R7074312036BDE-8D83-40CA-AA13-7AFEFCF03DD5230270External5040cGy28Regional siteNOComplete Response332015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,224.0,WHITE,TCGA-LL-A9Q3,LL,A9Q3,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,28.0,allred score 5 + 3 = 8,Allred (Biocare),Left Upper Outer Quadrant,2.791611328125003,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,L Total Mastectomy,Infiltrating Lobular Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Positive,0.0,28.0,Allred score = 7,Intensity=Strong,90-99%,CISH,Dako Hercept test,119.3115234375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,54,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.83,3 Point Scale,2+,7thStage IIICT3N3aMX,YES,NO,NO,21,5,2014,TCGA-LL-A9Q3-F6710321E69907-81F4-4C83-ACCC-E79FFE88B38CNOYESYESTUMOR FREEAlive532NO30102014,NOTCGA-LL-A9Q3-D59662637C53B9-68C5-43C6-802C-B9ACAD0B95E6118531ImmunotherapyHERCEPTINNOComplete Response1952014NOTCGA-LL-A9Q3-D596634DEAD1ED-B25F-493F-81D1-E0AF2833ACA3118216ChemotherapyTAXOLNO1952014NOTCGA-LL-A9Q3-D67101B225CCB0-5441-4D39-98BE-00AAA257CE40273Hormone TherapyARIMIDEXYES30102014,TCGA-LL-A9Q3-R67102F10086C3-8DB8-4FE5-ACD6-E85CC15E25F9251290External50.4Gy28Primary Tumor FieldNOComplete Response30102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,396.0,WHITE,TCGA-A8-A06O,A8,A06O,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.302734375,H-SCORE 190,Allred score = 8,Left,2.313710937499999,Sentinel node biopsy alone,axillary ultrasound,Other,Right Breast Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.8203125,0.103515625,Allred score 0,Strong,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,126.13671875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,66,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.0,3 Point Scale,2+,6thStage IT1cN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A06O-F408069AAAC44E-7751-40C8-84B7-D95B4899BABFNONOYESTUMOR FREEAlive396NO132013,NOTCGA-A8-A06O-D37896C45C3AB5-2102-4DC9-AABA-2E722C04807762Hormone TherapyLetrozoleYES6122012,TCGA-A7-A5ZV-R51144D208F7C1-8594-4935-AAA9-D798639B925F270316External6100cGy33Primary Tumor FieldNOComplete Response8112013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,169.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-AA11,S3,AA11,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,1.0,CAP scoring guideline 2010,CAP scoring guideline 2010,Right,1.5,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Lumpectomy,Right Breast Reexcision,Other,L Total Mastectomy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.0,0.0,Allred score 5,allred score = 0,<10%,ACIS,CAP scoring guideline 2010,20.0,HER2 amplification - negative,CAP scoring guideline 2010,YES,NO,40,LungBone,90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,59,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,NO,18,4,2014,TCGA-S3-AA11-F675639543CB0E-D4A5-447F-A0A4-AC2D3E56FC37NOYESYESTUMOR FREEAlive421NO7112014,NOTCGA-S3-AA11-D583580469F246-0A00-46F4-ACA0-0B25A14C6D0853169Hormone TherapyLETROZOLENOComplete Response1842014NOTCGA-S3-AA11-D5835988D345D0-A5BB-4598-983F-ABA5E9ADE52E169309Hormone TherapyEXEMESTANENOComplete Response1842014NOTCGA-S3-AA11-D67566FF58F7AA-3F5B-42A3-B786-9CD8F5B3998B309Hormone TherapyANASTROZOLEYESComplete Response7112014,TCGA-S3-AA11-R58357DC89E056-7189-4F52-A31E-1EB00BF6D61C77123External60Gy30Primary Tumor FieldNOComplete Response1842014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,230.0,WHITE,TCGA-AQ-A1H2,AQ,A1H2,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,19.0,CAP scoring guideline 2010,CAP scoring guideline 2010,Right Upper Outer Quadrant,2.7,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Positive,Positive,Indeterminate,0.0546875,13.0,Allred Score 5,250,30-39%,CISH,CAP scoring guideline 2010,99.611328125,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,40,LungBone,90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,60,3 Point Scale,2+,7thStage IIIAT2N2aMX,YES,NO,YES994Distant MetastasisBoneNOYESYES,20,4,2011,TCGA-AQ-A1H2-F19896BA3554E9-F416-4973-B66A-513126BBBB98Scheduled Follow-up SubmissionYESYESAlive475TUMOR FREENO312012,1TCGA-AQ-A1H2-D19898BB2A1345-F78E-4367-87E6-5C17B4221F192mg/kg98462ChemotherapyHerceptinADJUVANTIVNO3120121TCGA-AQ-A1H2-D19899C7DE7726-8978-4819-B64A-71AE48B4A1FF1mg/day378Hormone TherapyArimidexADJUVANTPOYES3120121TCGA-AQ-A1H2-D1989794375318-4D27-4A4B-A198-FD922F5A1BA180mg/m21298182ChemotherapyTaxolADJUVANTIVNO312012,TCGA-AQ-A1H2-R19901DB2A4469-F942-4E92-90EE-E8434E806487208246EXTERNAL BEAM5900cGy28Primary Tumor FieldADJUVANTNO1412012TCGA-AQ-A1H2-R19902D33D7E94-096B-44C0-BFB7-7CCA8794CE55208243EXTERNAL BEAM5000cGy25Regional siteADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,13.0,WHITE,TCGA-E9-A2JS,E9,A2JS,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,10.0,Allred 0 = 0+0,allred score 5+3+8,Left Upper Outer Quadrant,2.2540917968749943,Axillary lymph node dissection alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Lobular Carcinoma,Mixed invasive ductal and invasive lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.025390625,1.0,Intensity=Strong,250,90-99%,Hercep Test  TM Dako,Hercep Test TM DAKO,100.8359375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.7,LungBone,50-59%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.66,4 Point Scale,2+,7thStage IIBT2N1M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",20,12,2011,TCGA-E9-A2JS-F3410070D902D4-238E-44C9-AC2F-9DADFFD7D327Scheduled Follow-up SubmissionYESYESAlive540WITH TUMORYES524Distant MetastasisBoneLiverNONOYES1712014TCGA-E9-A2JS-F402932F028700-8717-47EE-B60E-F0D73A04C1B2NOYESYESWITH TUMORDead904YES524Distant MetastasisBoneNONOYES524Distant MetastasisLiverNONOYES1522013,NOTCGA-E9-A2JS-D3410209E54119-585C-4096-A9D8-13665647189321Hormone TherapyTamoxifenYES3072012NOTCGA-E9-A2JS-D34103786F4DB8-BC47-4FEF-9D2E-624B59F1E9A217191ChemotherapyCyclophosphamideNOComplete Response3072012NOTCGA-E9-A2JS-D3410411E5178D-A5E2-4AC3-BAD0-0664514A1B4117191ChemotherapyMethotrexateNOComplete Response3072012NOTCGA-E9-A2JS-D341068049BD0B-2078-4946-AFA8-BF2EEB3FD34E17191Chemotherapy5-FluorouracilNOComplete Response3072012NOTCGA-E9-A2JS-D4029498CD1B77-8557-4EBF-9914-8FF674101890524846AncillaryPamidronic acidNO1522013NOTCGA-E9-A2JS-D5589643929A44-3CE4-467E-85DC-FCF130402CFB677713Hormone TherapyZoladexNOClinical Progressive Disease1712014,TCGA-E9-A2JS-R3410774963151-D7B0-4C4B-8806-0961A312E981105133External45GyPrimary Tumor FieldNOComplete Response3072012TCGA-E9-A2JS-R55891E02F523B-959F-4754-B3BF-54778A1970F7105133External41GyRegional siteNOComplete Response1712014TCGA-E9-A2JS-R558924030FD77-DBC6-4EA9-8695-C17F48881165105133External38GyRegional siteNOComplete Response1712014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1312.0,WHITE,TCGA-E2-A1L6,E2,A1L6,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,6.0,allred score 5 + 3 = 8,allred score 5 + 3 = 8,Left Upper Outer Quadrant,1.8055175781250064,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Total mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,1.5048828125,1.0,allred score =  8,allred score = 8,40-49%,Hercep Test  TM Dako,Dako Hercept test,100.0537109375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,66,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,<4.0,3 Point Scale,2+,6thStage IIAT1cN1miM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,6,2011,TCGA-E2-A1L6-F2057078110A92-E50F-46A7-A227-ABEDC2F39EDCScheduled Follow-up SubmissionNOYESAlive1648TUMOR FREENO1012012,"1TCGA-E2-A1L6-D205712A551287-56B0-41BD-BFD3-1F24A796AAC33740mg935mg44991ChemotherapyCyclophosphamideADJUVANTIVNO10120123TCGA-E2-A1L6-D20576D638F4F1-F401-40B5-B9C4-16792E4F17183.75mg49Other, specify in notesPhase III Clinical TrialTriptorelinADJUVANTIMYES10120123TCGA-E2-A1L6-D20574C2F3080E-04F4-408F-945A-184A8E8F53AD1600mg/day1600mg/day491120Other, specify in notesPhase III Clinical TrialClodronateADJUVANTPONO10120121TCGA-E2-A1L6-D205725BDBE33A-381E-477B-B28D-073FCBA0DB9F380mg95mg44991ChemotherapyDoxorubicinADJUVANTIVNO10120124TCGA-E2-A1L6-D20577ED98E166-5C11-4AE6-82DC-463DE3C00BEE20mg/day20mg/day148Hormone TherapyTamoxifenADJUVANTPOYES10120122TCGA-E2-A1L6-D20573C239325B-6739-43DD-A6FB-832310B2644B1080mg270mg4105147ChemotherapyPaclitaxelADJUVANTIVNO1012012",TCGA-B6-A40C-R410442765DB95-8665-4445-B94B-390902724055218254ExternalPrimary Tumor FieldNO1132013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,6719.0,WHITE,TCGA-B6-A0IA,B6,A0IA,No,YES,C50.9,8523/3,C50.9,1992.0,TUMOR FREE,YES,15.0,IHC,IHC,Right,2.138242187500007,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,Excisional biopsy,"Other, specify",Ductal/Cribiform,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,4+,2+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Positive,Equivocal,0.013671875,0.0,Two-tier,H score,90-99%,ACIS,CAP scoring guideline 2010,190.8681640625,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,1.78,"Other, specifySkin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.3,4 Point Scale,1+,Stage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,11,2010,TCGA-B6-A0IA-F126104D334E64-3DE2-4A7D-BEAC-5E9B8813CA01Scheduled Follow-up SubmissionNOYESAlive6719TUMOR FREENO162011TCGA-B6-A0IA-F715130F55E065-C77C-4851-8F2E-1E223AF5CE7CNONOYESTUMOR FREEAlive8391NO2632015,1TCGA-AO-A12H-D59836712f22e-0667-4a78-baed-2051f7f4f05a1mg/day73Hormone TherapyArimidex (Anastrozole)ADJUVANTPOYES1012011,TCGA-A2-A0D2-R1825a912f4e0-99c5-408c-b321-73e7f5d077e0230270EXTERNAL BEAM5040cGy28Regional siteADJUVANTNO11792010TCGA-A2-A0D2-R7074312036BDE-8D83-40CA-AA13-7AFEFCF03DD5230270External5040cGy28Regional siteNOComplete Response332015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,404.0,WHITE,TCGA-A2-A0YG,A2,A0YG,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,18.0,Allred score = 8,Allred 5 = 2+3,Left Upper Outer Quadrant,2.0389453125000023,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Lumpectomy,Right Breast Reexcision,Other,Total mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Positive,Positive,0.3740234375,14.0,8,250,30-39%,Hercep Test  TM Dako,CAP scoring guideline 2010,427.5810546875,Vysis AutoVysion System,Ratio >=2.0,NO,YES,66,Lung,90-99%,<10%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.460605468749991,21,3 Point Scale,2+,Stage IIICT2N3aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",3,1,2011,TCGA-A2-A0YG-F16753AE70B861-9D94-44E5-8818-90AA283FD9C6Scheduled Follow-up SubmissionYESYESAlive666TUMOR FREENO1692011,3TCGA-A2-A0YG-D56367a5fb8b1-74dd-4cdf-a42e-10aa9ae382ad229mg229mg1173173ChemotherapyTaxotereADJUVANTIVNO21220104TCGA-A2-A0YG-D5637ea67ac32-9c00-4232-aa39-39d493f18b95178-185mg12152232ChemotherapyTaxolADJUVANTIVNO21220102TCGA-A2-A0YG-D5628310907f8-03bc-46fe-abfd-562722f267984896mg1224mg468131ChemotherapyCytoxanADJUVANTIVNO21220101TCGA-A2-A0YG-D5627854cdbfa-8797-4255-ae54-9a7b1278579e488mg122mg468131ChemotherapyAdriamycinADJUVANTIVNO21220105TCGA-A2-A0YG-D5638b3943b3d-4e9a-4ccc-bd23-65d88a9afc7e1mgHormone TherapyArimidexADJUVANTPOYES141220106TCGA-A2-A0YG-D5639a99a6cef-a2db-4dcb-aba7-24b62d65de98255-509mg152Targeted Molecular therapyHerceptinADJUVANTIVYES14122010,TCGA-A2-A0YG-R5625f5aff914-e9ce-4684-9fca-5e1ed11aa6c0257303EXTERNAL BEAM5940cGy25Primary Tumor FieldADJUVANTNO12122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3872.0,WHITE,TCGA-B6-A0IQ,B6,A0IQ,No,YES,C50.9,8500/3,C50.9,1996.0,TUMOR FREE,YES,26.0,Image Analysis,Image Analysis,Left Upper Outer QuadrantLeft,2.1480078125000186,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,4+,3+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Negative,Equivocal,0.47265625,1.0,Intensity=Strong,H score,90-99%,ACIS,dextran coated charcoal,60.169921875,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,33,"LungOther, specifyleft adrenal gland",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,145,4 Point Scale,1+,4thStage IIIAT3N1bM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,11,2010,TCGA-B6-A0IQ-F126298D04EFD2-BFDA-4F6B-ACA2-E86C4B2B9B74Scheduled Follow-up SubmissionYESYESAlive4285TUMOR FREENO262011,1TCGA-E2-A15T-D19143A71ADC96-7255-4D33-ABC9-4883E48C7DB31mg/day1mg/day34Hormone TherapyArimidexADJUVANTPOYES17112011,TCGA-S3-AA11-R58357DC89E056-7189-4F52-A31E-1EB00BF6D61C77123External60Gy30Primary Tumor FieldNOComplete Response1842014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,152.0,WHITE,TCGA-AC-A4ZE,AC,A4ZE,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,1.0,allred score 0 + 0 = 0,CAP SCORING GUIDELINE 2010,Right Lower Outer Quadrant,1.3376953125000044,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Lobular Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Positive,0.3564453125,0.0,Allred score 0,Allred Score 6,30-39%,ACIS,CAP SCORING GUIDELINE 2010,51.712890625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,69,LungBone,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.8,3 Point Scale,2+,7thStage IIBT3N0M0,NO,NO,NO,9,6,2015,TCGA-AC-A4ZE-F7237993BEFC77-D0BC-4528-A5D1-3774D3341331NONONOTUMOR FREEAlive890NO962015,NOTCGA-E9-A3X8-D417062813ED05-F03A-4919-B4DE-12415797A89714160ChemotherapyCyclophosphaneNOComplete Response2632013NOTCGA-E9-A3X8-D41708D74CCEFE-BE26-4C75-A3ED-DE683060F21F14160ChemotherapyDoxorubicinNOComplete Response2632013NOTCGA-E9-A3X8-D41709B42520B3-C869-4100-A31A-852F9255A6A214160Chemotherapy5-FluorouracilNOComplete Response2632013NOTCGA-E9-A3X8-D4171005473A78-6AD8-4AFA-A02B-61BFE72F46D4324Hormone TherapyTamoxifenYES2632013,TCGA-A2-A0YG-R5625f5aff914-e9ce-4684-9fca-5e1ed11aa6c0257303EXTERNAL BEAM5940cGy25Primary Tumor FieldADJUVANTNO12122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,210.0,WHITE,TCGA-D8-A13Z,D8,A13Z,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,% IHC,manual counting,Right Lower Outer Quadrant,1.337636718749997,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast Reexcision,Other,Surgical resection,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Negative,Negative,0.173828125,9.0,Allred score = 4,allred score = 8,90-99%,Hercep Test  TM Dako,Venten,338.0859375,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,YES,NO,2.38,Lung,70-79%,90-99%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,2+,Negative,1.816386718749996,3.8,3 Point Scale,2+,7thT2N2aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,2,2011,TCGA-D8-A13Z-F20731444554B2-937F-4327-A7CC-E6A2B5BDC2B7Scheduled Follow-up SubmissionYESYESAlive635TUMOR FREENO1412012,TCGA-D8-A13Z-D20732CB4478D0-5504-4268-A2E9-9EFE2B5C293F586.8mg6x97.8mg/m2652157ChemotherapydoxorubicineADJUVANTIVNO1412012NOTCGA-D8-A13Z-D653137EBDCBDC-E474-41D4-8D9F-2B99158B682952157ChemotherapycyclophosphamideNO2292014NOTCGA-D8-A13Z-D65314D08EFDD4-5EBB-4816-910D-C6EAC35DE99252157Hormone TherapytamoxifenNO2292014,TCGA-D8-A13Z-R20733022E96E7-CD23-4434-A287-97397DC0002B184210EXTERNAL BEAM4500cGy18Regional siteADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Dead,1993.0,4353.7353515625,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0IE,B6,A0IE,No,YES,C50.9,8520/3,C50.9,1995.0,WITH TUMOR,YES,24.0,Image Analysis,Image Analysis,Left Upper Outer QuadrantLeft,1.6435742187500102,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,Wide re-excisional biopsy,Mixed Histology (please specify),Lobular/Ductal,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,4 Point Scale,4+,3+,Negative,Close,Incisional Biopsy,"Biopsy, NOS",Negative,Negative,Equivocal,0.5234375,6.0,Allred score = 5,moderate,90-99%,ACIS,dextran coated charcoal,61.583984375,Vysis AutoVysion System,CAP SCORING GUIDELINE 2010,NO,YES,33,"LungOther, specifyleft adrenal gland",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.944414062499999,71,4 Point Scale,1+,4thStage IIIAT3N1bM0,YES,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,2,11,2010,TCGA-B6-A0IE-F126149B0D40DC-3C41-4873-8C8E-9B8D06A6EC6EScheduled Follow-up SubmissionYESYESDead1993WITH TUMORYES834Distant MetastasisBoneNOYESYES162011,YESTCGA-BH-A0HY-D433177EC3CB4B-FC47-4903-8C56-460C10384B0888190Hormone TherapyTaxotereNOComplete Response1652013YESTCGA-BH-A0HY-D43318136D0D8F-953A-40A9-AB68-828686DD333B88190ChemotherapyCarboplatinNOComplete Response1652013YESTCGA-BH-A0HY-D433196C77D915-C2F7-4ED7-A3BE-5658AA5B858088427ChemotherapyHerceptinNOComplete Response1652013,TCGA-AQ-A1H2-R19901DB2A4469-F942-4E92-90EE-E8434E806487208246EXTERNAL BEAM5900cGy28Primary Tumor FieldADJUVANTNO1412012TCGA-AQ-A1H2-R19902D33D7E94-096B-44C0-BFB7-7CCA8794CE55208243EXTERNAL BEAM5000cGy25Regional siteADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2179.0,WHITE,TCGA-A2-A04Q,A2,A04Q,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,3.0,allred score 0 + 0 = 0,Allred 5 = 2+3,Right Upper Outer QuadrantRight,1.4,Other (specify),SLN AND NON-SLN BX,Simple Mastectomy,Right Breast Reexcision,Lumpectomy,Excisional biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,2+,Negative,Negative,"Other method, specify:",SKIN BIOPSY,Negative,Negative,Equivocal,0.0,0.0,allred score = 6,Allred score = 7,10-19%,ACIS,DAKOHercepTest TM,45.541015625,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,1.45,"Other, specifySkin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.3,3 Point Scale,1+,6thStage IAT1N0 (i-)M0,NO,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",10,8,2010,TCGA-A2-A04Q-F9329B7EAC97B-63C1-4DB3-A0F0-62D03122CC882385AliveTUMOR FREENOYES2132011TCGA-A2-A04Q-F593148C018342-8251-45D4-B7B0-807B5F7BC07BYESNOYESAlive2385852014,TCGA-A2-A04Q-D2766df8339c3-f6d8-4121-a22d-949df819ce16204mg100-102mg42385ChemotherapyADRIAMYCINADJUVANTIVNO1282010TCGA-A2-A04Q-D27649f6d826b-b6b9-4f14-8640-7e859b8c7f954048mg1000-1020mg44385ChemotherapyCYTOXANADJUVANTIVNO1282010,TCGA-E9-A2JS-R3410774963151-D7B0-4C4B-8806-0961A312E981105133External45GyPrimary Tumor FieldNOComplete Response3072012TCGA-E9-A2JS-R55891E02F523B-959F-4754-B3BF-54778A1970F7105133External41GyRegional siteNOComplete Response1712014TCGA-E9-A2JS-R558924030FD77-DBC6-4EA9-8695-C17F48881165105133External38GyRegional siteNOComplete Response1712014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,513.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5RX,OL,A5RX,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,4.0,allred score 5 + 3 = 8,CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.0,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,0.005859375,8.2060546875,Allred Score 5,Allred Score 6,30-39%,CISH,Venten,77.634765625,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,NO,YES,69,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,3 Point Scale,2+,7thStage IAT1cN0MX,NO,NO,NO,16,5,2013,TCGA-OL-A5RX-F56570135BBA94-947F-4E8D-88E1-06FFE7C587ECNONONOTUMOR FREEAlive878NO1422014,1TCGA-AR-A1AW-D21880B118CFF2-8566-464E-BC22-044DA44E6715150mg75mg/m215050ChemotherapyDocetaxelADJUVANTIVNO28220121TCGA-AR-A1AW-D21882CFE3594C-AFCE-4DC0-9A24-2F3F93988BBE1210mg600mg/m215050ChemotherapyCytoxanADJUVANTIVNO28220122TCGA-AR-A1AW-D21884E157CFB4-4E3C-419E-B051-B1574E3EFECB1mg/day157Hormone TherapyAnastrozoleADJUVANTPOYES2822012,TCGA-A2-A0YG-R5625f5aff914-e9ce-4684-9fca-5e1ed11aa6c0257303EXTERNAL BEAM5940cGy25Primary Tumor FieldADJUVANTNO12122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,4.0,ASIAN,TCGA-C8-A26Z,C8,A26Z,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,5.94921875,H-SCORE 0,Allred (Biocare),Right Upper Inner Quadrant,1.5063867187499946,Axillary lymph node dissection alone,axillary ultrasound,Other,Right Breast Reexcision,Modified radical mastectomy,Patey's Surgery,Infiltrating Ductal Carcinoma,Mixed invasive ductal and invasive lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.029296875,0.005859375,Allred Score 4,Allred Score 8,90-99%,Hercep Test  TM Dako,Venten,109.228515625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,2.38,LungBone,10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.9,4 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,21,7,2011,TCGA-C8-A26Z-F202793D40203B-FE09-43E0-BDCC-643110359D34Scheduled Follow-up SubmissionNONOAlive252TUMOR FREENO912012TCGA-C8-A26Z-F70835EA721DF8-5AD0-46F3-A433-3CEF5C43AF19NONOYESTUMOR FREEAlive470NO932015,NOTCGA-C8-A26Z-D70836D3391CBA-5CB0-47AE-9813-D21384BF746611Hormone TherapyTamoxifenYESComplete Response932015,TCGA-E9-A2JS-R3410774963151-D7B0-4C4B-8806-0961A312E981105133External45GyPrimary Tumor FieldNOComplete Response3072012TCGA-E9-A2JS-R55891E02F523B-959F-4754-B3BF-54778A1970F7105133External41GyRegional siteNOComplete Response1712014TCGA-E9-A2JS-R558924030FD77-DBC6-4EA9-8695-C17F48881165105133External38GyRegional siteNOComplete Response1712014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,426.0,WHITE,TCGA-A8-A07I,A8,A07I,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,15.84765625,H-SCORE 300,allred score 2+2 = 4,Left Upper Outer Quadrant,2.2261132812499915,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Positive,Positive,Positive,0.7763671875,6.2900390625,allred score = 6,230,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,128.3017578125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,4,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,59,3 Point Scale,2+,6thStage IIIAT2N2aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A07I-F40828339036C6-8D30-466F-9CDD-9F7F28402C81NOYESYESTUMOR FREEAlive426NO232013,NOTCGA-A8-A07I-D378732E3715CB-3802-4392-A7FD-4A36AE0E3D4361122Chemotherapy5-FluorouracilNOComplete Response6122012NOTCGA-A8-A07I-D37874DEE16E8F-6322-49BB-8B56-D708F62283F361122ChemotherapyEpirubicinNOComplete Response6122012NOTCGA-A8-A07I-D37875D9C7F7BE-AA3C-45E5-B2B3-272DA8642C8861122ChemotherapyCyclophosphamideNOComplete Response6122012NOTCGA-A8-A07I-D37876AF49DCB1-E14E-4848-9903-7D13E60573C7122183ChemotherapyDocetaxelNOComplete Response6122012NOTCGA-A8-A07I-D378774626641D-270B-4338-980A-D4A594F94997183Hormone TherapyExemestaneYESClinical Progressive Disease6122012NOTCGA-A8-A07I-D378785488CE4C-EA04-476A-AA6B-6FE37646BC75183334Targeted Molecular therapyTrastuzumabNOComplete Response6122012,TCGA-A8-A07I-R381871BF7CBC3-B465-4421-911B-D37309EF031F245304ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,23.0,WHITE,TCGA-E9-A3X8,E9,A3X8,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,8.0,H-SCORE 300,allred score 5+3+8,Left Upper Outer Quadrant,2.129453124999997,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,Lobular/Ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Positive,0.0,4.0,8,8,<10%,Hercep Test  TM Dako,Dako Hercept test,111.1953125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,33,"LungBoneLiverOther, specifyskin",20-29%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.66,4 Point Scale,2+,7thStage IIBT2N1M0,YES,NO,NO,24,8,2012,TCGA-E9-A3X8-F4170408EF0574-225F-4327-8F2D-B72B71073D9FNOYESYESTUMOR FREEAlive478NO2632013TCGA-E9-A3X8-F5974221FB9BF8-1169-4200-8092-32FBE1250BC1NOYESYESTUMOR FREEAlive926NO2052014,NOTCGA-E9-A3X8-D417062813ED05-F03A-4919-B4DE-12415797A89714160ChemotherapyCyclophosphaneNOComplete Response2632013NOTCGA-E9-A3X8-D41708D74CCEFE-BE26-4C75-A3ED-DE683060F21F14160ChemotherapyDoxorubicinNOComplete Response2632013NOTCGA-E9-A3X8-D41709B42520B3-C869-4100-A31A-852F9255A6A214160Chemotherapy5-FluorouracilNOComplete Response2632013NOTCGA-E9-A3X8-D4171005473A78-6AD8-4AFA-A02B-61BFE72F46D4324Hormone TherapyTamoxifenYES2632013,TCGA-E9-A3X8-R41711EB81185F-05C4-4CD7-8DC8-9719C98B2E795278External40Gy16Regional siteNOComplete Response2632013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1072.0,WHITE,TCGA-AR-A1AW,AR,A1AW,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,1.0,H-SCORE 0,CAP scoring guideline 2010,Left Upper Inner Quadrant,1.2697949218749949,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Lumpectomy,surgical resection,Other,Excisional biopsy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Incisional Biopsy,intraoperative examination,Negative,Positive,Equivocal,0.01171875,0.0,H-SCORE,0,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,68.283203125,Vysis AutoVysion System,Path Vysion HER2 DNA Probe Kit,NO,YES,33,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,79,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,14,6,2011,TCGA-AR-A1AW-F21874E44B1D03-A203-409D-8BF8-0296FC2192B7Scheduled Follow-up SubmissionYESYESAlive1072NO2822012TCGA-AR-A1AW-F4947856185A8A-B29D-4B04-982B-0D3ABEE0D37ENOYESYESTUMOR FREEAlive1935NO2102013TCGA-AR-A1AW-F7171496D8CA37-5732-42D2-9984-18CAD787048FNOYESYESTUMOR FREEAlive2632NO3032015,1TCGA-AR-A1AW-D21880B118CFF2-8566-464E-BC22-044DA44E6715150mg75mg/m215050ChemotherapyDocetaxelADJUVANTIVNO28220121TCGA-AR-A1AW-D21882CFE3594C-AFCE-4DC0-9A24-2F3F93988BBE1210mg600mg/m215050ChemotherapyCytoxanADJUVANTIVNO28220122TCGA-AR-A1AW-D21884E157CFB4-4E3C-419E-B051-B1574E3EFECB1mg/day157Hormone TherapyAnastrozoleADJUVANTPOYES2822012,TCGA-AR-A1AW-R21878414051C6-7D5D-4256-86B8-C8F330A26C1B76115EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12822012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7.0,ASIAN,TCGA-C8-A1HK,C8,A1HK,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,8.0,Allred 0 = 0+0,H-Score 0,Right,1.4080664062500003,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,Patey's Surgery,Infiltrating Ductal Carcinoma,lobular/ductal,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,"Other method, specify:",Patey's Surgery,Positive,Negative,Positive,0.0888671875,1.0517578125,Allred score = 7,0%,90-99%,ACIS,Venten,162.4140625,Vysis AutoVysion System,Ratio >=2.0,YES,NO,74,Lung,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,4 Point Scale,1+,6thStage IIBT2N1M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",1,6,2011,TCGA-C8-A1HK-F19100A1CA0508-80BE-4CA1-A509-E54F50DEB1A9Scheduled Follow-up SubmissionNONOAlive366TUMOR FREENO2122011,TCGA-HN-A2NL-D60150FC632444-8B7E-4F7E-94DD-B12171B1E0D659ChemotherapyCyclophosphamide3052014TCGA-HN-A2NL-D60151D9161F5E-D3C5-4B6F-8267-C280BAEBD2D459ChemotherapyDoxorubicin3052014,TCGA-S3-AA11-R58357DC89E056-7189-4F52-A31E-1EB00BF6D61C77123External60Gy30Primary Tumor FieldNOComplete Response1842014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,169.0,WHITE,TCGA-LL-A5YL,LL,A5YL,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,23.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,RightRight Upper Inner Quadrant,0.9,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Simple Mastectomy,Right Breast Reexcision,Mastectomy NOS,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Positive,0.0,3.0,Intensity=Strong,allred score = 0,30-39%,CISH,Dako Hecept Test,65.0,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,2.9,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.6,3 Point Scale,2+,7thStage IIBT2N1aMX,YES,NO,NO,3,6,2013,TCGA-LL-A5YL-F596500FBEAAC5-77A9-4E92-9B8F-E11AA2F05535NOYESYESAlive519NO1952014,NOTCGA-LL-A5YL-D434108706E99F-7547-4F58-918E-66A8EA5EB23778150ChemotherapyAdriamycinNO2152013NOTCGA-LL-A5YL-D434114F99E58A-D90D-4DE0-9ABD-37B777EE111F78150ChemotherapyCytoxanNO2152013NOTCGA-LL-A5YL-D4375031AEC785-42C5-479C-B46B-3AB5E1479898169246ChemotherapyPaclitaxelNO362013NOTCGA-LL-A5YL-D4375198BC7928-4B13-46C1-AADD-C2FC86C0BB51169ChemotherapyHerceptinYES362013NOTCGA-LL-A5YL-D596538E7139E6-B6EF-403D-ABDE-AF79BD55D833341Hormone TherapyARIMIDEXYES1952014,TCGA-LL-A5YL-R5965142CD0077-F207-40F2-B347-0485C089500B273315External50.4Gy28Primary Tumor FieldNO1952014TCGA-LL-A5YL-R59652041DB4FA-27B4-4F06-B997-A6B2D1B2CC15273315External50.4Gy28Regional siteNO1952014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,608.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A1PB,EW,A1PB,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,8.0,H-SCORE 0,Allred score 5+3 = 8,Right Upper Outer Quadrant,1.3597265624999937,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Total mastectomy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.333984375,2.0,Strong,205,<10%,CISH,Venten,90.7744140625,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,2.13,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.23,3 Point Scale,3+,6thStage IIIAT3N1aMX,YES,YES,YES994Distant MetastasisBoneNOYESYES,18,5,2011,TCGA-EW-A1PB-F291073AAF57DA-E30C-45A6-B7DD-53CC5EA84417Scheduled Follow-up SubmissionNONOAlive608TUMOR FREENO832012,3TCGA-E2-A158-D18963B94489C2-71D2-40FE-86DD-A3E999BF3373mg1mg450ChemotherapyarimidexADJUVANTPOYES81120111TCGA-E2-A158-D18958A3051694-896A-4A9D-9178-CA248163F114228ChemotherapydoxorubicinADJUVANTNO81120111TCGA-E2-A158-D189608C16F7B2-EFBC-4B7E-AA40-8A152D0E4F0F228ChemotherapycytoxanADJUVANTNO81120112TCGA-E2-A158-D1896167C4C12D-8CB3-4ED8-8913-666D05A6057D228ChemotherapyTaxaneADJUVANTNO8112011,TCGA-AR-A1AQ-R218043579DB65-F66D-41A4-B13A-E32DD54BEBDF121163EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12722012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,79.0,BLACK OR AFRICAN AMERICAN,TCGA-HN-A2NL,HN,A2NL,No,YES,C50.9,8520/3,C50.9,2006.6064453125,TUMOR FREE,YES,3.0,Allred 0 = 0+0,Allred score 0+0=0,Left Upper Outer Quadrant,5.038222656249986,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Wide re-excisional biopsy,Infiltrating Lobular Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,SKIN BIOPSY,Negative,Negative,Negative,0.0,0.0,Allred score 0,Allred score 7 (per outside facility),90-99%,CISH,Dako Hercept test,141.0546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,64,"LungBoneLiverOther, specifyskin",70-79%,40-49%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,59,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,PositivePositiveNegative,30,5,2014,TCGA-HN-A2NL-F601490CBA7FE6-A784-4125-BBE8-43108D8E03E2YESYESTUMOR FREEAlive79NO3052014,TCGA-HN-A2NL-D60150FC632444-8B7E-4F7E-94DD-B12171B1E0D659ChemotherapyCyclophosphamide3052014TCGA-HN-A2NL-D60151D9161F5E-D3C5-4B6F-8267-C280BAEBD2D459ChemotherapyDoxorubicin3052014,TCGA-A7-A5ZV-R51144D208F7C1-8594-4935-AAA9-D798639B925F270316External6100cGy33Primary Tumor FieldNOComplete Response8112013
TCGAFPPP,Breast,No,FEMALE,Dead,255.0,1788.451171875,WHITE,TCGA-A2-A0T2,A2,A0T2,No,YES,C50.9,8500/3,C50.9,2009.0,WITH TUMOR,YES,14.0,ER Positive H-Score 95,allred score 4 + 3 = 7,Right,3.831523437500024,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,surgical resection,Modified radical mastectomy,L Total Mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,0,Negative,Close,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.3193359375,10.0,Allred Score,0%,10-19%,ACIS,Venten,84.8544921875,Vysis AutoVysion System,PathVysion Her-2 DNA,NO,YES,33,LiverAbdomen,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,52,3 Point Scale,1+,Stage IVT3N3M1,YES,YES,PositivePositiveNegativeNegative,12,11,2010,TCGA-A2-A0T2-F3706A366E180-A36C-447C-BDDE-931193A02AA4DeadWITH TUMOR255NONONONONO12112010,1TCGA-A2-A0T2-D3707374f0db8-26b8-4cd4-828d-1250a5a81df3g/day3g/day4105225ChemotherapyXelodaADJUVANTPONO12112010,TCGA-A2-A0T2-R370886535c68-8c55-421f-ad89-586c8d68c5ed179199EXTERNAL BEAM3000cGy12Regional siteADJUVANTNO112112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,124.0,BLACK OR AFRICAN AMERICAN,TCGA-LD-A7W5,LD,A7W5,No,YES,C50.9,8500/3,C50.9,2013.0,WITH TUMOR,YES,23.0,CAP SCORING GUIDELINE 2010,allred score 5+3+8,Left Upper Outer Quadrant,2.090126953124989,Axillary lymph node dissection alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.17578125,23.0,Intensity=Strong,200,20-29%,CISH,CAP scoring guideline 2010,259.0283203125,HER2 amplification - negative,Ratio >=2.0,YES,NO,2.38,LungBone,90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.62,3 Point Scale,2+,7thStage IIICT2N3aM0,YES,NO,NO,3,2,2014,TCGA-LD-A7W5-F6918432C744CB-6C00-4920-9077-111C970D52BANONOYESWITH TUMORAlive216NO30122014,NOTCGA-LD-A7W5-D5634571C98143-F9F6-4C6F-A7DD-168C6BC9E03482145ChemotherapyTaxotereNOStable Disease322014NOTCGA-LD-A7W5-D56346C0C80864-B5AF-43CC-9232-BC05B414149182ChemotherapyCytoxanYES322014,TCGA-A2-A0EU-R1714bc456128-c77d-444f-a359-a200d25bf391116193EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11282010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,863.0,BLACK OR AFRICAN AMERICAN,TCGA-AO-A12H,AO,A12H,No,YES,C50.9,8523/3,C50.9,2008.0,TUMOR FREE,YES,10.0,H-Score 295,H-Score 290,Right Upper Outer QuadrantRight,1.372695312499995,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,surgical resection,Modified radical mastectomy,Modified Radical Masectomy,"Other, specify",MUCINOUS & PAPILLARY,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,4+,0,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,230,STRONG,<10%,CISH,3+ Positive,35.2724609375,Vysis AutoVysion System,RATIO > = 2.0,NO,YES,1.45,LungBoneLiver,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,105,3 Point Scale,2+,6thStage IIAT2N0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,12,2010,TCGA-AO-A12H-F5910FCD6D02C-1D96-4158-B169-A5AAECD39B21863AliveTUMOR FREENOYES8122010TCGA-AO-A12H-F194511F5D7F28-3872-40B5-BD20-1E1E6418630DScheduled Follow-up SubmissionNOYESAlive1234TUMOR FREENO12122011,1TCGA-AO-A12H-D59836712f22e-0667-4a78-baed-2051f7f4f05a1mg/day73Hormone TherapyArimidex (Anastrozole)ADJUVANTPOYES1012011,TCGA-LQ-A4E4-R376118DA26ACA-40A2-4C08-90E0-BDECEEDE396463111External6040cGy33Primary Tumor FieldNOComplete Response5122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,6796.0,WHITE,TCGA-B6-A0RI,B6,A0RI,No,YES,C50.9,8500/3,C50.9,1992.0,WITH TUMOR,YES,15.0,IHC,IHC,Right Upper Outer QuadrantRight,1.2929003906249987,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,lobular/ductal,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,2+,3+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Positive,Equivocal,0.3095703125,6.0,Allred score 0,270 H,10-19%,Hercep Test  TM Dako,dextran coated charcoal,79.6591796875,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.38,"Other, specifySkin",70-79%,90-99%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.5,4 Point Scale,1+,3rdStage IIIBT4bN1bM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,11,2010,"TCGA-B6-A0RI-F13795654D049A-8513-4069-B954-CF23980C432EScheduled Follow-up SubmissionYESYESAlive7126WITH TUMORYES1100Locoregional DiseaseOther, specifyChest WallYES1100YESYESPositiveOther Reporting Scale133 fmol/mgimage cytometryPositiveOther Reporting Scale105 fmol/mgimage cytometry1272011",YESTCGA-A7-A5ZV-D431788F1125F3-DBBB-47BC-BACF-5CE4963DC96695137ChemotherapyDoxorubicinNOComplete Response1452013YESTCGA-A7-A5ZV-D43179EADD43A7-E14F-4643-A3BE-C251663F4AA095137ChemotherapyCyclophosphamideNOComplete Response1452013YESTCGA-A7-A5ZV-D4318052DC65F2-30C0-4BDD-89AC-641853A9E429151193ChemotherapyPaclitaxelNOComplete Response1452013,TCGA-E2-A572-R482486AF2B719-A8B2-4E95-BAF5-C4FAFA2FF01A19626360.4Gy28Primary Tumor FieldNOComplete Response1092013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2721.0,WHITE,TCGA-B6-A0RT,B6,A0RT,No,YES,C50.9,8500/3,C50.9,1996.0,TUMOR FREE,YES,23.0,Image Analysis,Image Analysis,Right Upper Outer QuadrantRight,1.2287988281249964,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,lobular/ductal,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,2+,3+,Negative,Close,Fine needle aspiration biopsy,intraoperative examination,Negative,Negative,Equivocal,0.224609375,1.0,Allred score 0,270 H,10-19%,Hercep Test  TM Dako,dextran coated charcoal,79.837890625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.38,"Other, specifySkin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,172,4 Point Scale,1+,4thStage IIIAT3N1M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,3,11,2010,TCGA-B6-A0RT-F137891E4F30E1-0F1A-4FD6-A858-B54D79689792Scheduled Follow-up SubmissionYESYESAlive2721TUMOR FREENO1272011,NOTCGA-B6-A40C-D410400EE50169-85A2-4749-923E-DC70257C063A37107Hormone TherapyCyclophosphamideNO1132013NOTCGA-B6-A40C-D41041AF65E574-4989-44B0-B73C-85E950DF1BC637107ChemotherapyDoxorubicinNO1132013NOTCGA-B6-A40C-D4104393C4C94A-4713-49E3-85A0-2D02AF47B8E8128170ChemotherapyPaclitaxelNO1132013,TCGA-BH-A0H3-R58600C0B72A02-DD39-4927-8682-60DBA02D627977115External5040cGy28Regional siteNOComplete Response1542014TCGA-BH-A0H3-R58601091A7641-7710-4553-8542-90FDEBEFA4AF118126External14Gy7Primary Tumor FieldNOComplete Response1542014
TCGAFPPP,Breast,No,FEMALE,Dead,1032.0,1526.298828125,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3XS,A2,A3XS,No,YES,C50.9,8500/3,C50.9,2003.0,WITH TUMOR,YES,19.0,No value Given,Allred score 4+3 = 7,Left Upper Outer Quadrant,1.3,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Right Breast Reexcision,Mastectomy NOS,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Equivocal,0.0,9.0,8,8,10-19%,ACIS,Dako Hercept test,100.4970703125,Vysis AutoVysion System,PathVysion Her-2 DNA,NO,YES,2.38,Lung,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,1.80,3 Point Scale,2+,6thStage IIIAT1N2aM0,YES,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,15,8,2012,TCGA-A2-A3XS-F344465BBB886F-91E0-431D-A6DC-E1BB89E95022Additional New Tumor EventNOYESDead1032WITH TUMORYES682Distant MetastasisLungNONOYES1582012,NOTCGA-A2-A3XS-D34447B3410728-5DD2-4C46-8F60-384AE7FD0DE0112154ChemotherapyCytoxanNOComplete Response1582012NOTCGA-A2-A3XS-D3444957BE30DA-D982-441F-9385-4A8F49FD6C7F112154ChemotherapyAdriamycinNOComplete Response1582012NOTCGA-A2-A3XS-D34450C4D6719C-2751-4CCD-A188-EC01BB23E1B0167210ChemotherapyPaclitaxelNOComplete Response1582012NOTCGA-A2-A3XS-D344518FC4D02E-D7CA-465A-A5DF-A4C2323A2ACC281682Hormone TherapyTamoxifenNOClinical Progressive Disease1582012NOTCGA-A2-A3XS-D344520E43D65F-FF3E-49BB-9DEA-8C8B0BF3AD17695806ChemotherapyDocetaxelNOClinical Progressive Disease1582012NOTCGA-A2-A3XS-D34453F4FCCE3E-BB62-4A80-909D-A1DC2198705D895958AncillaryAvastinNOClinical Progressive Disease1582012NOTCGA-A2-A3XS-D34454055A4779-B7FE-4F15-894F-81785BED5BE4874980ChemotherapyXelodaNOClinical Progressive Disease1582012NOTCGA-A2-A3XS-D344550221663A-3CAA-42B8-B315-073962FBD6FF9861022ChemotherapyNavelbineNOClinical Progressive Disease1582012,TCGA-E9-A1RE-R306323C41D803-3D12-4E01-B2D6-2940A6BE6E4C183209EXTERNAL BEAM4000cGy20Regional siteADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,218.0,WHITE,TCGA-AN-A0FN,AN,A0FN,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,dextran coated charcoal,dextran coated charcoal,Right Lower Outer Quadrant,3.0496777343749857,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Partial Mastectomy,Infiltrating Lobular Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Positive,0.0,0.0,Two-tier,250,20-29%,0,dextran coated charcoal,64.224609375,Vysis AutoVysion System,Path Vysion HER2 DNA Probe Kit,NO,YES,78,"Other, specifySkin",90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,105,3 Point Scale,1+,7thStage IAT1cN0M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,12,2010,TCGA-AN-A0FN-F6895316502F77-C804-49D7-99F6-20F92037D659YESNONOTUMOR FREEAlive21823122014,NOTCGA-AQ-A7U7-D54378F857DE6F-EDB7-4A82-8BE1-58094AF4D53A123193ImmunotherapyRituximabNOComplete Response18122013NOTCGA-AQ-A7U7-D54381EBE759A2-2DF0-4B0B-B155-47E54A053E90123193ChemotherapyCyclophosphamideNOComplete Response18122013NOTCGA-AQ-A7U7-D543825AC8BA1D-DEBC-48E8-83C5-2866BCF86F9B123193ChemotherapyDoxorubicinNOComplete Response18122013NOTCGA-AQ-A7U7-D54385894571F0-1421-4634-8EF3-350800E2C13A123165ChemotherapyVincristineNOComplete Response18122013NOTCGA-AQ-A7U7-D54386F2C99A5C-0BC4-4921-952F-76BF03F2B539123193Hormone TherapyPrednisoneNOComplete Response18122013NOTCGA-AQ-A7U7-D54387CCBE1A5B-B0E1-430F-9221-C2B446502EEC296Hormone TherapyLetrozoleYES18122013,TCGA-BH-A0H3-R58600C0B72A02-DD39-4927-8682-60DBA02D627977115External5040cGy28Regional siteNOComplete Response1542014TCGA-BH-A0H3-R58601091A7641-7710-4553-8542-90FDEBEFA4AF118126External14Gy7Primary Tumor FieldNOComplete Response1542014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,267.0,WHITE,TCGA-E2-A15T,E2,A15T,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,Allred score 5+3 = 8,Allred score 2+3 = 5,Left Upper Outer Quadrant,1.3,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Equivocal,0.8349609375,0.0,Allred score = 5,Allred score = 8,30-39%,Dako,Venten,95.4580078125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.38,"LungOther, specifyleft adrenal gland",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,131,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",14,4,2011,TCGA-E2-A15T-F191425FADD77F-D2D8-4A50-86D0-50425E3A96C6Scheduled Follow-up SubmissionNOYESAlive456TUMOR FREENO16112011TCGA-E2-A15T-F70019686DF890-B124-45EE-95DB-3848AB3F3B73NONOYESTUMOR FREEAlive1563NO922015,1TCGA-E2-A15T-D19143A71ADC96-7255-4D33-ABC9-4883E48C7DB31mg/day1mg/day34Hormone TherapyArimidexADJUVANTPOYES17112011,TCGA-A2-A0EO-R19929e36f785-838a-4b6a-a404-6cb8df45ea5a91137EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11182010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,868.0,WHITE,TCGA-BH-A0HY,BH,A0HY,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,3.0,Allread score 5+3 = 8,H-Score 290,Left,2.1293359375000134,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,surgical resection,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,0.384765625,0.0,Allred Score 5,Allred Score 5,10-19%,Hercep Test  TM Dako,Dako Hercept test,250.6484375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,33,Lung,<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,71,3 Point Scale,1+,6thStage IT1cN0M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,8,2011,TCGA-BH-A0HY-F19336AB886C18-3E2F-4605-A7DE-25582B252CF9Scheduled Follow-up SubmissionNOYESAlive1008TUMOR FREENO8122011TCGA-BH-A0HY-F4331642F0E658-C564-4BFE-BC03-51BBA0021726NONOYESTUMOR FREEAlive1545NO1652013,YESTCGA-BH-A0HY-D433177EC3CB4B-FC47-4903-8C56-460C10384B0888190Hormone TherapyTaxotereNOComplete Response1652013YESTCGA-BH-A0HY-D43318136D0D8F-953A-40A9-AB68-828686DD333B88190ChemotherapyCarboplatinNOComplete Response1652013YESTCGA-BH-A0HY-D433196C77D915-C2F7-4ED7-A3BE-5658AA5B858088427ChemotherapyHerceptinNOComplete Response1652013,TCGA-BH-A0DP-R453761E05A64-548D-49A2-82C0-BD15A10024CD136180EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,620.0,WHITE,TCGA-AR-A2LR,AR,A2LR,No,YES,C50.9,8575/3,C50.9,2010.0,TUMOR FREE,YES,4.0,IHC,Allred score 5+3 = 8,Right,1.3065820312499914,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,surgical resection,Other,segmental mastectomy with sentinel lymph node biopsy,Metaplastic Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.4638671875,0.0,Allred Score 8,Moderate,90-99%,Dako,CAP scoring guideline 2010,376.599609375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,3.1,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.8,3 Point Scale,2+,7thStage IT1N0M0,YES,YES,PositiveNegative,14,2,2012,TCGA-AR-A2LR-F3760022969DEA-7B38-42A9-95BD-4710D4BBFA96NONONOTUMOR FREEAlive846NO6122012TCGA-AR-A2LR-F71747E250D902-9F8D-4000-8C72-4DBD74E19452NONONOTUMOR FREEAlive1742NO3032015,NOTCGA-AR-A2LR-D3760203400FAC-D55D-4626-A257-9C1AE7178017-1428-1386ChemotherapyAdriamycinNO6122012NOTCGA-AR-A2LR-D37603CDD3764F-94E6-493E-8E99-6A9A7370E1B2-1428-1386ChemotherapyCytoxanNO6122012,TCGA-AR-A2LR-R37601892A1FE4-D10E-4BD7-B38E-303B77033602-1347-1306External6000cGy30Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1442.0,WHITE,TCGA-BH-A0DX,BH,A0DX,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,11.0,ER Positive H-Score 95,Allred score 4+3 = 7,Left Upper Inner Quadrant,1.7974609375000037,Sentinel node biopsy alone,axillary ultrasound,Other,Right Breast Reexcision,Modified radical mastectomy,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.66796875,0.0,allred score = 8,80,<10%,ACIS,CAP SCORING GUIDELINE 2010,62.318359375,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,40,Lung,<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,52,3 Point Scale,2+,6thStage IT1bN0M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,8,2011,TCGA-BH-A0DX-F59135982B9831-0BBC-4677-99EB-6A34B28D422CNOYESYESTUMOR FREEAlive2156NO152014,NOTCGA-BH-A0DX-D59137174495DC-4D02-47CB-8306-FF4E876B9A7E79143ChemotherapyTaxotereNOComplete Response152014NOTCGA-BH-A0DX-D591381FA0D545-9D52-4FDC-B43B-62C04A51EC4E79143ChemotherapyCytoxanNOComplete Response152014NOTCGA-BH-A0DX-D591409D0C1A3D-2B12-41EB-AF5F-8A97855518FE143171ChemotherapyCytoxanNOComplete Response152014NOTCGA-BH-A0DX-D59141E8FE1855-0A33-4663-A2E3-605059890515143171ChemotherapyMethotrexateNOComplete Response152014,TCGA-BH-A0DX-R59136CBDB023B-245F-4480-B77C-958E1430C45A171221External5040cGy36Primary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Dead,365.0,850.3525390625,WHITE,TCGA-BH-A1EV,BH,A1EV,No,YES,C50.9,8500/3,C50.9,1999.0,WITH TUMOR,YES,10.0,Allred score 7 (outside facility),H-Score 290,Left,2.0112890624999986,Sentinel node biopsy alone,Pateys surgery,Modified Radical Mastectomy,Right Breast Reexcision,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,0.8271484375,3.0,allred score = 8,8,10-19%,ACIS,Dako Hercept test,93.662109375,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,64,Lung,70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,3.3,3 Point Scale,2+,5thStage IIIAT3N1bM0,NO,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,7,9,2011,TCGA-BH-A1EV-F591546934F0BA-FA6D-4451-9935-E84F316DC61ANOYESNOWITH TUMORDead365NO152014,1TCGA-A2-A0D2-D18220b7ae681-1762-4598-b9c5-79d77a5f208a435mg108-109mg474123ChemotherapyAdriamycinADJUVANTIVNO17920102TCGA-A2-A0D2-D1823956680fa-6dc8-437e-8529-32d884b2e5724344mg1086mg474123ChemotherapyCytoxanADJUVANTIVNO17920103TCGA-A2-A0D2-D1824ef46d977-60f0-4915-9438-4c3e9c7e66d81308mg325-329mg4137179ChemotherapyTaxolADJUVANTIVNO1792010,TCGA-BH-A1EV-R5915514C932E3-F25E-44E0-B94B-C633091990EC48139External6000cGyPrimary Tumor FieldNORadiographic Progressive Disease152014TCGA-BH-A1EV-R5915670674749-BAAD-4C56-AA1E-92C3F0FB568C48139External5000cGyRegional siteNORadiographic Progressive Disease152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2576.0,BLACK OR AFRICAN AMERICAN,TCGA-AO-A03P,AO,A03P,No,YES,C50.9,8500/3,C50.9,2003.0,WITH TUMOR,YES,26.0,allred score 0 + 0 = 0,Allred 0 = 0+0,Right Upper Outer QuadrantRight,1.980556640624995,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,Total mastectomy,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,0,Negative,Close,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,2.0,0.0,230,Allred Score 5,<10%,CISH,3+ POSITIVE,36.2939453125,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,1.0,"Other, specifySkin",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,816,3 Point Scale,2+,6thStage IIBT2N1M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",19,9,2010,TCGA-AO-A03P-F3073E3386E19-D171-4D36-A0E4-E8278E44C2FAAliveWITH TUMOR2576YESNO1922YES1922Positive90-99%4+Positive80-89%2+Equivocal20-29%2+3+ POSITIVENegative4.02.4401.7RATIO > 2.2NOYES1992010TCGA-AO-A03P-F1545246278B90-E76B-4B39-B3C0-42D6AC1CF690Scheduled Follow-up SubmissionYESNODead2911WITH TUMORYES1922Distant MetastasisLiverNOPositive90-99%4 Point Scale4+Positive80-89%4 Point Scale2+Equivocal20-29%2+3 Point ScaleNegative4.02.4401.7RATIO >2.22282011,"3TCGA-AO-A03P-D3084a2e0b197-c210-47bf-94ae-a6c24311cc1720050mg10mg/kg2724512822ImmunotherapyBEVACIZUMABRECURRENCEIVNO6920103TCGA-AO-A03P-D30839d61ae92-631d-4965-be2d-59cb2d7b83eb1500mg/day24222839ChemotherapyCAPECITABINERECURRENCEPONO19920102TCGA-AO-A03P-D3082726efafa-90dd-4a5e-b0fd-4e283d1caebb25mg/day23322422Hormone TherapyEXEMESTANE (AROMASIN)RECURRENCEPONO19920101TCGA-AO-A03P-D3079fd50d042-4a2a-43d3-9cd4-d7f90dd15f4e2.5mg/day19182331Hormone TherapyLETROZOLE (FEMARA)RECURRENCEPONO19920105TCGA-AO-A03P-D154600431F2EF-29FF-4AD2-A3CC-BF47622615EA1500mg500mg328532881Hormone TherapyFULVESTRANTOTHER, SPECIFY IN NOTESEstrogen receptor antagonist in metastatic breast cancerIMNO2282011",TCGA-AO-A03P-R3077880c6fc2-c85f-4ab2-a92c-9cbb2dfd34ab98141EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO11992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,322.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-AA0Z,S3,AA0Z,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,12.0,CAP scoring guideline 2010,CAP scoring guideline 2010,LeftLeft Upper Outer Quadrant,1.3,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast Reexcision,Other,L Total Mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.0,2.0,allred score = 4,moderate,10-19%,ACIS,CAP scoring guideline 2010,20.0,HER2 amplification - negative,CAP scoring guideline 2010,YES,NO,33,LungBone,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,42,3 Point Scale,1+,7thStage IIBT2N1aM0,YES,NO,NO,18,4,2014,TCGA-S3-AA0Z-F67525397466CB-7104-4751-8B52-A50887F445FDNONOYESTUMOR FREEAlive511NO6112014TCGA-S3-AA0Z-F70168CD0FD114-2C9E-415B-A350-A4738DA7CB7CNONOYESTUMOR FREEAlive629NO2622015,NOTCGA-S3-AA0Z-D583533637BA55-6C9D-4F13-A47E-32FD9792653B8484AncillaryNEULASTANOComplete Response1842014NOTCGA-S3-AA0Z-D5834252E9F222-05FA-42AB-A37A-8494A24CC5698484ChemotherapyDOXORUBICINNOComplete Response1842014NOTCGA-S3-AA0Z-D58343B9B5E318-2BBB-4B47-82CC-96C736833EFC8484ChemotherapyCYTOXANNOComplete Response1842014NOTCGA-S3-AA0Z-D585512E454798-EBBB-4BE9-BC9A-A8A1E4A9C043113Hormone TherapyANASTROZOLEYES1842014,TCGA-BH-A0W7-R34078BEFB5D3C-A0C6-4F5D-8E1A-C0561BEFCEB9168229External1600cGy36Primary Tumor FieldNOComplete Response2972012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-LL-A6FP,LL,A6FP,Yes,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,NO,13.189453125,image cytometry,Allred score 2+2 = 4,Right Upper Outer Quadrant,0.9,No axillary staging,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Nipple Sparing Total Mastectomy,Infiltrating Lobular Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,1.3798828125,5.25390625,allred score = 6,Intensity=Strong,90-99%,CISH,Dako Hecept Test,549.0,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,YES,NO,3.1,Lung,90-99%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.6,3 Point Scale,1+,7thStage IIAT2NXMX,YES,NO,NO,3,9,2013,TCGA-LL-A6FP-F6405031BBE6D1-6AF1-4980-985B-A696679676AANONOYESAlive0NO2582014,NOTCGA-LL-A6FP-D479693D373A52-0D38-443C-AAC5-0376FC840F090Hormone TherapyArimidexYES392013NOTCGA-LL-A6FP-D479701ED178CF-05EE-41AD-B1AC-37FA1DAE065A00Hormone TherapyTamoxifenNO392013,TCGA-A2-A04T-R9342eac92060-57fb-4a09-8498-7c5e1e4b9924206249EXTERNAL BEAM6040cGyPrimary Tumor FieldADJUVANTNO12132011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,180.0,WHITE,TCGA-BH-A0W3,BH,A0W3,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,4.0,ER Positive H-Score 95,H-Score 160,Left Upper Inner Quadrant,1.5665136718749983,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,ductal/mucinous,Indeterminate (neither Pre or Postmenopausal),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,1.0,1.0,Allred score = 5,8,10-19%,Dako,CAP scoring guideline 2010,114.1337890625,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,50,Lung,<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,60,3 Point Scale,2+,7thStage IIAT1cN1aM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",14,2,2011,TCGA-BH-A0W3-F340650C4DAF8C-F0CA-4E03-9F35-21E17062ECEBScheduled Follow-up SubmissionYESNOAlive728TUMOR FREENO2972012,NOTCGA-E9-A1NH-D3505423703F4A-C80E-4EF7-BB6D-673805FC889933Hormone TherapyTamoxifenYES1492012,TCGA-BH-A0W3-R340662559A85D-0AA2-4EAE-937A-6BF2C5B279426398External46GyPrimary Tumor FieldNOComplete Response2972012TCGA-BH-A0W3-R34067A6B969D8-4A1C-4537-94C9-B06187812BFA6396External46GyRegional siteNOComplete Response2972012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0FX,AN,A0FX,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,12.0,CAP scoring guideline 2010,CAP scoring guideline 2010,Left Upper Outer Quadrant,2.310732421874991,No axillary staging,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,partial mastectomy,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Positive,0.0,0.0,0,0,40-49%,0,Venten,151.986328125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.0,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,<4.0,3 Point Scale,1+,Stage IIAT2N0M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,11,2010,TCGA-AN-A0FX-F6896729111D0E-E852-4132-98D1-EFDEB235F4F6YESNONOTUMOR FREEAlive1024122014,TCTCGA-EW-A1P4-D2968779E0A6AE-A364-45A1-9ED5-E0FBDD00DAA975mg/m2473144ChemotherapyDocetaxelADJUVANTIVNO2632012TCTCGA-EW-A1P4-D29689E8073733-F67A-40F9-88DA-22013C8ED597600mg/m2473144ChemotherapyCyclophosphamideADJUVANTIVNO2632012,TCGA-A2-A0CK-R326474B8B651E-F54C-4EB0-AC3F-BFEFB8E3BF05243280External5040cGyRegional siteNOComplete Response562012TCGA-A2-A0CK-R3265357C35411-3766-4C37-B699-47F58743FD98243280External5040cGyRegional siteNOComplete Response662012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,177.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A56D,A7,A56D,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,8.0,Allred score 7 (outside facility),Allred score 0+0=0,Left Lower Inner Quadrant,1.2827832031249948,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Lumpectomy,Right Breast Reexcision,Other,surgical resection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,240 H,moderate,90-99%,ACIS,CAP scoring guideline 2010,62.3662109375,HER2 amplification - negative,Ratio >=2.0,YES,NO,2.38,Lung,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,5,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,NO,1,4,2013,TCGA-A7-A56D-F50426EEF11DEE-7878-4235-9B8C-E0F6B2BCE27ANONOYESTUMOR FREEAlive448NO23102013,NOTCGA-A7-A56D-D4183580BF0AFC-29C9-4B5B-A9E4-95F4B5A4EEDC157Hormone TherapyArimidexYES142013,TCGA-AR-A0TP-R18481B4DEB351-1554-4E4E-90E0-E4F24497D2B3125166EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO112122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,673.0,WHITE,TCGA-BH-A0DI,BH,A0DI,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,28.0,No value Given,Allred 5 = 2+3,Right,1.842421875000007,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.46875,3.0,Allred Score 5,Allred Score,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,79.916015625,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,1.45,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.3,3 Point Scale,2+,6thStage IIBT2N1aM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,8,2011,TCGA-BH-A0DI-F5869831AD28DA-0E4B-4F0D-95BF-E74BE74D8070NOYESYESTUMOR FREEAlive912NO2242014,YESTCGA-BH-A0DI-D58707062DAD22-5616-49FF-9EE5-1C0763405FEE131194ChemotherapyAdriamycinNOComplete Response2242014YESTCGA-BH-A0DI-D58708CD0C2F47-0F49-4143-8B90-4DD1AEF83C03131194ChemotherapyCytoxanNOComplete Response2242014YESTCGA-BH-A0DI-D58709443925EA-94E1-4E24-96E1-9D9EAC2A280A215319ChemotherapyTaxolNOComplete Response2242014,TCGA-BH-A0DI-R58701F056AB35-31BF-4599-ABE9-440E2C255424362402External50Gy28Primary Tumor FieldNOComplete Response2242014TCGA-BH-A0DI-R5870467811850-0D4F-4182-8CBF-45970A1F7B64322357External45Gy25Regional siteNOComplete Response2242014TCGA-BH-A0DI-R58706638AB258-DB1B-4910-9106-5FA88FB73D59363369External10Gy5Primary Tumor FieldNOComplete Response2242014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1034.0,WHITE,TCGA-A8-A08X,A8,A08X,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,11.9775390625,H-SCORE 300,Allred score 5+3=8,Left,1.4131445312499955,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Negative,Positive,0.4365234375,3.396484375,Allred Score 5,230,10-19%,ACIS,CAP SCORING GUIDELINE 2010,133.51953125,Vysis AutoVysion System,Ratio >=2.0,NO,YES,2.38,"Other, specifySkin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,61,3 Point Scale,2+,6thStage IIICT4dN3aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A08X-F4055884AE03E2-883C-4C00-840D-ACBADE8ECEE0NOYESYESTUMOR FREEAlive1308YES3662422013,NOTCGA-A8-A08X-D37787BE723714-41E5-4FCD-A43A-AF09F02ECE83061ChemotherapyDoxorubicinn/aNOComplete Response6122012NOTCGA-A8-A08X-D37788FA20A7B4-6AD1-4A7C-885A-4A7B13295649061ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08X-D377891112F7D7-6984-4F61-85B5-5D60C66A006B91153ChemotherapyPaclitaxeln/aNOComplete Response6122012NOTCGA-A8-A08X-D3779077710F3F-EECC-49E3-AA85-02773DE4D2431821249Targeted Molecular therapyTrastuzumabn/aNOComplete Response6122012NOTCGA-A8-A08X-D3779168CC8611-6E89-4582-9597-FCA264BEE43C669884ChemotherapyVinorelbinen/aNOComplete Response6122012NOTCGA-A8-A08X-D377922DA191F1-8A7A-4538-A7E6-BD7F8ECA8A15366Hormone TherapyTamoxifenn/aYES6122012,TCGA-A8-A08X-R381636525F080-30D7-4E01-A26D-B5D03967F204153182External60GyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,492.0,WHITE,TCGA-D8-A73U,D8,A73U,No,YES,C50.9,8520/3,C50.9,2012.0,WITH TUMOR,NO,4.7294921875,Allred (Biocare),Allred (Biocare),Left Upper Outer Quadrant,4.655263671874999,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Right Breast Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,0.54296875,0.0107421875,0%,Moderate,<10%,Dako,DAKOHercepTest TM,194.7724609375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,33,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,NO,28,3,2014,TCGA-D8-A73U-F5787166FB6CC5-35C7-47CF-9FB4-63E3DB488520NONOYESWITH TUMORAlive492NO2832014,NOTCGA-D8-A73U-D5787296016F6D-6A93-4CA4-8261-A995B5304A9D75Hormone TherapytamoxifenYES2832014,TCGA-BH-A0BS-R633978727D0E4-840A-4524-962B-7AD1986FB858245302External6040cGy25Primary Tumor FieldNOComplete Response782014TCGA-BH-A0BS-R63398FB9FF030-2089-4C98-BB5C-D04016148325245302External46.8Gy26Regional siteNOComplete Response782014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,81.0,WHITE,TCGA-D8-A1XC,D8,A1XC,No,YES,C50.9,8480/3,C50.9,2010.0,TUMOR FREE,YES,20.0,% IHC,%IHC,Right Upper Inner Quadrant,1.7235058593749972,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast Reexcision,Other,TOTAL MASTECTOMY,Mucinous Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Positive,Negative,0.0,1.0,>75%,>75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,69.2763671875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,54,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2,3 Point Scale,2+,7thStage IIIBT4bN1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,16,5,2011,TCGA-D8-A1XC-F2943927296384-E750-4A9E-9214-F7D9E9040B5BScheduled Follow-up SubmissionNONODead377WITH TUMORYESDistant MetastasisBoneNO2632012,1TCGA-A2-A0YC-D56770c6ae6c0-6396-40ca-8f21-e1d33a8e9ad01mg103Hormone TherapyArimidexADJUVANTPOYES8122010,TCGA-BH-A0W3-R340662559A85D-0AA2-4EAE-937A-6BF2C5B279426398External46GyPrimary Tumor FieldNOComplete Response2972012TCGA-BH-A0W3-R34067A6B969D8-4A1C-4537-94C9-B06187812BFA6396External46GyRegional siteNOComplete Response2972012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,416.0,BLACK OR AFRICAN AMERICAN,TCGA-A1-A0SJ,A1,A0SJ,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,19.0,CAP scoring guideline 2010,Allred score 5+3 = 8,Left,1.0,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.109375,3.0,MODERATE,205,30-39%,CISH,Venten,138.6064453125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,4,"Other, specifySkin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,5,3 Point Scale,1+,6thStage IIIAT3N1aM0,YES,NO,YES766Distant MetastasisBoneNOYESNO,6,12,2010,TCGA-A7-A56D-F50426EEF11DEE-7878-4235-9B8C-E0F6B2BCE27ANONOYESTUMOR FREEAlive448NO23102013,TCGA-E9-A1RE-D3062988021F1F-6F05-49C2-974E-C81F92FBF7E1100mg100mg150145ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RE-D306257DC35BFA-9C80-4F0C-91E8-F45010BFF3A16000mg2000mg350145Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RE-D30626BC07A0C3-99D7-49FA-8CDA-8BDC0A5B3CFE1500mg1500mg150145Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RE-D306281955E286-AE41-4016-95CE-453A407709C080mg80mg150145ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RE-D30627E75E0ABA-5130-4FBE-B9D7-44081F1FF713120mg60mg250145ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RE-D30630AB669FF9-A215-4611-851F-9CF3F1DB948C6400mg1600mg450145ChemotherapyCyclophosphamideADJUVANTIVNO1342012TCGA-E9-A1RE-D306317E328C05-236F-4222-82CC-33615BDF912420mg/day39Hormone TherapyTamoxifenADJUVANTPOYES1342012,TCGA-LQ-A4E4-R376118DA26ACA-40A2-4C08-90E0-BDECEEDE396463111External6040cGy33Primary Tumor FieldNOComplete Response5122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,461.0,WHITE,TCGA-A2-A1FV,A2,A1FV,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,2.0,No value Given,allred score 4 + 3 = 7,Left,0.92,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast Reexcision,Other,Modified Radical Masectomy,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,1.0,0.0,Strong,Strong,10-19%,ACIS,Hercep Test  TM Dako,125.029296875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,50,"LungOther, specifyleft adrenal gland",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.3,3 Point Scale,3+,7thStage IIBT3N0 (i+)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,26,5,2011,TCGA-A2-A1FV-F20238AC3FEC50-CC82-40E1-968F-65B1B6619C0DScheduled Follow-up SubmissionYESYESAlive714TUMOR FREENO912012,1TCGA-A2-A1FV-D122634a36ce19-e3bb-4484-a0c0-8c815afa84a74128mg1032mg470133ChemotherapyCyclophosphamideADJUVANTIVNO26520113TCGA-A2-A1FV-D1226609c584e4-9d41-455c-9e08-87c9f0f931b71mg/day141Hormone TherapyArimidexADJUVANTPOYES26520112TCGA-A2-A1FV-D12265bad34945-e422-45a6-9c03-6f05d34514c8516mg129mg470133ChemotherapyDocetaxelADJUVANTIVNO2652011,TCGA-A2-A1FV-R12267f0cdeb52-224b-47d4-8e49-4f3783f09429169216EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO12652011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5.0,ASIAN,TCGA-C8-A1HJ,C8,A1HJ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,H-Score 150,H-Score 0,Right,1.3854785156249985,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,Patey's Surgery,Infiltrating Ductal Carcinoma,lobular/ductal,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Surgery,Positive,Negative,Negative,0.0986328125,0.0,Allred score = 7,0%,90-99%,Hercep Test  TM Dako,Venten,164.2060546875,Vysis AutoVysion System,Ratio >=2.0,YES,NO,1.78,Lung,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.1,4 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,PositivePositiveNegativeNegative1.09,1,6,2011,TCGA-E9-A228-F297617CC23D2A-F635-4B8A-92F5-F30A0C403E27Scheduled Follow-up SubmissionNOYESAlive381TUMOR FREENO2832012TCGA-E9-A228-F658049B040232-D621-4B8B-9E8A-B5499D08A9B4NONOYESTUMOR FREEAlive1285NO3092014,NOTCGA-D8-A73U-D5787296016F6D-6A93-4CA4-8261-A995B5304A9D75Hormone TherapytamoxifenYES2832014,TCGA-EW-A423-R389368A98C19C-07DE-43E1-8391-6975D585C79352162ExternalPrimary Tumor FieldNOComplete Response412013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A228,E9,A228,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,12.0,CAP scoring guideline 2010,Allred score 5+3 = 8,Right Lower Inner Quadrant,1.834453125000009,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,Excision,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,stereotactic biopsy,Negative,Positive,Equivocal,0.1103515625,2.0,moderately to strongly,250,<10%,Hercep Test  TM Dako,Hercep Test  TM Dako,63.26953125,Vysis AutoVysion System,Ratio >=2.0,YES,NO,54,Lung,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.3,4 Point Scale,1+,7thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,8,2011,TCGA-E9-A228-F297617CC23D2A-F635-4B8A-92F5-F30A0C403E27Scheduled Follow-up SubmissionNOYESAlive381TUMOR FREENO2832012TCGA-E9-A228-F658049B040232-D621-4B8B-9E8A-B5499D08A9B4NONOYESTUMOR FREEAlive1285NO3092014,TCGA-E9-A228-D2976419F31BA2-DE6B-46F0-AADB-37D011E8224C2240mg20mg/day287Hormone TherapyTamoxifenADJUVANTPOYES2832012TCGA-E9-A228-D297624C597D0D-8804-43BE-BE0A-3743B29B55BF360mg90mg/day435131ChemotherapyDoxorubicinADJUVANTIVNO2832012TCGA-E9-A228-D297638EE571E0-A2A2-4B47-A86B-8FFA4F553A223600mg900mg/day435131ChemotherapyCyclophosphamideADJUVANTIVNO2832012,TCGA-D8-A1X9-R29433104383D3-283E-4D53-AAA0-4A610BB320E7320350EXTERNAL BEAM4500cGy20Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,352.0,ASIAN,TCGA-JL-A3YX,JL,A3YX,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,16.0,Allred (Biocare),allred score 5+3+8,Left,1.7232226562499893,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,surgical resection,Modified radical mastectomy,Partial Mastectomy,Infiltrating Lobular Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,stereotactic biopsy,Negative,Positive,Positive,0.0,0.0,Allred score = 7,Allred score 7 (per outside facility),30-39%,CISH,Hercep Test TM DAKO,121.2197265625,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,YES,NO,50,Lung,30-39%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,52,3 Point Scale,2+,7thStage IIAT2N0M0,NO,NO,NO,8,11,2012,TCGA-D8-A145-F13811B69A91EE-1BA2-4163-A64D-36753ABD9880Scheduled Follow-up SubmissionNOYESAlive410TUMOR FREENO472011,1TCGA-E2-A155-D18962E7F98449-1AD2-4788-98A9-C1B731F13D28430ChemotherapyCytoxanADJUVANTNO81120113TCGA-E2-A155-D19107FF8866DF-0183-4B72-8285-E71C4F12035920mg/day20mg/day249Hormone TherapyTamoxifenADJUVANTPONO81120112TCGA-E2-A155-D1910539BFC0D7-45BC-4640-BA13-4397A0A9CE0612ChemotherapyTaxolADJUVANTNO81120111TCGA-E2-A155-D18944C399DF54-62D4-49E4-AB11-5B0008E16218430ChemotherapyAdriamycinADJUVANTNO81120114TCGA-E2-A155-D19111DFA20391-05F7-4053-9EC5-1BD5F52619681mg/day1mg/day249Hormone TherapyArimidexADJUVANTPOYES8112011,TCGA-3C-AALI-R629012FE462E5-9AEE-417B-BF7C-908AA69A55A93203525000cGy25Primary Tumor FieldNO2872014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,49.0,WHITE,TCGA-D8-A145,D8,A145,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,manual counting,manual counting,Right Upper Inner QuadrantRight,1.8060546874999908,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Right Breast Reexcision,Other,Mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.134765625,1.0,Allred score 5,>75%,10-19%,Dako,CAP SCORING GUIDELINE 2010,136.0693359375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,4.43,Lung,70-79%,<10%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.816386718749996,2.23,3 Point Scale,2+,7thStage IIAT1cN1aM0,YES,NO,YES994Distant MetastasisBoneNOYESYES,25,2,2011,TCGA-D8-A145-F13811B69A91EE-1BA2-4163-A64D-36753ABD9880Scheduled Follow-up SubmissionNOYESAlive410TUMOR FREENO472011,tamoxifen dailyTCGA-D8-A145-D138129C0F81FC-804B-4F15-901B-D5256B63E8AF20mg/day42Hormone TherapyTamoxifenADJUVANTPOYES472011,TCGA-D8-A1X9-R29433104383D3-283E-4D53-AAA0-4A610BB320E7320350EXTERNAL BEAM4500cGy20Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,220.0,WHITE,TCGA-BH-A18I,BH,A18I,No,YES,C50.2,8500/3,C50.2,2010.0,TUMOR FREE,YES,3.0,Allred score 7 (outside facility),H-Score 290,Left Upper Outer Quadrant,1.753085937499994,Sentinel node biopsy alone,axillary ultrasound,Other,Right Breast Reexcision,Modified radical mastectomy,segmental mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Biopsy not specified,Positive,Positive,Positive,1.0,1.0,H score,H score,90-99%,ACIS,Dako Hercept test,98.8349609375,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,40,"LungBoneLiverOther, specifyskin",70-79%,60-69%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.66,3 Point Scale,2+,7thStage IIAT1cN1acM0 (i+),NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,6,2011,TCGA-BH-A18I-F58710FDFEEC48-B8F2-49EE-B102-CCF1754E0818NONOYESTUMOR FREEAlive1093NO2242014,NOTCGA-BH-A18I-D5871162D6ACAF-3359-411A-9715-AC1D93B3EB27121220ChemotherapyTaxotereNOComplete Response2242014NOTCGA-BH-A18I-D58712B4CF288C-CBDD-493D-8CB6-198994F91639121220ChemotherapyCytoxanNOComplete Response2242014,TCGA-GM-A3NY-R404047B29BB47-1F8A-4F98-ADD3-B16DEDB079F682124External60Gy30Primary Tumor FieldNOStable Disease1922013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,47.0,WHITE,TCGA-E9-A1RE,E9,A1RE,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,image cytometry,Allred score 2+2 = 4,Left Upper Outer Quadrant,1.5188476562499904,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Excision,Infiltrating Ductal Carcinoma,ductal and lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Equivocal,0.375,9.0,8,Intensity=Strong,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,129.5009765625,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,YES,NO,50,LungBone,70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.9,4 Point Scale,1+,7thStage IIIAT2N2M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,7,2011,TCGA-E9-A1RE-F306153B025302-2864-4320-8F48-62483817A045Scheduled Follow-up SubmissionYESYESAlive659TUMOR FREENO2412014TCGA-E9-A1RE-F395323097477B-AE0C-423F-8D1B-82856ADEA544NOYESYESTUMOR FREEAlive1054NO2412013TCGA-E9-A1RE-F687324C8D48A2-1C70-473F-8AED-C5D3C3385E26NOYESYESTUMOR FREEAlive1419NO12122014,TCGA-E9-A1RE-D3062988021F1F-6F05-49C2-974E-C81F92FBF7E1100mg100mg150145ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RE-D306257DC35BFA-9C80-4F0C-91E8-F45010BFF3A16000mg2000mg350145Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RE-D30626BC07A0C3-99D7-49FA-8CDA-8BDC0A5B3CFE1500mg1500mg150145Chemotherapy5-FluorouracilADJUVANTIVNO1342012TCGA-E9-A1RE-D306281955E286-AE41-4016-95CE-453A407709C080mg80mg150145ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RE-D30627E75E0ABA-5130-4FBE-B9D7-44081F1FF713120mg60mg250145ChemotherapyDoxorubicinADJUVANTIVNO1342012TCGA-E9-A1RE-D30630AB669FF9-A215-4611-851F-9CF3F1DB948C6400mg1600mg450145ChemotherapyCyclophosphamideADJUVANTIVNO1342012TCGA-E9-A1RE-D306317E328C05-236F-4222-82CC-33615BDF912420mg/day39Hormone TherapyTamoxifenADJUVANTPOYES1342012,TCGA-E9-A1RE-R306323C41D803-3D12-4E01-B2D6-2940A6BE6E4C183209EXTERNAL BEAM4000cGy20Regional siteADJUVANTNO11342012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,229.0,WHITE,TCGA-A7-A426,A7,A426,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,20.0,H-SCORE 300,Allred score 2+2 = 4,Right,1.1454785156249965,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Lobular Carcinoma,Invasive tubulolobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.1484375,13.0,Allred score = 7,205,<10%,CISH,Dako Hecept Test,166.3828125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,YES,NO,54,"LungOther, specifyleft adrenal gland",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,61,3 Point Scale,3+,7thStage IIICT3N3aMX,YES,YES,NO,5,11,2012,TCGA-A7-A426-F417437D3C9088-BC36-4448-A5A3-B00DD0B124F0NOYESYESTUMOR FREEAlive364NO2632013,NOTCGA-A7-A426-D3657796AB3786-43CC-4EB7-B2CE-1A163FDA16475597ChemotherapyAdriamycinNO3112012NOTCGA-A7-A426-D36578942628C7-12A1-4EF8-8464-8813B3BE25365597ChemotherapyCytoxanNO3112012NOTCGA-A7-A426-D36579BD940BFE-90EE-4928-8D31-2084078B12E6111202ChemotherapyTaxolNO3112012NOTCGA-A7-A426-D41740E049A833-72A0-4C05-8F37-8DB9DDE9746D258Hormone TherapyTamoxifenYES2632013,TCGA-A7-A426-R417411A137F59-0C07-44D6-829F-E4B539D4F496220257External5040cGy28Primary Tumor FieldNOComplete Response2632013TCGA-A7-A426-R4174234569FAF-40C8-41C8-8CD2-79E24B283462220257External5040cGy28Regional siteNOComplete Response2632013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1547.0,WHITE,TCGA-AO-A0JC,AO,A0JC,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,12.0,H-SCORE 260,CAP scoring guideline 2010,Right Upper Outer QuadrantRight Lower Outer QuadrantRight,3.143857421874979,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,0,Negative,Negative,Core needle biopsy,stereotactic biopsy,Positive,Positive,Negative,0.0,0.0,60,Moderate,<10%,CISH,3+ POSITIVE,31.142578125,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,1.1,"LungOther, specifyleft adrenal gland",90-99%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,105,3 Point Scale,3+,Stage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",20,9,2010,TCGA-AO-A0JC-F317905FE3C54-5669-446E-867D-3327FB4279671547AliveTUMOR FREEYESYES2092010TCGA-AO-A0JC-F15486A1E5BE94-918A-4E6B-97DC-9C8BE85726A8Scheduled Follow-up SubmissionYESYESAlive1547NO2282011,2TCGA-AO-A0JC-D31847ca89abd-c5d1-4bb2-a0d8-80b329119bdd2.5mg/day292Hormone TherapyLETROZOLE (FEMARA)ADJUVANTPOYES20920101TCGA-AO-A0JC-D31838599b409-0662-4eea-a61a-c27500d39b918700mg600mg/m2870221ChemotherapyFLUOROURACILADJUVANTIVNO20920101TCGA-AO-A0JC-D3182ae622289-bf49-4818-8ada-6629cddbb9998700mg600mg/m2870221ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO20920101TCGA-AO-A0JC-D318104fadaa5-10b7-4b05-be8a-2f5ad9ea89b6560mg40mg/m2870221ChemotherapyMETHOTREXATEADJUVANTIVNO2092010,TCGA-AO-A0JC-R3180541d6c3c-3efe-4473-9818-68bb9f9a9693252298EXTERNAL BEAM21160cGy33Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1310.0,WHITE,TCGA-AR-A1AQ,AR,A1AQ,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,6.0,H-SCORE 190,IHC,Right Upper Inner QuadrantRight Upper Outer Quadrant,1.3950488281249918,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Right Breast Reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Negative,Equivocal,0.4404296875,0.0,Allred score = 8,allred score = 8,90-99%,Dako,CAP SCORING GUIDELINE 2010,53.478515625,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,40,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.8,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,14,6,2011,TCGA-AR-A1AQ-F218010E0D419B-0483-45CE-BD2D-C5F70BB17DDEScheduled Follow-up SubmissionYESYESAlive1310NO2722012TCGA-AR-A1AQ-F69276A25BE870-3A72-431A-A4A5-2B9C5FDAD5BANOYESYESTUMOR FREEAlive3021NO31122014,1TCGA-AR-A1AQ-D21806E3335007-9F30-4A8C-8027-2E69648DCB76480mg60mg/m243274ChemotherapyDoxorubicinADJUVANTIVNO27220121TCGA-AR-A1AQ-D21811FB4C564B-3B93-4B6F-98A5-FDCE6A415267340mg175mg/m218888ChemotherapyPaclitaxelADJUVANTIVNO27220121TCGA-AR-A1AQ-D2180826C8ACC1-6306-4A4B-AE2E-178288FA6A524780mg600mg/m243274ChemotherapyCytoxanADJUVANTIVNO2722012,TCGA-AR-A1AQ-R218043579DB65-F66D-41A4-B13A-E32DD54BEBDF121163EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12722012
TCGAFPPP,Breast,No,FEMALE,Dead,1174.0,872.7734375,WHITE,TCGA-BH-A203,BH,A203,No,YES,C50.9,8500/3,C50.9,1996.0,WITH TUMOR,YES,39.0,Allred score 7 (outside facility),Allred 5 = 2+3,Right,1.9933984375000056,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Biopsy not specified,Negative,Positive,Equivocal,0.5751953125,35.0,Allred Score 3,Allred Score 6,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,71.4501953125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,1.1,Lung,70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,52,3 Point Scale,2+,5thStage IIBT2N1bM0,NO,YES,PositivePositiveNegativeNegative,8,9,2011,TCGA-AR-A2LR-F3760022969DEA-7B38-42A9-95BD-4710D4BBFA96NONONOTUMOR FREEAlive846NO6122012TCGA-AR-A2LR-F71747E250D902-9F8D-4000-8C72-4DBD74E19452NONONOTUMOR FREEAlive1742NO3032015,YESTCGA-A7-A4SA-D40422D1394A9B-E263-4C3E-9B21-9C7C7A27F4DD73115ChemotherapyDoxorubicinNOComplete Response1922013YESTCGA-A7-A4SA-D4042390ABC9E4-87E8-4C1B-A001-A9A02F4B7AAB73115ChemotherapyCyclophosphamideNOComplete Response1922013YESTCGA-A7-A4SA-D404246BB3CF2B-3286-4031-A91D-48803A014612136213ChemotherapyPaclitaxelNOComplete Response1922013YESTCGA-A7-A4SA-D40425625C328C-CA7E-445E-A8AB-B77D5CC49C4A217Hormone TherapyTamoxifenYES1922013,TCGA-BH-A0W3-R340662559A85D-0AA2-4EAE-937A-6BF2C5B279426398External46GyPrimary Tumor FieldNOComplete Response2972012TCGA-BH-A0W3-R34067A6B969D8-4A1C-4537-94C9-B06187812BFA6396External46GyRegional siteNOComplete Response2972012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,118.0,WHITE,TCGA-D8-A1XW,D8,A1XW,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,1.0,% IHC,dextran coated charcoal,Left Upper Inner Quadrant,2.471503906250002,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Negative,Negative,0.0,0.0,H-SCORE,0%,90-99%,Hercep Test  TM Dako,Venten,66.3115234375,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,66,"LungOther, specifyleft adrenal gland",70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.8,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,5,2011,TCGA-D8-A1XW-F29459372FDE60-88B9-4D07-8F10-9929A463945AScheduled Follow-up SubmissionNOYESAlive385TUMOR FREENO1932012TCGA-D8-A1XW-F7220546CA0608-FFCA-4EEC-AA1E-7739ADCAD4C2NONOYESTUMOR FREEAlive1309NO2942015,TCGA-D8-A1XW-D29460DBD8AFC3-3C19-4ED7-A10C-F38A65FC6B47360+3600mg60+600mg/m2676181Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO1932012,TCGA-AR-A0TP-R18481B4DEB351-1554-4E4E-90E0-E4F24497D2B3125166EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO112122011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,55.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A3W5,AC,A3W5,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,3.0,H-SCORE 190,Allred score 2+2 = 4,Right,1.4790332031250024,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Lobular Carcinoma,ductal and lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Close,Core needle biopsy,intraoperative examination,Positive,Positive,Equivocal,0.0,0.0,Allred Score 4,8,<10%,ACIS,Hercep Test  TM Dako,119.3017578125,HER2 amplification - negative,Ratio >=2.0,YES,NO,66,Lung,50-59%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,172,3 Point Scale,2+,7thStage IIAT2N0MX,YES,YES,NO,24,9,2012,TCGA-AC-A3W5-F56177CAD3F986-FD23-42DF-A0E3-B22ADAE9F1A8NOYESYESTUMOR FREEAlive504NO2912014,NOTCGA-AC-A3W5-D561783299B6BC-BE87-4C84-91EA-AEF9CE77EACE56139ChemotherapyDocetaxelNOComplete Response2912014NOTCGA-AC-A3W5-D5617944D7F9EC-9D9E-48D2-A04D-33F37CEC738A56139ChemotherapyCyclophosphamideNOComplete Response2912014NOTCGA-AC-A3W5-D561808ABC79CD-6BDB-44B7-8F89-4E5762E620F856392Targeted Molecular therapyHerceptinNOComplete Response2912014NOTCGA-AC-A3W5-D56181402336C9-639C-49F2-BFA8-F0BA1A3636F2170Hormone TherapyLetrozoleYES2912014,TCGA-AC-A3W5-R56182D989D457-B8CB-4B67-871E-49FD6F55A4CB154182External5256cGy21Primary Tumor FieldNOComplete Response2912014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,463.0,WHITE,TCGA-E2-A1LA,E2,A1LA,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,35.0,allred score 5 + 3 = 8,allred score 5 +3 = 8,Right Upper Inner Quadrant,1.15,Sentinel lymph node biopsy plus axillary dissection,SLN and non-SLN biopsy,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.8896484375,1.0,allred score = 8,allred score = 8,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,72.3037109375,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,54,"LungOther, specifyleft adrenal gland",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.0,3 Point Scale,2+,6thStage IIAT1cN1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",1,6,2011,TCGA-E2-A1LA-F205861E00479E-F37F-4BC0-8819-1EE4A5496823Scheduled Follow-up SubmissionNOYESAlive748TUMOR FREENO1212012,1TCGA-E2-A1LA-D205872BE8D472-4522-4803-AA13-CA72D38B9A451mg/day1mg/day48Hormone TherapyArimidexADJUVANTPOYES1212012,TCGA-BH-A0BT-R591449C01B233-7499-4880-BDBF-74AE44ED26D6167227External66.4Gy36Primary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,316.0,WHITE,TCGA-E2-A15G,E2,A15G,No,YES,C50.9,8522/3,C50.9,2009.0,TUMOR FREE,YES,1.0,allred score 5+3=8,Allred 5 = 2+3,Left Upper Outer Quadrant,2.311611328124996,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Other,Surgical resection,Mixed Histology (please specify),Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.69140625,0.0,Allred score = 8,Allred score = 8,30-39%,Dako,Venten,92.9912109375,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,33,"LungOther, specifyleft adrenal gland",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,21,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,13,4,2011,TCGA-E2-A15G-F18901119A323C-CF89-4041-ADD3-34AF96D44CEEScheduled Follow-up SubmissionYESYESAlive554TUMOR FREENO14112011,1TCGA-E2-A15G-D18903BFCCD553-AC21-473B-BF95-489271D20DF11mg/day1mg/day125Hormone TherapyArimidexADJUVANTPOYES14112011,TCGA-E2-A15G-R18904B33EE5B5-9277-45F1-8B30-E68D495EB0A849103EXTERNAL BEAM6040cGyPrimary Tumor FieldADJUVANTNO114112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3330.0,WHITE,TCGA-B6-A1KN,B6,A1KN,No,YES,C50.9,8500/3,C50.9,1998.0,TUMOR FREE,YES,30.0,Allred score 5+3 = 8,%IHC,Right Upper Inner Quadrant,1.1658984374999957,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Negative,Equivocal,0.2158203125,24.0,230,200,30-39%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,61.6318359375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,2.6,Lung,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,79,4 Point Scale,2+,5thStage IIIBT4bN1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,19,7,2011,TCGA-B6-A1KN-F157389C9ED6D8-B891-45C3-AFFC-98008F6956BBScheduled Follow-up SubmissionYESYESAlive4233TUMOR FREENO2982011,NOTCGA-A8-A08X-D37787BE723714-41E5-4FCD-A43A-AF09F02ECE83061ChemotherapyDoxorubicinn/aNOComplete Response6122012NOTCGA-A8-A08X-D37788FA20A7B4-6AD1-4A7C-885A-4A7B13295649061ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08X-D377891112F7D7-6984-4F61-85B5-5D60C66A006B91153ChemotherapyPaclitaxeln/aNOComplete Response6122012NOTCGA-A8-A08X-D3779077710F3F-EECC-49E3-AA85-02773DE4D2431821249Targeted Molecular therapyTrastuzumabn/aNOComplete Response6122012NOTCGA-A8-A08X-D3779168CC8611-6E89-4582-9597-FCA264BEE43C669884ChemotherapyVinorelbinen/aNOComplete Response6122012NOTCGA-A8-A08X-D377922DA191F1-8A7A-4538-A7E6-BD7F8ECA8A15366Hormone TherapyTamoxifenn/aYES6122012,TCGA-A2-A0CS-R7285a50ef65d-3b95-41e4-82e7-f0ab5f9ae804106161EXTERNAL BEAM11080cGy61Primary Tumor FieldADJUVANTNO12812011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,983.0,WHITE,TCGA-E2-A1IE,E2,A1IE,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,3.0,allred score 5 + 3 = 8,allred score 3 + 3 = 6,Right,1.05,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Other,segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Equivocal,0.751953125,1.0,allred score = 6,allred score = 8,20-29%,Dako,Venten,145.0830078125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.13,"LungOther, specifyleft adrenal gland",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,79,3 Point Scale,2+,6thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,26,4,2011,TCGA-E2-A1IE-F19964D2C1D1D2-94EC-4BD9-9EF5-0F7C2604F6EEScheduled Follow-up SubmissionYESYESAlive1165TUMOR FREENO21122011TCGA-E2-A1IE-F702972D1B9C9B-B501-4643-91F8-FBF1D4B0A90CNOYESYESWITH TUMORAlive2362YES1810Distant MetastasisLiverNONOYESPositive3 Point Scale3+Positive3 Point Scale3+Negative2.12.22001.01632015,4TCGA-E2-A1IE-D19971FF2B7E21-B246-498D-8B7B-4B91A0FB342520mg/day20mg/day500Hormone TherapyTamoxifenADJUVANTPOYES211220111TCGA-E2-A1IE-D19965F1068428-E9F7-419B-B5A1-1C52A1E42A8E472mg118mg462104ChemotherapyDoxorubicinADJUVANTIVNO211220111TCGA-E2-A1IE-D1996765CC9CCD-D919-4BCD-96BF-619424B8D8BE4728mg1182mg462104ChemotherapyCyclophosphamideADJUVANTIMIVNO211220112TCGA-E2-A1IE-D1996821FD6890-254A-4F5F-B112-8D1EB3C233411364mg341mg4118171ChemotherapyPaclitaxelADJUVANTIVNO211220113TCGA-E2-A1IE-D19970D27CB74E-89DC-4859-81F9-CBA4A807E9E8185mg1mg/day252437Hormone TherapyArimidexADJUVANTPONO21122011NOTCGA-E2-A1IE-D70374FC87038A-95A3-4E05-9442-79BF251AF39F18441928Hormone TherapyFemaraNOClinical Progressive Disease1632015NOTCGA-E2-A1IE-D703756A7EB17B-231B-4C2C-B1B0-8825B0BD71CA19282187Hormone TherapyFaslodexNOClinical Progressive Disease1632015NOTCGA-E2-A1IE-D703767325CF50-8976-4A43-9E2F-6FA667BC428C2187Hormone TherapyExemestaneYES1632015NOTCGA-E2-A1IE-D7037707C275AD-3B22-436C-89C9-CCB6FD3D2B2E2187ChemotherapyEverolimusYES1632015,TCGA-E2-A1IE-R1997203BCA171-2C59-4E91-93E2-0BCEBAD1E9F7200251EXTERNAL BEAM6080cGy33Regional siteADJUVANTNO121122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2393.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A0CQ,A2,A0CQ,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,1.0,allred score 0 + 0 = 0,Allred 5 = 2+3,Right,1.3,Sentinel node biopsy alone,Pateys surgery,Lumpectomy,Right Breast Reexcision,Lumpectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.0,0.0,Allred Score 3,10-75%,<10%,ACIS,CAP SCORING GUIDELINE 2010,69.5615234375,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,1.45,LungBoneLiver,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.5,3 Point Scale,1+,6thStage IAT1N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",10,8,2010,TCGA-A2-A0CQ-F137233276C085-4370-48D5-9BA7-76ADDE69842DScheduled Follow-up SubmissionYESYESAlive2695TUMOR FREENO1062011,"2TCGA-A2-A0CQ-D19873bae8101-5295-4dd1-b21f-31ed7bf92ec2416mg104mg499162ChemotherapyAdriamycinADJUVANTIVNO30820103TCGA-A2-A0CQ-D1988865e1c55-d241-4076-bd9a-0bffed3475aa1mg201Hormone TherapyArimidexADJUVANTPOYES30820101TCGA-A2-A0CQ-D1986664f836e-85b0-4c5f-8869-42321a27e9834176mg1044mg499162ChemotherapyCytoxanADJUVANTIVNO30820104TCGA-A2-A0CQ-D199071de8349-bb98-4691-8138-1cdcc08f849c600ug100ug6492628ImmunotherapyAE-37OTHER, SPECIFY IN NOTESCancer Vaccine TrialNO992010",TCGA-A2-A0CQ-R1985e74c5228-76c3-41d0-99f3-307ae0373b37188236EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1992010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,162.0,WHITE,TCGA-AN-A0XV,AN,A0XV,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,16.0,dextran coated charcoal,dextran coated charcoal,Right Upper Outer Quadrant,1.098173828124997,Axillary lymph node dissection alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Positive,0.318359375,7.0,90 H,270 H,60-69%,CISH,DAKOHercepTest TM,199.4716796875,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,NO,YES,54,Lung,90-99%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.1,3 Point Scale,1+,7thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,29,3,2011,TCGA-AN-A0XV-F689620DB9CDF6-70F8-4923-AF76-D187338FB3AEYESNONOTUMOR FREEAlive162NO23122014,1TCGA-E2-A155-D18962E7F98449-1AD2-4788-98A9-C1B731F13D28430ChemotherapyCytoxanADJUVANTNO81120113TCGA-E2-A155-D19107FF8866DF-0183-4B72-8285-E71C4F12035920mg/day20mg/day249Hormone TherapyTamoxifenADJUVANTPONO81120112TCGA-E2-A155-D1910539BFC0D7-45BC-4640-BA13-4397A0A9CE0612ChemotherapyTaxolADJUVANTNO81120111TCGA-E2-A155-D18944C399DF54-62D4-49E4-AB11-5B0008E16218430ChemotherapyAdriamycinADJUVANTNO81120114TCGA-E2-A155-D19111DFA20391-05F7-4053-9EC5-1BD5F52619681mg/day1mg/day249Hormone TherapyArimidexADJUVANTPOYES8112011,TCGA-AO-A1KS-R9876dc16cc6f-20a3-44d0-b0ff-794d86ead108EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO1142011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1386.0,WHITE,TCGA-BH-A0BT,BH,A0BT,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,9.2998046875,Allred score = 8,Allred score 7 per outside facility report,Right Upper Inner Quadrant,2.0230371093750152,Sentinel node biopsy alone,SLN and non-SLN biopsy,Other,Right Breast Reexcision,Modified radical mastectomy,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.9453125,3.859375,Allred Score 5,205,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,61.7333984375,Vysis AutoVysion System,Ratio >=2.0,NO,YES,40,Lung,<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.3,3 Point Scale,1+,6thStage IIAT1cN1miM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,8,2011,TCGA-BH-A0BT-F59143539EDB85-18FF-4D9F-B1C5-F1C962551945NOYESYESTUMOR FREEAlive2365NO152014,NOTCGA-BH-A0BT-D59146162F9144-80E7-4C0F-BF74-1D23DDE80EF597139ChemotherapyAdriamycinNOComplete Response152014NOTCGA-BH-A0BT-D59148857A1D7C-790E-4A2E-9420-9E23B1F2B32F97139ChemotherapyCytoxanNOComplete Response152014,TCGA-BH-A0BT-R591449C01B233-7499-4880-BDBF-74AE44ED26D6167227External66.4Gy36Primary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,733.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5RV,OL,A5RV,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,29.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.0,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.8759765625,20.0,Allred Score 5,Intensity=Strong,30-39%,CISH,CAP SCORING GUIDELINE 2010,93.5791015625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.67,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,3 Point Scale,2+,7thStage IIICT2N3MX,YES,YES,NO,16,5,2013,TCGA-OL-A5RV-F56564AA52F64A-01A5-47BB-A85F-26B25B7BAED7NOYESYESTUMOR FREEAlive1062NO1422014,NOTCGA-OL-A5RV-D65254F0F4E472-BC9E-4970-A306-4702DE384D0F63161ChemotherapyDoxorubicinNOComplete Response2492014NOTCGA-OL-A5RV-D6525555A6BAAD-D9D1-432E-944D-57781807E2BD63161ChemotherapyCYTOXANNOComplete Response2492014NOTCGA-OL-A5RV-D65256D588C324-FD32-4951-B780-BE01F71AA7DD63161ChemotherapyPaclitaxelNOComplete Response2492014,TCGA-OL-A5RV-R6525709E25775-2A38-48D7-8505-A90B508ACD39202249External5040cGyRegional siteNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Dead,2361.0,2421.5732421875,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0I1,B6,A0I1,No,YES,C50.9,8500/3,C50.9,1998.0,TUMOR FREE,YES,7.0,image cytometry,image cytometry,Left Upper Outer Quadrant,1.9530273437499968,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,surgical resection,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Incisional Biopsy,Lumpectomy,Negative,Negative,Equivocal,0.1494140625,0.0,240 H,H score,90-99%,Dako,CAP scoring guideline 2010,239.8720703125,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,2.38,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.700488281249994,21,4 Point Scale,2+,5thStage IIAT2N0M0,YES,YES,PositivePositiveNegativeNegative,11,1,2012,TCGA-B6-A0I1-F3890931CBA550-5941-49DB-B716-73F9F87BA3E9NONONOTUMOR FREEDead2361YES1120Distant MetastasisLungYES1120NONONegativeNegative312013,NOTCGA-LQ-A4E4-D37612A6AB6FB7-5552-45E1-9CE2-F1DB3B0752D9111Hormone TherapyAnastrozoleYES5122012,TCGA-GM-A2D9-R47037BE3ADDFC-5406-471C-984B-8229F0EEA8D76896External60Gy30Primary Tumor FieldNO2182013TCGA-GM-A2D9-R4725321CA09CB-DF2B-458F-813B-66DA60B6C92314131434External30Gy10Distant RecurrenceNOStable Disease2382013
TCGAFPPP,Breast,No,FEMALE,Dead,2965.0,1018.595703125,WHITE,TCGA-BH-A1F6,BH,A1F6,No,YES,C50.9,8500/3,C50.9,1996.0,WITH TUMOR,YES,6.0,allred score 0 + 0 = 0,H-Score 160,Left,1.982734375000001,Sentinel node biopsy alone,axillary ultrasound,Modified Radical Mastectomy,surgical resection,Modified radical mastectomy,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Biopsy not specified,Negative,Negative,Negative,0.8271484375,6.0,allred score = 8,Moderate,10-19%,ACIS,Dako Hercept test,91.9599609375,Vysis AutoVysion System,CAP SCORING GUIDELINE 2010,NO,YES,33,LungBone,70-79%,40-49%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,2.5,3 Point Scale,2+,T4dN2aMX,NO,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,7,9,2011,TCGA-B6-A0I1-F3890931CBA550-5941-49DB-B716-73F9F87BA3E9NONONOTUMOR FREEDead2361YES1120Distant MetastasisLungYES1120NONONegativeNegative312013,NOTCGA-LL-A5YM-D57542EBAB50E8-81A5-49D8-92FB-7A44273418ABHormone TherapyletrozoleYES1432014,TCGA-BH-A0W3-R340662559A85D-0AA2-4EAE-937A-6BF2C5B279426398External46GyPrimary Tumor FieldNOComplete Response2972012TCGA-BH-A0W3-R34067A6B969D8-4A1C-4537-94C9-B06187812BFA6396External46GyRegional siteNOComplete Response2972012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,259.0,WHITE,TCGA-A1-A0SB,A1,A0SB,No,YES,C50.9,8200/3,C50.9,2008.0,TUMOR FREE,YES,2.0,image cytometry,allred score 5+3+8,Left,1.521904296875,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Other,Segmental Mastectomy,"Other, specify",Adenoid Cystic Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Negative,Positive,Negative,0.185546875,0.0,Intensity=Strong,Two-tier,90-99%,CISH,Dako Hercept test,154.5322265625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,64,Lung,70-79%,10-19%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.5,3 Point Scale,2+,6thStage IT1cN0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,30,6,2011,TCGA-E2-A2P6-F335140B4810CA-DB4D-49CD-BFB4-DAACBEE0DE41Scheduled Follow-up SubmissionNOYESAlive168TUMOR FREENO2962012TCGA-E2-A2P6-F6857451E462D5-D07F-4E42-A9E8-4171DEEE1AE1NONOYESTUMOR FREEAlive1051NO26112014,NOTCGA-BH-A18I-D5871162D6ACAF-3359-411A-9715-AC1D93B3EB27121220ChemotherapyTaxotereNOComplete Response2242014NOTCGA-BH-A18I-D58712B4CF288C-CBDD-493D-8CB6-198994F91639121220ChemotherapyCytoxanNOComplete Response2242014,TCGA-AO-A0JC-R3180541d6c3c-3efe-4473-9818-68bb9f9a9693252298EXTERNAL BEAM21160cGy33Regional siteADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,644.0,WHITE,TCGA-A2-A0YC,A2,A0YC,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,3.0,allred score 0 + 0 = 0,H-Score 160,Right Upper Inner Quadrant,1.18,Other (specify),Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,surgical resection,Modified radical mastectomy,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,3+,Negative,Close,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,1.0,0%,80,10-19%,ACIS,CAP scoring guideline 2010,60.0,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,66,"Other, specifySkin",90-99%,90-99%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.3,3 Point Scale,1+,Stage IIBT2N1miM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,8,12,2010,TCGA-A2-A0YC-F15845C96EBF68-77B8-4D7E-B54F-B4ACDA34E1BBScheduled Follow-up SubmissionYESYESAlive990WITH TUMORYES756Locoregional DiseaseYES756NOYESPositive90-99%Positive90-99%Negative2+3082011TCGA-A2-A0YC-F15846C0DCEDF1-D610-4EF2-B1BD-FA6DA338202AAdditional New Tumor EventYESYESAlive990WITH TUMORYES798Distant MetastasisBoneYES798NOYESPositivePositiveEquivocal3082011,1TCGA-A2-A0YC-D56770c6ae6c0-6396-40ca-8f21-e1d33a8e9ad01mg103Hormone TherapyArimidexADJUVANTPOYES8122010,TCGA-A2-A0YC-R5678f101ee98-6a56-48fc-9688-d737171c8f347178OTHERBrachytherapy (Iridium 192)3400cGy10Primary Tumor FieldADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,553.0,WHITE,TCGA-E2-A155,E2,A155,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,15.0,Allred score 5+3=8,allred score 4 + 3 = 7,Left Upper Inner QuadrantLeft Lower Inner Quadrant,1.6658789062499972,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Biopsy not specified,Negative,Positive,Negative,0.8544921875,2.0,MODERATE,H-Score,90-99%,Dako,CAP scoring guideline 2010,51.6083984375,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,54,"LungOther, specifyleft adrenal gland",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,1.1,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,4,2011,TCGA-E2-A155-F1894235A9196F-3E2C-44FE-822F-32FB066756A0Scheduled Follow-up SubmissionNOYESAlive640TUMOR FREENO8112011,1TCGA-E2-A155-D18962E7F98449-1AD2-4788-98A9-C1B731F13D28430ChemotherapyCytoxanADJUVANTNO81120113TCGA-E2-A155-D19107FF8866DF-0183-4B72-8285-E71C4F12035920mg/day20mg/day249Hormone TherapyTamoxifenADJUVANTPONO81120112TCGA-E2-A155-D1910539BFC0D7-45BC-4640-BA13-4397A0A9CE0612ChemotherapyTaxolADJUVANTNO81120111TCGA-E2-A155-D18944C399DF54-62D4-49E4-AB11-5B0008E16218430ChemotherapyAdriamycinADJUVANTNO81120114TCGA-E2-A155-D19111DFA20391-05F7-4053-9EC5-1BD5F52619681mg/day1mg/day249Hormone TherapyArimidexADJUVANTPOYES8112011,TCGA-E9-A1RE-R306323C41D803-3D12-4E01-B2D6-2940A6BE6E4C183209EXTERNAL BEAM4000cGy20Regional siteADJUVANTNO11342012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,16.0,WHITE,TCGA-AO-A1KS,AO,A1KS,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,5.0,H-Score 150,CAP SCORING GUIDELINE 2010,Left Lower Inner QuadrantLeft Lower Outer QuadrantLeft,1.0,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Right Breast Reexcision,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Lobular Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,4 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.0,0.0,Two-tier,Moderate,10-19%,ACIS,CAP scoring guideline 2010,40.0,Vysis AutoVysion System,Positive >2.2,NO,YES,3.2,"LungOther, specifyleft adrenal gland",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.2,4 Point Scale,2+,7thStage IIAT2N0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",1,4,2011,TCGA-AO-A1KS-F9872A2741227-EEE0-4B41-9C5E-22E3AE495BC916AliveTUMOR FREEYESYES142011TCGA-AO-A1KS-F21777507BCF20-7BA4-4C69-9D6F-41883512FAD1Scheduled Follow-up SubmissionYESYESAlive350TUMOR FREENO2022012,1TCGA-AO-A1KS-D98735cf6039b-6a9e-45da-a518-f9ed69ee620f1mg/day155Hormone TherapyArimidexADJUVANTPOYES142011,TCGA-AO-A1KS-R9876dc16cc6f-20a3-44d0-b0ff-794d86ead108EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO1142011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,309.0,WHITE,TCGA-EW-A423,EW,A423,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,2.0,Allred score 7 (outside facility),Allred (Biocare),Left Upper Inner Quadrant,1.8242382812500084,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Right Breast Reexcision,Other,Segmental Mastectomy,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,allred score = 4,moderate,90-99%,CISH,CAP scoring guideline 2010,92.3427734375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,1.78,"LungOther, specifyleft adrenal gland",50-59%,<10%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.5724609374999916,1.1,3 Point Scale,2+,7thStage IIAT2N0MX,YES,YES,NO,4,1,2013,TCGA-EW-A423-F388956E8F6BDC-E908-4D9C-94E3-779F98588303NOYESYESTUMOR FREEAlive309NO2632013TCGA-EW-A423-F42558CCAFBC43-EDB6-41CB-90F2-65B874EBD3E2YESTUMOR FREEAlive533NO1832014,NOTCGA-EW-A423-D38933C3B35A80-A856-4049-B06A-02E765F87BD0205Hormone TherapyAnastrozoleYES412013,TCGA-EW-A423-R389368A98C19C-07DE-43E1-8391-6975D585C79352162ExternalPrimary Tumor FieldNOComplete Response412013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2298.0,WHITE,TCGA-A2-A0CS,A2,A0CS,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,15.0,ER Positive H-Score 95,Allred 5 = 2+3,Left,1.3,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,"Other method, specify:",Skin biopsy,Negative,Positive,Equivocal,0.0,12.0,Allred Score 4,Two-tier,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,460.9931640625,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,64,"Other, specifyOvary",80-89%,80-89%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.09,5,3 Point Scale,2+,Stage IVT4bN3aM1,YES,YES,PositivePositiveNegativeNegative1.09,27,1,2011,TCGA-A2-A0CS-F14456F9BF7708-01D9-48C5-9E59-C6D9F33D0D89Scheduled Follow-up SubmissionYESYESAlive2298TUMOR FREENO1362011TCGA-A2-A0CS-F59316B08C8976-E321-45FD-AC53-648FE294B2C1NOYESYESDead2348852014,"2TCGA-A2-A0CS-D72800b827c0b-3829-40ed-8e56-86f2a957472b12mg4mg3217597Other, specify in notesBisphosphonateZometaOTHER, SPECIFY IN NOTESMaintenance therapyIVNO28120111TCGA-A2-A0CS-D7277c1d5ddf5-8870-4ff6-a547-018f3e5d0bc41mg190Hormone TherapyAnastrozoleADJUVANTPOYES2812011",TCGA-A2-A0CS-R7285a50ef65d-3b95-41e4-82e7-f0ab5f9ae804106161EXTERNAL BEAM11080cGy61Primary Tumor FieldADJUVANTNO12812011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,380.0,WHITE,TCGA-D8-A1X9,D8,A1X9,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,23.0,% IHC,%IHC,Left Lower Outer Quadrant,2.4867285156250003,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,partial mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Indeterminate,0.0,3.0,>75%,>75%,10-19%,Hercep Test  TM Dako,Venten,52.0126953125,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,40,"LungOther, specifyleft adrenal gland",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,not amplified,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,16,5,2011,TCGA-D8-A1X9-F294317DFB15F7-F9D2-4987-8254-9C11C8EAD28EScheduled Follow-up SubmissionYESYESAlive727TUMOR FREENO1932012,TCGA-D8-A1X9-D2943224E1ACCD-BB3A-4B2A-8E81-18F3452912AAmg60+600mg/m2197320Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO1932012,TCGA-D8-A1X9-R29433104383D3-283E-4D53-AAA0-4A610BB320E7320350EXTERNAL BEAM4500cGy20Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2521.0,WHITE,TCGA-AR-A0TP,AR,A0TP,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,5.0,H-SCORE 300,%IHC,Left Upper Inner Quadrant,1.2188183593749895,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Right Breast Reexcision,Other,Wide local excision,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,Strong,allred score = 8,90-99%,Dako,Venten,132.3095703125,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,NO,YES,2.38,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,79,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,25,2,2011,TCGA-AR-A0TP-F17840AEDD706C-7E02-4D35-9D8D-F14B61685DC5Scheduled Follow-up SubmissionYESYESAlive2521NO12122011TCGA-AR-A0TP-F49514DF520576-B6A2-4289-AA4C-EB29F269B2D6YESYESTUMOR FREEAlive3386NO2102013TCGA-AR-A0TP-F71715557AE19D-DF36-4F96-AC06-278AFCD2B451NOYESYESTUMOR FREEAlive4275NO3032015,1TCGA-AR-A0TP-D1902604948347-26AC-49B0-9E46-0812A85833EB555mg60mg/m243297ChemotherapyDoxorubicinADJUVANTIVNO121220111TCGA-AR-A0TP-D19030D1474BAA-9E44-4519-AAA2-B81A0B0F2E2D5510mg600mg/m243297ChemotherapyCytoxanADJUVANTIVNO12122011,TCGA-AR-A0TP-R18481B4DEB351-1554-4E4E-90E0-E4F24497D2B3125166EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO112122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3801.0,BLACK OR AFRICAN AMERICAN,TCGA-3C-AALI,3C,AALI,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,15.0,allred score 5 + 3 = 8,Allred (Biocare),Right Upper Outer Quadrant,1.6444335937499948,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Positive,0.08984375,1.0,allred score = 6,250,90-99%,CISH,CAP SCORING GUIDELINE 2010,144.822265625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.38,LungBone,<10%,<10%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,105,3 Point Scale,1+,6thStage IIBT2N1aM0,YES,YES,NO,28,7,2014,TCGA-3C-AALI-F680574A52CBB9-665B-420E-8AC4-6A19058F550ANOYESYESTUMOR FREEAlive4005NO13112014,YESTCGA-3C-AALI-D62900C09E3F7D-0FC8-4316-AF95-1D9CE349707143117Poly ENOComplete Response2872014,TCGA-3C-AALI-R629012FE462E5-9AEE-417B-BF7C-908AA69A55A93203525000cGy25Primary Tumor FieldNO2872014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,168.0,WHITE,TCGA-E2-A2P6,E2,A2P6,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,5.0,Allread score 5+3 = 8,Allred score 2+2 = 4,Left Upper Outer Quadrant,1.709580078124996,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Modified radical mastectomy,L Total Mastectomy,Infiltrating Lobular Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.7177734375,1.0,Allred score = 4,Allred score = 8,90-99%,Hercep Test  TM Dako,Hercep Test TM DAKO,93.5556640625,Vysis AutoVysion System,Ratio >=2.0,NO,YES,78,"LungOther, specifyleft adrenal gland",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.80,3 Point Scale,2+,7thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",19,12,2011,TCGA-E2-A2P6-F335140B4810CA-DB4D-49CD-BFB4-DAACBEE0DE41Scheduled Follow-up SubmissionNOYESAlive168TUMOR FREENO2962012TCGA-E2-A2P6-F6857451E462D5-D07F-4E42-A9E8-4171DEEE1AE1NONOYESTUMOR FREEAlive1051NO26112014,NOTCGA-E2-A2P6-D3351506510269-80AF-46F3-B6EA-7AE5484CBCC2106Hormone TherapyAnastrozoleYES572012,TCGA-GM-A3NY-R404047B29BB47-1F8A-4F98-ADD3-B16DEDB079F682124External60Gy30Primary Tumor FieldNOStable Disease1922013
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,450.0,WHITE,TCGA-E2-A158,E2,A158,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Left Upper Inner QuadrantLeft Upper Outer Quadrant,1.223056640624996,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Biopsy not specified,Negative,Negative,Negative,1.5458984375,1.0,Allred score = 0,Allred score = 0,<10%,Dako,Venten,50.9814453125,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,2.6,"LungOther, specifyleft adrenal gland",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,1.9,3 Point Scale,2+,6thStage IIAT1cN1miM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,4,2011,TCGA-E2-A158-F1895624E85CD5-EEC3-42FE-A66B-6A8DEE474B14Scheduled Follow-up SubmissionNOYESAlive450TUMOR FREENO8112011,3TCGA-E2-A158-D18963B94489C2-71D2-40FE-86DD-A3E999BF3373mg1mg450ChemotherapyarimidexADJUVANTPOYES81120111TCGA-E2-A158-D18958A3051694-896A-4A9D-9178-CA248163F114228ChemotherapydoxorubicinADJUVANTNO81120111TCGA-E2-A158-D189608C16F7B2-EFBC-4B7E-AA40-8A152D0E4F0F228ChemotherapycytoxanADJUVANTNO81120112TCGA-E2-A158-D1896167C4C12D-8CB3-4ED8-8913-666D05A6057D228ChemotherapyTaxaneADJUVANTNO8112011,TCGA-AO-A1KS-R9876dc16cc6f-20a3-44d0-b0ff-794d86ead108EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO1142011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,218.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-AA14,S3,AA14,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,4.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,Right,1.544277343749994,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Positive,3.0,0.0,Allred score 0,180,70-79%,CISH,CAP SCORING GUIDELINE 2010,92.51171875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,1.78,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,52,3 Point Scale,3+,7thStage IT1N0 (i+)cM0 (i+),YES,YES,NO,18,4,2014,TCGA-S3-AA14-F6762249A0491B-CE59-4BDF-98C3-5394E5691C3ENOYESYESTUMOR FREEAlive455NO7112014TCGA-S3-AA14-F70444436AD5C3-8095-4D66-BA22-A9384C74D951NOYESYESTUMOR FREEAlive529NO2622015,NOTCGA-S3-AA14-D5855983B53265-EDFD-4A74-ACCA-B6D07998331762104ChemotherapyADRIAMYCINNOComplete Response1842014NOTCGA-S3-AA14-D5856119C8BDA0-73FA-4112-A3E0-04738D2582BE62104ChemotherapyCYTOXANNOComplete Response1842014NOTCGA-S3-AA14-D585626E4C1CA4-4878-438D-BA03-D9E0A56288F462104AncillaryNEULASTANOComplete Response1842014NOTCGA-S3-AA14-D585633EE34E77-CAF8-4915-9C7F-49F74F3C750D118Targeted Molecular therapyTRASTUZUMABYES1842014NOTCGA-S3-AA14-D58564B5D44FCB-607E-4DB0-9F91-FC2787B93697118ChemotherapyTAXOLYES1842014,TCGA-S3-AA14-R58557FF05CFAD-F5C8-4C9F-9FA9-E785F6EFDDA9221267External6440cGy35Primary Tumor FieldNOComplete Response1842014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1881.0,WHITE,TCGA-AR-A1AI,AR,A1AI,No,YES,C50.9,8510/3,C50.9,2005.0,TUMOR FREE,YES,5.0,H-Score 300,CAP scoring guideline 2010,Left Upper Outer Quadrant,1.7871191406249896,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Total mastectomy,Medullary Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,2+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Negative,Equivocal,0.0205078125,0.0,Allred score = 0,Allred score = 0,90-99%,Hercep Test  TM Dako,Dako Hercept test,118.4755859375,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,33,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.62,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,15,6,2011,"TCGA-AR-A1AI-F22164FC799718-A25C-425A-8D9D-1648F02C42B1Scheduled Follow-up SubmissionNOYESAlive1881TUMOR FREEYES588New Primary TumorOther, specifyContralateral Breast132012TCGA-AR-A1AI-F69268133635BC-06CC-4DDD-A045-698C61BEB38CNONOYESTUMOR FREEAlive3296NO31122014",1TCGA-AR-A1AI-D2216690D5DC13-564D-48CD-8C71-641D9D8516285500mg600mg/m243577ChemotherapyCytoxanADJUVANTIVNO1320121TCGA-AR-A1AI-D221657DC45115-BA8C-4FCF-870E-DE0B34A8BB4A550mg60mg/m243577ChemotherapyDoxorubicinADJUVANTIVNO1320121TCGA-AR-A1AI-D221672B5F671F-53D9-4796-B9B5-CF32551C42321520mg175mg/m2491134ChemotherapyPaclitaxelADJUVANTIVNO132012,TCGA-A2-A0CK-R326474B8B651E-F54C-4EB0-AC3F-BFEFB8E3BF05243280External5040cGyRegional siteNOComplete Response562012TCGA-A2-A0CK-R3265357C35411-3766-4C37-B699-47F58743FD98243280External5040cGyRegional siteNOComplete Response662012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2982.0,WHITE,TCGA-GM-A3NW,GM,A3NW,No,YES,C50.9,8520/3,C50.9,2003.0,TUMOR FREE,YES,4.0,Allred (Biocare),Allred score 5+3=8,Left Upper Inner Quadrant,1.15,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,surgical resection,Other,Partial Mastectomy,Infiltrating Lobular Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Equivocal,0.0,0.0,60,moderate,30-39%,ACIS,CAP scoring guideline 2010,60.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.57,Lung,70-79%,20-29%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.5724609374999916,1.80,3 Point Scale,2+,6thStage IIAT2N0 (i-)M0,YES,YES,NO,3,1,2012,TCGA-GM-A3NW-F403988B23B0F0-7990-4F02-878A-3D61DF21DB52NONOYESTUMOR FREEAlive3361NO1822013,NOTCGA-GM-A3NW-D4040294E98AC3-6333-4A5B-A854-BE225AD37D6F2052055Hormone TherapyArimidexNOStable Disease1822013NOTCGA-GM-A3NW-D403995A6BEDB9-C5EB-404D-B70B-EA0253B4FC0565181ChemotherapyFluorouracilNOStable Disease1822013NOTCGA-GM-A3NW-D404010C26CDE2-DE29-4331-B678-BF68B7E1F9F865181ChemotherapyCytoxanNOStable Disease1922013NOTCGA-GM-A3NW-D40400F06F057C-E684-4B61-92FE-F22B0EF9A3F465181ChemotherapyEpirubicinNOStable Disease1922013,TCGA-A2-A0CS-R7285a50ef65d-3b95-41e4-82e7-f0ab5f9ae804106161EXTERNAL BEAM11080cGy61Primary Tumor FieldADJUVANTNO12812011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,518.0,WHITE,TCGA-A8-A07L,A8,A07L,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,12.8818359375,allred score 5 + 3 = 8,Allred score 5+3=8,Right Upper Outer Quadrant,1.5933203124999935,Sentinel node biopsy alone,axillary ultrasound,Other,Right Breast Reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,0,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.623046875,5.9306640625,Strong,Allred score 8,10-19%,Hercep Test  TM Dako,Venten,111.923828125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,50,"Other, specifySkin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.9,3 Point Scale,2+,6thStage IIIAT3N1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A07L-F40830E992C9F9-BF33-4063-A892-5ECD2958B1E6NOYESYESTUMOR FREEAlive975NO232013,TCGA-A8-A07L-D37866F05105AD-1CB2-444A-9701-65ECDF294EC231122ChemotherapyNOComplete Response6122012NOTCGA-A8-A07L-D37867F35579B1-B246-4D73-899D-43A1DAB766AD184Hormone TherapyAnastrozoleYES6122012,TCGA-A8-A07L-R38185A5E63D28-1725-4DCC-9576-232B048E4C4C153184ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,143.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A5YM,LL,A5YM,No,YES,C50.9,8541/3,C50.9,2012.0,WITH TUMOR,NO,12.7763671875,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,LeftLeft Upper Inner Quadrant,3.2,No axillary staging,FNA plus axillary lymph node dissection,Other,Right Breast Reexcision,Mastectomy NOS,partial mastectomy,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,SKIN BIOPSY,Positive,Positive,Equivocal,1.267578125,8.9453125,Allred score 5,moderately to strongly,30-39%,CISH,Dako Hecept Test,20.0,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,YES,NO,54,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,172,3 Point Scale,3+,7thStage IIIBT4bNXM0,NO,NO,NO,3,6,2013,"TCGA-LL-A5YM-F57541D396D059-CF4A-4F46-86D7-079FA3777796NONONOWITH TUMORAlive394YES258Locoregional RecurrenceOther, specifySkin left chest wallYES258YESYES1432014",NOTCGA-LL-A5YM-D57542EBAB50E8-81A5-49D8-92FB-7A44273418ABHormone TherapyletrozoleYES1432014,TCGA-LL-A5YM-R5754390327544-390D-4E11-88EB-FCDB0ABD67FA307339External50Gy20Local RecurrenceNOPartial Response1432014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,484.0,WHITE,TCGA-LQ-A4E4,LQ,A4E4,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,26.0,allred score 5+3=8,CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.05,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,Segmental Mastectomy,Infiltrating Lobular Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,1+,2+,Negative,Positive,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.0,3.0,allred score = 6,allred score = 7,30-39%,CISH,Dako Hecept Test,60.0,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,1.1,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.1,3 Point Scale,1+,7thStage IIIAT3N1aMX,YES,YES,NO,5,12,2012,TCGA-LQ-A4E4-F5229010069AFF-4C83-4D78-8926-50B590E2C1B3NOYESYESWITH TUMORAlive849YES681Distant MetastasisBoneNOYESYESPositiveNegative2122013,NOTCGA-LQ-A4E4-D37612A6AB6FB7-5552-45E1-9CE2-F1DB3B0752D9111Hormone TherapyAnastrozoleYES5122012,TCGA-LQ-A4E4-R376118DA26ACA-40A2-4C08-90E0-BDECEEDE396463111External6040cGy33Primary Tumor FieldNOComplete Response5122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,241.0,WHITE,TCGA-A7-A4SA,A7,A4SA,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,10.0,H-Score 150,image cytometry,Left Lower Outer Quadrant,1.2087109374999905,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Segmental Mastectomy,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,1.0,Intensity=Weak,moderate,10-19%,ACIS,CAP SCORING GUIDELINE 2010,69.3046875,HER2 amplification - negative,>= 2.0 Positive,YES,NO,33,Lung,80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.816386718749996,61,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,NO,19,2,2013,TCGA-A7-A4SA-F495608EE2B4A8-14AD-4A21-9746-83D9A7F27F14NONOYESTUMOR FREEAlive454NO3102013,YESTCGA-A7-A4SA-D40422D1394A9B-E263-4C3E-9B21-9C7C7A27F4DD73115ChemotherapyDoxorubicinNOComplete Response1922013YESTCGA-A7-A4SA-D4042390ABC9E4-87E8-4C1B-A001-A9A02F4B7AAB73115ChemotherapyCyclophosphamideNOComplete Response1922013YESTCGA-A7-A4SA-D404246BB3CF2B-3286-4031-A91D-48803A014612136213ChemotherapyPaclitaxelNOComplete Response1922013YESTCGA-A7-A4SA-D40425625C328C-CA7E-445E-A8AB-B77D5CC49C4A217Hormone TherapyTamoxifenYES1922013,TCGA-AO-A1KS-R9876dc16cc6f-20a3-44d0-b0ff-794d86ead108EXTERNAL BEAMPrimary Tumor FieldADJUVANTNO1142011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1519.0,WHITE,TCGA-BH-A0BV,BH,A0BV,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,25.0,allred score 0 + 0 = 0,H-Score 290,Right Upper Inner QuadrantRight,1.30024414062501,Sentinel lymph node biopsy plus axillary dissection,Pateys surgery,Modified Radical Mastectomy,Right Breast Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.49609375,2.0,0,Allred Score 8,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.8466796875,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,1.45,"Other, specifySkin",90-99%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,816,3 Point Scale,2+,Stage IIBT2N1aM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,11,2010,TCGA-BH-A0BV-F45133AB769BD-C3C1-422B-A9FD-F72E00FB2D371519AliveTUMOR FREENOYES16112010,1TCGA-BH-A0BV-D4511BAB8E980-A3BB-4674-AA19-F13ED3CD6E8B488153ChemotherapyDOXORUBICINADJUVANTIVNO151120101TCGA-BH-A0BV-D45063000F32E-2841-466F-83FF-0A0F01E272851mg/day262Hormone TherapyARIMIDEXADJUVANTPOYES151120101TCGA-BH-A0BV-D451011E80478-AE62-404C-9A63-6BC3B6785FA8488153ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO151120101TCGA-BH-A0BV-D451292F20E69-6E22-4D49-9016-E0127DA2806812174262ChemotherapyPACLITAXELADJUVANTIVNO16112010,TCGA-BH-A201-R6422394B7945B-92D9-4D1A-868B-84D66F2C3F4D56108External6640cGy28Primary Tumor FieldNOComplete Response2782014
TCGAFPPP,Breast,No,FEMALE,Dead,3461.0,2136.322265625,WHITE,TCGA-B6-A0WY,B6,A0WY,No,YES,C50.9,8500/3,C50.9,1996.0,WITH TUMOR,YES,21.0,Image Analysis,Image Analysis,Left Lower Inner QuadrantLeft,1.387177734374999,Axillary lymph node dissection alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,4 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,0.39453125,3.0,Intensity=Strong,H score,10-19%,Hercep Test  TM Dako,dextran coated charcoal,35.2021484375,Vysis AutoVysion System,Path Vysion HER-2 DNA probe kit,NO,YES,4.43,"Other, specifySkin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.944414062499999,2.5,4 Point Scale,1+,4thStage IIIAT3N1bM0,YES,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,14,12,2010,TCGA-B6-A0WY-F157303547C7D8-047E-4255-9E3B-662B6E1CBCB9Scheduled Follow-up SubmissionYESYESDead3461WITH TUMORYES2011Distant MetastasisBoneNOYESYESNegative2982011,1TCGA-AR-A1AI-D2216690D5DC13-564D-48CD-8C71-641D9D8516285500mg600mg/m243577ChemotherapyCytoxanADJUVANTIVNO1320121TCGA-AR-A1AI-D221657DC45115-BA8C-4FCF-870E-DE0B34A8BB4A550mg60mg/m243577ChemotherapyDoxorubicinADJUVANTIVNO1320121TCGA-AR-A1AI-D221672B5F671F-53D9-4796-B9B5-CF32551C42321520mg175mg/m2491134ChemotherapyPaclitaxelADJUVANTIVNO132012,TCGA-A2-A1FV-R12267f0cdeb52-224b-47d4-8e49-4f3783f09429169216EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO12652011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,210.0,WHITE,TCGA-BH-A201,BH,A201,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,2.0,Allred score 7 (outside facility),H-Score 290,Left,1.985966796874999,Sentinel node biopsy alone,axillary ultrasound,Other,surgical resection,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.490234375,0.0,Allred Score 5,8,<10%,ACIS,Dako Hercept test,106.81640625,Vysis AutoVysion System,Ratio >=2.0,NO,YES,2.38,Lung,<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,52,3 Point Scale,2+,7thStage IAT1N0M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,9,2011,TCGA-BH-A201-F64222D0597150-E8C6-47DC-A8B9-BD013573E573NOYESNOTUMOR FREEAlive856NO2782014,NOTCGA-LL-A5YM-D57542EBAB50E8-81A5-49D8-92FB-7A44273418ABHormone TherapyletrozoleYES1432014,TCGA-BH-A201-R6422394B7945B-92D9-4D1A-868B-84D66F2C3F4D56108External6640cGy28Primary Tumor FieldNOComplete Response2782014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,831.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A572,E2,A572,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,13.0,H-SCORE 190,Allred 0 = 0+0,Left,1.3749609374999914,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,8.0,0.0,Allred Score,Allred Score,<10%,Hercep Test  TM Dako,Dako Hercept test,116.224609375,Vysis AutoVysion System,Ratio >=2.0,NO,YES,69,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.3,3 Point Scale,1+,7thStage IIIAT2N2M0,YES,YES,NO,10,9,2013,TCGA-E2-A572-F650071E6255EF-F076-40C9-8A5B-35FC4FF7CA8BNOYESYESTUMOR FREEAlive1208NO1792014,NOTCGA-E2-A572-D48249E2D5FD02-12D8-4B62-B9C9-CF7275EFA17A91133ChemotherapyDoxorubicinNO1092013NOTCGA-E2-A572-D48250D7049B0E-CA68-4603-B147-7FE56C43BF18147200ChemotherapyTaxolNOComplete Response1092013NOTCGA-E2-A572-D4825150D48DA4-E3E7-49B4-9DCA-3BDA540825A4263Hormone TherapyArimidexYES1092013,TCGA-E2-A572-R482486AF2B719-A8B2-4E95-BAF5-C4FAFA2FF01A19626360.4Gy28Primary Tumor FieldNOComplete Response1092013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,457.0,WHITE,TCGA-A8-A09M,A8,A09M,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,13.25,allred score 5+3=8,H-Score 0,Right Lower Outer Quadrant,2.1048730468749874,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.9384765625,4.4296875,Allred Score,230,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,100.44140625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,40,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,1.1,3 Point Scale,2+,6thStage IIICT2N3aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A09M-F403316B25050A-F752-4FED-A111-E3D271B3BD15NOYESYESTUMOR FREEAlive1006NO1722013,NOTCGA-A8-A09M-D37785C1C79A95-B5D8-45E8-8FE0-B54E7E43563431184ChemotherapyPaclitaxeln/aNOComplete Response6122012NOTCGA-A8-A09M-D3778609FBDD53-0E66-4D9E-AACA-888BC15FA3CF276Hormone TherapyExemestanen/aYES6122012,TCGA-A8-A09M-R381625ACACE6F-008C-433C-9F3C-EED2853291D8214276ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,476.0,WHITE,TCGA-BH-A0DP,BH,A0DP,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,4.0,H-SCORE 280,H-SCORE 280,Right,1.9541992187499968,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,Re-Excision of Superior Margin,Other,Excision,Infiltrating Lobular Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,0,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.43359375,0.0,H-SCORE,H-SCORE,<10%,ACIS,Hercep Test  TM Dako,79.9423828125,Vysis AutoVysion System,Ratio >=2.0,NO,YES,40,"Other, specifySkin",80-89%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,52,3 Point Scale,3+,Stage IIBT3N0 (i-)M0,NO,YES,YES766Distant MetastasisBoneNOYESNO,9,11,2010,TCGA-BH-A0DP-F453876E54C1C-F786-46BA-8C0F-D377A4642890476AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0DP-D453609705E2D-CC53-4DA2-A6E5-73E70334B7271mg/day97Hormone TherapyARIMIDEXADJUVANTPOYES17112010,TCGA-BH-A0DP-R453761E05A64-548D-49A2-82C0-BD15A10024CD136180EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3913.0,WHITE,TCGA-AR-A2LE,AR,A2LE,No,YES,C50.9,8520/3,C50.9,2001.0,TUMOR FREE,YES,2.0,dextran coated charcoal,CAP scoring guideline 2010,Right,3.986533203124972,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Excision,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.6533203125,0.0,MODERATE,Strong,90-99%,Dako,DAKOHercepTest TM,367.4677734375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,69,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.5724609374999916,2.8,3 Point Scale,2+,5thStage IT1N0M0,YES,YES,Positive70-79%Positive<10%Negative1+,12,1,2012,"TCGA-AR-A2LE-F35164D8AE0195-68C0-4365-B4AE-30D683A89E3FNOYESYESAlive4239YES4203New Primary TumorOther, specifyEndometrium6122012TCGA-AR-A2LE-F4948649DFF8F1-B277-4E3B-A5EE-6B53EB73107EYESYESTUMOR FREEAlive4356NO2102013TCGA-AR-A2LE-F71711EFEB125E-2F60-48BB-9A7B-CFB8A1E7F38FNOYESYESTUMOR FREEAlive5062NO3032015",NOTCGA-AR-A2LE-D37189D5991C24-5B04-45B5-B05F-7F2C6C1167C2171869Hormone TherapyTamoxifenNO6122012,TCGA-AR-A2LE-R3719056389EF6-0220-40E9-B0B0-1CAB2EDF58DB4284External6000cGy30Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,229.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5D8,OL,A5D8,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,Allred (Biocare),Allred score 2+2 = 4,Left Lower Outer Quadrant,0.8,Other (specify),axillary ultrasound,Simple Mastectomy,Re-Excision of Superior Margin,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.734375,1.5107421875,Allred Score 6,120,90-99%,CISH,Venten,20.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.25,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2,3 Point Scale,3+,6thStage IIBT3N0MX,YES,YES,NO,19,4,2013,TCGA-OL-A5D8-F5543885CD1C5F-D1D1-4A4D-B071-233563FA3D44NOYESYESTUMOR FREEAlive973NO1012014,2TCGA-A2-A0CZ-D20078d024ed9-cab0-4645-9ef7-d2443495432a4180mg1045mg4106148ChemotherapyCytoxanADJUVANTIVNO16920101TCGA-A2-A0CZ-D2006b80c8dcd-95cb-43e8-baaf-50704eb883f9418mg104-105mg4106148ChemotherapyAdriamycinADJUVANTIVNO16920103TCGA-A2-A0CZ-D2008df7c95fe-5410-4be7-b482-c0d6c697367120mg/day236Hormone TherapyTamoxifenADJUVANTPOYES1692010,TCGA-BH-A0BO-R61950ABF66B91-2FC8-47CE-9799-E6CE80FF081872119External6040cGy33Primary Tumor FieldNOComplete Response1072014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1NH,E9,A1NH,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,5.0,CAP scoring guideline 2010,dextran coated charcoal,Left Upper Inner Quadrant,2.1599316406249893,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Excisional biopsy,Infiltrating Ductal Carcinoma,ductal and lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.0,3.0,230,Allred score 7 (per outside facility),10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,123.580078125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.6,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.9,3 Point Scale,3+,7thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,23,6,2011,TCGA-E9-A1NH-F350496610DD91-CA89-400B-83F5-1B08AEADAF1ANONOYESTUMOR FREEAlive576NO1492012,NOTCGA-E9-A1NH-D3505423703F4A-C80E-4EF7-BB6D-673805FC889933Hormone TherapyTamoxifenYES1492012,TCGA-E2-A9RU-R6075597D7F63A-20AB-4935-8123-943CFF3853D200External50.4GyRegional siteNOComplete Response1662014TCGA-E2-A9RU-R607564068FAFC-865C-49DB-8D79-51CEA29F727F00External10Gy5Primary Tumor FieldNOComplete Response1662014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,558.0,WHITE,TCGA-BH-A0W7,BH,A0W7,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,Allred score = 8,H-SCORE 150,Left Upper Outer Quadrant,1.7423535156249927,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.0,0.0,allred score = 4,Moderate,90-99%,Dako,CAP scoring guideline 2010,232.783203125,HER2 amplification - negative,Ratio >=2.0,NO,YES,4,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.66,3 Point Scale,2+,6thStage IT1cN0 (i-)M0,NO,YES,YES994Distant MetastasisBoneNOYESYES,15,2,2011,TCGA-BH-A0W7-F34073F6B25172-02C5-489E-9061-B951EE902CB0Scheduled Follow-up SubmissionYESYESAlive1363TUMOR FREENO2972012,NOTCGA-BH-A0W7-D340740A4EE347-EE11-4426-A666-055E6317A80576138ChemotherapyTaxotereNOComplete Response2972012NOTCGA-BH-A0W7-D340751D1011B2-5862-44A0-8E76-C71A08C733ED76138ChemotherapyCytoxanNOComplete Response2972012NOTCGA-BH-A0W7-D3407647152466-BCD7-423E-ACBE-8E1CC909F1341681233Hormone TherapyTamoxifenNOComplete Response2972012NOTCGA-BH-A0W7-D34077F892639C-D682-4FC7-AE4B-6FF21F29508511711324Hormone TherapyArimidexNOComplete Response2972012,TCGA-BH-A0W7-R34078BEFB5D3C-A0C6-4F5D-8E1A-C0561BEFCEB9168229External1600cGy36Primary Tumor FieldNOComplete Response2972012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1463.0,WHITE,TCGA-A1-A0SF,A1,A0SF,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,2.0,allred score 5 + 3 = 8,image cytometry,Left,2.2008105468749832,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Surgical resection,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Negative,Positive,Negative,0.00390625,0.0,allred score = 7,Moderate,10-19%,CISH,CAP SCORING GUIDELINE 2010,131.44921875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.78,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,52,3 Point Scale,2+,6thStage IIAT2N0M0,YES,NO,YES275Distant MetastasisLung,24,5,2011,TCGA-A8-A09R-F40330D44CD2FC-8E35-4FE5-94B7-1CF7C6BC3741NOYESYESTUMOR FREEAlive273NO1722013,"TCGA-A1-A0SF-D121567D85A866-4109-48A5-A927-6B9F5C64BD591010Other, specify in notesAromatase InhibitorarimidexADJUVANTPOYES2452011TCGA-A1-A0SF-D121548B91D294-5433-4D18-A271-253430DDD871157918Hormone TherapytamoxifenADJUVANTPONO2452011TCGA-A1-A0SF-D12152911C7AF6-25C0-4A50-BE12-4E139C861AC0465126ChemotherapytcADJUVANTIVNO2452011",TCGA-A7-A426-R417411A137F59-0C07-44D6-829F-E4B539D4F496220257External5040cGy28Primary Tumor FieldNOComplete Response2632013TCGA-A7-A426-R4174234569FAF-40C8-41C8-8CD2-79E24B283462220257External5040cGy28Regional siteNOComplete Response2632013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,273.0,WHITE,TCGA-A8-A09R,A8,A09R,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,9.9970703125,CAP SCORING GUIDELINE 2010,Allred score 4+3 = 7,Left Lower Inner Quadrant,2.873945312499986,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Modified Radical Masectomy,Negative,Positive,Negative,0.447265625,1.5673828125,allred score = 8,0%,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,102.9462890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.13,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,3.8,3 Point Scale,2+,6thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A09R-F40330D44CD2FC-8E35-4FE5-94B7-1CF7C6BC3741NOYESYESTUMOR FREEAlive273NO1722013,NOTCGA-A8-A09R-D37768E2A85158-819F-473B-AD84-8F5B443F5CCC0Hormone TherapyLetrozolen/aYES6122012,TCGA-A8-A09R-R38158CF62E51D-F3FB-4825-A290-6BF63239AAD161120ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,31.0,WHITE,TCGA-A8-A06Z,A8,A06Z,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,10.671875,IHC,H-SCORE 0,Right Upper Outer Quadrant,1.8185351562499876,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.3720703125,3.37109375,Allred Score 8,Allred score = 7,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,107.8232421875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,40,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.8,3 Point Scale,3+,6thStage IIBT3N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A2-A04T-F934394203642-8318-4406-9B37-865EB92880152246AliveTUMOR FREEYESYES1732011,Carboplatin/TaxolTCGA-EW-A1P7-D2923802AB6152-BB5D-4E54-9189-8B1A5D581075550mg1293ChemotherapyCarboplatinADJUVANTIVYES1232012Carboplatin/TaxolTCGA-EW-A1P7-D2927397468A51-638F-48FB-B604-59FE79E75919234mg1293ChemotherapyTaxolADJUVANTIVYES1332012,TCGA-AR-A1AQ-R218043579DB65-F66D-41A4-B13A-E32DD54BEBDF121163EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12722012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A8-A09G,A8,A09G,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,7.0908203125,CAP SCORING GUIDELINE 2010,H-Score 0,Right Lower Outer Quadrant,1.6976757812499883,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.2236328125,2.0810546875,Allred score 8,0%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,113.4736328125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.13,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.8,3 Point Scale,3+,6thStage IIICT3N3aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A09R-F40330D44CD2FC-8E35-4FE5-94B7-1CF7C6BC3741NOYESYESTUMOR FREEAlive273NO1722013,1TCGA-E2-A14Q-D1880138EC0589-8337-4CE8-B1F2-D4F29BB091A120mg/day20mg/day53Hormone TherapyTamoxifenADJUVANTPOYES20102011,TCGA-A7-A426-R417411A137F59-0C07-44D6-829F-E4B539D4F496220257External5040cGy28Primary Tumor FieldNOComplete Response2632013TCGA-A7-A426-R4174234569FAF-40C8-41C8-8CD2-79E24B283462220257External5040cGy28Regional siteNOComplete Response2632013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1950.0,WHITE,TCGA-A2-A04T,A2,A04T,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,3.0,Allred score 7 (outside facility),allred score 5 +3 = 8,Left Upper Inner Quadrant,1.1,Sentinel node biopsy alone,Pateys surgery,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,1+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Equivocal,0.0,0.0,MODERATE,Allred Score,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,57.9189453125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,66,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,52,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,8,2010,TCGA-A2-A04T-F934394203642-8318-4406-9B37-865EB92880152246AliveTUMOR FREEYESYES1732011,1TCGA-A2-A04T-D2759cd18d339-0df7-42da-a74d-2665046271114600mg1150mg475117ChemotherapyCyclophosphamideADJUVANTIVNO9820101TCGA-A2-A04T-D27616ad79761-aee6-43f7-83c2-d7f5f8ac6189838mg250-338mg3131173ChemotherapyTaxolADJUVANTIVNO9820101TCGA-A2-A04T-D2760dc41b9d2-298f-4934-b566-dfdda2dea217232mg58mg475117ChemotherapyAdriamycinADJUVANTIVNO982010,TCGA-A2-A04T-R9342eac92060-57fb-4a09-8498-7c5e1e4b9924206249EXTERNAL BEAM6040cGyPrimary Tumor FieldADJUVANTNO12132011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,186.0,WHITE,TCGA-D8-A27I,D8,A27I,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,10.0,manual counting,manual counting,Right Upper Outer Quadrant,1.4112011718750008,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0,4.0,>75%,>75%,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,76.7080078125,HER2 amplification - negative,Ratio >=2.0,YES,NO,66,LungBone,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.8,3 Point Scale,2+,7thStage IIIAT1cN2aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,18,7,2011,TCGA-D8-A27I-F29521174B98DC-4E11-40CA-A49E-0EA85C0029E0Scheduled Follow-up SubmissionYESYESAlive439TUMOR FREENO2132012,TCGA-D8-A27I-D2952394238A97-A6AB-4233-B4FD-23DF34B10383240+2400mg60+600mg/m2476160Chemotherapyadrimycin+cyclophosphamideADJUVANTIVNO2132012,TCGA-D8-A27I-R295246D6FB14C-78A7-435A-B30A-9FEC2D491CEC188212EXTERNAL BEAM4500cGy20Primary Tumor FieldADJUVANTNO2132012
TCGAFPPP,Breast,No,FEMALE,Dead,1365.0,1186.619140625,WHITE,TCGA-A2-A0SW,A2,A0SW,No,YES,C50.9,8500/3,C50.9,2006.0,WITH TUMOR,YES,15.0,Allred score 7 (outside facility),Allred score 7 per outside facility report,Right,1.2,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Lumpectomy,Re-Excision of Superior Margin,Other,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.408203125,4.0,10-75%,80,<10%,ACIS,Venten,60.0,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,2.13,Liver,40-49%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,172,3 Point Scale,1+,Stage IVT2N2M1,YES,YES,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,8,11,2010,TCGA-A2-A0SW-F370111921C4C-DBDF-41E9-B605-4FF55BB12DDEDeadWITH TUMOR1365YESYES653NONONO8112010,1TCGA-A2-A0SW-D37025751c947-6519-4f54-b423-fda73bc2b43amg1mg/day85479Hormone TherapyArimidexADJUVANTPONO81120102TCGA-A2-A0SW-D37031e0659e4-5a29-4057-a83b-90e3e8f398eemg20mg/day4791365Hormone TherapyTamoxifenADJUVANTPONO8112010,TCGA-A2-A0SW-R3704b82f6467-290c-4472-9248-1095701eaf2054EXTERNAL BEAM10680cGyPrimary Tumor FieldADJUVANTNO18112010
TCGAFPPP,Breast,No,FEMALE,Dead,1563.0,925.79296875,WHITE,TCGA-BH-A18U,BH,A18U,No,YES,C50.4,8500/3,C50.4,2003.0,TUMOR FREE,YES,16.0,Allread score 5+3 = 8,allred score 5 + 3 = 8,Left,2.062607421875008,Sentinel lymph node biopsy plus axillary dissection,SLN and non-SLN biopsy,Other,Re-Excision of Superior Margin,Other,total mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,3+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Positive,0.7001953125,9.0,Allred score 0,allred score = 7,10-19%,ACIS,Dako Hercept test,224.7802734375,HER2 amplification - negative,Positive >2.2,NO,YES,66,LungBone,80-89%,80-89%,Negative,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,1,3 Point Scale,1+,6thStage IIIAT2N2aM0,NO,YES,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,2,7,2011,TCGA-LD-A7W6-F6919351CDD6F7-8467-42F0-8B9F-4C3BD0C4AFD9NONOYESTUMOR FREEAlive404NO30122014,TCGA-E9-A22A-D298385D55C0D5-040F-4184-A845-1D4A4FEB2ADC7240mg20mg/day111Hormone TherapyTamoxifenADJUVANTPOYES2932012,TCGA-E2-A1L9-R20602FB33C7DC-7439-4DE4-B8CE-2F122C0D2BB8140177EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11112012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,140.0,WHITE,TCGA-EW-A1PF,EW,A1PF,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,H-SCORE 190,CAP scoring guideline 2010,Right Upper Outer Quadrant,1.97991210937498,Other (specify),sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Other,total mastectomy,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,Allred Score 4,Moderate,<10%,CISH,Venten,124.98046875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,54,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.1,3 Point Scale,3+,7thStage IAT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-EW-A1PF-F291099341ABC2-15C0-4C5D-B764-BB4F2E925C0FScheduled Follow-up SubmissionNOYESAlive439TUMOR FREENO832012,1TCGA-EW-A1PF-D302987E4FD718-8A92-44C0-995A-555BC0DA3615524mg130mg4125188ChemotherapyDocetaxelADJUVANTIVNO8320121TCGA-EW-A1PF-D3030104D4281E-70C8-4C99-9286-AE02449AB7754176mg1038mg4125188ChemotherapyCyclophosphamideADJUVANTIVNO8320122TCGA-EW-A1PF-D30302513C4EA7-1EE9-4A4C-ACC1-535D859B1EC51mg/day217Hormone TherapyArimidexADJUVANTPOYES832012,TCGA-BH-A0B5-R591860B41A50F-764D-4D7C-BC17-E313C18AA5F6257302External5040cGy28Primary Tumor FieldNOComplete Response252014TCGA-BH-A0B5-R59187B7B2EE6E-695B-4760-8724-30655D22136D257302External5936cGy43Regional siteNOComplete Response252014TCGA-BH-A0B5-R59188814C435B-99BC-4D04-AD11-C90E47DEBE5F300304External100Gy6Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,140.0,WHITE,TCGA-LD-A7W6,LD,A7W6,No,YES,C50.2,8524/3,C50.2,2013.0,TUMOR FREE,YES,18.0,image cytometry,image cytometry,RightRight Upper Inner Quadrant,1.7900683593749915,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,"Other, specify","Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.423828125,2.0,H score,Moderate to strong,90-99%,ACIS,CAP SCORING GUIDELINE 2010,79.9638671875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,2.6,"LungBoneLiverOther, specifyskin",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,71,3 Point Scale,1+,7thStage IIBT2N1aM0,YES,NO,NO,3,2,2014,TCGA-LD-A7W6-F6919351CDD6F7-8467-42F0-8B9F-4C3BD0C4AFD9NONOYESTUMOR FREEAlive404NO30122014,NOTCGA-LD-A7W6-D5635998AA201E-F562-487E-A7DC-EB64623A1085146ChemotherapyLetrozoleYES322014,TCGA-A2-A0CP-R20012bd9726c-9c8e-4177-a060-ea91da683282163210EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11382010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,134.0,WHITE,TCGA-BH-A0E0,BH,A0E0,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,21.0,H-SCORE 0,H-SCORE 0,Left Upper Outer QuadrantLeft Lower Outer QuadrantLeft,1.3588476562499987,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Right Breast Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,0,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Negative,0.482421875,10.0,H-SCORE,H-SCORE,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,42.58984375,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,33,"LungOther, specifyleft adrenal gland",80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,60,3 Point Scale,0,Stage IIICT3N3aM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,11,2010,TCGA-BH-A0E0-F46038EA495C0-4ADC-49A9-9235-6D360CB615E2134AliveTUMOR FREEYESYES16102010,1TCGA-BH-A0E0-D45998EB7D1DE-E03C-401A-A845-0B5329E85271763mg130mg638143ChemotherapyDOCETAXELADJUVANTIVNO181120101TCGA-BH-A0E0-D4596DF2372AA-F01A-4FB6-9656-6FE9E01FE4E1503mg87mg638143ChemotherapyDOXORUBICINADJUVANTIVNO181120101TCGA-BH-A0E0-D4593B2E22558-CF61-46B8-90DA-D2B204CF8D7A5034mg820mg638143ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO18112010,TCGA-BH-A0E0-R46017729AB44-C0F8-40F3-A012-E97C7F94CAC7198255EXTERNAL BEAM6040cGyPrimary Tumor FieldADJUVANTNO122112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,352.0,WHITE,TCGA-D8-A1XJ,D8,A1XJ,No,YES,C50.9,8523/3,C50.9,2010.0,TUMOR FREE,YES,43.0,manual counting,manual counting,Left Upper Outer QuadrantLeft Lower Outer Quadrant,1.098212890625001,Axillary lymph node dissection alone,Pateys surgery,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,TOTAL MASTECTOMY,"Other, specify",Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Negative,Positive,Positive,0.240234375,2.0,10-75%,>75%,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,54.212890625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.6,LungBone,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.23,3 Point Scale,2+,7thStage IIIAT3N1aMX,YES,YES,YES994Distant MetastasisBoneNOYESYES,9,6,2011,TCGA-D8-A1XJ-F29989D3BBE7A7-94B5-469E-8789-88FFAE42853CScheduled Follow-up SubmissionNOYESAlive664TUMOR FREENO3132012TCGA-D8-A1XJ-F30111113C903F-41E1-4D93-B084-A99AAED7A32DScheduled Follow-up SubmissionNOYESAlive663TUMOR FREENO242012,TCGA-D8-A1XJ-D29988B04923EA-FC7E-4EFA-B2B2-65D43ABA760Dmg/day20mg/day85Hormone TherapytamoxifenADJUVANTPOYES3132012,TCGA-A2-A3XU-R3470502DB7B9E-B9A1-471B-A309-5BFE13679395External4000cGy20Regional siteNO2882012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,122.0,WHITE,TCGA-A7-A26I,A7,A26I,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,2.0,H-Score 300,allred score 5+3+8,Left,1.1,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Close,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Negative,Equivocal,0.013671875,0.0,Allred Score 4,Allred Score 5,10-19%,CISH,Hercep Test  TM Dako,229.0,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,2.0,"LungBoneLiverOther, specifyskin",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.2,3 Point Scale,1+,7thStage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,29,7,2011,TCGA-A7-A26I-F30876E39CC129-3D21-4C50-A94A-6EA7E24F25CDScheduled Follow-up SubmissionYESYESAlive369TUMOR FREENO1842012TCGA-A7-A26I-F3979166A09C74-D0D8-438E-8C18-EC119CB56D3ANOYESYESTUMOR FREEAlive661NO122013,1TCGA-A7-A26I-D310708D9064E7-67A8-4172-A033-3A6E46CA915D6780mg1130mg660164ChemotherapyCytoxanADJUVANTIVNO23420121TCGA-A7-A26I-D31057B0D2110C-8FC3-414F-ABF8-61FEC6144D1D840mg140mg660164ChemotherapyTaxotereADJUVANTIVNO2342012,TCGA-A7-A26I-R3088972D346BE-A998-4B4F-919F-D0ACF1E8D7F2213258EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO11842012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1349.0,WHITE,TCGA-A2-A04X,A2,A04X,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,3.0,H-SCORE 280,allred score 5 +3 = 8,Left,3.2,Sentinel node biopsy alone,Pateys surgery,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,partial mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,1+,3+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Positive,0.0,0.0,MODERATE,STRONG,<10%,Hercep Test  TM Dako,Hercep Test  TM Dako,100.8017578125,HER2 amplification - negative,Ratio >=2.0,NO,YES,40,"LungOther, specifyleft adrenal gland",80-89%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,145,3 Point Scale,0,6thStage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,8,2010,TCGA-A2-A04X-F9335BA0997F8-5C6A-44FB-9BC5-B6F5C5DFCFC81686AliveTUMOR FREENOYES1832011,TCGA-A2-A04X-D2682b94cdbfc-4069-4d6a-8d85-c6b17dbc5d93456mg114mg480122ChemotherapyADRIAMYCINADJUVANTIVNO1182010TCGA-A2-A04X-D26819e16caf0-b8c7-4aed-a2d9-5a2494cafed14560mg1140mg480122ChemotherapyCYTOXANADJUVANTIVNO1182010TCGA-A2-A04X-D2684b8724add-8494-4d41-af82-b8a8e396c6df6471.5mg154-500mg20133383Targeted Molecular therapyHERCEPTINADJUVANTIVNO1182010TCGA-A2-A04X-D2683ca766a09-75f1-4329-9994-9dd95f79c4971858mg154-156mg12133210ChemotherapyTAXOLADJUVANTIVNO1182010TCGA-A2-A04X-D2685a4d66c51-5221-4ab9-aa36-900913040d4b10mg352490Hormone TherapyTAMOXIFENADJUVANTPONO1182010,TCGA-BH-A0AV-R591771E9BDB6B-495D-4881-8264-4717B2630D9B259308External66.4Gy36Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0XU,AN,A0XU,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,16.0,CAP SCORING GUIDELINE 2010,H-Score 0,Left Upper Outer Quadrant,5.818144531249978,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,stereotactic biopsy,Negative,Negative,Negative,0.001953125,0.0,0,0,40-49%,ACIS,DAKOHercepTest TM,209.0,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.13,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.62,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,28,3,2011,TCGA-AN-A0XU-F689614194E7B2-A2E1-4D92-80F0-394939FBCD04YESNONOTUMOR FREEAlive1023122014,1TCGA-A7-A26I-D310708D9064E7-67A8-4172-A033-3A6E46CA915D6780mg1130mg660164ChemotherapyCytoxanADJUVANTIVNO23420121TCGA-A7-A26I-D31057B0D2110C-8FC3-414F-ABF8-61FEC6144D1D840mg140mg660164ChemotherapyTaxotereADJUVANTIVNO2342012,TCGA-A8-A07U-R381800D5E6892-50BD-4919-9416-C6EA578D12B6212242External60GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,304.0,WHITE,TCGA-A8-A07O,A8,A07O,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.71484375,CAP scoring guideline 2010,image cytometry,Right Upper Outer Quadrant,2.197382812499984,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Negative,Negative,0.375,0.0,Allred Score 8,allred score = 8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,139.51171875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.78,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,79,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,27,5,2011,TCGA-A8-A07O-F40831A8FC8B58-BD10-40C0-BEE5-E0DA7F4431C4NOYESYESTUMOR FREEAlive304NO232013,TCGA-A8-A07O-D37865FE74A740-3180-4A13-A733-54DDF7212A9161151ChemotherapyNOComplete Response6122012,TCGA-A8-A07O-R38184B6552840-8AC7-4FA4-8CE2-7EAB6774004A182212ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2.0,WHITE,TCGA-D8-A147,D8,A147,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,% IHC,manual counting,Right Lower Outer Quadrant,1.2046972656249972,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Re-Excision of Superior Margin,Other,Total mastectomy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Indeterminate (neither Pre or Postmenopausal),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Modified Radical Masectomy,Negative,Negative,Negative,0.1494140625,0.0,Allred Score 8,Allred Score 7,90-99%,Dako,Hercep Test  TM Dako,341.4482421875,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,2.13,Lung,80-89%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,2.0,3 Point Scale,2+,7thT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,2,2011,TCGA-D8-A147-F207376B778912-AC2E-4C50-A3F5-4D28049BE764Scheduled Follow-up SubmissionYESYESAlive584TUMOR FREENO1412012,TCGA-D8-A147-D20738A5E59A9B-F5F1-45A0-B6D1-DB44F0A7168Bmg521135ChemotherapydoxorubicineADJUVANTIVNO1412012NOTCGA-D8-A147-D64911CEB8DA00-D300-4AFB-BE1C-2BD15BF0E02021135ChemotherapycyclophosphamideNO1592014NOTCGA-D8-A147-D64912C92110BF-B562-4AFE-A419-2217BD718E8F21135ChemotherapypaclitaxelNO1592014NOTCGA-D8-A147-D64913063BD28B-E3D7-44D7-BEA3-38407B9852F021135ChemotherapydocetaxelNO1592014,TCGA-D8-A147-R20739C093FF02-9F16-4B3D-89AA-4760FC8CA1DC188223EXTERNAL BEAM6000cGy1 brachy+25Primary Tumor FieldADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,854.0,WHITE,TCGA-E2-A10C,E2,A10C,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,13.0,Allred score 5+3=8,Allred score 3+3=6,Left Upper Outer Quadrant,1.646074218749994,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.3994140625,1.0,Allred score 6,Allred score 8,<10%,Dako,Venten,229.05859375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.13,LungBone,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,59,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,11,2,2011,TCGA-E2-A10C-F1735719E548DF-F99C-484B-84C4-C93E7FA746C6Scheduled Follow-up SubmissionYESYESAlive1220TUMOR FREENO2692011,2TCGA-E2-A10C-D77054cbad17f-9385-400c-bb9d-3a2291f3b143160mg/wk80mg/m2/wk12160252ChemotherapyTaxolADJUVANTIVNO14220111TCGA-E2-A10C-D77035c41cc1b-b8b3-448c-93a2-c30024ccf123495139ChemotherapyCytoxanADJUVANTIVNO14220113TCGA-E2-A10C-D7707d7774b1e-92e1-4644-a255-ea3a5ce1ad571mg/day1mg/day282343Hormone TherapyArimidexADJUVANTPONO14220114TCGA-E2-A10C-D771006a90674-8f6e-4a9b-97e0-2d52d0cf21dc2.5mg/day343Hormone TherapyFemaraADJUVANTPOYES14220111TCGA-E2-A10C-D17854A35F5E09-22C4-4854-B838-0F4399668114495139ChemotherapyAdriamycinADJUVANTIVNO2692011,TCGA-E2-A10C-R770268221d80-766f-4c8b-b59b-029f87ad94d2279328EXTERNAL BEAM6040cGy29Primary Tumor FieldADJUVANTNO11422011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,312.0,WHITE,TCGA-EW-A1P6,EW,A1P6,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,25.0,H-Score 150,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.9489355468749845,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Other,Total mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Close,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,2.0,allred score = 6,Two-tier,<10%,CISH,Venten,84.8603515625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,74,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.8,3 Point Scale,3+,7thStage IIBT2N1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,19,5,2011,TCGA-EW-A1P6-F291147A4439F1-4C6D-474E-B2DD-55E519D70AEAScheduled Follow-up SubmissionYESYESAlive562TUMOR FREENO832012,1TCGA-EW-A1P6-D30269D3941135-B841-428D-B697-006C00F9A2332590mg870mg3162205ChemotherapyCyclophosphamideADJUVANTIVNO7320123TCGA-EW-A1P6-D302710F16DDBE-E7EC-4A73-AD9D-C03723C57A191080mg131mg8254303ChemotherapyPaclitaxelADJUVANTIVNO7320122TCGA-EW-A1P6-D30270AFDF574F-0437-489B-AD18-43196C2A548A164mg164mg1233233ChemotherapyDocetaxelADJUVANTIVNO7320121TCGA-EW-A1P6-D302683A0A588D-DF4B-450F-A1BD-06F255D551B72590mg870mg3162205ChemotherapyFluorouracilADJUVANTIVNO7320121TCGA-EW-A1P6-D30267635E9C0E-99F9-4277-A604-E090DC019E30518mg172mg3162205ChemotherapyEpirubicinADJUVANTIVNO7320124TCGA-EW-A1P6-D30273B13DE4DD-820A-49D2-AD88-0F26B649546B1mg/day444Hormone TherapyArimidexADJUVANTPOYES732012,"TCGA-EW-A1P6-R302740BDDDA09-CD55-4750-91BC-0F28F73E5244321386EXTERNAL BEAM10,500cGyPrimary Tumor FieldADJUVANTNO1732012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1.0,ASIAN,TCGA-C8-A275,C8,A275,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,12.626953125,allred score 5+3=8,IHC,Left Upper Outer Quadrant,1.5478808593749955,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,4 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Negative,Negative,0.365234375,3.7470703125,allred score = 6,0%,90-99%,ACIS,CAP SCORING GUIDELINE 2010,102.09765625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,33,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.57,4 Point Scale,2+,6thStage IIAT1N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,21,7,2011,TCGA-AO-A12E-F5895FD98FD53-49BB-464D-9AA5-3167BBC632BF1743AliveTUMOR FREEYESYES8122010TCGA-AO-A12E-F194311CA8FF89-A5C5-4D7A-B043-F371A82CEA7CScheduled Follow-up SubmissionYESYESAlive2142TUMOR FREENO12122011,NOTCGA-A8-A079-D37842D30A1FC1-2462-464E-B8B4-6EC389A3392830183Chemotherapy5-Fluorouraciln/aNO6122012NOTCGA-A8-A079-D3784383CBDD5D-F540-4E22-BFF6-1977215312E530183ChemotherapyEpirubicinn/aNO6122012NOTCGA-A8-A079-D37844D39B1438-ADE8-40F1-A772-470F7B3FE40D30183ChemotherapyCyclophosphamiden/aNO6122012,TCGA-E2-A10C-R770268221d80-766f-4c8b-b59b-029f87ad94d2279328EXTERNAL BEAM6040cGy29Primary Tumor FieldADJUVANTNO11422011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1157.0,WHITE,TCGA-A8-A0AD,A8,A0AD,No,YES,C50.9,8522/3,C50.9,2007.0,TUMOR FREE,YES,4.560546875,allred score 5+3=8,Allred score 0+0=0,Right Upper Outer Quadrant,2.081230468749996,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Mixed Histology (please specify),lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.33203125,0.0,Allred Score 3,Allred score 8,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,129.98828125,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.38,Lung,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,79,3 Point Scale,2+,6thStage IT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A0AD-F40321AA110D07-3B8D-423A-8609-0393506BEC0ANONOYESTUMOR FREEAlive1157NO1622013,NOTCGA-A8-A0AD-D37897246120A5-AB0B-454B-B52D-6055129097FE61Hormone TherapyTamoxifenYES6122012,"TCGA-EW-A1P6-R302740BDDDA09-CD55-4750-91BC-0F28F73E5244321386EXTERNAL BEAM10,500cGyPrimary Tumor FieldADJUVANTNO1732012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,577.0,WHITE,TCGA-A8-A07F,A8,A07F,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,16.8349609375,CAP SCORING GUIDELINE 2010,Allred 0 = 0+0,Left Upper Outer Quadrant,2.9429101562499924,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.359375,1.767578125,allred score = 7,Allred score = 7,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,115.9345703125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,40,LungBone,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,125,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A07F-F40826820EEFC0-3A02-4112-A50A-CC0ABD447D83NOYESYESTUMOR FREEAlive577NO232013,NOTCGA-A8-A07F-D378839376A2EE-E979-4870-8EE1-39BC963B3B5331Chemotherapy5-FluorouracilNOComplete Response6122012NOTCGA-A8-A07F-D378841E1543B7-C41E-4E32-B36C-8B255B09B7C031ChemotherapyEpirubicinNOComplete Response6122012NOTCGA-A8-A07F-D378852EF8C377-0721-408E-BEFA-873ECE792E9831ChemotherapyCyclophosphamideNOComplete Response6122012NOTCGA-A8-A07F-D3788668745060-A6F4-4638-9ADB-D798AA9BF1F7365Hormone TherapyTamoxifenYES6122012,TCGA-A8-A07F-R381899B5CFAA3-D092-43B8-9105-C1EDC216D232181212ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1743.0,WHITE,TCGA-AO-A12E,AO,A12E,No,YES,C50.9,8520/3,C50.9,2005.0,TUMOR FREE,YES,13.0,Allred 0 = 0+0,Allred score 0+0 = 0,Right Lower Inner QuadrantRight Lower Outer QuadrantRight,1.2485937499999984,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Modified Radical Masectomy,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,0,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,1.0,0.0,Allred score 7 per outside facility report,80,<10%,CISH,3+ Positive,34.4267578125,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,40,"LungOther, specifyleft adrenal gland",80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,3.3,3 Point Scale,2+,6thStage IIBT3N0 (i+)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,12,2010,TCGA-AO-A12E-F5895FD98FD53-49BB-464D-9AA5-3167BBC632BF1743AliveTUMOR FREEYESYES8122010TCGA-AO-A12E-F194311CA8FF89-A5C5-4D7A-B043-F371A82CEA7CScheduled Follow-up SubmissionYESYESAlive2142TUMOR FREENO12122011,1TCGA-AO-A12E-D59766aaca2a6-421f-4cc8-a564-961b2eeef1e4408mg60mg/m2485127ChemotherapyDoxorubicinADJUVANTIVNO10120111TCGA-AO-A12E-D5977e02b1a51-def1-423d-ae62-08bfedaa5d901192mg175mg/m24141184ChemotherapyPaclitaxelADJUVANTIVNO10120111TCGA-AO-A12E-D5975d57c2221-a1f2-48a8-9c17-4f74b834b4654080mg600mg/m2485127ChemotherapyCyclophosphamideADJUVANTIVNO10120112TCGA-AO-A12E-D59788a8189d2-30da-4c99-b5d7-462cd2a6794e20mg/day222Hormone TherapyTamoxifenADJUVANTPOYES1012011,TCGA-AO-A12E-R58962f7dc558-30d7-46dc-8dfa-b8f59d9588bf251288EXTERNAL BEAM10080cGy28Regional siteADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,380.0,WHITE,TCGA-A2-A1G0,A2,A1G0,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,19.0,Allread score 5+3 = 8,allred score 5 + 3 = 8,Left Upper Inner Quadrant,1.2,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Simple Mastectomy,Re-Excision of Superior Margin,Other,Mastectomy,"Other, specify",Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.0,2.0,60,270 H,10-19%,Dako,Venten,109.3837890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,64,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.0,3 Point Scale,3+,7thStage IIBT2N1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,21,4,2011,TCGA-A2-A1G0-F2080299FAEFEA-9BBB-42E0-B43E-9020702DB5F9Scheduled Follow-up SubmissionYESYESAlive616TUMOR FREENO912012,1TCGA-A2-A1G0-D122773f7e4bbf-f665-40a2-b4ac-ec01e86be371574mg94-96mg672177ChemotherapyAdriamycinADJUVANTIVNO27420112TCGA-A2-A1G0-D1227898afbca9-9725-421f-98a6-9f7f299a0e0b872mg141-148mg652177ChemotherapyTaxotereADJUVANTIVNO27420113TCGA-A2-A1G0-D12279684a3831-0dbd-4c77-bcad-abc00bca6fcf5720mg940-960mg672177ChemotherapyCytoxanADJUVANTIVNO27420114TCGA-A2-A1G0-D12281ef4fe873-a6fc-46bb-a3f7-225d1f22dbc320mg/dayHormone TherapyTamoxifenADJUVANTPOYES2742011,TCGA-A2-A1G0-R12283d076e89d-1cdd-4918-a564-6081ad5fcb64201244EXTERNAL BEAM6000cGy31Regional siteADJUVANTNO12742011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,266.0,BLACK OR AFRICAN AMERICAN,TCGA-LD-A9QF,LD,A9QF,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,14.0,Allred score 5+3=8,IHC,Left,3.044414062499997,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Re-Excision of Superior Margin,Other,Excisional biospy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Positive,0.263671875,0.0,Allred score = 7,H score,90-99%,CISH,Hercep Test  TM Dako,108.779296875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,74,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,4.70,3 Point Scale,2+,7thStage IAT1cN0M0,YES,NO,NO,7,5,2014,TCGA-LD-A9QF-F692163602B53B-6E99-4063-AC77-94842CA333C4NONOYESTUMOR FREEAlive323NO30122014,NOTCGA-LD-A9QF-D69217DD58AC64-B826-4A72-A389-94813C6C0B32190ChemotherapyTaxolYES30122014NOTCGA-LD-A9QF-D69218C272D5D2-87EC-40F4-AE07-C273B787A7AA190ChemotherapyHerceptinYES30122014,TCGA-A8-A07F-R381899B5CFAA3-D092-43B8-9105-C1EDC216D232181212ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,13.0,WHITE,TCGA-AC-A6IX,AC,A6IX,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,21.0,H-Score 150,Allred (Biocare),Left Upper Outer Quadrant,2.605039062499989,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,segmental mastectomy with sentinel lymph node dissection,Infiltrating Lobular Carcinoma,Invasive tubulolobular carcinoma,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Negative,1.015625,19.0,Two-tier,8,10-19%,ACIS,Dako Hercept test,91.37109375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,74,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.66,3 Point Scale,2+,7thStage IIICT2N3aMX,YES,YES,NO,21,10,2013,TCGA-AC-A6IX-F6602523A43B78-CE3E-4306-96BB-F26BDC52FB61NOYESYESTUMOR FREEAlive373NO1102014,NOTCGA-A8-A0AD-D37897246120A5-AB0B-454B-B52D-6055129097FE61Hormone TherapyTamoxifenYES6122012,"TCGA-EW-A1P6-R302740BDDDA09-CD55-4750-91BC-0F28F73E5244321386EXTERNAL BEAM10,500cGyPrimary Tumor FieldADJUVANTNO1732012"
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2755.0,WHITE,TCGA-AO-A12A,AO,A12A,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,27.0,H-SCORE 190,dextran coated charcoal,Right Upper Outer QuadrantRight,1.0,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,1+,Negative,Close,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,1.0,0.0,230,80,<10%,CISH,3+ Positive,30.0,HER2 amplification - negative,>=2.0 Positive,NO,YES,58,"LungOther, specifyleft adrenal gland",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,61,3 Point Scale,4+,6thStage IIAT2N0 (i+)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,12,2010,TCGA-AO-A12A-F5885C93AD7CB-92B3-4437-8A76-B6F75E503D1C2755AliveTUMOR FREENOYES8122010TCGA-AO-A12A-F19418BFC6614A-A948-450E-AFF8-2973C401CDF9Scheduled Follow-up SubmissionNOYESAlive3112NO12122011,2TCGA-AO-A12A-D5955f0990117-c231-40b2-9fdd-2e0c99c5325920mg/day186830Hormone TherapyTamoxifenADJUVANTPONO10120111TCGA-AO-A12A-D59516e16923a-f894-4deb-96a0-7b875f5dd9c3600mg/m2467112ChemotherapyCyclophosphamideADJUVANTIVNO10120112TCGA-AO-A12A-D595612495058-61d2-4d20-850f-ddfc97c9b7e825mg/day8311918Hormone TherapyAromasinADJUVANTPONO10120111TCGA-AO-A12A-D5952da66efbf-8091-4e5b-b1ce-b9427f0eb0e360mg/m2467112ChemotherapyDoxorubicinADJUVANTIVNO10120111TCGA-AO-A12A-D5954b5aa7d03-a502-4ee1-97df-86d2ea4a1a5d175mg/m24126168ChemotherapyPaclitaxelADJUVANTIVNO1012011,TCGA-D8-A147-R20739C093FF02-9F16-4B3D-89AA-4760FC8CA1DC188223EXTERNAL BEAM6000cGy1 brachy+25Primary Tumor FieldADJUVANTNO1412012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,14.0,ASIAN,TCGA-C8-A131,C8,A131,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,8.0,dextran coated charcoal,dextran coated charcoal,Left,1.421416015624989,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Negative,Negative,Negative,0.396484375,4.0,Allred Score 5,0%,10-19%,Hercep Test  TM Dako,Venten,87.9462890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,3.1,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.8,4 Point Scale,2+,6thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,15,4,2011,TCGA-C8-A131-F190831EFBD51F-B7D9-44A2-9EB5-A651DD80FDC4Scheduled Follow-up SubmissionNOYESAlive68TUMOR FREENO2122010TCGA-C8-A131-F70827FD18DE54-343A-43E7-9EA3-010208D98744NONOYESTUMOR FREEAlive411NO932015,NOTCGA-C8-A131-D70828D5B3D28A-4333-4455-9FCB-220B0A14A5FB3457Chemotherapy5-FlourouracilNOComplete Response932015NOTCGA-C8-A131-D70829FF1D85A6-7EFA-489D-B455-FF6D8C7D3E333457ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A131-D70830F291DB2B-45ED-4BD2-98A3-63F012802AC33457ChemotherapyCyclophosphamideNOComplete Response932015,TCGA-EW-A2FW-R323378048DA7B-76F8-45CF-8B2D-46D6509CF44F279329EXTERNAL BEAM6400cGy30Primary Tumor FieldADJUVANTNO12352012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2317.0,WHITE,TCGA-AR-A0U3,AR,A0U3,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,4.0,CAP scoring guideline 2010,%IHC,Left Upper Inner QuadrantLeft Upper Outer Quadrant,2.0212109374999883,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Other,Wide local excision,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.123046875,1.0,Allred Score 6,0,90-99%,FISH,CAP SCORING GUIDELINE 2010,128.5732421875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.6,"LungBoneLiverOther, specifyskin",10-19%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,2.0,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,25,2,2011,TCGA-AR-A0U3-F184821FED9C55-51D0-4ED5-8150-2A0DDD73D8FFScheduled Follow-up SubmissionYESYESAlive2317NO12122011TCGA-AR-A0U3-F49481AABD784B-86D7-4F0B-B4BC-E08E71337DD7YESYESTUMOR FREEAlive3468NO2102013TCGA-AR-A0U3-F71712679643AA-E34B-4B54-B79A-C34ECCF1DD86NOYESYESTUMOR FREEAlive4080NO3032015,1TCGA-AR-A0U3-D190288B7D25A5-DF6C-4F1F-9018-189E343500BB420mg60mg/m234169ChemotherapyDoxorubicinADJUVANTIVNO121220112TCGA-AR-A0U3-D190343AB2189D-3925-4831-B00A-1E7791363CF81mg/day1662015Hormone TherapyAnastrozoleADJUVANTPONO121220111TCGA-AR-A0U3-D1903113CF7E01-51DD-4494-8E95-4C20C42A3E504160mg600mg/m234169ChemotherapyCytoxanADJUVANTIVNO121220111TCGA-AR-A0U3-D190330E604F50-B14A-4467-953D-6DDF693614521590mg175mg/m2495137ChemotherapyPaclitaxelADJUVANTIVNO12122011,TCGA-AR-A0U3-R18476E1B639A5-3CE0-4F0C-8250-286B8927236C171210EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO112122011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,19.0,WHITE,TCGA-D8-A27H,D8,A27H,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,1.0,manual counting,Image Analysis,Right Upper Outer Quadrant,1.3439648437499954,No axillary staging,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Negative,Negative,0.00390625,0.0,Allred score = 0,Allred score = 0,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,120.70703125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.6,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.0,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,18,7,2011,TCGA-D8-A27H-F2953624D385C9-D517-47C8-90B6-128C9B86C4ABScheduled Follow-up SubmissionNOYESAlive397TUMOR FREENO2232012,TCGA-D8-A27H-D295374AB576A6-1236-4F08-9245-2BA70A7A8F57360+3600mg60+600mg636141Chemotherapydoxorubicin+ cyclophosphamideADJUVANTIVNO2232012,TCGA-A2-A0T6-R3993d4bf30e0-a82d-445a-b39e-effcb98e7e05231279EXTERNAL BEAM5940cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,274.0,WHITE,TCGA-A8-A079,A8,A079,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,14.029296875,CAP SCORING GUIDELINE 2010,Allred 0 = 0+0,Left Upper Outer Quadrant,2.1858691406249853,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.2919921875,4.9736328125,MODERATE,Strong,10-19%,ACIS,Hercep Test  TM Dako,117.453125,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,2.13,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.85,3 Point Scale,3+,5thStage IIIBT4bN3M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-A8-A079-F408225AFF0910-3B7D-408F-A464-C3E105392A8CNOYESYESTUMOR FREEAlive274232013,NOTCGA-A8-A079-D37842D30A1FC1-2462-464E-B8B4-6EC389A3392830183Chemotherapy5-Fluorouraciln/aNO6122012NOTCGA-A8-A079-D3784383CBDD5D-F540-4E22-BFF6-1977215312E530183ChemotherapyEpirubicinn/aNO6122012NOTCGA-A8-A079-D37844D39B1438-ADE8-40F1-A772-470F7B3FE40D30183ChemotherapyCyclophosphamiden/aNO6122012,TCGA-A8-A079-R38176BFA37E0C-E6C7-4667-84A9-FAD16411E814214274External50GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,303.0,WHITE,TCGA-A8-A07U,A8,A07U,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,16.02734375,CAP scoring guideline 2010,H-SCORE 0,Right Upper Outer Quadrant,1.8765624999999848,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Negative,Negative,0.7734375,4.962890625,MODERATE,230,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,132.0439453125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,64,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.9,3 Point Scale,2+,6thStage IIIAT2N2aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A07U-F40834144DF477-24E5-4990-931F-2038B033AB05NOYESYESTUMOR FREEAlive760NO232013,NOTCGA-A8-A07U-D37854D0CD63EE-CD6F-43C9-9FB5-FB2114055A143030Chemotherapy5-Fluorouraciln/aNO6122012NOTCGA-A8-A07U-D378558D55552F-9B8D-4002-B654-C83EED6FD35E3030ChemotherapyEpirubicinn/aNO6122012NOTCGA-A8-A07U-D37856B2F4C015-EAF0-4448-B665-1B8C5A7B89083030ChemotherapyCyclophosphamiden/aNO6122012NOTCGA-A8-A07U-D37857B33C7BC7-4100-448C-AD46-5A4BE08C2A53122ChemotherapyDocetaxeln/aNO6122012,TCGA-A8-A07U-R381800D5E6892-50BD-4919-9416-C6EA578D12B6212242External60GyPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12O,C8,A12O,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,H-SCORE 190,Allred score 5+3=8,Left,1.3264257812499938,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.0048828125,0.001953125,Allred Score 7,Allred Score 7,90-99%,Dako,CAP scoring guideline 2010,84.0947265625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,74,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.1,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",13,4,2011,TCGA-C8-A12O-F202610FF852B6-07CA-4E22-8B58-A6EC5D9BC503Scheduled Follow-up SubmissionNOYESAlive385TUMOR FREENO912012,TCGA-E9-A1RC-D30607E58C5E86-0316-4F5B-99B0-A13F95BE2CA520mg20mg112221222ChemotherapyMitoxantronePALLIATIVEIVNO1342012TCGA-E9-A1RC-D3060962673F57-7FC4-4ED0-9E85-73C713C381A270mg70mg112221222ChemotherapyMethotrexatePALLIATIVEIVNO1342012TCGA-E9-A1RC-D306108DEF7FCD-2D76-448A-B718-638B681918AD20mg/day1220Hormone TherapyTamoxifenPALLIATIVEPOYES1342012TCGA-E9-A1RC-D306063D595692-CF03-4987-8958-AC8D85D1C26F20mg20mg112221222ChemotherapyMitomycinPALLIATIVEIVNO1342012,TCGA-B6-A402-R40853770A2F31-3163-492C-A9D0-4F49CD54D734278310External5256cGy21Primary Tumor FieldNO732013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1651.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A402,B6,A402,No,YES,C50.9,8500/3,C50.9,2008.0,WITH TUMOR,YES,3.0,Allred score 5+3=8,CAP scoring guideline 2010,Right Lower Outer Quadrant,1.1950488281250031,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,4 Point Scale,1+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Negative,Negative,0.0,0.0,170,270 H,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,42.5615234375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.78,"LungBoneLiverOther, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.5,4 Point Scale,1+,6thStage IT1cN0 (i-)M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",20,9,2012,"TCGA-B6-A402-F59668CE3A84EC-BBCB-4860-8564-F07B7D1F291ANOYESYESWITH TUMORAlive2281NO362014TCGA-B6-A402-F6075165F37E9F-5FDE-4D4D-BBC9-2698B4B4F03CNOYESYESWITH TUMORAlive2134YES2330Locoregional RecurrenceOther, specifyLymph NodeNONOYESPositive<10%3 Point Scale2+Negative70-79%3 Point Scale2+Positive<10%2+Negative4.43.14.1872014",NOTCGA-B6-A402-D4094835A74783-A336-48EF-8D16-8CE8F0E6FF7D3093ChemotherapyCyclophosphamideNOPartial Response732013NOTCGA-B6-A402-D40949A9104E79-C312-4005-9AF6-7BC7CCEF7C193093ChemotherapyDoxorubicinNOPartial Response732013NOTCGA-B6-A402-D40950DE8DFC8E-AD88-486E-85C9-DEDAC34CD8AA112191ChemotherapyPaclitaxelNOPartial Response732013NOTCGA-B6-A402-D59670AA69A790-B2B4-49B2-B8C3-907251C7338C21762232ChemotherapyDoxilNOPartial Response362014,TCGA-B6-A402-R40853770A2F31-3163-492C-A9D0-4F49CD54D734278310External5256cGy21Primary Tumor FieldNO732013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A22E,E9,A22E,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,CAP scoring guideline 2010,Allred score 5+3 = 8,Right Upper Inner Quadrant,1.226552734375,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Other,Re-Excision of Superior Margin,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Positive,0.0,4.0,Allred score 6,H score,<10%,Hercep Test  TM Dako,Hercep Test  TM Dako,71.3955078125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,3.0,"LungBoneLiverOther, specifyskin",10-19%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,52,4 Point Scale,1+,7thStage IIIAT2N2M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,8,2011,TCGA-E9-A22E-F29931521A96A8-8FE3-459F-A70A-1AC826A0EA55Scheduled Follow-up SubmissionYESYESAlive392TUMOR FREENO3032012TCGA-E9-A22E-F5557171C2365F-67A1-447E-87BF-BFFF492E00E9NOYESYESTUMOR FREEAlive912NO912014TCGA-E9-A22E-F635650D065B9C-234C-4A64-8BDB-604298451D32NOYESYESTUMOR FREEAlive1269NO1382014,TCGA-E9-A22E-D2993365C41709-5F20-4641-81E0-A088A34E3FBF3600mg900mg/day613226ChemotherapyCyclophosphaneADJUVANTIVNO912013TCGA-E9-A22E-D299375E6E3BA5-6698-470A-AEF8-FD14C58235763600mg900mg/day613226Chemotherapy5-FluorouracilADJUVANTIVNO912014TCGA-E9-A22E-D29932A08D578D-BE6C-4B00-A7A9-3F364189E4C6360mg90mg/day613226ChemotherapyDoxorubicinADJUVANTIVNO912014,TCGA-E9-A22E-R2993896410A12-7396-491A-B9A2-EC4CD9C55310105128EXTERNAL BEAM4600cGy23Primary Tumor FieldADJUVANTNO912014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,334.0,WHITE,TCGA-A8-A07P,A8,A07P,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,6.08203125,Allred 0 = 0+0,H-Score 0,Left Upper Outer Quadrant,5.8759374999999965,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.716796875,0.970703125,MODERATE,8,30-39%,Hercep Test  TM Dako,Hercep Test  TM Dako,142.6298828125,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.6,LungBone,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.9,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A07P-F40832B5B63F7A-129B-4BDA-9D97-8F173A9A02DANOYESYESTUMOR FREEAlive334232013,NOTCGA-A8-A07P-D3786051A06630-6788-4AF6-B0A3-C4B649D4966B61181Chemotherapy5-Fluorouraciln/aNO6122012NOTCGA-A8-A07P-D378618927D85C-E657-4253-9085-7F56495EEBCE61181ChemotherapyDoxorubicinn/aNO6122012NOTCGA-A8-A07P-D378629AA7C3E5-F877-4767-99B4-5D448798AE7961181ChemotherapyCyclophosphamiden/aNO6122012NOTCGA-A8-A07P-D3786375AA33AD-D619-4CF8-BA27-5431C367A9B361181ChemotherapyDocetaxeln/aNO6122012NOTCGA-A8-A07P-D378646E70AFEF-B5DD-4CDE-89B1-50C8857BA3CF273Hormone TherapyAnastrozolen/aYES6122012,TCGA-A8-A07P-R381830890E30B-F3E9-4908-8B48-F0D3D612D57D181212ExternalPrimary Tumor FieldNO11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,688.0,WHITE,TCGA-E2-A14Y,E2,A14Y,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,5.0,Allred score 5+3 = 8,Allred score 5+3 = 8,Right,1.2382128906249938,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,Re-Excision of Superior Margin,Other,Total mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Positive,Positive,Equivocal,0.767578125,0.0,Allred score = 8,H-Score,90-99%,Dako,CAP scoring guideline 2010,118.41796875,HER2 amplification - negative,Ratio >=2.0,NO,YES,74,LungBone,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,79,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,PositivePositiveNegativeNegative1.09,6,4,2011,TCGA-E2-A14Y-F184971C861536-87ED-4A24-9C82-A5CD3A573E3BScheduled Follow-up SubmissionNOYESAlive870TUMOR FREENO7112011TCGA-E2-A14Y-F7040169DD5AC7-10EB-49C5-B9C9-CCE7B1F28459NONOYESTUMOR FREEAlive2109NO1732015,3TCGA-E2-A14Y-D18512A7494061-D25A-4E53-91D6-9B5DB0B5D69F20mg/day20mg/day190547Hormone TherapyTamoxifenADJUVANTPONO71120111TCGA-E2-A14Y-D18499A5C3C97F-CCF1-4700-913A-C658584D28BB4092mg600mg644149ChemotherapyCarboplatinADJUVANTIVNO71120115TCGA-E2-A14Y-D18514BCD48E52-6804-43CF-8C55-E1980A6C15D660mg/day60mg/day548Hormone TherapyFarestonADJUVANTPOYES71120114TCGA-E2-A14Y-D1851367957E3D-E6D1-49EA-A0E8-11E99FB353A148mg4mg2121185ChemotherapyZoledronic AcidADJUVANTIVNO71120112TCGA-E2-A14Y-D185004D262684-171D-4544-A44F-60BFAC00AEAA7168mg536mg1744384ChemotherapyTrastuzumabADJUVANTIVNO71120111TCGA-E2-A14Y-D1849820803F10-4778-41BF-8D82-81E4DC7531C0829mg137mg644149ChemotherapyDocetaxelADJUVANTIVNO7112011,"TCGA-EW-A1P6-R302740BDDDA09-CD55-4750-91BC-0F28F73E5244321386EXTERNAL BEAM10,500cGyPrimary Tumor FieldADJUVANTNO1732012"
TCGAFPPP,Breast,No,FEMALE,Dead,921.0,763.388671875,WHITE,TCGA-BH-A18P,BH,A18P,No,YES,C50.3,8500/3,C50.3,2003.0,WITH TUMOR,YES,2.0,Allred score = 8,H-SCORE 290,Left Lower Inner Quadrant,2.3066113281249887,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Re-Excision of Superior Margin,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,1+,2+,Negative,Negative,Fine needle aspiration biopsy,Ultrasound-guided biopsy,Positive,Positive,Positive,0.9140625,0.0,allred score =  8,Allred score 7 (per outside facility),10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,108.5859375,HER2 amplification - negative,PathVysion,NO,YES,118,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.8325585937499964,5,3 Point Scale,2+,6thStage IT1N0M0,NO,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,22,6,2011,TCGA-AQ-A54N-F5573680219E7C-2608-4B42-B6EC-E9DA0D3B6EB5YESNONOTUMOR FREEAlive781412014,2TCGA-A2-A0EX-D2011a18f54ee-33e5-4dc3-a61a-ba662d4e192d11.25mg3.75mg3172222Hormone TherapyLupronADJUVANTIMNO13820101TCGA-A2-A0EX-D2010e8a75fe6-b841-46ea-9bd8-51b5fe21c01e10 mgmg165Hormone TherapyTamoxifenADJUVANTPOYES13820103TCGA-A2-A0EX-D20122a817b25-0580-4742-b337-8cd0a8bfb1433.6 mg monthlymg273Hormone TherapyZoladexADJUVANTSCYES1382010,TCGA-E2-A153-R1895509529206-8504-42D1-A155-E1C6D5539359237294EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO18112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1R0,E9,A1R0,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,12.0,IHC,Allred score 5+3 = 8,Left Upper Outer Quadrant,1.6548144531249875,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Other,Excision,Infiltrating Ductal Carcinoma,ductal and lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Equivocal,0.259765625,1.0,Allred Score 6,Two-tier,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,112.298828125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,33,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,6.4,4 Point Scale,1+,7thStage IIAT1cN1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,7,2011,TCGA-E9-A1R0-F297956DD81350-F039-458B-A58D-50192EE6C328Scheduled Follow-up SubmissionNOYESAlive435TUMOR FREENO2932012TCGA-E9-A1R0-F41214AD367CF1-62C6-4796-AB47-569755FE6836NONOYESTUMOR FREEAlive860NO1332013,TCGA-E9-A1R0-D2979762BE4AFA-184B-4008-A0DA-3C7ED6C00EB43200mg800mg/day436103ChemotherapyCyclophosphamideADJUVANTIVNO2932012TCGA-E9-A1R0-D29805B560F532-8633-49E9-A9C7-AE671251F874320mg80mg/day436103ChemotherapyDoxorubicinADJUVANTIVNO2932012,TCGA-AR-A5QQ-R4276536D43FF0-8472-4D18-9916-39F7D4FAF10C233External6120cGy34Primary Tumor FieldNO1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1004.0,WHITE,TCGA-A8-A07B,A8,A07B,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,8.1005859375,allred score 5+3=8,Allred 0 = 0+0,Left Lower Outer Quadrant,2.030478515624984,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.6875,0.0,Allred Score,allred score = 8,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,103.603515625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.6,LungBone,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,2.23,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A07B-F408234265C9DA-22B4-4682-A01B-71D9E453CB98NONONOTUMOR FREEAlive1308232013,4TCGA-A2-A0CY-D203718ee660a-937e-4b2e-8965-26eac0c8eeca8640mg4320mg2133147ChemotherapyGemzarADJUVANTIVNO13920109TCGA-A2-A0CY-D2042f939ece6-83f5-47de-903f-49a909ca253c2.5mg1261Hormone TherapyLetrozoleADJUVANTPOYES13920102TCGA-A2-A0CY-D20359b6cfae2-3c2c-4c37-9713-fe0ab090e6065216mg1300-1308mg477119ChemotherapyCytoxanADJUVANTIVNO13920103TCGA-A2-A0CY-D2036f14a412b-1425-4f47-ae9a-36a4915d9a261121mg216-378mg4133177ChemotherapyTaxolADJUVANTIVNO13920108TCGA-A2-A0CY-D2041d5d250f1-15c3-4766-94ed-40ac4f8f7cc025mg10711162Hormone TherapyExemestaneADJUVANTPONO13920105TCGA-A2-A0CY-D20383dd69ff8-546a-4ac3-bc5b-256b74c682b920mg/day197357Hormone TherapyTamoxifenADJUVANTPONO13920106TCGA-A2-A0CY-D2039447a07c8-be8d-45d3-8404-b6d76b16b0bc1mg455507Hormone TherapyAnastrozoleADJUVANTPONO13920101TCGA-A2-A0CY-D2034bb794a4d-53f8-4917-bb80-d7fc4646766c520mg130mg477119ChemotherapyAdriamycinADJUVANTIVNO14920107TCGA-A2-A0CY-D2040bad877aa-b726-4dc3-ab46-c4c508f5b58c1mg634665Hormone TherapyAnastrozoleADJUVANTPONO1492010,TCGA-E2-A153-R1895509529206-8504-42D1-A155-E1C6D5539359237294EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO18112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0FY,AN,A0FY,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,image cytometry,CAP SCORING GUIDELINE 2010,Left Upper Outer Quadrant,2.6062792968749933,No axillary staging,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,0,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,110,80,40-49%,0,Dako Hercept test,157.404296875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.0,Lung,80-89%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.85,3 Point Scale,1+,7thStage IAT1cN0M0,YES,NO,YES766Distant MetastasisBoneNOYESNO,29,12,2010,TCGA-AN-A0FY-F68968B6587F06-C3D0-4336-8B60-9DFAC3C4898ANONONOTUMOR FREEAlive1024122014,4TCGA-A2-A0T6-D39979a7b6e0f-5e16-4bcf-a58f-a0ee35e617afmg20mg/day232Hormone TherapyTamoxifenADJUVANTPOYES171120102TCGA-A2-A0T6-D399523fa8497-3a06-42ab-900c-69deab1936ed540mg90mg695204ChemotherapyAdriamycinADJUVANTIVNO171120101TCGA-A2-A0T6-D39943ea8097f-3255-4d00-85b9-5d1f6e426c5f810mg135mg695204ChemotherapyTaxotereADJUVANTIVNO171120103TCGA-A2-A0T6-D3996bd93c307-9d87-4a15-bb03-b8d02cc44b575400mg900mg695204ChemotherapyCytoxanADJUVANTIVNO17112010,TCGA-D8-A1XD-R29441EFC43768-3277-4FD5-8328-112033D69DF4109138EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,586.0,WHITE,TCGA-E2-A153,E2,A153,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,15.0,dextran coated charcoal,IHC,Left,1.3340624999999942,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Surgical resection,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.76171875,3.0,10-75%,0,10-19%,Dako,Venten,99.9990234375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,3.1,LungBone,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.0,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",7,4,2011,TCGA-E2-A153-F189453D500678-49CD-4335-9A43-AC504DE9E2B6Scheduled Follow-up SubmissionYESYESAlive707TUMOR FREENO8112011,3TCGA-E2-A153-D18954229BE9CD-B3B4-4B15-AA20-DFF1B19DF725mg20mg/day229Hormone TherapytamoxifenADJUVANTPOYES81120112TCGA-E2-A153-D18950DC77A2E0-D67A-46FB-8F56-EE1F16089F981722mg200mg9112196ChemotherapypaclitaxelADJUVANTIVNO81120111TCGA-E2-A153-D18948057F6C50-9E43-4775-9A1A-00A06EB7F9B4480mg120mg44298ChemotherapydoxorubicinADJUVANTIVNO81120111TCGA-E2-A153-D18947F3D8922B-7D20-47D4-9ECC-806723EFCE765700mg1500mg44298ChemotherapycyclophosphamideADJUVANTIVNO8112011,TCGA-E2-A153-R1895509529206-8504-42D1-A155-E1C6D5539359237294EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO18112011
TCGAFPPP,Breast,No,FEMALE,Dead,2573.0,4269.515625,WHITE,TCGA-B6-A0IN,B6,A0IN,No,YES,C50.9,8523/3,C50.9,1996.0,WITH TUMOR,YES,14.763671875,Image Analysis,Image Analysis,Right Upper Outer QuadrantRight,1.221972656250001,No axillary staging,Pateys surgery,Other,Re-Excision of Superior Margin,Modified radical mastectomy,Excisional biopsy,"Other, specify",Ductal with mucinous features,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,2+,2+,Negative,Positive,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Equivocal,0.8740234375,2.35546875,Allred score 7 per outside facility report,moderate,10-19%,Hercep Test  TM Dako,dextran coated charcoal,61.548828125,HER2 amplification - negative,Positive >2.2,NO,YES,33,"LungOther, specifyleft adrenal gland",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.944414062499999,816,4 Point Scale,1+,4thStage XT1cNXMX,YES,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,2,11,2010,"TCGA-B6-A0IN-F12625B47C325B-7239-402E-8708-8C6DE45E6459Scheduled Follow-up SubmissionNOYESDead2573WITH TUMORYES1412Distant MetastasisOther, specifybone, brainNOYES262011",2TCGA-A2-A0EX-D2011a18f54ee-33e5-4dc3-a61a-ba662d4e192d11.25mg3.75mg3172222Hormone TherapyLupronADJUVANTIMNO13820101TCGA-A2-A0EX-D2010e8a75fe6-b841-46ea-9bd8-51b5fe21c01e10 mgmg165Hormone TherapyTamoxifenADJUVANTPOYES13820103TCGA-A2-A0EX-D20122a817b25-0580-4742-b337-8cd0a8bfb1433.6 mg monthlymg273Hormone TherapyZoladexADJUVANTSCYES1382010,TCGA-BH-A0H7-R47368B3F8793-8DF3-477C-BFB8-CA5F68C9C608274314EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Dead,426.0,484.6025390625,WHITE,TCGA-A8-A09X,A8,A09X,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,16.1796875,allred score 5+3=8,H-Score 0,Left Upper Inner Quadrant,1.799287109374996,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Lobular Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Negative,Negative,0.7275390625,8.203125,MODERATE,Allred score 8,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,119.546875,HER2 amplification - negative,PathVysion,NO,YES,50,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,79,3 Point Scale,2+,6thStage IIICT2N3aM0,YES,YES,Negative<10%3 Point ScaleNegative<10%3 Point ScaleEquivocal<10%1+,27,5,2011,TCGA-A8-A08I-F4084598D30323-480E-40B0-825C-3EA0C137401CNOYESYESTUMOR FREEAlive365NO232013,4TCGA-A2-A0CY-D203718ee660a-937e-4b2e-8965-26eac0c8eeca8640mg4320mg2133147ChemotherapyGemzarADJUVANTIVNO13920109TCGA-A2-A0CY-D2042f939ece6-83f5-47de-903f-49a909ca253c2.5mg1261Hormone TherapyLetrozoleADJUVANTPOYES13920102TCGA-A2-A0CY-D20359b6cfae2-3c2c-4c37-9713-fe0ab090e6065216mg1300-1308mg477119ChemotherapyCytoxanADJUVANTIVNO13920103TCGA-A2-A0CY-D2036f14a412b-1425-4f47-ae9a-36a4915d9a261121mg216-378mg4133177ChemotherapyTaxolADJUVANTIVNO13920108TCGA-A2-A0CY-D2041d5d250f1-15c3-4766-94ed-40ac4f8f7cc025mg10711162Hormone TherapyExemestaneADJUVANTPONO13920105TCGA-A2-A0CY-D20383dd69ff8-546a-4ac3-bc5b-256b74c682b920mg/day197357Hormone TherapyTamoxifenADJUVANTPONO13920106TCGA-A2-A0CY-D2039447a07c8-be8d-45d3-8404-b6d76b16b0bc1mg455507Hormone TherapyAnastrozoleADJUVANTPONO13920101TCGA-A2-A0CY-D2034bb794a4d-53f8-4917-bb80-d7fc4646766c520mg130mg477119ChemotherapyAdriamycinADJUVANTIVNO14920107TCGA-A2-A0CY-D2040bad877aa-b726-4dc3-ab46-c4c508f5b58c1mg634665Hormone TherapyAnastrozoleADJUVANTPONO1492010,TCGA-AR-A254-R31900967465A7-0A86-4FBD-A554-CA1E36E827D2252291EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO11052012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,274.0,WHITE,TCGA-D8-A1JJ,D8,A1JJ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,manual counting,manual counting,Right Upper Inner Quadrant,1.1625097656249987,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Other,breast conserving therapy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.02734375,0.0,10-75%,>75%,90-99%,10-75%,DAKOHercepTest TM,100.6279296875,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.38,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.0,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,3,2011,TCGA-D8-A1JJ-F207542586900A-76A7-44D0-9D02-828DF5F321CDScheduled Follow-up SubmissionYESYESAlive611TUMOR FREENO1912012,TCGA-D8-A1JJ-D207521B097076-CB3B-448F-A602-0212DC8246E8434.4mg108.6mg/m2/day4137143ChemotherapydoxorubicineADJUVANTIVNO1912012NOTCGA-D8-A1JJ-D65328FC68628D-E031-42D2-9D8F-4D34ACDEEC56137143ChemotherapycyclophosphamideNO2292014,TCGA-D8-A1JJ-R20753765626E2-B396-481B-8720-E2A148CA748A189207EXTERNAL BEAM6500cGy25+1 boost 1500cGyRegional siteADJUVANTNO1912012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1288.0,WHITE,TCGA-A2-A0CY,A2,A0CY,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,22.0,allred score 0 + 0 = 0,H-Score 190,Left Lower Outer Quadrant,0.89,Sentinel lymph node biopsy plus axillary dissection,Pateys surgery,Simple Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Surgical resection,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,1+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,1.0,Allred Score,Strong,10-19%,Hercep Test  TM Dako,DAKOHercepTest TM,45.5947265625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4.43,"LungOther, specifyleft adrenal gland",90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.5,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",10,9,2010,TCGA-A2-A0CY-F13731AE7B55F3-F2F1-4FA6-9921-07C9E99F7EEBScheduled Follow-up SubmissionNOYESAlive1673TUMOR FREENO962011,4TCGA-A2-A0CY-D203718ee660a-937e-4b2e-8965-26eac0c8eeca8640mg4320mg2133147ChemotherapyGemzarADJUVANTIVNO13920109TCGA-A2-A0CY-D2042f939ece6-83f5-47de-903f-49a909ca253c2.5mg1261Hormone TherapyLetrozoleADJUVANTPOYES13920102TCGA-A2-A0CY-D20359b6cfae2-3c2c-4c37-9713-fe0ab090e6065216mg1300-1308mg477119ChemotherapyCytoxanADJUVANTIVNO13920103TCGA-A2-A0CY-D2036f14a412b-1425-4f47-ae9a-36a4915d9a261121mg216-378mg4133177ChemotherapyTaxolADJUVANTIVNO13920108TCGA-A2-A0CY-D2041d5d250f1-15c3-4766-94ed-40ac4f8f7cc025mg10711162Hormone TherapyExemestaneADJUVANTPONO13920105TCGA-A2-A0CY-D20383dd69ff8-546a-4ac3-bc5b-256b74c682b920mg/day197357Hormone TherapyTamoxifenADJUVANTPONO13920106TCGA-A2-A0CY-D2039447a07c8-be8d-45d3-8404-b6d76b16b0bc1mg455507Hormone TherapyAnastrozoleADJUVANTPONO13920101TCGA-A2-A0CY-D2034bb794a4d-53f8-4917-bb80-d7fc4646766c520mg130mg477119ChemotherapyAdriamycinADJUVANTIVNO14920107TCGA-A2-A0CY-D2040bad877aa-b726-4dc3-ab46-c4c508f5b58c1mg634665Hormone TherapyAnastrozoleADJUVANTPONO1492010,TCGA-A8-A09V-R3819319729E19-9B06-4822-85A2-5D7A869767643192ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,344.0,WHITE,TCGA-A2-A0T6,A2,A0T6,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,3.0,No value Given,H-Score 15,Left,1.633749999999994,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Re-Excision of Superior Margin,Other,Wide Local Excision,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,Allred score 8,Allred Score,10-19%,ACIS,Hercep Test  TM Dako,73.7802734375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,4,"Other, specifySkin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.3,3 Point Scale,3+,Stage IIBT3N0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,17,11,2010,TCGA-A2-A0T6-F139502B2337EC-2A4F-453E-8EE6-AA03BC570460Scheduled Follow-up SubmissionYESYESAlive575TUMOR FREENO1272011,4TCGA-A2-A0T6-D39979a7b6e0f-5e16-4bcf-a58f-a0ee35e617afmg20mg/day232Hormone TherapyTamoxifenADJUVANTPOYES171120102TCGA-A2-A0T6-D399523fa8497-3a06-42ab-900c-69deab1936ed540mg90mg695204ChemotherapyAdriamycinADJUVANTIVNO171120101TCGA-A2-A0T6-D39943ea8097f-3255-4d00-85b9-5d1f6e426c5f810mg135mg695204ChemotherapyTaxotereADJUVANTIVNO171120103TCGA-A2-A0T6-D3996bd93c307-9d87-4a15-bb03-b8d02cc44b575400mg900mg695204ChemotherapyCytoxanADJUVANTIVNO17112010,TCGA-A2-A0T6-R3993d4bf30e0-a82d-445a-b39e-effcb98e7e05231279EXTERNAL BEAM5940cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,155.0,WHITE,TCGA-D8-A1XD,D8,A1XD,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,18.0,% IHC,%IHC,Left Upper Outer Quadrant,2.7321972656249867,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Mastectomy NOS,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.109375,6.0,>75%,>75%,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,72.744140625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.6,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.85,3 Point Scale,2+,7thStage IIIAT1cN2aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,5,2011,TCGA-D8-A1XD-F29440CA295FC1-24C4-40F5-AF2F-AF0B56CE9B37Scheduled Follow-up SubmissionYESNOAlive522TUMOR FREENO1932012,NOTCGA-A8-A08I-D378299BEA877F-F02D-449C-96A0-557D8562442531153Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08I-D37830F5F19298-9376-430D-9F41-C332F2ABAB4F31153ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08I-D37831C33E9B1F-F94C-41BC-B949-028D039B668A31153ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08I-D378328817E13F-ED74-42EB-9E2A-B873D79488B6212Hormone TherapyLetrozolen/aYES6122012,TCGA-D8-A1XD-R29441EFC43768-3277-4FD5-8328-112033D69DF4109138EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A046,AN,A046,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,19.0,IHC,dextran coated charcoal,Right Lower Inner Quadrant,2.3912988281249845,No axillary staging,axillary ultrasound,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,108,205,30-39%,0,dextran coated charcoal,61.3984375,HER2 amplification - negative,>= 2.0 Positive,NO,YES,78,Lung,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,816,3 Point Scale,1+,Stage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,12,2010,TCGA-AN-A046-F68972F3D0B69A-E347-4523-9C79-5A50FAE60BB6NONONOTUMOR FREEAlive1024122014,NOTCGA-OL-A66O-D64491B0AF5BB3-D16F-4702-A5DA-AAA9B59EDEDE129192ChemotherapyCytoxanNOComplete Response2492014NOTCGA-OL-A66O-D65244A6C0E34D-00F1-42B6-883B-AE2C88CD9296129192ChemotherapyTaxotereNOComplete Response2492014,TCGA-A2-A0T6-R3993d4bf30e0-a82d-445a-b39e-effcb98e7e05231279EXTERNAL BEAM5940cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,42.0,WHITE,TCGA-E2-A15H,E2,A15H,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.0,dextran coated charcoal,image cytometry,Right Upper Outer Quadrant,1.2424121093749916,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Mastectomy NOS,segmental mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Positive,Positive,Equivocal,1.1044921875,1.0,Allred score = 8,Allred Score = 7,10-19%,Dako,Venten,80.013671875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.13,LungBone,<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,79,3 Point Scale,2+,6thStage IIAT1cN1miM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",13,4,2011,TCGA-E2-A15H-F189164D718A1D-4604-4750-AC77-52E35846B82EScheduled Follow-up SubmissionNOYESAlive393NO14112011,1TCGA-E2-A15H-D18923A307776F-37AE-46FE-A3D1-D0E79E1D73A883ChemotherapyHerceptinADJUVANTNO14112011,TCGA-D8-A1XD-R29441EFC43768-3277-4FD5-8328-112033D69DF4109138EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,365.0,WHITE,TCGA-A8-A08I,A8,A08I,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.638671875,Allred score 5+3=8,Allred (Biocare),Right Upper Inner Quadrant,2.0393847656249857,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.6640625,0.0,Allred Score,allred score = 8,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,114.4794921875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.13,LungBone,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,3.8,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A08I-F4084598D30323-480E-40B0-825C-3EA0C137401CNOYESYESTUMOR FREEAlive365NO232013,NOTCGA-A8-A08I-D378299BEA877F-F02D-449C-96A0-557D8562442531153Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08I-D37830F5F19298-9376-430D-9F41-C332F2ABAB4F31153ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08I-D37831C33E9B1F-F94C-41BC-B949-028D039B668A31153ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08I-D378328817E13F-ED74-42EB-9E2A-B873D79488B6212Hormone TherapyLetrozolen/aYES6122012,TCGA-A8-A08I-R381730322ED7F-C303-4755-B8C3-4FED19B89D49184212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,150.0,WHITE,TCGA-D8-A1XU,D8,A1XU,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,% IHC,%IHC,Left Upper Outer Quadrant,2.938095703125,Sentinel node biopsy alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Mastectomy NOS,Surgical resection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0,0.0,10-75%,>75%,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,79.7314453125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.38,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,185,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,5,2011,TCGA-D8-A1XU-F294566F200E00-AAAB-4ED7-A6A8-C21C9B30CF9EScheduled Follow-up SubmissionNONOAlive395TUMOR FREENO2632012,NOTCGA-A8-A08I-D378299BEA877F-F02D-449C-96A0-557D8562442531153Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08I-D37830F5F19298-9376-430D-9F41-C332F2ABAB4F31153ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08I-D37831C33E9B1F-F94C-41BC-B949-028D039B668A31153ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08I-D378328817E13F-ED74-42EB-9E2A-B873D79488B6212Hormone TherapyLetrozolen/aYES6122012,TCGA-A2-A0T6-R3993d4bf30e0-a82d-445a-b39e-effcb98e7e05231279EXTERNAL BEAM5940cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Dead,3669.0,940.1416015625,WHITE,TCGA-BH-A1FB,BH,A1FB,No,YES,C50.9,8500/3,C50.9,2000.0,WITH TUMOR,YES,15.0,allred score 0 + 0 = 0,allred score 5 + 3 = 8,Right,2.038447265625011,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,segmental mastectomy with sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.5048828125,0.0,MODERATE,Allred Score 6,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,74.2958984375,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,4.43,"LungBoneLiverOther, specifyskin",80-89%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,5,3 Point Scale,2+,5thStage IIBT2N1bM0,NO,YES,PositivePositiveNegativeNegative,7,9,2011,TCGA-E9-A1RC-F30605997C07ED-D89A-4AE4-B2F7-D1BD05D15E4EScheduled Follow-up SubmissionNOYESAlive1224TUMOR FREENO1342012TCGA-E9-A1RC-F487010590580D-9303-4488-AA52-6C6FA55009EFYES1992013,NOTCGA-OL-A66O-D64491B0AF5BB3-D16F-4702-A5DA-AAA9B59EDEDE129192ChemotherapyCytoxanNOComplete Response2492014NOTCGA-OL-A66O-D65244A6C0E34D-00F1-42B6-883B-AE2C88CD9296129192ChemotherapyTaxotereNOComplete Response2492014,TCGA-D8-A1XD-R29441EFC43768-3277-4FD5-8328-112033D69DF4109138EXTERNAL BEAM4500cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1623.0,BLACK OR AFRICAN AMERICAN,TCGA-GM-A2DO,GM,A2DO,No,YES,C50.9,8520/3,C50.9,2006.0,TUMOR FREE,YES,3.0,allred score 5+3=8,IHC,Right Upper Outer Quadrant,1.2944824218749993,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Lobular Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,60,Moderate,<10%,0,Dako Hecept Test,94.3212890625,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,160,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,105,3 Point Scale,2+,6thStage IT1cN0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",30,9,2011,TCGA-GM-A2DO-F471515EAB98B3-F7DE-4F1B-89A0-346CBBA6049ENOYESYESTUMOR FREEAlive2596NO2282013,NOTCGA-GM-A2DO-D47154C19E8E9F-4856-4D78-8214-60750D868B762192051Hormone TherapyTamoxifenNOComplete Response2282013,TCGA-GM-A2DO-R47153F35B749C-7FAE-4842-BE1A-15F2C44A28D1176218ExternalPrimary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,550.0,WHITE,TCGA-A2-A0EX,A2,A0EX,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,1.0,H-SCORE 255,Allred score 7 per outside facility report,Left Upper Outer Quadrant,1.22,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Mastectomy NOS,Excision,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,1.0,0.0,Allred Score 5,Allred Score 5,10-19%,ACIS,Hercep Test  TM Dako,75.6953125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,50,"LungOther, specifyleft adrenal gland",60-69%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.85,3 Point Scale,2+,6thStage IIBT3N0 (i+)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",13,8,2010,TCGA-A2-A0EX-F2323C5A96D70-A9CE-4CDB-AAA2-5894EEA7A773550AliveTUMOR FREENONONONO14102010TCGA-A2-A0EX-F13742622294E1-0361-4A19-8410-DE5E8A4CB231Scheduled Follow-up SubmissionNOYESAlive752TUMOR FREENO1062011,2TCGA-A2-A0EX-D2011a18f54ee-33e5-4dc3-a61a-ba662d4e192d11.25mg3.75mg3172222Hormone TherapyLupronADJUVANTIMNO13820101TCGA-A2-A0EX-D2010e8a75fe6-b841-46ea-9bd8-51b5fe21c01e10 mgmg165Hormone TherapyTamoxifenADJUVANTPOYES13820103TCGA-A2-A0EX-D20122a817b25-0580-4742-b337-8cd0a8bfb1433.6 mg monthlymg273Hormone TherapyZoladexADJUVANTSCYES1382010,TCGA-A8-A08I-R381730322ED7F-C303-4755-B8C3-4FED19B89D49184212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,912.0,WHITE,TCGA-A8-A09K,A8,A09K,Yes,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,7.6865234375,CAP SCORING GUIDELINE 2010,Allred score 2+3 = 5,Left Lower Outer Quadrant,1.6235253906249898,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Re-Excision of Superior Margin,Other,Surgical resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,0,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.216796875,1.8798828125,Allred score 8,Allred score = 7,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,113.5009765625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2.13,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.8,3 Point Scale,3+,6thStage IIAT1cN1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A09K-F40332094D8DCB-8317-4A5C-8A40-A134ADD8DBDENONONOTUMOR FREEAlive912NO1722013,NOTCGA-OL-A66O-D64491B0AF5BB3-D16F-4702-A5DA-AAA9B59EDEDE129192ChemotherapyCytoxanNOComplete Response2492014NOTCGA-OL-A66O-D65244A6C0E34D-00F1-42B6-883B-AE2C88CD9296129192ChemotherapyTaxotereNOComplete Response2492014,TCGA-A2-A0T6-R3993d4bf30e0-a82d-445a-b39e-effcb98e7e05231279EXTERNAL BEAM5940cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,220.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A66O,OL,A66O,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,17.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,Right Upper Outer Quadrant,1.2,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,breast conserving therapy,Infiltrating Ductal Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,0.6494140625,3.0,8,205,30-39%,CISH,Hercep Test  TM Dako,116.388671875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,3.0,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.9,3 Point Scale,3+,7thStage IIBT2N1aMX,YES,YES,NO,11,6,2013,TCGA-OL-A66O-F58497F6A56281-31A1-4289-A7C1-D2F3125484E4NOYESYESTUMOR FREEAlive528NO1142014,NOTCGA-OL-A66O-D64491B0AF5BB3-D16F-4702-A5DA-AAA9B59EDEDE129192ChemotherapyCytoxanNOComplete Response2492014NOTCGA-OL-A66O-D65244A6C0E34D-00F1-42B6-883B-AE2C88CD9296129192ChemotherapyTaxotereNOComplete Response2492014,TCGA-OL-A66O-R644922489265C-022C-47F6-BFDF-9A678B41BC7977121External6040cGyPrimary Tumor FieldNOComplete Response1292014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,551.0,WHITE,TCGA-A7-A13H,A7,A13H,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,12.0,H-SCORE 300,CAP SCORING GUIDELINE 2010,Right,2.2,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Re-Excision of Superior Margin,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Lobular Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,2.0,2.0,Allred Score 6,Allred Score 5,10-19%,CISH,Dako Hercept test,371.0,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,2.7,"LungBoneLiverOther, specifyskin",80-89%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,3.2,3 Point Scale,3+,7thStage IIBT2N1aMX,YES,YES,NO,22,6,2012,"TCGA-A7-A13H-F361437C078E97-824D-4A33-90D1-8E5589C7AFA3NONOYESTUMOR FREEAlive740NO19102012TCGA-A7-A13H-F41651C8F6BA58-704D-4F09-8511-4EA0A2C9B96ANONONOTUMOR FREEAlive899YES795New Primary TumorOther, specifySkin lesion-Basal Cell Left Lower Lateral BackYES840NONO2532013",NOTCGA-A7-A13H-D361445204919F-EBC8-4F13-A5D7-E1135D39773278Hormone TherapyAnastrozoleYES19102012,TCGA-GM-A2DO-R47153F35B749C-7FAE-4842-BE1A-15F2C44A28D1176218ExternalPrimary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,78.0,BLACK OR AFRICAN AMERICAN,TCGA-AQ-A54N,AQ,A54N,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,1.0,Allred 0 = 0+0,H-SCORE 280,Left Lower Inner Quadrant,1.1,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Other,surgical resection,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Negative,Equivocal,0.0,0.0,moderately to strongly,H score,90-99%,ACIS,Venten,90.0322265625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,40,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,2.5,3 Point Scale,2+,7thStage IIAT2N0M0,NO,NO,NO,26,2,2013,TCGA-AQ-A54N-F5573680219E7C-2608-4B42-B6EC-E9DA0D3B6EB5YESNONOTUMOR FREEAlive781412014,NOTCGA-A8-A08I-D378299BEA877F-F02D-449C-96A0-557D8562442531153Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08I-D37830F5F19298-9376-430D-9F41-C332F2ABAB4F31153ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08I-D37831C33E9B1F-F94C-41BC-B949-028D039B668A31153ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08I-D378328817E13F-ED74-42EB-9E2A-B873D79488B6212Hormone TherapyLetrozolen/aYES6122012,TCGA-A8-A08I-R381730322ED7F-C303-4755-B8C3-4FED19B89D49184212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A22A,E9,A22A,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,2.0,H-SCORE 190,H-Score 0,Right Lower Outer Quadrant,1.2295703125000002,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Other,Re-Excision of Superior Margin,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.0,0.0,H score,moderate,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,66.4541015625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,69,"LungBoneLiverOther, specifyskin",10-19%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,5,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,2,8,2011,TCGA-E9-A22A-F298376E69F7F7-D400-40B0-8969-107D3F5EC94CScheduled Follow-up SubmissionNOYESAlive713TUMOR FREENO2752014TCGA-E9-A22A-F397850A926351-9B94-4D55-9D38-4EB8CBCBB2D3NONOYESTUMOR FREEAlive1189NO122013,TCGA-E9-A22A-D298385D55C0D5-040F-4184-A845-1D4A4FEB2ADC7240mg20mg/day111Hormone TherapyTamoxifenADJUVANTPOYES2932012,TCGA-A2-A0YL-R581345b399c8-8af8-4a9a-9507-682af704063e177224EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO128122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,702.0,WHITE,TCGA-BH-A0H7,BH,A0H7,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,16.0,H-SCORE 255,H-SCORE 150,Right Upper Inner QuadrantRight Upper Outer QuadrantRight Lower Inner QuadrantRight Lower Outer QuadrantRight,1.2464355468749977,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Wide local excision,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.404296875,6.0,H-SCORE,H-SCORE,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,44.0732421875,Vysis AutoVysion System,PathVysion,NO,YES,2.38,LungBone,70-79%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,60,3 Point Scale,2+,Stage IIIAT1cN2aM0,NO,YES,YES994Distant MetastasisBoneNOYESYES,10,11,2010,TCGA-BH-A0H7-F4737A652B449-0747-4A34-B758-A6E67A1000F6702AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0H7-D47153A96F8DB-2BB6-4F01-A332-0CC10127499B1mg/day298Hormone TherapyARIMIDEXADJUVANTPOYES171120101TCGA-BH-A0H7-D47170D085B7B-5316-41F0-9FF4-0EF4C547C459344mg86mg485148ChemotherapyDOXORUBICINADJUVANTIVNO181120101TCGA-BH-A0H7-D47288C760D86-7F32-4842-8DB0-ADAFD53EA4146120mg765mg885232ChemotherapyBEVACIZUMAB (AVASTIN)/PLACEBO PROVIDED BY STUDYADJUVANTIVNO181120101TCGA-BH-A0H7-D4726C42E6C62-C1C9-46D9-B3BB-217B83E7D2ED1380mg115mg12169246ChemotherapyPACLITAXELADJUVANTIVNO181120101TCGA-BH-A0H7-D4719F4A15B10-F974-4196-AC98-13A14F2D66213440mg860mg485148ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO18112010,TCGA-BH-A0H7-R47368B3F8793-8DF3-477C-BFB8-CA5F68C9C608274314EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1212.0,WHITE,TCGA-AR-A254,AR,A254,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,30.0,Allred score 5+3 = 8,Image Analysis,Left Upper Inner QuadrantLeft Lower Inner Quadrant,3.0018847656249767,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Reexcision of segmental mastectomy,Mastectomy NOS,Wide local excision,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,4+,3+,Negative,Negative,"Other method, specify:",Wide local incision,Positive,Positive,Positive,0.548828125,9.0,10-75%,H-Score,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,85.4052734375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,4.43,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.5,3 Point Scale,2+,6thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,31,8,2011,TCGA-AR-A254-F3188928E4B542-285D-4875-AB72-9BBA6EB599D1Scheduled Follow-up SubmissionYESYESAlive1212NO1052012TCGA-AR-A254-F49511D6FF63CD-5109-4256-84D7-02F8243C8553YESYESTUMOR FREEAlive2213NO2102013TCGA-AR-A254-F717265CAA4B0A-9F82-4A99-AD51-4DF0011ECD25NOYESYESTUMOR FREEAlive2605NO3032015,NOTCGA-AR-A254-D31890276D5F77-4A5C-4323-9158-72968222455E2243ChemotherapyPaclitaxelNO2352012NOTCGA-AR-A254-D318913895A0CD-D7A0-4299-AA1D-0CDB266065425099ChemotherapyAbraxaneNO2352012NOTCGA-AR-A254-D3189233D981C7-C2D3-4B84-B64B-267D0B560FC1106173ChemotherapyFluorouracilNO2352012NOTCGA-AR-A254-D318938811257C-6F1A-45B1-93CF-66DB671186E7106170ChemotherapyEpirubicinNO2352012NOTCGA-AR-A254-D31895A0A91D98-9C6D-4F84-8E0F-B7124F907FAB106170ChemotherapyCytoxanNO2352012NOTCGA-AR-A254-D31896ADB0D2AC-132B-4083-91AF-52B43CA173F32222ImmunotherapyTrastuzumabNO2352012NOTCGA-AR-A254-D318970197F934-6D0A-489C-BB0C-B8BB754191DE29184ImmunotherapyTrastuzumabNO2352012NOTCGA-AR-A254-D318987B1B7CB1-6836-4211-916E-AFF61B5EC621232344ImmunotherapyTrastuzumabNO2352012NOTCGA-AR-A254-D3189982C6D00C-ABFC-4885-88F3-5A4E67579462262Hormone TherapyTamoxifenYES2352012,TCGA-AR-A254-R31900967465A7-0A86-4FBD-A554-CA1E36E827D2252291EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO11052012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1224.0,WHITE,TCGA-E9-A1RC,E9,A1RC,No,YES,C50.9,8522/3,C50.9,2007.0,TUMOR FREE,YES,10.0,% IHC,Allred score 0+0 = 0,Right Upper Outer Quadrant,1.3357128906249982,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Left segmental mastectomy with axillary lymph node dissection,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Lumpectomy,Negative,Positive,Negative,0.0,10.0,60,Allred Score 6,10-19%,Hercep Test  TM Dako,Venten,111.228515625,HER2 amplification - negative,Positive >2.2,YES,NO,54,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,61,4 Point Scale,2+,7thStage IIICT4bN3M0,YES,YES,PositivePositiveNegativeNegative1.09,28,7,2011,TCGA-E9-A1RC-F30605997C07ED-D89A-4AE4-B2F7-D1BD05D15E4EScheduled Follow-up SubmissionNOYESAlive1224TUMOR FREENO1342012TCGA-E9-A1RC-F487010590580D-9303-4488-AA52-6C6FA55009EFYES1992013,TCGA-E9-A1RC-D30607E58C5E86-0316-4F5B-99B0-A13F95BE2CA520mg20mg112221222ChemotherapyMitoxantronePALLIATIVEIVNO1342012TCGA-E9-A1RC-D3060962673F57-7FC4-4ED0-9E85-73C713C381A270mg70mg112221222ChemotherapyMethotrexatePALLIATIVEIVNO1342012TCGA-E9-A1RC-D306108DEF7FCD-2D76-448A-B718-638B681918AD20mg/day1220Hormone TherapyTamoxifenPALLIATIVEPOYES1342012TCGA-E9-A1RC-D306063D595692-CF03-4987-8958-AC8D85D1C26F20mg20mg112221222ChemotherapyMitomycinPALLIATIVEIVNO1342012,TCGA-E2-A15R-R19175DD5ECAD9-B60E-43D2-A390-69CCC0C71FD3218267EXTERNAL BEAM5900cGy33Regional siteADJUVANTNO0116112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1708.0,WHITE,TCGA-AR-A250,AR,A250,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,4.0,H-SCORE 190,Allred score 0+0 = 0,Left Upper Outer Quadrant,4.622519531249975,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Re-Excision of Superior Margin,Mastectomy NOS,Wide local excision and simple mastectomy,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,2+,Negative,Positive,Core needle biopsy,intraoperative examination,Positive,Positive,Equivocal,0.0400390625,0.0,10-75%,Allred Score 7,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,123.2099609375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,33,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.3,4 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,30,8,2011,TCGA-AR-A250-F31671E37895EF-CEFD-4679-99E6-58D11D96C6C9NOYESAlive1708NO852012TCGA-AR-A250-F495086501DF95-37C6-4C3A-952A-F585726826C1NOYESTUMOR FREEAlive2274NO2102013TCGA-AR-A250-F6579434C8A220-2C5D-4707-85EF-7585564FB291NONOYESTUMOR FREEAlive2707NO3092014,NOTCGA-AR-A250-D316732BB4B137-AA4E-42D6-876B-C9DE7B9103724588ChemotherapyDoxorubicinNO2152012NOTCGA-AR-A250-D3167528A6AC67-90F8-4C77-8281-C9887C7E6E724588ChemotherapyCytoxanNO2152012NOTCGA-AR-A250-D31676677A72C5-4625-4239-A896-2AB4FCD7EB83102179ChemotherapyPaclitaxelNO2152012NOTCGA-AR-A250-D316776C28195A-B380-475E-A6D9-97FBEAA7FE7F102102ImmunotherapyTrastuzumabNO2152012NOTCGA-AR-A250-D31678DBBFBEC9-088D-4F94-9353-A06600586DF8109179ImmunotherapyTrustuzumabNO2152012NOTCGA-AR-A250-D316817E468399-B2D5-45FC-A528-0CC24445CD24193466ImmunotherapyTrastuzumabNO2152012NOTCGA-AR-A250-D3168290EABCF1-AA20-4EB3-B2A9-B65F7B1C21F3194Hormone TherapyAnastrozoleYES2152012,TCGA-AR-A1AX-R22141FD178C27-E6A3-460C-95B5-BB1D1CC94E82194242EXTERNAL BEAM6060cGy33Primary Tumor FieldADJUVANTNO1132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,51.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A6NO,AC,A6NO,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,16.0,Allred score 7 (outside facility),CAP SCORING GUIDELINE 2010,Right,1.281875,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,biopsy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Fine needle aspiration biopsy,stereotactic biopsy,Negative,Positive,Negative,0.587890625,2.0,Intensity=Strong,8,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,89.3486328125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.8,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.8,3 Point Scale,2+,7thStage IIBT2N1aMX,YES,YES,NO,10,4,2014,TCGA-A8-A07O-F40831A8FC8B58-BD10-40C0-BEE5-E0DA7F4431C4NOYESYESTUMOR FREEAlive304NO232013,1TCGA-EW-A1P6-D30269D3941135-B841-428D-B697-006C00F9A2332590mg870mg3162205ChemotherapyCyclophosphamideADJUVANTIVNO7320123TCGA-EW-A1P6-D302710F16DDBE-E7EC-4A73-AD9D-C03723C57A191080mg131mg8254303ChemotherapyPaclitaxelADJUVANTIVNO7320122TCGA-EW-A1P6-D30270AFDF574F-0437-489B-AD18-43196C2A548A164mg164mg1233233ChemotherapyDocetaxelADJUVANTIVNO7320121TCGA-EW-A1P6-D302683A0A588D-DF4B-450F-A1BD-06F255D551B72590mg870mg3162205ChemotherapyFluorouracilADJUVANTIVNO7320121TCGA-EW-A1P6-D30267635E9C0E-99F9-4277-A604-E090DC019E30518mg172mg3162205ChemotherapyEpirubicinADJUVANTIVNO7320124TCGA-EW-A1P6-D30273B13DE4DD-820A-49D2-AD88-0F26B649546B1mg/day444Hormone TherapyArimidexADJUVANTPOYES732012,TCGA-EW-A6SD-R71031DD24B5DA-6930-49C2-80AD-BC5FF24B767B239288External4623Primary Tumor FieldNO1432015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1330.0,WHITE,TCGA-AR-A1AN,AR,A1AN,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,5.0,H-SCORE 190,Allred score 5+3 = 8,Right Upper Outer Quadrant,1.375136718749998,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Right Breast Reexcision,Other,Wide Local Excision,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0087890625,0.0,H-SCORE,Allred Score 8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,99.580078125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,1.78,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.9,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,14,6,2011,TCGA-AR-A1AN-F21986875F7CBA-C219-4206-A60C-ACFF4FC1F8C9Scheduled Follow-up SubmissionYESYESAlive1330TUMOR FREENO2822012TCGA-AR-A1AN-F69273D4512F43-4A80-4EAD-93CF-973446AA72BANOYESYESTUMOR FREEAlive2920NO31122014,4TCGA-AR-A1AN-D21999C9B603C0-0213-4B45-8199-72032C517BEA1mg/day442Hormone TherapyAnastrozoleADJUVANTPOYES28220122TCGA-AR-A1AN-D21996B97F58C1-DC5F-486E-BBF6-7A8E364CB1A51mg/day162300Hormone TherapyAnastrozoleADJUVANTPONO28220123TCGA-AR-A1AN-D2199899CC0213-C42E-4C37-B846-D21F96608C6020mg/day301441Hormone TherapyTamoxifenADJUVANTPONO28220121TCGA-AR-A1AN-D2199441723CA9-81FB-486E-8E7E-5ECB2997418E4310mg600mg/m244791ChemotherapyCytoxanADJUVANTIVNO28220121TCGA-AR-A1AN-D219910B897029-9392-428C-B8B8-6DA05D449134435mg60mg/m244791ChemotherapyDoxorubicinADJUVANTIVNO28220121TCGA-AR-A1AN-D219957FCC74A9-CFDF-4804-877F-E82ED18041AB1250mg175mg/m24105154ChemotherapyPaclitaxelADJUVANTIVNO2822012,TCGA-AR-A1AN-R21989467D9E15-348F-40CC-9E9C-FE3500CBD635169211EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12822012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,692.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A14X,E2,A14X,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,21.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Right Upper Outer Quadrant,1.205166015624997,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Negative,0.6396484375,5.0,Allred score = 0,Allred score = 0,<10%,Dako,Venten,104.2568359375,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.8,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.1,3 Point Scale,2+,6thStage IIIAT2N2M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",6,4,2011,TCGA-E2-A14X-F1885702DF16E7-CE1F-4746-952C-B32F958EF48BScheduled Follow-up SubmissionYESYESAlive972TUMOR FREENO4112011,"1TCGA-E2-A14X-D18865FE204945-F99F-464A-9E6F-D168A421C139512mg128mg25597ChemotherapydoxorubicinADJUVANTIVNO41120111TCGA-E2-A14X-D18863FCF5541F-112D-4384-BD87-6B4BCBAD598D9310mg1470mg755188ChemotherapyavastinADJUVANTIVNO41120111TCGA-E2-A14X-D18864A9E35661-F258-4F47-B234-1EEDC19E838C1642mg171mg5111199ChemotherapypaclitaxelADJUVANTIVNO41120112TCGA-E2-A14X-D18861A713574D-B6F2-4C3E-A90D-81F33EAB041C75200mg75200mg/day182280Other, specify in notesclinical trial - bisphosphonates as adjuvant therapyclodronic acidADJUVANTPONO41120111TCGA-E2-A14X-D18866DB24F34E-51A3-4AF7-A17C-27D81176D60D5136mg1284mg25597ChemotherapycyclophosphamideADJUVANTIVNO4112011",TCGA-E2-A14X-R18859F63A992C-A3FF-4949-86BE-6556F627B1A3218271EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO14112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,9.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A5XU,AC,A5XU,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,2.0,H-Score 300,CAP SCORING GUIDELINE 2010,Left Upper Outer Quadrant,2.667958984374993,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,1.0009765625,0.0,Intensity=Strong,Moderate,10-19%,ACIS,Hercep Test  TM Dako,81.466796875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,1.9,"Other, specifyskin",90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.73,3 Point Scale,2+,7thStage IIBT3N0 (i-)MX,YES,YES,NO,15,7,2013,TCGA-AC-A5XU-F601818F4EF134-A173-4B96-BCBC-EE7249039A4ENOYESYESTUMOR FREEAlive455NO3152014,NOTCGA-AC-A5XU-D60183C044891E-2E52-4DC9-BA16-4CA6D345F0D6235Hormone TherapyLetrozoleYES3152014,TCGA-AC-A5XU-R601821C1F9080-ED1B-4E9E-8B1F-3B8BA8E5F3FC156199External6000cGy30Primary Tumor FieldNOComplete Response3152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1N3,E9,A1N3,No,YES,C50.9,8522/3,C50.9,2010.0,TUMOR FREE,YES,7.0,% IHC,Allred score 0+0 = 0,Right Upper Inner Quadrant,1.823212890624994,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Total Mastectomy,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.5986328125,7.0,240 H,Two-tier,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,111.4765625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,66,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.8,3 Point Scale,3+,7thStage IIIAT1cN2M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",26,5,2011,TCGA-E9-A1N3-F29141E73FFC2F-744D-472F-8A61-29D66DA1494CScheduled Follow-up SubmissionNOYESAlive541TUMOR FREENO27112013TCGA-E9-A1N3-F6262751209566-A8D1-4EC8-8974-323532A10AABNONOYESTUMOR FREEAlive1059NO2272014,NOTCGA-E9-A1N3-D3976221C8B531-6DB2-4EDA-91D6-9A71B698CFFA1568Chemotherapy5-FluorouracilNOComplete Response122013NOTCGA-E9-A1N3-D39763896CF3A1-1C37-4ECE-8AAD-2408414FF8D71568ChemotherapyDoxorubicinNOComplete Response122013NOTCGA-E9-A1N3-D39764B6DFF894-6069-4D41-8556-D15BC03DD3BF1568ChemotherapyCyclophosphamideNOComplete Response1220132TCGA-E9-A1N3-D291423B2AB151-9032-4CCD-9351-CD95CFE9FBFDmg20mg/day130Hormone TherapyTamoxifenADJUVANTPOYES27112013,TCGA-GM-A2DO-R47153F35B749C-7FAE-4842-BE1A-15F2C44A28D1176218ExternalPrimary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,543.0,WHITE,TCGA-BH-A0W5,BH,A0W5,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,11.0,Allread score 5+3 = 8,H-SCORE 150,Left,1.7142480468749943,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,segmental mastectomy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Equivocal,Positive,Equivocal,1.0,1.0,Allred score 7 per outside facility report,Allred Score 5,90-99%,Dako,CAP scoring guideline 2010,234.341796875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.45,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,816,3 Point Scale,2+,6thStage IIAT1cN1aM0,NO,YES,YES994Distant MetastasisBoneNOYESYES,15,2,2011,TCGA-BH-A0W5-F3407082D27FD8-ED77-4388-9C3F-711EDCEF3A4DScheduled Follow-up SubmissionYESYESAlive1288TUMOR FREENO2972012,NOTCGA-BH-A0W5-D34071985E78AA-4536-424D-A1B5-8510D98A84D522144Hormone TherapyArimidexNOComplete Response2972012,TCGA-BH-A0W5-R3407238458462-2593-488B-927B-D274D9182D8F113144ExternalPrimary Tumor FieldNOComplete Response2972012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1132.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A3ZX,B6,A3ZX,No,YES,C50.9,8522/3,C50.9,2007.0,WITH TUMOR,YES,7.0,dextran coated charcoal,Allred score 5+3 = 8,Left Upper Inner Quadrant,1.2316503906250014,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Right Breast Reexcision,Lumpectomy,L Total Mastectomy,Mixed Histology (please specify),ductal and lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,4 Point Scale,1+,1+,Negative,Close,Core needle biopsy,Lumpectomy,Negative,Negative,Negative,0.666015625,1.0,H score,250,<10%,Hercep Test  TM Dako,Hercep Test  TM Dako,61.34375,HER2 amplification - negative,PathVysion,NO,YES,1.67,Bone,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,52,4 Point Scale,1+,6thStage IVT3N1M1,YES,YES,YES994Distant MetastasisBoneNOYESYES,20,9,2012,TCGA-B6-A3ZX-F595732242BB2F-C23E-4005-94CA-3E9F32043C1CNOYESYESWITH TUMORDead1152YES994Distant MetastasisBoneYES1096YESYES362014,NOTCGA-B6-A3ZX-D409511F002506-250B-498B-99E6-54FF46B5FB2391147ChemotherapyCyclophosphamideNO732013NOTCGA-B6-A3ZX-D40952BB2609B3-27AB-446D-85F7-5351CD9EC3A291147ChemotherapyDoxorubicinNO732013NOTCGA-B6-A3ZX-D40954F6C3B0B8-B9E0-4962-BCCD-705214844D6F148225ChemotherapyPaclitaxelNO732013,TCGA-B6-A3ZX-R409555B8D0E18-6490-40BE-80EC-6AD12BC416FA354386External200cGy25Primary Tumor FieldNO732013
TCGAFPPP,Breast,No,FEMALE,Dead,792.0,74.0869140625,WHITE,TCGA-AC-A2FM,AC,A2FM,No,YES,C50.9,8520/3,C50.9,2004.0,WITH TUMOR,YES,2.0,H-Score 150,CAP SCORING GUIDELINE 2010,Right Upper Inner Quadrant,1.6048632812499992,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast Reexcision,Other,Modified Radical Masectomy,Infiltrating Lobular Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,0.0,0.0,60,allred score = 0,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,136.5654296875,HER2 amplification - negative,Positive >2.2,NO,YES,33,"Other, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.1613867187500007,2.23,3 Point Scale,2+,6thStage IIBT2N1miM0,YES,YES,Negative<10%3 Point ScaleNegative<10%3 Point ScaleEquivocal<10%1+,22,2,2012,"TCGA-AC-A2FM-F43237B54C9682-B927-4790-A081-623844557F09NONONOWITH TUMORDead792YES780Distant MetastasisOther, specifyBone MarrowNONONO1552013",1TCGA-AO-A129-D59502c562434-088f-444b-82ca-9ad77b8fdaa2175mg/m2467162ChemotherapyPaclitaxelADJUVANTIVNO10120111TCGA-AO-A129-D5947592cacd9-a024-4b2d-a780-d45766869b1a600mg/m2467162ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A129-D59497a4726f6-1df6-4d6c-af20-b2116488289460mg/m2467162ChemotherapyDoxorubicinADJUVANTIVNO1012011,TCGA-AR-A254-R31900967465A7-0A86-4FBD-A554-CA1E36E827D2252291EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO11052012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,256.0,WHITE,TCGA-D8-A1J8,D8,A1J8,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,16.0,manual counting,manual counting,Right Upper Outer Quadrant,1.228515625,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast Reexcision,Other,Surgical resection,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Negative,0.0009765625,3.0,Allred score = 8,H-SCORE,90-99%,Dako,CAP scoring guideline 2010,186.9541015625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,1.78,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.23,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",23,3,2011,TCGA-D8-A1J8-F14040EE01E96E-58A8-4B56-AE04-E66483766188Scheduled Follow-up SubmissionNOYESAlive431TUMOR FREENO1872011,hormone therapyTCGA-D8-A1J8-D140413DDE2EBA-A85F-48E1-AAC2-D34371DCC95Dmg/day20mg/day32Hormone TherapynolvadexADJUVANTPOYES1872011,TCGA-BH-A0H7-R47368B3F8793-8DF3-477C-BFB8-CA5F68C9C608274314EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A54X,E9,A54X,No,YES,C50.9,8480/3,C50.9,2012.0,TUMOR FREE,YES,2.0,H-SCORE 0,Allred score 2+2 = 4,LeftLeft Upper Outer Quadrant,1.6289550781249975,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Lumpectomy,surgical resection,Other,Total mastectomy with sentinel lymoh node biopsy,Mucinous Carcinoma,invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.673828125,0.0,Two-tier,120,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,121.095703125,HER2 amplification - negative,Positive >2.2,YES,NO,3.2,BoneLiver,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,61,3 Point Scale,3+,7thStage IAT1bN0 (i-)M0,YES,YES,Positive90-99%,21,6,2013,TCGA-E9-A54X-F5139053D71BE3-FC14-4DA9-968B-918D9FC1117DNONONOTUMOR FREEAlive375NO18112013TCGA-E9-A54X-F66449AF2FFFFE-FAF6-48EC-893A-15C569E3387ANONONOTUMOR FREEAlive727NO15102014,NOTCGA-AC-A2FE-D37368B60BCD38-9FFA-43B5-B2C0-C855C05883BB67173ChemotherapyAdriamycinNOPartial Response3122012NOTCGA-AC-A2FE-D37369516F7FB6-37E9-4E44-AD00-37D688CD51FA67173ChemotherapyTaxolNOPartial Response3122012NOTCGA-AC-A2FE-D373704DF74C32-567B-4238-B008-44BA2231AC3A273Hormone TherapyArimidex3122012NOTCGA-AC-A2FE-D47779A99BF733-8B3D-4B21-921E-79FDE40A04AF67173ChemotherapyCytoxanNOComplete Response2882013NOTCGA-AC-A2FE-D477818AC64C61-1BA6-4891-B438-AFF91FC30F542516ChemotherapyXelodaNOClinical Progressive Disease2882013NOTCGA-AC-A2FE-D47782E2A083D8-3A0B-465B-9603-BE32342ACC482516ChemotherapyAbraxaneNOClinical Progressive Disease2882013,TCGA-E2-A14X-R18859F63A992C-A3FF-4949-86BE-6556F627B1A3218271EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO14112011
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,297.0,WHITE,TCGA-E2-A1BC,E2,A1BC,No,YES,C50.9,8524/3,C50.9,2010.0,TUMOR FREE,YES,4.0,Allred score 5+3=8,H-SCORE 0,Right,1.2229492187500028,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast Reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Positive,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.26171875,0.0,Allred Score,0,90-99%,Dako,Venten,146.796875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,33,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.1,3 Point Scale,3+,7thStage IAT1cN0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",25,4,2011,TCGA-E2-A1BC-F194273D5C68DA-26CB-4603-A39E-4BDB247D2704Scheduled Follow-up SubmissionNOYESAlive501TUMOR FREENO8122011,1TCGA-E2-A1BC-D1943713C0F950-43CA-42DC-8E5D-A36D4B38FED81mg/day1mg/day11Hormone TherapyArimidexADJUVANTPOYES9122011,TCGA-BH-A0H7-R47368B3F8793-8DF3-477C-BFB8-CA5F68C9C608274314EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,96.0,WHITE,TCGA-D8-A1JF,D8,A1JF,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,25.0,manual counting,manual counting,Left Upper Outer Quadrant,2.3799609374999946,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Right Breast Reexcision,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Negative,Negative,0.0849609375,8.0,Allred score = 8,H-SCORE,90-99%,Dako,DAKOHercepTest TM,255.6806640625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,4.43,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,59,3 Point Scale,2+,7thStage IIIAT1cN2aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,3,2011,TCGA-D8-A1JF-F14058B68084F0-7E58-4822-841C-EEF1C187A504Scheduled Follow-up SubmissionNOYESAlive366TUMOR FREENO1872011,NOTCGA-A8-A07E-D377614C0CE1A6-BDC8-4C9A-8A4B-C562220040B40Hormone TherapyLetrozolen/aYES6122012,TCGA-A8-A08I-R381730322ED7F-C303-4755-B8C3-4FED19B89D49184212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,714.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A66I,OL,A66I,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,13.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.04,Sentinel node biopsy alone,Sentinel lymph node and axillary lymph node biopsy,Lumpectomy,surgical resection,Other,Excisional biospy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Equivocal,1.2099609375,0.0,240 H,Allred Score 6,30-39%,CISH,CAP SCORING GUIDELINE 2010,92.7763671875,HER2 amplification - negative,Positive >2.2,NO,YES,49,BoneLiver,<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,172,3 Point Scale,3+,6thStage IIAT1cN1miMX,YES,YES,NO,11,6,2013,TCGA-OL-A66I-F5849643440205-5036-4417-B0CB-BF085DC77CFCYESYESYESTUMOR FREEAlive714NO1142014,NOTCGA-OL-A66I-D64844F22168A0-48F2-4929-8D24-FC96F98FBDD843312ChemotherapyADRIAMYCINNOComplete Response1292014NOTCGA-OL-A66I-D6524643174F1C-A7E8-41DB-91CD-79BF16DDA0CC43312ChemotherapyCYTOXANNOComplete Response2492014NOTCGA-OL-A66I-D65247BFFBBF56-08F9-40CB-99D1-13CE9A5FB33043312ChemotherapyTAXOLNOComplete Response2492014,TCGA-OL-A66I-R64843BD0C1305-129A-41D6-94AD-5D5CACC08ABB239285External5041cGyPrimary Tumor FieldNOComplete Response1292014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,21.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A6IW,AC,A6IW,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,2.0,H-SCORE 280,Allred (Biocare),Left Upper Outer Quadrant,2.623681640624994,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Right Breast Reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Negative,Negative,0.0,0.0,Allred score 0,8,10-19%,ACIS,Hercep Test  TM Dako,72.2626953125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,74,"Other, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,3 Point Scale,2+,7thStage IIAT2N0 (i-)MX,YES,YES,NO,15,10,2013,TCGA-AC-A6IW-F64106A62988AE-F527-4DAB-B4F0-F6FD96DC156FNONONOTUMOR FREEAlive413NO2682014,1TCGA-BH-A0AW-D15447B2148FF1-940F-45EC-8B2C-74F5951B58D16AUC53150ChemotherapyCarboplatinADJUVANTIVNO31120101TCGA-BH-A0AW-D154486D34C697-F428-4E3B-BD07-BB9E156CC9AB1mg/day200515Hormone TherapyArimidexADJUVANTPONO31120101TCGA-BH-A0AW-D154491D5E80DC-168A-47F1-BF39-F8031C06562675mg/m2653150ChemotherapyTaxotereADJUVANTIVNO31120101TCGA-BH-A0AW-D15446D6D6F047-A44A-41C1-A02C-277B2B508E086mg/kg53410ChemotherapyHerceptinADJUVANTIVNO31120101TCGA-BH-A0AW-D154502D1B4C2D-D268-45BF-9ABD-22F9D99DAB0750mg/day543Hormone TherapyAromasinADJUVANTPOYES3112010,TCGA-GM-A2DO-R47153F35B749C-7FAE-4842-BE1A-15F2C44A28D1176218ExternalPrimary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,622.0,WHITE,TCGA-BH-A0AW,BH,A0AW,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,12.0,ER Positive H-Score 95,PR Negative H-Score 0,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft,1.521552734374999,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Lumpectomy,surgical resection,Other,Total Mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,3+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Positive,0.0,2.0,H-Score,H-Score,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,52.634765625,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,4.43,"LungBoneLiverOther, specifyskin",<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,145,3 Point Scale,1+,Stage IIAT1cN1aM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",3,11,2010,TCGA-BH-A0AW-F15445179764C8-B58C-4FF9-9AB7-830D6A91DEF9Scheduled Follow-up SubmissionYESYESAlive622TUMOR FREENO3112010,1TCGA-BH-A0AW-D15447B2148FF1-940F-45EC-8B2C-74F5951B58D16AUC53150ChemotherapyCarboplatinADJUVANTIVNO31120101TCGA-BH-A0AW-D154486D34C697-F428-4E3B-BD07-BB9E156CC9AB1mg/day200515Hormone TherapyArimidexADJUVANTPONO31120101TCGA-BH-A0AW-D154491D5E80DC-168A-47F1-BF39-F8031C06562675mg/m2653150ChemotherapyTaxotereADJUVANTIVNO31120101TCGA-BH-A0AW-D15446D6D6F047-A44A-41C1-A02C-277B2B508E086mg/kg53410ChemotherapyHerceptinADJUVANTIVNO31120101TCGA-BH-A0AW-D154502D1B4C2D-D268-45BF-9ABD-22F9D99DAB0750mg/day543Hormone TherapyAromasinADJUVANTPOYES3112010,TCGA-BH-A0AW-R154512E78F368-4AD6-4F12-A487-FC57001C95A9201252EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1569.0,WHITE,TCGA-BH-A0B8,BH,A0B8,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,2.0,H-SCORE 255,Allred score 3+3=6,Right Upper Inner QuadrantRight,1.29,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,surgical resection,Other,Total mastectomy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.5478515625,0.0,Allred score = 8,allred score = 8,10-19%,ACIS,CAP scoring guideline 2010,67.3046875,Vysis AutoVysion System,Positive >2.2,NO,YES,2.38,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,816,3 Point Scale,3+,Stage IT1bN0 (i-)M0,NO,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",3,11,2010,TCGA-BH-A0B8-F154422CC2206F-9B64-41BB-A290-4AC1379C77B6Scheduled Follow-up SubmissionYESYESAlive1569TUMOR FREENO3112010,1TCGA-BH-A0B8-D1544300C007B0-1048-4B35-B0C6-48FD9B881A511mg/day114Hormone TherapyArimidexADJUVANTPOYES3112010,TCGA-BH-A0B8-R1544448351B36-41DF-4E03-839A-F3968397A16A63114EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Dead,912.0,1039.3818359375,BLACK OR AFRICAN AMERICAN,TCGA-A2-A3XU,A2,A3XU,No,YES,C50.9,8500/3,C50.9,2006.0,WITH TUMOR,YES,12.0,No value Given,Allred score = 8,Left,1.1,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Mastectomy NOS,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Negative,Negative,Excisional Biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.0,3.0,90 H,270 H,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,60.0,HER2 amplification - negative,PathVysion,NO,YES,1.5,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,1.66,3 Point Scale,2+,6thStage IIBT2N1miM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,8,2012,"TCGA-A2-A3XU-F3470471CBE6D1-7840-4A7C-AB59-CCDF29432FFANOYESYESWITH TUMORDead912YES596Locoregional RecurrenceOther, specifyBreastNONOYESPositivePositive596Locoregional RecurrenceOther, specifyChest wall, Breast RecurrenceNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES3082012",NOTCGA-A2-A3XU-D34706F99B1711-2441-4D81-BE35-E77D8DB5DD5C155ChemotherapyAdriamycinNO2882012NOTCGA-A2-A3XU-D3470722884654-200E-40BD-8E0D-C5BB2915AC39155ChemotherapyCytoxanNO2882012NOTCGA-A2-A3XU-D34708BF14305C-8340-470C-B0C2-57AD71B8C1DE155ChemotherapyTaxotereNO2882012NOTCGA-A2-A3XU-D34709D7667385-C63A-4D90-AE37-D95D1BC45AD5596718Hormone TherapyArimidexNOClinical Progressive Disease2882012NOTCGA-A2-A3XU-D3471045C67643-FF02-4C5B-874F-3D7D85A8FE9D657902ChemotherapyXelodaNOClinical Progressive Disease2882012,TCGA-A2-A3XU-R3470502DB7B9E-B9A1-471B-A309-5BFE13679395External4000cGy20Regional siteNO2882012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1519.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A408,B6,A408,No,YES,C50.9,8522/3,C50.9,2008.0,TUMOR FREE,YES,23.0,image cytometry,image cytometry,Left,1.2,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Right Breast Reexcision,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Mixed Histology (please specify),ductal and lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,3+,2+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Equivocal,0.123046875,10.0,Allred score 7 per outside facility report,allred score = 7,20-29%,Hercep Test  TM Dako,Dako Hecept Test,60.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.6,"Other, specifyskin",90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.9,4 Point Scale,3+,6thStage IIICT2N3aM0,YES,YES,NO,20,9,2012,TCGA-B6-A408-F596663C48974E-14E5-44BF-B964-C5E7C18FF99FNOYESYESTUMOR FREEAlive2072NO362014,NOTCGA-B6-A408-D41046921E7A16-C072-47C3-8810-22048A5B72E755163ChemotherapyCyclophosphamideNO1132013NOTCGA-B6-A408-D410490ED2B906-7178-435B-9882-692FBAA62DC058163ChemotherapyDocetaxelNO1132013NOTCGA-B6-A408-D410502ABDCF82-F819-4FBE-9C37-623C5AC0846758163ChemotherapyDoxorubicinNO1132013,TCGA-B6-A408-R41053A2EEA4E4-5B15-4FB4-A169-6ABF975476FF208244External4800cGy24Primary Tumor FieldNO1132013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,338.0,WHITE,TCGA-E2-A1B6,E2,A1B6,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Left,1.03,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Right Breast Reexcision,Other,total mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Equivocal,0.314453125,0.0,Allred score = 0,Allred score = 0,10-19%,Dako,Venten,131.2373046875,HER2 amplification - negative,Ratio >=2.0,NO,YES,54,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,25,4,2011,TCGA-E2-A1B6-F1938952C7E9E7-E0FB-4221-B4AF-7EDF9586E0D6Scheduled Follow-up SubmissionNOYESAlive867TUMOR FREENO8122011,1TCGA-E2-A1B6-D1941241211D2C-2E5E-4A2E-B31D-B8B5FD4053B04163ChemotherapyAdriamycinADJUVANTIVNO91220112TCGA-E2-A1B6-D194205B691CC0-6DE5-419D-96FB-0C8A7DEB398B4163ChemotherapyTaxolADJUVANTIVNO91220111TCGA-E2-A1B6-D193993110E408-194F-4231-98AC-379E031BB58E4163ChemotherapyCytoxanADJUVANTIVNO9122011,TCGA-B6-A408-R41053A2EEA4E4-5B15-4FB4-A169-6ABF975476FF208244External4800cGy24Primary Tumor FieldNO1132013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,7.0,ASIAN,TCGA-C8-A12W,C8,A12W,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,Image Analysis,Image Analysis,Left,1.2754199218749955,Axillary lymph node dissection alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Right Breast Reexcision,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.1796875,2.7255859375,Allred Score 6,Allred Score 7,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,86.1591796875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,3.0,"Other, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5,4 Point Scale,2+,6thStage IIIBT4N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,13,4,2011,TCGA-C8-A12W-F202448D4153E6-1D54-4375-9DDB-E9811157BA3EScheduled Follow-up SubmissionNOYESAlive385TUMOR FREENO912012,NOTCGA-B6-A408-D41046921E7A16-C072-47C3-8810-22048A5B72E755163ChemotherapyCyclophosphamideNO1132013NOTCGA-B6-A408-D410490ED2B906-7178-435B-9882-692FBAA62DC058163ChemotherapyDocetaxelNO1132013NOTCGA-B6-A408-D410502ABDCF82-F819-4FBE-9C37-623C5AC0846758163ChemotherapyDoxorubicinNO1132013,TCGA-A2-A0YL-R581345b399c8-8af8-4a9a-9507-682af704063e177224EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO128122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1277.0,WHITE,TCGA-A8-A095,A8,A095,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,4.560546875,image cytometry,H-Score 0,Left,2.223603515624988,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Other,Left breast reexcision,Other,Surgical Resection,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.3125,0.0,Allred score 8,230,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,105.96484375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.38,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,3.3,3 Point Scale,2+,6thStage IT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A095-F405546CCE328F-29A6-4589-B6C4-32FBE8EBA27ENOYESYESTUMOR FREEAlive1277NO2322013,NOTCGA-A8-A095-D3781157584D49-5DD8-4991-A154-50BB92C2FB5A0120Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A095-D378124968DB45-29C7-41D8-BC0A-204367F2EB4E0120ChemotherapyDoxorubicinn/aNOComplete Response6122012NOTCGA-A8-A095-D37813023B7F41-CB22-43B7-81EE-6DC8B72DD4F30120ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A095-D37814DD6C452A-B9DD-48FF-B9C3-2D1DCC1F1143181Hormone TherapyTamoxifenn/aYES6122012,TCGA-A8-A095-R38169424F7885-0277-4F10-91D2-8BB221F37C57120181ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Dead,2273.0,849.34375,WHITE,TCGA-BH-A1FE,BH,A1FE,No,YES,C50.9,8500/3,C50.9,1998.0,WITH TUMOR,YES,12.0,Allred score 7 (outside facility),H-Score 15,Left,2.0435058593750024,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Re-excision of the inferior margin,Other,segmental mastectomy with sentinel lymph node dissection,Infiltrating Ductal Carcinoma,secretory,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.94140625,1.0,Allred Score 3,205,10-19%,ACIS,Dako Hercept test,73.6328125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,64,"Other, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.94037109375,4.70,3 Point Scale,2+,5thStage IIBT2N1M0,NO,YES,YES456Distant MetastasisLungNOYESYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+,8,9,2011,TCGA-A2-A0T5-F13949FF9E318B-6811-4218-A62F-2D57AA48A597Scheduled Follow-up SubmissionNOYESAlive531TUMOR FREENO1272011,NOTCGA-LL-A6FR-D47889D0FB9FA8-EBF9-40CA-A6A9-33C21869179762104ChemotherapyAdriamycinNO3082013NOTCGA-LL-A6FR-D478916D5775A7-8E46-4707-97FE-6C70DDAFE0B862104ChemotherapyCYTOXANNO3082013NOTCGA-LL-A6FR-D47893A66D9CC5-476E-4593-A53E-FA86BC54E216118489ImmunotherapyHERCEPTINNO3082013NOTCGA-LL-A6FR-D47895CEC73C96-5595-4A8D-8D57-498C116A7957118195ChemotherapyTAXOLNO3082013,TCGA-E2-A15C-R18937B2859F7D-EF4C-413B-BDF2-D76014910FBF55102EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO19112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,764.0,WHITE,TCGA-A2-A04Y,A2,A04Y,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,13.0,allred score 0 + 0 = 0,allred score 5 +3 = 8,Right Upper Outer Quadrant,1.13,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Simple Mastectomy,Re-excision of the inferior margin,Other,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,1.0,Allred Score 8,Strong,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,70.4736328125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.57,"LungBoneLiverOther, specifyskin",90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,21,3 Point Scale,2+,6thStage IIBT2N1miM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,9,8,2010,TCGA-A2-A04Y-F93300CE61CBA-C744-4182-820C-81C33344DFCD1099AliveTUMOR FREEYESYES1832011,"1TCGA-A2-A04Y-D2729bb88b686-73af-4f28-b19b-97bdb837eddb4800mg1200mg493135ChemotherapyCytoxanADJUVANTIVNO11820104TCGA-A2-A04Y-D2733ea8b13ac-f088-4440-a155-06c71299a37e10037mg170-600mg22149659Targeted Molecular therapyHerceptinADJUVANTIVNO11820102TCGA-A2-A04Y-D2731351c5069-eb0c-468e-ba16-bf6ab636303f480mg120mg493135ChemotherapyAdriamycinADJUVANTIVNO11820107TCGA-A2-A04Y-D2754e34536c3-f6b1-4a30-8208-da6658e0d4bd4mg503Other, specify in notesBisphosphonate therapyZometaOTHER, SPECIFY IN NOTESPatient has oesteoporosis (Prevention of further bone lossIVYES11820103TCGA-A2-A04Y-D2732e7199f09-af18-4584-8015-6eebc968cd8c3900mg160-165mg12149226ChemotherapyTaxolADJUVANTIVNO11820105TCGA-A2-A04Y-D2741d6d00a85-5494-4f08-8711-63169285c19710mg273371Hormone TherapyTamoxifenADJUVANTPONO11820106TCGA-A2-A04Y-D2746227dd2b0-0b22-46bd-95d4-20775978c5dd1mg372Hormone TherapyArimidexADJUVANTPOYES1282010",TCGA-A2-A04Y-R2727e64c8ab7-4c64-47d5-b50e-188fb963eed4293297EXTERNAL BEAM1000cGyPrimary Tumor FieldADJUVANTNO11282010TCGA-A2-A04Y-R707408D05878C-2457-487F-8DF3-A4F0B1688D9E251290External5040cGyRegional siteNOComplete Response332015
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,608.0,WHITE,TCGA-A8-A07E,A8,A07E,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,12.873046875,CAP SCORING GUIDELINE 2010,Allred 0 = 0+0,Left Upper Outer Quadrant,3.364687499999996,Sentinel node biopsy alone,Sentinel lymph node and non-sentinel lymph node biopsy,Other,Re-excision of the inferior margin,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.2080078125,4.240234375,Allred score 8,0%,90-99%,ACIS,Hercep Test  TM Dako,104.7109375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2.13,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.3,3 Point Scale,2+,6thStage XT4bN3aMX,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A07E-F40825E36B92B8-AA12-4750-B2DC-517C7ABB7C81NONOYESTUMOR FREEAlive608NO232013,NOTCGA-A8-A07E-D377614C0CE1A6-BDC8-4C9A-8A4B-C562220040B40Hormone TherapyLetrozolen/aYES6122012,TCGA-BH-A42V-R61942623AE02D-1141-4C6D-A4E3-FB0DA24B911092141External66.4Gy36Primary Tumor FieldNOComplete Response1072014
TCGAFPPP,Breast,No,FEMALE,Dead,3945.0,2281.462890625,WHITE,TCGA-B6-A0X0,B6,A0X0,No,YES,C50.9,8201/3,C50.919,1996.0,TUMOR FREE,YES,31.0,Image Analysis,Image Analysis,Right Upper Outer QuadrantRight,1.9235644531250045,Axillary lymph node dissection alone,SN+1 non sentinel node,Modified Radical Mastectomy,Re-excision of the inferior margin,Modified radical mastectomy,Total mastectomy with sentinel lymoh node biopsy,"Other, specify",Cribiform,Indeterminate (neither Pre or Postmenopausal),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Equivocal,1.1513671875,0.0,allred score = 4,H score,90-99%,Dako,Venten,232.6181640625,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,1.78,BoneLiver,70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,3.0,4 Point Scale,2+,4thStage IT1cN0 (i-)M0,YES,YES,PositiveNegative1+,15,3,2011,TCGA-B6-A0X0-F15710B50DBB7C-6050-4E27-9FE2-3D444CD297A0Scheduled Follow-up SubmissionNOYESDead3945NO2982011,"1TCGA-A2-A04Y-D2729bb88b686-73af-4f28-b19b-97bdb837eddb4800mg1200mg493135ChemotherapyCytoxanADJUVANTIVNO11820104TCGA-A2-A04Y-D2733ea8b13ac-f088-4440-a155-06c71299a37e10037mg170-600mg22149659Targeted Molecular therapyHerceptinADJUVANTIVNO11820102TCGA-A2-A04Y-D2731351c5069-eb0c-468e-ba16-bf6ab636303f480mg120mg493135ChemotherapyAdriamycinADJUVANTIVNO11820107TCGA-A2-A04Y-D2754e34536c3-f6b1-4a30-8208-da6658e0d4bd4mg503Other, specify in notesBisphosphonate therapyZometaOTHER, SPECIFY IN NOTESPatient has oesteoporosis (Prevention of further bone lossIVYES11820103TCGA-A2-A04Y-D2732e7199f09-af18-4584-8015-6eebc968cd8c3900mg160-165mg12149226ChemotherapyTaxolADJUVANTIVNO11820105TCGA-A2-A04Y-D2741d6d00a85-5494-4f08-8711-63169285c19710mg273371Hormone TherapyTamoxifenADJUVANTPONO11820106TCGA-A2-A04Y-D2746227dd2b0-0b22-46bd-95d4-20775978c5dd1mg372Hormone TherapyArimidexADJUVANTPOYES1282010",TCGA-EW-A6SD-R71031DD24B5DA-6930-49C2-80AD-BC5FF24B767B239288External4623Primary Tumor FieldNO1432015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,321.0,WHITE,TCGA-A2-A0T5,A2,A0T5,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.0,allred score 0 + 0 = 0,Allred score 3+3=6,Left,1.3,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Left breast reexcision,Other,Wide Local Excision,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,Allred score = 4,Allred score = 7,10-19%,ACIS,Hercep Test  TM Dako,85.654296875,Vysis AutoVysion System,Ratio >=2.0,NO,YES,4.43,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.83,3 Point Scale,1+,Stage IIAT2N0 (i-)M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-A2-A0T5-F13949FF9E318B-6811-4218-A62F-2D57AA48A597Scheduled Follow-up SubmissionNOYESAlive531TUMOR FREENO1272011,1TCGA-A2-A0T5-D4004da0a191b-d070-4b24-a363-86c0b3ba4582mgmg4166ChemotherapyTaxotereADJUVANTIVNO91120102TCGA-A2-A0T5-D4005651802d7-8efb-4de1-acac-0cde103d8b74mgmg4166ChemotherapyCytoxanADJUVANTIVNO91120103TCGA-A2-A0T5-D4007ad72c4e8-6494-47a3-b46a-180feb91e7cemgmgHormone TherapyTamoxifenADJUVANTPONO9112010,TCGA-A2-A0ER-R1983a18a9176-c998-41d5-b7b2-07d966053c74200246EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11382010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,118.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A6FR,LL,A6FR,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,1.0,H-SCORE 0,allred score 5+3+8,RightRight Lower Inner Quadrant,2.7,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Re-excision of the inferior margin,Other,L Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Positive,Negative,Equivocal,0.0,0.0,Two-tier,Intensity=Weak,10-19%,0,Hercep Test  TM Dako,20.0,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,2.38,"Other, specifyaxilaary node negative but intrammary node positive",80-89%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,816,3 Point Scale,1+,7thStage IIAT2N0 (i-)MX,YES,NO,NO,30,8,2013,TCGA-LL-A6FR-F6404537B5965A-69C8-46A2-92CE-4A03623AF4ACNOYESYESAlive489NO2582014,NOTCGA-LL-A6FR-D47889D0FB9FA8-EBF9-40CA-A6A9-33C21869179762104ChemotherapyAdriamycinNO3082013NOTCGA-LL-A6FR-D478916D5775A7-8E46-4707-97FE-6C70DDAFE0B862104ChemotherapyCYTOXANNO3082013NOTCGA-LL-A6FR-D47893A66D9CC5-476E-4593-A53E-FA86BC54E216118489ImmunotherapyHERCEPTINNO3082013NOTCGA-LL-A6FR-D47895CEC73C96-5595-4A8D-8D57-498C116A7957118195ChemotherapyTAXOLNO3082013,TCGA-LL-A6FR-R640483D5B50EB-00E9-4CCE-9CCA-F0862B1AEC5E230262External54.72Gy22Primary Tumor FieldNO2582014
TCGAFPPP,Breast,No,FEMALE,Dead,1793.0,1665.3759765625,WHITE,TCGA-AO-A03U,AO,A03U,No,YES,C50.9,8502/3,C50.9,2001.0,TUMOR FREE,YES,8.0,Allread score 5+3 = 8,Allred (Biocare),Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft Lower Inner QuadrantLeft Lower Outer QuadrantLeft,2.3474999999999957,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Re-excision of the inferior margin,Other,right segmental mastectomy witrh axillary node dissection,"Other, specify",secretory,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,2+,0,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,Allred score 6,Allred Score 5,<10%,ACIS,3+ Positive,99.3115234375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,54,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.026621093750003,52,3 Point Scale,1+,6thStage IT1cN0 (i-)M0,YES,NO,NONO,9,1,2011,TCGA-AO-A03U-F586346826A53-3583-4996-BC0C-037B1A0AFCE5DeadTUMOR FREE1793NOYES912011TCGA-AO-A03U-F209072CBBFF6D-770D-4735-95B5-35ACF9B4A070Scheduled Follow-up SubmissionNOYESDead1793TUMOR FREEYES1614New Primary TumorLungNONegativeNegativeNegative2412012,1TCGA-AO-A03U-D598712f8a04a-2cf9-4e12-9417-eb6e8ca1ef3d8640mg600mg/m2870216ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A03U-D5990cd54a4e8-2031-4653-a3af-4a21b63888d78640mg600mg/m2870216ChemotherapyFluorouracilADJUVANTIVNO10120111TCGA-AO-A03U-D5989c1bd6420-c945-476c-afdc-c107a55824c4576mg40mg/m2870216ChemotherapyMethotrexateADJUVANTIVNO1012011,TCGA-AR-A1AU-R218605E3D53C1-AE5A-4CFE-94E9-C0B9F51931A0159202EXTERNAL BEAM4680cGy16Primary Tumor FieldADJUVANTNO12722012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1998.0,WHITE,TCGA-AR-A24O,AR,A24O,No,YES,C50.9,8522/3,C50.9,2005.0,TUMOR FREE,YES,19.0,Image Analysis,Image Analysis,Left,1.750029296874999,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Re-excision of the inferior margin,Mastectomy NOS,segmental mastectomy with sentinel lymph node biopsy,Mixed Histology (please specify),Lobular carcinoma with ductal features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Positive,Incisional Biopsy,intraoperative examination,Negative,Positive,Negative,0.5576171875,7.0,H-SCORE,Allred score = 8,10-19%,Hercep Test  TM Dako,Dako Hercept test,67.5048828125,HER2 amplification - negative,Ratio >=2.0,NO,YES,54,"Other, specifyskin",80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,71,4 Point Scale,2+,6thStage IIIAT3N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,16,8,2011,TCGA-AR-A24O-F313566C6CAD9C-079E-4CB1-BA22-BFB702D52A2EScheduled Follow-up SubmissionYESYESAlive1998WITH TUMORYES2561152012TCGA-AR-A24O-F4949293ABDAE4-8A54-4D8A-BA69-C7706A59F8D4NOYESYESWITH TUMORAlive2561YES25612102013TCGA-AR-A24O-F71713E72F8FEE-ED75-4BD3-9257-CC47C1D1BD62NOYESYESWITH TUMORAlive3607YES25613032015,1TCGA-AR-A24O-D31366473BCA10-A4E7-4AEE-AA89-5A8A66DABFEF1200mg175mg/m24107149ChemotherapyPaclitaxelADJUVANTIVNO1520121TCGA-AR-A24O-D313638B674BE2-3DB0-4A12-942B-F5E9B424F4A13820mg600mg/m244493ChemotherapyCytoxanADJUVANTIVNO1520121TCGA-AR-A24O-D3136038BF2C09-8748-454C-A56E-36FDD41E6268390mg60mg/m244493ChemotherapyDoxorubicinADJUVANTIVNO1520122TCGA-AR-A24O-D31367342B68A1-E8FE-4380-A4A7-669B934A259E20mg/day1531994Hormone TherapyTamoxifenADJUVANTPONO1520123TCGA-AR-A24O-D3136870462AEF-4D61-423E-9388-4DAA2DFDDAE52.5mg/day19982283Hormone TherapyLetrozoleADJUVANTPONO152012,TCGA-AR-A24O-R313577319E2CD-94B7-467E-A60A-FF7EBEA36F2C174218EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO1152010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,935.0,WHITE,TCGA-A2-A1FX,A2,A1FX,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,24.0,H-SCORE 255,H-Score 160,Right Upper Outer Quadrant,1.1,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Lumpectomy,Re-excision of the inferior margin,Mastectomy NOS,Excisional biopsy,Infiltrating Ductal Carcinoma,Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.2373046875,6.0,Allred Score 3,Allred Score 5,10-19%,ACIS,CAP SCORING GUIDELINE 2010,60.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,160,"Other, specifyskin",70-79%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,185,3 Point Scale,3+,6thStage IIIAT3N2aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",12,5,2011,TCGA-A2-A1FX-F2080606617655-F9F7-4EA6-BFAA-875AE6032908Scheduled Follow-up SubmissionYESYESAlive1119TUMOR FREENO1212012TCGA-A2-A1FX-F5965490A36B66-1105-46F9-AB5D-538C89E715E1NOYESYESTUMOR FREEAlive1847NO1952014,1TCGA-A2-A1FX-D11802b78310b5-e2f5-4a69-a170-d5d8b9f9ff96474155ChemotherapyTaxotereADJUVANTIVNO12520113TCGA-A2-A1FX-D11811d761afbc-f8fb-4593-8461-0b7bafa935e91mg/day198Hormone TherapyArimidexADJUVANTPOYES12520112TCGA-A2-A1FX-D11806a39f5502-14a7-4c8d-8d51-34ef34e9bb26474155ChemotherapyCytoxanADJUVANTIVNO1252011,TCGA-A2-A1FX-R118131afd58fc-db29-4e80-b23d-79c9ce04bff9186231EXTERNAL BEAM10560cGy31Primary Tumor FieldADJUVANTNO11252011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2800.0,WHITE,TCGA-Z7-A8R6,Z7,A8R6,No,YES,C50.8,8022/3,C50.8,2005.0,TUMOR FREE,YES,2.0,CAP SCORING GUIDELINE 2010,Allred 0 = 0+0,Left Upper Outer Quadrant,3.3093066406249974,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Lumpectomy,Left breast reexcision,Other,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Lobular Carcinoma,micropapillary carcinoma invasive,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,4 Point Scale,2+,1+,Negative,Negative,Tumor resection,Biopsy not specified,Negative,Positive,Negative,0.0,0.0,Allred score 0,200,30-39%,CISH,Hercep Test TM DAKO,125.0908203125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.13,"Other, specifyaxilaary node negative but intrammary node positive",<10%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,185,4 Point Scale,2+,6thStage IT1cN0M0,YES,NO,NO,9,7,2014,TCGA-Z7-A8R6-F5875205FE8EA0-A5C2-4172-8405-A7A30E1E43BFNONOYESTUMOR FREEAlive3256NO972014,NOTCGA-Z7-A8R6-D58749A2A69EA3-72CF-46C2-B6D6-DF0A093887A531153AdriamycinNOComplete Response972014NOTCGA-Z7-A8R6-D58750644F7063-1BA4-4B84-99E4-012DB9AE148631153CytoxanNOComplete Response972014NOTCGA-Z7-A8R6-D5875121D2B8CE-9A15-4401-936E-688113BD667831153TaxolNOComplete Response972014,TCGA-GM-A3XL-R355225579FB1C-390D-4919-A4B9-138CA5AF97BB274315External60Gy30Primary Tumor FieldNOComplete Response1102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,6.0,ASIAN,TCGA-C8-A1HM,C8,A1HM,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,6.9736328125,Allred score 7 (outside facility),Allred 0 = 0+0,Left,1.7415917968750017,Axillary lymph node dissection alone,Pateys surgery,Modified Radical Mastectomy,Left breast reexcision,Other,Surgical resection,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Surgery,Negative,Positive,Negative,0.005859375,0.0,Allred Score 5,Allred Score 8,90-99%,Hercep Test  TM Dako,Hercep Test  TM Dako,234.4052734375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,3.0,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.5,4 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,2,6,2011,TCGA-C8-A1HM-F19078C8F7334F-6542-49D1-95F5-9C41AB38E44DScheduled Follow-up SubmissionNOYESAlive70TUMOR FREENO2122011TCGA-C8-A1HM-F708066F012BB5-7730-453F-96B2-C41EEF03F8BCNONOYESTUMOR FREEAlive375NO932015,NOTCGA-C8-A1HM-D70807276724DA-C121-44EA-8584-13AB426F8DDD2649ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A1HM-D70808B2D0CDD7-747C-49EC-B329-F2427BA79DDB2649ChemotherapyCyclophosphamideNOComplete Response932015NOTCGA-C8-A1HM-D70809F67F216B-625D-4CDE-B551-FEBD1B76FE0F2649ChemotherapyTaxolNOComplete Response932015,TCGA-S3-A6ZH-R63634AFC090C0-5CB1-47EF-B9B4-4D7AEE7ADCA5304351External110Gy55Regional siteNOComplete Response2782014
TCGAFPPP,Breast,No,FEMALE,Dead,158.0,1073.4228515625,WHITE,TCGA-A2-A0CU,A2,A0CU,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,1.0,Allred score = 8,allred score 3 + 3 = 6,Right Lower Outer Quadrant,1.0,Sentinel node biopsy alone,Pateys surgery,Simple Mastectomy,surgical resection,Modified radical mastectomy,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,2+,Negative,Close,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,1.0,0.0,MODERATE,STRONG,10-19%,Hercep Test  TM Dako,DAKOHercepTest TM,44.880859375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,118,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0495312500000025,105,3 Point Scale,2+,6thStage IIAT2N0 (i+)M0,YES,YES,NONO,9,9,2010,TCGA-A2-A0CU-F1373599B03F76-5B6B-4C3C-899F-D63D8FC39C5DScheduled Follow-up SubmissionNOYESDead158TUMOR FREENO1062011,1TCGA-A2-A0CU-D1971a4307c98-baf1-4f65-b40b-87bb611d8a4a10mg98Hormone TherapyTamoxifenADJUVANTPONO10102010,TCGA-BH-A0B8-R1544448351B36-41DF-4E03-839A-F3968397A16A63114EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO13112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,829.0,WHITE,TCGA-BH-A0HX,BH,A0HX,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,24.0,H-Score 270,H-Score 190,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft Lower Inner QuadrantLeft Lower Outer QuadrantLeft,1.2607324218750002,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Simple Mastectomy,Re-Excision of Superior Margin,Mastectomy NOS,Segmental mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,2.0,2.0,H-Score,H-Score,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.681640625,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,33,LungBone,80-89%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,60,3 Point Scale,3+,Stage IIBT2N1aM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,11,2010,TCGA-BH-A0HX-F4838477758CF-349A-441F-B63C-93C9677D3415829AliveTUMOR FREENOYES16112010,1TCGA-BH-A0HX-D4837D1EDD48C-D395-40FC-AADC-7222D40374191mg/day278Hormone TherapyArimidexADJUVANTPOYES171120101TCGA-BH-A0HX-D4833B906D9FD-E934-49A6-B493-F9E15460BEDE117ChemotherapyAdrimycinADJUVANTIVNO181120101TCGA-BH-A0HX-D4836E0A73F7B-3621-4C44-B73F-4C6B1CEC05B8ChemotherapyTaxotereADJUVANTIVNO181120101TCGA-BH-A0HX-D483480535D9D-13BA-4040-A6CB-E650C6AC3E4D117ChemotherapyCytoxanADJUVANTIVNO18112010,TCGA-BH-A0BD-R15427BD660DD1-5058-42E5-A3E2-C3B039B665B4196247EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1903.0,WHITE,TCGA-A2-A0ER,A2,A0ER,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,14.0,No value Given,allred score 5 +3 = 8,Right Lower Inner Quadrant,1.0,Sentinel lymph node biopsy plus axillary dissection,FNA plus axillary lymph node dissection,Lumpectomy,Right Breast Reexcision,Lumpectomy,Total Mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,0.0,1.0,allred score = 7,Allred score = 7,10-19%,Hercep Test  TM Dako,DAKOHercepTest TM,47.794921875,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,33,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,5,3 Point Scale,2+,6thStage IBT1cN1miM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",13,8,2010,TCGA-A2-A0ER-F137191D5FC55A-1B4C-4319-89BB-1B2DF2C3FE55Scheduled Follow-up SubmissionYESYESAlive2263TUMOR FREENO1362011,"4TCGA-A2-A0ER-D198151090311-5909-4760-bf5a-1cefb8292222173mg173mg1154154ChemotherapyDocetaxelADJUVANTIVNO13820103TCGA-A2-A0ER-D198072972060-56c4-4ffe-971d-d5772839072a1mg183Hormone TherapyArimidexADJUVANTPOYES13820101TCGA-A2-A0ER-D197881147c8f-47a7-4712-8495-8af0047c51d94152mg1038mg498140ChemotherapyCytoxanADJUVANTIVNO13820102TCGA-A2-A0ER-D1979e44399f3-f0fc-40bf-8966-a2644119679e416mg104mg498140ChemotherapyAdriamycinADJUVANTIVNO13820105TCGA-A2-A0ER-D198272844d5d-8e7f-4b64-80a5-ee6e676e0b327000ug1000ug7327615ImmunotherapyE-75OTHER, SPECIFY IN NOTESCancer Vaccine TrialNO1092010",TCGA-A2-A0ER-R1983a18a9176-c998-41d5-b7b2-07d966053c74200246EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11382010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1409.0,WHITE,TCGA-AR-A1AU,AR,A1AU,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,37.0,Allred score 0+0 = 0,Image Analysis,Right Upper Inner QuadrantRight Upper Outer Quadrant,1.315332031249998,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Re-Excision of Superior Margin,Mastectomy NOS,Total Mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.3818359375,4.0,0,Allred score = 0,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,50.1396484375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.13,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,2.23,3 Point Scale,2+,6thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,14,6,2011,TCGA-AR-A1AU-F21858A71CFC53-16BF-448A-8B79-F8053B635F03Scheduled Follow-up SubmissionYESYESAlive1409NO2722012TCGA-AR-A1AU-F494722EF8415E-95BD-4EEF-9529-267C05B3273ENOYESYESTUMOR FREEAlive2318NO2102013TCGA-AR-A1AU-F71744CA3498DB-9604-4BDE-90A0-B890E45357A9NOYESYESTUMOR FREEAlive2868NO3032015,1TCGA-AR-A1AU-D21864AA98F6B4-F95F-42BE-8DC4-9453156E46D9460mg60mg/m244385ChemotherapyDoxorubicinADJUVANTIVNO28220122TCGA-AR-A1AU-D2187142C369BB-5B2B-41E6-AFEB-DD07F763415A20mg/day157Hormone TherapyTamoxifenADJUVANTPOYES28220121TCGA-AR-A1AU-D21866E590785D-CACD-47BA-B643-8C232EC60A724540mg600mg/m244385ChemotherapyCytoxanADJUVANTIVNO28220121TCGA-AR-A1AU-D2186904058D52-264A-4E9D-80C7-5F003B9F48C61320mg175mg/m2499141ChemotherapyPaclitaxelADJUVANTIVNO2822012,TCGA-AR-A1AU-R218605E3D53C1-AE5A-4CFE-94E9-C0B9F51931A0159202EXTERNAL BEAM4680cGy16Primary Tumor FieldADJUVANTNO12722012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12K,C8,A12K,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,H-Score 300,Allred 0 = 0+0,Right Upper Inner Quadrant,2.0086816406249905,Other (specify),Pateys surgery,Other,Re-Excision of Superior Margin,Other,Pateys surgery,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Negative,Equivocal,0.0322265625,1.0,Two-tier,230,90-99%,Dako,DAKOHercepTest TM,54.4921875,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,2.13,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,3.8,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,12,4,2011,TCGA-A8-A09T-F40329C0DB6775-BC42-4631-9AAD-006977242B0ENOYESYESTUMOR FREEAlive579NO1722013,NOTCGA-EW-A6SD-D710308617823B-CDC1-4292-A1A7-F1D9B9ABBA7386198ChemotherapyTCHNO1432015,TCGA-EW-A6SD-R71031DD24B5DA-6930-49C2-80AD-BC5FF24B767B239288External4623Primary Tumor FieldNO1432015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,791.0,WHITE,TCGA-AC-A2FE,AC,A2FE,No,YES,C50.9,8520/3,C50.9,2005.0,WITH TUMOR,YES,18.0,H-SCORE 300,Allred score 5+3 = 8,Right Upper Outer Quadrant,1.2781445312499962,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Right Breast Reexcision,Modified radical mastectomy,L Total Mastectomy,Infiltrating Lobular Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,intraoperative examination,Negative,Positive,Equivocal,1.2783203125,18.0,allred score =  8,8,10-19%,ACIS,Hercep Test  TM Dako,231.5810546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,2.25,"Other, specifyskin",60-69%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,52,3 Point Scale,2+,6thStage IIICT3N3aMX,YES,YES,YES766Distant MetastasisBoneNOYESNO,3,12,2012,TCGA-AC-A2FE-F47723D5ADEC6C-7EEA-4059-A611-D95C59BE08DDNOYESYESWITH TUMORAlive2240YES766Distant MetastasisBoneNOYESNO2882013TCGA-AC-A2FE-F4772519EC4E99-4AD7-41C8-A15C-7B826C486A39NOWITH TUMORDead2636YES2496Distant MetastasisLiverNONOYES2882013,NOTCGA-AC-A2FE-D37368B60BCD38-9FFA-43B5-B2C0-C855C05883BB67173ChemotherapyAdriamycinNOPartial Response3122012NOTCGA-AC-A2FE-D37369516F7FB6-37E9-4E44-AD00-37D688CD51FA67173ChemotherapyTaxolNOPartial Response3122012NOTCGA-AC-A2FE-D373704DF74C32-567B-4238-B008-44BA2231AC3A273Hormone TherapyArimidex3122012NOTCGA-AC-A2FE-D47779A99BF733-8B3D-4B21-921E-79FDE40A04AF67173ChemotherapyCytoxanNOComplete Response2882013NOTCGA-AC-A2FE-D477818AC64C61-1BA6-4891-B438-AFF91FC30F542516ChemotherapyXelodaNOClinical Progressive Disease2882013NOTCGA-AC-A2FE-D47782E2A083D8-3A0B-465B-9603-BE32342ACC482516ChemotherapyAbraxaneNOClinical Progressive Disease2882013,TCGA-AC-A2FE-R37361C5673D17-EA8E-4D12-A7A5-B160F1177F64178219External5040cGy28Primary Tumor FieldNOPartial Response3122012TCGA-AC-A2FE-R37371FA6DFCE6-F2F8-4D52-B805-C1B07A828C99791813ExternalDistant siteNOPartial Response3122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,147.0,WHITE,TCGA-D8-A1XV,D8,A1XV,No,YES,C50.9,8480/3,C50.9,2010.0,TUMOR FREE,YES,1.0,% IHC,%IHC,Right Lower Inner Quadrant,2.7007617187499893,Sentinel node biopsy alone,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,TOTAL MASTECTOMY,Mucinous Carcinoma,Ductal with mucinous features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.0,0.0,>75%,>75%,90-99%,Dako,CAP SCORING GUIDELINE 2010,55.16796875,HER2 amplification - negative,>= 2.0 Positive,YES,NO,33,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,not amplified,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",16,5,2011,TCGA-D8-A1XV-F29457A788378C-1EF4-49A8-B595-22C22A19823DScheduled Follow-up SubmissionNONOAlive461TUMOR FREENO1932012,NOTCGA-EW-A6SD-D710308617823B-CDC1-4292-A1A7-F1D9B9ABBA7386198ChemotherapyTCHNO1432015,TCGA-A8-A09T-R381913B9677B4-105D-478C-BB4A-25C46395FB946192ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,662.0,WHITE,TCGA-A2-A0YM,A2,A0YM,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.0,allred score 0 + 0 = 0,H-Score-230,Left Upper Outer Quadrant,1.08,Other (specify),Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Equivocal,0.0,0.0,Allred score = 4,STRONG,10-19%,ACIS,Dako Hercept test,60.0,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.45,Lung,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.57,3 Point Scale,1+,Stage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,12,2010,TCGA-A2-A0YM-F157675A91256B-618E-4365-9DE5-864FDFC51EE4Scheduled Follow-up SubmissionYESNOAlive965TUMOR FREENO3082011,2TCGA-AR-A1AX-D221458B22C59E-5DAE-4372-A2A9-CD57D6D84D532mg/kg117482ImmunotherapyTrastuzumabADJUVANTIVNO1320124TCGA-AR-A1AX-D22147B73644E2-BE84-462A-8A8A-7DD3B10963702.5mg/day341Hormone TherapyLetrozoleADJUVANTPOYES1320121TCGA-AR-A1AX-D2214434AD7E93-C4C1-4D25-AB5B-2DB9F3864B854160ChemotherapyPaclitaxelADJUVANTNO1320121TCGA-AR-A1AX-D221439E6B462C-33CD-4914-B565-BF5F728AA385454ChemotherapyCytoxanADJUVANTNO1320123TCGA-AR-A1AX-D22146D3CAF54C-B16D-4B4C-BB7E-85033DB79E0E25mg/day249295Hormone TherapyExemestaneADJUVANTPONO1320121TCGA-AR-A1AX-D22142EBFA7185-C765-4E3A-95B6-F841E01AD17C454ChemotherapyDoxorubicinADJUVANTNO132012,TCGA-A2-A0YM-R56809d0ac647-5f1f-4321-8e4f-dc1703bd515980126EXTERNAL BEAM5520cGy31Primary Tumor FieldADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,274.0,WHITE,TCGA-D8-A1XA,D8,A1XA,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,% IHC,%IHC,Left Upper Outer Quadrant,2.808437499999996,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Other,Total mastectomy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,"Other method, specify:",intraoperative examination,Negative,Positive,Equivocal,0.0,0.0,>75%,>75%,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,75.2900390625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,66,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,18,5,2011,TCGA-D8-A1XA-F2943423F14C5F-A612-4176-9B70-83C685679F1EScheduled Follow-up SubmissionYESNOAlive839TUMOR FREENO3122012,NOTCGA-A8-A093-D3775553987C58-785E-4E57-B53F-0CBD9C1C357928Hormone TherapyTamoxifenn/aYES6122012,TCGA-D8-A1XA-R29435D72884C9-451B-40F9-A7FE-C1FA19833923140185EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A03X,AN,A03X,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,19.0,CAP scoring guideline 2010,IHC,Left Upper Outer Quadrant,2.289082031249987,No axillary staging,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Positive,0.0,0.0,200,200,40-49%,0,Venten,135.05859375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.73,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,3 Point Scale,1+,Stage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,28,12,2010,TCGA-AN-A03X-F68976469F1ACF-B8FD-4F11-9FE1-D2DBA8D25947YESNONOTUMOR FREEAlive1024122014,1TCGA-AO-A129-D59502c562434-088f-444b-82ca-9ad77b8fdaa2175mg/m2467162ChemotherapyPaclitaxelADJUVANTIVNO10120111TCGA-AO-A129-D5947592cacd9-a024-4b2d-a780-d45766869b1a600mg/m2467162ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A129-D59497a4726f6-1df6-4d6c-af20-b2116488289460mg/m2467162ChemotherapyDoxorubicinADJUVANTIVNO1012011,TCGA-EW-A6SD-R71031DD24B5DA-6930-49C2-80AD-BC5FF24B767B239288External4623Primary Tumor FieldNO1432015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,272.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A42V,BH,A42V,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,3.0,No value Given,allred score 5 + 3 = 8,Left Lower Outer Quadrant,3.4782031249999723,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Positive,Core needle biopsy,Biopsy not specified,Positive,Positive,Negative,0.681640625,1.0,Intensity=Strong,120,90-99%,Dako,CAP scoring guideline 2010,291.564453125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.38,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.7867382812499957,61,3 Point Scale,3+,7thStage IBT1cN1miM0,NO,NO,NO,17,1,2013,TCGA-BH-A42V-F619412027C9E7-9C37-444B-A786-938EFDD802E6NOYESNOTUMOR FREEAlive635NO1072014,NOTCGA-AR-A2LH-D371750674353C-7BE2-4FF0-952E-236E7F1BCB934284ChemotherapyAdriamycinNO6122012NOTCGA-AR-A2LH-D3726002991FAB-6700-40A7-86F6-5C1C3507F3364284ChemotherapyCytoxanNO6122012NOTCGA-AR-A2LH-D3726140102DFF-32EF-4C9C-B97B-78B3CC02F99098140ChemotherapyPaclitaxelNO6122012,TCGA-BH-A42V-R61942623AE02D-1141-4C6D-A4E3-FB0DA24B911092141External66.4Gy36Primary Tumor FieldNOComplete Response1072014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,224.0,WHITE,TCGA-AR-A2LL,AR,A2LL,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,4.0,IHC,Allred score 5+3 = 8,Left,1.4017187499999968,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Re-Excision of Superior Margin,Other,partial mastectomy,Infiltrating Lobular Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,0.1005859375,0.0,allred score = 8,Allred Score,10-19%,Dako,Venten,260.216796875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,74,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,1.9,3 Point Scale,2+,6thStage IIBT3N0M0,YES,YES,Positive70-79%Positive<10%Negative1+,14,2,2012,TCGA-AR-A2LL-F352057E870DEF-F459-4137-9815-ABFC98FF18DFNONOYESAlive1719NO6122012TCGA-AR-A2LL-F49493A680A628-61D7-4619-A459-87CA6BAEE1D1NOYESTUMOR FREEAlive2012NO2102013,NOTCGA-AR-A2LL-D372728B4531C7-8D35-45BE-B28C-0497928B42F354224Hormone TherapyTamoxifenNO6122012,TCGA-A8-A09T-R381913B9677B4-105D-478C-BB4A-25C46395FB946192ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,268.0,WHITE,TCGA-A2-A4RY,A2,A4RY,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,30.0,No value Given,allred score 2+2 = 4,Right,1.413496093750002,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.0,18.0,240 H,allred score = 7,90-99%,Hercep Test  TM Dako,Venten,398.9658203125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,33,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.9,3 Point Scale,3+,7thStage IIICT3N3aM0,YES,YES,NO,26,2,2013,TCGA-A2-A4RY-F59208D3984B99-34DF-4EBE-B92B-EADBB216CA0BNOYESYESTUMOR FREEAlive648NO552014,NOTCGA-A2-A4RY-D406591BCAA28C-A1D9-45B4-993D-DC411B983F6C58164ChemotherapyTaxotereNOComplete Response2622013NOTCGA-A2-A4RY-D4066049B3D51C-F502-4AB9-9548-345C27375EA658164ChemotherapyAdriamycinNOComplete Response2622013NOTCGA-A2-A4RY-D40661026BFA4A-9212-4110-83E8-78389551376058164ChemotherapyCytoxanNOComplete Response2622013NOTCGA-A2-A4RY-D40662E5560868-E57D-4A2B-83C8-C2B50D5B8224203Hormone TherapyTamoxifenYES2622013,TCGA-A2-A4RY-R40664CF487209-10D6-4BC8-80BA-3FEED723600E192238External5000cGy25Primary Tumor FieldNOComplete Response2622013TCGA-A2-A4RY-R406656766D57B-2819-4D63-BAEA-6BE4E6712F77192241External5040cGy28Regional siteNOComplete Response2622013TCGA-A2-A4RY-R40666E7AA083C-CCB6-4495-9409-749A30265124224231External1000cGy5Primary Tumor FieldNOComplete Response2622013TCGA-A2-A4RY-R40667A727732D-1D49-47FA-A481-F1DF8B6221E4193238External4800cGy24Primary Tumor FieldNOComplete Response2622013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,579.0,WHITE,TCGA-A8-A09T,A8,A09T,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,11.45703125,image cytometry,Allred 0 = 0+0,Left,1.710546874999994,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Other,Re-Excision of Superior Margin,Other,Surgical Resection,Infiltrating Lobular Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.421875,6.3681640625,Allred score 8,Allred score 8,10-19%,ACIS,Hercep Test  TM Dako,111.6015625,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,2.13,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,5,3 Point Scale,3+,6thT1cN0MX,YES,YES,YES994Distant MetastasisBoneNOYESYES,27,5,2011,TCGA-A8-A09T-F40329C0DB6775-BC42-4631-9AAD-006977242B0ENOYESYESTUMOR FREEAlive579NO1722013,NOTCGA-A8-A09T-D37898BDD31916-FC21-4D48-B1B5-442465133D4B122Hormone TherapyAnastrozoleYES6122012,TCGA-A8-A09T-R381913B9677B4-105D-478C-BB4A-25C46395FB946192ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,21.0,WHITE,TCGA-AC-A3HN,AC,A3HN,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,3.0,H-SCORE 260,CAP SCORING GUIDELINE 2010,Left Upper Inner Quadrant,1.287402343749998,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Re-Excision of Superior Margin,Other,TOTAL MASTECTOMY,Infiltrating Lobular Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0,2.0,Intensity=Strong,Allred Score 5,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,51.138671875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,1.78,"Other, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.0,3 Point Scale,1+,7thStage IIBT2N1aMX,YES,YES,Positive70-79%Positive<10%Negative1+,13,4,2012,TCGA-AC-A3HN-F658353B8F9AB2-2433-441B-B393-4247E781E2F3NONOYESTUMOR FREEAlive496NO3092014,1TCGA-BH-A0HN-D4810606F5F31-0DDC-48DB-954F-474604A3B7ED1mg/day82Hormone TherapyARIMIDEXADJUVANTPOYES17112010,TCGA-A8-A09T-R381913B9677B4-105D-478C-BB4A-25C46395FB946192ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1010.0,BLACK OR AFRICAN AMERICAN,TCGA-EW-A6SD,EW,A6SD,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,31.0,H-Score 295,Allred (Biocare),LeftLeft Upper Outer Quadrant,1.3125292968749918,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Lumpectomy,Re-Excision of Superior Margin,Other,biopsy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Equivocal,0.0,2.0,Intensity=Weak,H score,30-39%,ACIS,DAKOHercepTest TM,37.62109375,HER2 amplification - negative,Path Vysion HER2 DNA Probe Kit,YES,NO,2.13,"Other, specifyskin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,60,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,YES,NO,14,3,2015,TCGA-AO-A129-F588263E8194B-C67D-4A8B-84CD-2773F597186A2923AliveTUMOR FREEYESYES8122010TCGA-AO-A129-F19415C40939D7-1F54-4652-BEEF-94586A5F9051Scheduled Follow-up SubmissionYESYESAlive3286TUMOR FREENO12122011,NOTCGA-EW-A6SD-D710308617823B-CDC1-4292-A1A7-F1D9B9ABBA7386198ChemotherapyTCHNO1432015,TCGA-EW-A6SD-R71031DD24B5DA-6930-49C2-80AD-BC5FF24B767B239288External4623Primary Tumor FieldNO1432015
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,546.0,WHITE,TCGA-A8-A093,A8,A093,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.6767578125,CAP scoring guideline 2010,image cytometry,Right,2.174199218749985,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Surgical resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.37890625,0.0,Allred Score,0,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,131.1474609375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,54,"LungBoneLiverOther, specifyskin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.23,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES275Distant MetastasisLung,27,5,2011,TCGA-A8-A093-F40555376223F3-2A05-4951-B83B-C798FF047DFDNOYESYESTUMOR FREEAlive546NO2322013,NOTCGA-A8-A093-D3775553987C58-785E-4E57-B53F-0CBD9C1C357928Hormone TherapyTamoxifenn/aYES6122012,TCGA-A8-A093-R38155A04E3037-0795-4C6C-8BD3-D7C3FB72AF9B2859ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Dead,2965.0,2052.6787109375,WHITE,TCGA-B6-A0IH,B6,A0IH,No,YES,C50.9,8520/3,C50.9,1995.0,TUMOR FREE,YES,27.0,Image Analysis,Image Analysis,Left Upper Outer QuadrantLeft,1.6591503906249934,Axillary lymph node dissection alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Modified radical mastectomy,Excisional biopsy,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Equivocal,0.41015625,25.0,60,moderate,90-99%,Dako,Venten,221.3720703125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,1.78,"Other, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,2.2,4 Point Scale,2+,4thStage IIIAT3N1bM0,YES,YES,PositiveNegative1+,15,3,2011,TCGA-B6-A0IH-F12617A5FE44D8-EFB4-473A-B201-4E3502C030D9Scheduled Follow-up SubmissionYESYESDead2965262011,TCGA-E9-A24A-D3125764424F2D-62A0-41E3-AC8A-8D4380E0149C20mg/day9Hormone TherapyTamoxifenADJUVANTPOYES2542012,TCGA-A2-A0CL-R74195579f19f-ae39-4394-8043-dd64e58b60f8206255EXTERNAL BEAM11080cGy61Primary Tumor FieldADJUVANTNO13112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1827.0,BLACK OR AFRICAN AMERICAN,TCGA-A2-A0CL,A2,A0CL,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,14.0,H-SCORE 255,allred score 5 + 3 = 8,Right Lower Outer Quadrant,1.1,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Positive,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,9.0,allred score = 4,120,90-99%,Dako,DAKOHercepTest TM,189.5419921875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.57,Lung,20-29%,<10%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.7867382812499957,3.0,3 Point Scale,2+,6thStage IIIAT3N2aM0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",28,1,2011,TCGA-A2-A0CL-F14457CE691542-B93E-4911-B72C-B246A8887DA1Scheduled Follow-up SubmissionYESYESAlive1964TUMOR FREENO962011TCGA-A2-A0CL-F59313EC083639-8177-453D-8451-0BF534DE6082NOYESYESTUMOR FREEAlive3015NO852014,"1TCGA-A2-A0CL-D74086e17a5be-5bf0-4bf3-8e88-caab1ca38aed1006mg230-298mg4126168ChemotherapyTaxolADJUVANTIVNO31120112TCGA-A2-A0CL-D74097f7f933f-bab0-42a9-b14f-e3b8eaee28664080mg1020mg469112ChemotherapyCytoxanADJUVANTIVNO31120115TCGA-A2-A0CL-D74159ded5455-e05f-4b38-b10a-0accda9fdabb1mg505Hormone TherapyArimidexADJUVANTPOYES31120113TCGA-A2-A0CL-D741168e80464-73a4-4094-9487-d45dc4d516d7408mg102mg469112ChemotherapyAdriamycinADJUVANTIVNO31120116TCGA-A2-A0CL-D74178844d562-a5b6-4ebb-9006-a8eba7177d294mg752Other, specify in notesBisphosphonateZometaOTHER, SPECIFY IN NOTESMaintenance (for osteopenia)IVYES31120114TCGA-A2-A0CL-D7412c002a4ce-ae2a-4c04-9941-a4fa99d9366610mg269504Hormone TherapyTamoxifenADJUVANTPONO3112011YESTCGA-A2-A0CL-D397843CD728D5-9818-47B3-AED9-099463BAC77E126168ChemotherapyGemcitabineAntimetaboliteNOComplete Response122013",TCGA-A2-A0CL-R74195579f19f-ae39-4394-8043-dd64e58b60f8206255EXTERNAL BEAM11080cGy61Primary Tumor FieldADJUVANTNO13112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2923.0,WHITE,TCGA-AO-A129,AO,A129,No,YES,C50.9,8500/3,C50.9,2002.0,TUMOR FREE,YES,21.0,Allred 0 = 0+0,Allred score 0+0 = 0,Left Lower Outer QuadrantLeft,1.0,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast Reexcision,Other,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,0,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Negative,Negative,0.4248046875,2.0,230,STRONG,<10%,CISH,3+ Positive,31.0,Vysis AutoVysion System,>=2.0 Positive,NO,YES,49,LungBone,<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,52,3 Point Scale,1+,5thStage IIBT2N1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,12,2010,TCGA-AO-A129-F588263E8194B-C67D-4A8B-84CD-2773F597186A2923AliveTUMOR FREEYESYES8122010TCGA-AO-A129-F19415C40939D7-1F54-4652-BEEF-94586A5F9051Scheduled Follow-up SubmissionYESYESAlive3286TUMOR FREENO12122011,1TCGA-AO-A129-D59502c562434-088f-444b-82ca-9ad77b8fdaa2175mg/m2467162ChemotherapyPaclitaxelADJUVANTIVNO10120111TCGA-AO-A129-D5947592cacd9-a024-4b2d-a780-d45766869b1a600mg/m2467162ChemotherapyCyclophosphamideADJUVANTIVNO10120111TCGA-AO-A129-D59497a4726f6-1df6-4d6c-af20-b2116488289460mg/m2467162ChemotherapyDoxorubicinADJUVANTIVNO1012011,TCGA-AO-A129-R58830417042c-5493-4b8d-b969-7077215b602d216246EXTERNAL BEAMRegional siteADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,167.0,WHITE,TCGA-D8-A1Y0,D8,A1Y0,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,15.0,manual counting,manual counting,Left,1.2757519531250023,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Incisional Biopsy,Lumpectomy,Negative,Positive,Negative,0.380859375,9.0,>75%,>75%,10-19%,Hercep Test  TM Dako,Dako Hercept test,84.2294921875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,3.0,"Other, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,5,3 Point Scale,2+,7thStage IIIAT1cN2aMX,YES,YES,YES994Distant MetastasisBoneNOYESYES,9,6,2011,TCGA-D8-A1Y0-F30080A1CF1328-C069-4C74-80C9-4C569F082DC1Scheduled Follow-up SubmissionYESYESAlive472TUMOR FREENO242012,TCGA-D8-A1Y0-D30083E9799A77-D625-4619-8775-110F09A13235mg20mg/day540Hormone TherapytamoxipheneADJUVANTPOYES242012TCGA-D8-A1Y0-D300822E4B995D-B134-417F-8651-39114BCED4625820+349.2+5820mg970+58.2+970mg/day662167Chemotherapycyclophosphamide+methotrexatum+fluorouracillumADJUVANTIVNO242012,TCGA-D8-A1Y0-R30081432151C6-E47F-4973-B1B2-57622A49678E201232EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO242012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1103.0,WHITE,TCGA-AR-A1AX,AR,A1AX,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,8.0,Allred score 0+0 = 0,Image Analysis,Left Upper Inner QuadrantLeft Upper Outer Quadrant,1.285097656249998,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Mastectomy NOS,Wide local excision,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,3+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Positive,0.0419921875,0.0,Allred score = 0,Allred score = 0,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,49.9482421875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.6,"Other, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,3.8,3 Point Scale,2+,6thStage IT1N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,14,6,2011,TCGA-AR-A1AX-F22140ED2AD3DF-F314-4146-A0BA-B3C01F970ED9Scheduled Follow-up SubmissionYESYESAlive1103NO132012TCGA-AR-A1AX-F494803C2C45B7-1BAB-4945-8691-5213ECC2496ANOYESYESTUMOR FREEAlive1890NO2102013TCGA-AR-A1AX-F717201A4724BC-BF17-4BE0-B7A2-9BD4E3960306NOYESYESTUMOR FREEAlive2629NO3032015,2TCGA-AR-A1AX-D221458B22C59E-5DAE-4372-A2A9-CD57D6D84D532mg/kg117482ImmunotherapyTrastuzumabADJUVANTIVNO1320124TCGA-AR-A1AX-D22147B73644E2-BE84-462A-8A8A-7DD3B10963702.5mg/day341Hormone TherapyLetrozoleADJUVANTPOYES1320121TCGA-AR-A1AX-D2214434AD7E93-C4C1-4D25-AB5B-2DB9F3864B854160ChemotherapyPaclitaxelADJUVANTNO1320121TCGA-AR-A1AX-D221439E6B462C-33CD-4914-B565-BF5F728AA385454ChemotherapyCytoxanADJUVANTNO1320123TCGA-AR-A1AX-D22146D3CAF54C-B16D-4B4C-BB7E-85033DB79E0E25mg/day249295Hormone TherapyExemestaneADJUVANTPONO1320121TCGA-AR-A1AX-D22142EBFA7185-C765-4E3A-95B6-F841E01AD17C454ChemotherapyDoxorubicinADJUVANTNO132012,TCGA-AR-A1AX-R22141FD178C27-E6A3-460C-95B5-BB1D1CC94E82194242EXTERNAL BEAM6060cGy33Primary Tumor FieldADJUVANTNO1132012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,11.0,WHITE,TCGA-E9-A24A,E9,A24A,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,% IHC,Allred score 0+0 = 0,Right Upper Outer Quadrant,1.295224609374997,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,"Other method, specify:",Lumpectomy,Negative,Positive,Negative,0.177734375,1.0,Allred Score 6,180,90-99%,Dako,CAP scoring guideline 2010,359.0849609375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,74,"Other, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,2.0,3 Point Scale,2+,7thStage IIAT1cN1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,22,3,2011,TCGA-E9-A24A-F31256BC9E264C-D8AE-4A8A-B55A-DCE0DAB97FBBScheduled Follow-up SubmissionYESYESAlive322TUMOR FREENO2542012TCGA-E9-A24A-F39541CE71B1A0-DB97-48A0-913F-05CD15EED1C9YESYESYESTUMOR FREEAlive747NO2412013,TCGA-E9-A24A-D3125764424F2D-62A0-41E3-AC8A-8D4380E0149C20mg/day9Hormone TherapyTamoxifenADJUVANTPOYES2542012,TCGA-E9-A24A-R31258048982EB-6799-422D-B7D8-045CE8B2D0323565EXTERNAL BEAM4000cGy20Primary Tumor FieldADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,516.0,WHITE,TCGA-BH-A0HN,BH,A0HN,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,H-SCORE 300,H-SCORE 290,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft,1.13,Sentinel node biopsy alone,Pateys surgery,Other,Re-Excision of Superior Margin,Mastectomy NOS,Segmental mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.482421875,0.0,H-SCORE,H-SCORE,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,40.0,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,1.78,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,2.0,3 Point Scale,3+,Stage IAT1cN0 (i-)M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,11,2010,TCGA-BH-A0HN-F4811979C6837-237A-4101-B902-FBDC71C7C474516AliveTUMOR FREENOYES16112010,1TCGA-BH-A0HN-D4810606F5F31-0DDC-48DB-954F-474604A3B7ED1mg/day82Hormone TherapyARIMIDEXADJUVANTPOYES17112010,TCGA-BH-A0DQ-R455954780F16-C78A-4736-AE8D-0FDF2D5C1D37329377EXTERNAL BEAM6040cGyPrimary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,172.0,WHITE,TCGA-D8-A143,D8,A143,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,11.0,% IHC,%IHC,Left Lower Inner Quadrant,1.8618359374999889,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Surgical resection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Negative,Negative,0.09375,0.0,Allred score = 5,H-Score,90-99%,FISH,CAP SCORING GUIDELINE 2010,131.69921875,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.38,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,90-99%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,2.0333593750000016,2.2,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",25,2,2011,TCGA-D8-A143-F13817A3F360DB-0BEF-4CC5-8175-D859A234AF9EScheduled Follow-up SubmissionNOYESAlive431TUMOR FREENO472011,ACTCGA-D8-A143-D13818786A632D-1981-4D67-B28C-DFEA95E74CCAmg/m260mg/m2667172ChemotherapydoxorubicinADJUVANTIVNO472011NOTCGA-D8-A143-D64910655A6770-6A40-4D7C-9453-094F1830916867172ChemotherapycyclophosphamideNO1592014,TCGA-BH-A0DQ-R455954780F16-C78A-4736-AE8D-0FDF2D5C1D37329377EXTERNAL BEAM6040cGyPrimary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,98.0,WHITE,TCGA-BH-A0DQ,BH,A0DQ,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,25.0,H-SCORE 136,H-SCORE 140,Right Upper Inner QuadrantRight,1.2551269531250049,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,1+,0,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.564453125,1.0,H-SCORE,H-SCORE,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,39.498046875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,64,LungBone,60-69%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,172,3 Point Scale,1+,Stage IIBT2N1M0,NO,YES,YES994Distant MetastasisBoneNOYESYES,9,11,2010,TCGA-BH-A0DQ-F4560CDBA9234-AC86-44D5-A25D-CDFA2E27F36D98AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0DQ-D4554B62A0DC1-F5F2-4A14-B4F0-D5F688D2387C4141204ChemotherapyDOXORUBICINADJUVANTIVNO171120101TCGA-BH-A0DQ-D4541A7564051-9FF3-4CF9-8103-E8F1EA0304754141204ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO171120101TCGA-BH-A0DQ-D45569B9ED158-839A-41DD-A7B0-844FA3D347A212225309ChemotherapyTAXOLADJUVANTIVNO30112010,TCGA-BH-A0DQ-R455954780F16-C78A-4736-AE8D-0FDF2D5C1D37329377EXTERNAL BEAM6040cGyPrimary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,31.0,WHITE,TCGA-A8-A09C,A8,A09C,No,YES,C50.9,8500/3,C50.9,2009.0,WITH TUMOR,YES,7.9306640625,allred score 5+3=8,allred score 5+3+8,Right,1.7592675781249922,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,Surgical resection,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,0,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.2783203125,2.0537109375,MODERATE,Allred Score 7,10-19%,ACIS,CAP SCORING GUIDELINE 2010,119.453125,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,54,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,1.9,3 Point Scale,3+,6thStage XT2N0MX,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",27,5,2011,TCGA-BH-A0DQ-F4560CDBA9234-AC86-44D5-A25D-CDFA2E27F36D98AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0DQ-D4554B62A0DC1-F5F2-4A14-B4F0-D5F688D2387C4141204ChemotherapyDOXORUBICINADJUVANTIVNO171120101TCGA-BH-A0DQ-D4541A7564051-9FF3-4CF9-8103-E8F1EA0304754141204ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO171120101TCGA-BH-A0DQ-D45569B9ED158-839A-41DD-A7B0-844FA3D347A212225309ChemotherapyTAXOLADJUVANTIVNO30112010,TCGA-BH-A0DQ-R455954780F16-C78A-4736-AE8D-0FDF2D5C1D37329377EXTERNAL BEAM6040cGyPrimary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,19.0,WHITE,TCGA-AN-A049,AN,A049,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,9.0,Allred (Biocare),Allred (Biocare),Left Upper Outer Quadrant,2.379677734374991,No axillary staging,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,0,Negative,Positive,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,100,80,40-49%,0,Dako Hercept test,129.9443359375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,160,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,125,3 Point Scale,2+,Stage IIAT2N0M0,YES,NO,YES994Distant MetastasisBoneNOYESYES,29,12,2010,TCGA-AN-A049-F68978FE2AC366-DA1D-44C8-ACF7-B1703E8DAFC4YESTUMOR FREEAlive1924122014,2TCGA-AR-A1AX-D221458B22C59E-5DAE-4372-A2A9-CD57D6D84D532mg/kg117482ImmunotherapyTrastuzumabADJUVANTIVNO1320124TCGA-AR-A1AX-D22147B73644E2-BE84-462A-8A8A-7DD3B10963702.5mg/day341Hormone TherapyLetrozoleADJUVANTPOYES1320121TCGA-AR-A1AX-D2214434AD7E93-C4C1-4D25-AB5B-2DB9F3864B854160ChemotherapyPaclitaxelADJUVANTNO1320121TCGA-AR-A1AX-D221439E6B462C-33CD-4914-B565-BF5F728AA385454ChemotherapyCytoxanADJUVANTNO1320123TCGA-AR-A1AX-D22146D3CAF54C-B16D-4B4C-BB7E-85033DB79E0E25mg/day249295Hormone TherapyExemestaneADJUVANTPONO1320121TCGA-AR-A1AX-D22142EBFA7185-C765-4E3A-95B6-F841E01AD17C454ChemotherapyDoxorubicinADJUVANTNO132012,TCGA-AR-A2LH-R37176C1A492A6-382A-4863-9A54-E60996E31148214External5000Gy25Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,16.0,WHITE,TCGA-E9-A226,E9,A226,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,allred score 5+3=8,IHC,Left Lower Inner Quadrant,1.1966894531249996,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Excision,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),Patey's Suregery,Negative,Positive,Equivocal,0.1572265625,6.0,100,250,<10%,Hercep Test  TM Dako,Hercep Test  TM Dako,57.3662109375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,2.8,"Other, specifyskin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.0333593750000016,172,4 Point Scale,1+,7thStage IIIAT2N2M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,3,8,2011,TCGA-E9-A226-F2995313947F51-BAED-4F88-969D-895B7BFFB55DScheduled Follow-up SubmissionYESYESAlive628TUMOR FREENO1712013TCGA-E9-A226-F395362E5DFE54-8DD8-45DF-AAE0-4C72C600C8A0NOYESYESWITH TUMORAlive1038YES790Distant MetastasisBoneNONOYES790Distant MetastasisLiverNONOYES2412013TCGA-E9-A226-F70682EFB0AAEA-6DB2-48ED-AB3F-020003E15D87NOYESYESWITH TUMORDead1048NO232015,TCGA-E9-A226-D299577D35CA2D-3C41-4DC3-BFFD-515E87E1796320mg/day13Hormone TherapyTamoxifenADJUVANTPOYES3032012TCGA-E9-A226-D29956DC196A0E-9253-4AAA-9BAB-196614D5855F9600mg1600mg613205ChemotherapyCyclophosphamideADJUVANTIVNO3032012TCGA-E9-A226-D2995423AD3108-BB86-4392-9D2B-0F09E09F978D7000mg2000613205Chemotherapy5-FluorouracilADJUVANTIVNO3032012TCGA-E9-A226-D2995563D2FA20-DF70-4A44-AF1C-A0C2D389F79A500mg100mg613205ChemotherapyDoxorubicinADJUVANTIVNO3032012NOTCGA-E9-A226-D558872C88B47F-36AA-43AF-95BB-33939622235F790937AncillaryPamidronateNOPartial Response1712014,TCGA-E9-A226-R299580516AC70-E0BC-4A79-B7E7-95CC9ED41DE094117EXTERNAL BEAM4000cGy20Regional siteADJUVANTNO3032012
TCGAFPPP,Breast,No,FEMALE,Dead,616.0,1960.455078125,WHITE,TCGA-AR-A2LH,AR,A2LH,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,39.0,CAP scoring guideline 2010,Allred score 5+3 = 8,Right Upper Outer Quadrant,3.334785156249989,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Right Breast Reexcision,Other,Segmental Mastectomy,Infiltrating Lobular Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Negative,Equivocal,0.60546875,29.0,Allred score 8,8,90-99%,Dako,DAKOHercepTest TM,432.11328125,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,69,BoneLiver,70-79%,70-79%,Positive,70-79%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.9174609375000005,1.9,4 Point Scale,2+,6thStage IIIT3N3M0,YES,YES,PositivePositiveNegativeNegative,12,1,2012,TCGA-AR-A2LH-F351650F86B9CC-D89A-47B8-A9D1-60EA8626DB04NOYESYESDead616YES434Distant MetastasisBone434Liver6122012,NOTCGA-AR-A2LH-D371750674353C-7BE2-4FF0-952E-236E7F1BCB934284ChemotherapyAdriamycinNO6122012NOTCGA-AR-A2LH-D3726002991FAB-6700-40A7-86F6-5C1C3507F3364284ChemotherapyCytoxanNO6122012NOTCGA-AR-A2LH-D3726140102DFF-32EF-4C9C-B97B-78B3CC02F99098140ChemotherapyPaclitaxelNO6122012,TCGA-AR-A2LH-R37176C1A492A6-382A-4863-9A54-E60996E31148214External5000Gy25Primary Tumor FieldNO6122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2009.0,WHITE,TCGA-AR-A24Q,AR,A24Q,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,2.0,Allred score 0+0 = 0,manual counting,Left Upper Inner Quadrant,1.2459082031249995,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Re-Excision of Superior Margin,Mastectomy NOS,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.078125,0.0,Allred score = 8,Allred score = 0,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,90.7783203125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.924199218749999,52,3 Point Scale,2+,6thStage IIBT3N0M0,YES,YES,"YES1516Locoregional RecurrenceOther, specifybreastNONOYESNegative<10%4 Point Scale1+Negative<10%4 Point Scale1+Negative<10%1+",30,8,2011,TCGA-AR-A24Q-F314057D993A0B-8469-4F77-BA53-8C25B48FD3B4Scheduled Follow-up SubmissionYESYESAlive3088NO252012TCGA-AR-A24Q-F494958704C7B2-E9AF-4A4A-813B-1B4FB8257422NOYESYESTUMOR FREEAlive3088NO2102013TCGA-AR-A24Q-F650678F8E0B9B-7D99-4B11-A510-C4DEC6682EF2NOYESYESTUMOR FREEAlive3172NO1892014TCGA-AR-A24Q-F658024516B9C5-D979-4A2D-837C-5E9079FAAD42NOYESYESTUMOR FREEAlive3172NO3092014,2TCGA-AR-A24Q-D31414F76C3A55-BA43-4C18-A156-8B352AE003021400mg2mg/kg486155ImmunotherapyTrastuzumabADJUVANTIVNO2520122TCGA-AR-A24Q-D314164476480D-D2D0-4265-8B55-C8622DC760467387mg6mg/kg14180511ImmunotherapyTrastuzumabADJUVANTIVNO2520121TCGA-AR-A24Q-D3140841C3CA51-2FA0-4FB2-B09E-5A39902B85FC220mg60mg/m223650ChemotherapyDoxorubicinADJUVANTIVNO2520123TCGA-AR-A24Q-D31418C01824C6-29F9-492F-9DA8-E9A25BD344921mg/day2081988Hormone TherapyAnastrozoleADJUVANTPONO2520121TCGA-AR-A24Q-D31409AA34E461-7470-4313-A778-7199FB3B12DF2210mg600mg/m223650ChemotherapyCytoxanADJUVANTIVNO2520121TCGA-AR-A24Q-D31410ECA92825-C9DC-44DF-A73D-AA6635A1F2B3310mg90mg/m2179155ChemotherapyPaclitaxelADJUVANTIVNO2520121TCGA-AR-A24Q-D31413BFC7D7CA-0605-47AB-8BD1-36E53660AD7F260mg4mg/kg7979ImmunotherapyTrastuzumabADJUVANTIVNO2520121TCGA-AR-A24Q-D3141204E1D133-F414-45DA-8B0A-F0508DAE0713970mg60mg/m2387155ChemotherapyDocetaxelADJUVANTIVNO252012,TCGA-AR-A24Q-R3140694DB3EB1-1ED0-4F5D-AA78-0482FB31D9FF196230EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1252012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,330.0,WHITE,TCGA-E2-A15R,E2,A15R,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,4.0,Allred score 5+3 = 8,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.3,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Re-Excision of Superior Margin,Mastectomy NOS,total mastectomy,Infiltrating Ductal Carcinoma,Ductal/Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.419921875,3.0,Allred score = 4,Allred score = 8,10-19%,Dako,Venten,65.5791015625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.9,"Other, specifyaxilaary node negative but intrammary node positive",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.812343749999996,2.4,3 Point Scale,2+,7thStage IIAT1cN1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,14,4,2011,TCGA-E2-A15R-F191702324E485-E1D1-4060-BC35-34CC59F89FD8Scheduled Follow-up SubmissionYESYESAlive519TUMOR FREENO16112011TCGA-E2-A15R-F70011942E79FF-F95B-4D03-A700-778F79C4083ANOYESYESTUMOR FREEAlive1732NO922015,01TCGA-E2-A15R-D1917128619333-01BE-42CB-9524-04AFE22A9D843600mg900mg492134ChemotherapycyclophosphamideADJUVANTIVNO1611201101TCGA-E2-A15R-D1917214E71F28-E7FC-4F5A-AAB3-781734D03604360mg90mg492134ChemotherapydoxorubicinADJUVANTIVNO1611201103TCGA-E2-A15R-D191741A8B3B00-0153-4DD2-8AC8-804B467C84CFmg1mg/day266Hormone TherapyarimidexADJUVANTPOYES1611201102TCGA-E2-A15R-D191731B56D8BF-E538-4CCC-B9F5-1F7CC5EA63661072mg268mg4148197ChemotherapypaclitaxelADJUVANTIVNO16112011,TCGA-E2-A15R-R19175DD5ECAD9-B60E-43D2-A390-69CCC0C71FD3218267EXTERNAL BEAM5900cGy33Regional siteADJUVANTNO0116112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,497.0,WHITE,TCGA-E2-A15C,E2,A15C,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.0,CAP scoring guideline 2010,Allred (Biocare),Right Lower Outer Quadrant,1.02,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Right Breast Reexcision,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.3857421875,0.0,Allred score = 4,0,20-29%,Dako,CAP scoring guideline 2010,53.310546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,54,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.9215039062499983,79,3 Point Scale,2+,6thStage IT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,13,4,2011,TCGA-E2-A15C-F18935C22968BC-CE2C-417D-B613-7801B0F89A52Scheduled Follow-up SubmissionYESYESAlive694TUMOR FREENO9112011,1TCGA-E2-A15C-D18936057D51BB-CBBC-401E-BB09-3E7A10ADCA74mg1mg/day65Hormone TherapyarimidexADJUVANTPOYES9112011,TCGA-E2-A15C-R18937B2859F7D-EF4C-413B-BDF2-D76014910FBF55102EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO19112011
TCGAFPPP,Breast,No,FEMALE,Dead,1430.0,1303.6796875,WHITE,TCGA-PE-A5DC,PE,A5DC,No,YES,C50.9,8520/3,C50.9,2005.0,TUMOR FREE,YES,31.0,H-Score 300,allred score 5+3+8,Right Upper Inner Quadrant,1.8662695312499944,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,Left segmental mastectomy with axillary lymph node dissection,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,SKIN BIOPSY,Negative,Positive,Positive,0.0791015625,5.0,allred score =  8,250,10-19%,ACIS,Dako Hercept test,72.08984375,HER2 amplification - negative,PathVysion,NO,YES,50,"Other, specifyaxilaary node negative but intrammary node positive",80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,2.1613867187500007,61,3 Point Scale,2+,6thStage IIIAT2N2aM0,YES,YES,NO,30,4,2013,TCGA-E2-A15C-F18935C22968BC-CE2C-417D-B613-7801B0F89A52Scheduled Follow-up SubmissionYESYESAlive694TUMOR FREENO9112011,2TCGA-AR-A24Q-D31414F76C3A55-BA43-4C18-A156-8B352AE003021400mg2mg/kg486155ImmunotherapyTrastuzumabADJUVANTIVNO2520122TCGA-AR-A24Q-D314164476480D-D2D0-4265-8B55-C8622DC760467387mg6mg/kg14180511ImmunotherapyTrastuzumabADJUVANTIVNO2520121TCGA-AR-A24Q-D3140841C3CA51-2FA0-4FB2-B09E-5A39902B85FC220mg60mg/m223650ChemotherapyDoxorubicinADJUVANTIVNO2520123TCGA-AR-A24Q-D31418C01824C6-29F9-492F-9DA8-E9A25BD344921mg/day2081988Hormone TherapyAnastrozoleADJUVANTPONO2520121TCGA-AR-A24Q-D31409AA34E461-7470-4313-A778-7199FB3B12DF2210mg600mg/m223650ChemotherapyCytoxanADJUVANTIVNO2520121TCGA-AR-A24Q-D31410ECA92825-C9DC-44DF-A73D-AA6635A1F2B3310mg90mg/m2179155ChemotherapyPaclitaxelADJUVANTIVNO2520121TCGA-AR-A24Q-D31413BFC7D7CA-0605-47AB-8BD1-36E53660AD7F260mg4mg/kg7979ImmunotherapyTrastuzumabADJUVANTIVNO2520121TCGA-AR-A24Q-D3141204E1D133-F414-45DA-8B0A-F0508DAE0713970mg60mg/m2387155ChemotherapyDocetaxelADJUVANTIVNO252012,TCGA-AR-A24Q-R3140694DB3EB1-1ED0-4F5D-AA78-0482FB31D9FF196230EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1252012
TCGAFPPP,Breast,Yes,FEMALE,Dead,749.0,4602.8232421875,WHITE,TCGA-B6-A0I8,B6,A0I8,No,YES,C50.9,8500/3,C50.9,1992.0,WITH TUMOR,YES,0.0,Allred score 0+0 = 0,%IHC,Right Upper Inner QuadrantRight,1.2620214843749986,No axillary staging,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,"Other method, specify:","Biopsy, NOS",Negative,Positive,Equivocal,0.5869140625,4.556640625,Allred score 7 per outside facility report,moderate,10-19%,ACIS,dextran coated charcoal,71.5048828125,Vysis AutoVysion System,CAP SCORING GUIDELINE 2010,NO,YES,2.13,LungBone,80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.944414062499999,71,4 Point Scale,1+,4thStage XT1NXM0,YES,YES,PositivePositiveNegative,2,11,2010,"TCGA-B6-A0I8-F12607939A3148-247E-4863-9E71-A8EB0B343009Scheduled Follow-up SubmissionNOYESDead749WITH TUMORYES746Locoregional DiseaseOther, specifyPectoral muscleYES746YESYES162011",1TCGA-BH-A0H7-D47153A96F8DB-2BB6-4F01-A332-0CC10127499B1mg/day298Hormone TherapyARIMIDEXADJUVANTPOYES171120101TCGA-BH-A0H7-D47170D085B7B-5316-41F0-9FF4-0EF4C547C459344mg86mg485148ChemotherapyDOXORUBICINADJUVANTIVNO181120101TCGA-BH-A0H7-D47288C760D86-7F32-4842-8DB0-ADAFD53EA4146120mg765mg885232ChemotherapyBEVACIZUMAB (AVASTIN)/PLACEBO PROVIDED BY STUDYADJUVANTIVNO181120101TCGA-BH-A0H7-D4726C42E6C62-C1C9-46D9-B3BB-217B83E7D2ED1380mg115mg12169246ChemotherapyPACLITAXELADJUVANTIVNO181120101TCGA-BH-A0H7-D4719F4A15B10-F974-4196-AC98-13A14F2D66213440mg860mg485148ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO18112010,TCGA-E2-A153-R1895509529206-8504-42D1-A155-E1C6D5539359237294EXTERNAL BEAM6040cGy33Regional siteADJUVANTNO18112011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,554.0,WHITE,TCGA-BH-A0BD,BH,A0BD,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,9.0,H-Score-190,H-Score-230,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft,1.4123535156250062,Sentinel lymph node biopsy plus axillary dissection,SLN and non-SLN biopsy,Other,Re-Excision of Superior Margin,Mastectomy NOS,segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.203125,2.0,H-Score,H-Score,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,60.09375,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,1.78,"LungOther, specifyleft adrenal gland",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,5,3 Point Scale,1+,6thStage IIAT1cN1aM0,NO,YES,YES766Distant MetastasisBoneNOYESNO,4,11,2010,TCGA-BH-A0BD-F15423E292A040-7F71-48F6-83E4-1D0BF934EF28Scheduled Follow-up SubmissionYESYESAlive554TUMOR FREENO4112010,1TCGA-BH-A0BD-D15425A100360C-297C-429F-B00F-42AC189E7E5B522mg86mg661166ChemotherapyDoxorubicinADJUVANTIVNO41120101TCGA-BH-A0BD-D15424C55EEF50-995F-4293-B338-42772744791A20mg/day244Hormone TherapyTamoxifenADJUVANTPOYES41120101TCGA-BH-A0BD-D1542640280B62-391E-46AB-BDFE-BCF96BA2B2A75230mg865mg661166ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO4112010,TCGA-BH-A0BD-R15427BD660DD1-5058-42E5-A3E2-C3B039B665B4196247EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,457.0,WHITE,TCGA-A8-A09V,A8,A09V,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,5.0322265625,image cytometry,Allred score 0+0=0,Right Upper Inner Quadrant,2.2564843749999928,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Lobular Carcinoma,Invasive tubulolobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,0,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.640625,0.0,Allred Score 3,allred score = 8,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,117.1962890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.6,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,2.8,3 Point Scale,2+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A09V-F403280021AB34-8C5F-451E-8B64-DF949CB50034NOYESYESTUMOR FREEAlive457NO1722013,NOTCGA-A8-A09V-D379034BD8862A-EC1F-43A3-8343-7616B73F5DB5123Hormone TherapyTamoxifenYES6122012,TCGA-A8-A09V-R3819319729E19-9B06-4822-85A2-5D7A869767643192ExternalPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1217.0,WHITE,TCGA-A8-A08Z,A8,A08Z,No,YES,C50.9,8500/3,C50.9,2004.0,TUMOR FREE,YES,11.4892578125,image cytometry,Allred score 0+0=0,Left,1.6224609374999897,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.392578125,3.8642578125,Allred score 8,Allred score = 7,10-19%,ACIS,CAP SCORING GUIDELINE 2010,120.6240234375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,54,LungBone,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,5,3 Point Scale,3+,6thT4bN3aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-E9-A1R0-F297956DD81350-F039-458B-A58D-50192EE6C328Scheduled Follow-up SubmissionNOYESAlive435TUMOR FREENO2932012TCGA-E9-A1R0-F41214AD367CF1-62C6-4796-AB47-569755FE6836NONOYESTUMOR FREEAlive860NO1332013,NOTCGA-AR-A254-D31890276D5F77-4A5C-4323-9158-72968222455E2243ChemotherapyPaclitaxelNO2352012NOTCGA-AR-A254-D318913895A0CD-D7A0-4299-AA1D-0CDB266065425099ChemotherapyAbraxaneNO2352012NOTCGA-AR-A254-D3189233D981C7-C2D3-4B84-B64B-267D0B560FC1106173ChemotherapyFluorouracilNO2352012NOTCGA-AR-A254-D318938811257C-6F1A-45B1-93CF-66DB671186E7106170ChemotherapyEpirubicinNO2352012NOTCGA-AR-A254-D31895A0A91D98-9C6D-4F84-8E0F-B7124F907FAB106170ChemotherapyCytoxanNO2352012NOTCGA-AR-A254-D31896ADB0D2AC-132B-4083-91AF-52B43CA173F32222ImmunotherapyTrastuzumabNO2352012NOTCGA-AR-A254-D318970197F934-6D0A-489C-BB0C-B8BB754191DE29184ImmunotherapyTrastuzumabNO2352012NOTCGA-AR-A254-D318987B1B7CB1-6836-4211-916E-AFF61B5EC621232344ImmunotherapyTrastuzumabNO2352012NOTCGA-AR-A254-D3189982C6D00C-ABFC-4885-88F3-5A4E67579462262Hormone TherapyTamoxifenYES2352012,TCGA-GM-A3XG-R355112085DEFE-099C-42C0-92EF-DF939B5A7AEF372415External60Gy30Primary Tumor FieldNOComplete Response1102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,268.0,WHITE,TCGA-A2-A0YL,A2,A0YL,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,29.0,Allred score 5+3= 8,Allred score 5+3=8,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft Lower Inner QuadrantLeft Lower Outer Quadrant,3.255605468749984,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Simple Mastectomy,Reexcision of segmental mastectomy,Other,TOTAL MASTECTOMY,Infiltrating Lobular Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Positive,Positive,Negative,0.0,4.0,8,8,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,84.845703125,Vysis AutoVysion System,Ratio >=2.0,NO,YES,4.43,"Other, specifySkin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,145,3 Point Scale,3+,Stage IIIAT3N2aM0,YES,NO,YES766Distant MetastasisBoneNOYESNO,27,12,2010,TCGA-A2-A0YL-F16749A6C1DE45-CB75-45AE-9712-C35C9D111F3BScheduled Follow-up SubmissionYESYESAlive445TUMOR FREENO1692011TCGA-A2-A0YL-F593871DAD0270-FD03-455C-9A03-28C55A7DC2B7NOYESYESTUMOR FREEAlive1474NO1252014,1TCGA-A2-A0YL-D581415d20bc4-14c3-4ec8-8005-389f518e1ac05640mg940mg650154ChemotherapyCytoxanADJUVANTIVNO281220103TCGA-A2-A0YL-D5816e0eb6325-2068-4cbc-83a8-228079ff9e5f840mg140mg650154ChemotherapyTaxotereADJUVANTIVNO281220102TCGA-A2-A0YL-D58159f659c06-6017-43f8-b229-7164566871f4564mg94mg650154ChemotherapyAdriamycinADJUVANTIVNO281220104TCGA-A2-A0YL-D581757d63ce1-4d7f-430f-930c-e6605a768c001mg177Hormone TherapyArimidexADJUVANTPOYES28122010,TCGA-A2-A0YL-R581345b399c8-8af8-4a9a-9507-682af704063e177224EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO128122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,786.0,WHITE,TCGA-A2-A0D1,A2,A0D1,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,H-SCORE 136,allred score 5 +3 = 8,Left Lower Inner Quadrant,5.5,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,3+,Negative,Negative,Core needle biopsy,Biopsy not specified,Positive,Negative,Positive,0.0,0.0,Intensity=Weak,Intensity=Weak,10-19%,Hercep Test  TM Dako,DAKOHercepTest TM,87.5556640625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.7,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,816,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,9,2010,TCGA-A2-A0D1-F1373300808159-4015-4B79-B29A-1BBE85BF2CF2Scheduled Follow-up SubmissionYESYESAlive1051TUMOR FREENO962011,1TCGA-A2-A0D1-D1836051e5eee-d34e-496f-bd8f-bdb8f99368a0140mg140mg17979ChemotherapyTaxotereADJUVANTIVNO21920104TCGA-A2-A0D1-D1840cb590dde-3e1f-4b38-a4fb-a6a1fc7eb4cc1600mg176-180mg3 cycles (9 doses)131201ChemotherapyAbraxaneADJUVANTIVNO21920102TCGA-A2-A0D1-D1837883b03cb-e338-4344-822c-fd144c3d5280366mg366mg17979ChemotherapyCarboplatinADJUVANTIVNO21920103TCGA-A2-A0D1-D18386ef785f5-54a6-46b8-a1bd-09fe99c2ed9a6575mg135-600mg23 doses79428Targeted Molecular therapyHerceptinADJUVANTIVNO2192010,TCGA-A2-A0D1-R1835699a1213-cb1d-4281-8197-7c2e6d3ed2d3252296EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO12192010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3827.0,WHITE,TCGA-B6-A0I2,B6,A0I2,No,YES,C50.9,8500/3,C50.9,1995.0,TUMOR FREE,YES,8.0,% IHC,Allred score 0+0 = 0,Left Upper Outer QuadrantLeft,1.4598339843749968,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,intraoperative examination,Negative,Negative,Equivocal,0.4384765625,0.0,Intensity=Strong,H score,10-19%,ACIS,dextran coated charcoal,75.921875,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,54,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.3,4 Point Scale,1+,4thStage IAT1cN0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,2,11,2010,TCGA-B6-A0I2-F1263057FE226B-27F7-407B-81E0-EB90A79DC9DBScheduled Follow-up SubmissionYESYESAlive4361TUMOR FREENO262011,2TCGA-A2-A0EX-D2011a18f54ee-33e5-4dc3-a61a-ba662d4e192d11.25mg3.75mg3172222Hormone TherapyLupronADJUVANTIMNO13820101TCGA-A2-A0EX-D2010e8a75fe6-b841-46ea-9bd8-51b5fe21c01e10 mgmg165Hormone TherapyTamoxifenADJUVANTPOYES13820103TCGA-A2-A0EX-D20122a817b25-0580-4742-b337-8cd0a8bfb1433.6 mg monthlymg273Hormone TherapyZoladexADJUVANTSCYES1382010,TCGA-B6-A3ZX-R409555B8D0E18-6490-40BE-80EC-6AD12BC416FA354386External200cGy25Primary Tumor FieldNO732013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1352.0,WHITE,TCGA-A2-A0SU,A2,A0SU,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,7.0,H-SCORE 136,H-Score 160,Left,1.523876953124992,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Reexcision of segmental mastectomy,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,1.0,0.0,allred score = 7,STRONG,<10%,ACIS,Hercep Test  TM Dako,84.7666015625,Vysis AutoVysion System,Ratio >=2.0,NO,YES,1.1,"Other, specifySkin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,71,3 Point Scale,2+,Stage IIAT2N0 (i+)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,17,11,2010,TCGA-A2-A0SU-F1395495DB2CB9-9078-478C-8496-948B59DEABE3Scheduled Follow-up SubmissionNOYESAlive1662TUMOR FREENO1272011,1TCGA-A2-A0SU-D398994ab7027-4e66-4e27-be4f-266bfe28933fmgmg93Hormone TherapyArimidexADJUVANTPOYES17112010,TCGA-GM-A3XG-R355112085DEFE-099C-42C0-92EF-DF939B5A7AEF372415External60Gy30Primary Tumor FieldNOComplete Response1102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,396.0,WHITE,TCGA-A8-A06P,A8,A06P,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,11.9345703125,allred score 5+3=8,Allred score 0+0=0,Right,2.0657714843749844,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.6513671875,3.69921875,MODERATE,Allred score = 7,10-19%,ACIS,Venten,130.3115234375,HER2 amplification - negative,>= 2.0 Positive,NO,YES,40,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.1,3 Point Scale,3+,6thStage IIIAT1cN2aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A06P-F40814F2C11286-6956-4C14-9C00-EE235CF900A8NOYESYESTUMOR FREEAlive396232013,NOTCGA-A8-A06P-D378945069E310-A864-427D-819F-D2601933A155Chemotherapy6122012NOTCGA-A8-A06P-D3789531453368-BCF6-42B5-AAC7-78DADCD6A50BHormone TherapyTamoxifen6122012,TCGA-A8-A06P-R3819032B9AD47-AE11-4A7B-B3A9-67D64A1A732FExternalPrimary Tumor Field11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1150.0,WHITE,TCGA-AO-A0JB,AO,A0JB,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,14.0,H-SCORE 0,dextran coated charcoal,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft Lower Outer QuadrantLeft,2.357568359374996,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,4+,0,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,1.0,Allred Score 4,Allred Score 6,<10%,CISH,3+ POSITIVE,31.087890625,Vysis AutoVysion System,Pathvysion HER2 DNA Probe Kit,NO,YES,64,Lung,90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,71,3 Point Scale,2+,Stage IIIAT3N1aM0,YES,YES,YES766Distant MetastasisBoneNOYESNO,19,9,2010,TCGA-AO-A0JB-F31723E04D8C6-0459-478A-8CDF-B490BF3F9A081150AliveTUMOR FREEYESYES1992010TCGA-AO-A0JB-F154854E6D473B-DBDC-4AB0-B7CA-6C8E595DCB23Scheduled Follow-up SubmissionYESYESAlive1542TUMOR FREENO2282011,1TCGA-AO-A0JB-D31776ffc6760-7989-43cc-a868-cacb2893c6993680mg600mg/m244992ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO19920102TCGA-AO-A0JB-D3174f1f16a87-8aa3-4ab9-8872-f3dba71b6d9320mg/day175Hormone TherapyTAMOXIFENADJUVANTPOYES19920101TCGA-AO-A0JB-D3178f228c0ee-6d98-4cde-b962-c60cf3e590851080mg175mg/m24105147ChemotherapyPACLITAXELADJUVANTIVNO19920101TCGA-AO-A0JB-D3176c5d0586b-c47f-494b-94ac-41f12deeb702368mg60mg/m244992ChemotherapyDOXORUBICINADJUVANTIVNO1992010,TCGA-AO-A0JB-R31754696646b-a422-4344-a88d-d9e532419e43216253EXTERNAL BEAM15120cGy28Regional siteADJUVANTNO1692010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,4840.0,WHITE,TCGA-B6-A2IU,B6,A2IU,No,YES,C50.9,8520/3,C50.9,1998.0,TUMOR FREE,YES,28.0,image cytometry,image cytometry,Right,2.685185546874985,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,partial mastectomy,Infiltrating Lobular Carcinoma,Ductal/micropapillary,Indeterminate (neither Pre or Postmenopausal),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Equivocal,0.1474609375,0.0,60,moderate,90-99%,Dako,DAKOHercepTest TM,181.00390625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.78,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.5724609374999916,1.9,4 Point Scale,2+,5thStage IIAT2N0M0,YES,YES,Positive70-79%Positive<10%Negative1+,11,1,2012,"TCGA-B6-A2IU-F3890763102408-1829-4144-8CE6-018FA7240B97NOYESYESWITH TUMORAlive5176YES4224New Primary TumorOther, specifyLungNOYESYES312013",TCGA-D8-A1Y2-D300878706F572-AB8C-430F-9761-2AEFA63F375Bmg20mg/day66Hormone TherapyTamoxifenADJUVANTPOYES242012,TCGA-AR-A5QQ-R4276536D43FF0-8472-4D18-9916-39F7D4FAF10C233External6120cGy34Primary Tumor FieldNO1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,6.0,ASIAN,TCGA-C8-A273,C8,A273,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,allred score 5 + 3 = 8,H-SCORE 0,Right Upper Inner Quadrant,1.654121093749997,Axillary lymph node dissection alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.046875,2.0,Allred Score 5,Allred Score 8,90-99%,Hercep Test  TM Dako,Venten,109.173828125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,1.78,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.8,4 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,7,2011,TCGA-C8-A273-F20280A517D06B-1DAC-4DD9-869F-98DBF8EFECF2Scheduled Follow-up SubmissionNOYESAlive294NO912012TCGA-C8-A273-F70833E0EA316B-AB47-4A36-8C89-6941291C208BNONOYESTUMOR FREEAlive513NO932015,NOTCGA-C8-A273-D7083434F9559E-95CB-4EBC-9B9D-042337C8811E13Hormone TherapyTamoxifenYES932015,TCGA-BH-A0AV-R591771E9BDB6B-495D-4881-8264-4717B2630D9B259308External66.4Gy36Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,278.0,WHITE,TCGA-XX-A89A,XX,A89A,No,YES,C50.9,8520/3,C50.9,2013.0,TUMOR FREE,YES,11.0,CAP SCORING GUIDELINE 2010,image cytometry,Left Upper Outer Quadrant,2.356728515624984,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision of segmental mastectomy,Other,Segmental Mastectomy,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Skin biopsy,Negative,Positive,Negative,0.208984375,0.0,moderately to strongly,moderately to strongly,30-39%,ACIS,CAP SCORING GUIDELINE 2010,306.94921875,HER2 amplification - negative,Ratio >=2.0,NO,YES,54,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1,3 Point Scale,2+,7thStage IIBT3N0MX,NO,YES,NO,21,2,2014,TCGA-XX-A89A-F674251807302C-1D1D-4F80-82EE-65C4D14723B7NOYESNOTUMOR FREEAlive488NO11112014,TCGA-E9-A22D-D29929CC819813-FFDB-48CC-BE92-4A82FEC5E8FA3160mg20mg/day193Hormone TherapyTamoxifenADJUVANTPOYES3032012TCGA-E9-A22D-D29928291C8DBC-432A-4B49-BDD4-FEDCC82245C13600mg900mg/day616189Chemotherapy5-FluorouracilADJUVANTIVNO3032012TCGA-E9-A22D-D2992719D3B016-37B3-4CD9-8EAD-68E4AE3A15C43600mg900mg/day616189ChemotherapyCyclophosphaneADJUVANTIVNO3032012TCGA-E9-A22D-D29913B2DEB206-A8C5-4371-9443-BC4CE3883311360mg90mg/day616189ChemotherapyDoxorubicinADJUVANTIVNO3032012,TCGA-XX-A89A-R67377D5D20F81-441E-41AB-AA19-72DF8214A04759112External1800cGy10Primary Tumor FieldNOComplete Response11112014TCGA-XX-A89A-R674282D465698-646A-4347-BBC1-1C97FF34D94059112External3240cGy18Regional siteNOComplete Response11112014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,1006.0,WHITE,TCGA-A8-A09I,A8,A09I,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.626953125,allred score 5+3=8,H-Score 0,Right Lower Outer Quadrant,2.3720214843749896,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.6875,0.0,MODERATE,Allred Score 7,90-99%,Hercep Test  TM Dako,Venten,106.2626953125,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.6,LungBone,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,2.8,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A09I-F4033375A6C6B1-5909-4715-B91F-CAAA3CBE8AD0NONOYESTUMOR FREEAlive1371NO1722013,NOTCGA-A8-A09I-D37746331D363E-6139-4987-8F35-4A2453871C0331Hormone TherapyAnastrozolen/aYES6122012,TCGA-D8-A1JH-R14057DF81712D-81A3-4CE4-B1EB-FEA240FD3B8C81105EXTERNAL BEAM45cGy20Primary Tumor FieldADJUVANTNO1872011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,371.0,ASIAN,TCGA-C8-A27A,C8,A27A,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,5.7099609375,allred score 5 + 3 = 8,Allred (Biocare),Right Upper Outer Quadrant,1.7195605468749924,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,total mastectomy,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Patey's Surgery,Negative,Positive,Negative,0.04296875,1.5087890625,Allred score 8,Allred Score 7,90-99%,ACIS,Venten,153.220703125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,74,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,4 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,7,2011,TCGA-C8-A27A-F70786ED1A7238-3D18-4031-891C-4DB84E6DCB36NONOYESTUMOR FREEAlive747NO932015,NOTCGA-C8-A27A-D70787839564A6-2E39-4BCE-9DCC-20EF59A3ABBB411434Chemotherapy5-FlourouracilNOComplete Response932015NOTCGA-C8-A27A-D707881E7B539F-54D5-456B-B74C-EBEB8406CD24411434ChemotherapyDoxorubicinNOComplete Response932015NOTCGA-C8-A27A-D707899E9A47A2-2C29-46A6-8CB5-842A186DA178411434ChemotherapyCyclophosphamideNOComplete Response932015NOTCGA-C8-A27A-D70790C72AD225-877E-4C85-904D-850850DAD36A411434ChemotherapyTaxolNOComplete Response932015,TCGA-E9-A1NE-R2916648473E9C-72DD-4F0A-8D3E-85B661B773F4141171EXTERNAL BEAM4600cGy23Regional siteADJUVANTNO932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1994.0,WHITE,TCGA-AO-A12C,AO,A12C,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,31.0,H-Score 300,Allred score 5+3 = 8,Left Upper Outer QuadrantLeft,1.6,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Lumpectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,3+,Negative,Positive,Core needle biopsy,Lumpectomy,Negative,Positive,Positive,0.0048828125,2.0,allred score =  8,Moderate,90-99%,CISH,3+ Positive,30.0,Vysis AutoVysion System,>=2.0 Positive,NO,YES,78,"LungOther, specifyleft adrenal gland",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,125,3 Point Scale,2+,6thStage IIBT2N1aM0,YES,YES,YES766Distant MetastasisBoneNOYESNO,8,12,2010,TCGA-AO-A12C-F5889FFD79690-4C63-448F-AD9B-07699806F9431994AliveTUMOR FREEYESYES8122010TCGA-AO-A12C-F19425C6079795-077B-4961-8C09-C9FAF4B8C1A2Scheduled Follow-up SubmissionYESYESAlive2372TUMOR FREENO12122011,1TCGA-AO-A12C-D59666147d681-b15d-4868-86c9-8f70bb709894444mg60mg/m24116158ChemotherapyDoxorubicinADJUVANTIVNO10120111TCGA-AO-A12C-D5967ab88616c-baf7-417e-b9d8-511b3458b8681296mg175mg/m24179221ChemotherapyPaclitaxelADJUVANTIVNO10120113TCGA-AO-A12C-D59698310a990-257e-49ec-96a6-4addbb579f3620mg/day3352149Hormone TherapyTamoxifenADJUVANTPONO10120112TCGA-AO-A12C-D5968acf716d9-c5e8-4e07-b741-6844bb0c2df96mg/kg22179524Targeted Molecular therapyTrastuzumabADJUVANTIVNO10120111TCGA-AO-A12C-D59659558d4f9-c6cd-495d-acea-01d22843ae194440mg600mg/m24116158ChemotherapyCyclophosphamideADJUVANTIVNO1012011,TCGA-AO-A12C-R58906902c82f-5fd7-4dcd-95bf-c393615f7531277321EXTERNAL BEAM9540cGy28Regional siteADJUVANTNO18122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,702.0,WHITE,TCGA-A8-A08B,A8,A08B,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.517578125,allred score 5+3=8,allred score 5+3+8,Right Upper Inner Quadrant,2.369160156249991,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.6875,0.0,MODERATE,Allred Score 7,90-99%,Hercep Test  TM Dako,Venten,113.99609375,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.13,LungBone,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,2.8,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A08B-F40841B37E2409-548D-421A-A840-34803C923738NOYESYESTUMOR FREEAlive1156NO232013,NOTCGA-A8-A08B-D3781961251669-19D4-4215-A0A6-13B53CB464EC31122Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08B-D37820DD7BF60D-0661-4F71-8217-FBA9068C17CB31122ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08B-D37821D7E15D1C-7E0D-4F82-86A7-8411A4207C2331122ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08B-D37822E1FC34BF-AF83-49E2-9FB0-6CE574F0AAE7214883Hormone TherapyTamoxifenn/aNOComplete Response6122012NOTCGA-A8-A08B-D378234E401259-435D-4C0B-AD8D-33361A32FEE6214579Targeted Molecular therapyTrastuzumabn/aNOComplete Response6122012NOTCGA-A8-A08B-D37824D84A4E44-43BA-4E63-8B8E-8CA529809BC3914Hormone TherapyLetrozolen/aYES6122012,TCGA-A8-A08B-R3817105C8AF27-7A23-4CF3-8294-437ABD8EE4C1122184ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A1HO,C8,A1HO,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,6.9287109375,Image Analysis,Allred score 0+0 = 0,Left Upper Inner Quadrant,3.773642578125008,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Modified radical mastectomy,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.14453125,1.3515625,Allred Score 5,Allred Score 7,90-99%,ACIS,Venten,58.2822265625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,2.8,"LungBoneLiverOther, specifyskin",80-89%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.8,4 Point Scale,2+,6thStage IIICT3N3M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",12,7,2011,TCGA-C8-A1HO-F70802D4532637-AF57-4952-9398-E0DE374DD889NONOYESTUMOR FREEAlive375NO932015,NOTCGA-C8-A1HO-D708033D258720-7215-4352-8F11-753D26984EF0-49-45Chemotherapy5-FluorouracilNOComplete Response932015NOTCGA-C8-A1HO-D7080425995E3D-C18A-42AE-B575-DF8521244005-49-45ChemotherapyEpirubicinNOComplete Response932015NOTCGA-C8-A1HO-D70805957DBA00-04EE-4C3E-A23E-68E9C478CD59-49-45ChemotherapyCyclophosphamideNOComplete Response932015,TCGA-A2-A0ST-R371547e3cb28-a8ec-4f8b-8219-929a312408ae190233EXTERNAL BEAM5040cGyPrimary Tumor FieldADJUVANTNO110112010TCGA-A2-A0ST-R70357CE471AA1-298A-487F-B6A3-445126A2578E190233External5040cGyRegional siteNOComplete Response922015TCGA-A2-A0ST-R70359793704FD-D7A0-4911-AC99-9ACD0E500467236240External1000cGyPrimary Tumor FieldNOComplete Response922015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A1HE,C8,A1HE,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,5.0,H-SCORE 190,Allred (Biocare),Right,2.1633691406249858,Axillary lymph node dissection alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Mixed invasive ductal and invasive lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Equivocal,0.013671875,0.0,Allred Score 4,Allred Score 7,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,141.19140625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,1.78,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,79,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,24,5,2011,TCGA-C8-A1HE-F2026916CB3317-31C3-4E95-9B3B-0EBE48FFF665Scheduled Follow-up SubmissionNOYESAlive375TUMOR FREENO912012,NOTCGA-A2-A4S2-D4076272B353D4-7256-4161-B9C8-EA9FDC872D784796ChemotherapyAdriamycinNOComplete Response2822013NOTCGA-A2-A4S2-D4076330184077-58DE-45BD-94A3-1F57F54195364796ChemotherapyCytoxanNOComplete Response2822013NOTCGA-A2-A4S2-D40764B81A498A-A3FC-4E99-A912-6B5CBC9E288D110173ChemotherapyPaclitaxelNOComplete Response2822013NOTCGA-A2-A4S2-D590848B0F87F5-E925-40EB-9A72-E44475BF4CB3261Hormone TherapyArimidexYES3042014,TCGA-EW-A424-R38939C62AE9A3-9871-4B68-9F34-E2B47A6E9C35231281External60Gy25Primary Tumor FieldNOComplete Response412013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1467.0,WHITE,TCGA-BH-A0DL,BH,A0DL,No,YES,C50.9,8575/3,C50.9,2007.0,TUMOR FREE,YES,3.0,ER Positive H-Score 95,H-Score 15,Left,1.8435742187500015,Sentinel node biopsy alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Segmental mastectomy with sentinel lymph node biopsy,"Other, specify",Infiltrating ductal carcinoma with metaplastic carcinoma and focal apocrine features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.30859375,0.0,Strong,10-75%,10-19%,Hercep Test  TM Dako,Dako Hecept Test,118.9013671875,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,40,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.3,3 Point Scale,1+,6thStage IIAT2N0M0,NO,YES,YES181Locoregional RecurrenceYES181NOYES,11,8,2011,TCGA-BH-A0DL-F6038968E48067-EBC1-4A4C-90F4-73945B7413ADNOYESYESTUMOR FREEAlive2381NO962014,NOTCGA-BH-A0DL-D60392ED098E0D-9D8B-45CE-BCD7-8583BBCAAE5858121ChemotherapyCytoxanNOComplete Response962014NOTCGA-BH-A0DL-D6039331BEEEBA-90EE-411E-AD7B-89ABD5BE59B958205ChemotherapyTaxotereNOComplete Response962014,TCGA-BH-A0DL-R603911BDA7B8A-1E8C-4A96-832E-5D9489A9F1AD154205External6640cGy36Primary Tumor FieldNOComplete Response962014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,293.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A6R8,BH,A6R8,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,4.0,Allread score 5+3 = 8,H-SCORE 140,Left,1.9973144531249956,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Re-Excision of Superior Margin,Other,L Total Mastectomy,Infiltrating Ductal Carcinoma,Infiltrating Tubulolobular Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.775390625,0.0,Intensity=Strong,Intensity=Strong,90-99%,Dako,CAP scoring guideline 2010,210.0302734375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,50,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.3,3 Point Scale,2+,7thStage IIAT2N0M0,NO,YES,NO,13,2,2014,TCGA-BH-A6R8-F63677DF7231E8-9032-4F1E-88AE-B322DE8EDCFDNOYESNOTUMOR FREEAlive293NO1582014,NOTCGA-GM-A3XN-D35531FC4B09BC-E04D-4AAD-8ADC-943214589F12134211ChemotherapyPaclitaxelNOComplete Response1102012NOTCGA-GM-A3XN-D355327594E8FE-166B-40DC-82BA-FAB360C98DB2218282ChemotherapyFluorouracilNOComplete Response1102012NOTCGA-GM-A3XN-D35534D27177DE-0207-41D5-AA50-1BF7FAE5FBDC218282ChemotherapyAdriamycinNOComplete Response1102012NOTCGA-GM-A3XN-D355358AD2952D-C463-426C-BCFF-674C4A1821B8218282ChemotherapyCytoxanNOComplete Response1102012NOTCGA-GM-A3XN-D419685A81151E-DC13-4510-B131-29DB3185B8154161591Hormone TherapyTamoxifenNOComplete Response842013NOTCGA-GM-A3XN-D41969F9D001E6-39C1-43A9-B5B7-5A833D67EBE71592Hormone TherapyArimidexYES842013,TCGA-BH-A6R8-R5658903ACA3BC-B3FB-419B-91CF-87F71BB7189B194253External61GyPrimary Tumor FieldNOComplete Response1322014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,191.0,WHITE,TCGA-EW-A2FW,EW,A2FW,No,YES,C50.9,8503/3,C50.9,2011.0,TUMOR FREE,YES,6.0,H-Score 300,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.2142578125,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,partial mastectomy,"Other, specify",invasive papillary carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,Allred Score 5,8,<10%,CISH,Dako Hercept test,131.8369140625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.38,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,105,3 Point Scale,3+,7thStage IIAT2N0 (i-)MX,YES,YES,YES766Distant MetastasisBoneNOYESNO,5,10,2011,TCGA-EW-A2FW-F32335E245BE5D-7CB8-4AF7-B953-7D2ED89114AEScheduled Follow-up SubmissionYESYESAlive412TUMOR FREENO2352012TCGA-EW-A2FW-F4206215C65211-A67D-4438-BA46-7DE122DB17FBNOYESYESTUMOR FREEAlive672NO1042013,NOTCGA-EW-A2FW-D3233942AD7850-0CAF-41A6-89C4-F5AB746C8401112154ChemotherapyFluorouracilNO2352012NOTCGA-EW-A2FW-D32340650B3C64-48F3-4FF7-B6F8-C1542FA0D9D1112154ChemotherapyEpirubicinNO2352012NOTCGA-EW-A2FW-D32341F099D2F0-2747-4610-9467-F7261F1C4137112154ChemotherapyCyclophosphamideNO2352012NOTCGA-EW-A2FW-D3234388241187-2654-4E09-872E-16C9376DC51F175217ChemotherapyDocetaxelNO2352012NOTCGA-EW-A2FW-D32344C01E02E6-1EE4-42C5-A55A-2C49B956BE8F0Hormone TherapyExemestaneYES2352012,TCGA-EW-A2FW-R323378048DA7B-76F8-45CF-8B2D-46D6509CF44F279329EXTERNAL BEAM6400cGy30Primary Tumor FieldADJUVANTNO12352012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,360.0,WHITE,TCGA-E2-A10F,E2,A10F,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,2.0,Allred score 5+3=8,Allred score 5+3=8,Left Upper Outer Quadrant,1.05,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Re-Excision of Superior Margin,Other,Excisional biopsy,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.6865234375,0.0,Allred score 8,Allred score 8,20-29%,Dako,CAP scoring guideline 2010,225.369140625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.13,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1,3 Point Scale,2+,6thStage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,2,2011,TCGA-E2-A10F-F1718730AF5AC3-356D-445F-AB37-B36BE75AE6EBScheduled Follow-up SubmissionYESYESAlive878TUMOR FREENO2792011,2TCGA-E2-A10F-D77501bd78b9a-fdb8-45a6-9848-9e03ad1b28fd20mg/day20mg/day223337Hormone TherapyTamoxifenADJUVANTPONO14220111TCGA-E2-A10F-D178723DE26760-A09A-4CD8-9EB1-5D20924A929A640mg160mg469132ChemotherapyDocetaxelADJUVANTIVNO27920111TCGA-E2-A10F-D17186A5A45F4A-EB30-4F25-8A01-B2CC187C6EF85136mg1284mg469132ChemotherapyCyclophosphamideADJUVANTIVNO2792011,TCGA-E2-A10F-R7744ddf6fed7-242c-4544-bb29-f2d335f2dcb7170216EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11422011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1641.0,WHITE,TCGA-GM-A3XN,GM,A3XN,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,34.0,image cytometry,IHC,LeftLeft Upper Outer Quadrant,1.07,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Nipple Sparing Total Mastectomy,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,1+,Negative,Negative,Incisional Biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,5.0,Allred score 5,Two-tier,10-19%,CISH,Dako Hecept Test,60.0,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,1.73,"LungBoneLiverOther, specifyskin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.85,4 Point Scale,1+,6thStage IIIAT1cN2aM0,YES,YES,NO,1,10,2012,TCGA-GM-A3XN-F46967D2D39B9A-798A-44E3-8BDB-5D3DA01F9BDDNOYESYESTUMOR FREEAlive2019NO2082013,NOTCGA-GM-A3XN-D35531FC4B09BC-E04D-4AAD-8ADC-943214589F12134211ChemotherapyPaclitaxelNOComplete Response1102012NOTCGA-GM-A3XN-D355327594E8FE-166B-40DC-82BA-FAB360C98DB2218282ChemotherapyFluorouracilNOComplete Response1102012NOTCGA-GM-A3XN-D35534D27177DE-0207-41D5-AA50-1BF7FAE5FBDC218282ChemotherapyAdriamycinNOComplete Response1102012NOTCGA-GM-A3XN-D355358AD2952D-C463-426C-BCFF-674C4A1821B8218282ChemotherapyCytoxanNOComplete Response1102012NOTCGA-GM-A3XN-D419685A81151E-DC13-4510-B131-29DB3185B8154161591Hormone TherapyTamoxifenNOComplete Response842013NOTCGA-GM-A3XN-D41969F9D001E6-39C1-43A9-B5B7-5A833D67EBE71592Hormone TherapyArimidexYES842013,TCGA-GM-A3XN-R35530BEB66920-DAD1-453E-A0F4-9C99FAAFDF03359394External60Gy30Primary Tumor FieldNOComplete Response1102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A12T,C8,A12T,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,5.0,H-Score 150,Allred score 0+0=0,Left,1.331093749999992,Axillary lymph node dissection alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Positive,0.009765625,0.0,Allred Score 8,Allred Score 6,10-19%,Dako,CAP scoring guideline 2010,101.734375,HER2 amplification - negative,>= 2.0 Positive,YES,NO,1.78,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,11,4,2011,TCGA-OL-A5D7-F5543981E1B508-543A-4E66-856F-86048DFAF64ANOYESYESTUMOR FREEAlive1780NO1012014,NOTCGA-GM-A3XN-D35531FC4B09BC-E04D-4AAD-8ADC-943214589F12134211ChemotherapyPaclitaxelNOComplete Response1102012NOTCGA-GM-A3XN-D355327594E8FE-166B-40DC-82BA-FAB360C98DB2218282ChemotherapyFluorouracilNOComplete Response1102012NOTCGA-GM-A3XN-D35534D27177DE-0207-41D5-AA50-1BF7FAE5FBDC218282ChemotherapyAdriamycinNOComplete Response1102012NOTCGA-GM-A3XN-D355358AD2952D-C463-426C-BCFF-674C4A1821B8218282ChemotherapyCytoxanNOComplete Response1102012NOTCGA-GM-A3XN-D419685A81151E-DC13-4510-B131-29DB3185B8154161591Hormone TherapyTamoxifenNOComplete Response842013NOTCGA-GM-A3XN-D41969F9D001E6-39C1-43A9-B5B7-5A833D67EBE71592Hormone TherapyArimidexYES842013,TCGA-A2-A0ST-R371547e3cb28-a8ec-4f8b-8219-929a312408ae190233EXTERNAL BEAM5040cGyPrimary Tumor FieldADJUVANTNO110112010TCGA-A2-A0ST-R70357CE471AA1-298A-487F-B6A3-445126A2578E190233External5040cGyRegional siteNOComplete Response922015TCGA-A2-A0ST-R70359793704FD-D7A0-4911-AC99-9ACD0E500467236240External1000cGyPrimary Tumor FieldNOComplete Response922015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1416.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A5D7,OL,A5D7,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,Left Upper Outer Quadrant,1.36,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Lumpectomy,Reexcision of segmental mastectomy,Other,surgical resection,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Negative,Negative,0.0,1.802734375,allred score = 8,moderate,20-29%,CISH,CAP SCORING GUIDELINE 2010,94.669921875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.78,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.80,3 Point Scale,3+,6thStage IIAT2N0MX,YES,YES,NO,19,4,2013,TCGA-OL-A5D7-F5543981E1B508-543A-4E66-856F-86048DFAF64ANOYESYESTUMOR FREEAlive1780NO1012014,NOTCGA-OL-A5D7-D652483B824D33-1415-4513-BD99-B3D2EB3268E041104ChemotherapyCytoxanNOComplete Response2492014NOTCGA-OL-A5D7-D6524934732C91-371D-4928-9C31-6B8D6A5D76CB41104ChemotherapyTaxotereNOComplete Response2492014,TCGA-OL-A5D7-R65250737BD5F1-6E92-4485-96EE-BA831B7A24C9134550External5040cGyPrimary Tumor FieldNOComplete Response2492014
TCGAFPPP,Breast,Yes,FEMALE,Dead,172.0,360.6640625,WHITE,TCGA-AQ-A0Y5,AQ,A0Y5,Yes,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,17.0,CAP SCORING GUIDELINE 2010,Allred score 5+3 = 8,Right,3.8,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Positive,Positive,Positive,0.17578125,5.0,allred score = 8,Allred Score = 7,90-99%,CISH,CAP scoring guideline 2010,84.693359375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,YES,NO,2.13,"LungBoneLiverOther, specifyskin",70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.8352539062499968,61,3 Point Scale,2+,7thStage IIIAT2N2aMX,YES,NO,PositivePositiveNegativeNegative,7,4,2011,TCGA-AQ-A0Y5-F101197CB4C161-65D3-44E6-82F7-CDAA2C40D530DeadTUMOR FREE172NOYES742011,1TCGA-AQ-A0Y5-D101175fbb7fe9-4b27-43af-8832-ae64ee3e4acc2400mg/m2600mg/m2483146ChemotherapyCytoxanADJUVANTIVNO7420111TCGA-AQ-A0Y5-D101185c09333c-d15e-4c62-ad09-c1984b22cbda32mg/kg8mg/kg483146ChemotherapyHerceptinADJUVANTIVNO7420111TCGA-AQ-A0Y5-D101161aef9741-6d96-4b9c-abcf-994ed14f4ce4300mg/m275mg/m2483146ChemotherapyTaxotereADJUVANTIVNO742011,TCGA-BH-A0DL-R603911BDA7B8A-1E8C-4A96-832E-5D9489A9F1AD154205External6640cGy36Primary Tumor FieldNOComplete Response962014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,410.0,WHITE,TCGA-A2-A1FZ,A2,A1FZ,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,3.0,Allred score = 8,H-Score 190,Right,1.4416601562499998,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Reexcision of segmental mastectomy,Other,Surgical resection,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,Allred score 7 per outside facility report,250,10-19%,Dako,Venten,116.685546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,1.57,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,172,3 Point Scale,3+,7thStage IIAT2N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,4,2011,TCGA-A2-A1FZ-F208036FB6D566-9B81-4637-9760-6071E917078BScheduled Follow-up SubmissionNOYESAlive683TUMOR FREENO912012,1TCGA-A2-A1FZ-D12285453a2e9f-7e83-478a-a0f5-0aa01232d4fbHormone TherapyArimidexADJUVANTPOYES2742011,TCGA-BH-A6R8-R5658903ACA3BC-B3FB-419B-91CF-87F71BB7189B194253External61GyPrimary Tumor FieldNOComplete Response1322014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1228.0,BLACK OR AFRICAN AMERICAN,TCGA-3C-AALJ,3C,AALJ,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,23.0,Allred (Biocare),Allred (Biocare),Right,1.6139453124999923,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Indeterminate,0.103515625,1.0,Allred score 0,250,10-19%,CISH,Venten,131.9638671875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,33,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,30-39%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,145,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,NO,NO,28,7,2014,TCGA-3C-AALJ-F68060DF650B2E-12C2-468A-9F26-9A43CA378AF2NONOTUMOR FREEAlive1302NO13112014TCGA-3C-AALJ-F71675AB533AC3-9333-4176-A6E3-E0E03E8A0FFCNONONOTUMOR FREEAlive1474NO2732015,YESTCGA-3C-AALJ-D62904D9762142-667A-4123-846B-B3B965CE9A90368511MetforminNO2872014NOTCGA-3C-AALJ-D65377EA7483F7-D53B-4A10-9E28-68A29E1F04A9154490ChemotherapyTrastuzumabNO2492014NOTCGA-3C-AALJ-D65375F0F4D7C5-9237-480F-876C-60663BBBE32563126ChemotherapyDoxorubicinNO2492014NOTCGA-3C-AALJ-D655274EFE0CA1-39BA-4A36-9BDD-55F322DA8C1163126ChemotherapyCyclophosphamideNO2492014NOTCGA-3C-AALJ-D65378B5D318C4-A505-475B-8ABC-DFEAA6B55593151511ChemotherapyHerceptinNO18122014,TCGA-EW-A2FW-R323378048DA7B-76F8-45CF-8B2D-46D6509CF44F279329EXTERNAL BEAM6400cGy30Primary Tumor FieldADJUVANTNO12352012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1590.0,BLACK OR AFRICAN AMERICAN,TCGA-V7-A7HQ,V7,A7HQ,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,18.0,H-SCORE 300,H-SCORE 0,Right Lower Outer Quadrant,1.1,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Additional resection/ margins (taken after first margin positive),Other,surgical resection,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Tumor resection,Skin biopsy,Negative,Positive,Equivocal,0.3134765625,5.0,230,Moderate to strong,30-39%,ACIS,CAP SCORING GUIDELINE 2010,20.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.0,"Other, specifyaxilaary node negative but intrammary node positive",60-69%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.1,3 Point Scale,3+,6thStage IIIAT1cN2aM0,NO,NO,NO,31,3,2015,TCGA-V7-A7HQ-F719705C6DF2E3-461B-4B41-B40C-9C1ED089EE74NOYESYESTUMOR FREEAlive2033NO3132015,NOTCGA-V7-A7HQ-D71971AAF9A475-0FCA-4018-A727-0BCEFFE5281D1291869Hormone TherapyletrozoleNOComplete Response3132015,TCGA-V7-A7HQ-R71972FFFCCFB6-6613-401F-9E04-8B3517F882FE90133External60Gy30Primary Tumor FieldNOComplete Response3132015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1059.0,WHITE,TCGA-AR-A255,AR,A255,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,2.0,Allred score 0+0 = 0,manual counting,Right Lower Inner Quadrant,1.5405664062499875,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Other,Reexcision of segmental mastectomy,Other,Wide local excision,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,3+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,0.0849609375,0.0,H-Score,Allred Score 8,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,89.6591796875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,816,3 Point Scale,2+,6thStage IT1N0M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",31,8,2011,TCGA-AR-A255-F319170ED6F967-D520-4A7B-83AA-C5501DAB6CCCScheduled Follow-up SubmissionYESYESAlive1059NO1152012TCGA-AR-A255-F49512B39FC06A-9138-40FC-9163-EF2896BEC091YESYESTUMOR FREEAlive1792NO2102013TCGA-AR-A255-F71745457F26CE-CD5A-44A1-9C9C-13AF3302B6BCNOYESYESTUMOR FREEAlive2161NO3032015,NOTCGA-AR-A255-D31920BB558EF4-41E7-493C-A6D2-FC80FE1216795454ImmunotherapyTrastuzumabNO2252012NOTCGA-AR-A255-D31921ECE7A0A4-959E-4CC4-8857-7193628243DC75419ImmunotherapyTrastuzumabNO2252012NOTCGA-AR-A255-D319225283FFF6-C4EA-4F3D-AD5E-CAB099B3DF3796Hormone TherapyAnastrozoleYES2252012,TCGA-AR-A255-R31919339C3612-78BA-4998-8944-2594F16E73154789EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO11152012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,176.0,BLACK OR AFRICAN AMERICAN,TCGA-A7-A6VW,A7,A6VW,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,2.0,allred score 0 + 0 = 0,H-Score 290,Left,1.5368261718749916,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Reexcision of segmental mastectomy,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Close,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.5263671875,0.0,allred score = 6,205,10-19%,CISH,Dako Hercept test,168.0078125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,64,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.5,3 Point Scale,2+,7thStage IIAT2N0M0,YES,NO,NO,29,10,2013,TCGA-A7-A6VW-F572274E6B8FB6-BAFC-4287-BC6A-AB3BA00294C9NOYESYESTUMOR FREEAlive285NO632014,NOTCGA-A7-A6VW-D57225037B0D49-1CCC-47FB-9442-F8841E1663C5148257ChemotherapyTaxolNOComplete Response632014NOTCGA-A7-A6VW-D57226DD497F99-3155-4D4E-904E-FD5904316A5284134ChemotherapyDoxorubicinNOComplete Response632014NOTCGA-A7-A6VW-D5725402D81B38-5418-4F7D-B18B-0AE11DBE806B84134ChemotherapyCyclophosphamideNOComplete Response632014,TCGA-A7-A6VW-R5725375FCD986-D2B7-4F5B-B37A-FE0AF6FC2AC8285331External50.40Gy28Primary Tumor FieldNOComplete Response3132014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,175.0,WHITE,TCGA-BH-A0W4,BH,A0W4,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,3.0,Allred score = 8,PR Negative H-Score 0,Left Upper Outer Quadrant,1.6922167968749893,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Total mastectomy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.419921875,0.009765625,240 H,8,90-99%,Dako,Venten,231.27734375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.9,3 Point Scale,2+,7thStage IIAT2N0 (i-)M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",15,2,2011,TCGA-BH-A0W4-F34069A10FFD93-E9C3-4083-A4E6-F61D9E83E9C9Scheduled Follow-up SubmissionNONOAlive759TUMOR FREENO2972012,NOTCGA-EW-A2FW-D3233942AD7850-0CAF-41A6-89C4-F5AB746C8401112154ChemotherapyFluorouracilNO2352012NOTCGA-EW-A2FW-D32340650B3C64-48F3-4FF7-B6F8-C1542FA0D9D1112154ChemotherapyEpirubicinNO2352012NOTCGA-EW-A2FW-D32341F099D2F0-2747-4610-9467-F7261F1C4137112154ChemotherapyCyclophosphamideNO2352012NOTCGA-EW-A2FW-D3234388241187-2654-4E09-872E-16C9376DC51F175217ChemotherapyDocetaxelNO2352012NOTCGA-EW-A2FW-D32344C01E02E6-1EE4-42C5-A55A-2C49B956BE8F0Hormone TherapyExemestaneYES2352012,TCGA-AR-A255-R31919339C3612-78BA-4998-8944-2594F16E73154789EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO11152012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1299.0,BLACK OR AFRICAN AMERICAN,TCGA-GM-A2DF,GM,A2DF,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,32.0,Allred score 5+3=8,CAP scoring guideline 2010,Left Lower Outer Quadrant,1.12,Axillary lymph node dissection alone,axillary ultrasound,Lumpectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0,1.0,moderately to strongly,205,<10%,0,CAP SCORING GUIDELINE 2010,60.0,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.40,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.57,3 Point Scale,2+,6thStage IIAT1cN1aM0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,9,2011,TCGA-GM-A2DF-F470745EA23820-4945-4615-B3D5-2407C809951BNOYESYESTUMOR FREEAlive2155NO2282013,NOTCGA-GM-A2DF-D470779309E85C-511C-4D64-A9FD-153D7D059F7682159ChemotherapyTaxolNOComplete Response2282013NOTCGA-GM-A2DF-D47078BD3CED99-2972-42AC-A40F-65D713B00CF1166229ChemotherapyFluorouracilNOComplete Response2282013NOTCGA-GM-A2DF-D470799759BFEA-6BA0-47F3-8697-D4BE5FD98515166229ChemotherapyEpirubicinNOComplete Response2282013NOTCGA-GM-A2DF-D470800DE09D9B-CDA0-4E1C-A438-47238333BAF8166229ChemotherapyCytoxanNOComplete Response2282013,TCGA-GM-A2DF-R47076097C40A5-1D8D-4E81-8D6E-2BCBC0783E3E250294External64Gy32Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2750.0,WHITE,TCGA-E2-A1LI,E2,A1LI,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,2.0,Allred score 5+3=8,Allred score 5+3 = 8,Left Upper Outer Quadrant,1.21,Sentinel node biopsy alone,SLN and non-SLN biopsy,Lumpectomy,Re-Excision of Superior Margin,Other,Mastectomy,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Close,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Equivocal,0.7802734375,0.0,Allred score = 8,allred score = 8,20-29%,ACIS,Dako Hercept test,254.625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2.8,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,<4.0,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,3,6,2011,TCGA-E2-A1LI-F206238BAE43AC-77BB-4AC6-9756-C0A746B794DCScheduled Follow-up SubmissionYESYESAlive3121TUMOR FREENO1212012,1TCGA-E2-A1LI-D206258E4821F1-29B2-4F8E-B282-225C81946E03240mg/m260mg/m2442112ChemotherapyAdriamycinADJUVANTNO12120121TCGA-E2-A1LI-D20624EDBA2340-0F7F-49B5-9FBD-5B68A1F315072400mg/m2600mg/m2442112ChemotherapyCytoxanADJUVANTNO1212012,TCGA-E2-A1LI-R20626B73909E2-58E4-42C3-AFFF-2F8746177C50152194Primary Tumor FieldADJUVANTNO11212012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,807.0,WHITE,TCGA-A2-A0ET,A2,A0ET,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,15.0,H-Score 270,Allred score = 8,Right Upper Outer Quadrant,1.09,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Lumpectomy,Reexcision of segmental mastectomy,Other,Fine Needle aspiration biopsy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.0,5.0,Intensity=Strong,Intensity=Strong,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,105.0947265625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,2.7,"LungOther, specifyleft adrenal gland",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,145,3 Point Scale,2+,6thStage IIIAT2N2aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",20,9,2010,TCGA-A2-A0ET-F13713ADFE6D4E-59FC-4293-AB60-DC1F69907AEEScheduled Follow-up SubmissionYESYESAlive1066TUMOR FREENO1062011,1TCGA-A2-A0ET-D186927062a5c-294b-42b5-83d5-4823fa303cf64650mg1140-1170mg4101169ChemotherapyCytoxanADJUVANTIVNO20920103TCGA-A2-A0ET-D18722b5d05ab-12db-4d8a-b19d-bfadbd0be27f464mg114-117mg4101169ChemotherapyAdriamycinADJUVANTIVNO20920104TCGA-A2-A0ET-D1873f4c9aca2-477b-48f3-8c8c-8bff0959670c1 mg dailymg282Hormone TherapyAnastrozoleADJUVANTPOYES20920102TCGA-A2-A0ET-D1871595833d0-af3e-4038-80c4-3f798f222a6d1367mg341-342mg4183225ChemotherapyTaxolADJUVANTIVNO2092010,TCGA-A2-A0ET-R1874771405be-178c-469b-9e42-e26011660284ADJUVANTNO12092010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,6435.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0RE,B6,A0RE,No,YES,C50.9,8500/3,C50.9,1989.0,TUMOR FREE,YES,14.0,% IHC,%IHC,Right Upper Outer QuadrantRight,1.3315039062499987,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Indeterminate (neither Pre or Postmenopausal),Negative,NO,4 Point Scale,2+,2+,Negative,Negative,"Other method, specify:",Lumpectomy,Negative,Negative,Equivocal,0.439453125,0.0,Intensity=Strong,moderate,10-19%,ACIS,dextran coated charcoal,76.0537109375,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,2.6,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.3,4 Point Scale,1+,Stage XTXN0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,2,11,2010,TCGA-B6-A0RE-F13792E5211DCF-42C5-4A93-8ED4-0BF0E83E5F30Scheduled Follow-up SubmissionYESNOAlive6435TUMOR FREENO1272011TCGA-B6-A0RE-F7150768A0A63C-7D7B-433D-AA9F-84E7F9365EA8NOYESNOTUMOR FREEAlive7777NO2632015,4TCGA-A2-A0YT-D56875b1e9a0c-a2c4-41f0-a952-c9b39c961f76mg1mg286723Hormone TherapyArimidexADJUVANTPONO10122010,TCGA-XX-A89A-R67377D5D20F81-441E-41AB-AA19-72DF8214A04759112External1800cGy10Primary Tumor FieldNOComplete Response11112014TCGA-XX-A89A-R674282D465698-646A-4347-BBC1-1C97FF34D94059112External3240cGy18Regional siteNOComplete Response11112014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,31.0,WHITE,TCGA-A8-A06Q,A8,A06Q,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,12.4853515625,CAP SCORING GUIDELINE 2010,Allred 0 = 0+0,Left Upper Outer Quadrant,2.287958984374981,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.41796875,4.0830078125,Allred score 8,Strong,10-19%,ACIS,CAP SCORING GUIDELINE 2010,127.9228515625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,54,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.83,3 Point Scale,2+,5thStage IIIAT3N2M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-BH-A0DH-F452903118CCF-5575-4CB5-840E-2DE55AA5F8FA1156AliveTUMOR FREEYESYES16112010,NOTCGA-E2-A573-D445013AF01D86-64C7-405F-887D-1A0D27831968104167ChemotherapyTaxotereNOComplete Response2062013NOTCGA-E2-A573-D445023A195E08-569B-4623-BF02-4176DE92D98C104167ChemotherapyCytoxanNOComplete Response2062013,TCGA-GM-A3XN-R35530BEB66920-DAD1-453E-A0F4-9C99FAAFDF03359394External60Gy30Primary Tumor FieldNOComplete Response1102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,91.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A441,LL,A441,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,4.0,allred score 5+3=8,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.3437988281250013,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,Allred Score 3,205,90-99%,CISH,Hercep Test  TM Dako,119.00390625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,3.1,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.0,3 Point Scale,2+,7thStage IAT1cN0MX,YES,NO,NO,5,11,2012,TCGA-LL-A441-F46386942378CA-13DA-43CB-9FE1-A95010C3B668NOYESYESTUMOR FREEAlive996NO782013,NOTCGA-LL-A441-D3659126759221-D07C-4BDA-BBB6-36A76DE3EDA661133ChemotherapyTaxotereNOComplete Response5112012NOTCGA-LL-A441-D36592EAC2A2A2-E81E-4A91-A483-5055C21238F361133ChemotherapyCytoxanNOComplete Response5112012,TCGA-LL-A441-R4638562DCBDEC-4D8A-446D-B28A-643F6BB679F7153216External6600cGy33Primary Tumor FieldNOComplete Response782013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1170.0,WHITE,TCGA-BH-A0DT,BH,A0DT,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,18.0,H-Score 270,Allred score 7 per outside facility report,Right,1.917265625,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Reexcision of segmental mastectomy,Other,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Ductal Carcinoma,ductal/mucinous,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.408203125,1.0,Strong,STRONG,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,75.0546875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,1.45,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,71,3 Point Scale,2+,6thStage IIAT1cN1aM0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",11,8,2011,TCGA-BH-A0DT-F59149547CCD51-6C97-4C0B-9A88-08154FBB4C87NOYESYESTUMOR FREEAlive2403NO152014,NOTCGA-BH-A0DT-D591503624978D-3FC4-4B29-A10C-B30306A0483B118287ChemotherapyTaxotereNOComplete Response152014NOTCGA-BH-A0DT-D59151C4190558-6F95-4A8A-9E8D-218E6E89D189118287ChemotherapyAdriamycinNOComplete Response152014NOTCGA-BH-A0DT-D591520F068054-E971-4558-AD6A-D6CD1FB72167118287ChemotherapyCytoxanNOComplete Response152014,TCGA-E2-A573-R44499400B06FE-ADCF-4256-98CF-9BA8697DB36C201251External66.4Gy36Primary Tumor FieldNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1.0,ASIAN,TCGA-C8-A274,C8,A274,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,5.94140625,H-SCORE 190,Allred (Biocare),Right,1.7252539062499908,Axillary lymph node dissection alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Patey's Surgery,Infiltrating Ductal Carcinoma,Mixed invasive ductal and invasive lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,1+,Negative,Negative,"Other method, specify:",Patey's Surgery,Negative,Positive,Negative,0.01953125,0.0,Allred Score 7,Allred Score 8,90-99%,Hercep Test  TM Dako,Venten,142.884765625,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,1.78,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,61,4 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,21,7,2011,TCGA-C8-A274-F20275EE62C6FF-017B-4C06-873D-47D00D8EB4AFScheduled Follow-up SubmissionNOYESAlive290NO912012TCGA-C8-A274-F7083152DC036E-216B-4745-ACB0-5EA2953BCF96NONOYESTUMOR FREEAlive508NO932015,NOTCGA-C8-A274-D708324593E9A7-6ECF-4C21-BADB-4309FC4239008Hormone TherapyTamoxifenYES932015,TCGA-C8-A137-R708166A57E479-51F6-4266-BF13-7BF4F13D224C137External60Gy30Local RecurrenceNOStable Disease932015
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,109.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A442,LL,A442,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,4.0,Allred score 5+3=8,CAP SCORING GUIDELINE 2010,Left Lower Outer Quadrant,1.7,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,Excision,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.0,0.0,Allred Score 5,Allred Score 5,10-19%,0,CAP SCORING GUIDELINE 2010,20.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,35,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,60,3 Point Scale,3+,7thStage IIAT2N0 (i-)MX,YES,NO,NO,26,10,2012,TCGA-LL-A442-F46384AB2B5DCA-684E-49C8-8594-0A66AD27B2F5NONOYESTUMOR FREEAlive889NO782013,NOTCGA-LL-A442-D36069E1D4E54E-9B75-48FF-AF1C-506222B5E941111Hormone TherapyArimidexYES17102012,TCGA-V7-A7HQ-R71972FFFCCFB6-6613-401F-9E04-8B3517F882FE90133External60Gy30Primary Tumor FieldNOComplete Response3132015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,677.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A573,E2,A573,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,4.0,Allred 0 = 0+0,Allred 0 = 0+0,Right Upper Outer Quadrant,1.3,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Partial Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Equivocal,1.5185546875,0.0,Allred Score,Allred Score,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,200.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.8,LungBone,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.3,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,NO,20,6,2013,TCGA-E2-A573-F61338E2709DF2-6524-4677-B518-338714E12666NOYESYESTUMOR FREEAlive1062NO2762014,NOTCGA-E2-A573-D445013AF01D86-64C7-405F-887D-1A0D27831968104167ChemotherapyTaxotereNOComplete Response2062013NOTCGA-E2-A573-D445023A195E08-569B-4623-BF02-4176DE92D98C104167ChemotherapyCytoxanNOComplete Response2062013,TCGA-E2-A573-R44499400B06FE-ADCF-4256-98CF-9BA8697DB36C201251External66.4Gy36Primary Tumor FieldNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,ASIAN,TCGA-C8-A26Y,C8,A26Y,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,NO,5.6787109375,H-SCORE 260,H-SCORE 0,Left Upper Outer Quadrant,3.892685546874993,Sentinel node biopsy alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,total mastectomy,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,4 Point Scale,4+,1+,Negative,Negative,Tumor resection,Patey's Surgery,Negative,Negative,Negative,0.013671875,0.0,MODERATE,Allred score 8,30-39%,Hercep Test  TM Dako,Hercep Test  TM Dako,150.7138671875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,54,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.66,4 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,21,7,2011,TCGA-C8-A26Y-F70791D698E40F-5055-4DF2-962D-C3BE9150CBE3NONONOTUMOR FREEAlive0NO932015,TCGA-A1-A0SN-D1206646FC4D8A-2EEC-454B-BC8F-447030B0D761487179ChemotherapyacADJUVANTIVNO2352011TCGA-A1-A0SN-D120676BE7B34C-4BFD-4AFD-B4FA-EF6DFA0CA6D0179270ChemotherapytaxolADJUVANTIVNO2352011TCGA-A1-A0SN-D121574E133864-9EDE-40C9-91C3-E5E05D9D8545179879Targeted Molecular therapyherceptinADJUVANTIVNO2452011,TCGA-A8-A08G-R38174565C6FF1-BC4D-4E70-8DAC-BEC6DFF29A9F150212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Dead,1812.0,1466.7880859375,WHITE,TCGA-GM-A2D9,GM,A2D9,No,YES,C50.9,8500/3,C50.9,2006.0,WITH TUMOR,YES,2.0,allred score 5 + 3 = 8,Allred score 5+3 = 8,Left Upper Inner Quadrant,1.16,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,Modified Radical Masectomy,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.0,0.0,allred score = 8,80,10-19%,0,CAP SCORING GUIDELINE 2010,60.0,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,1.93,Bone,90-99%,40-49%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.8352539062499968,2.23,3 Point Scale,3+,6thStage IT1cN0 (i-)M0,YES,NO,Positive90-99%,28,9,2011,"TCGA-GM-A2D9-F470336B63FE41-80F5-49EC-9AD0-40B71FED880DNOYESYESWITH TUMORDead1812YES536Distant MetastasisBoneYES536YESYESPositive1351Distant MetastasisOther, specifyIntrathoracic lymph nodeNONOYES1351Distant MetastasisLungNONOYES2182013",NOTCGA-GM-A2D9-D4725464CF04C2-4790-4726-A0F7-9B4EF1148E1D5591265Hormone TherapyArimidexNOStable Disease2382013NOTCGA-GM-A2D9-D472553BAECB5B-8DFC-452B-93BF-ED08CA82E4EC12661354Hormone TherapyTamoxifenNOStable Disease2382013NOTCGA-GM-A2D9-D472561BAEBAA5-762C-4559-8CFF-34C352DD5B0A13621455ChemotherapyXelodaNOClinical Progressive Disease2382013NOTCGA-GM-A2D9-D47257F83B835B-003A-4E5D-AA90-9504C8171A8D14701567ChemotherapyGemcitabineNOClinical Progressive Disease2382013,TCGA-GM-A2D9-R47037BE3ADDFC-5406-471C-984B-8229F0EEA8D76896External60Gy30Primary Tumor FieldNO2182013TCGA-GM-A2D9-R4725321CA09CB-DF2B-458F-813B-66DA60B6C92314131434External30Gy10Distant RecurrenceNOStable Disease2382013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2181.0,WHITE,TCGA-A2-A0EO,A2,A0EO,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,3.0,H-Score 295,H-Score 290,Left,1.6,Sentinel node biopsy alone,Pateys surgery,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Peri (6-12 months since last menstrual period),Positive,YES,3 Point Scale,2+,1+,Negative,Close,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,Allred score 8,80,<10%,ACIS,Hercep Test  TM Dako,76.4892578125,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,4.43,"Other, specifySkin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.3,3 Point Scale,1+,6thStage IAT1N0 (i-)M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",10,8,2010,TCGA-A2-A0EO-F13732934A43F9-9180-48A7-BE9D-F50B3E511901Scheduled Follow-up SubmissionYESYESAlive2442TUMOR FREENO1362011,"2TCGA-A2-A0EO-D19945d5957c7-956b-45b3-981b-3030c7aac47c25mg876Hormone TherapyExemestaneADJUVANTPOYES11820101TCGA-A2-A0EO-D19932292be73-49ad-45dd-a4af-0073e6cdf61e10 mg twice dailymg158876Hormone TherapyTamoxifenADJUVANTPONO11820103TCGA-A2-A0EO-D199527d60124-9f25-4998-9bd1-d10689365a732000ug500ug4244361ImmunotherapyE-75OTHER, SPECIFY IN NOTESCancer Vaccine TrialNO992010",TCGA-A2-A0EO-R19929e36f785-838a-4b6a-a404-6cb8df45ea5a91137EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11182010
TCGAFPPP,Breast,No,FEMALE,Dead,2965.0,2316.4013671875,BLACK OR AFRICAN AMERICAN,TCGA-B6-A0WS,B6,A0WS,No,YES,C50.9,8500/3,C50.9,1996.0,TUMOR FREE,NO,17.904296875,Image Analysis,Image Analysis,Left Upper Outer QuadrantLeft,1.734345703124992,No axillary staging,FNA plus axillary lymph node dissection,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Total mastectomy with sentinel lymoh node biopsy,Infiltrating Ductal Carcinoma,malignant phyllodes,Indeterminate (neither Pre or Postmenopausal),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Equivocal,0.6259765625,4.224609375,230,190,30-39%,Dako,CAP scoring guideline 2010,233.171875,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,1.78,"LungBoneLiverOther, specifyskin",80-89%,10-19%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.944414062499999,2.23,4 Point Scale,2+,4thStage XT1cNXMX,YES,YES,PositivePositiveNegativeNegative,15,3,2011,TCGA-B6-A0WS-F157072E7292CB-C5A8-4E31-B7BC-7029B5951134Scheduled Follow-up SubmissionNONODead2965TUMOR FREENO2982011,1TCGA-A2-A0EY-D18871c31f4fe-aaf3-45bb-85cc-ddc5a1ed81e9418mg104-105mg4105154ChemotherapyAdriamycinADJUVANTIVNO22920103TCGA-A2-A0EY-D18904ffd1583-1089-4c1a-9c65-3b1413b8983c516mg129mg4183245ChemotherapyDocetaxelADJUVANTIVNO22920104TCGA-A2-A0EY-D1891e621dfac-f2ac-4604-a5fa-520f61070b6cmg1000 mg dailymg183Targeted Molecular therapyLapatinibADJUVANTPOYES22920106TCGA-A2-A0EY-D18938da373c9-e16f-4a58-b3ff-6c294e12787c1 mg dailymg329Hormone TherapyArimidexADJUVANTPOYES22920105TCGA-A2-A0EY-D1892c5f2e97a-c397-4193-a55d-c10d91996a6b134.4-406mg183Targeted Molecular therapyHerceptinADJUVANTIVYES22920102TCGA-A2-A0EY-D18885da60b2a-4a81-450f-8a9a-f577b0f3dc834176mg1038-1050mg4105154ChemotherapyCytoxanADJUVANTIVNO2292010,TCGA-GM-A2DF-R47076097C40A5-1D8D-4E81-8D6E-2BCBC0783E3E250294External64Gy32Primary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,414.0,WHITE,TCGA-BH-A0HP,BH,A0HP,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,17.0,H-Score 280,H-Score 0,Left Upper Inner QuadrantLeft Upper Outer QuadrantLeft Lower Inner QuadrantLeft Lower Outer QuadrantLeft,1.487626953124995,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,total mastectomy,Infiltrating Lobular Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.5595703125,8.0,H-Score,H-Score,10-19%,Hercep Test  TM Dako,DAKOHercepTest TM,43.8486328125,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,4.43,"LungOther, specifyleft adrenal gland",80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,52,3 Point Scale,0,Stage IIIAT3N2aM0,NO,YES,PositiveNegative,11,11,2010,TCGA-BH-A0HP-F4784DD04D583-3871-4317-908D-8EDD22A879B7414AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0HP-D4781535233BD-5A0E-4EC4-8171-96C978C4AD612141mg180mg12147238ChemotherapyPaclitaxelADJUVANTIVNO181120101TCGA-BH-A0HP-D47789D6BD472-15A5-46D2-9EA7-B171AC022AE4533mg130mg463126ChemotherapyDoxorubicinADJUVANTIVNO181120101TCGA-BH-A0HP-D4779ACE2A3F8-7C97-4502-8EED-53F76CBF99685347mg1308mg463126ChemotherapyCyclophosphamideADJUVANTIVNO181120101TCGA-BH-A0HP-D4777B29234C4-907F-4C3B-9AE1-ECF150514F2E1mg/day347Hormone TherapyArimidexADJUVANTPOYES30112010,TCGA-BH-A0HP-R47822A420110-2D52-44D7-BF2D-5A5C6907AABE275330EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO130112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,106.0,WHITE,TCGA-D8-A1JU,D8,A1JU,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,manual counting,manual counting,Left Upper Outer Quadrant,2.010302734374984,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Reexcision of segmental mastectomy,Other,Segmental mastectomy with sentinel node biopsy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0703125,0.0,>75%,>75%,90-99%,Dako,Hecep Test TM DAKO,196.44921875,HER2 amplification - negative,>= 2.0 Positive,YES,NO,66,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,4.70,3 Point Scale,1+,7thStage IAT1cN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,3,2011,TCGA-D8-A1JU-F14045B6D244EC-4151-4FF5-BDCF-0C2E6D22101AScheduled Follow-up SubmissionNOYESAlive447TUMOR FREENO1872011,TCGA-D8-A1JU-D14044E80A862C-2FA5-4802-9986-D1635BD35BD720mg/day20mg/day87Hormone TherapyTamoxifenADJUVANTPOYES1872011,TCGA-BH-A0HP-R47822A420110-2D52-44D7-BF2D-5A5C6907AABE275330EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO130112010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,372.0,WHITE,TCGA-A2-A1G4,A2,A1G4,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,15.0,ER Positive H-Score 95,Allred score 4+3 = 7,Right Lower Outer Quadrant,1.4973339843749982,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.1572265625,2.0,Allred score = 5,allred score = 7,90-99%,Dako,Venten,109.5166015625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,4.43,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,172,3 Point Scale,3+,7thStage IIIAT3N1aM0,YES,YES,YES994Distant MetastasisBoneNOYESYES,22,4,2011,TCGA-A2-A1G4-F2080505CF4C23-40FE-4F52-B9E0-3BE877BC4F3FScheduled Follow-up SubmissionNOYESAlive595TUMOR FREENO912012,2TCGA-A2-A1G4-D123456491326b-97e4-4bc3-bc1b-3420c081b2bf480mg80mg680185ChemotherapyAdriamycinADJUVANTIVNO27420114TCGA-A2-A1G4-D12347f7d16c97-46c7-4712-83cb-f31c52b38ea42.5mg207Hormone TherapyFemaraADJUVANTPOYES27420111TCGA-A2-A1G4-D123445971ea22-14b8-49be-8ee4-c621e8529ea74770mg795mg680185ChemotherapyCytoxanADJUVANTIVNO27420113TCGA-A2-A1G4-D1234659b0a147-3154-47c9-907a-765fdba4002d720mg120mg680185ChemotherapyTaxotereADJUVANTIVNO2742011,TCGA-E2-A1LI-R20626B73909E2-58E4-42C3-AFFF-2F8746177C50152194Primary Tumor FieldADJUVANTNO11212012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-A8-A094,A8,A094,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.83984375,image cytometry,Allred score 0+0=0,Left,2.510742187500001,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.875,0.0,Allred score 8,Allred score 8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,145.03125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,54,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,60,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-BH-A0DT-F59149547CCD51-6C97-4C0B-9A88-08154FBB4C87NOYESYESTUMOR FREEAlive2403NO152014,"1TCGA-A2-A0CM-D201851cca21e-fd29-4d59-9de1-916fc77056e0424mg106mg498147ChemotherapyAdriamycinADJUVANTIVNO23820105TCGA-A2-A0CM-D202680df2add-560a-429f-9f42-6469a5e88bba24400mg2000-3500mg8391615ChemotherapyCapecetabinePROGRESSIONPONO23820102TCGA-A2-A0CM-D202088adeb77-bcc1-48cb-a270-92cdc1fe8f244248mg1062mg498147ChemotherapyCytoxanADJUVANTIVNO24820103TCGA-A2-A0CM-D2022afae9c46-2307-4844-b80b-cb436fc1e8bb20mg/day234Hormone TherapyTamoxifenADJUVANTPONO24820104TCGA-A2-A0CM-D20242a0f9e7d-47a8-4977-9845-f9255d292e92890mg100-131mg8391601ChemotherapyDocetaxelPROGRESSIONIVNO24820106TCGA-A2-A0CM-D2027e8027663-89df-4c62-9c8c-b7709606de608mg4mg2391433Other, specify in notesBisphosphonate therapyZometaPROGRESSIONIVNO2482010",TCGA-BH-A0DL-R603911BDA7B8A-1E8C-4A96-832E-5D9489A9F1AD154205External6640cGy36Primary Tumor FieldNOComplete Response962014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1374.0,WHITE,TCGA-BH-A0DV,BH,A0DV,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,9.0,H-Score 270,H-Score 290,Left Upper Inner QuadrantLeft Lower Inner QuadrantLeft Lower Outer QuadrantLeft,1.9426855468750015,Sentinel node biopsy alone,SLN and non-SLN biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Excision,Infiltrating Ductal Carcinoma,ductal/mucinous,Peri (6-12 months since last menstrual period),Positive,NO,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.9609375,9.0,Allred score 8,Allred Score,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,52.73046875,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,2.13,LungBone,70-79%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,145,3 Point Scale,1+,6thStage IIIAT2N2aM0,NO,YES,YES766Distant MetastasisBoneNOYESNO,2,8,2011,TCGA-BH-A0DV-F6367239C1B260-0C00-4D1C-93D1-6F57AB835DD1NOYESYESTUMOR FREEAlive2064NO1582014,NOTCGA-BH-A0DV-D63673C3346CC5-8B94-4A86-A119-C6A580D232C848176ChemotherapyTaxotereNOComplete Response1582014NOTCGA-BH-A0DV-D636746D3D306F-FA11-4AED-93F7-6388AEE8F08948177ChemotherapyAdriamycinNOComplete Response1582014NOTCGA-BH-A0DV-D63675BB94428A-1E62-47AC-BB42-8CA90FF6F1BD48177ChemotherapyCytoxanNOComplete Response1582014,TCGA-BH-A0DV-R636764BEA7C33-55A3-42B7-97E0-D43F494C6B9D177223External6040cGy33Primary Tumor FieldNOComplete Response1582014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,485.0,WHITE,TCGA-A2-A0EY,A2,A0EY,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,23.0,H-SCORE 136,Allred score 7 per outside facility report,Right Upper Outer Quadrant,7.0,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Lumpectomy,Reexcision of segmental mastectomy,Other,surgical resection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Patey's Suregery,Positive,Positive,Positive,0.0,1.0,230,250,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,106.8603515625,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.57,"LungOther, specifyleft adrenal gland",60-69%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,105,3 Point Scale,1+,6thStage IIBT2N1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,9,2010,TCGA-A2-A0EY-F13716B1FF94BC-9F0B-4998-9EF9-4163BAA4F01AScheduled Follow-up SubmissionYESYESAlive1925TUMOR FREENO1062011,1TCGA-A2-A0EY-D18871c31f4fe-aaf3-45bb-85cc-ddc5a1ed81e9418mg104-105mg4105154ChemotherapyAdriamycinADJUVANTIVNO22920103TCGA-A2-A0EY-D18904ffd1583-1089-4c1a-9c65-3b1413b8983c516mg129mg4183245ChemotherapyDocetaxelADJUVANTIVNO22920104TCGA-A2-A0EY-D1891e621dfac-f2ac-4604-a5fa-520f61070b6cmg1000 mg dailymg183Targeted Molecular therapyLapatinibADJUVANTPOYES22920106TCGA-A2-A0EY-D18938da373c9-e16f-4a58-b3ff-6c294e12787c1 mg dailymg329Hormone TherapyArimidexADJUVANTPOYES22920105TCGA-A2-A0EY-D1892c5f2e97a-c397-4193-a55d-c10d91996a6b134.4-406mg183Targeted Molecular therapyHerceptinADJUVANTIVYES22920102TCGA-A2-A0EY-D18885da60b2a-4a81-450f-8a9a-f577b0f3dc834176mg1038-1050mg4105154ChemotherapyCytoxanADJUVANTIVNO2292010,TCGA-A2-A0EY-R18865148e209-8e28-494c-899a-8125f2fc630a279316EXTERNAL BEAM5040cGy28Primary Tumor FieldADJUVANTNO12292010TCGA-A2-A0EY-R70741D655C090-1E63-49A2-B223-763B535B3287317328External1000cGy5Primary Tumor FieldNOComplete Response332015TCGA-A2-A0EY-R70742EBA1B640-7E29-4BCF-8368-04A1FBFF1329279316External5040cGy28Regional siteNOComplete Response332015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2074.0,WHITE,TCGA-AR-A24N,AR,A24N,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,4.0,Allred score 0+0 = 0,Image Analysis,Left Upper Inner Quadrant,1.583994140624995,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Simple Mastectomy,Reexcision of segmental mastectomy,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,malignant phyllodes,Peri (6-12 months since last menstrual period),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,0.0068359375,0.0,Allred score = 0,Allred Score 8,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,61.9150390625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,40,"LungBoneLiverOther, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,60,4 Point Scale,2+,6thStage IT1N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,8,2011,TCGA-AR-A24N-F31355BEF9D8BE-4363-4948-A6E3-37095E1903CCScheduled Follow-up SubmissionNONOAlive2074NO152012TCGA-AR-A24N-F494917FF92C18-C896-42D4-938C-B0891048B2AENONONOTUMOR FREEAlive2388NO2102013TCGA-AR-A24N-F717235A3C20C7-DC2F-4027-8996-DA5A07981E0ENONONOTUMOR FREEAlive3035NO3032015,4x chemotherapy+hormonotherapyTCGA-D8-A13Y-D13807EC2B79A5-64D5-43E1-BB6A-A4C03BD0615E60mg/m260mg/m247161ChemotherapydoxorubicinADJUVANTIVNO2062011NOTCGA-D8-A13Y-D653125BE46DF7-F6A7-4D7D-9ECD-B805B4C946017161ChemotherapycyclophosphamideNO2292014,TCGA-A2-A0EO-R19929e36f785-838a-4b6a-a404-6cb8df45ea5a91137EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO11182010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1150.0,ASIAN,TCGA-AR-A1AS,AR,A1AS,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,17.0,allred score 5+3=8,CAP scoring guideline 2010,Left Upper Inner Quadrant,1.574033203124996,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Other,Wide local excision,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0341796875,1.0,H-SCORE,H-Score,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,68.9453125,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,NO,YES,2.13,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.8,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",14,6,2011,TCGA-AR-A1AS-F220886568AC84-702A-4E37-9A5D-F8A2C0B5CEBEScheduled Follow-up SubmissionYESNOAlive1150NO2822012TCGA-AR-A1AS-F4947086521E70-553E-442A-BB81-F0E66AEFAE1BNOYESNOTUMOR FREEAlive1150NO2102013,2TCGA-AR-A1AS-D22098A43B3752-2843-4BA5-A3BA-DB1229CD3C621mg/day57Hormone TherapyAnastrozoleADJUVANTPOYES27220121TCGA-AR-A1AS-D2209231EE0BA4-5B45-4A29-BE1E-D544D6290707200mg60mg/m222943ChemotherapyDoxorubicinADJUVANTIVNO28220121TCGA-AR-A1AS-D22094FE2D8B3C-0216-4CAE-B606-2C2BF40EBB871970mg600mg/m222943ChemotherapyCytoxanADJUVANTIVNO2822012,TCGA-AR-A1AS-R2209082211072-5912-45D8-9836-6D27865EF38977118EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO12822012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,620.0,WHITE,TCGA-BH-A0HI,BH,A0HI,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,1.0,H-Score 240,H-Score 160,Right Upper Inner QuadrantRight Lower Inner QuadrantRight,1.482080078124997,Sentinel node biopsy alone,Pateys surgery,Other,Reexcision of segmental mastectomy,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.0,0.0,H-Score,H-Score,<10%,Hercep Test  TM Dako,DAKOHercepTest TM,40.2421875,Vysis AutoVysion System,PathVision HER2 DNA Probe Kit,NO,YES,40,"LungOther, specifyleft adrenal gland",50-59%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.3,3 Point Scale,1+,Stage IAT1cN0 (i-)M0,NO,YES,YES766Distant MetastasisBoneNOYESNO,10,11,2010,TCGA-BH-A0HI-F47560729B5EE-C7F0-4F0A-9F04-4A7E417515FC620AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0HI-D4751793A09D5-84AB-4A44-8D82-805D14E455731mg/day88Hormone TherapyArimidexADJUVANTPOYES17112010,TCGA-BH-A0HI-R475442D1C987-18FD-4ABB-A93D-5D836F4ED4C496141EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO122112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,287.0,WHITE,TCGA-A7-A13E,A7,A13E,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,12.0,Allred (Biocare),CAP scoring guideline 2010,Left Upper Outer Quadrant,1.1,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,breast conserving therapy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.361328125,2.0,Allred Score 4,moderate,90-99%,CISH,DAKOHercepTest TM,561.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe Kit,YES,NO,3.0,"LungBoneLiverOther, specifyskin",20-29%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.2,3 Point Scale,2+,Stage IIBT2N1MX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,2,2011,"TCGA-A7-A13E-F9345624C544A-EABA-4615-9912-C86A62D148EA326AliveTUMOR FREEYESYES2132011TCGA-A7-A13E-F3040510F815AF-1701-4E90-A5B7-C9A30984BF5EAdditional New Tumor EventNOYESDead614WITH TUMORYES556Distant MetastasisOther, specifyLung, Bone, Liver, Brain and Skin NodulesNOYESYESNegativeNegativeNegative1+942012",1TCGA-A7-A13E-D84816b9ba4ba-7f9d-4756-b32b-d5bc244ed7e71mg211Hormone TherapyArimidexADJUVANTPOYES28220111TCGA-A7-A13E-D83872a1cd4f5-b57f-4701-a524-65a4c933838e9136mg914-1364mg867193Targeted Molecular therapyBevacizumabADJUVANTIVNO21320111TCGA-A7-A13E-D8384ab9b71e4-bef4-4ef9-aee1-f529cd48d75e486mg120-122mg467108ChemotherapyDoxorubicinADJUVANTIVNO21320111TCGA-A7-A13E-D8385dacbe1fe-726e-49ea-807c-c058a56849ab4848mg1200-1230mg467108ChemotherapyCyclophosphamideADJUVANTIVNO21320111TCGA-A7-A13E-D8386d8fde920-62a6-411b-8bb4-b2d156e504c41908mg158-160mg4123207ChemotherapyPaclitaxelADJUVANTIVNO21320112TCGA-A7-A13E-D3041117FFDC6B-E84C-4E5B-999D-D68ED4BF7881157mg157mg1574574ChemotherapyTaxolPALLIATIVEIVNO9420121TCGA-A7-A13E-D30410983433D3-76A3-4F8C-9397-6496805CDAB0379mg1mg211589Hormone TherapyAnastrozoleADJUVANTPONO942012,TCGA-A7-A13E-R8473d0e25ccc-163e-4d8e-822f-3703bdff238e238287EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO12822011TCGA-A7-A13E-R30409B6E2B338-90E5-4321-A73B-84030A994930584598EXTERNAL BEAM3000cGy10Distant sitePALLIATIVENO3942012TCGA-A7-A13E-R304086001F2EF-D19E-42B5-8DB5-91084F93BFB8557563EXTERNAL BEAM2000cGy5Distant sitePALLIATIVENO2942012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0XL,AN,A0XL,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,CAP SCORING GUIDELINE 2010,H-Score 0,Left Upper Outer Quadrant,5.196113281249995,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Reexcision of segmental mastectomy,Other,Mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,stereotactic biopsy,Negative,Positive,Negative,0.001953125,0.0,60,130,40-49%,ACIS,CAP scoring guideline 2010,211.8662109375,HER2 amplification - negative,>= 2.0 Positive,NO,YES,3.1,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,816,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",25,3,2011,TCGA-AN-A0XL-F689553060F448-5814-4CF8-B2CF-AB1B70F1098BYESNONOTUMOR FREEAlive16323122014,NOTCGA-LL-A442-D36069E1D4E54E-9B75-48FF-AF1C-506222B5E941111Hormone TherapyArimidexYES17102012,TCGA-A2-A0ET-R1874771405be-178c-469b-9e42-e26011660284ADJUVANTNO12092010
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,458.0,WHITE,TCGA-A8-A084,A8,A084,Yes,YES,C50.9,8500/3,C50.9,2007.0,WITH TUMOR,YES,13.0810546875,image cytometry,Allred 0 = 0+0,Left,2.214970703124989,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Other,Surgical resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,1+,Negative,Positive,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.5986328125,5.154296875,MODERATE,0%,10-19%,ACIS,CAP SCORING GUIDELINE 2010,114.0810546875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,33,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,60,3 Point Scale,2+,5thStage IIBT2N1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A084-F40838F5462E4C-B26A-4A0D-A80C-E8B1595300E0NOYESNOWITH TUMORAlive458232013,TCGA-D8-A1JI-D2075647A735BC-1929-456F-A0AB-F5026052E183mg2.5mg/m2/day641162ChemotherapydoxorubicineADJUVANTIVNO1912012NOTCGA-D8-A1JI-D6532648F56CD7-78CE-4306-8B6C-236C717C7B5B41162ChemotherapycyclophosphamideNO2292014NOTCGA-D8-A1JI-D6532748CDB206-6F2C-4B85-AD7B-E40F9B481D4741162Hormone TherapyletrozolumNO2292014,TCGA-A8-A084-R3815191333E9B-66B8-4BFE-A799-B12A6394BE74ExternalGyPrimary Tumor Field11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,16.0,WHITE,TCGA-AN-A0G0,AN,A0G0,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,23.0,Allred score 5+3=8,CAP scoring guideline 2010,Right Upper Inner Quadrant,2.72683593749998,No axillary staging,axillary ultrasound,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,Partial Mastectomy,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,0,0,20-29%,0,CAP SCORING GUIDELINE 2010,71.6181640625,Vysis AutoVysion System,>= 2.0 Positive,NO,YES,2.7,Lung,<10%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,816,3 Point Scale,1+,Stage IIAT2N0M0,YES,NO,YES766Distant MetastasisBoneNOYESNO,29,12,2010,TCGA-AN-A0G0-F6897015A83D83-B3D3-45E7-8262-3E6CDC4B1C5DYESYESYESTUMOR FREEAlive1624122014,NOTCGA-LL-A442-D36069E1D4E54E-9B75-48FF-AF1C-506222B5E941111Hormone TherapyArimidexYES17102012,TCGA-OL-A5D7-R65250737BD5F1-6E92-4485-96EE-BA831B7A24C9134550External5040cGyPrimary Tumor FieldNOComplete Response2492014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,264.0,WHITE,TCGA-D8-A13Y,D8,A13Y,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,6.0,manual counting,manual counting,Right Upper Outer Quadrant,1.3484960937499937,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,Total mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.091796875,0.0,10-75%,10-75%,90-99%,Hercep Test  TM Dako,Hecep Test TM DAKO,452.2451171875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,74,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.0,3 Point Scale,2+,Stage IAT1cN0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,23,2,2011,TCGA-D8-A13Y-F138061EB415B3-10F0-4A5A-9621-E7D90A9C3650Scheduled Follow-up SubmissionNOYESAlive362TUMOR FREENO2062011TCGA-D8-A13Y-F72210F83FC2BB-608A-4335-94F9-3607FE7D1296NONOYESTUMOR FREEAlive1728NO2942015,4x chemotherapy+hormonotherapyTCGA-D8-A13Y-D13807EC2B79A5-64D5-43E1-BB6A-A4C03BD0615E60mg/m260mg/m247161ChemotherapydoxorubicinADJUVANTIVNO2062011NOTCGA-D8-A13Y-D653125BE46DF7-F6A7-4D7D-9ECD-B805B4C946017161ChemotherapycyclophosphamideNO2292014,TCGA-A7-A13E-R8473d0e25ccc-163e-4d8e-822f-3703bdff238e238287EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO12822011TCGA-A7-A13E-R30409B6E2B338-90E5-4321-A73B-84030A994930584598EXTERNAL BEAM3000cGy10Distant sitePALLIATIVENO3942012TCGA-A7-A13E-R304086001F2EF-D19E-42B5-8DB5-91084F93BFB8557563EXTERNAL BEAM2000cGy5Distant sitePALLIATIVENO2942012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,10.0,WHITE,TCGA-AN-A0XR,AN,A0XR,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,CAP scoring guideline 2010,IHC,Left Upper Outer Quadrant,1.988554687499977,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,Mastectomy,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Negative,0.318359375,7.0,0,160,50-59%,CISH,CAP scoring guideline 2010,217.4921875,HER2 amplification - negative,>= 2.0 Positive,NO,YES,3.1,"Other, specifyaxilaary node negative but intrammary node positive",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,816,3 Point Scale,2+,7thStage IIIAT2N2M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",25,3,2011,TCGA-AN-A0XR-F56951B7A4A241-84FC-4828-8CEA-3BA465FDF1CAYESNONOTUMOR FREEAlive1023122014,NOTCGA-E9-A227-D554753A15749D-3272-4218-A622-DE1C45896D3B92197ChemotherapyTaxotereNOComplete Response712014NOTCGA-E9-A227-D55476A7D3378B-00F0-4BCE-9E2F-C2E4045282A9239Hormone TherapyTamoxifenYES712014,TCGA-D8-A1JI-R20755A5565D0D-C16A-4574-BE2A-7D4C24927E76204231EXTERNAL BEAMcGy20Regional siteADJUVANTNO1912012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,21.0,WHITE,TCGA-D8-A1JI,D8,A1JI,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,22.0,manual counting,manual counting,Right Upper Outer Quadrant,1.2601953124999934,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,breast conserving therapy,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Negative,0.2314453125,2.0,>75%,>75%,90-99%,Dako,DAKOHercepTest TM,369.6318359375,HER2 amplification - negative,Ratio >=2.0,YES,NO,2.13,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.23,3 Point Scale,2+,7thStage IIAT1cN1aMX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",30,3,2011,TCGA-D8-A1JI-F2075764833FD0-E1B5-4773-8638-1E41D0B9B4F0Scheduled Follow-up SubmissionYESYESAlive577TUMOR FREENO1912012,TCGA-D8-A1JI-D2075647A735BC-1929-456F-A0AB-F5026052E183mg2.5mg/m2/day641162ChemotherapydoxorubicineADJUVANTIVNO1912012NOTCGA-D8-A1JI-D6532648F56CD7-78CE-4306-8B6C-236C717C7B5B41162ChemotherapycyclophosphamideNO2292014NOTCGA-D8-A1JI-D6532748CDB206-6F2C-4B85-AD7B-E40F9B481D4741162Hormone TherapyletrozolumNO2292014,TCGA-D8-A1JI-R20755A5565D0D-C16A-4574-BE2A-7D4C24927E76204231EXTERNAL BEAMcGy20Regional siteADJUVANTNO1912012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,24.0,WHITE,TCGA-E9-A227,E9,A227,No,YES,C50.9,8500/3,C50.9,2011.0,WITH TUMOR,YES,17.0,CAP SCORING GUIDELINE 2010,Allred score 2+2 = 4,Left Upper Outer Quadrant,2.208535156249978,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Lumpectomy,Re-excision of original lumpectomy site,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,ductal and lobular,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,4+,1+,Negative,Positive,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.00390625,1.0,Two-tier,Two-tier,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,130.09765625,HER2 amplification - negative,Ratio >=2.0,YES,NO,40,"LungBoneLiverOther, specifyskin",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,185,4 Point Scale,4+,7thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,7,2011,TCGA-E9-A227-F33186D4BCCFC5-9338-40F9-910E-E4D32F436FF8Scheduled Follow-up SubmissionYESYESAlive975TUMOR FREENO712013TCGA-E9-A227-F5857121BBE5D6-57A3-4D50-927B-D6C087DCDAAAYES2942014,NOTCGA-E9-A227-D554753A15749D-3272-4218-A622-DE1C45896D3B92197ChemotherapyTaxotereNOComplete Response712014NOTCGA-E9-A227-D55476A7D3378B-00F0-4BCE-9E2F-C2E4045282A9239Hormone TherapyTamoxifenYES712014,TCGA-E9-A227-R5547783F17951-387D-4703-A980-57BB2DCBB075216245External5256cGy21Primary Tumor FieldNOComplete Response712014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,605.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A574,E2,A574,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,4.0,Allred 0 = 0+0,Allred 0 = 0+0,Left,1.0,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Reexcision of segmental mastectomy,Other,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Equivocal,1.6455078125,0.0,Allred Score,Allred Score,10-19%,Hercep Test  TM Dako,Hercep Test  TM Dako,200.0,HER2 amplification - negative,Ratio >=2.0,NO,YES,2.8,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.8,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,NO,20,6,2013,TCGA-E2-A574-F675814F60D388-7BCF-4844-A47B-E143279BEA01NOYESYESTUMOR FREEAlive808NO6112014TCGA-E2-A574-F70296F674155C-12D0-46EA-BD0C-3A5AC675C845NOYESYESTUMOR FREEAlive1179NO922015,NOTCGA-E2-A574-D4449302DB6D61-50D4-4B55-B5BF-A0FA7D3B5B1364106ChemotherapyAdriamycinNO2062013NOTCGA-E2-A574-D44495CC66FB23-52DD-432E-87B3-4C10E78479AA64106ChemotherapyCytoxanNO2062013NOTCGA-E2-A574-D44497DCC1FD78-D8B4-4CFE-8322-0E57C1F1D14B120162ChemotherapyAbraxaneNO2062013,TCGA-E2-A574-R444924F7A8469-49C3-4615-884A-A4068C9C9597195246External6640cGy36Primary Tumor FieldNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,396.0,WHITE,TCGA-A8-A086,A8,A086,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,9.5205078125,image cytometry,Allred score 0+0=0,Right,2.3395996093749813,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,0,Negative,Negative,Tumor resection,intraoperative examination,Negative,Positive,Negative,0.771484375,1.1064453125,Allred score 8,Allred score 8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,129.9228515625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,40,Lung,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,3.0,3 Point Scale,2+,6thStage IIAT1cN1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A086-F40840EB8F9F5C-FC49-4DB0-95B6-F2FC583DE891NOYESYESTUMOR FREEAlive396NO232013,NOTCGA-A8-A086-D3777069FDE7B7-F6E1-48E5-B4EC-553EBEA6839C092ChemotherapyDocetaxeln/aNOComplete Response6122012NOTCGA-A8-A086-D377710C96C615-A569-425F-A761-07276A751736092ChemotherapyCyclophosphamiden/aNOComplete Response6122012,TCGA-A8-A086-R381594F1BECB4-7EA6-4768-8663-1670B1C4251D123153External62GyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1001.0,WHITE,TCGA-A2-A0ES,A2,A0ES,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,1.0,ER Positive H-Score 95,Allred score = 8,Left Upper Outer Quadrant,1.32,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Reexcision of segmental mastectomy,Other,partial mastectomy,Infiltrating Lobular Carcinoma,Ductal/Cribiform,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,0.0,240 H,180,30-39%,Dako,CAP scoring guideline 2010,251.373046875,HER2 amplification - negative,Ratio >=2.0,NO,YES,50,LungBone,60-69%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.460605468749991,1.62,3 Point Scale,2+,6thStage IIAT2N0 (i-)M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",25,1,2011,TCGA-A2-A0ES-F13718C9932931-F12D-40AD-BF47-AB513F33CA9BScheduled Follow-up SubmissionNOYESAlive1127TUMOR FREENO1062011TCGA-A2-A0ES-F59395478BA8B4-7059-4636-9A1A-07F93335C426NONOYESTUMOR FREEAlive2190NO1252014,3TCGA-A2-A0ES-D668408fef96e-bb08-4bf3-ad02-6018935a8f471mg203458Hormone TherapyAnastrozoleADJUVANTPONO7120112TCGA-A2-A0ES-D66836ea08fed-b015-4b7a-9ab3-d4beda0a721e640mg160mg477141ChemotherapyDocetaxelADJUVANTIVNO7120111TCGA-A2-A0ES-D66826c50633b-c480-4794-b943-a834c0c124635018mg1180-1280mg477141ChemotherapyCytoxanADJUVANTIVNO7120114TCGA-A2-A0ES-D6685410e1f53-15e7-4ae7-9d01-2fee31ecd2f625mg459Hormone TherapyExemestaneADJUVANTPOYES712011,TCGA-BH-A0HP-R47822A420110-2D52-44D7-BF2D-5A5C6907AABE275330EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO130112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,254.0,WHITE,TCGA-A7-A0CE,A7,A0CE,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,1.0,Allred 0 = 0+0,CAP scoring guideline 2010,Left,1.1,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Lumpectomy,Reexcision of segmental mastectomy,Other,TOTAL MASTECTOMY,Infiltrating Ductal Carcinoma,malignant phyllodes,Indeterminate (neither Pre or Postmenopausal),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Negative,Equivocal,0.0,0.0,Allred Score,Intensity=Strong,10-19%,0,CAP scoring guideline 2010,389.0,Vysis AutoVysion System,PathVysion,YES,NO,2.9,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.2,3 Point Scale,1+,Stage IIAT2N0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,4,10,2010,TCGA-A7-A0CE-F20716C5CD45B-C966-4982-A81F-CD4385029102310AliveTUMOR FREEYESYES9112010TCGA-A7-A0CE-F39153EAEC135D-263E-4230-97DF-BFEB960B4161NOYESYESTUMOR FREEAlive1074NO1412013,1TCGA-A7-A0CE-D314089072b52-11c9-4fe9-86c0-fff7dbaf8e8e520mg130mg463105ChemotherapyAdriamycinADJUVANTIVNO91120101TCGA-A7-A0CE-D31439464606d-3ece-43bd-aad1-7126b43626c91520mg380mg4119161ChemotherapyTaxolADJUVANTIVNO91120101TCGA-A7-A0CE-D314230d2d91e-18e4-4adb-87e1-e9154ad7cf0e5250mg1310-1320mg463105ChemotherapyCytoxanADJUVANTIVNO9112010,TCGA-A7-A0CE-R297903d6bcae-2761-4649-a609-07dd7316aa81189238EXTERNAL BEAM6100cGy33Primary Tumor FieldADJUVANTNO15112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1156.0,WHITE,TCGA-BH-A0DH,BH,A0DH,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,28.0,Allred score = 8,Allred score 3+3=6,Left Upper Outer QuadrantLeft,2.1394531249999984,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Mastectomy NOS,Segmental mastectomy,Infiltrating Ductal Carcinoma,ductal/mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,0,Negative,Positive,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.4375,3.0,Allred score = 8,Allred Score 6,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,41.0888671875,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,1.57,"LungOther, specifyleft adrenal gland",90-99%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,71,3 Point Scale,3+,Stage IIBT2N1aM0,NO,YES,YES766Distant MetastasisBoneNOYESNO,8,11,2010,TCGA-BH-A0DH-F452903118CCF-5575-4CB5-840E-2DE55AA5F8FA1156AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0DH-D4521739195B2-FD02-405E-9A84-3013536F114F471143ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO161120101TCGA-BH-A0DH-D45193CED1251-3C25-4394-9ACA-4BE463307C372.5mg/day164Hormone TherapyFEMARAADJUVANTPOYES161120101TCGA-BH-A0DH-D4524D3845BE6-7A25-470F-A220-34434866432E471143ChemotherapyTAXOTEREADJUVANTIVNO171120101TCGA-BH-A0DH-D452260D7BF55-6327-457F-973E-6A5BF4E8FDC3471143ChemotherapyDOXORUBICINADJUVANTIVNO17112010,TCGA-BH-A0DH-R45277A76D067-B17D-48A7-8210-123A89951ED4189233EXTERNAL BEAM6000cGy30Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,395.0,WHITE,TCGA-A2-A0T4,A2,A0T4,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,2.0,No value Given,H-Score 190,Right Upper Inner Quadrant,1.1,Other (specify),SLN and non-SLN biopsy,Simple Mastectomy,Reexcision of segmental mastectomy,Other,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Lobular Carcinoma,Invasive ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.0,0.0,Allred score 8,Strong,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,58.1513671875,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,2.7,"Other, specifySkin",90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,71,3 Point Scale,2+,Stage IIAT2N0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,17,11,2010,TCGA-A2-A0T4-F1394843B17021-D7A9-468C-8D2B-2554DDEBFC47Scheduled Follow-up SubmissionNOYESAlive624TUMOR FREENO1272011,1TCGA-A2-A0T4-D3991c3b20047-64e2-4f31-b600-d2eb3c74c467mg2.5mg85Hormone TherapyFemaraADJUVANTPOYES17112010,TCGA-GM-A2DB-R47157D6AC4D25-3614-447E-8DF4-09A1DBE09817271317ExternalPrimary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1989.0,BLACK OR AFRICAN AMERICAN,TCGA-B6-A401,B6,A401,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,4.0,allred score 5 + 3 = 8,image cytometry,Left Upper Outer Quadrant,1.380576171874994,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Lumpectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.0693359375,1.0,240 H,270 H,<10%,Hercep Test  TM Dako,Dako Hercept test,86.7275390625,HER2 amplification - negative,Ratio >=2.0,NO,YES,33,"LungBoneLiverOther, specifyskin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,42,4 Point Scale,3+,6thStage IIAT1cN1aM0,YES,YES,NO,20,9,2012,TCGA-B6-A401-F59658598C5FF1-2D6F-4041-98A3-D52614BAC4F3NONONOTUMOR FREEAlive2596NO362014,NOTCGA-B6-A401-D411009AC61F74-CB87-4FC6-B069-6DA7425DABAB50155ChemotherapyCyclophosphamideNO1232013NOTCGA-B6-A401-D41102AA65ED83-981C-42BA-9EDE-AA4991F5374C50155ChemotherapyDoxetaxelNO1232013NOTCGA-B6-A401-D41103583BFE0F-4663-46A0-81BE-C7282F6EBDE850155ChemotherapyDoxorubicinNO1232013NOTCGA-B6-A401-D41105218EF3A9-4E64-430C-8C51-B6EE6EA27054375ChemotherapyFemaraYES1232013,TCGA-B6-A401-R4109747DF79D5-C4F9-437F-9C6B-79FD20A4F17D205284ExternalPrimary Tumor FieldNO1232013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1218.0,WHITE,TCGA-AR-A2LM,AR,A2LM,No,YES,C50.9,8520/3,C50.9,2007.0,TUMOR FREE,YES,3.0,IHC,Allred score 5+3 = 8,Right,5.35599609375002,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node plus Level I and Level II lymph nodes,Simple Mastectomy,Re-Excision of Superior Margin,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Lobular Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Positive,Equivocal,0.5341796875,1.0,Allred Score,Moderate,90-99%,Hercep Test  TM Dako,DAKOHercepTest TM,379.3974609375,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,2.8,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.5724609374999916,1.1,3 Point Scale,2+,6thStage IIT1N1M0,YES,YES,Positive70-79%Positive<10%Negative1+,12,1,2012,TCGA-AR-A2LM-F37336D6D5F194-B9A7-44DB-B31C-AB8AF2E8F81BNONOYESTUMOR FREEAlive1585NO6122012TCGA-AR-A2LM-F717467E511158-49BC-41A4-B9B7-0A7639BED9D7NONOYESTUMOR FREEAlive1935NO3032015,NOTCGA-AR-A2LM-D37338AFF8E2B0-7981-4EDB-811C-11EBF3B60ED07899ChemotherapyDocetaxelNO6122012NOTCGA-AR-A2LM-D3733957372622-06C2-481D-8D49-98803E95907578141ChemotherapyCytoxanNO6122012NOTCGA-AR-A2LM-D37345955A2DF7-0D64-49CF-9A73-05F722680C2B120141ChemotherapyAbraxaneNO6122012NOTCGA-AR-A2LM-D37346F4D3BD0B-BC50-4E1A-A781-07B6C2A53B31170967Hormone TherapyTamoxifenNO6122012,TCGA-E2-A573-R44499400B06FE-ADCF-4256-98CF-9BA8697DB36C201251External66.4Gy36Primary Tumor FieldNOComplete Response2062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1616.0,WHITE,TCGA-GM-A2DB,GM,A2DB,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,3.0,CAP SCORING GUIDELINE 2010,Allred score 2+3 = 5,Left Upper Outer Quadrant,1.11,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Reexcision of segmental mastectomy,Other,Excision,Infiltrating Ductal Carcinoma,Ductal & Mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,allred score = 8,Allred Score 6,90-99%,0,CAP SCORING GUIDELINE 2010,60.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,1.50,"Other, specifyaxilaary node negative but intrammary node positive",<10%,<10%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.67,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,NO,YES766Distant MetastasisBoneNOYESNO,28,9,2011,TCGA-GM-A2DB-F471565F9BC2B1-50F3-4A6F-9B76-6BE7330FCA84NOYESYESTUMOR FREEAlive2406NO2282013,NOTCGA-GM-A2DB-D47159FCDFC8F4-07C3-4F53-A0E4-135FC08A31D691167ChemotherapyTaxolNOComplete Response2282013NOTCGA-GM-A2DB-D471618109884C-3338-42A4-8167-9ABEF5678D23181248ChemotherapyFluorouracilNOComplete Response2282013NOTCGA-GM-A2DB-D471629C452D7D-4120-4BFE-B788-AEF890F1DA60181248ChemotherapyEpirubicinNOComplete Response2282013NOTCGA-GM-A2DB-D471639DB393BE-D1F8-4423-BE3A-1201B189B8E6181248ChemotherapyCytoxanNOComplete Response2282013,TCGA-GM-A2DB-R47157D6AC4D25-3614-447E-8DF4-09A1DBE09817271317ExternalPrimary Tumor FieldNOComplete Response2282013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2619.0,WHITE,TCGA-A2-A0ST,A2,A0ST,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,9.0,H-SCORE 280,H-SCORE 250,Right Upper Outer Quadrant,1.3,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Lumpectomy,Reexcision of segmental mastectomy,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,2+,Negative,Negative,Excisional Biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.0,3.0,H-Score,230,<10%,ACIS,Hercep Test  TM Dako,85.1630859375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,64,"Other, specifySkin",<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,816,3 Point Scale,2+,6thStage IIAT1cN1aM0,YES,YES,YES766Distant MetastasisBoneNOYESNO,9,11,2010,TCGA-A2-A0ST-F140356E01D82D-BA83-4093-9E7A-387715D2F3A5Scheduled Follow-up SubmissionYESYESAlive3017WITH TUMORYES1472011,1TCGA-A2-A0ST-D37164c03e578-c8ca-49dd-abbd-aa6f1f676b33392mg98mg44485ChemotherapyAdriamycinADJUVANTIVNO101120103TCGA-A2-A0ST-D37180ad8fde3-e018-471c-a012-d97a9ad7a75e1148mg287mg485155ChemotherapyTaxolADJUVANTIVNO101120104TCGA-A2-A0ST-D37198c26b6ae-71a7-47c8-86ce-4f99b68272d02.5mg/day251286Hormone TherapyLetrozoleADJUVANTPONO101120102TCGA-A2-A0ST-D371747ecba15-fb35-479e-beaa-92b787d0d2c63936mg984mg44485ChemotherapyCytoxanADJUVANTIVNO101120105TCGA-A2-A0ST-D3720b18f2d63-850a-44b6-b52d-f59f6187d11a1mg/day287Hormone TherapyAnastrozoleADJUVANTPO101120106TCGA-A2-A0ST-D3721f6b4a321-022e-475b-8d7d-a813f500b33620mg/day495Hormone TherapyTamoxifenADJUVANTPO10112010,TCGA-A2-A0ST-R371547e3cb28-a8ec-4f8b-8219-929a312408ae190233EXTERNAL BEAM5040cGyPrimary Tumor FieldADJUVANTNO110112010TCGA-A2-A0ST-R70357CE471AA1-298A-487F-B6A3-445126A2578E190233External5040cGyRegional siteNOComplete Response922015TCGA-A2-A0ST-R70359793704FD-D7A0-4911-AC99-9ACD0E500467236240External1000cGyPrimary Tumor FieldNOComplete Response922015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,5396.0,WHITE,TCGA-B6-A0WT,B6,A0WT,No,YES,C50.9,8500/3,C50.9,1995.0,TUMOR FREE,YES,15.0,Image Analysis,Image Analysis,Left Lower Inner QuadrantLeft,1.2793359375000002,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,right segmental mastectomy witrh axillary node dissection,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Patey's Suregery,Negative,Positive,Equivocal,0.2119140625,1.0,Two-tier,H score,10-19%,Hercep Test  TM Dako,dextran coated charcoal,39.3251953125,Vysis AutoVysion System,Path Vysion HER-2 DNA probe kit,NO,YES,2.13,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.5,4 Point Scale,2+,4thStage IIBT2N1M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,14,12,2010,"TCGA-B6-A0WT-F157287B8507DD-57BE-4892-89F5-CE354094972FScheduled Follow-up SubmissionNOYESAlive5739TUMOR FREEYES3862New Primary TumorOther, specifyright breast cancer contralateralYES3862NOYESPositiveOther Reporting Scalefmol/mgimage cytometryPositiveOther Reporting Scalefmol/mgimage cytometryEquivocal2+Negative2982011",NOTCGA-GM-A2DF-D470779309E85C-511C-4D64-A9FD-153D7D059F7682159ChemotherapyTaxolNOComplete Response2282013NOTCGA-GM-A2DF-D47078BD3CED99-2972-42AC-A40F-65D713B00CF1166229ChemotherapyFluorouracilNOComplete Response2282013NOTCGA-GM-A2DF-D470799759BFEA-6BA0-47F3-8697-D4BE5FD98515166229ChemotherapyEpirubicinNOComplete Response2282013NOTCGA-GM-A2DF-D470800DE09D9B-CDA0-4E1C-A438-47238333BAF8166229ChemotherapyCytoxanNOComplete Response2282013,TCGA-BH-A0AV-R591771E9BDB6B-495D-4881-8264-4717B2630D9B259308External66.4Gy36Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,350.0,BLACK OR AFRICAN AMERICAN,TCGA-E2-A1LG,E2,A1LG,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,19.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Left Upper Outer Quadrant,1.1,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,Total mastectomy,Infiltrating Lobular Carcinoma,ductal/mucinous,Peri (6-12 months since last menstrual period),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Equivocal,0.7138671875,0.0,Allred score = 0,Allred score = 0,60-69%,Hercep Test  TM Dako,Dako Hercept test,253.76953125,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,69,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.66,3 Point Scale,2+,7thStage IIAT2N0M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,3,6,2011,TCGA-E2-A1LG-F206670CC64B15-C83B-4BF7-A4C0-A7F03654D49EScheduled Follow-up SubmissionNOYESAlive574TUMOR FREENO1712012TCGA-E2-A1LG-F70390F8B62F0A-6F64-498B-826E-51156ED65F81NONOYESTUMOR FREEAlive1523NO1632015,"1TCGA-E2-A1LG-D20670DF10E7FA-8490-438B-9DCA-DD142DC33D12484mg121mg470112ChemotherapyDoxorubicinADJUVANTIVNO17120122TCGA-E2-A1LG-D20672166CD47F-16CF-45F5-8581-239149E00AD11554mg162mg10126203ChemotherapyPaclitaxelADJUVANTIVNO17120121TCGA-E2-A1LG-D20669488371CC-2C95-4257-B1B6-36AB273051234848mg1212mg470112ChemotherapyCyclophosphamideADJUVANTIVNO17120121TCGA-E2-A1LG-D206769B0E366A-08A8-40E8-A5C4-5C424DAE717E8860mg880mg470179Other, specify in notesPhase III clinical trialBevacizumab or PlaceboADJUVANTIVNO1712012",TCGA-A2-A4S2-R59112DEAE1C6E-08EF-4645-92DA-D80F6A0E5147224260External4500cGy25Regional siteNOComplete Response152014TCGA-A2-A4S2-R591147B603231-EF4A-4100-AB4A-ACEAF43C323D224260External4500cGy25Regional siteNOComplete Response152014TCGA-A2-A4S2-R591165330A79E-4763-4522-A54F-B042170DDBAC261271External1400cGy7Regional siteNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,92.0,WHITE,TCGA-E9-A6HE,E9,A6HE,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,12.0,Allred (Biocare),Allred score 2+2 = 4,Right,1.08,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Reexcision of segmental mastectomy,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Lobular Carcinoma,ductal and lobular features,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,4 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.87109375,12.0,240 H,allred score = 7,<10%,Hercep Test  TM Dako,Dako Hercept test,30.0,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,YES,NO,1.7,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.8,4 Point Scale,2+,7thStage IIICT3N3MX,YES,YES,NO,16,10,2013,TCGA-E9-A6HE-F5681304C878A3-833B-4620-BFE5-089365972076NOYESYESTUMOR FREEAlive468NO2422014TCGA-E9-A6HE-F70947E4603D87-4400-4911-84C6-3A4D5F0371DCNOYESYESTUMOR FREEAlive847NO1032015,NOTCGA-E9-A6HE-D5681475161762-89C2-45DD-B3F6-2C5CE67185BB104174ChemotherapyAdriamycinNOComplete Response2422014NOTCGA-E9-A6HE-D56815A670D2BD-0DD4-415F-91E3-B74DFC267B86104174ChemotherapyCyclophosphamideNOComplete Response2422014NOTCGA-E9-A6HE-D5681633B0A4BB-DC7E-43C0-86E2-93A6B112CAC5104307ChemotherapyPaclitaxelNOComplete Response2422014NOTCGA-E9-A6HE-D70948841B570D-BF43-46C2-BA09-48D7F7A17424547Hormone TherapyTamoxifenYES1032015,TCGA-E9-A6HE-R5681735448ACB-8809-472B-873C-7B257ECB579D259299External50.4Gy28Primary Tumor FieldNOComplete Response2422014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,982.0,WHITE,TCGA-GM-A3XG,GM,A3XG,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,26.0,image cytometry,IHC,RightRight Upper Outer Quadrant,1.04,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Segmental Mastectomy,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,4 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.0,3.0,8,Intensity=Strong,90-99%,CISH,Dako Hecept Test,60.0,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,NO,YES,1.67,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.73,4 Point Scale,1+,6thStage IIIAT3N1aM0,YES,YES,NO,1,10,2012,TCGA-GM-A3XG-F469639CCD1072-5A2E-4CCA-AA65-DAEFDFE36A3ANOYESYESTUMOR FREEAlive1330NO2082013,NOTCGA-GM-A3XG-D35512E32E194C-8D7D-4B56-BB63-4D33F4B1082A163247ChemotherapyPaclitaxelNOComplete Response1102012NOTCGA-GM-A3XG-D3551540EF982A-EAA8-4F0A-A86D-5ED6DA2150F7261324ChemotherapyFluorouracilNOComplete Response1102012NOTCGA-GM-A3XG-D3551653DCF90D-749C-447D-BA77-62545A2CCAAA261324ChemotherapyAdriamycinNOComplete Response1102012NOTCGA-GM-A3XG-D3551934EC610D-426F-433C-94ED-1FB1BC4FF569261324ChemotherapyCytoxanNOComplete Response1102012NOTCGA-GM-A3XG-D41971D44E9F6A-E7B4-4C08-BF20-B6A744CD1C78434473Hormone TherapyTamoxifenNOComplete Response842013NOTCGA-GM-A3XG-D419721E050AB5-3F95-403F-9CD2-15E62549A9B0813843Hormone TherapyArimidexNOComplete Response842013,TCGA-GM-A3XG-R355112085DEFE-099C-42C0-92EF-DF939B5A7AEF372415External60Gy30Primary Tumor FieldNOComplete Response1102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,360.0,ASIAN,TCGA-JL-A3YW,JL,A3YW,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,16.0,image cytometry,Allred score 2+2 = 4,Left,2.6070312499999995,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,right segmental mastectomy witrh axillary node dissection,Infiltrating Lobular Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Positive,0.0,3.0,Allred Score 4,250,30-39%,CISH,No membrane staining or incomplete membrane staining in <10% of tumor cells is negative,108.578125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,2.13,"LungBoneLiverOther, specifyskin",30-39%,30-39%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,71,3 Point Scale,3+,7thStage IIBT2N1M0,NO,NO,NO,8,11,2012,TCGA-GM-A3XG-F469639CCD1072-5A2E-4CCA-AA65-DAEFDFE36A3ANOYESYESTUMOR FREEAlive1330NO2082013,TCGA-A1-A0SN-D1206646FC4D8A-2EEC-454B-BC8F-447030B0D761487179ChemotherapyacADJUVANTIVNO2352011TCGA-A1-A0SN-D120676BE7B34C-4BFD-4AFD-B4FA-EF6DFA0CA6D0179270ChemotherapytaxolADJUVANTIVNO2352011TCGA-A1-A0SN-D121574E133864-9EDE-40C9-91C3-E5E05D9D8545179879Targeted Molecular therapyherceptinADJUVANTIVNO2452011,TCGA-BH-A0B9-R15441BB3B3DEB-1D17-48BB-B0BF-5491D69AAC51132180EXTERNAL BEAM6240cGy34Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,217.0,WHITE,TCGA-D8-A1JN,D8,A1JN,No,YES,C50.9,8520/3,C50.9,2010.0,TUMOR FREE,YES,13.0,manual counting,manual counting,Left,1.3703320312500002,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,breast conserving therapy,Infiltrating Lobular Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Incisional Biopsy,Lumpectomy,Negative,Positive,Indeterminate,0.1201171875,11.0,H-Score,>75%,90-99%,Dako,DAKOHercepTest TM,262.7998046875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,64,LungBone,70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.1,3 Point Scale,2+,7thStage IIICT3N3aMX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,3,2011,TCGA-D8-A1JN-F207458392D4C7-1892-4B0D-873C-049A73A24FF4Scheduled Follow-up SubmissionNOYESAlive620TUMOR FREENO1512012,TCGA-D8-A1JN-D207462A418FF9-581C-4A9B-A4AB-B7B2C072C0EA1mg/day63Hormone TherapyanastrozolumADJUVANTPOYES1512012,TCGA-BH-A0B9-R15441BB3B3DEB-1D17-48BB-B0BF-5491D69AAC51132180EXTERNAL BEAM6240cGy34Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,73.0,WHITE,TCGA-D8-A1Y2,D8,A1Y2,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,7.0,manual counting,manual counting,Right Lower Outer Quadrant,1.1166894531249991,Axillary lymph node dissection alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,Wide Local Excision,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Positive,Indeterminate,0.0146484375,0.0,H-SCORE,>75%,10-19%,Hercep Test  TM Dako,Venten,59.9423828125,HER2 amplification - negative,>= 2.0 Positive,YES,NO,2.13,LungBone,70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,79,3 Point Scale,2+,7thStage IIAT2N0MX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,6,2011,TCGA-D8-A1Y2-F30086960BDA3C-DBB7-4271-AEBE-9C28BF0353A4Scheduled Follow-up SubmissionNOYESAlive433TUMOR FREENO242012,TCGA-D8-A1Y2-D300878706F572-AB8C-430F-9761-2AEFA63F375Bmg20mg/day66Hormone TherapyTamoxifenADJUVANTPOYES242012,TCGA-BH-A0BW-R591295D553E5C-3989-41EC-84FD-DB87F4560DE7146184External50.4Gy28Primary Tumor FieldNOComplete Response152014TCGA-BH-A0BW-R59130E65FC14F-8CC3-4FC3-8C54-D99CF8CB0D50187196External16GyPrimary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,218.0,WHITE,TCGA-D8-A1XM,D8,A1XM,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,% IHC,%IHC,Right Upper Inner Quadrant,3.0875976562499927,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Reexcision of segmental mastectomy,Other,partial mastectomy,Infiltrating Ductal Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.0,>75%,>75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,61.1923828125,HER2 amplification - negative,PathVysion HER-2 DNA probe kit.,YES,NO,2.38,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,79,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,5,2011,TCGA-D8-A1XM-F29445581291C6-5F3C-4477-A478-0A083B71FC3AScheduled Follow-up SubmissionYESNOAlive538TUMOR FREENO1932012,NOTCGA-BH-A0BW-D59133AFDD7926-10D2-458F-9188-C9634F0A81A651114ChemotherapyAdriamycinNOComplete Response152014NOTCGA-BH-A0BW-D59134E47D5A3A-3F23-45FE-AFF6-035D2D0D84BA51114ChemotherapyCytoxanNOComplete Response152014,TCGA-D8-A1XM-R29446D5715E1F-01E5-428C-BFBF-115F0D3438BB6193EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,355.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A0BW,BH,A0BW,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,8.0,allred score 0 + 0 = 0,H-SCORE 140,Left Lower Outer Quadrant,1.723466796875005,Sentinel node biopsy alone,Pateys surgery,Other,Re-Excision of Superior Margin,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.2197265625,0.0,MODERATE,Strong,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,47.8173828125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,40,"LungBoneLiverOther, specifyskin",70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,3.3,3 Point Scale,2+,6thStage IT1cN0M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",10,8,2011,TCGA-BH-A0BW-F59127B292C3C3-6CCE-4DB3-B3E2-B262836D0F7DNOYESYESTUMOR FREEAlive2371NO152014,NOTCGA-BH-A0BW-D59133AFDD7926-10D2-458F-9188-C9634F0A81A651114ChemotherapyAdriamycinNOComplete Response152014NOTCGA-BH-A0BW-D59134E47D5A3A-3F23-45FE-AFF6-035D2D0D84BA51114ChemotherapyCytoxanNOComplete Response152014,TCGA-BH-A0BW-R591295D553E5C-3989-41EC-84FD-DB87F4560DE7146184External50.4Gy28Primary Tumor FieldNOComplete Response152014TCGA-BH-A0BW-R59130E65FC14F-8CC3-4FC3-8C54-D99CF8CB0D50187196External16GyPrimary Tumor FieldNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,73.0,WHITE,TCGA-D8-A27V,D8,A27V,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,2.0,manual counting,%IHC,Right Upper Outer QuadrantRight Lower Outer Quadrant,2.141025390624994,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Reexcision of segmental mastectomy,Other,Excision,Infiltrating Lobular Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.1171875,0.0,Allred score = 4,>75%,30-39%,Dako,Venten,111.037109375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,2.6,"LungBoneLiverOther, specifyskin",70-79%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.8,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,21,7,2011,TCGA-D8-A27V-F30105E413E78A-B9CB-4D48-8CA1-3F5C41E8E3B0Scheduled Follow-up SubmissionNOYESAlive381TUMOR FREENO2932012,TCGA-D8-A27V-D30106C90BB84D-E867-45CE-BBAF-7A25BE220C0Emg20mg/day48Hormone TherapyTamoxifenADJUVANTPOYES242012,TCGA-GM-A3XG-R355112085DEFE-099C-42C0-92EF-DF939B5A7AEF372415External60Gy30Primary Tumor FieldNOComplete Response1102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,205.0,WHITE,TCGA-A2-A4S2,A2,A4S2,No,YES,C50.9,8524/3,C50.9,2012.0,TUMOR FREE,YES,10.0,ER Positive H-Score 95,allred score 2+2 = 4,Right,1.5104785156249965,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Lobular Carcinoma,Invasive ductal carcinoma with Metaplastic features (Area of sarcomatoid carcinoma),Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.0,5.0,Intensity=Strong,allred score = 0,90-99%,Hercep Test  TM Dako,DAKOHercepTest TM,407.5380859375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,2.38,Lung,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.1,3 Point Scale,2+,7thStage IIIAT3N2M0,YES,NO,NO,28,2,2013,TCGA-A2-A4S2-F5908589751129-F1B3-48E2-9375-C334B436639BNOYESYESTUMOR FREEAlive643NO3042014,NOTCGA-A2-A4S2-D4076272B353D4-7256-4161-B9C8-EA9FDC872D784796ChemotherapyAdriamycinNOComplete Response2822013NOTCGA-A2-A4S2-D4076330184077-58DE-45BD-94A3-1F57F54195364796ChemotherapyCytoxanNOComplete Response2822013NOTCGA-A2-A4S2-D40764B81A498A-A3FC-4E99-A912-6B5CBC9E288D110173ChemotherapyPaclitaxelNOComplete Response2822013NOTCGA-A2-A4S2-D590848B0F87F5-E925-40EB-9A72-E44475BF4CB3261Hormone TherapyArimidexYES3042014,TCGA-A2-A4S2-R59112DEAE1C6E-08EF-4645-92DA-D80F6A0E5147224260External4500cGy25Regional siteNOComplete Response152014TCGA-A2-A4S2-R591147B603231-EF4A-4100-AB4A-ACEAF43C323D224260External4500cGy25Regional siteNOComplete Response152014TCGA-A2-A4S2-R591165330A79E-4763-4522-A54F-B042170DDBAC261271External1400cGy7Regional siteNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,322.0,WHITE,TCGA-EW-A424,EW,A424,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,1.0,Allread score 5+3 = 8,allred score 5+3+8,Right,1.5024218749999911,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Reexcision of segmental mastectomy,Other,Segmental Mastectomy,Infiltrating Lobular Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Positive,1.0,0.0,230,moderate,90-99%,CISH,Venten,338.1240234375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,3.1,"LungBoneLiverOther, specifyskin",50-59%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.0,3 Point Scale,2+,7thStage IIIAT3N1MX,YES,YES,NO,26,3,2013,TCGA-EW-A424-F576129802329B-33EB-43F6-810F-6166CE0D1EC3NOYESYESTUMOR FREEAlive715NO1832014,NOTCGA-EW-A424-D38941A0C151E8-818E-4052-8F12-45E3CAC90A8C118181ChemotherapyDocetaxelNOComplete Response412013NOTCGA-EW-A424-D38943DA732694-A93F-487C-BB75-9D25A4235E0C118181ChemotherapyCyclophosphamideNOComplete Response412013NOTCGA-EW-A424-D57613B56289A2-A358-47AE-A1E7-F9C2A552156B154Hormone TherapyArimidexYES1832014,TCGA-EW-A424-R38939C62AE9A3-9871-4B68-9F34-E2B47A6E9C35231281External60Gy25Primary Tumor FieldNOComplete Response412013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,434.0,WHITE,TCGA-A1-A0SG,A1,A0SG,No,YES,C50.9,8507/3,C50.9,2006.0,TUMOR FREE,YES,11.0,Allred score 5+3=8,IHC,Right,2.30078124999999,Sentinel lymph node biopsy plus axillary dissection,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Reexcision of segmental mastectomy,Other,Wide re-excisional biopsy,"Other, specify",micropapillary carcinoma invasive,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.2001953125,1.0,Two-tier,Intensity=Strong,10-19%,CISH,Dako Hercept test,139.5673828125,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,50,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,90-99%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.3,3 Point Scale,3+,6thStage IIBT2N1aM0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",31,5,2011,TCGA-A2-A4S2-F5908589751129-F1B3-48E2-9375-C334B436639BNOYESYESTUMOR FREEAlive643NO3042014,TCGA-A1-A0SG-D123908D77AB37-9AB4-43CE-86A0-AFB9DF77E6FA111ChemotherapyADJUVANTIVNO3152011,TCGA-EW-A424-R38939C62AE9A3-9871-4B68-9F34-E2B47A6E9C35231281External60Gy25Primary Tumor FieldNOComplete Response412013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,189.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A8F5,LL,A8F5,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,3.0,image cytometry,CAP SCORING GUIDELINE 2010,RightRight Upper Inner Quadrant,1.6257812499999964,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Reexcision of segmental mastectomy,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,1+,1+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.0,0.0,Two-tier,Allred Score = 7,<10%,CISH,Venten,94.091796875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,54,"LungBoneLiverOther, specifyskin",20-29%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,2+,Negative,1.816386718749996,172,3 Point Scale,2+,7thStage IIAT2N0 (i-)MX,YES,NO,NO,19,2,2014,TCGA-LL-A8F5-F66965F431BC83-8B10-4B98-8517-31411BC2CC4ANOYESYESTUMOR FREEAlive596NO29102014,NOTCGA-LL-A8F5-D56702F5AE22A2-3E4F-4944-B374-7697B1786986112154ChemotherapycyclophosphamideNO1922014NOTCGA-LL-A8F5-D56703299217BC-C179-466A-80AB-9CCE9BF914EF112154Chemotherapydoxorubicin HCLNO1922014NOTCGA-LL-A8F5-D567040B7E86ED-9DCF-476C-A42C-FB9E98B7D14C175175ChemotherapypaclitaxelNO1922014NOTCGA-LL-A8F5-D567059B54A11A-0EAE-44E2-BBBF-A52A4FF67166189259ChemotherapyabraxaneNOComplete Response1922014NOTCGA-LL-A8F5-D669637E14293E-E235-410C-AD67-13482C7AEBB9315Hormone TherapyARIMIDEXYES29102014,TCGA-LL-A8F5-R66964492E3E55-5D5B-4E10-AB3F-6B271471D319282316External54.72Gy22Primary Tumor FieldNOComplete Response29102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,368.0,WHITE,TCGA-D8-A73X,D8,A73X,No,YES,C50.9,8211/3,C50.9,2013.0,TUMOR FREE,NO,5.228515625,allred score 5 + 3 = 8,image cytometry,Left Upper Outer Quadrant,5.394990234374974,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Reexcision of segmental mastectomy,Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,"Other, specify",tubular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.5849609375,0.009765625,Allred score = 4,80,90-99%,Dako,DAKOHercepTest TM,203.53125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,40,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,131,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,NO,28,3,2014,TCGA-D8-A73X-F5787947682239-B701-418A-AC8C-C0AB10D3F37DNOYESYESTUMOR FREEAlive368NO2832014TCGA-D8-A73X-F72193A7B1B400-8E75-4DE4-AC2C-60D227A635E6NOYESYESTUMOR FREEAlive767NO2942015,NOTCGA-D8-A73X-D5788043C74671-DCEB-4C5F-B13C-C3F184FEFDBD12Hormone TherapytamoxifenYES2832014,TCGA-D8-A73X-R57881A963F922-06B5-4D26-9E75-C79BF2E2B6E07575External50Gy25Primary Tumor FieldNOComplete Response2832014TCGA-D8-A73X-R72196481C16C4-941C-4E6D-8C08-66A6108AB13F4153External50GyPrimary Tumor FieldNOStable Disease2942015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,20.0,WHITE,TCGA-E9-A1RD,E9,A1RD,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,Allred (Biocare),allred score 5+3+8,Right Lower Inner Quadrant,1.578876953124989,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,4+,1+,Negative,Negative,Cytology (e.g. Peritoneal or pleural fluid),stereotactic biopsy,Negative,Positive,Equivocal,0.1435546875,0.0,moderately to strongly,180,90-99%,Hercep Test  TM Dako,Venten,105.060546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,2.38,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.8,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,7,2011,TCGA-E9-A1RD-F30612BD35F1B7-26FB-466A-A210-63C07140D93CScheduled Follow-up SubmissionNOYESAlive34TUMOR FREENO1342012TCGA-E9-A1RD-F487028873B70A-8C47-4F12-BC51-D40E6BEA4BEEYES1992013,TCGA-E9-A1RD-D30614559CEE81-681B-42E0-B0FF-A060CD274BE520mg/day13Hormone TherapyTamoxifenADJUVANTPOYES1342012,TCGA-A2-A4S2-R59112DEAE1C6E-08EF-4645-92DA-D80F6A0E5147224260External4500cGy25Regional siteNOComplete Response152014TCGA-A2-A4S2-R591147B603231-EF4A-4100-AB4A-ACEAF43C323D224260External4500cGy25Regional siteNOComplete Response152014TCGA-A2-A4S2-R591165330A79E-4763-4522-A54F-B042170DDBAC261271External1400cGy7Regional siteNOComplete Response152014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,480.0,BLACK OR AFRICAN AMERICAN,TCGA-OL-A6VO,OL,A6VO,No,YES,C50.9,8500/3,C50.9,2012.0,TUMOR FREE,YES,7.0,Allred 0 = 0+0,image cytometry,RightRight Lower Outer Quadrant,1.23,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Re-Excision of Superior Margin,Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,Ductal/Cribiform,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Negative,Negative,0.35546875,0.0,Allred Score 4,205,90-99%,0,CAP SCORING GUIDELINE 2010,58.537109375,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,3.1,"LungBoneLiverOther, specifyskin",80-89%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.5,3 Point Scale,1+,7thStage IAT1cN0MX,YES,YES,NO,5,12,2013,TCGA-OL-A6VO-F59365E7A38310-96E2-4B1D-93D6-BF1D8DC187E4NOYESYESTUMOR FREEAlive858NO1052014,NOTCGA-OL-A6VO-D63192CE66AA70-6EA4-4FAA-84F8-24A41673E3CE71147ChemotherapyTAXOTERENOComplete Response1282014NOTCGA-OL-A6VO-D65548AB34EC19-3799-4671-962A-F4C7E3E37EA671147ChemotherapyCytoxanNOComplete Response25102014,TCGA-OL-A6VO-R63547C53F9699-EC12-450E-A717-917D11632C0A156201ExternalPrimary Tumor FieldNOComplete Response1282014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,4550.0,WHITE,TCGA-B6-A0I5,B6,A0I5,No,YES,C50.9,8500/3,C50.9,1988.0,TUMOR FREE,YES,13.0,% IHC,Allred score 0+0 = 0,Right Lower Inner Quadrant,1.2664453124999973,Axillary lymph node dissection alone,axillary ultrasound,Other,Re-Excision of Superior Margin,Modified radical mastectomy,biopsy,Infiltrating Ductal Carcinoma,malignant phyllodes,Indeterminate (neither Pre or Postmenopausal),Positive,NO,4 Point Scale,2+,2+,Negative,Negative,"Other method, specify:","biopsy, NOS",Negative,Positive,Equivocal,0.484375,5.0,Two-tier,moderate,10-19%,ACIS,dextran coated charcoal,73.92578125,Vysis AutoVysion System,Path Vysion HER-2 DNA probe kit,NO,YES,2.13,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,145,4 Point Scale,1+,3rdStage IIBT2N1bM0,YES,YES,YES766Distant MetastasisBoneNOYESNO,2,11,2010,TCGA-B6-A0I5-F126038632E268-43BE-49FF-8314-3522D6CAF767Scheduled Follow-up SubmissionNOYESAlive4550TUMOR FREENO162011TCGA-B6-A0I5-F71505D037DF28-A91C-4F37-9DAE-68F9CB4A367ENONOYESTUMOR FREEAlive8556NO2632015,2TCGA-A2-A0YD-D5674678cae6d-29ae-4c7c-b9f8-72d3270dc4024400mg1100mg463136ChemotherapyCytoxanADJUVANTIVNO81220101TCGA-A2-A0YD-D567339d13e05-d042-4915-a89b-eb9460b38f36440mg110mg463136ChemotherapyAdriamycinADJUVANTIVNO81220103TCGA-A2-A0YD-D567594197033-7886-421d-a619-88769cecaade1mg143Hormone TherapyArimidexADJUVANTPOYES8122010,TCGA-BH-A0B9-R15441BB3B3DEB-1D17-48BB-B0BF-5491D69AAC51132180EXTERNAL BEAM6240cGy34Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Dead,1009.0,948.2001953125,WHITE,TCGA-BH-A1FD,BH,A1FD,No,YES,C50.9,8500/3,C50.9,1998.0,WITH TUMOR,YES,19.0,Allred score 7 (outside facility),Allred score = 8,Left,2.0745214843749964,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,EXCISION WITH NEEDLE WIRE LOCALIZATION,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.7861328125,0.0,Allred score 8,205,10-19%,ACIS,Dako Hercept test,75.7412109375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,40,"LungBoneLiverOther, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,145,3 Point Scale,2+,5thStage IT1cN0M0,NO,YES,PositivePositiveNegativeNegative,8,9,2011,TCGA-BH-A0AV-F59174F2F9895E-1F5D-4A27-9394-24906331E464NOYESYESTUMOR FREEAlive1820NO252014,NOTCGA-OL-A6VO-D63192CE66AA70-6EA4-4FAA-84F8-24A41673E3CE71147ChemotherapyTAXOTERENOComplete Response1282014NOTCGA-OL-A6VO-D65548AB34EC19-3799-4671-962A-F4C7E3E37EA671147ChemotherapyCytoxanNOComplete Response25102014,TCGA-A7-A4SC-R4046070B29690-4181-48E2-A7CC-FC358B2090F8130168External5040cGy28Primary Tumor FieldNOComplete Response2122013TCGA-A7-A4SC-R40463FA5C4F6B-BC17-4C50-A49D-9985D4D9ABDC130166External4680cGy26Regional siteNOComplete Response2122013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,168.0,WHITE,TCGA-D8-A1XR,D8,A1XR,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,% IHC,%IHC,Right Upper Outer Quadrant,2.607753906249993,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Total mastectomy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Lumpectomy,Negative,Positive,Negative,0.0,2.0,>75%,>75%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,77.38671875,HER2 amplification - negative,>= 2.0 Positive,YES,NO,54,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,3.8,3 Point Scale,2+,7thStage IIBT2N1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",16,5,2011,TCGA-D8-A1XR-F294511B14AB2D-AA4F-4BF6-9AE3-88DD7EF231A1Scheduled Follow-up SubmissionNOYESAlive482TUMOR FREENO632012,TCGA-D8-A1XR-D294505484F965-9C70-444A-8C52-BE87ECFA4EE5mg60+600mg/m2105168Chemotherapyadriamycin+cyclophosphamideADJUVANTIVNO1932012,TCGA-BH-A0HQ-R479371993FAC-819D-407E-A24D-9460EFFB2804104156EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1572.0,WHITE,TCGA-BH-A0B9,BH,A0B9,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,1.0,H-Score 280,H-SCORE 150,Right Lower Inner QuadrantRight Lower Outer QuadrantRight,1.5554492187500006,Sentinel node biopsy alone,SLN and non-SLN biopsy,Other,Re-Excision of Superior Margin,Mastectomy NOS,Segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,0,0,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Negative,Negative,0.3505859375,0.0,Allred score = 8,H-Score,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,57.455078125,Vysis AutoVysion System,PathVysion HER-2 DNA Probe kit,NO,YES,74,"LungOther, specifyleft adrenal gland",80-89%,40-49%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,172,3 Point Scale,0,Stage IAT1cN0 (i-)M0,NO,YES,YES766Distant MetastasisBoneNOYESNO,4,11,2010,TCGA-BH-A0B9-F154382C430BC9-3919-471B-B6F0-EE5346626686Scheduled Follow-up SubmissionYESYESAlive1572TUMOR FREENO4112010,1TCGA-BH-A0B9-D1544013B25C27-6D31-4812-9A44-FC50A5A1DFA83800mg950mg448111ChemotherapyCYCLOPHOSPHAMIDEADJUVANTIVNO41120101TCGA-BH-A0B9-D15439D648DF65-E9A7-46B4-8758-F6D2241D7892380mg95mg448111ChemotherapyDoxorubicinADJUVANTIVNO4112010,TCGA-BH-A0B9-R15441BB3B3DEB-1D17-48BB-B0BF-5491D69AAC51132180EXTERNAL BEAM6240cGy34Primary Tumor FieldADJUVANTNO14112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1180.0,BLACK OR AFRICAN AMERICAN,TCGA-BH-A0AV,BH,A0AV,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,2.0,Allread score 5+3 = 8,allred score 5 +3 = 8,Left Upper Inner Quadrant,2.0144726562499997,Sentinel node biopsy alone,SLN and non-SLN biopsy,Other,Re-Excision of Superior Margin,Other,Segmental mastectomy with left axillary lymph node dissection,Infiltrating Ductal Carcinoma,Invasive ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Equivocal,0.189453125,0.0,Allred score 8,Allred Score 5,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,77.6328125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,54,"LungBoneLiverOther, specifyskin",70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,71,3 Point Scale,1+,6thStage IT1cN0M0,NO,YES,YES766Distant MetastasisBoneNOYESNO,2,8,2011,TCGA-BH-A0AV-F59174F2F9895E-1F5D-4A27-9394-24906331E464NOYESYESTUMOR FREEAlive1820NO252014,NOTCGA-BH-A0AV-D591753FC0BA35-5F5A-4C4B-B4F7-34A5A6C872EF146259ChemotherapyTaxotereNOComplete Response252014NOTCGA-BH-A0AV-D59176BA9B227E-1B4A-469B-BCC4-E008C2CA2DAA146259ChemotherapyCytoxanNOComplete Response252014,TCGA-BH-A0AV-R591771E9BDB6B-495D-4881-8264-4717B2630D9B259308External66.4Gy36Primary Tumor FieldNOComplete Response252014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,217.0,WHITE,TCGA-E2-A3DX,E2,A3DX,No,YES,C50.9,8520/3,C50.9,2011.0,TUMOR FREE,YES,36.0,H-SCORE 0,Allred 5 = 2+3,Right,7.1,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,right segmental mastectomy,Infiltrating Lobular Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Positive,Core needle biopsy,Biopsy not specified,Positive,Positive,Equivocal,0.697265625,25.0,Allred score = 8,Allred score = 7,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,263.296875,HER2 amplification - negative,Ratio >=2.0,NO,YES,3.1,Lung,80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.460605468749991,2.8,3 Point Scale,3+,7thStage IIICT2N3M0,YES,YES,NO,17,1,2012,TCGA-E2-A3DX-F35822664B0755-6D22-478B-8659-88B17E648B78NOYESYESTUMOR FREEAlive478NO9102012TCGA-E2-A3DX-F700170009B079-7981-4E93-BEDA-673A97FF1137NOYESYESTUMOR FREEAlive1325NO922015,NOTCGA-E2-A3DX-D35823FB2F6144-201F-4111-AEB2-123019146F4563105ChemotherapyDoxorubicinNO9102012NOTCGA-E2-A3DX-D358257F0FA9CD-0E62-4C40-8FD4-10D3CC42DF9263105ChemotherapyCyclophosphamideNO9102012NOTCGA-E2-A3DX-D358263D6D5170-8502-4FC1-8187-1BFE6364B6EA119196ChemotherapyPaclitaxelNO9102012NOTCGA-E2-A3DX-D3582782FCFACE-DFFB-46A2-B4AB-EEB1D20CF49C119427ChemotherapyTrastuzumabNOComplete Response9102012NOTCGA-E2-A3DX-D3582853169165-315E-485D-A2BE-FAA021F7BBC2280Hormone TherapyTamoxifenYES9102012,TCGA-E2-A3DX-R35829012E4A45-96F2-4842-A729-363AC3BDF8E8218262External6040cGy33Regional siteNOComplete Response9102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1121.0,WHITE,TCGA-BH-A0HQ,BH,A0HQ,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,4.0,ER Positive H-Score 95,allred score 3 + 3 = 6,Left Upper Outer QuadrantLeft,2.0171191406250086,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.728515625,0.0,Allred score = 8,Allred score = 7,<10%,ACIS,CAP scoring guideline 2010,41.5966796875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,118,"LungOther, specifyleft adrenal gland",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,52,3 Point Scale,3+,Stage IIAT2N0 (i+)M0,NO,YES,YES766Distant MetastasisBoneNOYESNO,11,11,2010,TCGA-BH-A0HQ-F47953116F5DA-E215-4E25-808D-988778A6B5521121AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0HQ-D4790BA4DBB81-7F70-4C31-9A0A-D7FEB14DA7871mg/day70Hormone TherapyArimidexADJUVANTPOYES17112010,TCGA-BH-A0HQ-R479371993FAC-819D-407E-A24D-9460EFFB2804104156EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,215.0,WHITE,TCGA-A7-A4SC,A7,A4SC,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,1.0,H-SCORE 190,image cytometry,Right Upper Outer Quadrant,1.1,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Simple Mastectomy,Re-Excision of Superior Margin,Other,Wide re-excisional biopsy,Infiltrating Lobular Carcinoma,MUCINOUS & PAPILLARY,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Equivocal,0.0,0.0,230,250,10-19%,ACIS,Venten,303.0,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,2.2,"LungBoneLiverOther, specifyskin",90-99%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.4,3 Point Scale,3+,7thStage IIBT3N0MX,YES,YES,NO,20,2,2013,TCGA-A7-A4SC-F49714E86BB295-DEB8-4683-9676-D7244DFA8E00NOYESYESTUMOR FREEAlive446NO8102013,NOTCGA-A7-A4SC-D404664CDA31F3-7B21-4B73-9B41-8406C995805161139Hormone TherapyTAMOXIFENNO2122013NOTCGA-A7-A4SC-D40469D20C10DB-BE58-4536-9BE0-3547209715C7169Hormone TherapyTAMOXIFENYES2122013,TCGA-A7-A4SC-R4046070B29690-4181-48E2-A7CC-FC358B2090F8130168External5040cGy28Primary Tumor FieldNOComplete Response2122013TCGA-A7-A4SC-R40463FA5C4F6B-BC17-4C50-A49D-9985D4D9ABDC130166External4680cGy26Regional siteNOComplete Response2122013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,34.0,ASIAN,TCGA-C8-A137,C8,A137,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,2.0,H-SCORE 0,Allred score 0+0=0,Left,1.464130859374991,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Patey's Surgery,Negative,Negative,Positive,0.0361328125,1.1328125,Allred Score 8,Allred score 8,90-99%,Hercep Test  TM Dako,CAP scoring guideline 2010,94.7431640625,HER2 amplification - negative,>= 2.0 Positive,YES,NO,74,"LungBoneLiverOther, specifyskin",<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.8,4 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",15,4,2011,TCGA-C8-A137-F1907647D6F2FA-9859-4953-BE4F-C79803394070Scheduled Follow-up SubmissionNOYESAlive125TUMOR FREENO2122011TCGA-C8-A137-F708153319B260-E0F5-4ABA-9676-DA21E0BDF2CBNONOWITH TUMORAlive379YES136Locoregional RecurrenceNOYESNO932015,3TCGA-E2-A153-D18954229BE9CD-B3B4-4B15-AA20-DFF1B19DF725mg20mg/day229Hormone TherapytamoxifenADJUVANTPOYES81120112TCGA-E2-A153-D18950DC77A2E0-D67A-46FB-8F56-EE1F16089F981722mg200mg9112196ChemotherapypaclitaxelADJUVANTIVNO81120111TCGA-E2-A153-D18948057F6C50-9E43-4775-9A1A-00A06EB7F9B4480mg120mg44298ChemotherapydoxorubicinADJUVANTIVNO81120111TCGA-E2-A153-D18947F3D8922B-7D20-47D4-9ECC-806723EFCE765700mg1500mg44298ChemotherapycyclophosphamideADJUVANTIVNO8112011,TCGA-C8-A137-R708166A57E479-51F6-4266-BF13-7BF4F13D224C137External60Gy30Local RecurrenceNOStable Disease932015
TCGAFPPP,Breast,Yes,FEMALE,Alive,0.0,119.0,BLACK OR AFRICAN AMERICAN,TCGA-S3-AA17,S3,AA17,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,2.0,CAP SCORING GUIDELINE 2010,CAP SCORING GUIDELINE 2010,RightRight Lower Outer Quadrant,1.7,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Simple Mastectomy,Re-Excision of Superior Margin,Other,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,ductal and lobular features,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Skin biopsy,Negative,Positive,Equivocal,1.0,0.0,MODERATE,STRONG,90-99%,CISH,CAP SCORING GUIDELINE 2010,20.0,HER2 amplification - negative,CAP SCORING GUIDELINE 2010,YES,NO,35,"Other, specifyaxilaary node negative but intrammary node positive",90-99%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,61,3 Point Scale,2+,7thStage IIBT2N1micM0 (i+),YES,YES,NO,21,4,2014,TCGA-S3-AA17-F6770847914404-6847-4D22-91E8-F2BA8618EE3ENOYESYESTUMOR FREEAlive424NO11112014,NOTCGA-S3-AA17-D5837561D5661A-D46E-4B24-8512-602DE23D137399Hormone TherapyANASTROZOLEYES2142014,TCGA-S3-AA17-R58374FBDFCCD6-FB33-4827-8C3D-BA9F05070849119162External6000cGy30Primary Tumor FieldNOComplete Response1842014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,192.0,WHITE,TCGA-AC-A3W7,AC,A3W7,No,YES,C50.9,8520/3,C50.9,2012.0,TUMOR FREE,YES,2.0,H-Score 300,Allred score 2+2 = 4,Right Upper Outer Quadrant,1.6805761718749994,Sentinel node biopsy alone,FNA plus axillary lymph node dissection,Simple Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Wide Local Excision,Infiltrating Lobular Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Negative,0.580078125,1.0,Intensity=Strong,8,<10%,ACIS,Dako Hercept test,89.2568359375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,YES,NO,2.13,"LungBoneLiverOther, specifyskin",90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,60,3 Point Scale,2+,7thStage IIBT2N1aMX,YES,YES,NO,17,10,2012,TCGA-AC-A3W7-F5784751E87969-0929-4751-8663-2FB10328655BNONOYESTUMOR FREEAlive471NO2732014,NOTCGA-AC-A3W7-D5784899F4E33A-B847-43FF-98B1-80EBFB1944E965Hormone TherapyFemaraYES2732014,TCGA-A7-A4SC-R4046070B29690-4181-48E2-A7CC-FC358B2090F8130168External5040cGy28Primary Tumor FieldNOComplete Response2122013TCGA-A7-A4SC-R40463FA5C4F6B-BC17-4C50-A49D-9985D4D9ABDC130166External4680cGy26Regional siteNOComplete Response2122013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,213.0,WHITE,TCGA-AN-A0FK,AN,A0FK,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,7.0,dextran coated charcoal,dextran coated charcoal,Right Lower Outer Quadrant,1.5555859374999947,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,segmental mastectomy with sentinel lymph node excision and biopsy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,1+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Positive,0.0,0.0,230,230,20-29%,0,dextran coated charcoal,46.83984375,HER2 amplification - negative,Path Vysion HER-2 DNA probe kit,NO,YES,54,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.3,3 Point Scale,3+,Stage IIIBT4N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",20,12,2010,TCGA-AN-A0FK-F68951F72119D9-67B0-4548-B682-73E6069E2D9AYESNONOTUMOR FREEAlive21323122014,NOTCGA-S3-AA17-D5837561D5661A-D46E-4B24-8512-602DE23D137399Hormone TherapyANASTROZOLEYES2142014,TCGA-EW-A424-R38939C62AE9A3-9871-4B68-9F34-E2B47A6E9C35231281External60Gy25Primary Tumor FieldNOComplete Response412013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,550.0,WHITE,TCGA-A2-A0YD,A2,A0YD,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,2.0,allred score 0 + 0 = 0,allred score 5 + 3 = 8,Left Upper Outer Quadrant,1.04,Sentinel node biopsy alone,axillary ultrasound,Simple Mastectomy,Re-Excision of Superior Margin,Other,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,1.0,0.0,Allred Score 7,Allred Score 5,10-19%,ACIS,CAP SCORING GUIDELINE 2010,60.0,Vysis AutoVysion System,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.38,Lung,90-99%,80-89%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,185,3 Point Scale,2+,Stage IIBT3N0 (i+)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,8,12,2010,TCGA-A2-A0YD-F15770D23505E4-45DA-42D1-808A-CA517E53553FScheduled Follow-up SubmissionNOYESAlive769TUMOR FREENO3082011,2TCGA-A2-A0YD-D5674678cae6d-29ae-4c7c-b9f8-72d3270dc4024400mg1100mg463136ChemotherapyCytoxanADJUVANTIVNO81220101TCGA-A2-A0YD-D567339d13e05-d042-4915-a89b-eb9460b38f36440mg110mg463136ChemotherapyAdriamycinADJUVANTIVNO81220103TCGA-A2-A0YD-D567594197033-7886-421d-a619-88769cecaade1mg143Hormone TherapyArimidexADJUVANTPOYES8122010,TCGA-E2-A3DX-R35829012E4A45-96F2-4842-A729-363AC3BDF8E8218262External6040cGy33Regional siteNOComplete Response9102012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,284.0,WHITE,TCGA-D8-A1JH,D8,A1JH,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,9.0,manual counting,manual counting,Right Lower Outer Quadrant,1.1781249999999992,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,Wide re-excisional biopsy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Negative,0.0,0.052734375,>75%,>75%,90-99%,Dako,Hecep Test TM DAKO,94.63671875,HER2 amplification - negative,>= 2.0 Positive,YES,NO,64,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,79,3 Point Scale,2+,7thStage IAT1cN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,3,2011,TCGA-D8-A1JH-F1405527D2C49E-FEBC-47D6-8410-8912F0CE7977Scheduled Follow-up SubmissionYESYESAlive426TUMOR FREENO1872011,TCGA-D8-A1JH-D1405659F08533-A2E2-4306-8DF3-F18CCAA18F58mg/day20mg/day66Hormone TherapynolvadexADJUVANTPOYES1872011,TCGA-D8-A1JH-R14057DF81712D-81A3-4CE4-B1EB-FEA240FD3B8C81105EXTERNAL BEAM45cGy20Primary Tumor FieldADJUVANTNO1872011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,461.0,WHITE,TCGA-BH-A0H0,BH,A0H0,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,2.0,H-SCORE 190,H-SCORE 7,Right Upper Outer QuadrantRight,1.3664062500000052,Sentinel node biopsy alone,Pateys surgery,Other,Reexcision of segmental mastectomy,Other,Segmental mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,0,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Negative,0.240234375,0.0,H-SCORE,H-SCORE,<10%,Hercep Test  TM Dako,CAP scoring guideline 2010,41.181640625,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,50,"LungOther, specifyleft adrenal gland",50-59%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,145,3 Point Scale,2+,Stage IAT1cN0 (i-)M0,NO,YES,YES766Distant MetastasisBoneNOYESNO,10,11,2010,TCGA-BH-A0H0-F4704F6601BA3-50AC-41E2-B50D-CC6128A123B6461AliveTUMOR FREEYESYES16112010,1TCGA-BH-A0H0-D4700A14326DB-605D-438E-8A8A-4F57402939091mg/day67Hormone TherapyARIMIDEXADJUVANTPOYES17112010,TCGA-BH-A0H0-R4702BDB65034-26A9-4FFC-B432-29CCD467D1FD97148EXTERNAL BEAM6640cGy36Primary Tumor FieldADJUVANTNO117112010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,170.0,WHITE,TCGA-AN-A0XW,AN,A0XW,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,14.0,dextran coated charcoal,dextran coated charcoal,Left Upper Outer Quadrant,1.6886914062499818,Sentinel node biopsy alone,axillary ultrasound,Lumpectomy,Additional resection/ margins (taken after first margin positive),Other,segmental mastectomy with sentinel lymph node biopsy and wire localization,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Positive,Positive,0.185546875,1.0,240 H,240 H,60-69%,CISH,DAKOHercepTest TM,217.2705078125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,33,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.83,3 Point Scale,3+,7thStage IIIAT2N2M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,3,2011,TCGA-AN-A0XW-F68963038DA5D7-B5DC-4B04-9B85-82C2912AE73AYESNONOTUMOR FREEAlive170NO23122014,NOTCGA-LL-A73Z-D513247720FC0E-5AB6-4C6A-8EE4-97B0882078E71860ChemotherapyAdriamycinNOClinical Progressive Disease15112013NOTCGA-LL-A73Z-D51326C1E53020-8C36-4C1C-89EB-FFA09DCF92E61860ChemotherapyCytoxanNOClinical Progressive Disease15112013NOTCGA-LL-A73Z-D513273E79EC05-9045-43FC-94DB-E1CD163B0D8874109ChemotherapytaxolNOClinical Progressive Disease15112013NOTCGA-LL-A73Z-D51328D00B1B78-354F-4C0A-BA7A-27A54ECC394D123179Hormone TherapyfaslodexNOClinical Progressive Disease15112013,TCGA-D8-A3Z6-R513697BE92C39-4EED-4E33-85EB-996F80FEC082234260External45Gy22Primary Tumor FieldNOStable Disease18112013
TCGAFPPP,Breast,No,FEMALE,Dead,322.0,808.3994140625,WHITE,TCGA-AR-A5QQ,AR,A5QQ,No,YES,C50.9,8575/3,C50.9,2011.0,TUMOR FREE,YES,24.0,allred score 5 + 3 = 8,IHC,Right,2.203261718749983,Axillary lymph node dissection alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,Excisional biospy,"Other, specify",Squamous (metaplastic) carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Negative,0.888671875,1.0,0,0%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,97.775390625,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,2.5,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.8352539062499968,2.23,3 Point Scale,2+,7thStage IIIAT3N1M0,YES,YES,"YES301Locoregional RecurrenceOther, specifychestwall301Distant MetastasisLung301Distant MetastasisLiver301Distant MetastasisBone301Distant MetastasisOther, specifyAdrenal glands",15,5,2013,"TCGA-AR-A5QQ-F427348318BD8E-9128-4A44-AB63-98E5A2459230NOYESYESWITH TUMORDead322YES301Distant MetastasisLungLiver, bone, chest wall, adrenal glands1062013",NOTCGA-AR-A5QQ-D439541E5134F3-A59A-400F-B7B0-64A9497A18976991ChemotherapyCarboplatinNO1062013NOTCGA-AR-A5QQ-D43955BE51B815-9DB6-447D-8819-873D08EDAB686991ChemotherapyTaxolNO1062013NOTCGA-AR-A5QQ-D43958A25A87ED-0EBE-4D81-AE56-A8F243B5743B119143ChemotherapyIfosfamideNO1062013NOTCGA-AR-A5QQ-D439607E77E139-F8F0-4B5C-8487-8CAAF7C8D746119143AncillaryMESNA-1NO1062013NOTCGA-AR-A5QQ-D43962DD9E6CBF-F1BB-4B39-AEBA-AA7A777C9EEC119143AncillaryMESNA-2NO1062013NOTCGA-AR-A5QQ-D4396464A6D9AB-D9A7-47AE-BB5D-FC484F6E56ED119143ChemotherapyVP-16NO1062013,TCGA-AR-A5QQ-R4276536D43FF0-8472-4D18-9916-39F7D4FAF10C233External6120cGy34Primary Tumor FieldNO1062013
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1NC,E9,A1NC,No,YES,C50.9,8522/3,C50.9,2011.0,TUMOR FREE,YES,9.0,CAP scoring guideline 2010,CAP scoring guideline 2010,Right Upper Inner Quadrant,2.209423828124994,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Other,Reexcision of segmental mastectomy,Other,segmental mastectomy with sentinel lymph node biopsy,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Negative,Positive,0.0,1.0,90 H,270 H,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,125.7080078125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.38,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.9,3 Point Scale,3+,7thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",23,6,2011,TCGA-E9-A1NC-F2916213CA0108-5056-4497-AB23-DD66AF372D8AScheduled Follow-up SubmissionNOYESAlive708TUMOR FREENO462014TCGA-E9-A1NC-F406399D94E73F-C799-4D60-8226-7DEEBDA60156NONOYESTUMOR FREEAlive1203NO2622013,NOTCGA-E9-A1NC-D32903E78A504B-9523-4183-AF5D-ACF86478BB8210122ChemotherapyDoxorubicinNOComplete Response1562012NOTCGA-E9-A1NC-D3290686434E5A-26BE-4F46-AF34-769FA720848110122Chemotherapy5-FluorouracilNOComplete Response1562012NOTCGA-E9-A1NC-D32908DDF2090C-2AB2-4A9F-A37C-2D6945B8AA8E10122ChemotherapyCyclophosphaneNOComplete Response1562012NOTCGA-E9-A1NC-D32909A78DF706-2990-4314-934D-7EFD5C578BD5134708Hormone TherapyTamoxifenNOComplete Response1562012,TCGA-E9-A1NE-R2916648473E9C-72DD-4F0A-8D3E-85B661B773F4141171EXTERNAL BEAM4600cGy23Regional siteADJUVANTNO932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1463.0,WHITE,TCGA-B6-A1KI,B6,A1KI,No,YES,C50.9,8500/3,C50.9,2003.0,TUMOR FREE,YES,1.0,image cytometry,image cytometry,Right Upper Inner Quadrant,1.2,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Excisional biospy,Infiltrating Ductal Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,intraoperative examination,Negative,Positive,Equivocal,0.001953125,0.0,70 fmol/mg,288 fmol/mg,90-99%,Hercep Test  TM Dako,Venten,60.0,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,3.1,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,3.8,4 Point Scale,2+,6thStage IT1cN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",19,7,2011,TCGA-B6-A1KI-F1573759D24E41-B9FE-49F2-8B2C-08589B98F220Scheduled Follow-up SubmissionYESYESAlive2236TUMOR FREENO2982011,"1TCGA-A2-A0CM-D201851cca21e-fd29-4d59-9de1-916fc77056e0424mg106mg498147ChemotherapyAdriamycinADJUVANTIVNO23820105TCGA-A2-A0CM-D202680df2add-560a-429f-9f42-6469a5e88bba24400mg2000-3500mg8391615ChemotherapyCapecetabinePROGRESSIONPONO23820102TCGA-A2-A0CM-D202088adeb77-bcc1-48cb-a270-92cdc1fe8f244248mg1062mg498147ChemotherapyCytoxanADJUVANTIVNO24820103TCGA-A2-A0CM-D2022afae9c46-2307-4844-b80b-cb436fc1e8bb20mg/day234Hormone TherapyTamoxifenADJUVANTPONO24820104TCGA-A2-A0CM-D20242a0f9e7d-47a8-4977-9845-f9255d292e92890mg100-131mg8391601ChemotherapyDocetaxelPROGRESSIONIVNO24820106TCGA-A2-A0CM-D2027e8027663-89df-4c62-9c8c-b7709606de608mg4mg2391433Other, specify in notesBisphosphonate therapyZometaPROGRESSIONIVNO2482010",TCGA-BH-A0BO-R61950ABF66B91-2FC8-47CE-9799-E6CE80FF081872119External6040cGy33Primary Tumor FieldNOComplete Response1072014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,838.0,WHITE,TCGA-E2-A14U,E2,A14U,No,YES,C50.9,8520/3,C50.9,2008.0,TUMOR FREE,YES,8.0,Allred score 5+3 = 8,Allred score 5+3 = 8,Right Upper Outer Quadrant,1.04,Other (specify),Sentinel lymph node dissection,Lumpectomy,Re-Excision of Superior Margin,Other,Excisional biopsy,Infiltrating Lobular Carcinoma,Invasive Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Positive,Equivocal,0.71484375,0.0,Allred score = 8,Allred score = 8,40-49%,Dako,CAP scoring guideline 2010,131.7099609375,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,69,Lung,<10%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.9,3 Point Scale,2+,6thStage IT1cN0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",6,4,2011,TCGA-E2-A14U-F33622573201B2-5807-4344-A976-9996B93EAE55Scheduled Follow-up SubmissionNOYESAlive1318TUMOR FREENO1172012,NOTCGA-E2-A14U-D336230B0A2B1B-77FF-4EEF-B070-7C3DAB61221D129Hormone TherapyArimidexYES1172012,TCGA-AR-A1AR-R218513B2FC16E-C838-43CC-A732-D6C5969A0532251ADJUVANTNO12622012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1357.0,WHITE,TCGA-OL-A5DA,OL,A5DA,No,YES,C50.9,8520/3,C50.9,2009.0,TUMOR FREE,YES,1.0,Allred (Biocare),image cytometry,Right Upper Outer Quadrant,1.4545507812499974,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Other,partial mastectomy,Infiltrating Lobular Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,3+,2+,Negative,Negative,"Other method, specify:",Ultrasound-guided mammotome biopsy,Negative,Positive,Equivocal,0.0,2.3603515625,Allred Score 4,Allred score 7 (per outside facility),30-39%,CISH,CAP SCORING GUIDELINE 2010,133.1845703125,1,Ratio >=2.0,NO,YES,74,"LungBoneLiverOther, specifyskin",60-69%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,79,3 Point Scale,3+,6thStage IIAT2N0MX,NO,NO,NO,23,4,2013,TCGA-OL-A5DA-F5544023A668B0-A47F-47D6-BCDF-8E2A5C754314NONONOTUMOR FREEAlive1783NO1012014,"1TCGA-A2-A0CM-D201851cca21e-fd29-4d59-9de1-916fc77056e0424mg106mg498147ChemotherapyAdriamycinADJUVANTIVNO23820105TCGA-A2-A0CM-D202680df2add-560a-429f-9f42-6469a5e88bba24400mg2000-3500mg8391615ChemotherapyCapecetabinePROGRESSIONPONO23820102TCGA-A2-A0CM-D202088adeb77-bcc1-48cb-a270-92cdc1fe8f244248mg1062mg498147ChemotherapyCytoxanADJUVANTIVNO24820103TCGA-A2-A0CM-D2022afae9c46-2307-4844-b80b-cb436fc1e8bb20mg/day234Hormone TherapyTamoxifenADJUVANTPONO24820104TCGA-A2-A0CM-D20242a0f9e7d-47a8-4977-9845-f9255d292e92890mg100-131mg8391601ChemotherapyDocetaxelPROGRESSIONIVNO24820106TCGA-A2-A0CM-D2027e8027663-89df-4c62-9c8c-b7709606de608mg4mg2391433Other, specify in notesBisphosphonate therapyZometaPROGRESSIONIVNO2482010",TCGA-A8-A08G-R38174565C6FF1-BC4D-4E70-8DAC-BEC6DFF29A9F150212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,580.0,WHITE,TCGA-A8-A07C,A8,A07C,No,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,4.353515625,Allred score 5+3=8,H-SCORE 0,Right Upper Outer Quadrant,2.3541503906249903,Sentinel node biopsy alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,intraoperative examination,Negative,Negative,Negative,0.7109375,0.0,MODERATE,Allred score 8,10-19%,Hercep Test  TM Dako,Venten,138.5712890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,54,Lung,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,1.1,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A07C-F408248090BEDB-F551-48C4-81E1-F2BC695F9981NOYESYESTUMOR FREEAlive1034NO232013,NOTCGA-A8-A07C-D3783880A825CD-F344-4738-AB3F-163220CF126F062Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A07C-D3783944BA63A5-D965-4A75-BB06-9C2DD6F50AD6062ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A07C-D378401A826A54-48E2-429B-A130-9112B0552A47062ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A07C-D378414749D00E-48DA-45FB-BDBF-BAD8C06F103692123ChemotherapyDocetaxeln/aNOComplete Response6122012,TCGA-A8-A07C-R38175BFF5B463-20EA-48A9-8E45-19AE74E3112A153184ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,258.0,ASIAN,TCGA-EW-A1IY,EW,A1IY,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,6.0,Allred 0 = 0+0,dextran coated charcoal,Right Upper Inner Quadrant,2.7021875,Other (specify),sentinel LN and one non sentinel LN,Lumpectomy,Re-Excision of Superior Margin,Modified radical mastectomy,bilateral total mastectomies with right sentinel node biopsy,Infiltrating Ductal Carcinoma,malignant phyllodes,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,3+,1+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Negative,0.0,0.0,allred score = 8,Intensity=Strong,<10%,CISH,Venten,51.310546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,3.0,LungBone,90-99%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,2.8,3 Point Scale,3+,6thStage IT1cN0MX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",10,5,2011,TCGA-EW-A1IY-F29084147F2CD8-48E7-43BC-901D-A96966A4ABC2Scheduled Follow-up SubmissionNOYESAlive258TUMOR FREENO532012,TC regimenTCGA-EW-A1IY-D29086B9D6330E-568E-4DCD-8ED3-7D3138997A66T:544;C:4368mgT:136;C:1092mg457119ChemotherapyTaxotere/CytoxanADJUVANTIVNO532012,TCGA-AR-A24H-R312177926DA2C-4D80-45A5-8E14-24F769E48DF1371116300cGyPrimary Tumor FieldADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,198.0,WHITE,TCGA-AN-A0AL,AN,A0AL,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,5.0,dextran coated charcoal,dextran coated charcoal,Left Lower Outer Quadrant,2.361425781249993,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,total mastectomy with rigth axillary lymph node and sentinel lymph node dissection,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,0,0,Negative,Negative,Tumor resection,Patey's Suregery,Negative,Negative,Negative,0.0,0.0,allred score = 6,STRONG,<10%,0,dextran coated charcoal,56.3193359375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,NO,YES,2.6,"LungOther, specifyleft adrenal gland",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,71,3 Point Scale,0,7thStage IIIBT4N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",21,12,2010,TCGA-AN-A0AL-F6894402C99963-3C0B-4888-BD6F-F1C920E08720NONONOTUMOR FREEAlive227NO23122014,NOTCGA-A8-A08G-D37833E6829D65-9323-4DFA-86D6-AB3D485C11052889Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08G-D378344C83B99B-AD52-428E-B14F-0623E65A872F2889ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08G-D37835AD33A302-4E92-4716-B438-F7605A26337D2889ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08G-D378360B6BC52D-FF9B-4B29-9078-94FD2D4A935F89150ChemotherapyDocetaxeln/aNOComplete Response6122012NOTCGA-A8-A08G-D37837A2F25EB4-625A-4E4F-A809-B67F837EB7AE181Hormone TherapyExemestanen/aYES6122012,TCGA-C8-A137-R708166A57E479-51F6-4266-BF13-7BF4F13D224C137External60Gy30Local RecurrenceNOStable Disease932015
TCGAFPPP,Breast,No,FEMALE,Dead,754.0,1616.859375,BLACK OR AFRICAN AMERICAN,TCGA-A2-A0CM,A2,A0CM,No,YES,C50.9,8500/3,C50.9,2003.0,WITH TUMOR,YES,1.0,Allred score = 8,H-SCORE 290,Left,1.8110449218749975,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Simple Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,partial mastectomy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,YES,3 Point Scale,0,0,Negative,Negative,Excisional Biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.0,0.0,Allred score 8,Allred Score 5,<10%,Hercep Test  TM Dako,Hercep Test  TM Dako,151.42578125,HER2 amplification - negative,Positive >2.2,NO,YES,54,"Other, specifySkin",<10%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,105,3 Point Scale,0,6thStage IIAT2N0 (i-)M0,YES,YES,PositivePositiveNegative,6,9,2010,TCGA-A2-A0CM-F20135609C4A1-D006-4EAF-B197-174CAF31D43EDeadWITH TUMOR754NOYES382NONOYES692010,"1TCGA-A2-A0CM-D201851cca21e-fd29-4d59-9de1-916fc77056e0424mg106mg498147ChemotherapyAdriamycinADJUVANTIVNO23820105TCGA-A2-A0CM-D202680df2add-560a-429f-9f42-6469a5e88bba24400mg2000-3500mg8391615ChemotherapyCapecetabinePROGRESSIONPONO23820102TCGA-A2-A0CM-D202088adeb77-bcc1-48cb-a270-92cdc1fe8f244248mg1062mg498147ChemotherapyCytoxanADJUVANTIVNO24820103TCGA-A2-A0CM-D2022afae9c46-2307-4844-b80b-cb436fc1e8bb20mg/day234Hormone TherapyTamoxifenADJUVANTPONO24820104TCGA-A2-A0CM-D20242a0f9e7d-47a8-4977-9845-f9255d292e92890mg100-131mg8391601ChemotherapyDocetaxelPROGRESSIONIVNO24820106TCGA-A2-A0CM-D2027e8027663-89df-4c62-9c8c-b7709606de608mg4mg2391433Other, specify in notesBisphosphonate therapyZometaPROGRESSIONIVNO2482010",TCGA-A8-A07C-R38175BFF5B463-20EA-48A9-8E45-19AE74E3112A153184ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,3333.0,WHITE,TCGA-AR-A24H,AR,A24H,No,YES,C50.9,8520/3,C50.9,2001.0,TUMOR FREE,YES,4.0,Allred score 0+0 = 0,manual counting,Right Lower Inner QuadrantRight Lower Outer Quadrant,2.8052929687499777,Sentinel lymph node biopsy plus axillary dissection,sentinel + 2 non-sentinel LN,Other,Reexcision of segmental mastectomy,Mastectomy NOS,Excision,Infiltrating Lobular Carcinoma,lobular/ductal,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,YES,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Positive,Positive,Negative,0.1474609375,0.0,10-75%,Allred Score 8,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,87.251953125,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,50,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,71,3 Point Scale,2+,5thStage IIAT2N0M0,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",29,8,2011,TCGA-AR-A24H-F312128A8D77E4-29CE-4FC2-B271-FBF2BBA3FD77Scheduled Follow-up SubmissionYESYESAlive3333NO2542012TCGA-AR-A24H-F49484BDA1D14F-8B56-49F4-B1DE-D36E3C2E506BNOYESYESTUMOR FREEAlive4776NO2102013TCGA-AR-A24H-F657977BBA9594-4A67-4A39-9664-D97928D1413FNOYESYESTUMOR FREEAlive4894NO3092014,1TCGA-AR-A24H-D31252D5707F24-629C-4F1F-9D73-89CD2F7CA8A320mg/day231042Hormone TherapyTamoxifenADJUVANTPONO25420122TCGA-AR-A24H-D31253FB37D0A3-9242-440E-A64A-2859934FB1A91mg/day10423094Hormone TherapyAnastrozoleADJUVANTPONO2542012,TCGA-AR-A24H-R312177926DA2C-4D80-45A5-8E14-24F769E48DF1371116300cGyPrimary Tumor FieldADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,170.0,BLACK OR AFRICAN AMERICAN,TCGA-LL-A7SZ,LL,A7SZ,No,YES,C50.9,8500/3,C50.9,2013.0,TUMOR FREE,YES,11.0,image cytometry,CAP SCORING GUIDELINE 2010,Left Upper Outer Quadrant,2.407236328124992,Axillary lymph node dissection alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,SKIN SPARING RADICAL MASTECTOMY,Infiltrating Ductal Carcinoma,Ductal/Micropapillary,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,1+,Negative,Negative,Core needle biopsy,SKIN BIOPSY,Negative,Positive,Negative,0.0,2.0,Allred Score 4,200,30-39%,CISH,CAP scoring guideline 2010,209.80078125,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,54,"LungBoneLiverOther, specifyskin",90-99%,90-99%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,1.5724609374999916,1.66,3 Point Scale,2+,7thStage IIBT2N1aMX,YES,NO,NO,7,1,2014,TCGA-LL-A7SZ-F669731D00374C-84A6-4DC5-97F4-0C60D6ADA5BENOYESYESTUMOR FREEAlive594NO29102014,YESTCGA-LL-A7SZ-D55457A3E71F68-6309-4BB8-BF4D-BE485E3E1A0D62104ChemotherapyADRIAMYCINNOComplete Response712014YESTCGA-LL-A7SZ-D554585B4EB4C7-43B4-486D-92BD-4B7E69E4413D62104ChemotherapyCYTOXANNOComplete Response712014YESTCGA-LL-A7SZ-D55460329A77EB-2FCC-4B16-9067-24F677050B03132209ChemotherapyTAXOLNOComplete Response712014YESTCGA-LL-A7SZ-D669767B392814-A441-40A9-8A1B-24106473A188237Hormone TherapyTAMOXIFENYES29102014,TCGA-LL-A7SZ-R669744C950E6E-B651-4FE5-842B-46976BEF8BC8239275External45Gy28Regional siteNOComplete Response29102014TCGA-LL-A7SZ-R6697573EF3361-48B3-4F10-A4CF-137ACCA6B8C8239275External50.4Gy28Primary Tumor FieldNOComplete Response29102014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,57.0,WHITE,TCGA-D8-A1JE,D8,A1JE,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,10.0,manual counting,manual counting,Left Upper Outer Quadrant,1.5782421874999866,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Additional resection/ margins (taken after first margin positive),Other,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Fine needle aspiration biopsy,Lumpectomy,Negative,Positive,Negative,0.041015625,3.0,10-75%,>75%,90-99%,Dako,Hecep Test TM DAKO,199.2490234375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,40,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,59,3 Point Scale,2+,7thStage IIAT1cN1aM0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,3,2011,TCGA-D8-A1JE-F207595A7761FF-5F3F-43F6-93D6-DE3358891478Scheduled Follow-up SubmissionNOYESAlive575TUMOR FREENO812012,TCGA-D8-A1JE-D20761A21FF951-1D85-43F8-B890-E68699047B3E540mg600mg/m29103162ChemotherapyadriamicinADJUVANTIVNO812012NOTCGA-D8-A1JE-D65322B2854BDF-784F-41A1-AB7D-354A86C7F89E103162ChemotherapycyclophosphamidNO2292014,TCGA-BH-A0BO-R61950ABF66B91-2FC8-47CE-9799-E6CE80FF081872119External6040cGy33Primary Tumor FieldNOComplete Response1072014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1N5,E9,A1N5,No,YES,C50.9,8522/3,C50.9,2010.0,TUMOR FREE,YES,11.0,Allred (Biocare),H-SCORE 0,Left Upper Outer Quadrant,2.3055078124999846,Axillary lymph node dissection alone,axillary ultrasound,Other,Reexcision of segmental mastectomy,Other,Surgical resection,Mixed Histology (please specify),Infiltrating ductal and lobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,1+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Positive,0.0,2.0,Allred score = 5,allred score = 0,90-99%,Hercep Test  TM Dako,Dako Hercept test,133.978515625,HER2 amplification - negative,Ratio >=2.0,YES,NO,33,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.85,3 Point Scale,3+,7thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",23,6,2011,TCGA-E9-A1N5-F29150BFF144B5-6704-4A2E-990B-275BD153D6F4Scheduled Follow-up SubmissionNOYESAlive508TUMOR FREENO932012TCGA-E9-A1N5-F39765B4847252-8EFC-42E5-A862-992780803AD3NONOYESTUMOR FREEAlive1120NO122013,1TCGA-E9-A1N5-D2915137B2E899-6C5E-4AC5-993C-7D0CC5659174480mg80mg/day622133ChemotherapyDoxorubicinADJUVANTIVNO9320121TCGA-E9-A1N5-D30708C1DD8D4B-44DC-4476-9E5A-BCCA90CA080E4800mg800mg/day622133Chemotherapy5-FluorouracilADJUVANTIVNO16420122TCGA-E9-A1N5-D307094635036F-43AC-41A4-91E0-672BE9D92DA720mg/day173Hormone TherapyTamoxifenADJUVANTPOYES16420121TCGA-E9-A1N5-D30707D9225842-4B81-41D8-A299-BC1B204AEDD64800mg800mg/day622133ChemotherapyCyclophosphaneADJUVANTIVNO1642012,TCGA-A8-A08G-R38174565C6FF1-BC4D-4E70-8DAC-BEC6DFF29A9F150212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1085.0,WHITE,TCGA-BH-A0BO,BH,A0BO,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,3.0,H-SCORE 280,allred score 2+2 = 4,Left Upper Inner Quadrant,1.8699023437500044,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Re-Excision of Superior Margin,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Positive,Negative,0.6396484375,0.0,Allred Score 8,10-75%,<10%,ACIS,CAP SCORING GUIDELINE 2010,60.0283203125,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,33,LungBone,70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,71,3 Point Scale,2+,6thStage IT1bN0M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",9,8,2011,TCGA-BH-A0BO-F619499BC4BD65-416A-4031-AA01-5C1BAA89DD04NOYESNOTUMOR FREEAlive2197NO1072014,NOTCGA-A8-A08G-D37833E6829D65-9323-4DFA-86D6-AB3D485C11052889Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08G-D378344C83B99B-AD52-428E-B14F-0623E65A872F2889ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08G-D37835AD33A302-4E92-4716-B438-F7605A26337D2889ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08G-D378360B6BC52D-FF9B-4B29-9078-94FD2D4A935F89150ChemotherapyDocetaxeln/aNOComplete Response6122012NOTCGA-A8-A08G-D37837A2F25EB4-625A-4E4F-A809-B67F837EB7AE181Hormone TherapyExemestanen/aYES6122012,TCGA-BH-A0BO-R61950ABF66B91-2FC8-47CE-9799-E6CE80FF081872119External6040cGy33Primary Tumor FieldNOComplete Response1072014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,607.0,WHITE,TCGA-A8-A08G,A8,A08G,No,YES,C50.9,8500/3,C50.9,2009.0,TUMOR FREE,YES,4.48046875,allred score 5+3=8,allred score 5+3+8,Left Upper Inner Quadrant,2.306669921874989,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,intraoperative examination,Positive,Positive,Positive,0.7109375,0.0,MODERATE,Allred score 8,90-99%,Hercep Test  TM Dako,Venten,116.37890625,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,2.13,LungBone,<10%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.8,3 Point Scale,1+,6thStage IIAT2N0M0,YES,YES,YES181Locoregional RecurrenceYES181NOYES,27,5,2011,TCGA-A8-A08G-F408442E2652A5-951A-4B3B-AF47-55EC819C68F2NOYESYESTUMOR FREEAlive607NO232013,NOTCGA-A8-A08G-D37833E6829D65-9323-4DFA-86D6-AB3D485C11052889Chemotherapy5-Fluorouraciln/aNOComplete Response6122012NOTCGA-A8-A08G-D378344C83B99B-AD52-428E-B14F-0623E65A872F2889ChemotherapyEpirubicinn/aNOComplete Response6122012NOTCGA-A8-A08G-D37835AD33A302-4E92-4716-B438-F7605A26337D2889ChemotherapyCyclophosphamiden/aNOComplete Response6122012NOTCGA-A8-A08G-D378360B6BC52D-FF9B-4B29-9078-94FD2D4A935F89150ChemotherapyDocetaxeln/aNOComplete Response6122012NOTCGA-A8-A08G-D37837A2F25EB4-625A-4E4F-A809-B67F837EB7AE181Hormone TherapyExemestanen/aYES6122012,TCGA-A8-A08G-R38174565C6FF1-BC4D-4E70-8DAC-BEC6DFF29A9F150212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,Yes,FEMALE,Dead,524.0,1434.3134765625,WHITE,TCGA-AR-A1AR,AR,A1AR,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,14.0,Image Analysis,manual counting,Left Lower Inner Quadrant,1.9591503906249916,Axillary lymph node dissection alone,Sentinel lymph node plus Level I and Level II lymph nodes,Lumpectomy,Reexcision of segmental mastectomy,Other,Nipple Sparing Total Mastectomy,Infiltrating Ductal Carcinoma,Invasive tubulolobular carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,3 Point Scale,4+,1+,Negative,Negative,Core needle biopsy,stereotactic biopsy,Negative,Negative,Negative,0.3017578125,5.0,H-Score,0,10-19%,Hercep Test  TM Dako,Venten,107.896484375,HER2 amplification - negative,PathVysion,NO,YES,2.38,"LungBoneLiverOther, specifyskin",80-89%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.944414062499999,61,3 Point Scale,2+,6thStage IIIAT1N2M0,YES,NO,Negative<10%3 Point ScaleNegative<10%3 Point ScaleEquivocal<10%1+,28,6,2011,"TCGA-AR-A1AR-F21816A22FFD2C-82FF-4832-A3C3-258EE37920E3Scheduled Follow-up SubmissionYESYESDead524WITH TUMORYES268New Primary TumorOther, specifyBreast2722012TCGA-AR-A1AR-F218259CEE3AB5-7F21-46B0-AB2D-B2102DC1113CAdditional New Tumor EventYESYESDead524WITH TUMORYES387New Primary TumorOther, specifyBreast2722012",1TCGA-AR-A1AR-D21852A68EA7A7-0E11-4956-8188-70EA2C45DECF159ChemotherapyDocetaxelADJUVANTNO27220121TCGA-AR-A1AR-D218547B4BBD98-19AC-4156-B24A-AE9E584860AB159ChemotherapyADJUVANTNO27220121TCGA-AR-A1AR-D218538E6652BF-209E-4F74-87AE-371F6CB1244D159ChemotherapyDoxorubicinADJUVANTNO2722012,TCGA-AR-A1AR-R218513B2FC16E-C838-43CC-A732-D6C5969A0532251ADJUVANTNO12622012
TCGAFPPP,Breast,No,FEMALE,Dead,723.0,1157.7099609375,WHITE,TCGA-A2-A0YT,A2,A0YT,Yes,YES,C50.9,8500/3,C50.9,2008.0,TUMOR FREE,YES,5.0,H-Score 295,allred score 3 + 3 = 6,Left Upper Outer Quadrant,1.3,Axillary lymph node dissection alone,FNA plus axillary lymph node dissection,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,Total mastectomy with left sentinel lymph node biospy,Infiltrating Ductal Carcinoma,"Invasive lobular carcinoma, mixed classical (70%) and pleomorphic/solid (30%) types",Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,3+,Negative,Negative,Core needle biopsy,Biopsy not specified,Negative,Positive,Equivocal,0.50390625,5.0,Allred score = 4,Strong,10-19%,ACIS,CAP SCORING GUIDELINE 2010,60.0,Vysis AutoVysion System,Enumerate 60 tumor cells; Ratio of HER2/Centromere 17 >=2.1 is amplified,NO,YES,2.38,Lung,90-99%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.723398437499993,2.3,3 Point Scale,2+,Stage IIIBT4bN2aM0,YES,YES,Positive90-99%3 Point Scale3+Negative<10%3 Point Scale1+Negative<10%1+,10,12,2010,TCGA-A2-A0YT-F1576811090CD1-89D2-476B-BC1F-AA586743C2A8Scheduled Follow-up SubmissionYESYESDead723TUMOR FREENO3082011,4TCGA-A2-A0YT-D56875b1e9a0c-a2c4-41f0-a952-c9b39c961f76mg1mg286723Hormone TherapyArimidexADJUVANTPONO10122010,TCGA-A2-A0YT-R56832af6a586-e409-4367-a05b-da5e9fd37b28231280EXTERNAL BEAM11080cGy61Primary Tumor FieldADJUVANTNO110122010
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,375.0,WHITE,TCGA-AN-A0XO,AN,A0XO,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,12.0,Allred (Biocare),Allred score 0+0=0,Left Upper Outer Quadrant,2.615312499999995,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Lumpectomy,Reexcision of segmental mastectomy,Other,right segmental mastectomy,Infiltrating Ductal Carcinoma,malignant phyllodes,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,YES,4 Point Scale,2+,1+,Negative,Negative,Tumor resection,stereotactic biopsy,Positive,Positive,Negative,0.275390625,2.0,0,180,20-29%,CISH,Hercep Test  TM Dako,291.3623046875,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,NO,YES,1.67,"LungBoneLiverOther, specifyskin",<10%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,125,3 Point Scale,2+,7thStage IIIAT2N2M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",1,5,2011,TCGA-AN-A0XO-F6895724DEF0F1-801A-49B6-B800-68003374231AYESNONOTUMOR FREEAlive37523122014,2TCGA-A2-A0CZ-D20078d024ed9-cab0-4645-9ef7-d2443495432a4180mg1045mg4106148ChemotherapyCytoxanADJUVANTIVNO16920101TCGA-A2-A0CZ-D2006b80c8dcd-95cb-43e8-baaf-50704eb883f9418mg104-105mg4106148ChemotherapyAdriamycinADJUVANTIVNO16920103TCGA-A2-A0CZ-D2008df7c95fe-5410-4be7-b482-c0d6c697367120mg/day236Hormone TherapyTamoxifenADJUVANTPOYES1692010,TCGA-E9-A1NE-R2916648473E9C-72DD-4F0A-8D3E-85B661B773F4141171EXTERNAL BEAM4600cGy23Regional siteADJUVANTNO932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1339.0,WHITE,TCGA-A2-A0CZ,A2,A0CZ,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,2.0,No value Given,H-SCORE 290,Right Upper Inner Quadrant,1.1,Sentinel node biopsy alone,sentinel + 2 non-sentinel LN,Simple Mastectomy,Re-Excision of Superior Margin,Modified radical mastectomy,Excision,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Peri (6-12 months since last menstrual period),Positive,YES,3 Point Scale,1+,1+,Negative,Positive,Core needle biopsy,Patey's Suregery,Negative,Positive,Negative,0.0,0.0,Allred score 5,STRONG,10-19%,Hercep Test  TM Dako,DAKOHercepTest TM,55.1796875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4.43,"LungOther, specifyleft adrenal gland",90-99%,20-29%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.704531249999993,145,3 Point Scale,1+,6thStage IIAT2N0 (i-)M0,YES,YES,YES766Distant MetastasisBoneNOYESNO,14,9,2010,TCGA-A2-A0CZ-F13728A104937A-EABD-4777-8D6C-1EC71D882F19Scheduled Follow-up SubmissionNOYESAlive1616TUMOR FREENO1062011,2TCGA-A2-A0CZ-D20078d024ed9-cab0-4645-9ef7-d2443495432a4180mg1045mg4106148ChemotherapyCytoxanADJUVANTIVNO16920101TCGA-A2-A0CZ-D2006b80c8dcd-95cb-43e8-baaf-50704eb883f9418mg104-105mg4106148ChemotherapyAdriamycinADJUVANTIVNO16920103TCGA-A2-A0CZ-D2008df7c95fe-5410-4be7-b482-c0d6c697367120mg/day236Hormone TherapyTamoxifenADJUVANTPOYES1692010,TCGA-C8-A137-R708166A57E479-51F6-4266-BF13-7BF4F13D224C137External60Gy30Local RecurrenceNOStable Disease932015
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A1NE,E9,A1NE,No,YES,C50.9,8522/3,C50.9,2011.0,TUMOR FREE,YES,2.0,CAP scoring guideline 2010,CAP scoring guideline 2010,Right Lower Outer Quadrant,2.192099609374993,Axillary lymph node dissection alone,sentinel + 2 non-sentinel LN,Other,Reexcision of segmental mastectomy,Other,Total mastectomy,Infiltrating Ductal Carcinoma,Infiltrating ductal and lobular carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Lumpectomy,Negative,Positive,Negative,0.0,1.0,Allred score 6,allred score = 7,90-99%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,117.91796875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,YES,NO,2.38,"LungBoneLiverOther, specifyskin",70-79%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.816386718749996,1.9,3 Point Scale,3+,7thStage IIBT2N1M0,YES,YES,YES994Distant MetastasisBoneNOYESYES,23,6,2011,TCGA-E9-A1NE-F29165714D5ED8-026F-4E91-AC35-781F105265E8Scheduled Follow-up SubmissionYESYESAlive420TUMOR FREENO932012TCGA-E9-A1NE-F397818A04ABC1-6244-42ED-B3A7-4BF655854F46NOYESYESTUMOR FREEAlive1088NO122013,NOTCGA-E9-A1NE-D32914F4561048-074E-457D-A181-125FDEB51F2210121ChemotherapyDoxorubicinNOComplete Response1562012NOTCGA-E9-A1NE-D3291584F7B524-80E6-4D79-871F-8AD30E6A998710121ChemotherapyCyclophosphamideNOComplete Response1562012NOTCGA-E9-A1NE-D3291655ECA12D-C3E9-48D5-8BC7-77BC7D78929010121Chemotherapy5-FluorouracilNOComplete Response1562012NOTCGA-E9-A1NE-D32918ED962811-FC2D-4B99-B1B0-B0B606EC40AC184Hormone TherapyTamoxifenYES1562012,TCGA-E9-A1NE-R2916648473E9C-72DD-4F0A-8D3E-85B661B773F4141171EXTERNAL BEAM4600cGy23Regional siteADJUVANTNO932012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,19.0,WHITE,TCGA-E9-A1R2,E9,A1R2,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,19.0,IHC,Allred score 5+3 = 8,Left Upper Outer Quadrant,1.6265917968749857,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Additional resection/ margins (taken after first margin positive),Other,Excision,Infiltrating Ductal Carcinoma,ductal and lobular,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,1+,Negative,Positive,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.2646484375,17.0,Two-tier,Two-tier,90-99%,ACIS,CAP SCORING GUIDELINE 2010,109.3447265625,HER2 amplification - negative,Pathvysion HER2 DNA Probe Kit,YES,NO,74,"LungBoneLiverOther, specifyskin",90-99%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,114,4 Point Scale,1+,7thStage IIICT2N3MX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",28,7,2011,TCGA-E9-A1R2-F33184CD0E60BD-4C4D-4205-B1BD-644352B5816EScheduled Follow-up SubmissionYESYESAlive1063TUMOR FREENO812013TCGA-E9-A1R2-F5794162EFCDC5-4570-4B6F-A920-8FE3F82173CFYES3132014,NOTCGA-E9-A1R2-D55472659FE77A-7EC8-4976-A86E-8D54BB201D8E36144ChemotherapyTaxotereNOComplete Response712014NOTCGA-E9-A1R2-D55473102D03D1-BC76-4688-BFA9-5EFD862C35D736144ChemotherapyAdriamycinNOComplete Response712014NOTCGA-E9-A1R2-D5547457A9F155-B541-4EFD-8BFE-CBD7447C24D136144ChemotherapyCytoxanNOComplete Response712014,TCGA-E9-A1R2-R56895D7CA210D-C2B0-4BF4-8D15-3C719E3FD2D8174223External6240cGyPrimary Tumor FieldNOComplete Response2522014TCGA-E9-A1R2-R56896850B4523-573A-4F66-A0BA-85E00855505E174223External5040cGyRegional siteNOComplete Response2522014
TCGAFPPP,Breast,No,FEMALE,Dead,4267.0,2324.2685546875,WHITE,TCGA-B6-A0RQ,B6,A0RQ,No,YES,C50.9,8520/3,C50.9,1994.0,TUMOR FREE,YES,14.0,Image Analysis,Image Analysis,Right Upper Outer QuadrantRight,1.6428124999999931,Axillary lymph node dissection alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Modified radical mastectomy,excisional biopsy,Infiltrating Lobular Carcinoma,Ductal/Metaplastic,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Positive,Fine needle aspiration biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.6220703125,0.0,Allred score 7 per outside facility report,H score,90-99%,Dako,Venten,232.9951171875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,54,"LungBoneLiverOther, specifyskin",70-79%,70-79%,Positive,70-79%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.944414062499999,2.23,4 Point Scale,2+,4thStage IIBT3N0 (i-)M0,YES,YES,NONO,15,3,2011,TCGA-B6-A0RQ-F13787A826EFB1-9FF7-48D1-9C56-36E5A2747CA7Scheduled Follow-up SubmissionNOYESDead4267TUMOR FREENO1272011,NOTCGA-BH-A0BL-D591903DFD3BA5-2A34-4B70-AC12-5D1FAFE9471172142ChemotherapyAdriamycinNOComplete Response252014NOTCGA-BH-A0BL-D591919D3B5CF6-D53E-4A6E-9E36-96AEF566A22F72142ChemotherapyCytoxanNOComplete Response252014NOTCGA-BH-A0BL-D59192A18467A5-0B9F-4D1C-97E4-44F1D31AE8F3163240ChemotherapyTaxolNOComplete Response252014,TCGA-A8-A08G-R38174565C6FF1-BC4D-4E70-8DAC-BEC6DFF29A9F150212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,29.0,WHITE,TCGA-AC-A23C,AC,A23C,No,YES,C50.9,8500/3,C50.9,2010.0,TUMOR FREE,YES,1.0,Allred (Biocare),Image Analysis,Left,1.3358007812499986,Sentinel node biopsy alone,Sentinel lymph node plus Level I and Level II lymph nodes,Modified Radical Mastectomy,Reexcision of segmental mastectomy,Other,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,"Biopsy, NOS",Positive,Positive,Positive,0.517578125,1.0,allred score = 8,230,10-19%,ACIS,CAP SCORING GUIDELINE 2010,71.576171875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,3.1,LungBone,90-99%,50-59%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,60,3 Point Scale,2+,7thStage IIBT2N1MX,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",14,7,2011,TCGA-AC-A23C-F4323537E3974F-7A96-4CFC-B4DF-D9C320C34423NONOYESTUMOR FREEAlive585NO1552013,"NOTCGA-AC-A23C-D4323676E26F66-B516-401D-8620-D4CEF98B70D277204ChemotherapyChemo, NOSNOComplete Response1552013",TCGA-A8-A08G-R38174565C6FF1-BC4D-4E70-8DAC-BEC6DFF29A9F150212ExternalGyPrimary Tumor FieldNOComplete Response11122012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1340.0,WHITE,TCGA-BH-A0BL,BH,A0BL,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,2.0,H-Score 150,H-SCORE 150,Right Upper Outer Quadrant,2.081484374999995,Sentinel node biopsy alone,Sentinel lymph node biopsy and non-sentinel lymph node biopsy,Other,Re-Excision of Superior Margin,Other,Segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,Invasive Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Ultrasound-guided biopsy,Negative,Negative,Negative,0.212890625,0.0,MODERATE,Allred Score 5,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,89.875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,NO,YES,64,LungBone,70-79%,80-89%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,145,3 Point Scale,2+,6thStage IT1cN0M0,NO,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",8,8,2011,TCGA-BH-A0BL-F591893F9A600B-3723-4F22-9943-AFDBE30523C5NONOYESTUMOR FREEAlive2278NO252014,NOTCGA-BH-A0BL-D591903DFD3BA5-2A34-4B70-AC12-5D1FAFE9471172142ChemotherapyAdriamycinNOComplete Response252014NOTCGA-BH-A0BL-D591919D3B5CF6-D53E-4A6E-9E36-96AEF566A22F72142ChemotherapyCytoxanNOComplete Response252014NOTCGA-BH-A0BL-D59192A18467A5-0B9F-4D1C-97E4-44F1D31AE8F3163240ChemotherapyTaxolNOComplete Response252014,TCGA-S3-AA17-R58374FBDFCCD6-FB33-4827-8C3D-BA9F05070849119162External6000cGy30Primary Tumor FieldNOComplete Response1842014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1642.0,WHITE,TCGA-A8-A076,A8,A076,No,YES,C50.9,8500/3,C50.9,2006.0,TUMOR FREE,YES,11.93359375,Allred score 5+3=8,allred score 5+3+8,Left Upper Outer Quadrant,2.417226562499982,Sentinel node biopsy alone,axillary ultrasound,Other,Additional resection/ margins (taken after first margin positive),Mastectomy NOS,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,2+,3+,Negative,Negative,Tumor resection,Lumpectomy,Positive,Positive,Positive,0.673828125,3.5615234375,Allred Score,0%,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,103.6279296875,HER2 amplification - negative,PathVision HER2 DNA Probe Kit,NO,YES,4.43,LungBone,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,2.3,3 Point Scale,2+,5thStage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A076-F40821AF505FDD-767F-4C9C-8BB2-2C2EB76FC975NONOYESTUMOR FREEAlive1642NO232013,NOTCGA-A8-A076-D37845D9725F84-E2BD-4A29-8D96-2689DDF06EB059Hormone TherapyAnastrozolen/aYES6122012,TCGA-D8-A1JH-R14057DF81712D-81A3-4CE4-B1EB-FEA240FD3B8C81105EXTERNAL BEAM45cGy20Primary Tumor FieldADJUVANTNO1872011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,1196.0,WHITE,TCGA-A1-A0SN,A1,A0SN,No,YES,C50.9,8500/3,C50.9,2007.0,TUMOR FREE,YES,13.0,IHC,Allred score 5+3 = 8,Left,2.148525390624989,Sentinel lymph node biopsy plus axillary dissection,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Lumpectomy,Reexcision of segmental mastectomy,Modified radical mastectomy,segmental mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,infiltrating ductal and mucinous,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Positive,NO,3 Point Scale,3+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Positive,Positive,0.5986328125,4.0,allred score = 8,120,10-19%,CISH,Hercep Test  TM Dako,140.2197265625,HER2 amplification - negative,PathVysion HER-2 DNA Probe kit,NO,YES,74,"LungBoneLiverOther, specifyskin",90-99%,60-69%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.5,3 Point Scale,3+,6thStage IIAT1cN1MX,YES,NO,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",23,5,2011,TCGA-BH-A0BO-F619499BC4BD65-416A-4031-AA01-5C1BAA89DD04NOYESNOTUMOR FREEAlive2197NO1072014,TCGA-A1-A0SN-D1206646FC4D8A-2EEC-454B-BC8F-447030B0D761487179ChemotherapyacADJUVANTIVNO2352011TCGA-A1-A0SN-D120676BE7B34C-4BFD-4AFD-B4FA-EF6DFA0CA6D0179270ChemotherapytaxolADJUVANTIVNO2352011TCGA-A1-A0SN-D121574E133864-9EDE-40C9-91C3-E5E05D9D8545179879Targeted Molecular therapyherceptinADJUVANTIVNO2452011,TCGA-A1-A0SN-R12068C407753A-0959-403F-A289-925E56F5B012331361ADJUVANTNO2352011
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,943.0,WHITE,TCGA-A8-A08O,A8,A08O,No,YES,C50.9,8500/3,C50.9,2008.0,WITH TUMOR,YES,9.3505859375,image cytometry,H-Score 0,Right,1.8731738281249883,Sentinel node biopsy alone,Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy,Other,Reexcision of segmental mastectomy,Other,Surgical Resection,Infiltrating Ductal Carcinoma,Papillary Carcinoma,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,NO,3 Point Scale,2+,1+,Negative,Positive,Tumor resection,Modified Radical Masectomy,Negative,Positive,Negative,0.3349609375,2.23828125,MODERATE,0%,10-19%,ACIS,CAP SCORING GUIDELINE 2010,133.193359375,HER2 amplification - negative,Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified,NO,YES,54,Lung,70-79%,70-79%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.595371093749991,61,3 Point Scale,3+,6thStage IVT2N3aM1,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",27,5,2011,TCGA-A8-A08O-F40848A5B49570-AA8E-44E1-9B60-EF845AFFDC60NONOYESWITH TUMORAlive943YES762762232013,NOTCGA-A8-A08O-D37779985B0E53-6F65-4082-B0F8-813791E8AFC331121ChemotherapyDocetaxeln/aNOClinical Progressive Disease6122012NOTCGA-A8-A08O-D377804301A8E9-4F7C-4D4F-BD1B-6ACEB2E8A058790790ChemotherapyVinorelbinen/aNOClinical Progressive Disease6122012NOTCGA-A8-A08O-D3778111802BE2-DDBF-48C1-A327-EDE548A2FF37366397Hormone TherapyAnastrozolen/aNOClinical Progressive Disease6122012NOTCGA-A8-A08O-D377826AA48F49-4040-4A21-B74C-DACF035A783D943Hormone TherapyTamoxifenn/aYES6122012NOTCGA-A8-A08O-D37783AF51E7FE-12FB-4680-9277-972D6F24103560335Targeted Molecular therapyBevacizumabn/aNOClinical Progressive Disease6122012NOTCGA-A8-A08O-D37784A70656EE-B142-4029-AB38-FAC922222B5A60AncillaryIbandronaten/aYES6122012,TCGA-E9-A24A-R31258048982EB-6799-422D-B7D8-045CE8B2D0323565EXTERNAL BEAM4000cGy20Primary Tumor FieldADJUVANTNO12542012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,34.0,BLACK OR AFRICAN AMERICAN,TCGA-AC-A8OQ,AC,A8OQ,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,2.0,H-SCORE 280,allred score 5+3+8,Right Upper Outer Quadrant,1.4099804687499922,Sentinel node biopsy alone,Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy,Lumpectomy,Reexcision of segmental mastectomy,Other,surgical resection,Infiltrating Ductal Carcinoma,Ductal/micropapillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,2+,2+,Negative,Negative,Core needle biopsy,Patey's Suregery,Negative,Negative,Indeterminate,0.328125,1.0,Allred Score 6,allred score = 7,10-19%,Hercep Test  TM Dako,CAP scoring guideline 2010,252.0341796875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified,YES,NO,1.78,LungBone,70-79%,90-99%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,1.9,3 Point Scale,2+,7thStage IIBT2N1aMX,YES,YES,NO,26,2,2014,TCGA-B6-A0RQ-F13787A826EFB1-9FF7-48D1-9C56-36E5A2747CA7Scheduled Follow-up SubmissionNOYESDead4267TUMOR FREENO1272011,NOTCGA-OL-A6VO-D63192CE66AA70-6EA4-4FAA-84F8-24A41673E3CE71147ChemotherapyTAXOTERENOComplete Response1282014NOTCGA-OL-A6VO-D65548AB34EC19-3799-4671-962A-F4C7E3E37EA671147ChemotherapyCytoxanNOComplete Response25102014,TCGA-AR-A24Q-R3140694DB3EB1-1ED0-4F5D-AA78-0482FB31D9FF196230EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO1252012
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,0.0,WHITE,TCGA-E9-A22D,E9,A22D,No,YES,C50.9,8500/3,C50.9,2011.0,TUMOR FREE,YES,10.0,Allred 0 = 0+0,H-Score 0,Right Upper Outer Quadrant,1.3820312499999974,Axillary lymph node dissection alone,SLN and non-SLN biopsy,Modified Radical Mastectomy,Re-Excision of Superior Margin,Other,Total mastectomy with sentinel lymph node biopsy,Infiltrating Ductal Carcinoma,"Neuroendocrine carcinoma, large-cell type, high-grade",Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,2+,2+,Negative,Negative,Tumor resection,Modified Radical Masectomy,Negative,Positive,Positive,0.0,0.0,8,250,<10%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,235.935546875,HER2 amplification - negative,Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified,YES,NO,2.8,LungBone,10-19%,<10%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,2.5,3 Point Scale,1+,7thStage IIAT2N0M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",2,8,2011,TCGA-E9-A22D-F29912E2BBDAB7-AC72-4F40-B2CF-8892D5B09CD1Scheduled Follow-up SubmissionNOYESAlive402TUMOR FREENO27112013TCGA-E9-A22D-F39787708BFBE6-3708-4A7E-A6BA-1AFC6260F3ECNONOYESTUMOR FREEAlive1248NO122013,TCGA-E9-A22D-D29929CC819813-FFDB-48CC-BE92-4A82FEC5E8FA3160mg20mg/day193Hormone TherapyTamoxifenADJUVANTPOYES3032012TCGA-E9-A22D-D29928291C8DBC-432A-4B49-BDD4-FEDCC82245C13600mg900mg/day616189Chemotherapy5-FluorouracilADJUVANTIVNO3032012TCGA-E9-A22D-D2992719D3B016-37B3-4CD9-8EAD-68E4AE3A15C43600mg900mg/day616189ChemotherapyCyclophosphaneADJUVANTIVNO3032012TCGA-E9-A22D-D29913B2DEB206-A8C5-4371-9443-BC4CE3883311360mg90mg/day616189ChemotherapyDoxorubicinADJUVANTIVNO3032012,TCGA-LL-A5YN-R593268260F398-2067-486D-ABC6-787644B80D64194224External54.72Gy22Primary Tumor FieldNO952014
TCGAFPPP,Breast,No,FEMALE,Alive,0.0,2221.0,WHITE,TCGA-AR-A24L,AR,A24L,No,YES,C50.9,8500/3,C50.9,2005.0,TUMOR FREE,YES,12.0,image cytometry,Allred score 5+3 = 8,Right,4.033447265624993,Sentinel lymph node biopsy plus axillary dissection,axillary ultrasound,Other,Re-Excision of Superior Margin,Other,Wide local excision,Infiltrating Ductal Carcinoma,MUCINOUS & PAPILLARY,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),Positive,YES,3 Point Scale,4+,2+,Negative,Negative,Core needle biopsy,Modified Radical Masectomy,Negative,Positive,Equivocal,0.0390625,2.0,Allred score = 0,H-Score,10-19%,Hercep Test  TM Dako,CAP SCORING GUIDELINE 2010,86.2431640625,HER2 amplification - negative,>= 2.0 Positive,NO,YES,2.6,"LungBoneLiverOther, specifyskin",10-19%,10-19%,Positive,<10%,3+,Negative,Negative,<10%,1+,<10%,1+,Negative,1.7072265624999932,60,3 Point Scale,1+,6thStage IIBT2N1M0,YES,YES,"YESLocoregional RecurrenceOther, specifyBreast recurrenceYES596NOYES667Locoregional RecurrenceOther, specifyChest wallNOYESYESNegativeNegativeNegative574Distant MetastasisBoneNONOYES",12,8,2011,TCGA-AR-A24L-F3126635D4250F-9553-4152-BC03-40C5E38F5A33Scheduled Follow-up SubmissionYESYESAlive2221YES1414Locoregional Disease2642012TCGA-AR-A24L-F4948898A5DD07-6036-40E1-AE50-9958B67DE1EFNOYESYESWITH TUMORDead2866YES14142102013,1TCGA-AR-A24L-D312715B4FA9C9-DE69-4615-BE89-619E2F835DEA4ChemotherapyPaclitaxelADJUVANTNO26420121TCGA-AR-A24L-D31269F4B58638-1544-44FA-9E05-9CA0F74B82324ChemotherapyDoxorubicinADJUVANTNO26420121TCGA-AR-A24L-D31270F6EC056E-4FA3-4E3B-890D-E3B8307E19B14ChemotherapyCytoxanADJUVANTNO26420122TCGA-AR-A24L-D31272D11B2960-E58A-4BCC-B247-CD1E491660A220mg/day1451414Hormone TherapyTamoxifenADJUVANTPONO2642012,TCGA-AR-A24L-R31268FA585658-1B63-499E-B19C-2E464838C89F243275EXTERNAL BEAM5000cGy25Primary Tumor FieldADJUVANTNO12642012
TCGAFPPP,Breast,No,FEMALE,Dead,266.0,1605.5009765625,BLACK OR AFRICAN AMERICAN,TCGA-E2-A1LK,E2,A1LK,No,YES,C50.9,8500/3,C50.9,2008.0,WITH TUMOR,YES,15.0,Allred score 0+0 = 0,Allred score 0+0 = 0,Left Upper Outer QuadrantLeft Lower Outer Quadrant,1.41,Axillary lymph node dissection alone,axillary ultrasound,Modified Radical Mastectomy,Right Breast reexcision,Other,Segmental Mastectomy,Infiltrating Ductal Carcinoma,Ductal partially papillary,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),Negative,NO,3 Point Scale,4+,2+,Positive,Negative,Tumor resection,Ultrasound-guided biopsy,Negative,Negative,Equivocal,1.056640625,11.0,Allred score = 0,Allred score = 0,80-89%,Hercep Test  TM Dako,Hercep Test TM DAKO,194.171875,HER2 amplification - negative,PathVysion Her-2 DNA,NO,YES,2.8,BoneLiver,10-19%,10-19%,Positive,<10%,3+,Positive,Negative,<10%,1+,<10%,1+,Negative,2.0495312500000025,59,3 Point Scale,2+,6thStage IIICT4bN3aM0,NO,NO,PositivePositiveNegativeNegative,3,6,2011,"TCGA-E2-A1LK-F2062084091637-DEEE-4309-9AAE-75A596E9218DScheduled Follow-up SubmissionNONODead266WITH TUMORYES155Locoregional DiseaseOther, specifyLeft axillaYES200NONONegativeAllred score = 0Allred score 0+0 = 0NegativeAllred Score = 0Allred score 0+0 = 0Equivocal30-39%2+Negative0.951212012",1TCGA-A7-A26F-D15010C3FD872C-2A13-45EF-9151-361979053F67600mg150mg477140ChemotherapyTaxotereADJUVANTIVNO11820111TCGA-A7-A26F-D1501152516E85-91DF-4339-92FC-15606CA088754800mg1200mg477140ChemotherapyCytoxanADJUVANTIVNO1182011,TCGA-E2-A15D-R1878536563FC0-3E99-4312-B812-D3595CDCFEE461106EXTERNAL BEAM6040cGy33Primary Tumor FieldADJUVANTNO19112011
